Back grey_arrow_rt.gif
 
Latest articles about Hepatitis C.
 
null.gif
 
 
  1. CROI: Summary from virtual CROI 2022 for HIV and liver disease Hepatitis elimination for 2030 on track? Is fatty liver disease a growing concern? New insights from CROI 2022. - Prof. Dr. Jurgen K. Rockstroh Department of Medicine I University Hospital Bonn Venusberg-Campus 1 53127 Bonn Germany - (03/21/22)
     
  2. CROI: Summary from CROI 2024 for HIV and liver disease - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/25/24)
     
  3. Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV) - (12/11/24)
     
  4. AASLD: Bemnifosbuvir Does Not Alter Cardiac Repolarization in Healthy Participants: Results from a Thorough QT Study - (12/11/24)
     
  5. AASLD: Multiscale modeling of lead-in results from a phase 2 study of an 8-week combination regimen of Bemnifosbuvir and Ruzasvir in patients with chronic hepatitis C virus infection - (12/11/24)
     
  6. AASLD: Bemnifosbuvir Poses High Barrier for Resistance in Both Preclinical and Phase 1b Monotherapy Studies - (12/11/24)
     
  7. AASLD: HIGH PREVALENCE AND LOW AWARENESS OF CHRONIC LIVER DISEASE AMONG SEXUAL MINORITY MEN IN LOS ANGELES - (12/04/24)
     
  8. AASLD: Hepatitis C Treatment Uptake Differs by Gender Among a Commercially Insured Population in the United States - (12/04/24)
     
  9. AASLD: Factors associated with long-term risk of liver-related and non-liver-related death after sustained virologic response in patients with hepatitis C virus treated with direct-acting antiviral - (12/04/24)
     
  10. AASLD: RAPID START-UP OF A FIELD-BASED HEPATITIS C ELIMINATION PROGRAM ENABLED BY STATE FUNDED 340B INITIATIVE, Specialized Mobile Outreach - (11/26/24)
     
  11. AASLD: Characteristics and Treatment Patterns of Transgender Men and Women Living With Hepatitis C in the United States - (11/26/24)
     
  12. AASLD: PREVALENCE AND RISK FACTORS FOR HCC AMONG PATIENTS WITH CURENT AND PRIOR HCV IN A REAL-WORLD COHORT IN THE POST-DAA ERA - (11/26/24)
     
  13. AASLD: Hepatitis C Treatment Uptake Differs by Gender Among a Commercially Insured Population in the United States, young women 35% less likely to start DAA treatment - (11/26/24)
     
  14. AASLD: Delineating gaps in the cascade of care among pregnant women with HCV: An observational retrospective analysis of real-world data on a commercially insured cohort in the US - (11/26/24)
     
  15. AASLD: The SVR10K study: Real-World Data with Pangenotypic Direct-Acting Antivirals (SOF/VEL) Across Multiple Diverse Regions - (11/26/24)
     
  16. AASLD: Characteristics of persons treated for hepatitis C in the United States, 2014-2023 - (11/26/24)
     
  17. AASLD: Hepatic steatosis in chronic hepatitis C affects the risk of hepatocellular carcinoma mainly in women - (11/26/24)
     
  18. Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study - (11/25/24)
     
  19. AASLD: Glecaprevir/Pibrentasvir in Chronic HCV: An Integrated Analysis of Patients on Multiple Concomitant Medications - (11/25/24)
     
  20. AASLD: Effectiveness of Glecaprevir/Pibrentasvir for 8 Weeks in People Taking Antipsychotics, Buprenorphine/Naloxone, or Illicit Drugs - (11/25/24)
     
  21. AASLD: A COMPARISON OF SOFOSBUVIR/VELPATASVIR (S/V) AND GLECAPREVIR/PIBRENTASVIR (G/P) FOR THE TREATMENT OF HCV INFECTION AMONG HCV-INFECTED PEOPLE WHO USE DRUGS (PWUD) - (11/25/24)
     
  22. AASLD: A Multicenter, Single-Arm, Prospective, Phase 3b Study to Evaluate Safety and Efficacy of Glecaprevir/Pibrentasvir 8-Week Treatment in Adults With Acute Hepatitis C Virus Infection - (11/25/24)
     
  23. AASLD: Safety, Tolerability, and Outcomes of SofosbuviR/Velpatasvir in Treatment of Chronic Hepatitis C Virus during Pregnancy: Interim results from the STORC study - (11/25/24)
     
  24. AASLD: HEPATITIS C MANAGEMENT OF WOMEN IN THE THIRD TRIMESTER OF PREGNANCY IN LA BODEGA - (11/25/24)
     
  25. AASLD: Same Day and Rapid Start HCV Management in La Bodega Clinic - (11/25/24)
     
  26. AASLD: Liver stiffness as a predictive factor for hepatocellular carcinoma development after sustained virologic response by direct-acting antivirals for chronic hepatitis C; HCC can occur after SVR at low rates - (11/25/24)
     
  27. AASLD: LONG TERM OUTCOME AMONG HCV-INFECTED PEOPLE WHO USE DRUGS (PWUD) SUCCESSFULLY TREATED FOR HCV INFECTION WITH GLECAPREVIR/PIBRENTASVIR (G/P) - (11/25/24)
     
  28. AASLD: SUCCESSFUL PERFORMANCE OF THE XPERT® HCV TEST FOR POINT OF CARE DETECTION OF HCV RNA IN A CLIA-WAIVED SETTING - (11/25/24)
     
  29. AASLD: COMMUNITY POP-UP CLINIC: CASCADE OF CARE AND HCV TREATMENT OF VANCOUVER'S INNER-CITY PWID POPULATIONS - (11/25/24)
     
  30. AASLD: Association of MASLD Phenotypes with Liver Fibrosis in Hepatitis C: The Role of Cardiometabolic Risk Factors - (11/25/24)
     
  31. AASLD: Sofosbuvir/Velpatasvir Effectiveness in Treating Chronic Hepatitis C Genotype 3: A Real-World Study in Xinjiang, China. - (11/25/24)
     
  32. AASLD: HCV REINFECTION AMONG PEOPLE WHO USE DRUGS (PWUD) TREATED FOR HCV INFECTION: A LONG-TERM REVIEW - (11/25/24)
     
  33. AASLD: Rapid Hepatitis C Test and Treat with Peer Support at Opioid Treatment Programs (RAPID HCV): A multicenter randomized control trial - (11/25/24)
     
  34. AASLD: A multicenter real world study of sofosbuvir/velpatasvir for HIV/HCV coinfected patients - (11/25/24)
     
  35. AASLD: CLINICAL PERFORMANCE EVALUATION OF THE XPERT® HCV TEST AT POINT OF CARE IN A MULTI-SITE PROSPECTIVE CLINICAL STUDY - (11/25/24)
     
  36. Glasgow: Long-term outcomes following liver transplantation (LT) in patients with HIV (PWH): a retrospective single-centre case-control study - (11/18/24)
     
  37. Glasgow: Acute/Recent Infections and Reinfections by HCV in MSM with and without HIV in the Region of Madrid (ATHENS Study) - (11/18/24)
     
  38. Glasgow: Prevalence Trends of Active HCV Infection Among People with HIV in Spain (2002-2023): Nearing Elimination - (11/18/24)
     
  39. ID Week: Should HCV Be Treated in Pregnant Persons? - (10/24/24)
     
  40. CBO Issues Paper: "A Call for New Research in the Area of Hepatitis C" creates inordinate barrier to HCV elimination - (08/06/24)
     
  41. CBO Statement: "Budgetary Effects of Policies That Would Increase Hepatitis C Treatment", creates impossible unique barrier to eliminate HCV - (08/06/24)
     
  42. Hepatitis C Virus Reinfection Among Men Who Have Sex With Men With HIV in New York City - (08/02/24)
     
  43. IAS: HCV incidence among MSM using HIV PrEP and MSM with HIV in a New York City Health Care System over 2 decades - (08/02/24)
     
  44. IAS: Community-Based HCV Self-Testing Widens Testing Access in Big Vietnam Study - Mark Mascolini (07/27/24)
     
  45. Medicaid Expansion and Restriction Policies for Hepatitis C Treatment - (07/20/24)
     
  46. PWH HCV Reinfection Increased as % of New HCV Incidence Despite Decline in Reinfection - (07/19/24)
     
  47. Estimated Number of People Who Inject Drugs in the United States.and Globally - (07/11/24)
     
  48. Estimating hepatitis C prevalence in the United States, 2017-2020 - see below, adj. PWD Model 4 million - (07/11/24)
     
  49. Estimated [UNDER-ESTIMATED] Prevalence and Awareness of Hepatitis C Virus Infection Among US Adults: National Health and Nutrition Examination Survey, January 2017-March 2020 - see full paper below - (07/09/24)
     
  50. NYS Requires HCV Screening <18> & During Pregnancy; Intensifies HCV Elimination Effort - (07/09/24)
     
  51. FDA Permits Marketing of First Point-of-Care Hepatitis C RNA Test - (07/01/24)
     
  52. Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study - (07/01/24)
     
  53. CBO Issues Comments on National HCV Elimination Plan: A Call for New Research in the Area of Hepatitis C - (06/18/24)
     
  54. EASL Validation of a Modified Pediatric Formulation of Sofosbuvir and Daclatasvir in Genotype-4 HCV-infected Children Weighing 17-35 Kg - (06/18/24)
     
  55. EASL Ravidasvir in combination with sofosbuvir for 12 or 24 weeks achieved high sustained virological response rates in genotype 3 chronic hepatitis C without or with compensated liver cirrhosis - (06/18/24)
     
  56. EASL Modeling suggests that undetectable HCV at week 2 of DAA therapy could identify patients for shorter treatment duration - (06/18/24)
     
  57. EASL Is hepatitis C screening based on risk factors enough in primary care setting? - (06/18/24)
     
  58. EASL Impact of a "one-stop" simplified diagnosis-monitoring strategy on Glecaprevir/Pibrentasvir (G/P) treatment initiation and response in patients with chronic hepatitis C virus(HCV) infection receiving Opioid-Substitute Therapy (OST) in Israel - A Real World Evidence, retrospective analysis - (06/18/24)
     
  59. EASL Model Says Treating Only 75 of 1000 PWID 7.5% Would Eliminate HCV in This Group - Mark Mascolini (06/17/24)
     
  60. EASL A prospective, blinded multicenter US evaluation of a multi-analysis blood-based test for the detection of hepatocellular carcinoma (HCC) in patients with cirrhosis. New Simple Blood Test More Sensitive Than Ultrasound for Early HCC - Mark Mascolini (06/17/24)
     
  61. EASL Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients Good Outcomes With Liver Transplants From HCV Viremic and Nonviremic Donors - Mark Mascolini (06/17/24)
     
  62. EASL Sofosbuvir/Velpatasvir (S/V) for the treatment of HCV infection among vulnerable inner-city residents: extending the results of the SIMPLIFY study - (06/17/24)
     
  63. EASL Long term outcome among HCV-infected people who use drugs (PWUD) successfully treated for HCV infection with Glecaprevir/ Pibrentasvir (G/P) - (06/17/24)
     
  64. EASL Absorption, Distribution, Metabolism and Excretion of [14C]-Bemnifosbuvir in Rats - (06/17/24)
     
  65. EASL Low Risk of Drug-Drug Interactions for Ruzasvir Based Upon In Vitro Metabolism and Transporter Interaction Studies - (06/17/24)
     
  66. EASL Bemnifosbuvir is a potent HCV NS5B inhibitor with a favorable antiviral profile and high resistance barrier - (06/14/24)
     
  67. EASL Lead-in Cohort Results From a Phase 2 Study of a Novel 8-week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients With Chronic Hepatitis C Virus Infection - (06/14/24)
     
  68. EASL Long-term liver morbidity and mortality after HCV elimination by direct-acting antivirals in patients with chronic hepatitis C: results from a large-scale, multicenter cohort study HCV Cure With DAAs Improves Survival Regardless of HCC - Mark Mascolini (06/14/24)
     
  69. EASL Effectiveness and safety of direct-acting antivirals in the treatment of elderly people infected with HCV - (06/14/24)
     
  70. EASL When glecaprevir/pibrentasvir ultra-short therapy is enough to eradicate HCV infection - (06/14/24)
     
  71. EASL A prospective, blinded, multicenter U.S. evaluation of a multi-analyte blood-based test for the detection of hepatocellular carcinoma (HCC) in patients with cirrhosis - (06/14/24)
     
  72. EASL Age at Incident Cirrhosis in Individuals With Hepatitis C Virus Infection: A US Administrative Claims Analysis - (06/14/24)
     
  73. EASL Use of proton pump inhibitors among German Hepatitis C patients treated with sofosbuvir/velpatasvir: Data from the German Hepatitis C-Registry (2016 - 2022 - (06/14/24)
     
  74. EASL Hepatocellular carcinoma development despite histological regression of liver fibrosis following HCV cure (ANRS CirVir, Hepather, LICAVIR) - (06/14/24)
     
  75. EASL Long-term liver morbidity and mortality after HCV elimination by direct-acting antivirals in patients with chronic hepatitis C: results from a large-scale, multicenter cohort study HCV Cure With DAAs Improves Survival Regardless of HCC - written by Mark Mascolini (06/10/24)
     
  76. EASL Testing for hepatitis C virus infection in prisons in England: room for improvement. Only One Quarter Entering 3 Prisons in England Tested for HCV - written by Mark Mascolini (06/10/24)
     
  77. EASL What happens to HCV incidence after WHO elimination goal is met? Agent-based modeling predicts sustained availability of direct-acting antivirals among people who inject drugs (PWID) is required to prevent returning to pre-elimination levels - (06/10/24)
     
  78. EASL Prediction of outcomes in patients with HCV compensated liver cirrhosis after SVR: results from 5-years of follow-up - (06/10/24)
     
  79. EASL Safety and efficacy of two pangenotypic direct acting antivirals (sofosbuvir/velpatasvir and glecaprevir/pibrentasvir) for the treatment of hepatitis C in children - (06/10/24)
     
  80. EASL Prognostic implications of liver stiffness impairment after HCV cure in cACLD patients - (06/10/24)
     
  81. EASL Evaluation of liver fibrosis in patients with advanced chronic liver disease due to hcv after 6 years of sustained viral response. study with paired biopsies at 3 and 6 years - (06/10/24)
     
  82. EASL Regression of hepatic fibrosis in patients with chronic hepatitis C treated with direct-acting antivirals (DAAs). A long-term, prospective, observational study - (06/10/24)
     
  83. EASL Effects of direct-acting antivirals on end-stage liver disease and mortality among Florida Medicaid beneficiaries with chronic hepatitis C: 31% with cirrhosis received DAA, 12% without cirrhosis 2013-2019 - (06/10/24)
     
  84. EASL Liver stiffness measurement before and after antiviral treatment for hepatitis C: results from an OST-based hepatology service facility - (06/10/24)
     
  85. EASL Hepatocellular carcinoma development post hepatitis C virus cure is associated with distinct changes in the dynamics of the soluble inflammatory milieu - (06/10/24)
     
  86. EASL Impact of Hepatitis C virus direct acting antivirals on HCC evolution - (06/10/24)
     
  87. EASL Hepatocellular carcinoma development despite histological regression of liver fibrosis following HCV cure (ANRS CirVir, Hepather, LICAVIR) - (06/09/24)
     
  88. EASL Description of age, sex, and characteristics of Hepatitis C patients in the SVR10K study: A real-world SOF/VEL analysis performed across five global regions - (06/09/24)
     
  89. EASL Incidence of hepatocellular carcinoma in patients with hepatitis C treated with direct-acting antiviral agents: results of a long-term prospective study period - (06/09/24)
     
  90. EASL In the era of effective antiviral therapy, cured hepatitis C remains a main cause of HCC - (06/09/24)
     
  91. EASL Point of Care Hepatitis C Screening and Treatment Among People Who Use Drugs in New York City Addiction Centers: Barriers and Opportunities - (06/09/24)
     
  92. EASL Increasing Hepatitis C screening rates at a New York City primary care clinic: a continuation - (06/09/24)
     
  93. EASL Impact of direct acting antiviral market access policy barriers and restrictions for Hepatitis C (HCV) patients: a database analysis of claims from states with and without Medicaid restrictions - (06/09/24)
     
  94. EASL Real-world effectiveness and safety of 8-week glecaprevir/pibrentasvir for treatment-naïve patients from Taiwan nationwide HCV registry - (06/09/24)
     
  95. Missouri Healthnet extends contract with hepatitis C drugmaker - (05/22/24)
     
  96. DDW: COMBATING HEPATITIS C IN MISSOURI: PUBLIC-PRIVATE PARTNERSHIP WITH LOCAL PUBLIC HEALTH AGENCIES TO ERADICATE HCV IN MISSOURI - (05/21/24)
     
  97. DDW: HCV+ Organ transplants Successful 98% Cure Rate: HEPATITIS C TREATMENT AFTER SOLID ORGAN TRANSPLANT IS EFFECTIVE USING ANY DAA REGIMEN AND DOES NOT NEGATIVELY IMPACT REJECTION RATES OR GRAFT FUNCTION - (05/21/24)
     
  98. DDW: SGLT2I REDUCES THE RISK OF DEVELOPING HCC IN PATIENTS WITH CO-EXISTING HEPATITIS C INFECTION AND TYPE 2 DIABETES: A GLOBAL MULTICENTER PROPENSITY-MATCHED STUDY - (05/21/24)
     
  99. DDW: CHECKING IS LACKING: SUBOPTIMAL SURVEILLANCE [38%] FOR HEPATOCELLULAR CARCINOMA IN PATIENTS WITH SUSTAINED VIROLOGIC RESPONSE AFTER DIRECT-ACTING ANTIVIRAL THERAPY FOR HEPATITIS C....GI/liver specialty clinics provided better surveillance - (05/21/24)
     
  100. DDW: HCC Rates Predicted Black Disparities Widening 33% by 2028 USA - (05/21/24)
     
  101. DDW: HIDDEN LINK BETWEEN HEPATITIS C INFECTION AND HEPATOCELLULAR CARCINOMA IN NON-CIRRHOTIC PATIENTS: A NATIONAL INPATIENT SAMPLE ANALYSIS - (05/21/24)
     
  102. DDW: Delayed Diagnosis of HCV - Results of Nationwide US Study - (05/21/24)
     
  103. DDW: PERCEPTIONS OF QUALITY OF LIFE, FATIGUE AND HEALTH OUTCOMES IN CHRONIC LIVER DISEASE PATIENTS - (05/20/24)
     
  104. DDW: DE NOVO HEPATOCELLULAR CARCINOMA (HCC) IN NON-CIRRHOTIC CHRONIC VIRAL HEPATITIS C (HCV) PATIENTS: A CASE SERIES - (05/20/24)
     
  105. DDW: THERE IS A PERSISTENT GAP IN THE QUALITY OF TIMELY HEPATITIS C ERADICATION DESPITE EFFORTS TO STREAMLINE SPECIALIST REFERRALS FROM PRIMARY CARE - (05/20/24)
     
  106. DDW: PREDICTORS OF THE RECEIPT OF HEPATITIS C VIRUS (HCV) TREATMENT AMONG CURRENT PATIENTS IN A LARGE URBAN HEALTHCARE SYSTEM - (05/20/24)
     
  107. DDW: MORTALITY RATES AMONG PATIENTS SUCCESSFULLY TREATED FOR HEPATITIS C: A REAL WORLD MULTINATIONAL COHORT STUDY - (05/20/24)
     
  108. DDW: HEPATITIS C RESURGENCE IN THE U.S: A DETAILED STUDY OF INCIDENCE AND MORTALITY TRENDS (1990-2019) - (05/20/24)
     
  109. Glecaprevir, Pibrentasvir Effective for HCV Regardless of Cirrhosis, Treatment Period - (05/15/24)
     
  110. Women Reproductive Age Acute HCV & Cirrhosis Increased - (05/15/24)
     
  111. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir - (05/15/24)
     
  112. Point-of-Care Testing - Advancing Diagnosis of Current Hepatitis C Virus Infection: A Key to Hepatitis C Elimination in the United States - (05/14/24)
     
  113. Hepatitis C Surveillance 2022: new acute, chronic HCV cases; racial disparity; death rates; switch from IDU to snorting, smoking - (04/15/24)
     
  114. Integrated Hepatitis C Opioid Use Disorder Care Through Facilitated Telemedicine A Randomized Trial - (04/15/24)
     
  115. WHO sounds alarm on viral hepatitis infections claiming 3500 lives each day - (04/15/24)
     
  116. AASLD: Implementation of Universal Hepatitis C Virus Screening in a Tertiary Care Cancer Center - (04/15/24)
     
  117. CROI: Hepatitis C Screening in the Emergency Department The Multi-Center DETECT Hep C Clinical Trial - (03/30/24)
     
  118. CROI: Navigation is Superior to Clinician Referral for Linkage to HCV Care from the Emergency Department - (03/30/24)
     
  119. CROI: A Model to Eliminate Viral Hepatitis Infection in Migrants: A Prospective Study in Southern Italy - (03/30/24)
     
  120. CROI: Immunophenotypic and T-cell Senescence Profile Modifications After Spontaneous HCV Clearance or After DAAs Treatment in People Living with HIV - (03/30/24)
     
  121. CROI: ELIMINATION OF HCV AMONG PEOPLE WITH HIV IN AUSTRALIA: reduced prevalence; but death incidence persists - (03/30/24)
     
  122. CROI: Cost Savings Modeling of Telehealth Services for Hepatitis C Virus Infection, Cherokee Nation - (03/30/24)
     
  123. CROI: Preclinical Characterization of GS-5894, a Potent NNRTI With Once Weekly Oral Dosing Potential - (03/30/24)
     
  124. CROI: Hepatitis C Reinfection Among Men Who Have Sex With Men in an Acute HIV Cohort in Thailand - (03/30/24)
     
  125. CROI: HIGH COMPLETION AND CURE RATES WITH A DECENTRALIZED, INTEGRATED HCV TREATMENT APPROACH IN VIETNAM (PWH) - (03/28/24)
     
  126. CROI: Nationwide HCV Elimination Program and the Status of Microelimination in People With HIV in Taiwan - (03/28/24)
     
  127. CROI: High rate of Hepatitis C incidence in Vietnamese MSM living with HIV; substance use; group sex; STIs - (03/28/24)
     
  128. CROI: HIV-1 coinfection skews iNKT cells towards anergy and exhaustion in persons living with hepatitis C virus - (03/28/24)
     
  129. CROI: Trends in HIV and HCV Prevention Efforts and Incidence Among People Who Inject Drugs in Baltimore: not enough HCV treatment - (03/28/24)
     
  130. CROI: HIV and HCV Screen Rates for Hospitalized PWUD Are Heterogeneous & Suboptimal Across 11 States - (03/28/24)
     
  131. CROI: Prevalence and resistance profiles of "Unusual" HCV subtypes in Italy, Retreatment - (03/26/24)
     
  132. CROI: A PRECISION RANDOMIZED TRIAL OF HEPATITIS C TREATMENT ADHERENCE SUPPORT AMONG 3000 PWID IN INDIA - (03/26/24)
     
  133. CROI: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver's inner-city PWID Populations: 87% engaged in care, started treatment, high cure rates - (03/26/24)
     
  134. CROI: Navigation is Superior to Clinician Referral for Linkage to HCV Care from the Emergency Department - (03/26/24)
     
  135. CROI: A Model to Eliminate Viral Hepatitis Infection in Migrants: A Prospective Study in Southern Italy - (03/26/24)
     
  136. CROI: A Phase II Trial of 4 Weeks of Glecaprevir/Pibrentasvir for Early Hepatitis C Virus: ACTG A5380 - (03/21/24)
     
  137. CROI: Prevalence (Remains Higher vs HCV monoinfected) and Risk Factors for Hepatitis C Viremia in People with HIV in the US During the DAA Era - (03/21/24)
     
  138. CROI: Predictors of liver-related events following DAA HCV cure in PWH with advanced fibrosis/cirrhosis - (03/21/24)
     
  139. CROI: Influence of Markers Related to Biological Aging (cellular aging) on Liver Regeneration in HCV Patients Achieving SVR: telomerase length associated with absence of liver regeneration - (03/21/24)
     
  140. CROI: Similar mortality among individuals with HIV/HCV-coinfection and HCV-monoinfection after SVR - (03/21/24)
     
  141. CROI: High RE-INFECTION FOLLOWING A MINIMAL MONITORING APPROACH FOR TREATMENT OF HEPATITIS C VIRUS INFECTION - (03/21/24)
     
  142. CROI: Transfer of Sofosbuvir/Velpatasvir into Breastmilk - (03/21/24)
     
  143. CROI: Intracellular Sofosbuvir Concentrations in Pregnant Women With Hepatitis C Virus - (03/21/24)
     
  144. CROI: Using County Notification Data to Characterize Recently Reported Hepatitis C Cases, Los Angeles - (03/21/24)
     
  145. CROI: Direct-Acting Antivirals and Risk of Hepatocellular Carcinoma in People With HIV/HCV Coinfection - (03/21/24)
     
  146. CROI: Preclinical Pharmacokinetic Assessment of a Hepatitis C Virus Long-Acting Injectable Formulation - (03/15/24)
     
  147. CROI: Leading Causes of Death Among People With HIV in the US, 2001-2019...4x greater death risk than gen. pop., cancer & heart disease, HIV leading causes of death, Blacks have higher death rates - (03/13/24)
     
  148. CROI: Peripartum Linkage to Care in Hepatitis C: Maternal Treatment and Infant Testing - (03/07/24)
     
  149. Hepatitis C Virus Elimination Programs in Louisiana and Washington: Importance of Screening and Surveillance Systems - (02/26/24)
     
  150. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions - (02/26/24)
     
  151. Eliminating viral hepatitis: no room for complacency; lack of political will - (02/26/24)
     
  152. 'not very good' Progress towards global elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update - (02/26/24)
     
  153. NYS Mandates HCV Screening During Pregnancy - (02/16/24)
     
  154. Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Treatment of Chronic Hepatitis C: A Prospective Cohort Study in Portugal - (02/13/24)
     
  155. Undertesting & Under Diagnosing of Children with Perinatal HCV - (02/07/24)
     
  156. 2021 Viral Hepatitis Surveillance Report Overview: 60% increase in acute HCV infections since 2017 - (01/29/24)
     
  157. 2021 Viral Hepatitis Surveillance Report Overview: 60% increase in acute HCV infections since 2017 - (01/29/24)
     
  158. New HCV DAA Treatments Initiations 2020 Decreasing - (01/29/24)
     
  159. Departments of Justice and Health and Human Services Issue Letter to State Medicaid Administrators Urging Coverage for Life-Saving Hepatitis C Medications - press release - (01/29/24)
     
  160. Optimal Hepatitis C Treatment Adherence Patterns and Sustained Virologic Response. among People Who Inject Drugs: The HERO Study - (01/29/24)
     
  161. NYS Funding for 10 New Outpatient & Opioid Treatment Programs (OTP) - (01/29/24)
     
  162. Hepatitis C Excerpts from NYS Gov Hochel State-of-State Talk - (01/15/24)
     
  163. Hepatitis C Newly Reported Cases, New York State, 2022 by Region - (01/15/24)
     
  164. New York State Department of Health Hepatitis B and C ANNUAL REPORT 2022 - (01/15/24)
     
  165. CDC Hepatitis C Virus Clearance Cascade US 2013-2022: increased HCV screening required to achieve elimination - (01/15/24)
     
  166. Increased Screening & New Models of Care are Key. Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C - (01/02/24)
     
  167. Advancing Hepatitis C Elimination: Implementation Strategy for the Proposed National Program; policy brief from Duke-Margolis Center - (12/08/23)
     
  168. Hepatitis C in Black Individuals in the USA Review - (12/05/23)
     
  169. AASLD: Total HCV patients treated with direct acting antivirals since 2014: Generics of Latest DAAs Are Key to Continuing Global Expansion of HCV Therapy - Mark Mascolini (11/29/23)
     
  170. AASLD: 100% SVR Rate in National Pediatric HCV Network for England-Wales-Ireland - Mark Mascolini (11/29/23)
     
  171. AASLD: Alcohol and Low Health Literacy Hamper Access to Curative Therapy for HCC - Mark Mascolini (11/21/23)
     
  172. AASLD: MUSCLE FAT INFILTRATION IS ELEVATED IN PREFRAIL AND MODERATELY PHYSICALLY IMPAIRED PATIENTS - INTERIM RESULTS FROM THE PROSPECTIVE MULTI-CENTER CIRRHOSIS COHORT STUDY ACCESS-ESLD - (11/21/23)
     
  173. AASLD: Early Read-Time Performance of the OraQuick®
    HCV Rapid Antibody Assay for the Exclusion of HCV Viremia     - (11/21/23)
     
  174. AASLD: Successful Screening, Linkage to Care, and Treatment of Hepatitis C in a Tiny Shelter Encampment on Veterans Affairs Grounds - (11/21/23)
     
  175. AASLD: HCV Medication Adherence Outcomes for the Louisiana Medicaid Subscription-Based Model at Specialty Pharmacy - (11/21/23)
     
  176. AASLD: Update on Congress Around White House Plan to Eliminate HCV - (11/21/23)
     
  177. AASLD: Long-term risk of liver-related and non-liver-related death after direct-acting antiviral-mediated sustained virologic response in hepatitis C virus patients - (11/21/23)
     
  178. AASLD: Long-term risk of liver-related and non-liver-related death after direct-acting antiviral-mediated sustained virologic response in hepatitis C virus patients - (11/20/23)
     
  179. AASLD: Long-Term Safety and Efficacy of Sofosbuvir-Based Direct-Acting Antivirals in Pediatric Patients With Hepatitis C Virus - (11/17/23)
     
  180. AASLD: Early Menopause and Primary Ovarian Insufficiency in Women With and Without Chronic Hepatitis C: A Retrospective Observational Study of Women in the United States - (11/17/23)
     
  181. AASLD: Local Gilead Elimination Programs Leading to Global Action in HCV (LEGA-C): Outcome of Studies and the Impact Focusing on Activities Within the United States - (11/17/23)
     
  182. AASLD: LOW ANTIVIRAL TREATMENT RATE (24%) FOR PATIENTS WITH HEPATITIS C (HCV)-RELATED HEPATOCELLULAR CARCINOMA (HCC)- A REAL-WORLD NATIONWIDE U.S. STUDY - (11/17/23)
     
  183. AASLD: ONGOING EXPERIENCE OF IMPLEMENTING THE TORONTO PROTOCOL: AN ULTRA-SHORT COURSE GLECAPRIVER/PIBRENTASVIR WITH EZETIMIBE FOR SOLID ORGAN TRANSPLANTATION FROM HCV-INFECTED DONORS TO HCV-UNINFECTED RECIPIENTS - (11/17/23)
     
  184. AASLD: CHARACTERIZING LINKAGE TO HEPATITIS C VIRUS CARE DURING AND FOLLOWING PREGNANCY: IDENTIFYING MISSED OPPORTUNITIES FOR TESTING AND TREATMENT, as many as 500 HCV+ infants missed, preventable - (11/17/23)
     
  185. AASLD: HEALTHCARE ACCESS THROUGH FACILITATED TELEMEDICINE FOR UNDERSERVED POPULATIONS: A STEPPED WEDGE CLUSTER RANDOMIZED CONTROLLED TRIAL OF HEPATITIS C VIRUS TREATMENT AMONG PERSONS WITH OPIOID USE DISORDER - (11/17/23)
     
  186. AASLD: RECOMPENSATION OF CHRONIC HEPATITIS C-RELATED DECOMPENSATED CIRRHOSIS FOLLOWING DIRECT-ACTING ANTIVIRAL THERAPY: REAL-WORLD DATA FROM THE PUNJAB HCV ELIMINATION MODEL - (11/17/23)
     
  187. AASLD: Hepatitis Debrief at AASLD 2023 (HCV, HBV, HDV), Jennifer Price MD - (11/15/23)
     
  188. AASLD: The efficacy and safety of 12-week SOF/VEL regimen combined with prophylactic use of TAF for treatment-naive genotype1-6 HCV/HBV co-infection adult patients with or without compensated cirrhosis in China: a multi-center prospective, single-arm, open-label trial - (11/15/23)
     
  189. AASLD: A HEPATITIS C (HCV) TEST AND TREAT INITIATIVE IN RESIDENT ASSOCIATED ACADEMIC PRIMARY CARE CLINIC: UPDATES IN AN ERA OF EXPANDED SCREENING GUIDELINES - (11/15/23)
     
  190. AASLD: The Relationship of VADOC [prison] Inmates with Hepatitis C and the Barriers Preventing the Initiation of DAA Treatment - (11/15/23)
     
  191. AASLD: Evolution over two years of the annual incidence of HCV viral load detected by rapid RT PCR (Xpert HCV Viral Load Fingerstick assay) directly on site in 3 addiction centers - (11/15/23)
     
  192. AASLD: EXPLORING HEPATITIS C VIRUS TRANSMISSION AMONG PEOPLE WHO INJECT DRUGS AND MEN WHO HAVE SEX WITH MEN: RARE AND LIMITED RISK GROUPS IN JAPAN: prioritize MSM control measures - (11/15/23)
     
  193. AASLD: Hepatitis C Virus Infection and COVID-19 Inpatient Mortality: HCV cirrhosis increased COVID mortality - (11/15/23)
     
  194. AASLD: Under 25% With HCV and HCC Got DAAs in Nationwide US Insurance Database - Mark Mascolini (11/15/23)
     
  195. AASLD: Estimating Prevalence (over 4 million, up to 5.6 mill.) of Hepatitis C Virus Infection in the United States, 2017-2020 - (11/15/23)
     
  196. AASLD: RECOMPENSATION OF CHRONIC HEPATITIS C-RELATED DECOMPENSATED CIRRHOSIS FOLLOWING DIRECT-ACTING ANTIVIRAL THERAPY: REAL-WORLD DATA FROM THE PUNJAB HCV ELIMINATION MODEL - (11/15/23)
     
  197. AASLD: Poor Followup After HVC SVR: High Rate of Liver and Nonliver Problems After SVR in People With Cirrhosis - Mark Mascolini (11/13/23)
     
  198. AASLD: Safety, Tolerability, and Outcomes of Sofosbuvir/Velpatasvir in Treatment of Chronic Hepatitis C Virus during Pregnancy: interim results from the STORC study - (11/13/23)
     
  199. AASLD: Bemnifosbuvir and ruzasvir are potent HCV DAAs with favorable antiviral profiles against major HCV NS5A and NS5B RAVs supporting use in combination - (11/13/23)
     
  200. AASLD: Lack of pharmacokinetic drug-drug interaction between bemnifosbuvir and ruzasvir in healthy participants - (11/13/23)
     
  201. AASLD: Efficacy and safety of SOF/VEL treatment in recently acquired hepatitis C virus infection among people living with human immunodeficiency virus: a single-center study in Southwest China - (11/13/23)
     
  202. AASLD: Effectiveness and safety of sofobuvir/velpatasvir/vosilaprevir as a rescue therapy for chronic hepatitis C patients GT 3b with failed previous direct-acting antivirals treatment in Southwest China - (11/13/23)
     
  203. AASLD: Eliminating HepC in children; Care closer to home UK - (11/13/23)
     
  204. AASLD: Towards ultra-short DAA therapy to eradicate HCV infection? - (11/13/23)
     
  205. AASLD: EFFICACY AND SAFETY OF 8-WEEK GLECAPREVIR/PIBRENTASVIR FOR THE TREATMENT OF PATIENTS WITH ACUTE HEPATITIS C: A SINGLE-ARM RETROSPECTIVE STUDY 99% - (11/13/23)
     
  206. AASLD: SAFETY AND TOLERABILITY OF AN ORAL CONTRACEPTIVE CONTAINING LOW-DOSE ETHINYL ESTRADIOL COMBINED WITH GLECAPREVIR/PIBRENTASVIR TREATMENT IN HEALTHY PREMENOPAUSAL WOMEN: RESULTS OF A PHASE 1 STUDY - (11/13/23)
     
  207. AASLD: HCV in USA: treated, diagnosed, deaths: 39% diagnosed - (11/13/23)
     
  208. AASLD: Total HCV patients treated with direct acting antivirals since 2014 - (11/14/23)
     
  209. AASLD: Increased Risk for NAFLD, MASLD to 34% - (11/13/23)
     
  210. EACS: To the liver and beyond: the impact of HCV clearance with direct antiviral agents in people living with HIV/HCV - (11/8/23)
     
  211. EACS: The status of hepatitis C micro-elimination among people living with HIV in Central and Eastern Europe in 2022 - data from Euroguidelines in Central and Eastern Europe Network Group - (11/8/23)
     
  212. EACS: Impact of directly acting-antivirals and behaviour change on HCV micro-elimination in MSM due to the COVID 19 pandemic in Germany - Results from the NoCo cohort - (11/8/23)
     
  213. Northwestern Medicine and Lurie Childrens Hospital collaborate to address the unmet need of treating hepatitis C in pregnancy and infancy - (11/08/23)
     
  214. CDC Recommendations for Hepatitis C Testing Among Perinatally Exposed Infants and Children - United States, 2023: "HCV testing for all perinatally exposed infants, consultation with experienced health care provider" - (11/08/23)
     
  215. 40% of the US population remains unaware of their HCV infection, US Study; Screening is Paramount. NHANES - (11/08/23)
     
  216. ID Week : HEPATITIS C VIRUS CARE CONTINUUM IN THE DIRECT- ACTING ANTIVIRAL ERA WITHIN THE US VETERANS HEALTH ADMINISTRATION - (10/26/23)
     
  217. EACS: Total and LDL Cholesterol Climb After HCV Cure in People With HIV - Mark Mascolini (10/26/23)
     
  218. ID Week : High Death and Hospital Rates in US Group With HIV and Cirrhosis - Mark Mascolini (10/18/23)
     
  219. ID Week : Creating HCV Care Cascades in HIV Clinics in Real Time - (10/11/23)
     
  220. ID Week : Hepatitis C Virus infection and cure by priority population among New York City Ryan White HIV/AIDS Program Part A - (10/11/23)
     
  221. ID Week : Massachusetts HCV Treatment Report Card: Hepatitis C Virus Care Cascade for Females of Reproductive Age with Opioid Use Disorder, 2014-2021 - (10/11/23)
     
  222. ID Week : Hepatitis C Virus Among Inpatients in the Direct-acting Antiviral Era: Prevalence, Linkage to Care, Treatment Disparities, and Comorbidity Burden - (10/11/23)
     
  223. ID Week : Trends in viral hepatitis and hepatocellular carcinoma in New York City, 2001-2018 - (10/11/23)
     
  224. ID Week : An Analysis of Social Determinants of Health and their Implications for Hepatitis C Virus Treatment in People Who Inject Drugs: The Case of Baltimore. - (10/11/23)
     
  225. ID Week : Anti-HCV Therapy Starts Faster, Finishes More Often With Community Pharmacy Than Medicaid Mail-Order System - Mark Mascolini (10/11/23)
     
  226. ID Week : IMPACT OF AN INNOVATIVE COMMUNITY BASED CONTRACTED PHARMACY ON HCV ELIMINATION IN NEW JERSEY, USA - (10/11/23)
     
  227. Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis - (10/01/23)
     
  228. Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis - (09/28/23)
     
  229. Incidence of Etiology-specific Hepatocellular Carcinoma: diverging trends and significant heterogeneity by race and ethnicity - (09/26/23)
     
  230. The national hepatitis C elimination program-AASLD's coalition and call to action - (09/24/23)
     
  231. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study - (09/24/23)
     
  232. Eliminating hepatitis C in a rural Appalachian county: protocol for the Kentucky Viral Hepatitis Treatment Study (KeY Treat), a phase IV, single-arm, open-label trial of sofosbuvir/velpatasvir for the treatment of hepatitis C - ongoing - (09/22/23)
     
  233. The Urgent Need to Implement Point-of-Care RNA Testing for Hepatitis C Virus to Support Elimination - (09/22/23)
     
  234. Reinfection incidence and risk among people treated for recent hepatitis C virus infection - (09/12/23)
     
  235. Mavyret + Sofosbuvir (RBV) for Sof/Vel/Vox Failures - (08/27/23)
     
  236. New CDC HCV Acute, Chronic & Deaths in USA: doubled acute cases; death rates highest among 55-74 year-olds - (08/19/23)
     
  237. IAS: HIV-1 Low level viremia predicts virological failure in first-line and second-line ART experienced individuals in India - (08/14/23)
     
  238. IAS: Dynamics of cellular senescence markers after HCV elimination spontaneously or by DAAs in people living with HIV - (08/14/23)
     
  239. Hepatitis C Treatment Initiation Among US Medicaid Enrollees - (08/09/23)
     
  240. High Mortality despite SVR Cure Due to Lack of Surveillance & Continued Drug/Alcohol Use - (08/09/23)
     
  241. HCV DAA Costs & Use Gilead Millman Report - (08/09/23)
     
  242. IAS: Integrating hepatitis C services into ART clinics in low and middle income countries (LMICs) as an approach toward hepatitis C micro-elimination: pilot experience in Nigeria - (08/07/23)
     
  243. IAS: Risk of hepatitis C infection following bacterial sexually transmissible infections among gay and bisexual men in Australia 2016-2020 - Mark Mascolini (08/03/23)
     
  244. IAS: Triple Test and Treat for HIV/HBV/HCV-Simple Way to Slow Hep Epidemics? - Mark Mascolini (08/03/23)
     
  245. IAS: STIs Tied to Higher Risk of New HCV Infection in Gay and Bisexual Men - Mark Mascolini - (07/24/23)
     
  246. HCV Care Cascade 26% SVR Rate - (07/06/23)
     
  247. CDC Reports 34% or less HCV Cured - Hepatitis C Virus Clearance Cascade - United States, 2013-2022 - (07/05/23)
     
  248. EASL: HCV and HBV prevalence and associated risk factors among people who inject drugs in Kenya - (07/05/23)
     
  249. EASL: HCV and HBV prevalence and associated risk factors among people who inject drugs in Kenya - (07/05/23)
     
  250. EASL: Effectiveness of a direct care action strategy at the drug addiction center (test and treat in point of care) for the detection and treatment of hepatitis C in drug users on opioid agonist substitution therapy - (07/05/23)
     
  251. EASL: Finding undiagnosed hepatitis C cases: using machine learning to identify clinical attributes and social determinants of health to improve the screening-to-diagnosis ratio and improve efficiency and linkage to care - (07/05/23)
     
  252. EASL: Est. 1.7 Milllion HCV+ in EU/EEA Estimation of prevalence of chronic HCV infection in EU/EEA countries using multiparameter evidence synthesis - (07/05/23)
     
  253. EASL: Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in DAA failure patients: an integrative analysis - (06/30/23)
     
  254. EASL: Trends in hepatitis B and hepatitis C related hepatocellular carcinoma - Increasing Cases, 2015 to 2030 - (07/02/23)
     
  255. EASL: Risk of developing cancer - comparison of HBV, HCV, and smoking - (07/02/23)
     
  256. EASL: Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in DAA failure patients: an integrative analysis - (06/30/23)
     
  257. EASL: Outcomes of early vs late treatment initiation in solid organ transplantation from HCV NAT+ donors to HCV-uninfected recipients: Results from the HCV-TARGET study - (06/30/23)
     
  258. EASL: Unusual HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients - (06/30/23)
     
  259. EASL: Evaluating utilization and management of comedications with potential for drug-drug interactions among patients with chronic hepatitis C initiating treatment with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir - (06/30/23)
     
  260. EASL: Concomitant use of Proton Pump Inhibitors and Sofosbuvir/Velpatasvir: Evidence from Randomized Clinical Trials and Real-World Data - (06/30/23)
     
  261. EASL: Achieving hepatitis C micro-eliminating in 4 female prisons through a nurse led test and treat approach of pathway optimisation and whole prison testing - (06/30/23)
     
  262. EASL: HCV micro-elimination strategy in a tertiary hospital: identification of lost cases and linkage to care - (06/30/23)
     
  263. EASL: HCV screening before endoscopy in hepatogastroenterology outpatient clinic: results of DEPISTC-ENDO study - (06/30/23)
     
  264. EASL: Improving blood borne virus screening in immigration removal centres in the UK - (06/30/23)
     
  265. EASL: AUTOMATION OF HEPATITIS C SCREENING IN THE HOSPITAL SETTING BASED ON EXTRAHEPATIC MANIFESTATIONS AND RISK PROFILE. PRELIMINARY RESULTS FROM THE HOSPITALS WITHOUT C PROGRAM (HOSPITALES SIN C) - (06/30/23)
     
  266. EASL: Screening for hepatitis C virus using rapid diagnostic test (RDT) coupled with mammography in women aged from 50 to 74 years in Montpellier (France). (Mamm'OC NCT05067374) - (06/30/23)
     
  267. EASL: Simple Record Review Finds 37% With HCV Who Fell Between Care Cascade Cracks - Mark Mascolini (06/30/23)
     
  268. EASL: The risks of first hepatic decompensation and HCC remain constant during long-term follow-up and can be stratified by a one-time assessment after HCV-cure - (06/30/23)
     
  269. EASL: A prospective, pragmatic post-authorisation safety study of early recurrence of hepatocellular carcinoma in hepatitis C virus-infected patients after direct-acting antiviral (DAA) therapy: DAA-PASS - Mark Mascolini (06/30/23)
     
  270. EASL: Achieving Hepatitis C micro-elimination in 4 female prisons through a nurse led test and treat approach of pathway optimisation and whole prison testin - (06/30/23)
     
  271. EASL: HCV & HBV Summary Wrap-Up/ Lost Our Way on HCV - (06/30/23)
     
  272. EASL: Final results of a hepatitis C micro-elimination campaign in a highly endemic, well-defined demographic area of peri-urban Karachi, Pakistan. - (06/26/23)
     
  273. EASL: Estimating the Economic Value Allocation of the Social Surplus Generated by the Utilization of All-Oral Direct-Acting Antivirals for Hepatitis C in the United States, 2015-2019 - (06/26/23)
     
  274. EASL: CHALLENGES AND STRATEGIES TO IMPROVE LINKAGE TO CARE AND TREATMENT FOR HEPATITIS C IN PREGNANCY: PERSPECTIVES FROM A GLOBAL COMMUNITY OF PRACTICE - (06/26/23)
     
  275. EASL: Care cascade for perinatal HCV and implications of early RNA testing (46% tested)a - (06/26/23)
     
  276. EASL: Achieving a Hepatitis C cure in those with hepatocellular carcinoma is associated with an improvement in overall survival: Real world data - (06/26/23)
     
  277. EASL: HCV Screening Rates in Reproductive Age Women After Universal Screening Guidelines - (06/26/23)
     
  278. EASL: Most vulnerable HCV patient groups (PWID) treated with direct acting antivirals achieve high response rates and gain quality of life - Data from the German Hepatitis C-Registry (DHC-R) - (06/26/23)
     
  279. EASL: HCV elimination in persons living with HIV (PLWH): the NoCo (No-Coinfection) study of the ICONA network - (06/26/23)
     
  280. EASL: The prevalence of hepatitis C virus infection in high-risk patients with high normal alanine aminotransferase (ALT) in Israel: A bio bank analysis - (06/26/23)
     
  281. EASL: The Impact of HCV cure on glycemic indices in patients using glecaprevir/pibrentasvir from nationwide Taiwan HCV registry - (06/26/23)
     
  282. EASL: Same Day Test, treat and cure patients with CHC undergoing opioid agonist substitution therapy at Drug Addiction Center - (06/26/23)
     
  283. EASL: Cost-effectiveness analysis of a new paradigm to simplify testing, monitoring and treatment of hepatitis C virus in the United States - (06/26/23)
     
  284. EASL: Real-life effectiveness of VOX/SOF/VEL in hepatitis C patients previously treated with SOF/VEL or GLE/PIB - (06/26/23)
     
  285. EASL: Sofosbuvir/ Velpatasvir/ Voxilaprevir for DAA-experienced HCV Patients: A Systematic Review and Meta-Analysis - (06/26/23)
     
  286. EASL: Sofosbuvir/Velpatasvir (S/V) For The Treatment Of HCV Infection Among Vulnerable Inner-city (PWID) Residents: Extending The Results Of Clinical Trial Part 2 - (06/26/23)
     
  287. EASL: Cascade of care and HCV treatment of inner city (PWID) populations engaged in care through community pop-up clinics (CPCs) SVR 97% - (06/26/23)
     
  288. EASL: Sofosbuvir/Velpatasvir (S/V) For The Treatment Of HCV Infection Among Vulnerable Inner-city (PWID) Residents: Extending The Results Of Clinical Trial Part 2 - (06/26/23)
     
  289. EASL: Real-world Data on Long-term Quality Of Life After Glecaprevir/Pibrentasvir Therapy: Data From the German Hepatitis C Registry (DHC-R) - (06/26/23)
     
  290. EASL: Results of the hepatitis B and C screening within the "Check-Up35+" in the German primary care setting one year after implementation by the Federal Joint Committee - (06/26/23)
     
  291. EASL: Real-world Data on Long-term Quality Of Life After Glecaprevir/Pibrentasvir Therapy: Data From the German Hepatitis C Registry (DHC-R) - (06/26/23)
     
  292. EASL: Viral hepatitis C: Therapy and resistance Retreatment of patients experiencing failure with Hepatitis C direct-acting antivirals. Sof/Vel/Vox, G/P+Sof - (06/26/23)
     
  293. EASL: Predictors of long-term mortality after HCV eradication among PLWH - (06/26/23)
     
  294. EASL: HCV elimination in persons living with HIV (PLWH): the NoCo (No-Coinfection) study of the ICONA network - (06/26/23)
     
  295. Glecaprevir/Pibrentasvir is safe and effective in Italian patients with chronic Hepatitis C aged 75 years or older: a multicenter study (Global Hepatitis Summit 2023 April Paris) - (06/07/23)
     
  296. IDSA/AASLD changes in HCV guidance: An update on the latest recommendations - (06/05/23)
     
  297. Barriers and enablers to testing for hepatitis C virus infection in people who inject drugs - (06/05/23)
     
  298. Global HCV Cascade No Progress/Worse Liver Deaths/HCC Increase Expected 2015-2020 Modelling
    Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study     - (06/05/23)
     
  299. CDC New Increasing HCV Cases 2019-2020 Rates by State - (06/01/23)
     
  300. Updated HCV Maternal Infection Rates - (05/23/23)
     
  301. A Proclamation on National Hepatitis Testing Day, 2023 by Pres. Biden - (05/22/23)
     
  302. NYS HCV Treatment OTPs Billing Guide - (05/19/23)
     
  303. HCV DAAs During Pregnancy - (05/17/23)
     
  304. Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals - (05/12/23)
     
  305. HCV Debrief: Global Hepatitis Summit 2023 - (05/08/23)
     
  306. CDC: Trends and Characteristics in Maternal Hepatitis C Virus Infection Rates During Pregnancy: United States, 2016-2021 - (05/03/23)
     
  307. Efficacity of two last-generation DAA in infrequent Hepatitis C genotypes/subtypes: Real-world data from the Centre hospitalier de l'Universite de Montreal - (Global Hepatitis Summit 2023 April 28 Paris) - (05/01/23)
     
  308. Virological characterization of treatment failures and retreatment outcomes in patients infected with "unusual" HCV genotype 1 subtypes (Global Hepatitis Summit 2023, Paris April 28) - (05/01/23)
     
  309. Hepatitis C Care Cascade and Progress Toward Elimination in the United States, 2021 (Global Hepatitis Summit 2023, Paris April 28) - (05/01/23)
     
  310. Hard to treat Genotypes Are Treatable with G/P & Sof/Vel/Vox (Global Hepatitis Summit 2023, April 28 Paris) - (05/01/23)
     
  311. 25% Decline in HCV Treatment/Cure 2021 vs 2019 (Global Hepatitis Summit 2023, Paris April 28) - (05/01/23)
     
  312. HCV DAA Updated 2023 Treatment Restrictions Developing a Continuum of Care (Care Cascade) for Hepatitis C - (04/21/23)
     
  313. Estimated Number of People Who Inject Drugs in the United States - (04/21/23)
     
  314. Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct-acting antivirals - (04/18/23)
     
  315. Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis - (04/18/23)
     
  316. Overcome Health Inequities to Eliminate Viral Hepatitis - (04/18/23)
     
  317. HCV in Pregnancy Increased 10-Fold - Deliveries Among Patients With Maternal Hepatitis C Virus Infection in the United States, 2000-2019 - (04/11/23)
     
  318. The number of new cases and deaths from liver cancer could rise by >55% by 2040. Global burden of primary liver cancer in 2020 and predictions to 2040 - (04/09/23)
     
  319. Early Adherence Predicts SVR in ACTG MINMON study Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment - (04/04/23)
     
  320. FDA approves over-the-counter sales of lifesaving opioid overdose treatment Narcan nasal spray - (04/04/23)
     
  321. CROI: CLINICAL AND LABORATORY OUTCOMES OF HEPATITIS C TREATMENT IN AN ACUTE HIV COHORT - (03/22/23)
     
  322. CROI: Risk factors for liver fibrosis progression in HIV: a multi-center longitudinal study - (03/16/23)
     
  323. CROI: Summary from CROI 2023 for HIV and liver disease What is new in viral hepatitis coinfection? Is fatty liver disease a growing concern? New insights from CROI 2023. - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/16/23)
     
  324. CROI: Sofosbuvir/Velpatasvir Pharmacokinetics in Pregnant Women with Hepatitis C Virus - (03/14/23)
     
  325. Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States - (03/14/23)
     
  326. A National Hepatitis C Elimination Program in the United States - A Historic Opportunity - (03/14/23)
     
  327. Biden $5 Bill HCV Ask for HCV Elimination in New Budget Submitted to Congress - (03/14/23)
     
  328. CROI: Intervention efficacy on COVID-19 testing and vaccination in people who inject drugs - Mark Mascolini (03/02/23)
     
  329. CROI: PRIMARY HCV INCIDENCE AMONG MSM USING PREP AND MSM WITH HIV IN NEW YORK CITY 2012-2022 - (03/01/23)
     
  330. CROI: TARGET3D: glecaprevir-pibrentasvir for four weeks among people with recent HCV infection - (02/23/23)
     
  331. Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection - (02/19/23)
     
  332. Global- Only 2% & 13% of HCV & HBV Infections Treated - (02/15/23)
     
  333. Homeless HCV Treatment-Holistic Care - Patient Centered Required - (02/09/23)
     
  334. Recommendations for Implementing Hepatitis C Virus Care in Homeless Shelters: The Stakeholder Perspective - (02/09/23)
     
  335. Treating Hepatitis C in Individuals With Previous Incarceration: The Veterans Health Administration, 2012-2019 - (02/08/23)
     
  336. New WHO study: Making diagnosis of hepatitis C more accessible and closer to the community using point-of-care HCV viral load assays - (02/03/23)
     
  337. HCV Treatment During Pregnancy; Guidelines, New Study; Outcomes Among Pregnant Women With HCV - (02/01/23)
     
  338. Modelling the potential effectiveness of hepatitis C screening and treatment strategies during pregnancy in Egypt and Ukraine - (01/18/23)
     
  339. New Street Drugs Xylazine + Fentanyl Replacing "street heroin" - Widespread Distribution of Xylazine Detected Throughout the United States in Healthcare Patient Samples - (01/10/23)
     
  340. Increasing presence of xylazine in heroin and/or fentanyl deaths, Philadelphia, Pennsylvania, 2010-2019 - Fentanyl & xylazine have replaced heroin in "street heroin" - (01/10/23)
     
  341. "Travesty" of US Not Dealing with HCV - (01/07/23)
     
  342. IDUs - HCV DAA High Adherence 90% & SVR Among IDUs at Buffalo Clinic - (01/22/22)
     
  343. Postpartum Follow-up Care for Pregnant Persons With Opioid Use Disorder and Hepatitis C Virus Infection - (01/22/22)
     
  344. Reverse inflammaging: Long-term effects of HCV cure on biological age - (12/22/22)
     
  345. Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment - (12/21/22)
     
  346. Low Treatment & SVR Rates on MOUD - Medications for opioid use disorder (MOUD; eg, buprenorphine, methadone, and extended-release naltrexone), 10.6% SVR - (12/21/22)
     
  347. HCV in NY -Disparities/Cancer Deaths Up, Older People New Cases Up - (12/19/22)
     
  348. New Texas Hepatitis C Treatment Coverage and PDL Update Scheduled for January 1, 2023 - Prior Authorization Not Required, Drug Screening Not required - (12/19/22)
     
  349. Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C - (12/14/22)
     
  350. AASLD: Time from HCV testing to subspecialty care linkage and DAA initiation in the Philadelphia jail system - (12/13/22)
     
  351. AASLD: Routine opt out hepatitis C testing upon intake in the Philadelphia jail system - (12/13/22)
     
  352. Impact of Direct-Acting Antiviral Use for Chronic Hepatitis C on Health Care Costs in Medicaid: Economic Model Update - (12/13/22)
     
  353. Justice Department Secures Agreement with Alabama Medicaid to Remove Unlawful Sobriety Mandate for Health Care Access - (12/13/22)
     
  354.  Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States - (12/12/22)
     
  355. Diabetes medications and risk of HCC - (12/12/22)
     
  356. Global burden of primary liver cancer in 2020 and predictions to 2040 - (11/30/22)
     
  357. Patient-centred models of hepatitis C treatment for people who inject drugs (HERO Study): a multicentre, pragmatic randomised trial - (11/30/22)
     
  358. AASLD: 3 Hot HCV Posters: Fatty Liver in HCV cured; Cannabis Slows Liver improvement; Non-invasive HCC prediction test; - (11/30/22)
     
  359. AASLD: NEGATIVE IMPACT OF CANNABIS CONSUMPTION ON THE REGRESSION OF THE HEPATIC FIBROSIS AFTER SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PATIENTS WITH CHRONIC HCV INFECTION TREATED WITH DIRECT ACTING ANTIVIRALS - (11/30/22)
     
  360. AASLD: HCV PI vs Non-PI DAA in Advanced Cirrhosis - Outcomes Real-World REAL-C study - (11/29/22)
     
  361. AASLD: HCC Risk in HCV After SVR in Cirrhosis or No Cirrhosis - (11/29/22)
     
  362. AASLD: Screening, linkage, to care and treatment of chronic hepatitis C infection in high-risk populations in Hong Kong - (11/28/22)
     
  363. AASLD: An Innovative Model to Eradicate HCV in Undocumented Migrants and Low-Income Refugees in Italy - (11/28/22)
     
  364. AASLD: Models to Eliminate HCV in the USA: A Multisite Randomized Pragmatic Trial of Patient-Centered Models of Hepatitis C Treatment for People Who Inject Drugs: The HERO Study - (11/28/22)
     
  365. AASLD: Real-World Treatment Outcome with Protease Inhibitor (PI) vs Non-PI Direct Acting Antivirals (DAAs) in advanced HCV Cirrhosis: A REAL-C study - (11/28/22)
     
  366. New Study HCV Treatment During Pregnancy - Enrollment Open STORC Study - (11/22/22)
     
  367. AASLD: Hepatocellular Carcinoma: State of the Art - missing is & Post HCV Cure Surveillance in Patients with Cirrhosis ! - (11/21/22)
     
  368. AASLD: Effect of DAA treatment on extrahepatic manifestations incidence: a population-based study in British Columbia, Canada - (11/21/22)
     
  369. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study - (11/17/22)
     
  370. AASLD: THE AGILE 3+ AND 4 SCORES MOST ACCURATELY PREDICT MAJOR ADVERSE LIVER OUTCOMES AND DEATH COMPARED TO LIVER STIFFNESS MEASUREMENT AND FIBROSCAN- AST SCORE - (11/17/22)
     
  371. AASLD: CORRELATES OF HCV REINFECTION AMONG ACTIVE DRUG USERS - (11/17/22)
     
  372. AASLD: AN INNOVATIVE MODEL TO ENSURE ACCESS TO HCV TREATMENT AMONG VULNERABLE INNER CITY RESIDENTS IN COVIDWORLD - (11/17/22)
     
  373. AASLD: HCV TREATMENT AMONG FENTANYL USERS: TOWARD UNIVERSAL ACROSS TO ANTIVIRAL THERAPY - (11/17/22)
     
  374. AASLD: The impact of direct-acting antiviral treatment for HCV on hepatocellular carcinoma risk in a large population-based cohort study - (11/17/22)
     
  375. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review - (11/15/22)
     
  376. AASLD: A National Plan to Eliminate Hepatitis C, White House - (11/14/22)
     
  377. AASLD: HCV Elimination Review: Target PWUDs for Treatment - EXCELLENT CURE RATES DESPITE INCREASING COMPLEXITY OF PEOPLE WHO USE DRUGS: FINAL CLINICAL OUTCOMES FROM THE ITTREAT HCV SERVICE - (11/14/22)
     
  378. AASLD: Use of Psychiatric Medication and Drug-Drug Interactions in Patients with HCV Infection Treated with Pangenotypic Direct-Acting Antivirals - (11/14/22)
     
  379. AASLD: Risk factor of hepatocellular carcinoma occurrence after sustained virologic responses in hepatitis C virus patients without advanced liver fibrosis - (11/14/22)
     
  380. EASL: Curing HCV with Direct-Acting Antiviral (DAA) Treatment: Adherence and Rapid Onset of HCV-RNA Undetectability after 4 Weeks of Treatment with Sofosbuvir/Velpatasvir - (11/10/22)
     
  381. AASLD: Young Recent Drug Injectors Run High HCV Reinfection Risk in BC - Mark Mascolini (11/10/22)
     
  382. AASLD: Cirrhosis Linked to More Than Doubled Odds of Severe COVID - Mark Mascolini (11/10/22)
     
  383. AASLD: Updated evaluation of global progress towards HBV and HCV elimination, preliminary data through 2021 (not good) - (11/10/22)
     
  384. AASLD: Liver-Related Mortality Soared in US After COVID-19 Arrived - Mark Mascolini (11/10/22)
     
  385. AASLD: CHANGES IN MORTALITY DUE TO CHRONIC LIVER DISEASES (CLD) DURING THE COVID- 19 PANDEMIC: DATA FROM THE UNITED STATES' NATIONAL VITAL STATISTICS SYSTEM - (11/10/22)
     
  386. AASLD: Increasing time since eradication of HCV is independently associated with a lower risk of HCC - (11/09/22)
     
  387. AASLD: Glecaprevir/Pibrentasvir (G/P) and Ezetimibe for 8 Days Should Be the New Standard of Care With 100% Efficacy to Prevent Chronic HCV Infection in Non-liver Solid Organ Transplant (Sot) Recipients of HCV-VIREMIC Grafts - (11/09/22)
     
  388. AASLD: Patients with chronic hepatitis C could be treated with Sofosbuvir/Velpatasvir for 12 weeks by non-specialists: 2nd interim analysis of prospective study Helios-3 - (11/09/22)
     
  389. AASLD: Effectiveness of ReLink initiatives to re-engage diagnosed-but-untreated HCV-positive patients with direct-acting antiviral treatment Effectiveness of ReLink initiatives to re-engage diagnosed-but-untreated HCV-positive patients with direct-acting antiviral treatment - (11/09/22)
     
  390. AASLD: The Kentucky Viral Hepatitis Treatment Project (KeY Treat): Preliminary Outcomes from a Phase 4 Clinical Trial in Rural Appalachia - (11/09/22)
     
  391. AASLD: HCV Treatment Rates Decreased During COVID: CHARACTERISTICS AND TREATMENT RATE OF PATIENTS WITH HEPATITIS C VIRUS INFECTION IN THE DAA AND COVID- 19 ERAS IN THE UNITED STATES - (11/09/22)
     
  392. AASLD: ULTRA- SHORT COURSE GLECAPREVIR/PIBRENTASVIR WITH EZETIMIBE IN THE PREVENTION OF HEPATITIS C (HCV) TRANSMISSION FROM HCV- POSITIVE ORGAN DONORS TO HCV- NEGATIVE RECIPIENTS: ONGOING EXPERIENCE - (11/08/22)
     
  393. AASLD: EARLY INITIATION OF GLECAPREVIR AND PIBRENTASVIR AFTER TRANSPLANTATION OF HCV- VIREMIC INTO HCV- UNINFECTED KIDNEY TRANSPLANT RECIPIENTS RAPIDLY NORMALIZES HCV- INDUCED ALTERATIONS IN THE SOLUBLE INFLAMMATORY MILIEU - (11/08/22)
     
  394. AASLD: CASCADE OF CARE FOR CHRONIC HCV INFECTION IN A LARGE HOMELESS METROPOLITAN POPULATION - (11/08/22)
     
  395. AASLD: HCV Universal EHR Prompt Successfully Increases Screening, Highlights Potential Disparities - (11/08/22)
     
  396. AASLD: EHR HCV Screening - OPTIMIZING HIGH- RISK HEPATITIS C VIRUS (HCV) IDENTIFICATION BY THE INCLUSION OF STRUCTURED, SEMI- STRUCTURED AND FREE- TEXT ELECTRONIC HEALTH RECORD DATA - (11/08/22)
     
  397. AASLD: HEPATITIS C VIRUS PREVALENCE AND OUTCOMES AMONG PREGNANT WOMEN WHO INJECT DRUGS - (11/08/22)
     
  398. AASLD: 67% Remain Untreated - Burden of Illness Associated with Remaining Untreated Following a Diagnosis of Chronic Hepatitis C Virus - (11/08/22)
     
  399. AASLD: Under Two Thirds With Viremic HCV and Insurance Get DAAs in US - Mark Mascolini (11/08/22)
     
  400. AASLD: Curing HCV with Direct-Acting Antiviral (DAA) Treatment: Adherence and Rapid Onset of HCV-RNA Undetectability after 4 Weeks of Treatment with Sofosbuvir/Velpatasvir - (11/08/22)
     
  401. AASLD: Effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients previously treated with direct-acting antiviral agents (DAA) - (11/08/22)
     
  402. AASLD: Burden of Illness Associated with Remaining Untreated Following a Diagnosis of Chronic Hepatitis C Virus - 67% Untreated - (11/07/22)
     
  403. AASLD: FINAL ANALYSIS OF THE GRAND PLAN STUDY: EFFICACY OF 8 weeks GLECAPREVIR/PIBRENTASVIR (G/P) FOR HCV- INFECTED PEOPLE WHO USE DRUGS (PWUD) DISENGAGED FROM HEALTH CARE: A SYSTEMATIC APPROACH TO ENGAGEMENT AND HCV TREATMENT - (11/07/22)
     
  404. AASLD: Early initiation of glecaprevir and pibrentasvir after transplantation of HCV-viremic into HCV-uninfected kidney transplant recipients rapidly normalizes HCV-induced alterations in the soluble inflammatory milieu - (11/07/22)
     
  405. AASLD: An HCV transmission model for evaluating complex treatment policies in people who inject drugs (PWID), prisoners, and the general population - (11/07/22)
     
  406. AASLD: Estimating the HCV treatment reach in high-risk groups in order to meet 2030 WHO elimination targets - (11/07/22)
     
  407. AASLD: High HCV SVR in Rural US Group With Heavy Use of Opioids, Other Drugs - Mark Mascolini (11/07/22)
     
  408. AASLD: Burden of Illness Associated with Remaining Untreated Following a Diagnosis of Chronic Hepatitis C Virus - 67% Untreated - (11/07/22)
     
  409. AASLD: FINAL ANALYSIS OF THE GRAND PLAN STUDY: EFFICACY OF 8 weeks GLECAPREVIR/PIBRENTASVIR (G/P) FOR HCV- INFECTED PEOPLE WHO USE DRUGS (PWUD) DISENGAGED FROM HEALTH CARE: A SYSTEMATIC APPROACH TO ENGAGEMENT AND HCV TREATMENT - (11/07/22)
     
  410. AASLD: Early initiation of glecaprevir and pibrentasvir after transplantation of HCV-viremic into HCV-uninfected kidney transplant recipients rapidly normalizes HCV-induced alterations in the soluble inflammatory milieu - (11/07/22)
     
  411. AASLD: An HCV transmission model for evaluating complex treatment policies in people who inject drugs (PWID), prisoners, and the general population - (11/07/22)
     
  412. AASLD: Estimating the HCV treatment reach in high-risk groups in order to meet 2030 WHO elimination targets - (11/07/22)
     
  413. AASLD: High HCV SVR in Rural US Group With Heavy Use of Opioids, Other Drugs - Mark Mascolini (11/07/22)
     
  414. Administration eyes national hepatitis C treatment plan - (11/01/22)
     
  415. ID Week: A Step Toward Universal HCV Screening: Write a Letter - Mark Mascolini (10/23/22)
     
  416. ID Week: HEPATITIS C CASCADE OF CARE IN A MULTIDISCIPLINARY SUBSTANCE USE BRIDGE CLINIC MODEL - (10/23/22)
     
  417. ID Week: Hepatitis C Treatment as a Complement to Syringe Service Programs: Pilot Progress and Pathways Forward - (10/23/22)
     
  418. ID Week: Analysis of an Automated Letter HCV Screening Program within a Veterans Affairs Health System: Implications for Universal HCV Screening - (10/23/22)
     
  419. ID Week: Screening for Hepatitis C as Part of an Opioid Stewardship Initiative: Identifying Infected Patients and Analyzing Linkage to Care - (10/23/22)
     
  420. High HCV Death Rates in NYC; Estimating the Number of IDUs in the USA - (09/29/22)
     
  421. HCV Elimination; states failing efforts - (09/14/22)
     
  422. Letter to the Editor: Successful treatment of multidrug resistant hepatitis C after >12 months of continuous therapy with direct-acting antivirals - (08/17/22)
     
  423. CDC: Too Few People - 33% - Treated for Hepatitis C - Reducing Barriers Can Increase Treatment and Save Lives - (08/15/22)
     
  424. 30% of HCV+ Adults Start DAAs Within 360 Days - CDC - Low HCV Treatment Rates - Disparities Persist - (08/15/22)
     
  425. IAC: Putting HBV/HCV Testing and Treatment in HIV Clinics Has Benefits in Vietnam - Mark Mascolini - (08/03/22)
     
  426. Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection - (07/25/22)
     
  427. EASL: Early post liver transplant rescue treatment with sofosbuvir/velpatasvir/voxilaprevir in patients experienced to NS5A-inhibitors - (07/18/22)
     
  428. EASL: Approaches for a Hepatitis C-free city: preliminary results - (07/18/22)
     
  429. EASL: A cluster randomized controlled study of secondary distribution of HCV self-test to support micro-elimination in Karachi, Pakistan - (07/18/22)
     
  430. EASL: From extensive to intensive screening, co-operation model of hepatitis C elimination in out-patients and people who inject drug population in southwest of China - (07/18/22)
     
  431. EASL: Improved recurrence-free survival rates in patients with HCV-related hepatocellular carcinoma and sustained virological response to direct-acting antivirals - (07/18/22)
     
  432. EASL: Hepatocellular carcinoma risks of liver fibrosis changes after viral eradication in chronic hepatitis C patients - (07/18/22)
     
  433. EASL: Evaluation of the clinical and economic value of sofosbuvir / velpatasvir (SOF / VEL) in patients with chronic hepatitis C in Spain during the last 5 years - (07/14/22)
     
  434. EASL: Reverse Inflammaging: Biological age in HCV after cure - (07/11/22)
     
  435. EASL: Screening for hepatitis C in Denmark- the effect of a mobile outreach intervention - (07/11/22)
     
  436. EASL: Change in fibrosis and clinical progression three years after sustained virological response induced by direct antiviral agents in HIV/HCV subjects - (07/11/22)
     
  437. EASL: Hepatitis C virus reinfection [high] following direct acting antiviral treatment in the prison setting: the SToP-C study - (07/11/22)
     
  438. EASL: Macroeconomic assessment of overall and per-patient healthcare costs of Hepatitis C-infected patients in an integrated health system in the era of direct-acting antiviral therapy - (07/11/22)
     
  439. EASL: Point of care [Cepheid GeneXpert assay] testing for hepatitis C in mental health, prison and drug & alcohol settings - (07/11/22)
     
  440. EASL: HCV Rapid Xpert Point-of-Care Fingerstick Onsite at Addiction Centers in France - (07/11/22)
     
  441. EASL: HCV Homeless Mobile Van with Rapid Xpert Cepheid RNA Test - (07/11/22)
     
  442. EASL: Maximizing the potential of Cepheid, GeneXpert PCR rapid testing for hepatitis C through use of finger prick blood samples collected into EDTA capillary tubes - (07/11/22)
     
  443. EASL: HEALTH ECONOMIC OUTCOMES OF A5360 MINMON - (07/08/22)
     
  444. EASL: Hepatitis C Screening Rates in NY by Age Cohort 1945-1965 in a Large, Community Health System (Northwell), Before, During and After the COVID Pandemic - (07/08/22)
     
  445. Can treatment, without prevention, eliminate hepatitis C among men who have sex with men? Commentary - (07/08/22)
     
  446. The 'Viennese epidemic' of acute HCV in the era of direct-acting antivirals - (07/08/22)
     
  447. EASL: Towards elimination: A clinical and public health approach to control of hepatitis C and B infection in England - (07/07/22)
     
  448. EASL: Excess mortality risk among hepatitis C patients after being ''cured'' in the interferon-free era: results from three population-based cohorts - (07/07/22)
     
  449. EASL: Associations Between Serum Biomarkers Chitinase-2-Like Protein, Type IV Collagen, and Thrombospondin-2 With Fibrosis Stage and Clinical Outcome in Patients With Primary Sclerosing Cholangitis - (07/07/22)
     
  450. EASL: HCV cure in people with psychiatric disorders is associated with a global reduction in hospitalizations - (07/02/22)
     
  451. EASL: Identifying risk factors associated with hepatitis C virus infection in participants in the National Health and Nutrition Examination Survey using Super Learner - (07/02/22)
     
  452. EASL: Multicenter prospective study for the use of shortened pre-emptive therapy with Glecaprevir/Pibrentasvir (G/P) and Ezetimibe in hepatitis C (HCV) seronegative non-liver solid organ transplant recipients of HCV viremic grafts - (07/02/22)
     
  453. EASL: Micro-eliminating Hepatitis C in a network of 48 English Prisons through an industry, prison healthcare and patient organisation partnership - (07/02/22)
     
  454. EASL: The disease burden of hepatitis B and hepatitis C from 2015 to 2030: the long and winding road New HBV and HCV Projected to Decline Thru 2030, But New HCC Cases Will Rise for both HCV & HBV, HBV liver related deaths expected to increase by 30% - Mark Mascolini - (07/01/22)
     
  455. EASL: GLE/PIB + SOF Effective After Failure of Prior DAAs, Including GLE/PIB - Mark Mascolini - (07/01/22)
     
  456. EASL: Waist-to-Hip Ratio Predicts Liver Disease Better Than Body Mass Index - Mark Mascolini - (07/01/22)
     
  457. EASL: Risk of Dangerous Interactions When Giving DAAs With Other Meds - Mark Mascolini - (07/01/22)
     
  458. EASL: DAAs Cut Cardio Event Rate in HCV+ But Boost Arrhythmia Risk - Mark Mascolini - (07/01/22)
     
  459. EASL: All-Cause Mortality 3 to 15 Times Higher After HCV SVR Than in General Population - Mark Mascolini - (07/01/22)
     
  460. EASL: One Third With HDV Respond to Bulevirtide Monotherapy Through 24 Weeks (2 & 10 mg) - Integrated Analysis from 2 Phase 2 & 1 Phase 3 Trials - Mark Mascolini - (07/01/22)
     
  461. EASL: The 'Viennese epidemic' of acute HCV in the era of direct - acting antivirals - (06/30/22)
     
  462. EASL: Randomized controlled trial of home-based hepatitis C self-testing for key populations in Malaysia - (06/30/22)
     
  463. EASL: Evidence of Past Hepatitis C and D Co-Infection in Hepatitis B Seronegative Individuals - (06/27/22)
     
  464. EASL: EASL 2022 HCV Wrap-Up: Very Far from WHO Goals-HCC & Deaths Increasing-Infections Not Improving Much - (06/27/22)
     
  465. EASL: Glecaprevir/pibrentasvir & sofosbuvir for 16 weeks without ribavirin is safe and highly effective retreatment for patients who have failed an NS5A inhibitor containing antiviral regimen - (06/27/22)
     
  466. EASL: The disease burden of hepatitis B and C from 2015- 2030: The long and winding road towards elimination - (06/27/22)
     
  467. EASL: The Global Burden of Liver Cancer (LC) and Chronic Liver Diseases (CLD) is Driven by Nonalcoholic Steatohepatitis (NASH) and Alcohol Liver Disease (ALD) - (06/27/22)
     
  468. EASL: Voxilaprevir/Velpatasvir/Sofosbuvir Efficacy in hepatitis C patients previously treated with direct-acting antiviral agents (DAA) VOX/VEL/SOF Effective Rescue After DAA Failure-With Limits - Mark Mascolini (06/25/22)
     
  469. EASL: Effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients previously treated with direct-acting antiviral agents (DAA) - (06/25/22)
     
  470. EASL: Full-length genome characterization of inherently resistant african HCV genotype 1, subtype 1l in patients failing DAA-based therapy - (06/24/22)
     
  471. EASL: Impact of Direct-Acting Antiviral Treatment for Hepatitis C on Cardiovascular Diseases and Extrahepatic Cancers - (06/24/22)
     
  472. EASL: Don't Delay Rescue 2nd Line HCV Therapy "Dismal Prognosis" After First DAA Failure in People With Pretreatment Cirrhosis - Mark Mascolini (06/24/22)
     
  473. EASL: Don't Delay DAAs in People Taking Antiepileptics, Elite Experts Advise - Mark Mascolini (06/24/22)
     
  474. EASL: Clinical impact of drug interaction in the use of antipsychotics by HCV patients treated with pangenotypic direct-acting antivirals - (06/24/22)
     
  475. EASL: Infrequent hepatitis C genotypes/subtypes in patients treated with DAA-based regimens: successes and failures - (06/24/22)
     
  476. EASL: Early post liver transplant rescue treatment with sofosbuvir/velpatasvir/voxilaprevir in patients experienced to NS5A-inhibitors - (06/24/22)
     
  477. EASL: Polypharmacy and prevalence of multiple drug-drug interactions in hepatitis C patients treated with pangenotypic direct-acting antivirals: an analysis from three European countries - (06/24/22)
     
  478. EASL: Use of comedication in patients with hepatitis C and addiction or drug abusetreated with direct-acting antivirals: implication in drug-drug interactions - (06/24/22)
     
  479. EASL: Evaluation of Global Progress towards HBV and HCV elimination - off track - (06/23/22)
     
  480. EASL: Healthcare Resource Utilization in Treatment-Naïve Patients With Compensated Cirrhosis Receiving 8-Weeks' Glecaprevir/Pibrentasvir Stratified by Drug Use and Socioeconomic Status: A Retrospective Chart Review - (06/23/22)
     
  481. EASL: Eight Weeks of Glecaprevir/Pibrentasvir is Well Tolerated and Yields High Sustained Virological Response in HCV-Infected Treatment-Naïve Patients With Compensated Cirrhosis: Final Results From the CREST Study - (06/23/22)
     
  482. EASL: Reported Safety of HCV Direct-Acting Antivirals With Opioids: 2017 to 2021 - (06/23/22)
     
  483. EASL: Use of Glecaprevir/Pibrentasvir (G/P) for the treatment of HCV infection among fentanyl users: an interim analysis of the GRAND PLAN study - High Cure Rates - (06/23/22)
     
  484. EASL: Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment naïve patients with compensated cirrhosis: real-world experience from Taiwan HCV Registry - (06/23/22)
     
  485. EASL: Treating HCV in Dual Diagnosis Acute Psychiatric Inpatients with Substance Use Disorder - (06/23/22)
     
  486. EASL: Efficacy and safety of direct-acting antivirals in children and adolescents with chronic hepatitis C virus infection: a systematic review and meta-analysis - (06/23/22)
     
  487. EASL: Association of sustained virologic response with measures of direct-acting antiviral adherence in patients with Hepatitis C: Data from the ASCEND and ANCHOR investigations - (06/23/22)
     
  488. EASL: Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset - in order to achieve HCV Elimination with Focused Treatment Approaches - (06/23/22)
     
  489. EASL: Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: Multicenter, single arm, phase 2 Study The HepNet acute HCV V study - (06/23/22)
     
  490. EASL: Sofosbuvir/Velpatasvir (S/V) for the treatment of HCV infection among vulnerable inner-city residents: extending the results of clinical trial - (06/23/22)
     
  491. EASL: Long-term follow-up of HCV resistance-associated substitutions after DAA treatment failure - (06/23/22)
     
  492. EASL: Real-life effectiveness and safety of sofosbuvir/velpatasvir in difficult to treat hepatitis C patients - (06/23/22)
     
  493. EASL: Establishing a Protocol for Management and DAA Treatment of HCV During Pregnancy: adherence to a co-located care protocol - (06/23/22)
     
  494. EASL: National HCV Paediatric Multidisciplinary Operational Delivery Network (pMDT ODN) - (06/23/22)
     
  495. EASL: From extensive to intensive screening, co-operation model of hepatitis C elimination in out-patients and people who inject drug population in southwest of China - (06/23/22)
     
  496. EASL: REAL-WORLD VALUE AND INNOVATION OF DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF CHRONIC HEPATITIS C AT Kaiser PERMANENTE SOUTHERN CALIFORNIA - (06/23/22)
     
  497. Risk of hepatitis C reinfection following successful therapy among people living with HIV (MSM): a global systematic review, meta-analysis, and meta-regression - (06/09/22)
     
  498. Sofosbuvir-based Therapy for Late Pregnant Women and Infant with Severe Chronic Hepatitis C: A Case Series Study - (05/25/22)
     
  499. Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission - (05/25/22)
     
  500. The Hepatitis C Care Cascade During the Direct-Acting Antiviral Era Within a US Health Claims Database - (05/23/22)
     
  501. Louisiana's HCV Elimination Plan- ("Netflix" Model) - (04/27/22)
     
  502. Overall vertical transmission of HCV, transmission net of clearance, and timing of transmission. - (04/20/22)
     
  503. Overall vertical transmission of HCV, transmission net of clearance, and timing of transmission. - (04/18/22)
     
  504. Curing Hepatitis C-Requires More Than a Prescription - 'accessible care model for injection drug users focused on low-threshold, collocated, destigmatized & flexible care with facilitated referral' - (04/11/22)
     
  505. HCV Treatments in 2020 new data; HCV Death Rates: Characteristics of persons treated for hepatitis C using national pharmacy claims data, United States, 2014-2020 - (04/06/22)
     
  506. Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication - (03/24/22)
     
  507. CROI: EFFICACY & SAFETY OF RAVIDASVIR + SOFOSBUVIR IN HEPATITIS C: STORM-C-1 FINAL RESULTS - (03/24/22)
     
  508. Direct-acting antiviral regimens and HCV treatment failure and re-treatment in sub-Saharan Africa - (03/24/22)
     
  509. Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial - (03/24/22)
     
  510. Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial - (03/24/22)
     
  511. CROI: IMPACT OF SVR WITH DAAs IN COINFECTED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS - (03/22/22)
     
  512. CROI: ADHERENCE IN THE ACTG A5360 HCV MINIMAL MONITORING (MINMON) TRIAL - (03/22/22)
     
  513. CROI: Progress toward HCV microelimination among HIV-positive patients in Taiwan - (03/21/22)
     
  514. CROI: IMPACT OF SVR WITH DAAs IN COINFECTED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS - (03/21/22)
     
  515. CROI: Integration of HIV and HCV Services with Medication for Opioid Use Disorder in the U.S. - (03/21/22)
     
  516. CROI: Summary from virtual CROI 2022 for HIV and liver disease Hepatitis elimination for 2030 on track? Is fatty liver disease a growing concern? New insights from CROI 2022. - Prof. Dr. Jurgen K. Rockstroh Department of Medicine I University Hospital Bonn Venusberg-Campus 1 53127 Bonn Germany - (03/21/22)
     
  517. CROI: Integration of HIV and HCV Services with Medication for Opioid Use Disorder in the U.S. - (03/18/22)
     
  518. Accessible Hepatitis C Care for People Who Inject Drugs - A Randomized Clinical Trial - 67% vs 23% SVR - (03/15/22)
     
  519. Sustained impact of the COVID-2019 pandemic on HCV treatment initiations in the United States - (03/14/22)
     
  520. CROI: IMPACT OF MATERNAL HIV/HBV CO-INFECTION ON PREGNANCY AND INFANT OUTCOMES (02/23/22)
     
  521. CROI: The role of HIV/HBV/HCV triple infection in end stage liver disease (ESLD) and all cause mortality in Europe (02/23/22)
     
  522. CROI: PrEP Indications and PrEP Knowledge, Access, and Interest Among Individuals with HCV - (02/22/22)
     
  523. CROI: HCV MICROELIMINATION AMONG PEOPLE LIVING WITH HIV IN SAN DIEGO: ARE WE ON TRACK? - (02/22/22)
     
  524. CROI: HBIg-Free Strategy Prevents Vertical HBV Transmission-If Mothers Start TDF Soon Enough - Mark Mascolini (02/22/22)
     
  525. CROI: Universal hepatitis C virus screening in pregnancy HCV Testing Quadruples With Switch to Universal Screening in Pregnancy - Mark Mascolini (02/16/22)
     
  526. CROI: EFFECT OF DIRECT-ACTING ANTIVIRALS ON HCV INCIDENCE AMONG PEOPLE LIVING WITH HIV (02/17/22)
     
  527. CROI: COVID Pushes USA Farther Off Course to Meet HCV Elimination Goals - Mark Mascolini (02/17/22)
     
  528. CROI: TREATMENT WITH SOF/VEL/VOX IN HIV-HCV COINFECTED PATIENTS PREVIOUSLY EXPOSED TO DAAs - (02/14/22)
     
  529. CROI: Impact of HCV cure on depressive symptoms in the HIV-HCV co-infected population - (02/14/22)
     
  530. HCV 60 Minute Rapid Screening - Same Day Treatment  FDA Facilitates Approval - (02/05/22)
     
  531. Establishing a Protocol for Management and DAA Treatment of HCV during Pregnancy: Adherence to a Co-Located Care Protocol - (02/05/22)
     
  532. NYS & NYC HCV Elimination Plans by 2030 - (02/05/22)
     
  533. CDC: Older Adults Overlooked - Age 50-69 Highest Chronic HCV Rates along with Young - (02/05/22)
     
  534. Substance Abuse Treatment Facilities - NYC Detox & Tri-State - (02/01/22)
     
  535. Syringe access expansion laws passed by New Jersey Senate and Assembly - (01/25/22)
     
  536. Virginia Medicaid is removing its final barrier to treatment for hepatitis C - (01/19/22)
     
  537. Older adult opioid overdose death rates on the rise - 4 times higher for African-American Men - (01/16/22)
     
  538. NYC HCV Deaths Mostly Blacks & Latinos, Older People 65-84 - (01/18/22)
     
  539. HCV Death Rates in NYS by Age Group, 65-84 Increased 32% - (01/18/22)
     
  540. Liver Cancer Deaths, HCV & HBV HCC Increasing - (01/18/22)
     
  541. NYS Hepatitis C Elimination Virtual Regional Discussion Sessions - (01/13/22)
     
  542. HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers-Led Model for HCV Microelimination in Thailand - (01/03/22)
     
  543. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients - (12/28/21)
     
  544. Gilead Canada launches national educational and screening initiative to address Hepatitis C infections - (12/10/21)
     
  545. AASLD: LONG-TERM EVALUATION OF HCV RE-INFECTION RATES AMONG INNER CITY VULNERABLE POPULATIONS (12/14/21)
     
  546. AASLD: Point-of-Care 60-minute Rapid HCV RNA Screening for IDUs Studies at AASLD & FDA Approval (12/10/21)
     
  547. Gilead Canada launches national educational and screening initiative to address Hepatitis C infections - (12/10/21)
     
  548. Early HCV Treatment During Acute HCV Within few, 6 Months of Infection with Short-Duration of 4-6 Weeks - (12/09/21)
     
  549. HCV TREATMENT AMONG ACTIVE INNER CITY DRUG USERS WITH GLECAPREVIR/PIBRENTASVIR: THE GRAND PLAN STUDY - (12/09/21)
     
  550. Velpatasvir-Based Regimens in Treatment-Naïve and Treatment-Experienced Adults with Resistant HCV GT4 Subtypes Endemic to Sub-Saharan Africa Findings from the SHARED-3 Study in Rwanda - (11/06/21)
     
  551. Pregnancy outcome of anti-HCV direct-acting antivirals: Real-life data from an Egyptian cohort - (11/06/21)
     
  552. AASLD: CONCURRENT FATTY LIVER IS ASSOCIATED WITH HIGHER RISK OF HEPATOCELLULAR CARCINOMA AND MORTALITY IN PATIENTS WITH CHRONIC VIRAL HEPATITIS (12/03/21)
     
  553. AASLD: HCV Prior Authorization & Elimination Barriers - One Small Step for Rhode Island Medicaid, One Giant Leap Towards Hepatitis C Elimination (12/03/21)
     
  554. AASLD: RESULTS OF A TEN YEAR PROSPECTIVE OBSERVATIONAL STUDY ON ACUTE HEPATITIS C IN HCV-MONO- AND HCV/HIV- COINFECTED PATIENTS (12/03/21)
     
  555. AASLD: TREATMENT OF HEPATITIS C RECURRENCE POST LIVER TRANSPLANT WITH ORAL DIRECT ACTING ANTI-VIRAL: A REAL-WORLD EXPERIENCE FROM A SATELLITE CLINIC IN THE SOUTHERN UNITED STATES (12/03/21)
     
  556. AASLD: IDENTIFYING PERSISTING LIVER DISEASE AND LIVER ASSOCIATED MORBIDITY AND MORTALITY AFTER VIRAL CURE OF HCV - DATA FROM THE GERMAN HEPATITIS C-REGISTRY (DHC-R) (12/02/21)
     
  557. AASLD: SIMULTANEOUS HEPATITIS B AND C SCREENING IN AN EMERGENCY DEPARTMENT: A BROAD LINKAGE TO CARE STRATEGY (12/02/21)
     
  558. AASLD: RARE HCV GENOTYPES: PREVALENCE AND RESISTANCE-ASSOCIATED SUBSTITUTIONS IN DAA-NAÏVE AND DAA-EXPERIENCED PATIENTS (12/01/21)
     
  559. AASLD: HIGH RATE OF HEPATITIS C REINFECTION IN AN ADULT CUSTODIAL SETTING IN AUSTRALIA (12/01/21)
     
  560. AASLD: LONG-TERM PERSISTENCE OF RESISTANCE-ASSOCIATED SUBSTITUTIONS (RASS) AFTER DAA TREATMENT FAILURE IN PATIENTS WITH CHRONIC HCV INFECTION (12/01/21)
     
  561. AASLD: HEPATITIS C VIRUS REINFECTION AFTER SUCCESSFUL TREATMENT WITH DIRECT ACTING ANTIVIRAL THERAPY IN CANADA (12/01/21)
     
  562. AASLD: IMPLEMENTATION OF RAPID POINT-OF-CARE DIAGNOSTIC SYSTEMS TO SUPPORT HCV MICRO-ELIMINATION STRATEGIES IN A TERTIARY HOSPITAL IN SPAIN (12/01/21)
     
  563. AASLD: IMPLEMENTATION OF ROUTINE OPT OUT HEPATITIS C TESTING IN THE PHILADELPHIA JAIL SYSTEM (12/01/21)
     
  564. AASLD: POINT-OF-CARE TESTING FOR HEPATITIS C IN PUBLIC CLINICAL LABORATORIES REVEALS SIGNIFICANT RATES OF HIDDEN HCV AMONG ELDERLY POPULATION IN SOUTHERN ITALY (12/01/21)
     
  565. AASLD: Pentavalent HCV Vaccine Candidate Elicits Broadly Neutralizing Antibodies to Neutralization-Resistant Variants (11/30/21)
     
  566. AASLD: PROTEASE INHIBITORS (PI) IN TREATMENT OF HEPATITIS C AND THE RISK OF HEPATIC DECOMPENSATION: A SYSTEMATIC REVIEW OF ALL PI USE VS SOFOSBUVIR + NS5A INHIBITOR +/-RIBAVIRIN (11/30/21)
     
  567. AASLD: POTENTIAL COST-EFFECTIVENESS OF A MACHINE LEARNING ALGORITHM TO IDENTIFY UNDIAGNOSED HEPATITIS C PATIENTS IN THE UNITED STATES (11/30/21)
     
  568. AASLD: PROVISION OF HEPATITIS C CARE IN A FEDERALLY QUALIFIED HEALTH CENTER DURING THE COVID-19 PANDEMIC AND BEYOND - telemedicine & delivery of DAA medications (11/30/21)
     
  569. AASLD: MODIFIED ECHO MODEL TO INCREASE ACCESS TO HEPATITIS C TREATMENT: A HYBRID OF ECHO AND CO-MANAGEMENT
    BETWEEN SPECIALTY PROVIDERS AND COMMUNITY PROVIDERS & Rapid Same Day Models of Treatment     (11/30/21)
     
  570. AASLD: Open access case consultations with HCV experts in [rural] Michigan for Opioid Users AN OPEN ACCESS HEPATITIS C VIRUS CASE CONSULTING PROGRAM TO EXPAND FRONTLINE COMMUNITY PROVIDER CAPACITY (11/30/21)
     
  571. AASLD: PARTNERSHIPS FOR ELIMINATION: AMBULATORY CARE CLINICAL PHARMACISTS DISMANTLING BARRIERS TO HEPATITIS C CURE at St Barnabas in NJ (11/30/21)
     
  572. AASLD: Treat HCV Early; SOF/DCV Had Lower SVR Rates (11/30/21)
     
  573. AASLD: HCV TREATMENT AMONG ACTIVE INNER CITY DRUG USERS WITH GLECAPREVIR/PIBRENTASVIR: THE GRAND PLAN STUDY (11/30/21)
     
  574. Point-of-care HCV RNA testing with peer-led and nurse-based support to enhance HCV treatment among people with recent injecting drug use at a community-led needle and syringe program: the TEMPO pilot study - see study results below - (11/22/21)
     
  575. FDA In Brief: FDA Issues Final Orders Reclassifying Certain Hepatitis C Diagnostic Tests from Class III to Class II - improving submission process for HCV point-of-care HCV RNA testing - (11/22/21)
     
  576. AASLD: GLOBAL TRENDS IN CAUSE-SPECIFIC MORTALITY AND DISABILITY ADJUSTED LIFE YEARS RELATED TO HEPATITIS B VIRUS AND HEPATITIS C VIRUS FROM 2010 TO 2019 (11/22/21)
     
  577. AASLD: BENEFITS OF DAA TREATMENT ON MORTALITY RELATED TO EXTRAHEPATIC MANIFESTATIONS AMONG PEOPLE WHO INJECT DRUGS: A POPULATION-BASED STUDY IN BRITISH COLUMBIA, CANADA (11/22/21)
     
  578. AASLD: CHRONIC HEPATITIS C INFECTION AND INCIDENCE OF EXTRAHEPATIC CANCERS IN A CANADIAN POPULATION-BASED COHORT (11/22/21)
     
  579. AASLD: HCV CASCADE OF CARE [Big Gaps] AND NEXT STEPS FOR HCV ELIMINATION IN THE UNITED STATES FOLLOWING THE COVID-19 PANDEMIC - new updated improved HCV screening guidelines needed including for pregnant women & high-risk populations (11/22/21)
     
  580. AASLD: IMPACT OF HCV VIRAL PARAMETERS ON PREGNANCY COMPLICATIONS AND RISK OF MOTHER-TO-CHILD TRANSMISSION (11/22/21)
     
  581. AASLD: HCC Risk Factors After HCV Cure Differ With vs Without Cirrhosis and Over Time - Mark Mascolini (11/20/21)
     
  582. AASLD: DE NOVO HEPATOCELLULAR CARCINOMA OCCURRENCE FOLLOWING THE HCV VIRAL ERADICATION BY DIRECT ANTING ANTIVIRALS (DAA): MEDIUM TO LONG TERM OBSERVATIONS FROM THE ONGOING PITER COHORT - (11/19/21)
     
  583. AASLD: Largest Case Series of SOF + GLE/PIB + RBV for Deep HCV Salvage: 100% SVR12 - (11/19/21)
     
  584. AASLD: Worse Antibody and Cellular Response to SARS-CoV-2 Vax With Cirrhosis - Mark Mascolini (11/17/21)
     
  585. AASLD: The impact of the COVID-2019 pandemic on HCV testing and treatment in the United States - (11/17/21)
     
  586. AASLD: INTERFERON DRIVES HEPATITIS C VIRUS SCARRING OF THE EPIGENOME AND CREATES TARGETABLE VULNERABILITIES FOLLOWING VIRAL CLEARANCE - (11/17/21)
     
  587. AASLD: NATIONAL AND LOCAL POLICY CHANGES ARE ASSOCIATED WITH INCREASED HEPATITIS C VIRUS TREATMENT RATES, BUT DISPARITIES REMAIN - (11/17/21)
     
  588. AASLD: LONG-TERM ASSESSMENT OF RECURRENCE OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS C AFTER VIRAL CURE BY DAAs - (11/17/21)
     
  589. AASLD: HEPATITIS C TREATMENT IN THE UNITED STATES, 2014-2020 numbers of treated is "below that needed to ensure elimination in USA by 2030, increased screening needed, remove all rstrictions" - (11/17/21)
     
  590. AASLD: PROTEASE INHIBITORS (PI) IN TREATMENT OF HEPATITIS C AND THE RISK OF HEPATIC DECOMPENSATION: A META-ANALYSIS OF PI REGIMEN SAFETY - (11/17/21)
     
  591. AASLD: HEALTH DISPARITIES IN LIVER TRANSPLANT EVALUATION BY THE PATIENT'S NEIGHBORHOOD DEPRIVATION - "The most deprived group had a significantly higher proportion of patients that were black" - (11/17/21)
     
  592. AASLD: Global Status Update on the HCV Prevalence and Cascade of Care Entering 2020 - (11/17/21)
     
  593. AASLD: A COMMUNITY-BASED TRIAL OF HEPATITIS C TREATMENT AT POINT OF DIAGNOSIS FOR MARGINALIZED POPULATIONS: PRELIMINARY RESULTS FROM THE NO ONE WAITS (NOW) STUDY - (11/16/21)
     
  594. AASLD: INSTIs and DAAs Boost Liver Transplant Survival in HIV+ and HIV+/HCV+ in US - (11/16/21)
     
  595. AASLD: Rapid HCV Testing and Treating Young Drug Injectors Yields Higher SVR12 - Mark Mascolini (11/16/21)
     
  596. AASLD: Failure to Attain SVR With DAAs Tied to Shorter HCC-Free Survival - Mark Mascolini (11/16/21)
     
  597. AASLD: Excellent Efficacy and Safety of Sofosbuvir, Glecaprevir, Pibrentasvir and Ribavirin for Retreatment of Chronic Hepatitis C after Sofosbuvir, Velpatasvir and Voxilaprevir Failure - (11/16/21)
     
  598. HCV Doubles Among Pregnant People - Association of Individual and Community Factors With Hepatitis C Infections Among Pregnant People and Newborns - (11/15/21)
     
  599. AASLD: Global status update on the HCV prevalence and cascade of care entering 2020 - lack of progress - Mark Mascolini - (11/15/21)
     
  600. AASLD: HCV-RNA VIRAL LOAD FINGERSTICK ASSAY AS A SIMPLIFIED STRATEGY FOR SCREENING AND LINKAGE TO CARE OF PEOPLE WHO USE DRUGS ATTENDING ITALIAN ADDICTION TREATMENT CENTRES: A PILOT PROJECT - (11/15/21)
     
  601. AASLD: Rapid Hepatitis C Treatment Initiation in Young People Who Inject Drugs: Final Results from the HCV-Seek, Test & Rapid Treatment (HCV-ST&RT) Randomized Pilot Clinical Trial - (11/15/21)
     
  602. AASLD: HCC Incidence Threshold for Routine Surveillance is Much Lower in Hepatitis C Cirrhosis Individuals Who Achieve Virological Cure - (11/15/21)
     
  603. AASLD: Hospital Rate Falls More Than 12% With COVID Vax for Cirrhosis Patients - Mark Mascolini (11/15/21)
     
  604. AASLD: COVID Takes Big Bite Out of HBV/HCV Care in 37-Center Global Study - Mark Mascolini (11/15/21)
     
  605. AASLD: One in 5 With Cirrhosis Suffers Anxiety-1 in 12 Also Has Depression - Mark Mascolini (11/15/21)
     
  606. AASLD: HCC Incidence Threshold for Cost-Effective Surveillance Much Lower Than Prior Standard - Mark Mascolini (11/13/21)
     
  607. AASLD: Non-alcoholic Steatohepatitis is the Most Common Indication for Liver Transplantation among the Elderly: Data from the U.S. Scientific Registry of Transplant Recipients - (11/13/21)
     
  608. AASLD: Risk of Multiple Drug Interactions Potentially Linked to Safety in Patients Receiving Pangenotypic Direct-acting Antivirals for the Treatment of Hepatitis C - (11/13/21)
     
  609. AASLD: HBV and HCV are Each Associated with Adverse Pregnancy Complications: a 7-year Nationwide Inpatient Sample Study - (11/13/21)
     
  610. AASLD: HDV seropositivity was common amongst HBsAg+ women enrolled in WIHS. 26 (22%) of the 117 HBsAg+ women were HDV seropositive - (11/12/21)
     
  611. AASLD: USE OF SOFOSBUVIR/VELPATASVIR IN TEST AND TREAT STRATEGY IN FRANCE: SNAPSHOT ANALYSIS OF PROSPECTIVE COHORT STUDY HELIOS 3 - (11/12/21)
     
  612. AASLD: A Case Series of Safety and Efficacy of Crushed Sofosbuvir/Velpatasvir in Hepatitis C Infected Patients - (11/12/21)
     
  613. AASLD: CIRRHOSIS IS ASSOCIATED WITH SIGNIFICANT ADVERSE PREGNANCY COMPLICATIONS: A 7-YEAR NATIONWIDE INPATIENT SAMPLE STUDY - (11/12/21)
     
  614. AASLD: SUCCESSFUL IMPLEMENTATION OF UNIVERSAL HCV SCREENING AT A SAFETY-NET HOSPITAL'S EMERGENCY DEPARTMENT DURING THE COVID-19 PANDEMIC - 6% Overall HCV prevalence: 13% in baby boomers; 4% in nonBBs, overall chronic infection 2.5%; low linkage to care - (11/12/21)
     
  615. AASLD: THE IMPACT OF THE COVID-19 PANDEMIC ON HCV TESTING AND TREATMENT IN THE UNITED STATES - Between February 2020 and March 2020, the predicted number of tests dropped significantly by 33% but started to improve; Treatment Initiation dropped by 31% - (11/12/21)
     
  616. AASLD: CIRRHOSIS IN HIV VERSUS NON-HIV PATIENTS - ANALYSIS OF DEMOGRAPHICS, OUTCOMES AND HEALTHCARE UTILIZATION FROM A NATIONAL DATABASE - Ethnic Disparities, PLWH Have Longer Hospital Stays & Greater Hospital Charges - (11/12/21)
     
  617. AASLD: HCC Risk Factors After SVR - LONGITUDINAL ASSOCIATIONS BETWEEN RISK FACTORS AND SUBSEQUENT RISK OF HEPATOCELLULAR CANCER IN PATIENTS WITH HEPATITIS C VIRUS INFECTION AND VIROLOGICAL CURE - (11/12/21)
     
  618. AASLD: Change in HCV Epidemiology From 2018 to 2019: A Comparison Between States With No Medicaid Restrictions and States With Several Medicaid Restrictions - (11/12/21)
     
  619. AASLD: Retreatment of Hepatitis C Virus-infected Patients Who Failed Glecaprevir/Pibrentasvir - (11/12/21)
     
  620. AASLD: Shorter Duration Hepatitis C Virus Treatment is Associated With Better Persistence to Prescription Fills in People Who Inject Drugs - (11/12/21)
     
  621. AASLD: Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study - (11/12/21)
     
  622. AASLD: Non-Overweight Patients with Nonalcoholic Fatty Liver Disease, Diabetes Fare Worse Than Overweight Patients Before and After Liver Transplant - (11/12/21)
     
  623. CDC: Acute HCV Quadruples, 63% Increase, Race & States Rates - (11/09/21)
     
  624. New estimates reveal declines in hepatitis C treatment in the U.S. between 2015 and 2020 by 50% & Quadrupling of Acute HCV - (11/09/21)
     
  625. EACS: Liver disease in people living with HIV (PLWHIV) after the microelimination of HCV infection: non-viral hepatitis & NAFLD - (11/02/21)
     
  626. EACS: Hepatitis C elimination in time of COVID-19 pandemic: the experience of University Hospital Center in Paris, France - (11/01/21)
     
  627. EACS: New HCV Diagnoses Down by Two Thirds in HIV+ Swiss MSM 2010-2020 - Mark Mascolini (10/30/21)
     
  628. Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study - (10/15/21)
     
  629. Hepatitis C incidence and prevalence among Puerto Rican people who use drugs in New York City - (10/14/21)
     
  630. Texas Removed Medicaid HCV DAA Treatment Restrictions - (10/05/21)
     
  631. IDWeek: Accessible HCV Care for People who Inject Drugs: Randomized Clinical Trial Comparing Low-Threshold Treatment at a Syringe Service Program versus Facilitated Referral. - (10/04/21)
     
  632. IDWeek: Automated Hepatitis C Screening and Linkage to Care among Hospitalized Patients Born Between 1945-1965 - (10/04/21)
     
  633. IDWeek: EFFICACY AND SAFETY OF LONG-ACTING CABOTEGRAVIR + RILPIVIRINE IN PARTICIPANTS WITH HIV/HCV CO-INFECTION: ATLAS-2M 48-WEEK RESULTS - (10/04/21)
     
  634. Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients - (10/04/21)
     
  635. NIAID Scientists Find a Key to Hepatitis C Entry into Cells - (09/27/21)
     
  636. Intl Wrkshp Clin Pharm: Proposed Fostemsavir Precautions With HCV Meds - Mark Mascolini - (09/21/21)
     
  637. HCV Screening & Treatment Saves Billions$$$ & Prevents Liver Cancer, Diseases & Deaths "Treating all Medicaid patients with chronic HCV...... resulted in a 39.4% ($3.8 billion) savings" - (09/15/21)
     
  638. Patients with HIV and cirrhosis: the risk for hepatocellular carcinoma after direct-acting antivirals for hepatitis C virus - (09/15/21)
     
  639. HCV Innovative Payment Models, Eliminating HCV - (09/13/21)
     
  640. The Impact of Direct-Acting Antiviral Therapy on End-Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders - (09/10/21)
     
  641. HCV Death Rate Trends in USA County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017 - (09/10/21)
     
  642. Michigan HCV Initiative Launched - Universal Screening & Treatment - (09/07/21)
     
  643. "EXISTING MODELS FALL SHORT OF ACHIEVING THEIR FULL POTENTIAL": AN ANALYSIS OF THE PROMISE AND PRACTICE OF NOVEL HEPATITIS C MEDICATION PROCUREMENT STRATEGIES IN THE U.S. - (09/07/21)
     
  644. Medicaid Subscription-Based Payment Models and Implications for Access to Hepatitis C Medications - (09/07/21)
     
  645. HCV Elimination Model Forecast Reduced Prevalence to 0.3% by Improving Harm Reduction, HCV Testing & Treatment, Removing Restrictions - Mandated Universal Screening Needed - (09/07/21)
     
  646. HCV Elimination- the "Social Approach" for PWID - transformative potential of DAAs treatment for HCV among people who inject drugs - (09/07/21)
     
  647. IAS: Progress towards HCV elimination among HIV-positive men who have sex with men in Germany: a modeling analysis - (08/23/21)
     
  648. IAS: The prevalence of hepatitis C virus (HCV) co-infection among people living with HIV (PLHIV) in Egypt: a cross-sectional study - (08/23/21)
     
  649. Noninvasive Markers for Monitoring Fibrosis Regression After Hepatitis C Virus Cure: What Do They Promise? - (08/11/21)
     
  650. Increased Prevalence of Liver Fibrosis in People Living With Human Immunodeficiency Virus Without Viral Hepatitis Compared to Population Controls - (08/11/21)
     
  651. Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study - (08/11/21)
     
  652. EASL: Persistent long-term risk of liver related complications in HCV patients after antiviral therapy - Data from the German Hepatitis C-Registry - (07/26/21)
     
  653. IAS: Immunoscenescence and HIV: mutual interactions? - (07/26/21)
     
  654. IAS: Poor sleep quality in people with HIV linked to lower CSF amyloid beta 42 - (07/26/21)
     
  655. IAS: HCV Reinfection Rate Almost 4% in Global Analysis of People With HIV - Mark Mascolini (07/26/21)
     
  656. IAS: Drug Injecting Remains Barrier to HCV Elimination in Netherlands - Mark Mascolini (07/26/21)
     
  657. IAS: HCV Cure Rate 92% in Hard-to-Reach Vietnam Drug-Injecting Group - Mark Mascolini (07/26/21)
     
  658. IAS: HCV Reinfection Rate Almost 4% in Global Analysis of People With HIV - Mark Mascolini (07/25/21)
     
  659. IAS: Drug Injecting Remains Barrier to HCV Elimination in Netherlands - Mark Mascolini (07/25/21)
     
  660. IAS: HCV Cure Rate 92% in Hard-to-Reach Vietnam Drug-Injecting Group - Mark Mascolini (07/25/21)
     
  661. EASL: Summary from EASL 2021 for Hepatitis B, C, D and fatty liver disease. Liver disease in 2021: advances and remaining challenges. Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (07/25/21)
     
  662. Kinetics of emergence of liver complications in HCV-infected patients and advanced fibrosis, with and without HIV-coinfection, after SVR - (07/15/21)
     
  663. Drug Overdoses Increase 30% - (07/10/21)
     
  664. EASL: The Impact of COVID-19 Pandemic on Patients with Chronic Liver Disease (CLD): Data from the Global Registry - (07/12/21)
     
  665. EASL: Liver Stiffness by Vibration-Controlled Transient Elastography Predicts Disease Progression in Patients With Advanced Fibrosis Due to NASH - (07/12/21)
     
  666. EASL: AI-based histologic measurement of NASH (AIM-NASH): A drug development tool for assessing clinical trial endpoints - (07/12/21)
     
  667. EASL: INCIDENCE OF LIVER AND NON-LIVER RELATED EVENTS AND MORTALITY IN A LARGE COHORT OF HCV CIRRHOTICS WITH AN SVR TO DAA: A 5-YEAR SINGLE CENTER STUDY - (07/12/21)
     
  668. Drug Overdoses Increase 30% - (07/10/21)
     
  669. Hepatitis C testing and treatment uptake among young people who use opioids in New York City: A cross-sectional study - (07/10/21)
     
  670. HCV 40% Unaware HBV 65% in USA. New WHO Viral Hepatitis Elimination Guidance - (07/10/21)
     
  671. EASL: Noninvasive Tools Can Spot Liver Transplant Patients With No Alloimmune Damage - Mark Mascolini (07/09/21)
     
  672. Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City - (07/08/21)
     
  673. Epidemiological trends (MSM) in HCV transmission and prevalence in the Viennese HIV+ population - (07/08/21)
     
  674. Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey - (07/08/21)
     
  675. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study - (07/08/21)
     
  676. "Raising HOPE": Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era - (07/08/21)
     
  677. EASL: THE ALARMING IMPACT OF COVID-19 PANDEMIC ON ALCOHOL-RELATED LIVER DISEASE: A POPULATION-BASED CANADIAN STUDY (07/08/21)
     
  678. EASL: Hepatitis C in Connecticut Community Health Centers: Measuring the Impact of the project ECHO model on treatment in primary care (07/08/21)
     
  679. EASL: A tailored program for screening, improved access to care and prioritization of treatment for PWUD with HCV chronic infection (07/08/21)
     
  680. EASL: No Change in Alcoholic Cirrhosis Mortality in 20 Years-But Causes of Death Shift - Mark Mascolini (07/07/21)
     
  681. EASL: Alcohol Dependence More Frequent in UK Inpatients During Than Before COVID - Mark Mascolini (07/07/21)
     
  682. EASL: Simplified test and treat protocols for population level screening and elimination of hepatitis B and hepatitis C in Uzbekistan (07/07/21)
     
  683. EASL: Beating Hepatitis C together in challenging times: an evaluation of a multi-disciplinary approach to testing and treating homeless people temporarily housed during the COVID-19 pandemic (07/06/21)
     
  684. EASL: Mortality risk following HCV cure among people with HCV/HIV co-infection (07/06/21)
     
  685. EASL: Is the Gender of Hepatitis C Patients Influencing Rapid Direct-acting Antiviral Treatment Start? Results from a Large Multinational Real-world Dataset (07/06/21)
     
  686. EASL: Is the Age of Hepatitis C Patients Influencing Rapid Direct-acting Antiviral Treatment Start? Results from a Large multinational Real-world Dataset (07/06/21)
     
  687. EASL: The road to HCV elimination: entering the final stretch or chasing a moving finish line? - (07/03/21)
     
  688. EASL: High rates of hidden HCV infections among hospitalized patients aged 55-85 - (07/02/21)
     
  689. EASL: Improvement of all HCV care cascade steps in IVDU treated with DAAs within a dedicated program - (07/02/21)
     
  690. EASL: Cost-effectiveness of a Core Antigen Based Rapid Diagnostic Test for Hepatitis C - (07/02/21)
     
  691. EASL: From screening to therapy: Anti-HCV screening and linkage to care in a network of general practitioners and a private gastroenterology practice - (07/02/21)
     
  692. EASL: Hepatitis C Elimination in the Netherlands (CELINE): nationwide retrieval of lost to follow-up chronic hepatitis C patients - (06/28/21)
     
  693. EASL: Anticipated timing of hepatitis C virus elimination in the Netherlands and the impact of COVID-19 - (06/28/21)
     
  694. EASL: New WHO Guidance on Viral Hepatitis Elimination - (06/26/21)
     
  695. EASL: NAFLD Doubles Risk of CVD and Cuts up to 6 Years off Life Expectancy - Mark Mascolini (06/26/21)
     
  696. EASL: Liver Impairment With COVID-19 Tied to More Severe Coronavirus Disease - Mark Mascolini (06/26/21)
     
  697. EASL: Late Entry to Care in Almost Half of People With Chronic HCV in France - Mark Mascolini (06/26/21)
     
  698. EASL: Frequency and impact of potential multiple drug-drug interactions (DDIs) associated with pangenotypic direct-acting antivirals in patients receiving opioid substitution therapy - (06/26/21)
     
  699. EASL: Risk of multiple drug-drug interactions (DDIs) in HCV patients receiving pangenotypic DAAs (pDAAs): A complex drug interaction scenario first time evaluated in German patients - (06/26/21)
     
  700. EASL: VALUE ASSESSMENT OF SOFOSBUVIR-BASED REGIMENS FOR (CHRONIC) HEPATITIS C IN SPAIN - (06/26/21)
     
  701. EASL: Estimating the contribution of viral hepatitis and other etiologies to the burden of cirrhosis: a worldwide systematic review - (06/26/21)
     
  702. EASL: Estimating the contribution of viral hepatitis and other etiologies to the burden of cirrhosis: a worldwide systematic review Together, HBV and HCV Less Prevalent in Cirrhosis Than in HCC Cases Worldwide - Mark Mascolini (06/26/21)
     
  703. EASL: Together, HBV and HCV Less Prevalent in Cirrhosis Than in HCC Cases Worldwide - Mark Mascolini (06/25/21)
     
  704. EASL: Liver stiffness measurement for the prediction of liver-related outcomes in chronic hepatitis C patients after viral eradication - (06/25/21)
     
  705. EASL: INCIDENCE OF LIVER AND NON-LIVER RELATED EVENTS AND MORTALITY IN A LARGE COHORT OF HCV CIRRHOTICS WITH AN SVR TO DAA: A 5-YEAR SINGLE CENTER STUDY....a reminder to treat early - (06/25/21)
     
  706. EASL: Concordance Between SVR4, SVR12, and SVR24 in HCV-Infected Patients Who Received Fixed-Dose Combination Sofosbuvir/Velpatasvir in Phase 3 Clinical Trials - (06/24/21)
     
  707. EASL: Cost and Effectiveness of combining treatment on Day 1 (Rapid Start) for hepatitis C and higher screening effort in at-risk populations (T&T strategy) in France - (06/24/21)
     
  708. EASL: Good practice hepatitis C screening and linkage to care initiatives at the SLTC Summit 2020: three out of four diagnosed patients were able to start direct-acting antiviral treatment - (06/24/21)
     
  709. EASL: Bulevirtide Monotherapy at Low and High Doses in Patients With Chronic Hepatitis Delta: 24-Week Interim Data of the Phase 3 MYR301 Study - (06/24/21)
     
  710. EASL: Chronic liver disease and risk of mortality after COVID-19: a national, retrospective, cohort study for 2020 - Mark Mascolini (06/24/21)
     
  711. EASL: ASSOCIATION OF MAFLD WITH MORTALITY IN PATIENTS WITH COVID-19 IN MEXICO - (06/23/21)
     
  712. EASL: A novel approach to age cohort screening for hepatitis C in the primary care setting of a large urban health care setting with linkage to care - (06/23/21)
     
  713. EASL: DETECTION OF ACTIVE HEPATITIS C BY A TWO-STEP POINT-OF-CARE BASED STRATEGY AND LINK-TO-CARE AMONG EXCLUDED PEOPLE IN MADRID, SPAIN - (06/23/21)
     
  714. EASL: Cirrhosis regression based on both Enhanced Liver Fibrosis (ELF) and Fibrotest after Direct-acting Hepatitis C therapeutics corresponds to a lower incidence rate of hepatocellular carcinoma below the cost-effective threshold for surveillance - (06/23/21)
     
  715. EASL: Impact of the COVID-19 Pandemic on Hepatitis C Virus Screening in Drug Treatment Settings in England and Implications for Future Testing Protocols - (06/23/21)
     
  716. EASL: Impact of direct-acting antiviral treatment on mortality related to extrahepatic manifestations: findings from a large population-based cohort in British Columbia, Canada - (06/23/21)
     
  717. EASL: Modeling HCV elimination recovery following the COVID-19 pandemic in the United States: Pathways to regain progress - (06/23/21)
     
  718. EASL: Prevalence and origin of rare HCV genotypes in DAA-naive and DAA-experienced patients - (06/23/21)
     
  719. EASL: RAPID POINT OF CARE HCV TESTING ALLOWS HIGH VOLUME SCREENING AND RAPID TREATMENT UPTAKE AMONG PWID ATTENDING A MEDICALLY SUPERVISED INJECTING ROOM - (06/23/21)
     
  720. EASL: Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients With Signs of Portal Hypertension - (06/23/21)
     
  721. EASL: COVID Impact on Global Liver Disease - press releases from EASL 2021 EASL press releases - (06/23/21)
     
  722. Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic - (06/21/21)
     
  723. Medicaid Expansion Association with End-Stage Liver Disease Mortality Depends on Leniency of Medicaid Hepatitis C Virus Coverage - (06/13/21)
     
  724. U.S. Food and Drug Administration Approves New Formulation of Epclusa®, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C - (06/11/21)
     
  725. FDA Approves Mavyret (G/P, glecaprevir and pibrentasvir) for Pediatric HCV Treatment 3 Years & Older - (06/11/21)
     
  726. Letter to the Editor: Pregnant women and their providers want DAAs and we are missing the mark - (06/11/21)
     
  727. Letter to the Editor: Pregnant women and their providers want DAAs and we are missing the mark - (06/11/21)
     
  728. AASLD: The Future of HCV Vaccine Development - (06/01/21)
     
  729. Cost-effectiveness of Total State Coverage for Hepatitis C Medications - (06/01/21)
     
  730. HIV and Hepatitis C Linkage-to-Care Initiative for New Orleans Residents Experiencing Homelessness During the COVID-19 Pandemic - (06/01/21)
     
  731. HCV Elimination: Universal Routine Screening Should be Mandated - (06/01/21)
     
  732. HEPATITIS C VIRUS INFECTION AND CO-INFECTION WITH HIV AMONG PWID IN 10 U.S. CITIES - (05/28/21)
     
  733. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial - (05/24/21)
     
  734. HCV Screening During Pregnancy Recommended by ACOG: Am Coll. of Obstetricians & Gynecologists - (05/19/21)
     
  735. New CDC Update - Acute HCV Increased 14% from 2018 to 2019 - (05/19/21)
     
  736. Our Nation has set a goal to eliminate viral hepatitis by 2030.", Pres. Biden - (05/19/21)
     
  737. Treatment failure with DAA therapy: Importance of resistance - (05/16/21)
     
  738. Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study - (05/3/21)
     
  739. Black Patients Have Unequal Access to Listing for Liver Transplantation in the United States - (05/3/21)
     
  740. Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings - (04/19/21)
     
  741. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in children with chronic hepatitis C virus: part 2 of the DORA study - (04/12/21)
     
  742. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy - (04/05/21)
     
  743. Responsible Inclusion of Pregnant Individuals in Eradicating Hepatitis C Virus - (02/27/21)
     
  744. CROI: A SIMPLE AND SAFE APPROACH TO HCV TREATMENT: FINDINGS FROM THE A5360 (MINMON) TRIAL - (03/23/21)
     
  745. CROI: DRUG-USE STIGMA AND HEPATITIS C VIRUS INFECTION AMONG PWID IN INDIA - (03/17/21)
     
  746. CROI: ACCESS TO HCV CARE AMONG HIV/HCV-COINFECTED PEOPLE WHO INJECT DRUGS ACROSS CANADA - (03/16/21)
     
  747. CROI: HIV/HCV COINFECTION TRENDS IN SPAIN (2015-2019) - (03/16/21)
     
  748. CROI: NO CHANGE IN INCIDENCE OF RECENTLY ACQUIRED HCV IN HIV+ MSM IN GERMANY (NOCO COHORT) - (03/16/21)
     
  749. CROI: HEPATITIS C CASCADE OF CARE IN HIV/HCV-COINFECTED PERSONS IN EUROPE IN THE DAA ERA - (03/16/21)
     
  750. CROI: SELF-TESTING FOR HCV: MULTICOUNTRY EVIDENCE ON USABILITY AND ACCEPTABILITY - (03/16/21)
     
  751. CROI: COST-EFFECTIVENESS OF HCV TESTING STRATEGIES FOR HCV ELIMINATION AMONG MSM IN THE US - (03/16/21)
     
  752. CROI: REINFECTION WITH THE HEPATITIS C VIRUS IN MEN WHO HAVE SEX WITH MEN - (03/16/21)
     
  753. CROI: ACCESS TO HCV CARE AMONG HIV/HCV-COINFECTED PEOPLE WHO INJECT DRUGS ACROSS CANADA - (03/16/21)
     
  754. CROI: HIV/HCV COINFECTION TRENDS IN SPAIN (2015-2019) - (03/16/21)
     
  755. CROI: NO CHANGE IN INCIDENCE OF RECENTLY ACQUIRED HCV IN HIV+ MSM IN GERMANY (NOCO COHORT) - (03/16/21)
     
  756. CROI: HEPATITIS C CASCADE OF CARE IN HIV/HCV-COINFECTED PERSONS IN EUROPE IN THE DAA ERA - (03/16/21)
     
  757. CROI: SELF-TESTING FOR HCV: MULTICOUNTRY EVIDENCE ON USABILITY AND ACCEPTABILITY - (03/16/21)
     
  758. CROI: COST-EFFECTIVENESS OF HCV TESTING STRATEGIES FOR HCV ELIMINATION AMONG MSM IN THE US - (03/16/21)
     
  759. CROI: REINFECTION WITH THE HEPATITIS C VIRUS IN MEN WHO HAVE SEX WITH MEN - (03/16/21)
     
  760. CROI: Tight HBV Control Essential to HCC Prevention in People With HIV - Mark Mascolini (03/09/21)
     
  761. Racial disparities in hepatocellular carcinoma, Hepatitis C positive Black patients develop hepatocellular carcinoma at earlier stages of liver disease and present with a more aggressive phenotype - (02/27/21)
     
  762. AASLD Selected Highlights - HCV Elimination, Screening, Treatment - (02/26/21)
     
  763. New HCV / HBV Bill in California - (02/26/21)
     
  764. The persistence of underreporting of hepatitis C as an underlying or contributing cause of death, 2011-2017 - (02/23/21)
     
  765. AASLD: Shelter-Based Integrated HCV Care Model is Effective in Scaling up HCV Testing and Treatment in Homeless Clients Across Two Large Urban Settings - (02/01/21)
     
  766. County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017 - (02/21/21)
     
  767. The LONGEVITY project aims to develop long-acting formulations for malaria and TB prevention, and a single-injection cure for hepatitis C - (02/21/21)
     
  768. HCV Treatment / Vulnerable Populations - (02/21/21)
     
  769. Will the COVID-19 pandemic affect HCV disease burden? - (02/21/21)
     
  770. Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine - (02/21/21)
     
  771. Remaining challenges in HCV elimination - (02/21/21)
     
  772. Impact of the 2020 COVID-19 Pandemic on Ambulatory Hepatitis C Testing - (02/21/21)
     
  773. AASLD: Shelter-Based Integrated HCV Care Model is Effective in Scaling up HCV Testing and Treatment in Homeless Clients Across Two Large Urban Settings - (02/20/21)
     
  774. The Impact of Directacting Antiviral Therapy on End Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders - (02/10/21)
     
  775. AASLD EXPERT PANEL CONSENSUS STATEMENT: VACCINES TO PREVENT COVID-19 INFECTION IN PATIENTS WITH LIVER DISEASE - (02/08/21)
     
  776. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients - (02/08/21)
     
  777. Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study - HCV Elimination - (02/04/21)
     
  778. Study Suggests Fatty Liver and Cirrhosis Doubles Mortality Risk in COVID-19 - (02/01/21)
     
  779. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study - (02/01/21)
     
  780. High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis - (01/29/21)
     
  781. The impact of COVID-19 on hepatitis elimination - (01/15/21)
     
  782. SARS-CoV-2 massive testing: A window of opportunity to catch up with HCV elimination - (01/15/21)
     
  783. Microelimination or not? The changing epidemiology of HIV-HCV coinfection in France 2012-2018...MSM - (01/11/21)
     
  784. State of the Hepatitis C Virus Care Cascade, USA, Gobally - (01/11/21)
     
  785. Increased casefinding and uptake of directacting antiviral treatment essential for microelimination of hepatitis C among people living with HIV: a national record linkage study in Scotland, England, MSM - (01/11/21)
     
  786. New infections were associated with sharing chemsex drugs among MSM in Spain Among HIV+ has the potential to reseed the HCV epidemic and, consequently, preclude HCV elimination. - (01/11/21)
     
  787. HCV SCREENING AND LINKAGE TO CARE AT COMMUNITY HOSPITAL EMERGENCY DEPARTMENT: RETROSPECTIVE REVIEW OF PATIENT CHARACTERISTICS AND FUTURE IMPLICATIONS - (01/07/21)
     
  788. HCC surveillance after SVR in patients with F3/F4 fibrosis - (01/06/21)
     
  789. Impact of the COVID 19 Pandemic on HCV Elimination in Spain - (12/22/20)
     
  790. AASLD: HIGH PREVALENCE OF FATTY LIVER DISEASE [FLD] AND ADVANCED FIBROSIS IN AN URBAN MULTIETHNIC US COHORT OF PERSONS WITH HIV - (12/21/20)
     
  791. AASLD: PREVALENCE AND RISK FACTORS OF HEPATIC STEATOSIS AND FIBROSIS IN AMERICAN ADULTS: A POPULATION-BASED STUDY - (12/21/20)
     
  792. AASLD: GLOBAL PREVALENCE OF HEPATITIS C VIRUS IN WOMEN OF CHILDBEARING AGE IN 2019: A MODELING STUDY - (12/21/20)
     
  793. AASLD: AUTOMATED VIRAL HEPATITIS (HCV AND HBV) SCREENING: LESSONS ON EXPANSION & SUSTAINABILITY AMIDST THE COVID-19 PANDEMIC - (12/21/20)
     
  794. AASLD: AUTOMATED VIRAL HEPATITIS (HCV AND HBV) SCREENING: LESSONS ON EXPANSION & SUSTAINABILITY AMIDST THE COVID-19 PANDEMIC - (01/08/21)
     
  795. HBV & HCV & Accelerated Senescence: premature aging - (12/18/20)
     
  796. New York State Department of Health Hepatitis B and C Annual Report 2018 - (12/18/20)
     
  797. Hepatitis A, B and C in New York City: 2019 Annual Report - (12/16/20)
     
  798. Changing epidemiology, implications, and recommendations for Hepatitis C in Women of Childbearing Age and During Pregnancy - (12/15/20)
     
  799. Women & HCV at AASLD. HCV screening for pregnant women. Routine HCV screening required for elimination. - (12/15/20)
     
  800. AASLD: Novel Paradigms of HCV Care Delivery - Treatment Beyond the Specialty Clinic - (12/10/20)
     
  801. A study of therapy for hepatitis C in pregnancy with Sofosbuvir/Velpatasvir in Australia - (12/08/20)
     
  802. Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir - (12/04/20)
     
  803. AASLD: OPPORTUNITIES FOR EARLY DIAGNOSIS OF UNRECOGNIZED CIRRHOSIS IN THE DEPARTMENT OF VETERANS AFFAIRS - (11/28/20)
     
  804. AASLD: OPPORTUNITIES FOR EARLY DIAGNOSIS OF UNRECOGNIZED CIRRHOSIS IN THE DEPARTMENT OF VETERANS AFFAIRS - (11/28/20)
     
  805. AASLD: AFFORDABLE CARE ACT MEDICAID EXPANSION IMPROVED LIVER TRANSPLANT WAITLIST PLACEMENT AND SLOWED RACIAL DISPARITIES - (11/28/20)
     
  806. AASLD: Treatment As Prevention: Addressing HCV in Persons Who Inject Drugs (PWID) - (11/28/20)
     
  807. AASLD: CONTINUED INEQUITIES IN THE HEPATITIS C CASCADE OF CARE EXPERIENCED BY PEOPLE WHO INJECT DRUGS IN BRITISH COLUMBIA IN 2019: A POPULATION-LEVEL LINKED DATA STUDY - (11/28/20)
     
  808. AASLD: The impact of direct acting antiviral treatments on all-cause, liver- and drug-related mortality in a large population-based cohort study - (11/28/20)
     
  809. AASLD: WOMEN AND THE 2019 HEPATITIS C CASCADE OF CARE: FINDINGS FROM THE BC-HEPATITIS TESTERS COHORT - (11/28/20)
     
  810. AASLD: DAAs Improve HCC Liver Transplant Survival - Outcomes of transplantation for HBV- vs. HCV-related HCC: impact of DAA HCV therapy in a national analysis of >18,000w patients: HCC Liver Transplant Survival No Longer Worse With HCV Than HBV - Mark Mascolini (11/28/20)
     
  811. AASLD: Elbasvir/Grazoprevir in Children Aged 3 to <18 Years With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: Final Results From an Iterative Pharmacokinetic Modeling Study - (11/28/20)
     
  812. AASLD: Progression of the FIB-4 Index among Patients with Chronic HCV Infection - (11/28/20)
     
  813. AASLD: BILE DUCT INJURY AND SEVERE CHOLESTASIS IN PATIENTS RECOVERING FROM SEVERE COVID-19: A NOVEL ENTITY OF COVID-ASSOCIATED-CHOLANGIOPATHY - (11/28/20)
     
  814. AASLD: Early phase implementation of routine opt out hepatitis C testing in the Philadelphia jail system - (11/28/20)
     
  815. AASLD: Liver Transplant Evaluation Within 30 Days Improves Pretransplant Survival - Mark Mascolini (11/28/20)
     
  816. AASLD: Risk of severe acute liver injury among initiators of potentially hepatotoxic drugs. - Mark Mascolini (11/28/20)
     
  817. AASLD: Fibrosis Assessed by Non-Invasive Tests is Similar to Liver Biopsy for Predicting Clinical Outcomes: A TARGET-NASH Study - (11/28/20)
     
  818. Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study - (11/24/20)
     
  819. Drug Interactions between DAAs & Illicit/recreational drugs or drugs of abuse - from the EASL Guidelines - (11/24/20)
     
  820. AASLD: Obesity Plus High Liver Fat Boost Odds of Hospital Admission With Severe COVID-19 - Mark Mascolini - (11/24/20)
     
  821. AASLD: Breastfeeding Linked to Lower Chance of Severe Fibrosis in US Women With NAFLD - Mark Mascolini - (11/24/20)
     
  822. AASLD: COST-EFFECTIVENESS OF ANTENATAL RESCREENING AMONG PREGNANT WOMEN FOR HEPATITIS C IN THE UNITED STATES (11/20/20)
     
  823. AASLD: HEPATITIS C SCREENING IN THE GENERAL POPULATION IN A FRENCH CITY: A NEEDLE IN A HAYSTACK (11/20/20)
     
  824. AASLD: State Policies Limiting Progress Towards HCV Elimination in the U.S. (11/20/20)
     
  825. AASLD: Use of antipsychotic medication in active drug users, patients receiving opioid substitution therapy (OST) and HCV patients (11/20/20)
     
  826. AASLD: High Rates Of HCV Reinfection And Retreatment In A Cohort Of PWID With HCV Cure: Two Year Follow Up Data From The ANCHOR Study (11/20/20)
     
  827. AASLD: POINT-OF-CARE HEPATITIS C TESTING AND TREATING STRATEGY IN PEOPLE WHO INJECT DRUGS IN HARM REDUCTION AND ADDICTION CENTERS FOR HEPATITIS C ELIMINATION (11/19/20)
     
  828. AASLD: Time from diagnosis to treatment in vulnerable populations versus general population: Do we test-and-treat our HCV patients in the same way? (11/19/20)
     
  829. AASLD: MICROELIMINATION BEYOND PRISON WALLS: SUBJECTS SERVING NON-CUSTODIAL SENTENCES, SCREENING AND IMMEDIATE ASSISTED TREATMENT WITH "NAVIGATOR" FIGURE AND TELEMEDICINE (11/19/20)
     
  830. AASLD: Addressing Barriers to HCV Elimination in Italy: Health Care Resource Utilization and Cost Savings From Using 8 vs 12 Weeks of Glecaprevir/Pibrentasvir Therapy (11/19/20)
     
  831. AASLD: Preliminary results of the NORTHERN-HCV study assessing the impact of a simplified care model on direct-acting antivirals treatment for RNA-positive hepatitis C virus patients: A retrospective review of the TrueNorth Medical Centres database in Ontario, Canada (11/19/20)
     
  832. AASLD: Real-World Outcomes in Patients With Chronic Hepatitis C Virus Infection and Substance Use Disorders Treated With Glecaprevir/Pibrentasvir for 8 Weeks: A Pooled Analysis of Multinational Postmarketing Observational Studies (11/19/20)
     
  833. AASLD: Prevalence of Undiagnosed Hepatitis C Virus Infected Individuals Estimated by Regional Mathematical-Modelling in Italy (11/19/20)
     
  834. AASLD: The "Keep It Simple and Safe" Approach to HCV Treatment: Primary Outcomes from the ACTG A5360 (MINMON) Study (11/19/20)
     
  835. AASLD: HCC Incidence Gains in US Slowed in Urban But Not Rural Areas. - Mark Mascolini (11/19/20)
     
  836. AASLD: Abnormal Liver Tests at COVID Hospitalization Tied to Severe Disease, Death - Mark Mascolini (11/18/20)
     
  837. AASLD: Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis - (11/17/20)
     
  838. AASLD: Sugary Drinks, High Trans Fats Lead Dietary Risks for Death With NAFLD - Mark Mascolini (11/17/20)
     
  839. AASLD: The Lipidomics of HIV-related NAFLD - (11/17/20)
     
  840. AASLD: Dietary Risks for Liver Related Morality Among Nonalcoholic Fatty Liver Disease (NAFLD) - (11/17/20)
     
  841. AASLD: Treatment with Growth Hormone-Releasing Hormone Analog Reduces VEGFA, TGFβ1, and CSF1: Mechanisms of Tesamorelin Effect in Nonalcoholic Fatty Liver Disease - (11/17/20)
     
  842. AASLD: Country and WHO Regional Trends for Hepatitis C Virus (HCV) Mortality, 1990-2019: An Analysis of the Global Burden of Disease (GBD) Study - (11/17/20)
     
  843. AASLD: Statins Tied to Lower HCC Risk in HBV Group Without Cirrhosis - Mark Mascolini (11/17/20)
     
  844. AASLD: Country and WHO Regional Trends for Hepatitis C Virus (HCV) Mortality, 1990-2019: An Analysis of the Global Burden of Disease (GBD) Study - (11/17/20)
     
  845. AASLD: Statins Tied to Lower HCC Risk in HBV Group Without Cirrhosis - Mark Mascolini (11/17/20)
     
  846. AASLD: Periodontitis is associated with chronic liver disease in a population-based cohort of US adults - Mark Mascolini (11/17/20)
     
  847. AASLD: Risk of hepatocellular carcinoma in patients with chronic hepatitis C and stage-3 liver fibrosis after sustained virological response (SVR) with direct-acting antivirals - Mark Mascolini (11/17/20)
     
  848. AASLD: Can Hepatitis C Treatment with Direct-Acting Antivirals be Cost Saving? A Global Modeling Study of 158 Countries - (11/17/20)
     
  849. AASLD: A Multisite Randomized Pragmatic Trial of Patient-Centered Models of Hepatitis C Treatment for People Who Inject Drugs: The HERO Study - Hepatitis C Real Options - (11/16/20)
     
  850. AASLD: Hepatitis C elimination in Europe - (11/16/20)
     
  851. AASLD: Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes - (11/16/20)
     
  852. AASLD: Patient characteristics and efficacy of pangenotypic direct-acting antiviral regimens among a cohort of chronic hepatitis C patients receiving routine clinical care in the U.S. - (11/16/20)
     
  853. AASLD: Low adherence to infant HCV testing guidelines among pregnant women with HCV cirrhosis - (11/16/20)
     
  854. AASLD: Outcomes following resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. - Mark Mascolini - (11/16/20)
     
  855. AASLD: Predictors and outcomes of steroid-refractory immune checkpoint inhibitor hepatitis. - Mark Mascolini - (11/16/20)
     
  856. AASLD: Addition of structured psychosocial assessment and intervention to interdisciplinary Hepatitis C team increases treatment uptake: Results of the prospective, randomized, controlled CARE-C trial - (11/16/20)
     
  857. AASLD: Determining Feasibility of Hepatitis C Elimination in the United States Using a Simulation Model - (11/16/20)
     
  858. AASLD: Age-Related Co-Morbidities and Polypharmacy in HCV-Infected Patients With Substance Use Disorders Treated With G/P: A Real-World Analysis From 9 Countries - (11/16/20)
     
  859. AASLD: Drug-drug interactions (DDIs) in Italian patients with chronic hepatitis C (HCV) treated with pangenotypic direct acting agents (pDAAs): focus on cardiovascular and central nervous system co-medications - (11/16/20)
     
  860. AASLD: Safety and Efficacy of Sofosbuvir/Velpatasvir for the Treatment of Chronic Hepatitis C Infection in Children and Adolescents Aged 3 to 17 Years Old Through 24 Weeks Posttreatment - (11/16/20)
     
  861. AASLD: Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adolescents With Chronic Hepatitis C Virus Infection - (11/16/20)
     
  862. AASLD: Active Drug Use Is Not Associated with Treatment Failure Among PWID Patients With Variable Adherence to HCV Treatment - (11/16/20)
     
  863. AASLD: Variable Adherence To HCV Treatment Among People Who Inject Drugs Treated with 8 Versus 12 Weeks of Antiviral Therapy Resulted In High Rates of SVR - (11/16/20)
     
  864. AASLD: A hospital free of Hepatitis C: Hepatitis C virus screening program in an Emergency Department of a tertiary hospital of a high-income country. (Preliminary results) - (11/16/20)
     
  865. AASLD: Barriers to Hepatitis C Virus Elimination in Germany in Patients Receiving Opioid Substitution Therapy - (11/16/20)
     
  866. AASLD: Positive Predictive Value of SVR4 in Patients Who Achieved SVR12 From Phase 2 and 3 Clinical Trials With Glecaprevir/Pibrentasvir - (11/16/20)
     
  867. AASLD: All Adult HCV Testing Global and US Implementation - (11/16/20)
     
  868. AASLD: Safety, Efficacy, and Pharmacokinetic Analysis of Glecaprevir/Pibrentasvir in Pediatric Patients With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection: Part 2 of the DORA Study - (11/13/20)
     
  869. AASLD: Real-World Outcomes in Patients With Chronic Hepatitis C Virus Infection and Substance Use Disorders Treated With Glecaprevir/Pibrentasvir for 8 Weeks: A Pooled Analysis of Multinational Postmarketing Observational Studies - (11/13/20)
     
  870. AASLD: POINT-OF-CARE HEPATITIS C TESTING AND TREATING STRATEGY IN PEOPLE WHO INJECT DRUGS IN HARM REDUCTION AND ADDICTION CENTERS FOR HEPATITIS C ELIMINATION - (11/13/20)
     
  871. AASLD: HCV elimination in homeless patients is possible: a pooled real-world analysis of homeless patients with HCV treated with sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks - (11/13/20)
     
  872. AASLD: The value of sofosbuvir/velpatasvir (SOF/VEL) as a pangenotypic and panfibrotic HCV treatment in implementing a test-and-treat strategy in prisons: real-world care management from 6 countries - (11/13/20)
     
  873. AASLD: Integrated Efficacy and Safety Analysis of Genotypes 1-6 Treatment-Naïve, Non-Cirrhotic, and Compensated Cirrhotic Hispanic/Latino Patients Who Received 8 Weeks of Glecaprevir/Pibrentasvir - (11/13/20)
     
  874. AASLD: The risk of HCV recurrence in HCV infected patients treated with DAA after achieving a sustained virological response: a comprehensive analysis - (11/13/20)
     
  875. AASLD: ELIMINATING HEPATITIS C: A COMPREHENSIVE PROGRAM OF DIGITAL CASE FINDING AND LINKAGE TO CARE ACROSS A LARGE URBAN HEALTHCARE SYSTEM - (11/13/20)
     
  876. AASLD: Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes - (11/13/20)
     
  877. AASLD: INCIDENCE OF LIVER-RELATED EVENTS IN 647 DAA-CURED HCV CIRRHOTIC PATIENTS: A 5-YEAR SINGLE-CENTER STUDY - (11/13/20)
     
  878. AASLD: Provision of Hepatitis C Care in a Federally Qualified Health Center during the COVID-19 Pandemic - (11/13/20)
     
  879. AASLD: Clinically important changes in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a large real-world setting- results from the German Hepatitis C-Registry (DHC-R) - (11/13/20)
     
  880. AASLD: Impact of the COVID19 pandemic lockdown in an externalized HCV linkage to care model focusing on PWID patients with ongoing high risk practices - (11/13/20)
     
  881. AASLD: Effectiveness of sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic HCV infection and mental health disorders: real-world care management from 8 countries - (11/13/20)
     
  882. AASLD: REAL-WORLD ANALYSIS OF BIRTH COHORT HEPATITIS C ANTIBODY PREVALENCE IN ONTARIO, CANADA - (11/13/20)
     
  883. AASLD: An Integrated Community-Based Approach to Manage and Eliminate Hepatitis C in Vulnerable Populations: The Ontario Hepatitis C Teams Experience - (11/13/20)
     
  884. AASLD: The Impact of COVID-19 on an Outpatient HCV Testing and Treatment Program in New York City: A Natural Experiment In Sudden HCV Treatment Simplification - (11/13/20)
     
  885. EASL Obeticholic Acid Demonstrates Sustained Improvements at Month 24 in Transaminases and Non-invasive Markers of Fibrosis: Results of a Post Hoc Analysis From the Interim Analysis of the REGENERATE Study - (11/10/20)
     
  886. Impact of COVID-19 on global HCV elimination efforts - (11/09/20)
     
  887. Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis - (11/05/20)
     
  888. Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-center Study - (11/05/20)
     
  889. HCV Can Be Eliminated - Marginalized, IDUs & homeless can be successfully treated for HCV - (11/03/20)
     
  890. The Nobel Prize for discovery of HCV is a call to end hepatitis - (11/03/20)
     
  891. ID Week: Rates of COVID Testing, Diagnosis, and Hospital Admission Higher With HIV - Mark Mascolini (11/02/22)
     
  892. ID Week: COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States - increased risk of COVID & had worse outcomes, heroin the worst - (11/02/22)
     
  893. ID Week: HCV Treatment Less Likely for Women, Current Drug Users, Detectable HIV Load - Mark Mascolini (11/02/22)
     
  894. ID Week: Opioid Clinic Use Doubles After COVID Arrives at Alabama HIV Center - Mark Mascolini (11/02/22)
     
  895. Colocated HCV Treatment at Methadone Maintenance in Providence Rhode Island...Road to HCV Elimination - (10/20/20)
     
  896. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19 - (09/28/20)
     
  897. Clin Pharm: Ledipasvir Exposure Linked to SVR, But Overall Response Rate High - By Mark Mascolini for NATAP and Virology Education (10/01/20)
     
  898. EASL Real-life experience of direct acting antiviral treatment for chronic hepatitis C infection in adolescent patients in a low prevalence setting - (09/28/20)
     
  899. EASL Microelimination & Elimination at EASL 2020 - (09/28/20)
     
  900. EASL EDP-297, a novel and potent fxr agonist, exhibit robust anti- fibrotic effects with significant liver function in a rat model of non-alcoholic steatohepatitis - (09/28/20)
     
  901. EASL A novel FXR agonist EDP-297 exerts anti-inflammatory and hepatoprotective effects in human liver 3D microtissues and in rodent models of liver injury and NASH - (09/28/20)
     
  902. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19 - (09/28/20)
     
  903. Difficult to treat Genotypes, sub-Saharan Africa, China or South-East Asia, migrants, Genotype Testing: EASL 2020 Recommendations - (09/28/20)
     
  904. EASL A multidisciplinary approach to non-alcoholic fatty liver disease (NAFLD) improves cardiovascular risk factors - (09/25/20)
     
  905. EASL Progression of liver stiffness and the development of cirrhosis in histologically characterized patients with nonalcoholic fatty liver disease - (09/25/20)
     
  906. EASL Optimal Non-Invasive Screening Strategy for Nonalcoholic Fatty Liver Disease in a Prospective Cohort of Patients with Type 2 Diabetes - (09/25/20)
     
  907. EASL Associations Between Serum Bile-Acid Species With Liver Fibrosis and Prognosis in Patients With Primary Sclerosing Cholangitis - (09/23/20)
     
  908. EASL Machine Learning Models Accurately Interpret Liver Histology and Are Associated With Disease Progression in Patients With Primary Sclerosing Cholangitis - (09/23/20)
     
  909. EASL Hepatic Transcriptomic Analysis Identifies a Mast Cell Gene Expression Signature That Correlates With Fibrosis Stage and Is Prognostic in Patients With Primary Sclerosing Cholangitis - (09/23/20)
     
  910. EASL Removal of Fibrosis-Related Genes Identifies a Hepatic Gene Expression Signature That Identifies Canonical Signaling Pathways and Is Correlated With Clinical Outcomes in Patients With Primary Sclerosing Cholangitis - (09/23/20)
     
  911. EASL Hepatitis C infection in the Spanish Prison System. Elimination is a dream at our fingertips - (09/23/20)
     
  912. EASL Treatment of hepatitis C at the Stockholm needle exchange program - treatment success, reinfection rates and challenges for HCV elimination - (09/23/20)
     
  913. EASL Real-world efficacy and safety of direct-acting antivirals in patients with liver cirrhosis and history of hepatic decompensation: Epi-Ter2 Study. - (09/21/20)
     
  914. EASL HEALTH-RELATED QUALITY OF LIFE (HRQOL) BEFORE AND AFTER TREATMENT OF GENOTYPE 1 (GT1) INFECTION WITH ELBASVIR/GRAZOPREVIR (EBR/GZR): RESULTS FROM THE GERMAN HEPATITIS C REGISTRY (DHC-R) - (09/21/20)
     
  915. EASL Impact of universal access to direct-acting antivirals in the profile of the Hepatitis C treated patient - (09/21/20)
     
  916. EASL INNOVATIVE PROCEDURES FOR MICRO-ELIMINATION OF HCV INFECTION IN A HIGH-RISK POPULATION OF UNDOCUMENTED MIGRANTS AND LOW-INCOME REFUGEES - (09/21/20)
     
  917. EASL Direct-acting antiviral treatment in patients infected with a nonepidemic hepatitis C genotype in the Netherlands: results from a nationwide cohort study - (09/21/20)
     
  918. EASL The dynamics of FIB4 after sustained viral response predicts the risk of liver-related complication in HCV cirrhosis (ANRS CO12 CirVir) - (09/21/20)
     
  919. EASL GES score: A simple score for HCC risk stratification in CHC patients with cirrhosis who achieved SVR following DAAs - (09/21/20)
     
  920. EASL The English hepatitis C registry shows only a modest effect from non- completion of directly-acting antivirals for hepatitis C: SVR rates over 80% in genotype 1, 2 or 3 HCV if more than one third of planned treatment is complete - (09/21/20)
     
  921. EASL Cotadutide Tames Metabolic Markers in Overweight/Obese With Diabetes - Mark Mascolini - (09/17/20)
     
  922. Reply to: "Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action" - (09/17/20)
     
  923. Optimal Non-Invasive Screening Strategy for Nonalcoholic Fatty Liver Disease in a Prospective Cohort of Patients with Type 2 Diabetes - (09/17/20)
     
  924. Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion - (09/17/20)
     
  925. Impact of Pre-existing Chronic Liver Disease on the Outcome of Patients with COVID-19 Disease - comment - (09/17/20)
     
  926. Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study - (09/17/20)
     
  927. Donor and transplant candidate selection for solid organ transplantation during the COVID19 pandemic - (09/17/20)
     
  928. EASL THERATECHNOLOGIES TO DEVELOP TESAMORELIN FOR THE TREATMENT OF NASH IN THE GENERAL POPULATION - (09/15/20)
     
  929. EASL Myosteatosisis strongly associated with NASH in humans and in preclinical NAFLD models - (09/15/20)
     
  930. EASL Machine learning to predict recurrence of early-stage HCC before therapy using baseline MRI - (09/15/20)
     
  931. EASL Glympse Liver Test for Noninvasive Monitoring of Combination Drug Therapy in a Rat Model of Nonalcoholic Steatohepatitis - (09/15/20)
     
  932. The Pharmacokinetics, Pharmacodynamics, and Short-term Safety of Cilofexor, a Nonsteroidal Farnesoid X Receptor Agonist, in Subjects With Hepatic Impairment - (09/15/20)
     
  933. EASL Concentration-QT Analysis of Firsocostat, a Liver-Targeted Acetyl-CoA Carboxylase Inhibitor - (09/15/20)
     
  934. EASL Improvements in the ELF Test Are Associated With Widespread Changes in the Hepatic Transcriptome in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis - (09/15/20)
     
  935. EASL Machine Learning Models Identify Novel Histologic Features Predictive of Clinical Disease Progression in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis - (09/15/20)
     
  936. EASL Predictive modelling to identify and characterize fast progressors among patients with non-alcoholic steatohepatitis (NASH) - (09/15/20)
     
  937. EASL Europe's largest meta-analysis on the prevalence of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis and advanced fibrosis (F3-F4) - (09/15/20)
     
  938. EASL Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with nonalcoholic steatohepatitis - (09/15/20)
     
  939. EASL Proton Beam Radiotherapy Noninferior to Radiofrequency Ablation for HCC - Mark Mascolini (09/04/20)
     
  940. EASL Adherence & DAAs: how much is necessary to Achieve SVR: 75% in 1 study Achieves SVR & 50% in 2nd Study Achieves >90% SVR rate - (09/04/20)
     
  941. EASL Screening and treatment difficulties of hepatitis C virus infected patients with substance use disorders or dual pathology, despite centralized management in an addiction and dual diagnosis center - (09/04/20)
     
  942. EASL HIV co-infection and risk of morbidity and mortality in HCV patients treated by DAA After DAAs for HCV, Liver Events and Liver Mortality Not Affected by HIV - Mark Mascolini (09/04/20)
     
  943. EASL Direct-acting antivirals have substantially modified the profile of patients with cirrhosis who require hospitalization in Spain - Mark Mascolini (09/04/20)
     
  944. EASL Noninvasive Tests of Fibrosis and Risk of Liver-Related Complications: Lessons From Patients With HCV Cirrhosis Following Successful Sofosbuvir-Based Treatment - (09/04/20)
     
  945. EASL Risk of end-stage renal disease among hepatitis C patients with chronic kidney disease treated with and without sofosbuvir - (09/04/20)
     
  946. EASL Health-Related Quality of Life Among People Receiving Opioid Agonist Therapy and Treatment for Hepatitis C Virus Infection: Results From CO-STAR - (09/04/20)
     
  947. EASL Development of a Novel Model to Support Elbasvir/Grazoprevir Use in Children With Chronic Hepatitis C Virus Genotypes 1 or 4 Infection - (09/04/20)
     
  948. EASL Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics - (09/04/20)
     
  949. EASL Decline in HCV incidence in HIV positive MSM -progress to HCV micro-elimination in the UK? - (09/04/20)
     
  950. EASL Acute HCV Rate Down 68% in HIV+ UK MSM Since 2015 - Mark Mascolini (09/04/20)
     
  951. EASL COVID-19 and the liver - data from international registries - (09/04/20)
     
  952. EASL FXR Agonist EDP-305 Lowers ALT and Liver Fat in NASH - Mark Mascolini (08/31/20)
     
  953. EASL Nidufexor Lowers ALT and Liver Fat at 12 Weeks in NASH Patients - Mark Mascolini (08/31/20)
     
  954. EASL TVB-2640 Lowers Liver Fat, Improves Fibrosis, in Phase 2a NASH Trial - Mark Mascolini (08/31/20)
     
  955. EASL Liver and Heart Disease, Nonsolid Cancers, Lead Causes of Death With NAFLD - Mark Mascolini (08/31/20)
     
  956. EASL Safety and Efficacy of Combination Therapies Including Cilofexor/Firsocostat in Patients With Bridging Fibrosis and Cirrhosis Due to NASH: Results of the Phase 2b ATLAS Trial (08/31/20)
     
  957. EASL CCR2/5 Antagonist Plus FGF21 Analog Quell Liver Fat, Fibrosis in Mice - Mark Mascolini (08/31/20)
     
  958. EASL NASH and Visceral Fat Tied to Adipose IR Independently of BMI - Mark Mascolini (08/31/20)
     
  959. EASL Despite Evidence of Benefit in NASH, GLP1a and SGLT2i Use Low in US - Mark Mascolini (08/31/20)
     
  960. EASL More Comorbidities With NAFLD/NASH Than Hepatitis in Global Survey - Mark Mascolini (08/31/20)
     
  961. EASL Causes of Death in Patients with Nonalcoholic Fatty Liver Disease (NAFLD): Data from National Vital Statistics System (NVSS) - (08/31/20)
     
  962. EASL Multidisciplinary NAFLD Approach Yields Strong CVD Risk Gains - Mark Mascolini (08/27/20)
     
  963. EASL Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials - (08/27/20)
     
  964. EASL Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression Vs Men: A Systematic Review and Meta-analysis - (08/27/20)
     
  965. EASL Global real-world evidence of sofosbuvir/velpatasvir(SOF/VEL) as a highly effective treatment and elimination tool in underserved patient populations experiencing mental health disorders, incarceration or homelessness - (08/27/20)
     
  966. EASL Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials - (08/27/20)
     
  967. EASL Efficacy of Sofosbuvir/Velpatasvir (S/V): Impact of Treatment Adherence - (08/27/20)
     
  968. EASL HCV in the Australian primary care setting: Real-world effectiveness of 12 weeks of sofosbuvir/velpatasvirfor the treatment of chronic hepatitis C - (08/27/20)
     
  969. EASL Virological characterization of patients with CHC and failure to a glecaprevir/pibrentasvir or voxilaprevir/velpatasvir/sofosbuvir treatment in the international SHARED collaboration - (08/27/20)
     
  970. EASL Pangenotypic Therapies Glecaprevir-Pibrentasvir (GLE-PIB) and Sofosbuvir-Velpatasvir-Voxilaprevir (SOF-VEL-VOX) After Failure with Interferon (IFN)-Free Direct-Acting Antiviral (DAA) Treatment for Hepatitis C - (08/27/20)
     
  971. EASL New HCV Rate Dropping in German HIV+ MSM-But Reinfection Rate 18% - Mark Mascolini (08/27/20)
     
  972. EASL Directly observed therapy for hepatitis C with sofosbuvir/velpatasvir alongside opioid substitution as a tailored microelimination strategy in PWIDs with a high risk of nonadherence - real-world data from Vienna, Austria - (08/27/20)
     
  973. EASL Barriers to Hepatitis C Virus Elimination in Germany: Why Aren't Diagnosed Patients Initiating Therapy? - (08/27/20)
     
  974. EASL Real-World Clinical Practice Outcomes in Hepatitis C-Infected Patients With Psychiatric and Substance Use Disorders Treated With Glecaprevir/Pibrentasvir for 8 or 12 Weeks: A Pooled Analysis Across 9 Countries - (08/27/20)
     
  975. EASL Declining HCV incidence following rapid HCV treatment scale-up in a prison network in Australia: evidence of treatment as prevention from the SToP-C study - (08/27/20)
     
  976. EASL Global timing of hepatitis C virus elimination in high-income countries: an updated analysis - (08/27/20)
     
  977. EASL Anticipated timing of elimination of hepatitis C virus in Canada's four most populous provinces - (08/27/20)
     
  978. EASL EARLY TREATMENT OF HEPATITIS C VIRUS IMPROVES HEALTH OUTCOMES AND YIELDS COST-SAVINGS: A MODELING STUDY IN ARGENTINA - (08/27/20)
     
  979. EASL Integrated Efficacy and Safety Analysis of GT1-6 Treatment-Naïve, Non-Cirrhotic and Compensated Cirrhotic Patients Who Received 8 Weeks of Glecaprevir/Pibrentasvir - (08/27/20)
     
  980. EASL Timing of Hepatitis C Elimination in the United States: Estimating the year each state will achieve the World Health Organizations targets - (08/27/20)
     
  981. EASL Real World SOF/VEL/VOX Retreatment Outcomes and Viral Resistance Analysis for HCV Patients with Prior Failure to DAA Therapy - (08/27/20)
     
  982. SARS-CoV-2 and the Liver: Considerations in Hepatitis B and Hepatitis C Infections - (08/25/20)
     
  983. Hepatitis B and C Virus Considerations in COVID-19 - (08/25/20)
     
  984. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort - (08/25/20)
     
  985. Multicenter analysis of clinical characteristics and outcome of COVID-19 patients with liver injury - (08/25/20)
     
  986. Characteristics of Liver Tests in COVID-19 Patients - (08/25/20)
     
  987. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19 - (08/25/20)
     
  988. Colocalization in Hepatitis C Virus Infection Care: The Role of Opioid Agonist Therapy Clinics - (08/25/20)
     
  989. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort - (08/25/20)
     
  990. Colocalization in Hepatitis C Virus Infection Care: The Role of Opioid Agonist Therapy Clinics - (08/25/20)
     
  991. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort - (08/25/20)
     
  992. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry - (08/24/20)
     
  993. People with Hepatitis C Who Inject Drugs - Underserved, Not Undeserving - Editorial - (08/24/20)
     
  994. HCV Elimination in USA WAY Behind - (08/24/20)
     
  995. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis - (08/10/20)
     
  996. Research Needs Editorial - Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub Saharan Africa and South East Asia
    About the absolute need to keep active research on the efficacy of direct-acting antiviral drugs against the hepatitis C virus     - (07/30/20)
     
  997. IAC 2020 Virtual: High HCV Rate in Both Young and Older Drug Injectors--HIV Ups HCV Risk - Mark Mascolini (07/15/20)
     
  998. IAC 2020 Virtual: Almost Half of Older HIV+ Adults Report Poor Overall Health in 25-Country Survey - (07/15/20)
     
  999. IAC 2020 Virtual: HCV Drugs for COVID-19? Three Small Studies Have Positive Hints - Mark Mascolini (07/15/20)
     
  1000. IAC 2020 Virtual: Prevalence and Incidence of Hepatitis C Virus Infection in Men Who Have Sex With Men: A Global Systematic Review - (07/13/20)
     
  1001. IAC 2020 Virtual: Incidence of HCV reinfection among HIV-positive MSM and its association with sexual risk behavior: A longitudinal analysis - (07/13/20)
     
  1002. IAC 2020 Virtual: HCV Reinfection Rate 40% in Netherlands HIV+ MSM 5 Years After Clearance - Mark Mascolini (07/13/20)
     
  1003. IAC 2020 Virtual: Global HCV Burden Greater in MSM, Especially HIV+ Men: Meta-Analysis - Mark Mascolini (07/13/20)
     
  1004. Intercept Receives Complete Response Letter from FDA for Obeticholic Acid for the Treatment of Fibrosis Due to NASH - press release - (06/29/20)
     
  1005. Barriers to HCV Treatment: Prior Authorization for PWID Must Be Removed, It Delays Cure & Encourages Disease Progression & Death - (06/19/20)
     
  1006. HCV Testing for HIV+ - Only 50% Are Tested - (06/18/20)
     
  1007. Timing of hepatitis C elimination in the United States: Estimating the year each state will achieve the World Health Organization's elimination targets - (06/17/20)
     
  1008. A Call to Action: HCV Treatment of People Who Inject Drugs in the United States - PWID can be successfully cured - (06/17/20)
     
  1009. HCV Vaccine - Is it Possible ? - (06/12/20)
     
  1010. Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes - (06/12/20)
     
  1011. Hepatitis C: Is eradication possible? - (06/12/20)
     
  1012. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub Saharan Africa and South East Asia - (06/12/20)
     
  1013. High rates of 30-day mortality in patients with cirrhosis and COVID-19 - (06/12/20)
     
  1014. New HCV Cases Tripled / 1 Million Unaware they have HCV / Get Tested - Get Cured - (06/10/20)
     
  1015. EASL: Prevalence of hepatitis C virus infection among men who have sex with men in Moscow - (06/03/20)
     
  1016. Diet Associations With Nonalcoholic Fatty Liver Disease in an Ethnically Diverse Population: The Multiethnic Cohort - (06/01/20)
     
  1017. HCV Elimination in Australia vs USA - (05/21/20)
     
  1018. VAT & Fatty Liver/Fibrosis - "Clinical Predictors of Liver Fibrosis Presence and Progression in HIV-Associated NAFLD" - (05/15/20)
     
  1019. New HCV Infections Tripled: 4 times Higher than in 2009 - (05/14/20)
     
  1020. Short Duration Pan Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection - (05/14/20)
     
  1021. HCV Cure Reduced End Stage Liver Disease - (05/13/20)
     
  1022. High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis - (05/13/20)
     
  1023. CDC: During 2009-2018 the number of reported acute hepatitis C cases per 100,000 population increased threefold. - (05/12/20)
     
  1024. CDC - Beyond baby boomers: Hepatitis C now heavily impacting multiple generations - still no federal funded national screening program ! - (05/12/20)
     
  1025. After Years on the Decline, Hepatitis C Is Returning - Primarily Among Millennials - (05/12/20)
     
  1026. COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care - (05/11/20)
     
  1027. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort - (05/11/20)
     
  1028. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement - (05/08/20)
     
  1029. Non-alcoholic fatty liver disease predicts development of metabolic comorbidities in HIV-infected patients - (05/08/20)
     
  1030. Study Finds Highly Elevated Levels of Fatty Liver Disease for 9/11 First Responders - (05/08/20)
     
  1031. Hepatic Fibrosis Determined with MRE Significantly Predicts Cognitive Impairment - (05/08/20)
     
  1032. Study Finds Highly Elevated Levels of Fatty Liver Disease for 9/11 First Responders - (05/05/20)
     
  1033. CROI: There is a long Long History of Sexual Transmission of HCV in MSM, Heterosexual Men, Women, IDUs & Reinfection too - (05/18/20)
     
  1034. CROI: Hepatitis, HCV, HBV & Fatty Liver at CROI 2020 - (04/29/20)
     
  1035. NYS New Cases HCV Report 2017/ Here the story is young white injectors & HCC Death Rates Still High - (04/28/20)
     
  1036. Baby Boomers & Blacks Dominate the Story: - (04/28/20)
     
  1037. CROI: INDIVIDUAL AND POPULATION-LEVEL IMPACT OF HCV TREATMENT AMONG PEOPLE WHO INJECT DRUGS (04/10/20)
     
  1038. CROI: LARGE HEPATITIS C TRANSMISSION CLUSTER IDENTIFIED AMONG HIV POSITIVE MSM IN BANGKOK (04/10/20)
     
  1039. U.S. Food And Drug Administration Approves Epclusa (Sofosbuvir/Velpatasvir) for Children Ages 6 and Older or Weighing at Least 17 kg with Chronic Hepatitis C Infection - (04/13/20)
     
  1040. CROI: Barriers To Direct-Acting Antiviral Therapy Among HIV/HCV-Coinfected Adults (04/10/20)
     
  1041. CROI: EXPLOSIVE HIV AND HCV EPIDEMICS DRIVEN BY NETWORK VIREMIA (04/04/20)
     
  1042. CROI: HCV INCIDENCE AMONG HIV-INFECTED MSM IN FRANCE: RESULTS FROM THE FHDH-ANRS CO4 COHORT (04/04/20)
     
  1043. CROI: HPTN 078: HIGH INCIDENCE OF HEPATITIS C VIRUS INFECTIONS AMONG MSM (04/02/20)
     
  1044. CROI: HEPATITIS C VIRUS INFECTION AND COINFECTION WITH HIV AMONG PWID IN 10 US CITIES (04/02/20)
     
  1045. CROI: Mobile HCV Screening in At-Risk Urban Population Identifies Significant Fibrosis (04/02/20)
     
  1046. CROI: HCV REINFECTION AFTER DAA TREATMENT AMONG PEOPLE LIVING WITH HIV IN SAN DIEGO (04/02/20)
     
  1047. CROI: HCV TRANSMISSION AMONG MSM: EXTERNAL INTRODUCTIONS COULD COMPLICATE MICRO-ELIMINATION (04/02/20)
     
  1048. CROI: INVESTIGATION OF CLASSIC AND HIV-RELATED FACTORS FOR HEPATIC STEATOSIS AMONG PWID - 20% ALIVE Cohort (04/02/20)
     
  1049. CROI: EXPLOSIVE HIV AND HCV EPIDEMICS DRIVEN BY NETWORK VIREMIA AMONG PWID (03/31/20)
     
  1050. CROI: SEX, NOT DRUG USE, IS DRIVING HCV RE-INFECTION AMONG HIV-INFECTED MSM IN NEW YORK CITY (03/30/20)
     
  1051. CROI: Hepatic Fibrosis Determined with MRE Significantly Predicts Cognitive Impairment (03/30/20)
     
  1052. CROI: Hepatitis C Coinfection and Extrahepatic Cancer Incidence among People with HIV (03/30/20)
     
  1053. CROI: HCV, Opioid Use, Psych Illness Cluster in Veterans Group--Treatment of Opioid Use Very Low (03/30/20)
     
  1054. U.S. Food And Drug Administration Approves Epclusa (Sofosbuvir/Velpatasvir) for Children Ages 6 and Older or Weighing at Least 17 kg with Chronic Hepatitis C Infection - (03/23/20)
     
  1055. CROI: HCV Retreatment, Multiple DAA Failures - Case Study (03/18/20)
     
  1056. CROI: Real-world effectiveness of Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection (03/18/20)
     
  1057. CROI: Real-world effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C Virus Infection (03/18/20)
     
  1058. CROI: Progress and Real-Life Challenges for HCV Elimination in People Living with HIV (03/18/20)
     
  1059. CROI: CAUSES OF DEATH IN PERSONS WITH AND WITHOUT HCV INFECTION (03/18/20)
     
  1060. CROI: A Multicenter Registry in HIV/HCV Co-infected Patients Initiating Ledipasvir/Sofosbuvir (03/18/20)
     
  1061. CROI: Risk of Hepatocellular Carcinoma among Persons Living with HIV and Viral Hepatitis Coinfection in the United States and Canada, 1996-2015 (03/18/20)
     
  1062. CROI: Six-Week SOF/VEL Inferior to 12 Weeks for Recently Acquired HCV - Mark Mascolini (03/18/20)
     
  1063. CROI: Liver Cancer Rate Rising Since 1996 in North Americans With HIV - Mark Mascolini (03/18/20)
     
  1064. CROI: Six-Week SOF/VEL Inferior to 12 Weeks for Recently Acquired HCV - Mark Mascolini (03/18/20)
     
  1065. CROI: CLINICAL PREDICTORS OF LIVER FIBROSIS PRESENCE & PROGRESSION IN HIV-ASSOCIATED NAFLD - (03/11/20)
     
  1066. CROI: NEWBORN TESTING REVEALS HIGH HCV SEROPREVALENCE IN PREGNANT WOMEN FROM NEW YORK STATE - (03/11/20)
     
  1067. CROI: HCV Prevalence Almost 2% in New Mothers in 2 New York State Regions - Mark Mascolini (03/11/20)
     
  1068. CROI: NEWBORN TESTING REVEALS HIGH HCV SEROPREVALENCE IN PREGNANT WOMEN FROM NEW YORK STATE - (03/11/20)
     
  1069. CROI: Falling Cirrhosis and HCV Viremia in Baltimore PWID, Maybe Reflecting DAAs - Mark Mascolini (03/11/20)
     
  1070. Universal Screening for Hepatitis C Virus Infection - A Step Toward Elimination, + Editorial - (03/02/20)
     
  1071. New HCV Drug CC-31244 Non Nucleoside Inhibitor - (02/28/20)
     
  1072. The Medicines Patent Pool and Mylan sign agreement to scale up access to first generic version of hepatitis C treatment glecaprevir/pibrentasvir - (02/27/20)
     
  1073. The cost of eliminating hepatitis C in Pakistan Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis - (02/21/20)
     
  1074. AbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis - (02/14/20)
     
  1075. 20% Treated - Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore - (02/10/20)
     
  1076. AASLD: Assessing the Real-World Effectiveness and Clinical Efficacy of 8198 Patients Receiving Elbasvir/Grazoprevir for the Treatment of HCV Infection - (02/03/20)
     
  1077. HCV in USA Current Status - (01/30/20)
     
  1078. USA is last globally in HCV Elimination - (01/30/20)
     
  1079. Sexually Acquired Hepatitis C Infection in HIV-Uninfected Men Who Have Sex With Men Using Preexposure Prophylaxis Against HIV - (01/17/20)
     
  1080. Acute HCV & PrEP/MSM HIV+ & HIV-Neg - (01/17/20)
     
  1081. EACS: High HCV re infection rate in MSM living with HIV in Barcelona: The need to focus on high risk population to achieve HCV elimination (01/17/20)
     
  1082. EACS: Hepatic steatosis in HIV+ individuals: which impact has baseline BMI and treatment with integrase inhibitors? (01/13/20)
     
  1083. EACS: Evolutive NAFLD predicts frailty in people living with HIV - Mark Mascolini (01/13/20)
     
  1084. AASLD: Changes in Insulin Resistance Out to 3 Years After Successful Interferon-Free Treatment of Chronic HCV Infection - (01/13/20)
     
  1085. AASLD: Impact of Prescribed Treatment Duration on Hepatitis C Treatment Adherence: Comparison of 8- and 12-Week Treatment With Glecaprevir/Pibrentasvir - (01/13/20)
     
  1086. AASLD: Effect of Spatial Access on HCV Linkage to Care In the US (2016) Based On Large Real-world Dataset - (01/13/20)
     
  1087. AASLD: Outcomes of Patients Interrupting Glecaprevir/Pibrentasvir Treatment: A Case Series From Clinical Trials - (01/13/20)
     
  1088. Gilead Announces Topline Results From Phase 2 ATLAS Study in Patients With Bridging Fibrosis (F3) and Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) - (01/08/20)
     
  1089. Vitamin E for Fatty Liver in AASLD Guidelines - (01/08/20)
     
  1090. Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients - (01/08/20)
     
  1091. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure - (01/07/20)
     
  1092. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia - (01/07/20)
     
  1093. Gilead Sciences' Commitment to Global Elimination of Hepatitis C Virus - (01/07/20)
     
  1094. Safety of Sofosbuvir-Based Regimens for the Treatment of Chronic HCV Infection in Patients with Mild or Moderate Renal Impairment - (01/07/20)
     
  1095. AASLD: Short duration sofosbuvir-velpatasvir is inferior to standard duration therapy in the treatment of recently acquired HCV infection: results from the REACT study - (12/06/19)
     
  1096. AASLD: Mission possible: In Iceland 95% of eligible HCV infected patients were initated on treatment within three years. Results from the Treatment as Prevention for Hepatitis C (TraP HepC) program - (12/06/19)
     
  1097. AASLD: Italian real life experience of resistance guided retreatment in HCV infected patients who previously failed a NS5A inhibitor containing regimen - (12/06/19)
     
  1098. AASLD: Salvage Therapy in Cancer Patients with Hepatitis C without Sustained VirologicResponse after Direct-Acting Antivirals -A Prospective Study - (12/06/19)
     
  1099. Acute HCV Increasing/Doubled - (12/20/19)
     
  1100. AASLD: 8 weeks of Glecaprevir/pibrentasvir is effective and well tolerated in non-GT3 HCV patients with cirrhosis - (12/20/19)
     
  1101. AASLD: Efficacy and Safety of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With Chronic Hepatitis C Virus Genotypes 1-6 in Brazil - (12/20/19)
     
  1102. Global Efforts on HCV Elimination John Ward MD at African HCV Conference - (12/16/19)
     
  1103. Obeticholic acid: towards first approval for NASH - Comment - (12/13/19)
     
  1104. AASLD: Zydus Announces Positive Results From EVIDENCES IV Phase 2 Clinical Trial of Saroglitazar Magnesium in NAFLD and NASH - (12/13/19)
     
  1105. AASLD: Tropifexor (TXR), an FXR Agonist for the Treatment of NASH - Interim Results from First Two Parts of Phase 2b Study FLIGHT-FXR - (12/13/19)
     
  1106. AASLD: Effects of Cotadutide (MEDI0382) on Biomarkers of Nonalcoholic Steatohepatitis in Overweight or Obese Subjects with Type 2 Diabetes Mellitus: A 26-Week Analysis of a Randomized Phase 2b Study - (12/13/19)
     
  1107. AASLD: SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF OBETICHOLIC ACID IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS OR CIRRHOSIS - (12/03/19)
     
  1108. AASLD: ASSESSMENT OF PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) TREATED WITH OBETICHOLIC ACID (OCA): RESULTS FROM REGENERATE PHASE 3 CLINICAL TRIAL - (12/03/19)
     
  1109. AASLD: Obeticholic Acid Treatment in Patients with Non-alcoholic Steatohepatitis: A Secondary Analysis of the REGENERATE Study Across Fibrosis Stages - (12/03/19)
     
  1110. Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action - (12/12/19)
     
  1111. No Identified Association Between Glecaprevir/Pibrentasvir Use and Risk of Hepatic Decompensation in HCV-Infected Patients With Compensated Cirrhosis at Baseline: An Active Comparator Cohort Study - (12/12/19)
     
  1112. Outcomes of Patients Interrupting Glecaprevir/Pibrentasvir Treatment: A Case Series From Clinical Trials - (12/12/19)
     
  1113. Impact of Prescribed Treatment Duration on Hepatitis C Treatment Adherence: Comparison of 8- and 12-Week Treatment With Glecaprevir/Pibrentasvir - (12/12/19)
     
  1114. Safety of Sofosbuvir-Based Regimens for the Treatment of Chronic HCV Infection in Patients with Mild or Moderate Renal Impairment - (12/12/19)
     
  1115. Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C - (12/12/19)
     
  1116. Safety and Efficacy at 48 Weeks After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients With Risk Factors for TDF Use - (12/12/19)
     
  1117. AASLD: LIK066 (licogliflozin), an SGLT1/2 inhibitor, robustly decreases ALT and improves markers of hepatic and metabolic health in patients with nonalcoholic fatty liver disease: Interim analysis of a 12-week, randomized, placebo-controlled, Phase 2a study - (12/10/19)
     
  1118. Impact of Prescribed Treatment Duration on Hepatitis C Treatment Adherence: Comparison of 8- and 12-Week Treatment With Glecaprevir/Pibrentasvir (HepDart) - (12/10/19)
     
  1119. Outcomes of Patients Interrupting Glecaprevir/Pibrentasvir Treatment: A Case Series From Clinical Trials (HepDart) - (12/10/19)
     
  1120. No Identified Association Between Glecaprevir/Pibrentasvir Use and Risk of Hepatic Decompensation in HCV-Infected Patients With Compensated Cirrhosis at Baseline: An Active Comparator Cohort Study (HepDart) - (12/10/19)
     
  1121. AASLD: LIK066 (licogliflozin), an SGLT1/2 inhibitor, robustly decreases ALT and improves markers of hepatic and metabolic health in patients with nonalcoholic fatty liver disease: Interim analysis of a 12-week, randomized, placebo-controlled, Phase 2a study - (12/09/19)
     
  1122. AASLD: Higher Number of Concurrent Metabolic Co-Morbidities Is Associated with Increasingly Higher Risk of Significant Hepatic Fibrosis and Cirrhosis in Nonalcoholic Fatty Liver Disease Patients - (12/09/19)
     
  1123. AASLD: MELD-score changes in relation to clinical outcome following DAAs in HCV-infected patients with cirrhosis - (12/09/19)
     
  1124. AASLD: Effects of Cotadutide (MEDI0382) on Biomarkers of Nonalcoholic Steatohepatitis in Overweight or Obese Subjects with Type 2 Diabetes Mellitus: A 26-Week Analysis of a Randomized Phase 2b Study - (12/09/19)
     
  1125. AASLD: Ongoing analysis of virologic control / functional cure of HBV and HDV infection following REP 2139-Ca and pegylated interferon alpha-2a therapy in patients with chronic HBV / HDV co-infection: 3.5-year follow-up results from the REP 301-LTF study - (12/05/19)
     
  1126. AASLD: Ultrasound-based Controlled Attenuation Parameter (CAP) to Detect Longitudinal Changes in Liver Fat When Effect Size is Large -Experience From a Phase 2a, Dose-ranging Study Assessing MRI-Proton Density Fat Fraction (PDFF) and CAP In Parallel - (12/05/19)
     
  1127. AASLD: PF-05221304 (PF'1304), a liver-targeted acetyl-CoA carboxylase inhibitor (ACCi), in adults with nonalcoholic fatty liver disease (NAFLD) demonstrates robust reductions in liver fat and ALT-Phase 2a, dose-ranging study - (12/05/19)
     
  1128. AASLD: Safety and Efficacy of 10mg (high-dose) bulevirtide (Myrcludex B) in combination with PEG-IFNa or TDF in patients with chronic HBV/HDV co-infection: interim results. - (12/05/19)
     
  1129. AASLD: A Phase 2 Study of Lonafarnib, Ritonavir & Peginterferon Lambda for 24 Weeks: Interim End-of-Treatment Results from the LIFT HDV Study - (12/05/19)
     
  1130. AASLD: THE IMPACT OF PRURITUS ON PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) TREATED WITH OBETICHOLIC ACID (OCA) - (12/05/19)
     
  1131. AASLD: Obeticholic Acid Treatment in Patients with Non-alcoholic Steatohepatitis: A Secondary Analysis of the REGENERATE Study Across Fibrosis Stages - (12/03/19)
     
  1132. AASLD: ASSESSMENT OF PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) TREATED WITH OBETICHOLIC ACID (OCA): RESULTS FROM REGENERATE PHASE 3 CLINICAL TRIAL - (12/03/19)
     
  1133. AASLD: SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF OBETICHOLIC ACID IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS OR CIRRHOSIS - (12/03/19)
     
  1134. AASLD: Epidemiological Greek multicenter study of NAFLD: data from a large national cohort - (12/03/19)
     
  1135. AASLD: Assessment of Non Alcoholic Fatty Liver Disease in a cohort of HIV mono-infected patients - (11/25/19)
     
  1136. AASLD: Validation of the Diagnostic Accuracy of Magnetic Resonance Elastography for the Detection of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis Across Multiple Phase 2 and 3 Clinical Trials - (11/26/19)
     
  1137. AASLD: Routinely Available Noninvasive Tests Perform Well in Identifying Patients with Advanced Fibrosis Due to NASH: Data from the TARGET-NASH Observational Cohort - (11/26/19)
     
  1138. AASLD: Higher Number of Concurrent Metabolic Co-Morbidities Is Associated with Increasingly Higher Risk of Significant Hepatic Fibrosis and Cirrhosis in Nonalcoholic Fatty Liver Disease Patients - (11/26/19)
     
  1139. AASLD: Underestimation of Liver Disease in the Medicare Eligible Population - (11/26/19)
     
  1140. AASLD: HCV-RNA Is Readily Detectable in Nasal and Rectal Fluids of HCV Patients with High Viremia - (11/25/19)
     
  1141. AASLD: Course of Cirrhosis Regression: Lessons From Patients With HCV Cirrhosis Following Successful Sofosbuvir-Based Treatment - (11/25/19)
     
  1142. AASLD: Prevalence and profile of non-alcoholic fatty liver disease in lean adults: Systematic review and meta-analysis - (11/25/19)
     
  1143. AASLD: The global prevalence of resistance-associated substitutions (RAS) in "unusual" HCV subtypes - (11/25/19)
     
  1144. AASLD: Factors Associated with Mortality in Lean, Overweight and Obese Patients with Non-alcoholic Fatty Liver Disease - (11/25/19)
     
  1145. EACS: Untreated HCV in HIV/HCV-Coinfected US Population Despite an Abundance of Curative Therapies (11/22/19)
     
  1146. AASLD: REAL-LIFE EFFECTIVENESS AND SAFETY OF SOFOSBUVIR/VELPATASVIR/ VOXILAPREVIR FOR CHRONIC HEPATITIS C PATIENTS WITH PRIOR DAA FAILURE: FINAL RESULTS OF THE NAVIGATORE NETWORK - (11/20/19)
     
  1147. AASLD: Pharmacokinetics of Glecaprevir/Pibrentasvir in Children With Chronic HCV Infection: Interim Analysis of Part 2 of the DORA Study - (11/18/19)
     
  1148. AASLD: Hepatitis C Virus Reinfection After Successful Treatment with Direct Acting Anti-viral Therapy among MSM - (11/18/19)
     
  1149. AASLD: Drug Use and Reinfection Following HCV Treatment With Elbasvir/Grazoprevir Among Patients Receiving Opioid Agonist Therapy: Final Results From the CO-STAR Study - (11/18/19)
     
  1150. AASLD: Effectiveness of Sofosbuvir / Velpatasvir in Treating Hepatitis C Virus Infection in a Real-world Setting - (11/18/19)
     
  1151. AASLD: Strategic Treatment Optimizationon for HCV (STOPHCV-1): an open-label factorial randomised controlled trial of short duration therapy for chronic hepatitis C - (11/18/19)
     
  1152. AASLD: CLINICAL AND VIROLOGICAL CHARACTERISTICS OF PATIENTS WITH CHRONIC HEPATITIS C AND FAILURE TO A GLECAPREVIR AND PIBRENTASVIR (G/P) TREATMENT IN REAL WORLD - (11/18/19)
     
  1153. AASLD: Short duration sofosbuvir-velpatasvir is inferior to standard duration therapy in the treatment of recently acquired HCV infection: results from the REACT study - (11/18/19)
     
  1154. AASLD: HCV Resistance Patterns in a Worldwide Network of Cohorts of GT-3a infected patients - (11/18/19)
     
  1155. AASLD: HCV cure by IFN-free DAAs is associated with increased survival in patients with HCV-related HCC - (11/18/19)
     
  1156. AASLD: PRIOR THERAPY WITH SOFOSBUVIR/VELPATASVIR ASSOCIATED WITH REDUCED RESPONSE TO SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR: RESULTS FROM A CANADIAN PROSPECTIVE REGISTRY - (11/18/19)
     
  1157. AASLD: Hepatitis Debrief The Liver Meeting 2019 - (11/15/19)
     
  1158. AASLD: Pangenotypic Therapies Glecaprevir-Pibrentasvir (GLE-PIB) and Sofosbuvir-Velpatasvir-Voxilaprevir (SOF-VEL-VOX) After Failure with Interferon (IFN)-Free Direct-Acting Antiviral (DAA) Treatment for Hepatitis C - (11/14/19)
     
  1159. AASLD: Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir as a hepatitis C virus infection salvage treatment - (11/14/19)
     
  1160. AASLD: Antiviral treatment status and risk of renal and cardiovascular outcomes in patients with chronic hepatitis C - (11/14/19)
     
  1161. AASLD: High Risk of Non-alcoholic Liver Disease Mortality in Patients With Chronic Hepatitis C With Illicit Substance Use Disorder - (11/14/19)
     
  1162. AASLD: Glecaprevir/Pibrentasvir is Effective and Well Tolerated in Hepatitis C Patients With Cirrhosis: Real-World Experience From the German Hepatitis C-Registry - (11/13/19)
     
  1163. AASLD: Addressing Barriers to Hepatitis C Virus (HCV) Elimination: Real-World Outcomes in Historically Underserved Patients With Chronic HCV Infection Treated With Glecaprevir/Pibrentasvir - (11/13/19)
     
  1164. AASLD: From Clinical Trials to Real-World Evidence: Similar Virologic Cure Rates and Safety Outcomes Following Treatment With Glecaprevir/Pibrentasvir Among Patients With Chronic Hepatitis C Virus Infection and Recent Drug Use - (11/13/19)
     
  1165. AASLD: Safety and Efficacy of Velpatasvir, Sofosbuvir and Voxilaprevir-based Regimens for the Treatment of HCV Genotype 1-6: Results of the HCV-TARGET Study - (11/13/19)
     
  1166. AASLD: Efficacy and Safety of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, 5, or 6 Infection and Compensated Cirrhosis: EXPEDITION-8 Complete Results - (11/13/19)
     
  1167. AASLD: DAA REGIMENS ARE ASSOCIATED WITH SIGNIFICANT REDUCTION IN LIVER RELATED MORTALITY DRIVEN LARGELY BY HIGHER SVR RATES: RESULTS FROM THE ERCHIVES COHORT - (11/13/19)
     
  1168. AASLD: Course of Cirrhosis Regression: Lessons From Patients With HCV Cirrhosis Following Successful Sofosbuvir-Based Treatment - (11/13/19)
     
  1169. AASLD: SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR IN PEDIATRIC PATIENTS 6 TO < 18 YEARS OLD WITH CHRONIC HEPATITIS C INFECTION - (11/13/19)
     
  1170. AASLD: Efficacy and Safety of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With Chronic Hepatitis C Virus Genotypes 1-6 in Brazil - (11/13/19)
     
  1171. EACS: Fibrosis, Steatosis, and NAFLD Boost Odds of Frailty in HIV Group - Mark Mascolini (11/13/19)
     
  1172. AASLD: Gilead Announces New Data from Viral Hepatitis Research Programs at The Liver Meeting® 2019 - (11/12/19)
     
  1173. AASLD: Data Showing Potential for Machine Learning to Advance Understanding of Nonalcoholic Steatohepatitis (NASH) Presented at the Liver Meeting® 2019 - Gilead Press Release - (11/12/19)
     
  1174. Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study - (10/31/19)
     
  1175. Short duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with recent HCV infection - (10/31/19)
     
  1176. IDWeek 2019: HCV Testing and Diagnosis and their relationship to STI Screening and New Infections in a HIV+ MSM Outpatient Cohort - Syphilis, Gonorrhea Tied to HCV in MSM and Trans Women With HIV - (10/28/19)
     
  1177. IDWeek 2019: Results of the First Prophylactic Hepatitis C Virus Vaccine Efficacy Trial - (10/28/19)
     
  1178. IDWeek 2019: HCV-Related Mortality in US Fell 4% Yearly After Arrival of DAAs - Mark Mascolini (10/7/19)
     
  1179. CDC HCV Surveillance 2017: High HCV Mortality Rates Among 55-74 Age Group & Highest Among Blacks & Latinos - (09/19/19)
     
  1180. USPSTF issues draft recommendation statement for HCV screening in adults - (09/02/19)
     
  1181. FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease - (09/02/19)
     
  1182. Hepatitis C Elimination in Scotland - (09/02/19)
     
  1183. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY) - (09/02/19)
     
  1184. Letter to Officials Requesting Access to Hepatitis C Treatment for Rhode Island Medicaid Patients - (09/02/19)
     
  1185. Letter to Officials Requesting Access to Hepatitis C Treatment for Rhode Island Medicaid Patients - (09/02/19)
     
  1186. Suboptimal SVR rates in African patients with atypical Genotype 1 subtypes: implications for global elimination of Hepatitis C - (08/13/19)
     
  1187. IAS: HCV Reinfection Rate in People With HCV/HIV 13% Across Europe - Mark Mascolini - (08/01/19)
     
  1188. IAS: High STI Prevalence in German MSM, But Low Rates of HIV, HCV, HBV - Mark Mascolini - (07/25/19)
     
  1189. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA - (07/10/19)
     
  1190. Ribavrin Added in GT3 Compensated Cirrhotics in Large England NHS Treatment Registry with 16,567 DAA Treated  "Effectiveness of therapy in 16,567 directly-acting antiviral treated people in England: high response rates in genotype 3 hepatitis C infection regardless of degree of fibrosis, but ribavirin improves response in cirrhosis" - (07/08/19)
     
  1191. EASL: Effectiveness of therapy in 16,567 directly-acting antiviral treated people in England: high response rates in genotype 3 hepatitis C infection regardless of degree of fibrosis, but ribavirin improves response in cirrhosis - (07/08/19)
     
  1192. AASLD: Risk of Parkinson's Disease in Hepatitis C Patients Following Exposure to Direct-Acting Antiviral Treatment: An Analysis of US Administrative Claims Data - (06/10/19)
     
  1193. Interferon Stops Parkinson Disease: Association of Antiviral Therapy With Risk of Parkinson Disease in Patients With Chronic Hepatitis C Virus Infection - (06/07/19)
     
  1194. EASL: Genotype 3 patients treated with glecaprevir/pibrentasvir: Real world outcomes from an unselected cohort - (05/30/19)
     
  1195. EASL: High efficacy of SOF+VEL regardless of patients' clinical characteristics - (05/30/19)
     
  1196. EASL: Prospective Evaluation of Serum Alkaline Phosphatase Variability and Prognostic Utility in Primary Sclerosing Cholangitis Using Controlled Clinical Trial Data - (05/28/19)
     
  1197. EASL: Validation of Histologic and Noninvasive Measures of Fibrosis as Surrogate Endpoints of Disease Progression in Patients with Primary Sclerosing Cholangitis - (05/28/19)
     
  1198. 20th Intnl Wrkshp Clin Pharm: High incidence of drug-drug interactions with hepatitis C direct-acting antivirals in patients hospitalized during their treatment (MONTREAL-C) (05/23/19)
     
  1199. EASL: The hepatitis C cascade of care and treatment outcomes among people who inject drugs in a Norwegian low-threshold setting: A real life experience - (05/21/19)
     
  1200. 20th Intnl Wrkshp Clin Pharm: Sofosbuvir exposure higher in opioid users, lower with darunavir - Mark Mascolini (05/20/19)
     
  1201. 20th Intnl Wrkshp Clin Pharm: Glecaprevir/pibrentasvir pharmacokinetics in HCV/HIV patients co-administered with antiretroviral drugs - (05/20/19)
     
  1202. 20th Intnl Wrkshp Clin Pharm: Physiologically based pharmacokinetic modelling to determine pharmacokinetic alterations driving ritonavir exposure changes in aging people living with HIV - (05/16/19)
     
  1203. 20th Intnl Wrkshp Clin Pharm: Management of antiretrovirals in Seniors - The importance of assisted treatment for adherence to treatment - (05/16/19)
     
  1204. 20th Intnl Wrkshp Clin Pharm: IV PPIs and H2 antagonists did not thwart response to ledipasvir or velpatasvir - Mark Mascolini - (05/16/19)
     
  1205. 20th Intnl Wrkshp Clin Pharm: Two thirds of Montreal in-hospital HCV group have interactions with DAAs - Mark Mascolini - (05/16/19)
     
  1206. 20th Intnl Wrkshp Clin Pharm: Lower cobicistat and atazanavir troughs in smokers with HIV - Mark Mascolini - (05/16/19)
     
  1207. 20th Intnl Wrkshp Clin Pharm: Sofosbuvir exposure higher in opioid users, lower with darunavir - Mark Mascolini - (05/16/19)
     
  1208. 20th Intnl Wrkshp Clin Pharm: Predose concentrations of DTG and RPV steady through 100 weeks in SWORD trials - Mark Mascolini - (05/16/19)
     
  1209. EASL: CANCER RISK AMONG PEOPLE WITH HIV, HBV AND/OR HCV INFECTIONS - (05/16/19)
     
  1210. EASL: Access to Direct Acting Antiviral Agents in HIV/HCV Co-Infected Population in the US - (05/16/19)
     
  1211. EASL: CANCER RISK AMONG PEOPLE WITH HIV, HBV AND/OR HCV INFECTIONS - (05/16/19)
     
  1212. EASL: Iceland may already have reached the WHO 2030 targets for diagnosis and treatment of hepatitis C virus infection. Results from the Treatment as Prevention for Hepatitis C (TrapHepC) program - (05/14/19)
     
  1213. EASL: Uptake of testing and treatment for HCV among PWID in Australia: The ETHOS Engage Study - "59% HCV treatment uptake" - (05/13/19)
     
  1214. EASL: Is it possible to successfully link migrants to HBV, HCV and HIV services upon arrival in the European Union? - (05/13/19)
     
  1215. EASL: Is homelessness the biggest hurdle to treatment success in the management of HCV in the era of direct acting antivirals? - Results from the TraP HepC nationwide treatment initiative in Iceland - - (05/13/19)
     
  1216. EASL: Factors associated with hepatitis C treatment uptake among people who inject drugs in a population based data linkage study Next Steps - (05/13/19)
     
  1217. Cocrystal Pharma Provides Update on Clinical Development Program Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C Virus - (05/13/19)
     
  1218. Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication - (05/13/19)
     
  1219. EASL: THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders - (05/09/19)
     
  1220. EASL: EASL 2019 HCV Highlights Report: Treatment, Retreatment, Elimination, Fatty Liver/HIV, Resistance Testing, Reinfection - (05/09/19)
     
  1221. EASL: NGM313, a Novel Activator of β-Klotho/FGFR1c: A Single Dose Significantly Reduces Steatosis (Liver Fat by MRI-PDFF), Inflammation (ALT, AST) and FibrogenicActivity (Pro-C3) in NAFLD Subjects - (05/08/19)
     
  1222. EASL: Merck (Fatty Liver Disease/NASH) and NGM Bio Announce Extension of Broad, Multi-Year Strategic Collaboration to 2022 - (05/08/19)
     
  1223. EASL: New Non-Invasive NASH/Fibrosis Biomarkers - A Comparative Study of Fibrosis Treatments using Aptamer-Based Quantitative Proteomics in a Model of Nonalcoholic Steatohepatitis Cirrhosis - (05/08/19)
     
  1224. EASL: A Novel Approach to Funding HCV and HBV Treatment for all -Uzbekistan Pilot Project - (05/08/19)
     
  1225. EASL: The short and long term impact of scaling up treatment for hepatitis B and C on disease burden - (05/08/19)
     
  1226. EASL: A comparison of currently available direct acting antiviral HCV therapy in Canada - On the path to elimination - (05/08/19)
     
  1227. EASL: MR elastography based fibrosis correlates with clinical liver events in patients with non-alcoholic fatty liver disease: A multi-center study - (05/08/19)
     
  1228. EASL: A comparison of currently available direct acting antiviral HCV therapy in Canada - On the path to elimination - (05/07/19)
     
  1229. EASL: HCV treatment outcomes among current and remote people who inject drugs (PWID): real life data - (05/07/19)
     
  1230. EASL: MR elastography based fibrosis correlates with clinical liver events in patients with non-alcoholic fatty liver disease: A multi-center study - (05/07/19)
     
  1231. EASL: Liver enzymes cut offs in patients with advanced non-alcoholic fatty liver disease: A multi-center study - (05/07/19)
     
  1232. EASL: A Simple Algorithm Based on Electronic Medical Records to Identify NAFLD with Advanced Fibrosis in Patients with Type 2 Diabetes - (05/07/19)
     
  1233. EASL: The natural history of NASH-induced advanced fibrosis in a large cohort of patients with type-2 diabetes - (05/07/19)
     
  1234. EASL: Rwanda HCV Elimination Project - (05/07/19)
     
  1235. EASL: New in France: Universal Access for HCV-treatment as demonstrated by a nationwide real-world cohort - (05/07/19)
     
  1236. EASL: Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C - (05/07/19)
     
  1237. EASL: The combination of HEPAmet fibrosis score and transient elastography shows a high diagnostic accuracy in predicting advanced fibrosis in NAFLD - (05/07/19)
     
  1238. EASL: Resistance-guided retreatment of HCV infected patients with a previous failure to an NS5A inhibitor-containing regimen: Italian real life experience - (04/30/19)
     
  1239. EASL: Food, Obesity and Non-Alcoholic Fatty Liver Disease (NAFLD) - (04/30/19)
     
  1240. EASL: LIFESTYLE FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE - (04/30/19)
     
  1241. EASL: CONTRA Testing for HCV RASs after DAA Failure and Choices of Retreatment - (04/30/19)
     
  1242. EASL: 4 week treatment [G/P+/-Rbv] for hepatitis C - a randomized controlled trial (4RIBC) - (04/30/19)
     
  1243. AbbVie wins hep C contract with Washington state in latest 'Netflix' deal - (04/30/19)
     
  1244. Health Care Authority announces AbbVie US LLC as apparently successful bidder for hepatitis C virus treatment drug - (04/30/19)
     
  1245. HCV EASL Treatment Guidelines / 16-24 Weeks Retreatment / Retreatment of patients who failed after a protease inhibitor- and/or NS5A inhibitor-containing regimen - (04/30/19)
     
  1246. EASL: Comparison of HCV resistance-associated substitutions in patients infected with HCV genotype 3 before and after failure to DAA combination therapies - (04/26/19)
     
  1247. EASL: EVALUATION OF HEPATITIS C VIRUS RAPID DIAGNOSTIC TESTS IN HCV MONO- AND HCV/HIV CO-INFECTED PATIENTS FROM LOW- AND MIDDLE-INCOME COUNTRIES - (04/26/19)
     
  1248. EASL: PRO: Testing for HCV Resistance-Associated Variants (RAVs) in Patients After DAA Failure and Impact on Subsequent Drug Selection - (04/26/19)
     
  1249. EASL: The socio-economic burden of NASH in Europe and the United States: the GAIN study - (04/26/19)
     
  1250. EASL: A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases - (04/23/19)
     
  1251. EASL: High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance - (04/23/19)
     
  1252. EASL: Liver Disease in UK General Population: Fatty & Alcohol Liver Disease; Lack of Awareness: 4% aware; High Rate of Risk Factors: 89% - (04/23/19)
     
  1253. EASL: EVALUATION OF HEPATITIS C VIRUS RAPID DIAGNOSTIC TESTS IN HCV MONO- AND HCV/HIV CO-INFECTED PATIENTS FROM LOW- AND MIDDLE-INCOME COUNTRIES - (04/23/19)
     
  1254. EASL: EASL Wrap-up session: Metabolic and alcohol related liver disease, Fatty Liver/NASH - (04/23/19)
     
  1255. EASL: Incidence of hepatocellular carcinoma and mortality after HCV elimination by all-oral DAA therapy: Results from a large-scale, multicenter [older age] cohort study - (04/22/19)
     
  1256. EASL: Efficacy and safety of Glecaprevir/Pibrentasvir in patients with severe renal impairment in Japan: a prospective, multicenter study (KTK 49 Liver Study Group) - (04/22/19)
     
  1257. EASL: Treatment of genotype 3 cirrhotic patients with 12 weeks of Sofosbuvir/Velpatasvir with or without Ribavirin: Real life experience from Italy - (04/22/19)
     
  1258. EASL: Efficacy and Safety of glecaprevir/pibrentasvir for the Pangenotypic Treatment of Chronic Hepatitis C in former intravenous drug users: Subanalysis from a Spanish Real-World Cohort (Hepa-C) - (04/22/19)
     
  1259. EASL: Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvirfor six weeks among people with acute and recent HCV infection - (04/22/19)
     
  1260. EASL: 4 week treatment [G/P+/-Rbv] for hepatitis C - a randomized controlled trial (4RIBC) - (04/22/19)
     
  1261. EASL: Prospective Multicenter Study of Glecaprevir + Pibrentasvir Combination Therapy for Patients with Chronic Hepatitis C - (04/22/19)
     
  1262. EASL: Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in HCV-infected patients with chronic kidney disease - (04/22/19)
     
  1263. EASL: An observational, prospective, multicenter study on the utilization and effectiveness of elbasvir/grazoprevir treatment association for chronic hepatitis C in France : No effect of alcohol consumption or dependence on treatment outcome - (04/22/19)
     
  1264. EASL: Increasing Number of Metabolic Co-Morbidities are Associated with Higher Risk of Advanced Fibrosis in Patients with Nonalcoholic Steatohepatitis - (04/22/19)
     
  1265. EASL: A Combination of the ACC Inhibitor GS-0976 (firsocostat) and the Nonsteroidal FXR Agonist GS-9674 (cilofexor) Improves Hepatic Steatosis, Biochemistry, and Stiffness in Patients With Nonalcoholic Steatohepatitis - (04/22/19)
     
  1266. EASL: APPLICATION OF GUIDELINES FOR FATTY LIVER IN TWO PROSPECTIVE COHORTS OF HIV+ PATIENTS: 32% have NAFLD; among those without NAFLD 18% with elevated ALT - (04/22/19)
     
  1267. EASL: Increasing incidence of HCV-GT2 and reinfections within the ongoing epidemic of acute HCV infections among MSM in Central Europe - (04/18/19)
     
  1268. EASL: The impact of SVR from direct acting antiviral and interferon-based treatments for HCV on hepatocellular carcinoma risk in a large population based cohort - (04/18/19)
     
  1269. EASL: Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein Following Sorafenib: Outcomes by Liver Disease Aetiology from Two Randomised, Placebo-Controlled Phase 3 Studies (REACH-2 And REACH) - (04/18/19)
     
  1270. EASL: Unacceptably low SVR rates in African patients with unusual HCV sub-genotypes: Implications for global elimination - (04/18/19)
     
  1271. EASL: Best of ILC 2019 Viral hepatitis - (04/18/19)
     
  1272. EASL: Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study - (04/18/19)
     
  1273. EASL: The Increasing Importance of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients with Human Immunodeficiency Virus (HIV) - (04/18/19)
     
  1274. EASL: HCV RE-INFECTION AMONG HIV-INFECTED MSM IN NEW YORK CITY - (04/17/19)
     
  1275. EASL: The global investment case for hepatitis C elimination - (04/17/19)
     
  1276. EASL: EFFECTIVENESS OF ELBASVIR/GRAZOPREVIR IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION WHO RECEIVE OPIOID AGONIST THERAPY: TREATMENT UTILIZATION AND THE IMPACT OF CONCOMITANT PSYCHIATRIC MEDICATIONS - (04/17/19)
     
  1277. EASL: Real world effectiveness and utilization patterns of Elbasvir/Grazoprevir for treatment of HCV G1 G4 infected patients in Italy - (04/17/19)
     
  1278. EASL: Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review and meta-analysis - (04/15/19)
     
  1279. EASL: Reinfection following successful HCV DAA therapy among people with recent injecting drug use - (04/15/19)
     
  1280. EASL: HIGH REAL-WORLD EFFECTIVENESS OF ELBASVIR/GRAZOPREVIR (EBR/GZR) IN PWID ON OPIOID SUBSTITUTION THERAPY WITH HCV GENOTYPE 1 (GT1) INFECTION: RESULTS FROM THE GERMAN HEPATITIS C REGISTRY (DHC-R) - (04/15/19)
     
  1281. EASL: HIGH EFFECTIVENESS OF ELBASVIR/GRAZOPREVIR (EBR/GZR) TREATMENT IN PATIENTS WITH HCV GENOTYPE 1A (GT1A) INFECTION IN GERMAN REAL-WORLD: RESULTS FROM THE GERMAN HEPATITIS C REGISTRY (DHC-R) - (04/15/19)
     
  1282. EASL: HIGH REAL-WORLD EFFECTIVENESS OF ELBASVIR/GRAZOPREVIR (EBR/GZR) IN A HCV GENOTYPE 1 (GT1) POPULATION WITH A MIGRATION BACKGROUND AND PREDOMINANT SUBTYPE 1B INFECTION: RESULTS FROM THE GERMAN HEPATITIS C REGISTRY (DHC-R) - (04/15/19)
     
  1283. EASL: Effectiveness of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Genotype 1 Infection Receiving Dialysis - (04/15/19)
     
  1284. EASL: Safety and Efficacy of Glecaprevir/Pibrentasvir for the Treatment of HCV Genotype 1-6: Results of the HCV-TARGET Study - (04/15/19)
     
  1285. EASL: Immediate versus delayed hepatitis C treatment in the United Kingdom: A pan-genotypic cost-effectiveness analysis - (04/15/19)
     
  1286. EASL: HCV Elimination Off-Track WHO Targets/Countries Estimates - Global timing of hepatitis C virus elimination: estimating the year countries will achieve the World Health Organization elimination targets - (04/15/19)
     
  1287. EASL: Achieving accelerated elimination of hepatitis C virus infection by 2025: a case study in France - (04/15/19)
     
  1288. EASL: Global timing of hepatitis C virus elimination: estimating the year countries will achieve the World Health Organization elimination targets - (04/15/19)
     
  1289. EASL: REAL-WORLD EFFECTIVENESS AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN ADULTS WITH CHRONIC HEPATITIS C VIRUS INFECTION: A META-ANALYSIS - (04/15/19)
     
  1290. EASL: Real-World Health Care Resource Utilizati on and Quality of Life With Glecaprevir/Pibrentasvir Treatment: A Pooled Analysis From Post-Marketing Observational Studies - (04/13/19)
     
  1291. EASL: High Efficacy and Improvement in CPT Class With Sofosbuvir/Velpatasvir Plus Ribavirin for 12 Weeks in Patients With CPT C Decompensated Cirrhosis - (04/13/19)
     
  1292. EASL: Clinical and virological characteristics of patients with chronic hepatitis C and failure to a Voxilaprevir (VOX)/Velpatasvir (VEL)/Sofosbuvir (SOF) treatment - (04/13/19)
     
  1293. EASL: Treatment of genotype 3 cirrhotic patients with 12 weeks of Sofosbuvir/Velpatasvir with or without Ribavirin: Real life experience from Italy - (04/13/19)
     
  1294. EASL: EFFECTIVENESS AND SAFETY OF SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR FOR RETREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH A PREVIOUS FAILURE TO DIRECT-ACTING ANTIVIRALS: A REAL-LIFE STUDY FROM THE NAVIGATORE LOMBARDIA AND VENETO NETWORKS - (04/13/19)
     
  1295. EASL: High cure rates of Hepatitis C in a genotype 3 predominant Pakistani community using generic direct acting antivirals - (04/13/19)
     
  1296. EASL: REAL-WORLD SAFETY, EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR: DATA FROM THE GERMAN HEPATITIS C-REGISTRY - (04/13/19)
     
  1297. EASL: Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With HCV Genotype 5 or 6 Infection: An Integrated Analysis of Phase 2 and 3 Studies - (04/13/19)
     
  1298. EASL: Sofosbuvir + Velpatasvir + Voxilaprevir in DAA Failure Patients with Cirrhosis Final Results of the French Compassionate Use Program - (04/13/19)
     
  1299. EASL: Efficacy and Safety of Glecaprevir/Pibrentasvir Treatment for 8 Weeks in Treatment-Naïve Patients With Chronic Hepatitis C Virus Infection Without Cirrhosis or With Compensated Cirrhosis: Analysis of Data Pooled From Phase 2 and 3 Studies - (04/13/19)
     
  1300. EASL: Patient Flow Across Physician Specialties Over the Course of the Hepatitis C Care Cascade: A Real-World Analysis From the United States - (04/13/19)
     
  1301. EASL: Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH - (04/13/19)
     
  1302. EASL: Real world outcomes from NS5a treatment failures undergoing therapy with sofosbuvir/velpatasvir/voxilaprevir and sofosbuvir/glecaprevir/pibrentasvir - (04/12/19)
     
  1303. EASL: HIV-infected individuals at high risk of non-alcoholic fatty liver disease (NAFLD) and progressive liver disease- ILC 2019: Latest studies confirm increasing burden of NAFLD in people with HIV infection as viral hepatitis prevalence and associated mortality decline - (04/12/19)
     
  1304. EASL: Clinical practice experience with pangenotypic therapies glecaprevir/pibrentasvir and sofosbuvir/velpatasvir; data from the TRIO Network - (04/12/19)
     
  1305. EASL: Retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and prior DAA failure - an analysis from the German Hepatitis C-Registry (DHC-R) - (04/12/19)
     
  1306. EASL: Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C: Integrated analysis of 12 clinical practice cohorts - (04/12/19)
     
  1307. EASL: Real-World Effectiveness and Safety of Glecaprevir Plus Pibrentasvir in HCV: A Multi -Country Analysis of Post-Marketing Observational Studies - (04/12/19)
     
  1308. EASL: Effectiveness of the salvage therapy sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in chronic hepatitis C; clinical practice experience from the TRIO network - (04/12/19)
     
  1309. The Interplay Between Nonalcoholic Fatty Liver Disease and Atherosclerotic Heart Disease - Editorial - (04/10/19)
     
  1310. Rwanda HCV Elimination Project - (04/10/19)
     
  1311. Cirrhosis Causes Cognitive impairment, Poor Patient Outcomes - Despite HCV, SVR in the Presence of NAFLD, Alcoholic Fatty Liver Frailty, Psychoactive Medications, and Cognitive Dysfunction Are Associated With Poor PatientReported Outcomes in Cirrhosis - (04/10/19)
     
  1312. Treating Hepatitis C in the Homeless at the Greater Los Angeles Veterans Affairs .....Two thirds of HVs referred for treatment received treatment with 100% [13/13] achieving SVR12. - (04/10/19)
     
  1313. New Global Hepatitis Funding - HCV-HBV-NASH-HCV/HIV Coinfection  Screening, Care , Linkage to Care - (04/09/19)
     
  1314. CROI: CAN'T BUY ME LOVE? OBSTACLES TO MICRO-ELIMINATION OF ACUTE HCV COINFECTION IN EUROPE - (04/08/19)
     
  1315. CROI: Summary from CROI 2019 for viral Hepatitis Curing viral hepatitis: what are the clinical implications and what are the remaining barriers to overcome? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany (04/08/19)
     
  1316. Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients - (04/08/19)
     
  1317. Gilead Launches HepConnect Initiative to Reduce Hepatitis C Infections in Greater Appalachia - (04/05/19)
     
  1318. CROI: Hepatitis at CROI 2019: HCV, NASH, HBV; HIV+ MSM Reinfection in NYC; New HCV Cases Sharp Drop in London - (03/27/19)
     
  1319. Louisiana has drug company for subscription-style hepatitis C treatment plan - (03/27/19)
     
  1320. Gilead's Asegua Therapeutics selected to partner with health department for hepatitis C drug subscription model - (03/27/19)
     
  1321. CROI: Delayed HCC Diagnosis in HIV/HCV Coinfected: HIV not linked to worse liver cancer survival in people with HCV - Mark Mascolini (03/26/19)
     
  1322. CROI: Real-life efficacy and safety of Glecaprevir/Pibrentasvir in a large cohort of HCV-infected patients: the MISTRAL study - (03/20/19)
     
  1323. CROI: Liver stiffness at SVR predicts hepatic complications in HCV-infected patients - (03/20/19)
     
  1324. CROI: Inflammation, Arterial Stiffness and Directly-Acting Antivirals in HCV and HIV/HCV, no beneft observed in this study - (03/20/19)
     
  1325. CROI: Successful HCV treatment does not affect rate of heart disease or non-AIDS cancer - Mark Mascolini (03/20/19)
     
  1326. CROI: DAA therapy for HCV lowers risk of cardiovascular disease at all fibrosis stages - (03/20/19)
     
  1327. CROI: Maternal HBV Viremia Is Associated With Adverse Infant Outcomes In HIV/HBV Women: Post-Hoc Analysis of HPTN 046 - (03/20/19)
     
  1328. CROI: HCV treatment with DAAs halves risk of new diabetes diagnosis - Mark Mascolini (03/20/19)
     
  1329. CROI: Sharp drop in acute HCV among London MSM with HIV after DAAs arrived - Mark Mascolini (03/15/19)
     
  1330. CROI: RETREATMENT OF HCV IN ADVANCED LIVER DISEASE / CROI 2019 - (03/12/19)
     
  1331. CROI: A PHASE ONE STUDY OF LEDIPASVIR/SOFOSBUVIR IN PREGNANT WOMEN WITH HEPATITIS C VIRUS - (03/12/19)
     
  1332. CROI: Primary HCV in HIV+ MSM: US Epidemic Incidence - (03/12/19)
     
  1333. CROI: Fall in HCV incidence in HIV+ MSM in London following expansion of access to DAA therapy - (03/12/19)
     
  1334. CROI: Successful HCV treatment does not affect rate of heart disease or non-AIDS cancer - Mark Mascolini (03/12/19)
     
  1335. CROI: Successful HCV treatment does not affect rate of heart disease or non-AIDS cancer - Mark Mascolini (03/07/19)
     
  1336. CROI: Clinical Outcomes in Persons Coinfected with HIV and HCV: Impact of HCV Treatment - (03/07/19)
     
  1337. CROI: INCIDENT DIABETES AND GLUCOSE CONTROL AFTER HCV TREATMENT WITH DAAS IN ERCHIVES - (03/07/19)
     
  1338. CROI: Effects of eradication of HCV on bone mineral density in HIV/HCV-coinfected patients - Bone density stable over 96 weeks after DAA cure in HIV/HCV group - Mark Mascolini - (03/07/19)
     
  1339. CROI: Clinical Outcomes in Persons Coinfected with HIV and HCV: Impact of HCV Treatment - Mark Mascolini - (03/07/19)
     
  1340. CROI: Higher HIV load, lower CD4s predict liver cancer without advanced fibrosis - Mark Mascolini - (03/07/19)
     
  1341. CROI: NASH IN HIV - CROI 2019 - (03/05/19)
     
  1342. Estimating [increased] Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016 - (03/01/19)
     
  1343. Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States - (03/01/19)
     
  1344. Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) - (02/27/19)
     
  1345. Direct-acting antiviral treatment for hepatitis C - Comment - (02/12/19)
     
  1346. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study - decrease mortality/ HCC - (02/12/19)
     
  1347. DAAs: confirmation of their short-term clinical efficacy in "real life" - (02/12/19)
     
  1348. AASLD/EASL Special Conf: Homeless shelter client and provider barriers and facilitators to implementing HCV testing, access, and linkage to care in the homeless population - (02/07/19)
     
  1349. AASLD/EASL Special Conf: Universal access to Direct Acting Antiviral treatment and high engagement in care results in a major drop in hepatitis C viremia in people who inject drugs Results from TraPHepCin Iceland (Treatment as Prevention) poster - Miami AASLD-EASL HCV Special Conference 2/1/19 - (02/07/19)
     
  1350. AASLD/EASL Special Conf: Homeless Shelter Client and Provider Barriers and Facilitators To Implementing HCV Testing, Access, and Linkage To Care In The Homeless Population - (02/06/19)
     
  1351. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model - (02/06/19)
     
  1352. Are We Targeting Correct Populations? - (02/06/19)
     
  1353. AASLD/EASL Special Conf: Is There a Need to Re-Focus our Efforts for Hepatitis C Screening Away from Baby Boomers? 23% HCV+ in Rural Drug Users Pennsylvania - (02/05/19)
     
  1354. AASLD/EASL Special Conf: Worldwide HCV Epidemiology and Impact of Treatment - (02/05/19)
     
  1355. AASLD/EASL Special Conf: Hepatitis C care continuum at a safety-net health system among adults enrolled in probations in Denver, Colorado - AASLD-EASL HCV Special Conference Miami 2019 Feb 1 - (02/05/19)
     
  1356. AASLD/EASL Special Conf: Universal Access to Direct Acting Antiviral Treatment and High Engagement in Care Results in a Major Drop in Hepatitis C Viremia in People Who Inject DrugsResults from TraPHepCin Iceland (Treatment as Prevention) - AASLD-EASL HCV Special Conference Miami 2/1/19 - (02/05/19)
     
  1357. AASLD/EASL Special Conf: The Intersection Between the Opioid Epidemic and HCV Infection: An Opportunity to Save Lives with HCV Cure and Overdose Prevention - (02/04/19)
     
  1358. AASLD/EASL Special Conf: Commitment to Global Elimination of Hepatitis C Virus - (02/04/19)
     
  1359. AASLD/EASL Special Conf: The Cost of HCV Elimination - AASLD-EASL HCV Special Conference Miami 2/1/19 - (02/04/19)
     
  1360. AASLD/EASL Special Conf: Real-World Health Care Resource Utilization and Quality of Life With Glecaprevir/Pibrentasvir Treatment: A Pooled Analysis From Post-Marketing Observational Studies - (02/04/19)
     
  1361. AASLD/EASL Special Conf: Global timing of hepatitis C virus elimination: estimating the year countries will achieve the World Health Organization elimination targets - AASLD/EASL HCV Special Conference Miami 2/1/19 - (02/04/19)
     
  1362. AASLD/EASL Special Conf: Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Infection: A Meta-Analysis - AASLD-EASL Special HCV Conference Miami - (02/04/19)
     
  1363. AASLD/EASL Special Conf: Real-World Health Care Resource Utilization and Quality of Life With Glecaprevir/Pibrentasvir Treatment: A Pooled Analysis From Post-Marketing Observational Studies - AASLD/EASL Special HCV Conference Miami - (02/04/19)
     
  1364. AASLD/EASL Special Conf: Global timing of hepatitis C virus elimination: estimating the year countries will achieve the World Health Organization elimination targets - (02/04/19)
     
  1365. Funding Hepatitis C Treatment in Correctional Facilities by Using a Nominal Pricing Mechanism - (01/16/19)
     
  1366. Japan's Ministry of Health, Labour and Welfare Approves Gilead's Epclusa® (Sofosbuvir/Velpatasvir) - (01/15/19)
     
  1367. AASLD: Systematic Review: Prevalence and Natural History of Alcohol Related Liver Disease - (01/07/19)
     
  1368. AASLD: Inspired Study: Utilization Patterns and Outcomes of Elbasvir/Grazoprevir in the Real-World Greek Setting (interim analysis) - (01/07/19)
     
  1369. AASLD: Trends in Causes of Mortality in Liver Transplantation Recipients: Comparison Among NASH, ALD, and HCV Cohorts - (01/04/19)
     
  1370. AASLD: Health care costs associated with NAFLD - a long-term follow up study - (01/04/19)
     
  1371. AASLD: Systematic Review: Prevalence and Natural History of Alcohol Related Liver Disease - (01/03/19)
     
  1372. AASLD: Alcoholic Liver Disease Has Rapidly Emerged As the Leading Indication for Liver Transplant Evaluation - (01/03/19)
     
  1373. AASLD: Systematic Review: Prevalence and Natural History of Alcohol Related Liver Disease - (01/03/19)
     
  1374. AASLD: Alcoholic Liver Disease Has Rapidly Emerged As the Leading Indication for Liver Transplant Evaluation - (01/03/19)
     
  1375. AASLD: Economic Burden of Progression to Cirrhosis in Patients with Non-Alcoholic Steatohepatitis (NASH) in the United States - (12/14/18)
     
  1376. AASLD: Prevalence and Long-term Outcomes of Non-alcoholic Fatty Liver Disease (NAFLD) Among Elderly Individuals from the United States - (12/14/18)
     
  1377. AASLD: Non-Alcoholic Fatty Liver Disease and Alcoholic Fatty Liver Disease: The Impact of Alcohol Consumption and Metabolic Syndrome to Mortality - (12/14/18)
     
  1378. AASLD: NGM282 DEMONSTRATES ANTI-INFLAMMATORY AND ANTI-FIBROTIC ACTIVITIES THAT ARE INDEPENDENT OF STEATOSIS REDUCTION IN A FARNESOIDX RECEPTOR (FXR)-DEFICIENT, DIET-INDUCED ANIMAL MODEL OF NON-ALCOHOLIC STEATOHEPATITIS(NASH) - (12/14/18)
     
  1379. AASLD: NGM282 Rapidly Improves NAFLD Activity Score (NAS) and Fibrosis in 12 Weeks in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis(NASH) Results of a Phase 2 Multi-Center Dose Finding Study - (12/14/18)
     
  1380. AASLD: Interim results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of Myrcludex B in combination with PEG-IFNα in patients with chronic HBV/HDV co-infection - (12/12/18)
     
  1381. AASLD: One-year results of the Global Phase 2b randomized placebo-controlled ARREST Trial of Aramchol, a Stearoyl CoA Desaturasemodulator in NASH patients - (12/12/18)
     
  1382. AASLD: FIBROSIS REGRESSION OBSERVED IN TREATMENT WITH FGF19 VARIANTS INA DIET INDUCED MOUSE MODEL OF NASH IS PREDOMINANTLY MEDIATED BY FGFR4 ACTIVITY AND INDEPENDENT OF WEIGHT LOSS OR DECREASES IN HEPATIC STEATOSIS - (12/12/18)
     
  1383. AASLD: NGM282 Rapidly Improves NAFLD Activity Score (NAS) and Fibrosis in 12 Weeks in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis(NASH) Results of a Phase 2 Multi-Center Dose Finding Study - (12/12/18)
     
  1384. AASLD: NGM282 Maintains a Durable Off-Treatment Response on Hepatic Steatosis, Inflammation and Fibrogenesis in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis: Results of a Multi-Center Phase 2 Dose-Finding Study - (12/12/18)
     
  1385. AASLD: NGM313, a Novel Once-Monthly Activator of bKlotho-FGFR1c, Significantly Reduces Hepatic Steatosis and Key Biomarkers of Non- Alcoholic Steatohepatitis: Results of a Randomized, Active-Controlled Clamp Study in Obese Insulin-Resistant Patients with NAFLD - (12/12/18)
     
  1386. AASLD: GS-0976, a Liver-Targeted Acetyl-CoA Carboxylase Inhibitor, Reduces Plasma Acylcarnitines in Patients With Nonalcoholic Steatohepatitis - (12/11/18)
     
  1387. AASLD: Validation of Fractional Synthesis Rate of Plasma Lumican as a Noninvasive Marker of Fibrogenesis in Patients With Nonalcoholic Steatohepatitis - (12/11/18)
     
  1388. AASLD: The Incidence of Malignancies in Nonalcoholic Fatty Liver Disease - (12/11/18)
     
  1389. AASLD: Evaluation of Cytochrome P450- and Transporter-Mediated Drug-Drug Interactions With the Acetyl-CoA Carboxylase Inhibitor GS-0976, and Phenotypic Probe Substrates and Inhibitors - (12/11/18)
     
  1390. AASLD: Prevalence of Chronic Hepatitis C Virus Infection US States and District of Columbia, 2013-2016 - (12/10/18)
     
  1391. AASLD: A REAL WORLD RESISTANCE PROFILE OF VIROLOGIC FAILURES COLLECTED FROM AN INTERNATIONAL COLLABORATION (SHARED) - (12/10/18)
     
  1392. AASLD: Prevalence of NS3 and NS5A resistance associated substitutions through European DAA-failures - (12/10/18)
     
  1393. AASLD: The prevalence of hepatitis C virus NS5A polymorphisms in Europe - (12/10/18)
     
  1394. AASLD: Disparities in Accessing HCV Care under Medicaid Programs Across the US; Experience from the TRIO Network - (12/10/18)
     
  1395. AASLD: The Worldwide Prevalence of Non-alcoholic Steatohepatitis (NASH) in Patients with Type 2 Diabetes Mellitus (DM) - (12/10/18)
     
  1396. HIV & Liver Disease Research Grants up to $130,000 - (11/28/18)
     
  1397. AASLD: Alteration of Hepatic OATP Activity Does Not Alter the Pharmacodynamic Effect of GS-0976, a Liver-Targeted ACC Inhibitor, on De Novo Lipogenesis - (12/07/18)
     
  1398. AASLD: Association Between Apolipoprotein C3 and Serum Triglycerides in Nonalcoholic Steatohepatitis Patients Treated With the Acetyl-CoA Carboxylase Inhibitor GS-0976 - (12/07/18)
     
  1399. AASLD: ASK1 Inhibition Reduces Progression of Liver Cirrhosis and Prevents Tumor Development in the BALB/c.Mdr2-/- Mouse Model of Biliary Fibrosis - (12/07/18)
     
  1400. AASLD: Hepatic Protease Expression in Patients With NASH Correlates With Fibrosis Stage and Treatment Response in a Phase 2 Trial of Selonsertib - (12/07/18)
     
  1401. AASLD: Hepatic Metabolomics and Plasma MicroRNA Analysis of Combinations of an ASK1 Inhibitor, an ACC Inhibitor, and an FXR Agonist in a Rat Choline-Deficient High-Fat Diet Model Reveal Reductions in Oxidative Stress, Inflammation, and Fibrosis - (12/07/18)
     
  1402. AASLD: DAA HCV Retreatment Studies at AASLD 2018 - (12/07/18)
     
  1403. AASLD: Cenicriviroc Treatment over 2 Years Results in Clinically Meaningful and Sustained Improvement in Fibrosis in Adults with Nonalcoholic Steatohepatitis and Severe Liver Fibrosis - (11/16/18)
     
  1404. AASLD: Sustained Virologic Response Reduces the Incidence of Extrahepatic Manifestations in Chronic Hepatitis C Infection - (11/16/18)
     
  1405. AASLD: Impact of Baseline HCV RNA Levels as Assessed by 2 Different Assays on the Efficacy of 8-Week Glecaprevir/Pibrentasvir in Patients With HCV GT1-6 Infection - (11/16/18)
     
  1406. AASLD: Risk of Cardiovascular Disease Events after HCV Treatment: Results from ERCHIVES - (11/16/18)
     
  1407. AASLD: Rising and Higher Healthcare Resource Utilization (HCRU) and Costs of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH) Patients with Advanced Liver Disease of Increasing Severity - Results of a US Real-World Analysis - (11/16/18)
     
  1408. AASLD: Effectiveness of 8-week glecaprevir/pibrentasvir(G/P) for treatment naïve, non-cirrhotic patients with HCV infection in the TRIO Health network - (11/16/18)
     
  1409. AASLD: Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Prior Treartment Failures with Glecaprevir/Pibrentasvir (G/P) in Chronic Hepatitis C Infection - (11/16/18)
     
  1410. AASLD: REAL-WORLD SAFETY AND EFFECTIVENESS OF SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR AND GLECAPREVIR/PIBRENTASVIR IN HEPATITIS C INFECTED PATIENTS - (11/16/18)
     
  1411. AASLD: HEPATITIS C VIRUS REINFECTION AND INJECTING RISK BEHAVIOR FOLLOWING ELBASVIR/GRAZOPREVIR TREATMENT IN PARTICIPANTS ON OPIATE AGONIST THERAPY: C-EDGE CO-STAR PART B - (11/16/18)
     
  1412. AASLD: Pharmacokinetics of Once-Daily Sofosbuvir or Ledipasvir/Sofosbuvir in HCV-Infected Pediatrics Aged 3-<6 Years - (11/16/18)
     
  1413. AASLD: Ledipasvir/Sofosbuvir for 12 Weeks Is Safe and Effective in Children 3 to <6 years old with Chronic Hepatitis C Virus Infection - (11/16/18)
     
  1414. AASLD: Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With Chronic HCV Infection and Moderate to Severe Renal Impairment: An Integrated Analysis - (11/16/18)
     
  1415. AASLD: Durability of Sustained Virologic Response and Liver-Related Safety in Patients Treated With Glecaprevir/Pibrentasvir: A Long-Term Follow-Up Study - (11/16/18)
     
  1416. AASLD: Sofosbuvir / Velpatasvir / Voxilaprevir in DAA Failure Patients with Cirrhosis. Final Results of the French Compassionate Use Program - (11/16/18)
     
  1417. AASLD: Retreatment with voxilaprevir/velpatasvir/sofosbuvir in patients with chronic hepatitis C virus infection and prior DAA failure - results from the German Hepatitis C-Registry (DHC-R) - (11/16/18)
     
  1418. AASLD: Safety and Efficacy of Sofosbuvir/Velpatasvir in Genotype 1-6 HCV-Infected Patients in China: Results From a Phase 3 Clinical Trial - (11/16/18)
     
  1419. AASLD: High SVR in PWID with HCV Despite Imperfect Medication Adherence: Data from the ANCHOR Study updated - (11/16/18)
     
  1420. AASLD: ASK1 Inhibition Reduces Progression of Liver Cirrhosis and Prevents Tumor Development in the BALB/c.Mdr2-/- Mouse Model of Biliary Fibrosis - (11/15/18)
     
  1421. AASLD: Routinely Available Noninvasive Tests Discriminate Advanced Fibrosis Due to NASH in the Phase 3 STELLAR Trials of the ASK1 Inhibitor Selonsertib - (11/15/18)
     
  1422. AASLD: GS-0976, a Liver-Targeted Acetyl-CoA Carboxylase Inhibitor, Reduces Plasma Acylcarnitines in Patients With Nonalcoholic Steatohepatitis - (11/15/18)
     
  1423. AASLD: The Nonsteroidal FXR Agonist GS-9674 Leads to Significant Reductions in Hepatic Steatosis, Serum Bile Acids, and Liver Biochemistry in a Phase 2, Randomized, Placebo-Controlled Trial of Patients With NASH - (11/15/18)
     
  1424. AASLD: The Nonsteroidal Farnesoid X Receptor Agonist GS-9674 Improves Liver Biochemistry and Decreases Serum Bile Acids in Patients with Primary Sclerosing Cholangitis: A Phase 2, Randomized, Placebo-Controlled Trial - (11/15/18)
     
  1425. AASLD: Safety and Efficacy of Sofosbuvir/Velpatasvir in Genotype 1-6 HCV-Infected Patients in China: Results From a Phase 3 Clinical Trial - (11/15/18)
     
  1426. AASLD: Incidence and Predictors of de Novo Hepatocellular Carcinoma Following Achievement of Sustained Virologic Response With Direct-Acting Antivirals: Results From the Gilead SVR and Cirrhosis Registries - (11/14/18)
     
  1427. AASLD: Retreatment with SOF/VEL/VOX in Treatment-Experienced Patients with and without HIV: The RESOLVE Study - (11/14/18)
     
  1428. AASLD: Effectiveness of Elbasvir/Grazoprevir in Black Persons With Genotype 1 Hepatitis C Virus - (11/14/18)
     
  1429. AASLD: Efficacy and Safety of Elbasvir/Grazoprevir for 8 or 12 Weeks in Participants With Hepatitis C Virus Genotype 4 Infection - (11/14/18)
     
  1430. AASLD: Utilization and Effectiveness of Elbasvir/Grazoprevir for the Treatment of Hepatitis C Virus Genotype 1b Infection: Updated Cohort From the US Veteran Affairs Healthcare System - (11/14/18)
     
  1431. AASLD: Sofosbuvir/Velpatasvir for Patients With Chronic Genotype 3 HCV Infection With Compensated Cirrhosis: an Integrated Analysis of Phase 2 and Phase 3 Clinical Trials - (11/14/18)
     
  1432. AASLD: Effectiveness of Sofosbuvir/Velpatasvir for 12 Weeks in HCV Genotype 3 Patients with Compensated Cirrhosis in Clinical Practice Cohorts from Around the World - (11/14/18)
     
  1433. AASLD: Sustained Viral Response Following Treatment With Direct-Acting Antiviral Regimens Is Durable in More Than 6600 Patients: Results of the Gilead Sustained Virologic Response Registry Study - (11/14/18)
     
  1434. AASLD: Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1 - (11/14/18)
     
  1435. AASLD: Response-Guided Therapy with DAA Shortens Treatment Duration in 50% of HCV Treated Patients - (11/14/18)
     
  1436. AASLD: Early Treatment with Direct-Acting Antivirals Saves Medical Costs in Non-Cirrhotic Patients with Chronic Hepatitis C Virus Infection in the United States - (11/14/18)
     
  1437. AASLD: Changes in the characteristics of hepatitis C patients treated with direct-acting antivirals from 2014-2017 - (11/13/18)
     
  1438. AASLD: Nivolumab in Patients With Child-Pugh B Advanced Hepatocellular Carcinoma in the CheckMate040 Study - (11/13/18)
     
  1439. AASLD: Changes in the characteristics of hepatitis C patients treated with direct-acting antivirals from 2014-2017 - (11/13/18)
     
  1440. AASLD: Short-Duration Sofosbuvir/Velpatasvir Safe and Effective in Treating HCV Infection Immediately After Liver Transplant - (11/13/18)
     
  1441. AASLD: Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With HCV Genotype 5 or 6 Infection: Final Results of the ENDURANCE-5,6 Study - (11/13/18)
     
  1442. AASLD: Changing Cascade of Care for Hepatitis C in the Era of Direct-Acting Antivirals - (11/13/18)
     
  1443. AASLD: Quality of Life in Patients with Psychiatric Disorders: Pooled Analysis from Glecaprevir/Pibrentasvir Registrational Studies - (11/13/18)
     
  1444. AASLD: Real-World Effectiveness of Glecaprevir/Pibrentasvir in 1,941 Patients with Hepatitis C Genotypes 1 through 4 - (11/13/18)
     
  1445. AASLD: Lower Likelihood of Graft Failure and Death after Liver Transplantation in the Era of Current Direct Acting Antivirals: An Analysis of the 2002-2018 United Network for Organ Sharing Registry - (11/13/18)
     
  1446. AASLD: Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C virus-infected patients in the U.S. - (11/13/18)
     
  1447. AASLD: High efficacy of glecaprevir/pibrentasvir in patients with chronic HCV GT1 infection who failed prior treatment with NS5A-inhibitor plus sofosbuvir regimens - (11/13/18)
     
  1448. AASLD: Sofosbuvir/Velpatasvir for 12 Weeks Is Safe and Effective in Patients Undergoing Dialysis - (11/13/18)
     
  1449. AASLD: The impact of HCV SVR from direct acting antiviral and interferon-based treatments on mortality in a large population based cohort study - (11/13/18)
     
  1450. AASLD: PRELIMINARY EFFICACY AND SAFETY OF 8-WEEK GLECAPREVIR/PIBRENTASVIR IN PATIENTS WITH HCV GENOTYPE 1-6 INFECTION AND COMPENSATED CIRRHOSIS: THE EXPEDITION-8 STUDY - (11/13/18)
     
  1451. AASLD: Real World Effectiveness of Sofosbuvir/velpatasvir/voxilaprevir in 573 Treatment-Experienced Patients with Hepatitis C - (11/13/18)
     
  1452. AASLD: High SVR in PWID with HCV Despite Imperfect Medication Adherence: Data from the ANCHOR Study - (11/13/18)
     
  1453. AASLD: Retreatment with SOF/VEL/VOX in Treatment-Experienced Patients with and without HIV: The RESOLVE Study - (11/13/18)
     
  1454. Incidence of Hepatocellular Carcinoma Among Patients With Hepatitis C Virus Infection Following Treatment With a Grazoprevir-Containing Regimen - (11/13/18)
     
  1455. AASLD: Real-World Impact of Resistance-Associated Substitutions on Re-Treatment after Ledipasvir/Sofosbuvir Virologic Failure in Hepatitis C Patients (VA) - (11/13/18)
     
  1456. AASLD: The Medicines Patent Pool Signs Licence with AbbVie to Expand Access to Key Hepatitis C Treatment, Glecaprevir/Pibrentasvir - (11/13/18)
     
  1457. AASLD: Universal HCV Screening on the Way? - (11/13/18)
     
  1458. AASLD: Real-life effectiveness and safety of velpatasvir/sofosbuvir/voxilaprevir for previously DAA treated patients with chronic hepatitis C - (11/13/18)
     
  1459. AASLD: Sofosbuvir/velpatasvir/voxilaprevir(SOF/VEL/VOX) in care of chronic hepatitis C patients; clinical practice experience from the TRIO network - (11/13/18)
     
  1460. AASLD: Glecaprevir/Pibrentasvir for the Treatment of Patients With Chronic Hepatitis C Virus Infection: Updated Real-World Data From the German Hepatitis C-Registry - (11/11/18)
     
  1461. AASLD: National Estimates for HCV Screening and Diagnosis Rates in the United States (2013-2016) Based on a Large Real-World Dataset - (11/11/18)
     
  1462. MappingHepC is a comprehensive source of Hep C epidemiology data in the United States - (11/09/18)
     
  1463. AASLD: National Examination of HCV Linkage to Care in the United States (2013-2016) Based on Large Real-World Dataset - (11/09/18)
     
  1464. AASLD: Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting® 2018 - (11/09/18)
     
  1465. AASLD: Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018 - (11/09/18)
     
  1466. AASLD: Gilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting® 2018 - (11/09/18)
     
  1467. AASLD: AbbVie Characterizes Evolving Hepatitis C (HCV) Patient Landscape in the United States Using Comprehensive Dataset - (11/09/18)
     
  1468. GLASGOW: SVR With DAAs--and Darunavir--Tied to Lipid Jumps in Big HCV/HIV Group - Mark Mascolini (11/07/18)
     
  1469. Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016 (underestimated still) - (11/07/18)
     
  1470. HCV Elimination Federal Grant for Kentucky - (10/24/18)
     
  1471. Analysis of AST to Platelet Ratio Index (APRI) for Determining Eligibility for 8 Weeks of Glecaprevir/Pibrentasvir - (10/15/18)
     
  1472. IDWeek: Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Genotypes 1-6 and Human Immunodeficiency Virus-1 Coinfection: An Integrated Analysis of Two Phase 3 Clinical Trials - (10/12/18)
     
  1473. IDWeek: The Hepatitis C Virus Cascade of Care at Stony Brook University Hospital: Risk Factors for Linkage to Care (20% linkage to care) - (10/12/18)
     
  1474. IDWeek: Real-World Data on Safety and Effectiveness of Glecaprevir/Pibrentasvir for the Treatment of Patients With Chronic Hepatitis C Virus Infection on Opioid Substitution Therapy: Latest Results From the German Hepatitis C-Registry - (10/12/18)
     
  1475. IDWeek: Time to Viral Suppression Does not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir - (10/12/18)
     
  1476. IDWeek: Hospital Rates Rise With Age for Cancer, Cardio, Other Diseases in US HIV Group - Mark Mascolini - (10/12/18)
     
  1477. IDWeek: HCV Testing Among Adolescents and Young Adults in a National Sample of Federally Qualified Health Centers - (10/10/18)
     
  1478. IDWeek: Only 30% With HCV/HIV in Safety-Net System Get HCV Therapy in DAA Era - Hepatitis C eradication: who is being left behind in the HIV population? - Mark Mascolini - (10/10/18)
     
  1479. IDWeek: Time to Viral Suppression Does not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir - (10/09/18)
     
  1480. IDWeek: Only 30% With HCV/HIV in Safety-Net System Get HCV Therapy in DAA Era - Hepatitis C eradication: who is being left behind in the HIV population? - Mark Mascolini (10/09/18)
     
  1481. INSHU: High Cure Rates in a Real world Cohort of HCV Infected Patients on Opioid Substitution Therapy (OST) Despite Alcohol and Cannabis Consumption Data from The German Hepatitis C-Registry (DHC-R) - (10/01/18)
     
  1482. INSHU: Treatment as prevention approach results in early and marked prevalence reduction of hepatitis C viremia among people who recently injected drugs. Results from Iceland: Treatment as Prevention (TraPHepC) - (10/01/18)
     
  1483. INSHU: Drug use and reinfection during and following Hepatitis C Virus treatment with Elbasvir/Grazoprevir among patients receiving Opiate Agonist Therapy: C-EDGE Co-STAR study - (10/01/18)
     
  1484. INSHU: New Questions About HCV From a New Generation - (10/01/18)
     
  1485. INSHU: C Change: Philadelphia's Plan to Eliminate Hepatitis C Among People Who Use Injection Drugs - (10/01/18)
     
  1486. INSHU: Building Bridges to Eliminate HCV in PWID Building Bridges to Reach People Who Inject Drugs with the Goal to Eliminate HCV - (10/01/18)
     
  1487. INSHU: A Screening Program for Hepatitis C among Baby Boomers in the Northeast United States reveals an Alarmingly High Prevalence of HCV among People who Inject Drugs - (10/01/18)
     
  1488. INSHU: Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: the SIMPLIFY study - (09/28/18)
     
  1489. INSHU: Reinfection following successful HCV DAA therapy among people with recent injecting drug use: the SIMPLIFY and D3FEAT studies - (09/28/18)
     
  1490. INSHU: !Dale! !Vale!: Tracking the HCV Epidemic in young people who inject drugs in New Mexico - (09/28/18)
     
  1491. INSHU: Real World Direct-Acting Antiviral (DAA) Outcomes Among People Who Inject Drugs (PWID) in the United States: Hepatitis C Real Options (HERO) - (09/28/18)
     
  1492. HCV Court rulings, Indiana, Prisons & Medicaid - (09/26/18)
     
  1493. Gilead subsidiary to launch authorized generics of Epclusa and Harvoni - (09/25/18)
     
  1494. INSHU: REAL-WORLD DATA ON SAFETY AND EFFECTIVENESS OF GLECAPREVIR/PIBRENTASVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION ON OPIOID SUBSTITUTION THERAPY: LATEST RESULTS FROM THE GERMAN HEPATITIS C-REGISTRY - (09/25/18)
     
  1495. Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With Psychiatric Disorders - (09/25/18)
     
  1496. Global Hepatitis Summit June 14-17 2018 Toronto A Few Selected Highlights - (09/05/18)
     
  1497. Integrating HCV and HIV services improves HCV testing and awareness among people who inject drugs in India: Findings from a cluster randomized trio; - (09/05/18)
     
  1498. HCV & HCV/HIV Coinfection Micro-Elimination Grants: funding for 30+ projects - - (09/04/18)
     
  1499. 6 weeks HCV Treatment New Study with CC-31244 - (08/10/18)
     
  1500. IAC: High incidence of HCV (re-)infections among PrEP users in the Netherlands: implications for prevention, monitoring and treatment (08/09/18)
     
  1501. IAC: Will hepatitis C transmission be eliminated by 2025 among HIV-positive men who have sex with men in Australia? - Mark Mascolini (08/06/18)
     
  1502. IAC: Shared HCV transmission networks among HIV-1 positive and HIV-1 negative men having sex with men in Paris (08/06/18)
     
  1503. Governor Cuomo Announces First-In-Nation Strategy To Eliminate Hepatitis C - (08/02/18)
     
  1504. HCV & HCV/HIV Coinfection Micro-Elimination Grants: funding for 30+ projects - - (08/02/18)
     
  1505. New Treatment Options for Hepatitis C Virus Infection in End-Stage Kidney Disease: To Treat or Not to Treat - (07/12/18)
     
  1506. Transplanting Hepatitis C Virus-Infected Versus Uninfected Kidneys Into Hepatitis C Virus-Infected Recipients: A Cost-Effectiveness Analysis - (07/12/18)
     
  1507. New Treatment Options for Hepatitis C Virus Infection in End-Stage Kidney Disease: To Treat or Not to Treat - (07/10/18)
     
  1508. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment - (07/10/18)
     
  1509. Risk of hepatocellular carcinoma after DAA treatment in cirrhotic HIV-HCV-coinfected patients: where do we stand? - (07/10/18)
     
  1510. New Gilead HCV Elimination Funding: HIV/HCV No Co-Infection (NoCo) Program: Micro-Elimination of HCV in HIV-Infected and High-Risk HIV-Uninfected Populations - (07/06/18)
     
  1511. EASL: Hepatitis C (HCV) patients with HIV co-infection demonstrate unique liver-related complications and health behaviors compared to HCV mono-infected patients - (07/03/18)
     
  1512. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study - (06/27/18)
     
  1513. Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial - (06/27/18)
     
  1514. Sofosbuvir/Ledipasvir in Treatment of Early (Acute) HCV Infection in HIV+ Men - (06/22/18)
     
  1515. Acute HCV - Duration of Treatment? - (06/22/18)
     
  1516. Global Hepatitis Summit: HIGH EFFICACY OF HCV THERAPY FOLLOWING UNIVERSAL DAA ACCESS IN AUSTRALIA The REACH-C Cohort - (06/21/18)
     
  1517. Global Hepatitis Summit: Global Hepatitis Summit - Hepatitis C treatment with Ledipasvir and Sofosbuvir in low socioeconomic population in a Federally Qualified Health Center (FQHC) - (06/21/18)
     
  1518. Global Hepatitis Summit: Global Hepatitis Summit - Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With Metabolic Syndrome and HCV Infection: An Integrated Analysis - (06/21/18)
     
  1519. Global Hepatitis Summit: Global Hepatitis Summit - AST to Platelet Ratio Index (APRI) for Determining Eligibility for 8 Weeks of Glecaprevir/Pibrentasvir: An Exploratory Post-hoc Analysis - (06/21/18)
     
  1520. Global Hepatitis Summit: Global Hepatitis Summit - Retreatment With Sofosbuvir/Velpatasvir/Voxilaprevir for 12 Weeks Is Safe and Effective for Patients Who Have Previously Received Sofosbuvir/Velpatasvir or Sofosbuvir/Velpatasvir/Voxilaprevir - (06/21/18)
     
  1521. Global Hepatitis Summit: Global Hepatitis Summit - Efficacy and Safety of Elbasvir/Grazoprevir in People With Hepatitis C Virus Infection Aged 35 Years or Younger - (06/21/18)
     
  1522. Global Hepatitis Summit: Global Hep Summit Toronto - Real-World Data on Safety and Effectiveness of Glecaprevir/Pibrentasvir for the Treatment of Patients With Chronic Hepatitis C Virus Infection: Latest Results From the German Hepatitis C-Registry - (06/21/18)
     
  1523. Global Hepatitis Summit: Global Hep Summit - Efficacy and Safety of Sofosbuvir/Velpatasvir in Treatment-Naïve, Non-Cirrhotic Patients with Chronic Hepatitis C Genotype 3 Infection: Integrated Analysis of Three Phase 3 Clinical Trials - (06/21/18)
     
  1524. Global Hepatitis Summit: Global Hepatitis Summit - Z-PROFILE: Real-World Utilization And Effectiveness Of Elbasvir/Grazoprevir In Adult Patients With Chronic Hepatitis C In Canada - Final Study Results - (06/21/18)
     
  1525. HCV Test & Treat - Hepatitis C Virus Diagnosis and the Holy Grail - (06/21/18)
     
  1526. Global Hepatitis Summit: Global Hepatitis Summit - Extension of Hepatitis C Screening, Diagnosis and Treatment into the Community: A Low Cost, Point of Care, Test and Treat Model for Pakistan - (06/21/18)
     
  1527. Global Hepatitis Summit: Global Hepatitis Summit - Working towards eliminating HCV among men who have sex with men in Amsterdam using an innovative multilevel approach: The NoMoreC project - (06/21/18)
     
  1528. Women Have Higher Rate of Spontaneous Clearance of Hepatitis C Virus (full text/pdf below) - (06/21/18)
     
  1529. Should we treat acute hepatitis C? A decision and cost-effectiveness analysis - (06/21/18)
     
  1530. DDW: Validation of a low cost, point of care screening device for HCV antibody detection in low resource peri-urban settings of Karachi, Pakistan - (06/19/18)
     
  1531. DDW: Sofosbuvir + Glecaprevir/Pibrentasvir (G/P) in patients with difficult to treat HCV infection. Final results of the French compassionate use - (06/19/18)
     
  1532. DDW: PATTERNS OF DRUG AND ALCOHOL USE AND INJECTION RISK BEHAVIOURS AMONG PEOPLE WHO INJECT DRUGS DURING AND FOLLOWING HCV DIRECT-ACTING ANTIVIRAL TREATMENT: INSIGHTS FROM TRAJECTORY ANALYSES - (06/19/18)
     
  1533. DDW: A Comparison of Insurance Approval Rates and Economic Disparity for Ledipasvir/Sofosbuvir Based Hepatitis C Therapy Versus Velpatasvir/Sofosbuvir in a Single Urban Center - (06/19/18)
     
  1534. DDW: Access to and Utilization of Sofosbuvir/Velpatasvir/Voxilaprevir in Care of Chronic Hepatitis C Patients: Data from the TRIO Network - (06/18/18)
     
  1535. DDW: SOF/VEL/VOX for 12 Weeks is a Safe and Effective Salvage Regimen for NS5A Inhibitor-Experienced Patients with Genotype 1-6 HCV Infection: An Integrated Analysis of Phase 2 and Phase 3 Studies - (06/18/18)
     
  1536. DDW: Emergence and Long-term Persistence of NS3, NS5A, and NS5B Resistance Associated Substitutions After Treatment With Direct-acting Antivirals - (06/01/18)
     
  1537. DDW: Long-Term Follow-up of Patients with Chronic HCV and F2-F3 Fibrosis After Achieving SVR with DAA-Based Therapy: Results from the Gilead SVR Registry - (06/01/18)
     
  1538. Nonalcoholic fatty liver disease, metabolic syndrome, and the fight that will define clinical practice for a generation of hepatologists - (06/15/18)
     
  1539. Sofosbuvir/Velpatasvir for 12 Weeks in Genotype 1-4 HCV-Infected Liver Transplant Recipients - (06/12/18)
     
  1540. HCV 99.7% SVR-Cure Rates in GT1a - (06/09/18)
     
  1541. We know DAAs work for PWID, now what? Simplifying HCV testing, linkage to care and treatment - (06/09/18)
     
  1542. Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus - (06/09/18)
     
  1543. Achieving hepatitis C elimination in Europe - To treatment scale-up and beyond - (06/09/18)
     
  1544. EASL: Field evaluation of Xpert (Cepheid) Hepatitis C Virus assay for RNA quantification in Genotype 6 predominant patient population in Cambodia - (06/07/18)
     
  1545. EASL: Evaluation of the Xpert fingerstick HCV viral load assay - (06/07/18)
     
  1546. EASL: The Rapid-EC Study - a Feasibility Study of Point-Of-Care Testing in Community Clinics Targeted to People Who Inject Drugs in Melbourne, Australia - (06/07/18)
     
  1547. EASL: One-Step Diagnostic Strategy of Viraemic Hepatitis C Virus infection From Dried-Blood Spots: feasibility and usefulness in people who inject drugs - (06/07/18)
     
  1548. Pharm: Glecaprevir/pibrentasvir SVR12 at 97% regardless of psychiatric disorders - Mark Mascolini - (05/25/18)
     
  1549. Pharm: Elvitegravir pharmacokinetics during pregnancy and postpartum Low elvitegravir troughs in third trimester confirm caution in pregnancy - Mark Mascolini - (05/25/18)
     
  1550. EASL: The Association of Circulating MicroRNAs (miRs) With Liver Fibrosis Stage and the Impact of Selonsertib Treatment in Patients With NASH - (05/23/18)
     
  1551. EASL: BMS-986036, a PEGylated Fibroblast Growth Factor 21 Analogue for the Treatment of Non-Alcoholic Steatohepatitis: A Population Pharmacokinetics and Exposure-Response Analysis - (05/22/18)
     
  1552. EASL: BMS-986036, a PEGylated Fibroblast Growth Factor 21 Analogue, Reduces Fibrosis and PRO-C3 in a Mouse Model of Non-Alcoholic Steatohepatitis - (05/22/18)
     
  1553. Evaluation of SOMAscan® as a Discovery Platform to Identify Noninvasive
    Protein Biomarkers for Diagnosis and Monitoring of NASH     - (05/21/18)
     
  1554. The Association of Circulating MicroRNAs (miRs) With Liver Fibrosis Stage and the Impact of Selonsertib Treatment in Patients With NASH - (05/21/18)
     
  1555. EASL: ACC Inhibitor Demonstrates Potent Antifibrotic Activity In Vitro and In Vivo - (05/17/18)
     
  1556. EASL: Responsiveness of Controlled Attenuation Parameter and Its Correlation With Magnetic Resonance Imaging-Proton Density Fat Fraction in a Multicenter Clinical Trial of Subjects With Nonalcoholic Steatohepatitis - (05/15/18)
     
  1557. EASL: Combination of an FXR Agonist and an ACC Inhibitor Increases Antifibrotic Efficacy in Rodent Models of NASH - (05/15/18)
     
  1558. EASL: Preliminary Efficacy and Safety of Acetyl-CoA Carboxylase Inhibitor GS-0976 in Patients With Compensated Cirrhosis Due To NASH - (05/15/18)
     
  1559. EASL: Accurate Prediction of Clinical Disease Progression in Patients With Advanced Fibrosis Due to NASH Using a Bayesian Machine Learning Approach - (05/15/18)
     
  1560. EASL: The Conundrum of Cryptogenic Liver Disease [NASH] with Advanced Fibrosis: Poor Clinical Outcomes without Treatment Options - (05/15/18)
     
  1561. EASL: Novel Characterization of the Gut Microbiome in Patients With NASH and Longitudinal Changes Associated With Histologic Improvement - (05/15/18)
     
  1562. CROI: Insurer Denial of DAA Prescription Requests Rising Across United States - Mark Mascolini (05/14/18)
     
  1563. EASL: Mechanism for Hypertriglyceridemia and Effect of Fibrate Coadministration During Acetyl-CoA Carboxylase Inhibitor Treatment - (05/11/18)
     
  1564. SVR & Comorbidities [Kidney/CVD/Bone/Cancer/Diabetes] in HCV/HIV+ - Hepatitis C Infection and the Risk of Non-Liver-Related Morbidity and Mortality in HIV-Infected Persons in the Swiss HIV Cohort Study - (05/10/18)
     
  1565. Among SVR patients, recent injection cocaine use was associated with rapid eGFR decline ["Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients"] - (05/10/18)
     
  1566. Low HCV Screening Rates in USA - Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015 - (05/09/18)
     
  1567. EASL: Characterization of Changes in Lipoprotein Profiles of Patients With Nonalcoholic Steatohepatitis Treated With the Acetyl-CoA Carboxylase Inhibitor GS-0976 - (05/09/18)
     
  1568. EASL: MINIMAL MONITORING OF DIRECT-ACTING ANTIVIRAL THERAPY WITHIN A REAL WORLD, URBAN.......Adherence to provider visits/Adherence to prescriptions - (05/08/18)
     
  1569. EASL: Ledipasvir/Sofosbuvir for 12 Weeks Is Safe and Effective in Adolescents With Chronic Hepatitis C Virus Infection and Hematologic Malignancies Undergoing Chemotherapy - (05/08/18)
     
  1570. EASL: Summary from EASL 2018 for Hepatitis C (HCV) HCV in 2018: Success stories and remaining challenges? - Prof. Dr. J.K. Rockstroh Department of Medicine I University of Bonn Sigmund-Freud-Str. 25 53105 Bonn Germany- (05/04/18)
     
  1571. EASL: Has increased rollout of direct acting antiviral therapy decreased the burden of late presentation and advanced liver disease in patients starting Hepatitis C Virus therapy in Germany? - (05/04/18)
     
  1572. EASL: The percentage of patients with HCV infection in need of a liver transplant is rapidly declining while their survival after transplantation is improving: A study based on European Liver Transplant Registry - (05/04/18)
     
  1573. Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network - (04/26/18)
     
  1574. EASL: An Integrated Safety Analysis of Phase 2 Studies of BMS-986036, a PEGylated Fibroblast Growth Factor 21 Analogue for the Treatment of Non-Alcoholic Steatohepatitis - (04/25/18)
     
  1575. EASL: Safety, Tolerability, and Pharmacokinetics of BMS-986263/ND-L02-s0201, A Novel Targeted Lipid Nanoparticle Delivering HSP47 siRNA, in Healthy Participants: A Randomised, Placebo-Controlled, Double-Blind, Phase 1 Study - (04/25/18)
     
  1576. EASL: Marked reduction in prevalence of hepatitis C viremia among people who inject drugs (PWID) during 2nd year of the Treatment as Prevention (TraPHepC) program in Iceland - (04/24/18)
     
  1577. EASL: Hepatitis C Care Cascade in the Country of Georgia After 3 years of Starting National Hepatitis C Elimination Program - (04/24/18)
     
  1578. EASL: Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia - (04/24/18)
     
  1579. EASL: Prevalence and stratification of NAFLD/NASH in a UK and US cohort using non-invasive multiparametric MRI - (04/24/18)
     
  1580. EASL: Safety, Tolerability, and Pharmacokinetics of BMS-986263/ND-L02-s0201, A Novel Targeted Lipid Nanoparticle Delivering HSP47 siRNA, in Healthy Participants: A Randomised, Placebo-Controlled, Double-Blind, Phase 1 Study - (04/24/18)
     
  1581. EASL: Marked reduction in prevalence of hepatitis C viremia among people who inject drugs (PWID) during 2nd year of the Treatment as Prevention (TraPHepC) program in Iceland - (04/23/18)
     
  1582. EASL: HCV Testing and Linkage to Care: Expanding Access to HCV Care Through Electronic Health Engagement - (04/23/18)
     
  1583. EASL: Substantial comorbidities and rising economic burden in real-world non-alcoholic fatty liver disease (NAFLD)/ non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (CC): A large German claims database study - (04/23/18)
     
  1584. EASL: Early versus Delayed Hepatitis C Treatment Provides Increased Health Benefits at Lower Costs: A Pan-Genotypic Cost-Effectiveness Analysis Set in Scotland - (04/23/18)
     
  1585. EASL: Time to Viral Suppression Does not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir for 8 Weeks - (04/23/18)
     
  1586. EASL: Role Of Physician Specialties To Close Gaps in the Care Cascade of Hepatitis C: Evidence From Paid Claims in the United States From 2010 To 2016 - (04/23/18)
     
  1587. EASL: Post-treatment liver stiffness measurement is not useful to predict hepatocellular carcinoma in HCV patients who achieve SVR - (04/23/18)
     
  1588. EASL: Safety And Efficacy At 1 Year After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide In Chronic HBV Patients With Risk Factors For TDF Use - (04/23/18)
     
  1589. CDC- HCV Increased New Cases: increased about 3.5-fold from 2010 through 2016; increased 21.8% to 2,967 cases in 2016 - (03/20/18)
     
  1590. EASL: Clinical and virological characteristics of DAA-experienced patients with chronic HCV infection treated with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX): results from the Frankfurt Resistance Database - (04/20/18)
     
  1591. EASL: DIRECT-ACTING ANTIVIRAL TREATMENT IN SUB-SAHARAN AFRICA: A PROSPECTIVE TRIAL OF LEDIPASVIR/SOFOSBUVIRFOR CHRONIC HEPATITIS C INFECTION IN RWANDA (THE SHAREDSTUDY) - (04/20/18)
     
  1592. EASL: Collocation of Buprenorphine with HCV Treatment to Improve Adherence and Reduce Harm in PWID with HCV Preliminary Data from the ANCHOR STUDY - (04/20/18)
     
  1593. EASL: HepFree: Screening migrant patients for viral hepatitis in primary care. A 90,000 patient randomised controlled trial indicates benefits are most obvious in older patients/UK-London - (04/20/18)
     
  1594. EASL: Glomerular filtration rate changes after treatment of chronic hepatitis C patients with direct-acting antivirals: an observational study - (04/20/18)
     
  1595. EASL: Spontaneous Clearance of HCV RNA after Documented Relapse following DAA-therapyA case-control study - (04/20/18)
     
  1596. EASL: Efficacy and Safety of Elbasvir/Grazoprevir in Women Infected With Hepatitis C Virus Genotypes 1 or 4 and Coadministered Oral Contraceptives or Hormone Replacement Therapy - (04/20/18)
     
  1597. EASL: Reduction in the incidence of hepatitis C-related decompensated cirrhosis associated with national scale-up of direct-acting antiviral therapies targeting patients with advanced liver fibrosis - (04/20/18)
     
  1598. EASL: DNA Methylation and Immune Cell Markers Demonstrate Evidence of Accelerated Aging in Patients with Chronic HBV Infection, with Improvement During Treatment - (04/20/18)
     
  1599. EASL: NGM282 Significantly Improves Markers of Bile Acid Synthesis, Hepatic Injury and Fibrosis in PSC Patients: Results of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial - (04/20/18)
     
  1600. EASL: NAFLD and risk of incident steatohepatitis, cirrhosis and hepatocellular carcinoma in four European primary care databases - (04/19/18)
     
  1601. EASL: The Worldwide Prevalence of Non-alcoholic Steatohepatitis (NASH) in Patients with Type 2 Diabetes Mellitus (DM) - (04/19/18)
     
  1602. EASL: NGM282 Improves Fibrosis and NASH-Related Histology in 12 Weeks in Patients With Biopsy-Confirmed NASH, Which is Preceded By Significant Decreases in Hepatic Steatosis, Liver Transaminases and Fibrosis Markers at 6 Weeks - (04/19/18)
     
  1603. EASL: A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH) - (04/19/18)
     
  1604. EASL: MGL-3196, a selective thyroid hormone receptor-beta agonist, significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study - (04/19/18)
     
  1605. EASL: Cenicriviroc Treatment for Adults with Non-Alcoholic Steatohepatitis: Year 2 Analysis of the Phase 2b CENTAUR Study - (04/19/18)
     
  1606. EASL: Proof-of-concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor (FXR) agonist (GS-9674) in NASH - (04/18/18)
     
  1607. EASL: NAFLD and risk of incident steatohepatitis, cirrhosis and hepatocellular carcinoma in four European primary care databases - (04/18/18)
     
  1608. EASL: Efficacy and Safety of Elbasvir/Grazoprevir in Women Infected With Hepatitis C Virus Genotypes 1 or 4 and Coadministered Oral Contraceptives or Hormone Replacement Therapy - (04/17/18)
     
  1609. EASL: NS5A resistance patterns and treatment outcomes in DAA-naïve genotype 1a (GT1a) chronic hepatitis C patients with and without baseline resistance-associated substitutions (RASs) - (04/17/18)
     
  1610. EASL: DISEASE OUTCOMES AFTER DAA-INDUCED SVR: DATA FROM THE RESIST-HCV COHORT - (04/17/18)
     
  1611. EASL: SVR IS THE STRONGEST PREDICTOR OF OCCURRENCE AND RECURRENCE OF HEPATOCELLULAR CARCINOMA IN HCV CIRRHOTIC PATIENTS AFTER TREATMENT WITH DIRECT ACTING ANTIVIRALS: A PROSPECTIVE MULTICENTER ITALIAN STUDY. - (04/17/18)
     
  1612. EASL: Effectiveness Of Hepatitis C Virus Screening Laws in the United States: Evidence From Paid Claims Data From 2010 To 2016 - (04/17/18)
     
  1613. EASL: Testing and linkage to care outcomes in baby boomers verses young adults tested in the community and linked to care at a Federally Qualified Health Center in the US - (04/17/18)
     
  1614. EASL: UTILIZATION OF ELBASVIR / GRAZOPREVIR (EBR/GZR) AND ADOPTION OF RESISTANCE ASSOCIATED SUBSTITUTIONS (RAS) TESTING IN REAL-WORLD TREATMENT OF HCV GENOTYPE 1 (GT1) INFECTION: RESULTS FROM THE GERMAN HEPATITIS C REGISTRY (DHC-R) - (04/17/18)
     
  1615. EASL: Z-PROFILE: Real-world utilization and effectiveness of elbasvir/grazoprevir in adult patients with chronic hepatitis C in Canada - (04/17/18)
     
  1616. EASL: Impact of Acid-Reducing Agents on Effectiveness of Elbasvir/Grazoprevir in Treating US Veterans Affairs Population with Hepatitis C Virus - (04/17/18)
     
  1617. EASL: Incidence and Prevalence of Extrahepatic Manifestations of HCV - (04/17/18)
     
  1618. EASL: C-EDGE Treatment Experienced: Effect of 12-Week Oral Regimens of Elbasvir and Grazoprevir on Health Related Quality of Life in Prior Treatment Experienced Patients With Chronic Hepatitis C Infection - (04/17/18)
     
  1619. EASL: Hepatic Safety and Biomarker Assessments in Sorafenib-experienced Patients With Advanced Hepatocellular Carcinoma Treated With Nivolumab in the CheckMate-040 Study - (04/16/18)
     
  1620. EASL: IFN-free DAA treatment of cirrhotic HCV patients with or without history of HCC: a multicenter prospective trial in Italy - (04/16/18)
     
  1621. EASL: Long-term impact of HCV eradication after all oral therapy in patients with clinical significant portal hypertension - (04/16/18)
     
  1622. EASL: No evidence of fibrosis regression in HCV/HIV co-infected and HCV mono-infected participants up to 3 years after achieving SVR with DAA treatment: interim results from the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS) - (04/16/18)
     
  1623. EASL: Survival Benefits of Direct-Acting Antiviral Therapy in Patients with Decompensated Hepatitis C Cirrhosis - (04/16/18)
     
  1624. EASL: Survival Benefits of Direct-Acting Antiviral Therapy in Patients with Decompensated Hepatitis C Cirrhosis - (04/16/18)
     
  1625. EASL: Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir Among 723 Patients with Chronic Hepatitis C: The NAVIGATOR-II Study - Interim Analysis - (04/16/18)
     
  1626. EASL: Risk of Total Non-hepatic Cancer Following Treatment for HCV Infection with Direct-acting Antiviral Agents - (04/16/18)
     
  1627. EASL: Long-Term Follow-up of Patients with Chronic HCV Infection and Compensated or Decompensated Cirrhosis Following Treatment with Sofosbuvir-Based Regimens - (04/16/18)
     
  1628. EASL: Scaling up HCV-DAA treatment in patients on opioid substitution therapy - does alcohol or cannabis consumption diminish cure rates? Data from the German Hepatitis C Registry (DHC-R) - (04/16/18)
     
  1629. EASL: Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects with Chronic Hepatitis C Previously Treated with an NS5A Inhibitor + Sofosbuvir Therapy - (04/16/18)
     
  1630. EASL: Treatment of non-cirrhotic HCV genotype 4 infected patients with 8 weeks of ledipasvir/sofosbuvir: an open-label, multicenter clinical trial - (04/16/18)
     
  1631. EASL: NGM282 Significantly Improves Markers of Bile Acid Synthesis, Hepatic Injury and Fibrosis in PSC Patients: Results of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial - (04/16/18)
     
  1632. EASL: HCC RECURRENCE UNDER ALL-ORAL DAAs-BASED ANTIVIRAL THERAPY IN HCV-INFECTED PATIENTS: DATA FROM THE NAVIGATORE WEB PLATFORM - (04/16/18)
     
  1633. EASL: A Phase 3, Global, Multicenter, Open-Label Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non-severe fibrosis : STREAGER - (04/16/18)
     
  1634. EASL: Hepatic Safety and Biomarker Assessments in Sorafenib-experienced Patients With Advanced Hepatocellular Carcinoma Treated With Nivolumab in the CheckMate-040 Study - (04/13/18)
     
  1635. EASL: 8 weeks sofosbuvir/velpatasvir in genotype 3 patients with significant fibrosis: Highly effective amongst an OST cohort - (04/13/18)
     
  1636. EASL: FIRST REAL-WORLD DATA ON SAFETY AND EFFECTIVENESS OF GLECAPREVIR/PIBRENTASVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION: DATA FROM THE GERMAN HEPATITIS C-REGISTRY - (04/13/18)
     
  1637. EASL: EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN PATIENTS WITH HCV GENOTYPE 5 OR 6 INFECTION: THE ENDURANCE-5, 6 STUDY - (04/13/18)
     
  1638. EASL: Impact of HCV Viral Load on Elbasvir/Grazoprevir Effectiveness in Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network - (04/13/18)
     
  1639. EASL: Effectiveness of Elbasvir/Grazoprevir in Patients with Cirrhotic Genotype 1 or 4 Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network - (04/13/18)
     
  1640. EASL: Safety and Efficacy of Sofosbuvir/Velpatasvir with and without Ribavirin in Genotype 3 HCV-Infected Patients with Cirrhosis - (04/13/18)
     
  1641. EASL: Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With Psychiatric Disorders - (04/13/18)
     
  1642. EASL: Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Patients With Chronic HCV Genotype 1-6 Infection - (04/12/18)
     
  1643. EASL: Direct Acting Antiviral HCV Therapy is Safe and Effective in Patients with Decompensated Cirrhosis: Real World Experience from the HCV-TARGET Cohort - (04/12/18)
     
  1644. EASL: Efficacy and safety of 8 weeks of elbasvir/grazoprevir in HCV GT4-infected treatment-naive participants - (04/12/18)
     
  1645. EASL: RETREATMENT OF HEPATITIS C VIRUS INFECTION IN PATIENTS WHO FAILED GLECAPREVIR/PIBRENTASVIR - (04/12/18)
     
  1646. EASL: Effectiveness of 8 vs. 12 Week Ledipasvir/Sofosbuvir (LDV/SOF) in Black, Treatment Naïve Patients with Non-Cirrhotic, Genotype 1 HCV and Baseline Viral Load: Analyses of Real-World Data from the TRIO Network - (04/12/18)
     
  1647. EASL: Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Infection and Prior Treatment Experience: An Integrated Phase II/III Analysis - (04/12/18)
     
  1648. EASL: HCV Micro-Elimination Funding Grants Available - (04/12/18)
     
  1649. Cocrystal Pharma Receives FDA Clearance to Initiate Phase 2a Clinical Study Evaluating CC-31244 for the Treatment of Hepatitis C Virus - (04/11/18)
     
  1650. CROI: Summary from CROI 2018 for viral Hepatitis HCV micro-elimination in HIV/HCV coinfection: successes and challenges - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany (03/29/18)
     
  1651. CROI: A Multicenter Registry in HIV/HCV Co-infected Patients Initiating Ledipasvir/Sofosbuvir - (03/29/18)
     
  1652. CROI: HCV RNA and Antigen Detection for Diagnosis of Acute Hepatitis C Among MSM on PreP..... In the ANRS IPERGAY PrEP trial among high risk MSM - (03/29/18)
     
  1653. CROI: Nine of 100 MSM in German Cohort Get HCV Reinfection Every Year in DAA Era - Mark Mascolini (03/29/18)
     
  1654. CROI: HCV incidence in HIV-infected and in PrEP-using MSM - New HCV Rate Similar in HIV+ MSM and HIV- MSM on PrEP in France - Mark Mascolini (03/27/18)
     
  1655. CROI: New HCV Infections Still Rising Among MSM With HIV in France - Mark Mascolini (03/21/18)
     
  1656. APASL: REAL-WORLD EFFECTIVENESS OF 12 WEEK ELBASVIR/GRAZOPREVIR (EBR-GZR) IN PATIENTS WITH GENOTYPE 1 (GT1) CHRONIC HEPATITIS C (HCV) AND CHRONIC KIDNEY DISEASE (CKD): RETROSPECTIVE DATA ANALYSES FROM THE TRIO NETWORK - (03/21/18)
     
  1657. APASL: SAFETY AND EFFICACY OF ELBASVIR/GRAZOPREVIR IN ASIAN PARTICIPANTS WITH HEPATITIS C VIRUS INFECTION: AN INTEGRATED ANALYSIS OF DATA FROM 11 PHASE 2/3 TRIALS - (03/21/18)
     
  1658. APASL: BURDEN OF COMORBIDITIES AND COMEDICATIONS IN A CHRONIC HCV POPULATION COMPARED WITH A NON-HCV POPULATION IN JAPAN BETWEEN 2015 AND 2016 - (03/21/18)
     
  1659. APASL: Sofosbuvir/Velpatasvir Is Safe and Effective in a Phase 3 Study of Genotype 1-3 HCV-infected Russian and Swedish Patients - (03/21/18)
     
  1660. APASL: Twelve Weeks of Ledipasvir/Sofosbuvir All-oral Regimen for Patients with Chronic Hepatitis C Genotype 2 Infection: Integrated Analysis of Three Clinical Studies - (03/21/18)
     
  1661. Gov Cuomo Announces 1st State-Level HCV Elimination Strategy to Increase Access to Medication, Expand Comprehensive Programs and Enhance Treatment Services - (03/18/18)
     
  1662. CROI: Low Prevalence of Hepatitis C Virus Among New York City MSM Initiating PrEP and PEP, 2016-2017 at NYC Sexual Health Clinics (03/15/18)
     
  1663. CROI: A treatment as prevention trial to eliminate HCV in HIV positive men who have sex with men: The Swiss HCVree Trial - e-health assisted behavioral intervention to reduce risk in HCV re-infection in MSM - Mark Mascolini (03/15/18)
     
  1664. CROI: FUELING THE EPIDEMIC: Low Spontaneous HCV Clearance in Big European HCV/HIV Cohort - Mark Mascolini (03/15/18)
     
  1665. CROI: 8 weeks of grazoprevir plus elbasvir for acute hepatitis C virus genotype 1 or 4 infection - the DAHHS 2 study - a single-arm, prospective, open-label, multicenter phase 3b trial (03/12/18)
     
  1666. CROI: Retreatment of Hepatitis C Infection in Patients Who Failed Glecaprevir/Pibrentasvir (03/09/18)
     
  1667. The VA Will Eliminate Hepatitis C In Veterans By Year-End - (03/05/18)
     
  1668. New Results - Interim impact evaluation of the hepatitis C virus elimination program in Georgia published - (02/26/18)
     
  1669. Time to end treatment restrictions for people with hepatitis C who inject drugs - Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial - (02/26/18)
     
  1670. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection - (02/23/18)
     
  1671. HCV Screening For All One Time, Cost & Health Effective - "Population level outcomes and cost-effectiveness of expanding the recommendation for age-based hepatitis C testing in the United States" - (02/23/18)
     
  1672. Heroin vaccine blocks lethal overdose - (02/14/18)
     
  1673. HCV Elimination / IDUs - (02/14/18)
     
  1674. The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen - (02/09/18)
     
  1675. Achieving hepatitis C elimination in Europe - To treatment scale-up and beyond - Editorial - (02/09/18)
     
  1676. Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease - (01/31/18)
     
  1677. Direct-Acting Antiviral Sustained Virologic Response: Impact on Mortality in Patients without Advanced Liver Disease - (01/31/18)
     
  1678. HCV Increases Risk for Comorbid Conditions - (01/31/18)
     
  1679. Recovery of Infectious Hepatitis C Virus From Injection Paraphernalia: Implications for Prevention Programs Serving People Who Inject Drugs - (01/31/18)
     
  1680. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection - (01/25/18)
     
  1681. HCV Cocrystal Drug Development Update - (01/24/18)
     
  1682. New HCV Drug - NNI CC-31244 - (01/24/18)
     
  1683. Increase in hepatitis C infections linked to worsening opioid crisis - (01/19/18)
     
  1684. Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014 - (01/19/18)
     
  1685. SVR in HIV/HCV Coinfected / DDIs - (01/17/18)
     
  1686. New HCV Drugs Selected Studies - (01/17/18)
     
  1687. Green tea consumption: A potential chemopreventive measure for hepatocellular carcinoma? - Editorial - (01/12/18)
     
  1688. Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030 - (01/12/18)
     
  1689. The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong - (01/12/18)
     
  1690. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial - (01/11/18)
     
  1691. IAS: Prevalence and Mapping of Hepatitis C Infections among Men Who Have Sex with Men in New York City - (01/04/18)
     
  1692. EACS: HCV Reinfection Intervention in HCV/HIV MSM - Swiss Cohort - (01/04/18)
     
  1693. Addressing the increasing global burden of viral hepatitis - Editorial - (12/29/17)
     
  1694. Towards the Elimination of Hepatitis C in the United States - (12/29/17)
     
  1695. France Reaches Agreement With Gilead To Drop Prices Of Hepatitis C Treatment - (12/29/17)
     
  1696. Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States - $7.2 Bill in 2016 - (12/29/17)
     
  1697. Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD - (12/29/17)
     
  1698. SVR Reduced HCC by 71% - (12/22/17)
     
  1699. Burden of Illness Economic Model for Patients with Non-alcoholic Steatohepatitis (NASH) in the United States - (12/19/17)
     
  1700. The Global Epidemiology of Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis - (12/19/17)
     
  1701. Long-Term Outcomes of Diabetic Patients with Non-alcoholic Fatty Liver Disease (NAFLD) / HIV & the Liver, Fatty Liver/NALFD - (12/18/17)
     
  1702. Hepatocellular Carcinoma (HCC) in Patients with Non-Cirrhotic and Cirrhotic Nonalcoholic Fatty Liver Disease - (12/18/17)
     
  1703. HEP DART presentations 3 -7 Dec 2017 - (12/12/17)
     
  1704. HEP-DART presentations 3 Dec - 7, 2017 - (12/11/17)
     
  1705. HIV New Cases among IDUs Alert / Mass Dept of Health - (12/11/17)
     
  1706. County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States - (12/08/17)
     
  1707. PPIs Increase NASH Risk - Microbiome & Fatty Liver: gut barrier dysfunction reported by speaker, leads to increased microbes into gut going to liver, increasing inflammation, and fatty liver - (12/11/17)
     
  1708. County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States - (12/08/17)
     
  1709. AASLD: AL-034 (or TQ-A3334), a Selective Toll-like Receptor 7 Agonist for Oral Treatment of Chronic Hepatitis B Virus Infection - (12/05/17)
     
  1710. AASLD: AASLD 2017 Viral Hepatitis Debrief - (12/05/17)
     
  1711. AASLD: Survival Benefit of Direct-Acting Antiviral Therapy in Patients with Decompensated Cirrhosis - (12/05/17)
     
  1712. AASLD: Failure to multiple Interferon-free direct Antiviral therapies: could Chronic hepatitis C become incurable? - (12/02/17)
     
  1713. DAA Cure Denied - (12/01/17)
     
  1714. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial - (12/01/17)
     
  1715. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection - (12/01/17)
     
  1716. AASLD: Virology analyses from HCV-infected patients treated with the combination of AL-335 and odalasvir, with and without simeprevir, in Phase II studies - (12/01/17)
     
  1717. AASLD: Summary from AASLD 2017 for Hepatitis C HCV: Game over? - Jurgen K. Rockstroh M.D., Professor of Medicine Department of Medicine I, University Hospital Bonn, Bonn, Germany - (11/29/17)
     
  1718. EASL: HCV Micro-Elimination Funding Grants Available - (04/12/18)
     
  1719. AASLD: Hepatitis C Care in the Department of Veterans Affairs: HIT Process Improvement Program - (11/29/17)
     
  1720. AASLD: Cardiovascular risk in NAFLD- not an equal opportunity: implications for women's health - (11/29/17)
     
  1721. AASLD: No Evidence of 1-Year Reinfection after Treating HCV at a Methadone Program - (11/29/17)
     
  1722. AASLD: C-BREEZE 1: Efficacy and Safety of Ruzasvir 60 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection - (11/29/17)
     
  1723. AASLD: Survival Benefit of Direct-Acting Antiviral Therapy in Patients with Decompensated Cirrhosis - (11/29/17)
     
  1724. AASLD: Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts early NASH and disease activity - (11/29/17)
     
  1725. AASLD: NAFLD Debrief AASLD 2017 - (11/29/17)
     
  1726. AASLD: Serum-Based Biomarker Test Accurately Stratifies Hepatic Fibrosis in Patients with Nonalcoholic Steatohepatitis - (11/29/17)
     
  1727. AASLD: Multi-Biomarker Validation of MRI-PDFF- and MRE-Derived Treatment Response with BMS-986036 (PEG-FGF21): A Secondary Analysis of a Multi-Center Clinical Trial in Non-Alcoholic Steatohepatitis (NASH) - (11/29/17)
     
  1728. AASLD: Baseline Serum Pro-C3 Predicts Response to BMS-986036 (PEG-FGF21): A Secondary Analysis of a Multi-Center Clinical Trial in Non-Alcoholic Steatohepatitis (NASH) - (11/29/17)
     
  1729. AASLD: Failure to multiple Interferon-free direct Antiviral therapies: could Chronic hepatitis C become incurable? - (11/27/17)
     
  1730. AASLD: Can HCV be eliminated among HIV---infected MSM in Berlin? Modeling a setting with increasing incidence and high treatment rates - (11/27/17)
     
  1731. AASLD: Effectiveness of Elbasvir/Grazoprevir in Patients With Chronic Hepatitis C and Chronic Kidney Disease:Results From the Veterans Affairs System - (11/27/17)
     
  1732. AASLD: Sofosbuvir/Velpatasvir for 12 Weeks in Genotype 1-4 HCV-Infected Liver Transplant Recipients - (11/27/17)
     
  1733. AASLD: Efficacy and Safety of Glecaprevir / Pibrentasvir in Patients Infected with HCV GT1 - 3 by Renal Impairment Status: A Pooled Analysis of Two Phase 3 Japanese Trials - (11/27/17)
     
  1734. AASLD: Real World Effectiveness of 8 and 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) in Blacks with HCV: A Comparative Analysis of Clinical Trials with Real World Cohorts - (11/27/17)
     
  1735. AASLD: Long-term Follow-Up of Patients With Chronic HCV and No or Minimal Fibrosis Shows Low Risk for Liver-Related Morbidity and Mortality After Achieving SVR With DAA-Based Therapy: Results From the Gilead SVR Registry - (11/27/17)
     
  1736. AASLD: Real-World Study Shows ZEPATIER® (Elbasvir and Grazoprevir) Resulted in High Rates of Sustained Virologic Response in Patients with Chronic Hepatitis C Infection Who Have Chronic Kidney Disease - (11/27/17)
     
  1737. AASLD: Serious adverse events and direct-acting antivirals drugs (DAA): ANRS CO22 HEPATHER cohort - (11/27/17)
     
  1738. AASLD: Safety and Efficacy of Glecaprevir / Pibrentasvir in Patients with Chronic Hepatitis C Genotypes 1 - 6 and Recent Drug Use - (11/27/17)
     
  1739. Public-Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals [HCV-TARGET] - (11/20/17)
     
  1740. AASLD: Development and Validation of the Collagen Neo-Epitope Biomarker Pro-C3 "FIB-C3 Score" for Detection and Staging of Advanced Non-Alcoholic Fatty Liver Disease in a Large International Multi-Centre Patient Cohort - (11/20/17)
     
  1741. AASLD: Prevalence and Clinical Characteristics of Nonalcoholic Fatty Liver Disease in Lean Subjects in Comparison with Overweight or Obese Individuals: A cross-sectional study - (11/20/17)
     
  1742. AASLD: Advanced machine learning techniques to identify a panel of biomarkers that identify non-alcoholic steatohepatitis - (11/20/17)
     
  1743. AASLD: Diagnosing NASH and Assessing NASH Disease Severity with HepQuant-STAT, a Simple Quantitative Liver Function Test - (11/20/17)
     
  1744. AASLD: Serum-Based Biomarker Test Accurately Stratifies Hepatic Fibrosis in Patients with Nonalcoholic Steatohepatitis - (11/20/17)
     
  1745. AASLD: CM-101 a novel CCL24 blocking monoclonal antibody ameliorates hepatic injury in NASH induced mouse model - (11/20/17)
     
  1746. AASLD: Significant anti-fibrotic efficacy of EDP-305, a highly potent and selective farnesoid X receptor (FXR) agonist, in a rat model of thioacetamide-induced liver fibrosis and cirrhosis - (11/20/17)
     
  1747. AASLD: Cure denied and cure delayed in Chronic Hepatitis C; monitoring non-start rates and increased time to start using real-world data from the TRIO Network - (11/20/17)
     
  1748. AASLD: Access to HCV Care for 31,154 Patients in the United States Real-world experience from the TRIO Network - (11/20/17)
     
  1749. AASLD: Impact of Hepatocellular Carcinoma (HCC) and Tumor Treatment on Sustained Virologic Response (SVR) Rates with Direct-Acting Antiviral (DAA) Therapy for Hepatitis C: HCV-TARGET Results - (11/20/17)
     
  1750. AASLD: Treatment of HCV-induced cryoglobulinemic vasculitis with new direct acting antiviral (DAA) regimens - (11/20/17)
     
  1751. AASLD: Safety and Efficacy of Velpatasvir and Sofosbuvir-based Regimens for the Treatment of HCV Genotype 1-6: Results of the HCV-TARGET Study - (11/20/17)
     
  1752. AASLD: The Long-Term Clinical Course of Histologically Advanced NAFLD. Impact of Fibrosis Severity on Major Clinical Outcomes. - An International and Multicenter Cohort Study - (11/17/17)
     
  1753. AASLD: Natural History of Nonalcoholic Fatty Liver Disease in Children - (11/17/17)
     
  1754. AASLD: Evaluation of an early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C patients treated with All-Oral DAAs - (11/17/17)
     
  1755. AASLD: Real life clinical outcomes in DAA-treated and untreated patients with HCV advanced liver disease. Interim one year data from the ongoing PITER cohort - (11/17/17)
     
  1756. AASLD: Long-term Follow-Up of Patients With Chronic HCV and No or Minimal Fibrosis Shows Low Risk for Liver-Related Morbidity and Mortality After Achieving SVR With DAA-Based Therapy: Results From the Gilead SVR Registry - (11/16/17)
     
  1757. AASLD: Low Rates of De Novo or Recurrent Hepatocellular Carcinoma in HCV Cirrhotic Patients Treated with Direct-Acting Antivirals (DAAs): A Single-Center Experience - (11/16/17)
     
  1758. AASLD: HCC Trends, Disparities in Tumor Stage at Diagnosis - Less Than Half of Hepatocellular Carcinoma Patients Among the 1945-1965 Birth Cohort in the U.S. Were Within Milan Criteria at Time of Diagnosis - (11/16/17)
     
  1759. AASLD: Routine Hepatocellular Carcinoma Surveillance for Hepatitis C Virus-Infected Alaska Native Persons Associated with Increased Likelihood of HCC Diagnosis at an Early Stage During 1991-2016 - (11/16/17)
     
  1760. AASLD: Economic Burden of Chronic Hepatitis C (CHC) in Medicaid and Commercially Insured Patients in the United States - (11/16/17)
     
  1761. AASLD: Utilization and Effectiveness of Elbasvir/Grazoprevir (EBR/GZR) in Treatment Naïve (TN) Genotype 1a (GT1A) Chronic Hepatitis C Virus (HCV) Patients with/without Baseline NS5A resistance-associated substitutions (RASs) - (11/16/17)
     
  1762. AASLD: Epidemiologic Impact of Expanding Chronic Hepatitis C (CHC) Treatment in People Who Inject Drug in the United States: A Mathematical Model Using Data From the C-EDGE CO-STAR Study - (11/16/17)
     
  1763. EASL: Summary from EASL 2017 for Hepatitis C - Global implementation of Hepatitis C (HCV) treatment: What are the successes, what are the remaining challenges? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany -
     
  1764. AASLD: Evaluation of Cytochrome P450- and Transporter-Mediated Drug-Drug Interactions Between the Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor Selonsertib and Phenotypic Probe Substrates or Prototypic Inhibitors/Inducers - (11/16/17)
     
  1765. AASLD: Radiologic Progression in Primary Sclerosing Cholangitis by Two-Dimensional Magnetic Resonance Cholangiopancreatography: Prospective Data From a Randomized Controlled Trial - (11/16/17)
     
  1766. AASLD: Quantification of Biliary Tree Volume in Patients With PSC Using Three-Dimensional Reconstruction of Magnetic Resonance Cholangiopancreatography: Clinical Associations and Prognostic Significance - (11/16/17)
     
  1767. FDA - Sovaldi, Harvoni, Epclusa and Vosevi Labels Were Updated - (11/15/17)
     
  1768. FDA - VIEKIRA PAK, VIEKIRA XR and TECHNIVIE Label Updated - (11/15/17)
     
  1769. EACS: Analysis of the performance of non-invasive markers of steatosis and fibrosis in HIV-monoinfected patients at-risk of NAFLD: Results from the ERANET-HIVERA ECHAM study - (11/15/17)
     
  1770. AASLD: Identification of Circulating MicroRNAs Altered by an Apoptosis Signal-Regulating Kinase 1 Inhibitor in a Fast-food Diet NAFLD Mouse Model - (11/14/17)
     
  1771. AASLD: Plasma Metabolites for de Novo Lipogenesis and Pharmacodynamic Activity of Acetyl-CoA Carboxylase Inhibitor GS-0976 - (11/14/17)
     
  1772. AASLD: Variability in Measurement of Hepatic Venous Pressure Gradient in Patients With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis: Results From a Randomized, Controlled Trial - (11/14/17)
     
  1773. AASLD: Hepatic Venous Pressure Gradient Predicts Clinical Disease Progression in Patients With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis - (11/14/17)
     
  1774. AASLD: Hepatic de Novo Lipogenesis Is Elevated in Patients With NASH Across the Spectrum of Disease Severity - (11/14/17)
     
  1775. AASLD: Reductions in Hepatic Proton Density Fat Fraction Predict Histologic Improvement in a Multicenter Clinical Trial of Subjects With Nonalcoholic Steatohepatitis - (11/14/17)
     
  1776. AASLD: Reductions in Liver Stiffness by Magnetic Resonance Elastography Predict Fibrosis Improvement in a Multicenter Clinical Trial of Subjects With Nonalcoholic Steatohepatitis - (11/14/17)
     
  1777. AASLD: Serum Pro-C3 Is Associated With Hepatic Steatosis and Fibrosis, and Responsive to Changes in Steatosis in Patients With NASH - (11/13/17)
     
  1778. AASLD: Prospective Validation of the Enhanced Liver Fibrosis (ELF) Test for the Prediction of Disease Progression in Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis - (11/13/17)
     
  1779. AASLD: Prospective Validation of Hepatic Collagen Content for the Prediction of Clinical Disease Progression in Patients With Advanced Fibrosis Due to NASH - (11/13/17)
     
  1780. AASLD: Gilead Announces Phase 2 Results for GS-0976 in Nonalcoholic Steatohepatitis (NASH) - (11/13/17)
     
  1781. AASLD: Acetyl-CoA Carboxylase Inhibitor GS-0976 Leads to Significant Improvements in MRI-PDFF in a Phase 2, Randomized, Placebo-Controlled Trial of Patients with NASH - (11/13/17)
     
  1782. AASLD: Combination of ASK1 and ACC Inhibitors Increases Efficacy in Rodent Models of NASH - (11/13/17)
     
  1783. AASLD: Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamic Effects on de Novo Lipogenesis of the Acetyl-CoA Carboxylase Inhibitor GS-0976 in Healthy Volunteers - (11/13/17)
     
  1784. AASLD: A Liver-Targeted Acetyl-CoA Carboxylase Inhibitor Increases Fatty Acid Oxidation, Improves Mitochondrial Function, and Reduces Bile Acids and Oxidative Stress in a Murine Model of NASH - (11/13/17)
     
  1785. AASLD: norUrsodeoxycholic acid (norUDCA) improves non-alcoholic fatty liver disease (NAFLD): Results from a randomized placebo-controlled, double-blind phase IIa study - (11/13/17)
     
  1786. AASLD: Racial and Ethnic Disparities in Non-Alcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Meta-Analysis - (11/13/17)
     
  1787. AASLD: Performance of liver stiffness by FibroScan in a Large Prospective Multicenter UK Study: Applicability, reliability, diagnostic performance and influence of the probe type and of steatosis on the liver stiffness measurement - (11/13/17)
     
  1788. AASLD: The incidence of hepatocellular carcinoma is not increased after DAA therapy - (11/13/17)
     
  1789. AASLD: Treatment of Hepatitis C Virus (HCV) Leads to Economic Gains Related to Reduction in Cases of Hepatocellular Carcinoma (HCC) and Decompensated Cirrhosis (DCC) in Japan - (11/13/17)
     
  1790. AASLD: Impact of a Structured Hepatocellular Carcinoma Surveillance Program in Patients with Cirrhosis: Frequency, Evaluation and Subsequent Clinical Outcomes of Patients with Abnormal Imaging Findings - (11/13/17)
     
  1791. AASLD: Improved Short-term Survival among HCV Patients following Liver Transplantation in the Era of Direct Acting Antiviral Agents - (11/13/17)
     
  1792. AASLD: The Declining Burden of HCV on the Liver Transplant Waitlist associated with the DAA era - (11/13/17)
     
  1793. AASLD: Treatment of HCV with Direct Acting Antivirals Significantly Reduces Liver-Related Hospitalizations in Patients with Cirrhosis - (11/13/17)
     
  1794. AASLD: INCIDENCE OF HEPATITIS C AMONG HIV-INFECTED MEN WHO HAVE SEX WITH MEN IN SAN DIEGO, 2000-2015 - (11/10/17)
     
  1795. AASLD: Risk of Hepatitis C transmission from antibody positive-nucleic acid negative liver organs to non-Hepatitis C recipients - (11/10/17)
     
  1796. AASLD: Ledipasvir/Sofosbuvir in the Treatment of Japanese Patients With Chronic HCV Genotype 2 Infection - (11/08/17)
     
  1797. AASLD: Identification of Novel HCV Genotype and Subtypes in Patients Treated with Sofosbuvir-Based Regimens - (11/08/17)
     
  1798. AASLD: The road to elimination of Hepatitis C: Analysis of SVR versus new HCV infections in 91 countries - (11/08/17)
     
  1799. AASLD: Regression of liver stiffness (LS) after direct acting anti-viral (DAA) therapy for hepatitis C in the country of Georgia - (11/06/17)
     
  1800. AASLD: Real-World Effectiveness of Sofosbuvir and Ledipasvir/Sofosbuvir Based Regimens in Hepatitis C Virus Genotype 3 Infection Within National Hepatitis C Elimination Program in the Country of Georgia - (11/06/17)
     
  1801. AASLD: Ledipasvir / Sofosbuvir plus Ribavirin as highly effective regimen for RF1_2k/1b patients within Georgian national hepatitis C elimination program - (11/06/17)
     
  1802. (DURB) Medicaid review board lifts liver damage restriction on life-saving cures for Vermonters with hepatitis C - (11/02/17)
     
  1803. EACS: The Burden of HCV-Related Cirrhosis Among HIV/HCV Coinfected Individuals in Spain in the DAA Era: What will the battlefield look like once the battle is over? - (11/02/17)
     
  1804. EACS: HCV Prevalence in HIV Patients Falls Nearly 50% in Spain in 1 Year - Mark Mascolini (11/02/17)
     
  1805. EACS: Big Gaps in HCV/HIV Care Continuum Across Europe at Start of 2015 - Mark Mascolini (11/02/17)
     
  1806. EACS: High incidence of HCV reinfection in HIV-positive MSM in the DAA era - (10/30/17)
     
  1807. EACS: Big Gaps in HCV/HIV Care Continuum Across Europe at Start of 2015 - written by Mark Mascolini (10/30/17)
     
  1808. EACS: HCV Prevalence in HIV Patients Falls Nearly 50% in Spain in 1 Year - written by Mark Mascolini (10/30/17)
     
  1809. EACS: Impact of Diabetes and Age on Kidneys During DAA Therapy for HCV/HIV - written by Mark Mascolini (10/30/17)
     
  1810. EACS: Global Analysis Projects World Far From Goal of Eliminating HCV - written by Mark Mascolini (10/30/17)
     
  1811. EACS: High SVR 12 rates with grazoprevir/elbasvir ï ribavirin for 12-16 weeks guided by genotypic resistance testing among HIV/HCV coinfected MSM in the Swiss HCVree Trial (10/30/17)
     
  1812. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review - (10/28/17)
     
  1813. HCV Medicaid Drug Access Restrictions-new report - (10/28/17)
     
  1814. AASLD: Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients Aged 65 Years or Older With Chronic Hepatitis C: A Pooled Analysis of Phase 2 and 3 Clinical Trials - (10/29/17)
     
  1815. AASLD: Pan-Genotypic Hepatitis C Treatment With Glecaprevir/Pibrentasvir Achieves Greatest Improvements in Quality-Adjusted Life-Years and Lifetime Risk Reductions in Liver-Related Morbidity and Mortality vs Standards of Care: A Cost-Utility Analysis - (10/29/17)
     
  1816. AASLD: Hepatitis C in Patients Without Fibrosis or with Minimal Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes - (10/29/17)
     
  1817. AASLD: Significant and Sustained Improvement of Health-Related Quality of Life Scores in Patients with Hepatitis C and Sustained Virologic Response - (10/29/17)
     
  1818. AASLD: Treatment with Glecaprevir/Pibrentasvir (G/P)-based regimens of patients with difficult to treat HCV infection. A compassionate use study. - (10/29/17)
     
  1819. AASLD: Impact of Hepatitis C Treatment With Glecaprevir + Pibrentasvir on Patient's Health Related Quality of Life: Results From Phase 3 CERTAIN Trials - (10/29/17)
     
  1820. EACS: Cure Rate 99% With Grazoprevir/Elbasvir in HCV/HIV-Infected MSM in Switzerland - written by Mark Mascolini (10/29/17)
     
  1821. AASLD: Chronic kidney disease and hepatitis C mutually advance liver and renal disease progression: real-world evidence from the United States - (10/28/17)
     
  1822. AASLD: Pan-genotypic Hepatitis C Treatment With Glecaprevir+ Pibrentasvir Resulted in Improvement in Cardiovascular and Metabolic Extrahepatic Manifestations and Stable Renal Function: Results From Phase 3 Clinical Trials - (10/28/17)
     
  1823. AASLD: New York City Hospitals' Capacity to Support the Elimination of Hepatitis C: A Follow-up Survey - (10/28/17)
     
  1824. AASLD: Acetyl-CoA Carboxylase Inhibitor GS-0976 Leads to Significant Improvements in MRI-PDFF in a Phase 2, Randomized, Placebo-Controlled Trial of Patients with NASH - (10/28/17)
     
  1825. AASLD: Nivolumab in Sorafenib-Naive and -Experienced Patients With Advanced Hepatocellular Carcinoma: Survival, Hepatic Safety, and Biomarker Assessments in CheckMate-040 - (10/26/17)
     
  1826. AASLD: BMS-986036 (PEGylated FGF21) in Patients with Non-Alcoholic Steatohepatitis: A Phase 2 Study - (10/26/17)
     
  1827. AASLD: Adherence to Pangenotypic Glecaprevir/Pibrentasvir Treatment and SVR12 in HCV-infected Patients: An Integrated Analysis of the Phase 2/3 Clinical Trial Program - (10/26/17)
     
  1828. AASLD: Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin for 12 or 24 Weeks in Genotype 1 or 2 HCV-infected Japanese Patients with Prior Treatment Failure to DAA-Based Regimens - (10/26/17)
     
  1829. AASLD: HEPATITIS C VIRUS REINFECTION AND INJECTING RISK BEHAVIOR FOLLOWING ELBASVIR/GRAZOPREVIR TREATMENT IN PARTICIPANTS ON OPIATE AGONIST THERAPY: C-EDGE CO-STAR PART B - (10/26/17)
     
  1830. AASLD: Susceptibility to Voxilaprevir of NS3 Resistance-Associated Substitutions and Clinical Isolates From Direct-Acting Antiviral-Experienced and -Naïve Patients - (10/26/17)
     
  1831. AASLD: No Resistance to Tenofovir Alafenamide Detected Through 96 Weeks of Treatment in Patients with Chronic Hepatitis B - (10/26/17)
     
  1832. AASLD: A5327 Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1-infected Individuals (SWIFT-C) - (10/24/17)
     
  1833. AASLD: A Phrase 3, French Multicenter, Open-Label Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve HCV GT1b-Infected Patients with non-severe Fibrosis: STREAGER study - (10/24/17)
     
  1834. AASLD: Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality and Hepatocellular Carcinoma - significantly lower mortality, HCC 60% to 84% - (10/24/17)
     
  1835. AASLD: Eradication of HCV induced by DAAs is associated with a 71% reduction in HCC risk - (10/24/17)
     
  1836. AASLD: Randomized Controlled Trial of Cash Incentives or Peer Mentors to Improve HCV Linkage and Treatment Among HIV/HCV Coinfected Persons Who Inject Drugs: The CHAMPS Study - (10/24/17)
     
  1837. AASLD: The Impact of Hepatitis C Diagnosis on Substance-Use Behaviors in Patients Engaged in Opioid Substitution Therapy - HCV screening/diagnosis reduces drug use by 33% (non-prescribed opioids, benzodiazepines and cocaine) - (10/24/17)
     
  1838. AASLD: Efficacy, Safety, and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis - (10/24/17)
     
  1839. AASLD: Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread® - (10/24/17)
     
  1840. AASLD: Exercise improves age-related inflammation, liver damage and cancer. - (10/23/17)
     
  1841. AASLD: Safety and Efficacy of Ledipasvir/Sofosbuvir in a Genotype 1 HCV-Infected Chinese Population: Results From a Phase 3, Clinical Trial - (10/23/17)
     
  1842. AASLD: Evaluation of the efficacy and tolerability of JNJ-4178 (AL-335, odalasvir, and simeprevir) in hepatitis C virus-infected patients without cirrhosis: The Phase IIb OMEGA-1 study - (10/23/17)
     
  1843. AASLD: Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-naïve Patients with Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis - (10/23/17)
     
  1844. AASLD: Do resistance associated substitutions (RAS) or Ribavirin (RBV) use influence treatment success of Sofosbuvir (SOF)/Velpatasvir (VEL) in chronic hepatitis C genotype 3 (GT 3) infection? - Results from the GErman hepatitis C COhort (GECCO) - (10/23/17)
     
  1845. AASLD: C-BREEZE-2: Efficacy and Safety of a Two-Drug Direct-Acting Antiviral Agent Regimen Ruzasvir 180 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, 5, or 6 - (10/23/17)
     
  1846. AASLD: Safety and Efficacy of Elbasvir/Grazoprevir in Asian Participants With Hepatitis C Virus Genotypes 1 and 4 Infection: An Integrated Analysis of Data From 11 Phase 2/3 Trials - (10/23/17)
     
  1847. AASLD: Safety and Efficacy of 12 Weeks of Elbasvir (EBR)/Grazoprevir (GZR) in Hepatitis C Virus (HCV) GT1- and GT4-Infected Participants 65 Years and Older: An Integrated Analysis of Twelve Clinical Trials - (10/23/17)
     
  1848. AASLD: SOF/VEL/VOX for 12 Weeks in NS5A-Inhibitor-Experienced HCV-Infected Patients: Results of the Deferred Treatment Group in the Phase 3 POLARIS-1 Study - (10/23/17)
     
  1849. AASLD: Safety and Efficacy of Treatment With Once-Daily Ledipasvir/Sofosbuvir (90/400 mg) for 12 Weeks in Genotype 1 HCV-Infected Patients With Severe Renal Impairment - (10/23/17)
     
  1850. AASLD: Economic Burden of Chronic Hepatitis C (CHC) in Medicaid and Commercially Insured Patients in the United States - (10/23/17)
     
  1851. AASLD: Epidemiologic Impact of Expanding Chronic Hepatitis C (CHC) Treatment in People Who Inject Drug in the United States: A Mathematical Model Using Data From the C-EDGE CO-STAR Study - (10/23/17)
     
  1852. AASLD: Real-World Cost-Effectiveness of Elbasvir/Grazoprevir (EBR/GZR) in Treatment-Naïve (TN) Patients With Chronic Hepatitis C (CHC) Virus Genotype 1 (GT1) in the United States (US) - (10/23/17)
     
  1853. AASLD: A Pragmatic Approach to Optimizing the Efficacy of Elbasvir/Grazoprevir Using Baseline Viral Load in Participants With Hepatitis C Virus Genotype 1a Infection: A Post Hoc Analysis of 11 Clinical Trials - (10/23/17)
     
  1854. AASLD: Safety and efficacy of the combination Sofosbuvir-Ledipasvir in HCV mono-infected patients from the French observational Cohort ANRS CO22 HEPATHER The ANRS-AFEF HEPATHER study group - (10/23/17)
     
  1855. AASLD: Impact of treatment duration and ribavirin (RBV) addition on real-world effectiveness of elbasvir/grazoprevir (EBR-GZR) in select patient subgroups with Genotype 1 (GT1) Chronic Hepatitis C (HCV): Retrospective Data Analyses from the Trio Network. - (10/23/17)
     
  1856. AASLD: Perceived Barriers Related to the Management of HCVInfection Among Physicians Prescribing Opioid Agonist Therapy:The C-SCOPE Study - (10/23/17)
     
  1857. Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread® - (10/23/17)
     
  1858. Merck to Present New Data on ZEPATIER® (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Infection at The Liver Meeting® 2017 - (10/20/17)
     
  1859. AbbVie Demonstrates Leadership in HCV with New MAVYRET™ (glecaprevir/pibrentasvir) Data to be Presented at The Liver Meeting® 2017 - (10/17/17)
     
  1860. Integrated Efficacy, Pharmacokinetics, and Safety of Glecaprevir/Pibrentasvir in Patients Taking Concomitant Proton Pump Inhibitors and Other Acid-Reducing Drugs - (10/18/17)
     
  1861. IDWeek: Implementation of Hepatitis C Elimination - John Ward, MD, CDC (10/12/17)
     
  1862. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial - (10/12/17)
     
  1863. IDWeek: Real World Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Weeks in Patients Coinfected With HCV GT 1 and HIV-1 - (10/11/17)
     
  1864. IDWeek: Hepatitis C Virus Treatment Response to Ledipasvir/Sofosbuvir among patients co-infected with HIV and HCV: Real World Data in a Black Population - (10/11/17)
     
  1865. IDWeek: Glycemic Control & HbA1C Change After SVR - Mark Mascolini - (10/11/17)
     
  1866. IDWeek: Good In-Practice SVR12 With Sofosbuvir Regimens After HCV PI Failure in HIV/HCV Coinfected - Mark Mascolini - (10/11/17)
     
  1867. IDWeek: Barriers to Hepatitis C Treatment in HIV co-infected Patients in the Era of New Direct-Acting Antiviral Therapy (Philadelphia): Just Over Half With HCV/HIV at Academic Center Get DAAs for HCV - Mark Mascolini - (10/11/17)
     
  1868. China Food and Drug Administration Approves Gilead's Sovaldi® (Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Infection - (10/02/17)
     
  1869. Merck Discontinues MK-3682B and MK-3682C Development Programs - (09/29/17)
     
  1870. Glecaprevir/Pibrentasvir in Japanese Patients - (09/27/17)
     
  1871. AbbVie Announces Approval of MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in Japan - (09/27/17)
     
  1872. Cannabis Worsens Fibrosis (Liver Disease) in HCV By 3 to 7 Times - (09/27/17)
     
  1873. ≥3 cups/day of coffee per day halves all-cause mortality risk in patients co-infected with HIV-HCV... - (09/27/17)
     
  1874. Bristol-Myers Squibb's Opdivo® (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib - (09/27/17)
     
  1875. Fatty Liver: Treatment of NAFLD with diet, physical activity and exercise - (09/26/17)
     
  1876. New HCV Drug Approvals - studies - (09/22/17)
     
  1877. New HCV AASLD IDSA Guidelines Update Sept 21 2017: New Treatment-Naive & Treatment-Experienced Guidance / Genotype 1 & Genotype 3 - (09/22/17)
     
  1878. Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial - (09/22/17)
     
  1879. A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis - CENTAUR Study - (09/19/17)
     
  1880. Effectiveness of DAA-based treatment of HCV in active people who inject drugs living in middle income countries (MIC): the results of a prospective cohort study in Tbilisi, Georgia - (09/19/17)
     
  1881. Effectiveness of DAA-based treatment of HCV in active people who inject drugs living in middle income countries (MIC): the results of a prospective cohort study in Tbilisi, Georgia - (09/13/17)
     
  1882. SVR Reduces Kidney Disease Risks/ HCV Causes Increased Kidney Disease Risks - (09/13/17)
     
  1883. Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus - (09/13/17)
     
  1884. IAS: Maviret /G-P in HIV+ Coinfected / ART DDIs - (09/12/17)
     
  1885. New study - (1) DAA SVR Reduced by 71% HCC Risk / (2) DAA Treatment NOT Associated with HCC Increased Risk Compared to Interferon Based Treatment.....[Jules: and cirrhosis increases risk of HCC SO Treat Early] - (09/11/17)
     
  1886. Janssen to Discontinue Hepatitis C Development Program - (09/11/17)
     
  1887. EASL: Hepatic Fibrosis is Associated With Histological Activity in Non-alcoholic Steatohepatitis: an Analysis From a Large Database of Screening Biopsies in the CENTAUR Trial - (09/09/17)
     
  1888. Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter - (09/05/17)
     
  1889. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD - (09/05/17)
     
  1890. HCV Treatment-Exoerienced - Sofosbuvir+Velpatasvir+Voxilaprevir - (09/05/17)
     
  1891. Maviret in HCV Treatment-Experienced - (09/05/17)
     
  1892. AbbVie's MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes - (09/05/17)
     
  1893. Cocrystal Announces Positive Data from the Successful Completion of Phase 1a/1b Trial of the Non-Nucleoside Polymerase Inhibitor CC-31244 for the Treatment of Chronic Hepatitis C Infection - (08/14/17)
     
  1894. HCV-DAA 57% Survival Benefit - Effect of paritaprevir/ritonavir/ombitasvir/dasabuvir and ledipasvir/sofosbuvir regimens on survival compared with untreated hepatitis C virus-infected persons: results from ERCHIVES - (08/11/17)
     
  1895. U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV - (08/11/17)
     
  1896. Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial - ASCEND Study - (08/10/17)
     
  1897. IAS: Only 5% DAA Failure Rate in Large French Cohort With HCV/HIV - Mark Mascolini (08/07/17)
     
  1898. Gilead Vosevi FDA PI, Package Insert / Label - (08/06/17)
     
  1899. FDA - G/P - Trials, Package Insert, MAVYRET approved to treat HCV - (08/05/17)
     
  1900. FDA Approves Abbvie G/P, Mavyret, List Price, FDA Package Insert - (08/05/17)
     
  1901. AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks - (08/05/17)
     
  1902. FDA approves Mavyret (G/P - Abbvie) for Hepatitis C - (08/05/17)
     
  1903. IAS: Mortality Benefit From DAAs Most Likely With Advanced Fibrosis in Canada - Trends in cause-specific mortality in HIV-HCV co-infected patients in Canada (2003-2016): Early impact of HCV therapy - Mark Mascolini (08/04/17)
     
  1904. IAS: Overweight/Obesity Rate Rises After SVR in HCV/HIV-Coinfected People - Mark Mascolini - (08/04/17)
     
  1905. Revisions to the Epclusa Label Approved/ Coinfection Approval - (08/03/17)
     
  1906. U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV - (08/03/17)
     
  1907. IAS: Overweight/Obesity Rate Rises After SVR in HCV/HIV-Coinfected People - Mark Mascolini (07/31/17)
     
  1908. European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) - (07/28/17)
     
  1909. European Commission Grants Marketing Authorization for Gilead's Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Genotypes of Chronic Hepatitis C - (07/28/17)
     
  1910. IAS: Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients: results of the METAFIB study - (07/25/17)
     
  1911. IAS: Predictor factors associated with liver fibrosis and steatosis by transient elastography in HIV mono-infected patients under long-term combined antiretroviral therapy - (07/26/17)
     
  1912. IAS: Glecaprevir/Pibrentasvir Fixed-Dose Combination for 8 or 12 Weeks in Patients Co-Infected With HCV and HIV-1: A Sub-Analysis of the Phase 3 ENDURANCE-1 Study - (07/24/17)
     
  1913. IAS: Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1: The EXPEDITION-2 Study - (07/24/17)
     
  1914. Pharm: MK-3682B Is Not a Clinically Significant CYP3A Inhibitor or Inducer - (07/22/17)
     
  1915. Pharm: No Clinically Significant Interaction of the Proton Pump Inhibitor Omeprazole With the Components of MK-3682B - (07/22/17)
     
  1916. Pharm: Small Increase in Dolutegravir Trough, but Equivalent Total Exposure with Simeprevir - (07/22/17)
     
  1917. Pharm: Dose-selection of odalasvir for use in combination with AL-335 and simeprevir in a phase 2A study using a population pharmacokinetic modelling and simulation approach - (07/22/17)
     
  1918. Pharm: Lack of clinically significant pharmacokinetic interaction between the 3-DAA combination of AL-335, odalasvir and simeprevir for the treatment of chronic HCV infection and an oral contraceptive containing ethinylestradiol and drospirenone - (07/22/17)
     
  1919. U.S. Food and Drug Administration Approves Gilead's Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-Treatment of Adults with Chronic Hepatitis C Virus - (07/22/17)
     
  1920. AASLD: Nivolumab in Patients With Advanced Hepatocellular Carcinoma: the CheckMate 040 Study - (07/22/17)
     
  1921. HCV/IDU-African Americans Bear Greatest Burden-NHANES - (07/18/17)
     
  1922. EASL: A NEW NON-INVASIVE DIAGNOSTIC SCORE TO MONITOR CHANGE IN DISEASE ACTIVITY AND PREDICT FIBROSIS EVOLUTION IN PATIENT WITH NASH - (07/17/17)
     
  1923. EASL: Prospective Prevalence Study of Adult NAFLD/NASH Utilizing Multi-Modality Imaging Compared with Liver Biopsy - (07/17/17)
     
  1924. EASL: Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies - (07/17/17)
     
  1925. EASL: Simple non-invasive fibrosis scores identify patients with NAFLD who progress to advanced fibrosis/cirrhosis: evidence from a large cohort of patients with sequential liver biopsies. - (07/17/17)
     
  1926. New NYS HCV Guidelines - (07/11/17)
     
  1927. EASL: DNA Methylation Signatures in Blood Show Accelerated Epigenetic Aging in Patients with Nonalcoholic Steatohepatitis Compared to Healthy Controls - (07/07/17)
     
  1928. EASL: Changes in Fibrosis, But Not the NAFLD Activity Score, Are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis and Advanced Fibrosis - (07/06/17)
     
  1929. EASL: Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial - (07/05/17)
     
  1930. EASL: INT 747 (obeticholic acid) fails to achieve goals in Japanese study for non-alcoholic steatohepatitis (NASH)- Intercept Pharma + Sumitomo - (07/05/17)
     
  1931. EASL: Starting the battle to control non-alcoholic steatohepatitis [OCA FLINT Study] - Comment - (07/05/17)
     
  1932. EASL: Nonalcoholic Steatohepatitis Drug Pipeline Overview - (07/05/17)
     
  1933. EASL: Regenerate: a phase 3, double-blind, randomized, placebo-controlled multicenter study of obeticholic acid therapy for nonalcoholic steatohepatitis - (07/05/17)
     
  1934. EASL: Elafibranor - (GFT505) NASH Treatment - GOLDEN 505 Study & Commentary - (07/05/17)
     
  1935. EASL: Improvement of hepatic fibrosis in patients with non-alcoholic steatohepatitis treated with selonsertib is associated with improvement of patient-reported outcomes - (07/05/17)
     
  1936. EASL: Evaluation of Cytochrome P450- and Transporter-Mediated Drug-Drug Interactions With the Farnesoid X Receptor Agonist GS-9674, and Phenotypic Probe Substrates and Inhibitors/Inducers - (07/03/17)
     
  1937. EASL: Longitudinal Changes in Liver Stiffness by Magnetic Resonance Elastography, Liver Fibrosis, and Serum Markers of Fibrosis in a Multicenter Clinical Trial in Nonalcoholic Steatohepatitis - (07/03/17)
     
  1938. EASL: Emerging Treatments for ASH & NASH - Rohit Loomba, MD / AASLD 2016 - (07/03/17)
     
  1939. EASL: A Liver-Targeted Acetyl-CoA Carboxylase Inhibitor Reduces Hepatic Steatosis and Liver Injury in a Murine Model of NASH - (07/03/17)
     
  1940. EASL: Hepatic Proton Density Fat Fraction Correlates With Histologic Measures of Steatosis and Is Responsive to Changes in Those Measures in a Multicenter Nonalcoholic Steatohepatitis Clinical Trial - (07/03/17)
     
  1941. EASL: Apoptosis Signal-Regulating Kinase 1 Inhibition Reduces Liver Fibrosis and Apoptosis in an NLRP3 Mutant Model of NASH - (07/03/17)
     
  1942. EASL: Impact of Weight Reduction on Serum Markers and Liver Histology Including Progression to Cirrhosis in Patients With Nonalcoholic Steatohepatitis and Bridging Fibrosis - (07/03/17)
     
  1943. EASL: Impact of Modest Weight Reduction on Liver Histology, Portal Pressure, and Clinical Events in Patients With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis - (07/03/17)
     
  1944. EASL: Longitudinal Changes in Liver Stiffness by Magnetic Resonance Elastography, Liver Fibrosis, and Serum Markers of Fibrosis in a Multicenter Clinical Trial in Nonalcoholic Steatohepatitis - (07/03/17)
     
  1945. EASL Responds to Cochrane Report - (06/28/17)
     
  1946. EASL: Evaluation of the Xpert® HCV Viral Load point-of-care assay from venipuncture-collected and finger-stick capillary whole-blood samples: A prospective study - (06/26/17)
     
  1947. AASLD Expresses Concern for Cochrane Review of DAAs - (06/26/17)
     
  1948. Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study - (06/26/17)
     
  1949. New CDC Hepatitis Surveillance Report - 33,900 New HCV Infections - (06/23/17)
     
  1950. Clinical effects of antivirals for hepatitis C: context is critical - Editorial - (06/23/17)
     
  1951. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial - (06/23/17)
     
  1952. Two new medicines recommended for the treatment of chronic hepatitis C - EMA - (06/23/17)
     
  1953. European CHMP Adopts Positive Opinion for Gilead's Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Chronic Hepatitis C Genotypes - (06/23/17)
     
  1954. AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) - (06/23/17)
     
  1955. Pharm: Lack of Pharmacokinetic Drug-Drug Interaction Between Norgestimate/Ethinyl Estradiol and Sofosbuvir/Velpatasvir/Voxilaprevir - (06/22/17)
     
  1956. Pharm: Population Pharmacokinetic Analysis of Voxilaprevir, a Pangenotypic HCV NS3/4A Protease Inhibitor in Hepatitis C Virus-Infected Subjects - (06/22/17)
     
  1957. Pharm: Evaluation of Drug-Drug Interaction Potential Between Sofosbuvir/Velpatasvir and Atorvastatin - (06/22/17)
     
  1958. Pharm: Evaluation of Drug-Drug Interaction Potential Between Sofosbuvir/Velpatasvir and Atorvastatin - (06/20/17)
     
  1959. Pharm: Doravirine Does Not Have a Clinically Meaningful Pharmacokinetic Interaction with Elbasvir Plus Grazoprevir - (06/20/17)
     
  1960. Pharm: Doravirine Does Not Have a Clinically Meaningful Pharmacokinetic Interaction with Ledipasvir/Sofosbuvitr (HARVONI) - (06/20/17)
     
  1961. Pharm: Evaluation of Drug-Drug Interactions Between Sofosbuvir/Velpatasvir/Voxilapevir and Boosted or Unboosted HIV Antiretroviral Regimens - report 2 - Mark Mascolini - (06/20/17)
     
  1962. Pharm: DRUG-DRUG INTERACTIONS OF GLECAPREVIR AND PIBRENTASVIR WITH PRAVASTATIN, ROSUVASTATIN, OR DABIGATRAN ETEXILATE - (06/20/17)
     
  1963. HRSA Grant - Curing Hepatitis C among People of Color Living with HIV - (06/15/17)
     
  1964. Pharm Pharmacokinetics of darunavir/cobicistat (DRV/c) and etravirine (ETR) alone and coadministered in HIV-infected patients - (06/15/17)
     
  1965. EASL: TREATMENT CASCADE OF HEPATITIS B AND C IN GENERAL, MIGRANT AND ROMA POPULATIONS - (06/15/17)
     
  1966. Reversion of disease manifestations after HCV eradication / The Benefits of SVR & HCV Treatment with DAAs - (06/13/17)
     
  1967. Direct-Acting Antiviral Therapy and Immune Tolerance in Hepatitis C Virus-Induced Vasculitis - (06/13/17)
     
  1968. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis - (06/13/17)
     
  1969. EASL: Multi-Target DAA Therapy is Associated with Superior Immunologic Recovery in HIV/HCV Co-Infected Patients - (06/07/17)
     
  1970. EASL: CCR5+ T cells are primary responders to HCV subject to exhaustion and contribute to ongoing hepatic inflammation - (06/07/17)
     
  1971. EASL: No change in HCV-specific T cell functionality after successful DAA treatment in chronic hepatitis C patients. - (06/02/17)
     
  1972. SAN FRANCISCO COMPLETES FIRST ESTIMATEOF CITY'S HEPATITIS C INFECTIONS / NY too - (06/13/17)
     
  1973. EASL: High Efficacy of Sofosbuvir/Velpatasvir/GS-9857 With or Without Ribavirin for 12 Weeks in Direct-Acting Antiviral-Experienced Patients With Genotype 1 HCV Infection - (04/15/16)
     
  1974. Liver Cancer - Liver cancer mortality rates Double Since 1990 - Disparities in liver cancer occurrence in the United States by race/ethnicity and state - (06/12/17)
     
  1975. SVR Improves Mortality 3-Fold - Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis - (06/12/17)
     
  1976. HCV Treatment for IDUs and Comorbidities (Cancer, CVD, Kidney, Psych Issues) - (06/09/17)
     
  1977. DAA / HBV Reactivation - Making Do With What We Have - Editorial - (06/07/17)
     
  1978. EASL: Prevalence and Risk factors of Nonalcoholic Fatty Liver Disease in Metabolically Healthy Obese Adolescents in the United States: An Analysis of National Health and Nutrition Examination Survey Data - (06/07/17)
     
  1979. EASL: Trends in hospital charges and encounters for patients with nonalcoholic fatty liver disease compared to patients with alcoholic liver disease in the United States between 2005 and 2013 - (06/07/17)
     
  1980. EASL: Incidence and prevalence of recorded non-alcoholic fatty liver disease in four European primary care databases covering 21.9 million adults - (06/02/17)
     
  1981. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication - (06/05/17)
     
  1982. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort - (06/05/17)
     
  1983. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome - (06/05/17)
     
  1984. Late presentation of chronic viral hepatitis for medical care: a consensus definition - (06/05/17)
     
  1985. Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1hepatitis C virus-coinfected individuals - (06/05/17)
     
  1986. European Report on Gaps HCV & HBV Testing & Prevalence by ECDC- May 31 2017 - (06/05/17)
     
  1987. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials - (06/05/17)
     
  1988. A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study (MAGELLAN-3) - (06/05/17)
     
  1989. EASL: THE IMPACT OF BROADER HEPATITIS C VIRUS TREATMENT STRATEGIES ON POPULATION HEALTH AND SOCIAL VALUE IN ENGLAND - (06/02/17)
     
  1990. EASL: A pilot study for safety and efficacy of 12 weeks sofosbuvir plus daclatasvir with or without ribavirin in egyptian adolescents with chronic hepatitis C virus Infection - (06/02/17)
     
  1991. EASL: Summary from EASL 2017 for Hepatitis C - Global implementation of Hepatitis C (HCV) treatment: What are the successes, what are the remaining challenges? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (06/01/17)
     
  1992. Regional Differences across Europe in Advanced Fibrosis and Cirrhosis among HIV/HCV Co-infected Persons between 2010-2015....26% of individuals with HIV/HCV had fibrosis ≥F3.... need to prioritise HIV and HCV screening, linkage to care and treatment across Europe - (05/30/17)
     
  1993. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis - (05/30/17)
     
  1994. EASL: Access to hepatitis C treatment in Europe: findings from the 2016 Hep-CORE study - (05/30/17)
     
  1995. EASL: High prevalence of chronic hepatitis C in injecting drug users in Tanzania, East Africa: a neglected burden of disease - (05/30/17)
     
  1996. EASL: HCC Occurrence or Recurrence After DAA SVR at EASL 2017 - (05/30/17)
     
  1997. EASL: Outcomes of Treatment for Hepatitis C Virus Infection in the Prison Setting - (05/30/17)
     
  1998. EASL: Projected impact and pathways to success of the hepatitis C virus elimination program in Georgia, 2015-2020 - (05/30/17)
     
  1999. EASL: Prevention of Liver-Related Complications With Elbasvir/Grazoprevir in Hepatitis C Infected Patients Who Are Receiving Opioid Agonist Therapy (OAT) - (05/26/17)
     
  2000. EASL: Safety and Efficacy of Ombitasvir, Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Chronic Hepatitis C Patients Receiving Opioid Substitution Therapy: A Pooled Analysis Across 12 Clinical Trials - (05/26/17)
     
  2001. EASL: The Novel FXR Agonist, EDP-305, Reduces Fibrosis Progression in Rodent Models of Primary Biliary Cholangitis and Non-alcoholic Steatohepatitis - (05/26/17)
     
  2002. Treatment of NAFLD with diet, physical activity and exercise - (05/26/17)
     
  2003. Safety and pharmacokinetics of DUR-928 in patients with non-alcoholic steatohepatitis-A Phase 1b study - (05/26/17)
     
  2004. DUR-928, an endogenous regulatory molecule, exhibits anti-inflammatory and antifibrotic activity in a mouse model of NASH - (05/26/17)
     
  2005. EASL: A novel farnesoid X receptor agonist: EDP-305, reduces fibrosis progression in animal models of fibrosis - (05/23/17)
     
  2006. EASL: Enanta Announces New Preclinical Data on its FXR Agonist EDP-305 for Non-Alcoholic Steatohepatitis (NASH) and Primary Biliary Cholangitis (PBC) at The International Liver Congress™ 2017 - (05/23/17)
     
  2007. EASL: EDP-305, a novel and highly potent farnesoid X receptor agonist, improves liver steatosis, ballooning and non-alcoholic fatty liver disease (NAFLD) activity score (NAS) in a diet-induced murine model of non-alcoholic steatohepatitis - (05/23/17)
     
  2008. EASL: Efficacy and Safety of Simtuzumab for the Treatment of NASH with Bridging Fibrosis or Cirrhosis: Results of Two Phase 2b, Dose-Ranging, Randomized, Placebo-Controlled Trials - (05/23/17)
     
  2009. EASL: Treatment with Selonsertib, an Inhibitor of Apoptosis Signal-Regulating Kinase 1 (ASK1), Reduces Hepatic Phospho-p38 Expression and Markers of Hepatocellular Apoptosis and Necrosis in Patients with NASH - (05/23/17)
     
  2010. EASL: Acetyl-CoA Carboxylase Inhibitor GS-0976 Leads to Suppression of Hepatic De Novo Lipogenesis and Significant Improvements in MRI-PDFF, MRE and Markers of Fibrosis after 12 Weeks of Therapy in Patients with NASH - (05/23/17)
     
  2011. EASL: Pharmacokinetics of Selonsertib, GS-9674, and/or GS-0976 in Combination in Healthy Subjects - (05/23/17)
     
  2012. EASL: EFFECTIVENESS AND SAFETY OF SOFOSBUVIR/LEDIPASVIR TREATMENT FOR MONOINFECTED GENOTYPE 1 HCV PATIENTS IN REAL-LIFE CLINICAL PRACTICE: RESULTS FROM SPANISH HEPA-C COHORT - (05/23/17)
     
  2013. HCV Retreatment Studies - (05/22/17)
     
  2014. Fatty Liver / NASH - A silent liver disease epidemic - (05/22/17)
     
  2015. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis - (05/22/17)
     
  2016. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus - Phase 2 - (05/22/17)
     
  2017. State HCV Incidence and Policies Related to HCV Preventive and Treatment Services for Persons Who Inject Drugs - United States, 2015-2016 - (05/20/17)
     
  2018. Hepatitis C Virus Infection Among Women Giving Birth - Tennessee and United States, 2009-2014 - (05/20/17)
     
  2019. Pennsylvania HCV Medicaid Policy Removes Restrictions, State Announcement - (05/17/17)
     
  2020. Medicaid Lifts Restrictions Due to Patient Legal Challenge in Pennsylvania - (05/16/17)
     
  2021. EASL: Restrictions for reimbursement of interferon-free direct acting antiviral therapies for HCV infection in Europe - (05/15/17)
     
  2022. EASL: The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments - (05/15/17)
     
  2023. Real-World Experience of Elbasvir/Grazoprevir in the Veterans Affairs Healthcare System at DDW 2017 - (05/15/17)
     
  2024. SVR Reduces Kidney Disease & CVD, Cancer Risk - 'These findings argue for the prescription of HCV therapy in coinfected/all patients regardless of fibrosis stage.' - (05/15/17)
     
  2025. CDC - May 11, 2017 - New Hepatitis C Infections Nearly Tripled Over Five Years - (05/15/17)
     
  2026. Federal & State Govts Ignore HCV Epidemic - Immediate HCV Treatment is BEST / Delayed Treatment Increases Risk 7-20 fold for Death & Liver Cancer - federal & state governments support denial of early treatment - HCV is CURABLE with 12 weeks therapy!!!! - (05/12/17)
     
  2027. Hearing From the Silent Epidemic - Hepatitis C Virus Infection Among Reproductive-Aged Women and Children in the United States, 2006 to 2014 - 'screening of pregnant women needed & newborns of infected mothers' needed - (05/12/17)
     
  2028. Global Prevalence of HCV - Polaris Observatory at AASLD 2016 - (05/10/17)
     
  2029. UK-NICE Guidance - Sofosbuvir-velpatasvir for treating chronic hepatitis C - (05/10/17)
     
  2030. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modeling study - (05/10/17)
     
  2031. EASL: Rising healthcare utilization and cost of chronic hepatitis B: real-world analysis of 44,026 chronic hepatitis B patients and 121,568 matched non-chronic hepatitis B controls in the United States - (05/09/17)
     
  2032. CROI: Peripheral endothelial function is suboptimal in HCV-untreated, HIV-suppressed adults - - (05/09/17)
     
  2033. EASL: New HCV Drugs at EASL 2017 - (05/09/17)
     
  2034. EASL: Treatment as Prevention for Hepatitis C in Iceland (TraP HepC). Real-world experience from a nationwide elimination program using direct acting antiviral agents - (05/09/17)
     
  2035. EASL: Comparison of Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ï Ribavirin Between Asian and Western HCV GT1b-infected Patients - (05/09/17)
     
  2036. EASL: Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Non-Cirrhotic Asian Patients With Genotype 1b Chronic Hepatitis C Virus Infection: ONYX-I Post-Treatment Week 24 Results - (05/09/17)
     
  2037. EASL: Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Non-Cirrhotic Asian Patients With Genotype 1b Chronic Hepatitis C Virus Infection: ONYX-I Post-Treatment Week 24 Results - (05/08/17)
     
  2038. EASL: Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Asian Patients With Genotype 1b Chronic Hepatitis C Virus Infection and Compensated Cirrhosis: ONYX-II Post-Treatment Week 24 Results - (05/08/17)
     
  2039. EASL: Safety and Efficacy of Ombitasvir, Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Chronic Hepatitis C Patients Receiving Opioid Substitution Therapy: A Pooled Analysis Across 12 Clinical Trials - (05/08/17)
     
  2040. EASL: Changes in Markers of Liver Function in Hepatitis C Virus Genotype 1b Asian Patients With Compensated Cirrhosis Treated With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With Ribavirin in the ONYX-II Study - (05/08/17)
     
  2041. EASL: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir ï Dasabuvir and ï Ribavirin in Adult Renal or Liver Transplant Recipients With HCV Infection (CORAL-I: Cohorts 3-6) - (05/08/17)
     
  2042. EASL: ZIRCON: Pharmacokinetics, Safety, and Efficacy of Ombitasvir/Paritaprevir/Ritonavir ï Dasabuvir ï Ribavirin in Adolescents With Genotype 1 or 4 Hepatitis C Virus Infection - (05/08/17)
     
  2043. EASL: The Effect of Ribavirin Dosage on the Kinetics of Viral Load Decline and Drug Exposures in Plasma and Liver With OBV/PTV/r + DSV Treatment in Patients With Chronic Hepatitis C Virus Genotype 1a Infection - (05/08/17)
     
  2044. EASL: Effect of hepatitis C treatment with ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on patient's health-related quality of life: Analysis of Phase 3a and Phase 3b clinical trials - (05/03/17)
     
  2045. EASL: Patients Above 65 Years of Age Achieved the Same SVR12 as Younger Patients Despite Increased Comorbidities: Findings From a Large Real-World, Multi -Country, Observational Cohort of 12-Week Ombitasvir/Paritaprevir/Ritonavir ï Dasabuvir ï Ribavirin - (05/03/17)
     
  2046. EASL: Early versus delayed hepatitis C treatment provides increased health benefits at lower costs: A UK cost-effectiveness analysis of genotypes 1 and 4 treatment-naïve patients - (05/03/17)
     
  2047. EASL: The cumulative prevalence and incidence of extra-hepatic manifestations in patients with hepatitis C virus infection: real-world evidence from the United States - (05/03/17)
     
  2048. EASL: A budget optimization analysis for the treatment and potential elimination of hepatitis C virus infection in the United States - (05/03/17)
     
  2049. EASL: Extra-hepatic manifestations from hepatitis C virus infection related to female infertility and adverse pregnancy outcomes: A real-world observation - (05/03/17)
     
  2050. EASL: Impact of Hepatoprotective Medications on the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ï Ribavirin in Hepatitis C Virus Genotype 1b-infected Asian Patients With and Without Cirrhosis in the ONYX-I and -II Studies - (05/03/17)
     
  2051. EASL: Real-world treatment utilization and results in the renaissance of HCV Care: Analyses of treatment for 8,955 Patients from the TRIO Network - (05/03/17)
     
  2052. EASL: Impact of Elbasvir/Grazoprevir (EBR/GZR) on Health-Related Quality of Life (HRQOL) and Fatigue in Patients With Chronic Hepatitis C Virus (HCV) Infection and Inherited Blood Disorders (IBLD): Data From the C-EDGE IBLD Study - (05/03/17)
     
  2053. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older - (05/03/17)
     
  2054. Bristol-Myers Squibb Foundation Reaches New Heights to Help Lower Viral Hepatitis Burden in China - (05/03/17)
     
  2055. China FDA Approves Country's First All-Oral Regimen for Chronic Hepatitis C, Daklinza® (daclatasvir) in Combination with Sunvepra® (asunaprevir) - (05/03/17)
     
  2056. CROI: Cataloguing the Impact of Y93 Substitutions on HCV NS5A Inhibitor Susceptibility - - (05/03/17)
     
  2057. CROI: Identification of HCV Inter-Subtype Recombinant Strains with Breakpoint in NS5A - - (05/03/17)
     
  2058. EASL: High Efficacy is Accompanied with Substantial Gains in Patient Reported Outcomes in Cirrhotic Patients with Chronic Hepatitis C Treated with Sofosbuvir, Velpatasvir with or without Voxilaprevir: The Data from POLARIS-1, -2, -3 and -4 - (05/02/17)
     
  2059. EASL: Safety and Efficacy of Elbasvir and Grazoprevir with or without Ribavirin for the Treatment of HCV Genotype 1: Results of the HCV-TARGET Study - (05/02/17)
     
  2060. EASL: Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C - (05/02/17)
     
  2061. EASL: Efficacy and Safety of Glecaprevir/Pibrentasvir in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection With and Without Cirrhosis - (05/01/17)
     
  2062. EASL: CERTAIN-1: Efficacy and Safety of Glecaprevir/Pibrentasvir in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection With and Without Cirrhosis - (05/01/17)
     
  2063. EASL: Safety and Efficacy of Sofosbuvir and Velpatasvir with or without Ribavirin for the Treatment of HCV Genotype 1-6: Results of the HCV-TARGET Study - (05/01/17)
     
  2064. EASL: Safety and Efficacy of Sofosbuvir/Velpatasvir for the Treatment of Chronic Hepatitis C in Patients Aged 65 Years or Older: A Retrospective Analysis of Phase 3 Studies - (05/01/17)
     
  2065. EASL: Real-world effectiveness and cost per SVR of Sofosbuvir/Velpatasvir in chronic hepatitis C treatment - (05/01/17)
     
  2066. EASL: Real World Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Weeks in Patients Coinfected With HCV GT 1 and HIV-1 - (05/01/17)
     
  2067. EASL: Efficacy and safety of sofosbuvir and daclatasvir for 8 weeks in treatment-naïve non-cirrhotic patients with chronic HCV genotype 3 infection - (05/01/17)
     
  2068. EASL: HCV clearance after direct-acting antivirals in cirrhotic [advanced] patients by stages of liver impairment: the ITAL-C network study - (05/01/17)
     
  2069. EASL: Real-world utilization of the new fixed-dose combination elbasvir/grazoprevir in adult patients with chronic hepatitis C in Canada: Z-PROFILE study - (04/28/17)
     
  2070. EASL: High Sustained Virologic Response Rates at 24 Weeks in Participants With Chronic HCV GT1, 2, or 3 Infection Following 16 Weeks of Grazoprevir/Ruzasvir/Uprifosbuvir (MK-3682) Plus Ribavirin After Having Failed 8 Weeks of a Triple Drug Regimen (Part C of C-CREST-1 & 2) - (04/28/17)
     
  2071. EASL: HIGH SUSTAINED VIROLOGICAL RESPONSE RATES IN GENOTYPES 1a AND 4 HEPATITIS C PATIENTS TREATED WITH ELBASVIR AND GRAZOPREVIR AND BASAL VIREMIA >800.000 UI/ML - (04/28/17)
     
  2072. EASL: Potential effect of hepatitis C treatment on renal, cardiovascular and metabolic extrahepatic manifestations: Results from clinical trials of ombitasvir/paritaprevir/ritonavir and dasabuvir ï ribavirin - (04/28/17)
     
  2073. EASL: Does Sofosbuvir (SOF)/Velpatasvir (VEL) with or without Ribavirin (RBV) change the landscape of therapy in chronic hepatitis C genotype 3 (GT 3) infection? - Results from the GErman hepatitis C COhort (GECCO) - (04/28/17)
     
  2074. EASL: No increase in the occurrence rate of HCC in Chinese treated by DAAs compared to PR after eradication of HCV: a long-term follow-up - (04/28/17)
     
  2075. EASL: Efficacy and Safety of Elbasvir/Grazoprevir in Treatment-Naive Participants With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection (C-CORAL): A Phase 3 Randomized, International Trial - (04/28/17)
     
  2076. EASL: Real-world effectiveness and cost per SVR of Sofosbuvir/Velpatasvir in chronic hepatitis C treatment / GT3 - (04/26/17)
     
  2077. EASL: Direct-acting Antivirals for Hepatitis C Do Not Increase the Risk of Hepatocellular Carcinoma Recurrence After Locoregional Therapy or Liver Transplant Waitlist Dropout - (04/26/17)
     
  2078. EASL: Occurrence and Recurrence of Malignancies Post DAA Treatment in 5.1% of Patients- Single Center Experience - (04/26/17)
     
  2079. EASL: Degree of Liver Fibrosis Regression Predicted by Transient Elastography after Cure of Chronic Hepatitis C with Direct Acting Antivirals is Overestimated but Confirmed by Liver Biopsy - (04/26/17)
     
  2080. EASL: Long-term follow-up after IFN-free therapy of advanced HCV-associated liver cirrhosis: Continued improvement of liver function parameters Results from the German Hepatitis C-Registry (DHC-R) - (04/26/17)
     
  2081. EASL: No evidence for higher risk of hepatocellular carcinoma occurrence or recurrence following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression - (04/26/17)
     
  2082. EASL: Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure? - (04/26/17)
     
  2083. EASL: THERAPY WITH DIRECT ANTIVIRAL AGENTS IN PATIENTS WITH HCV-RELATED LYMPHOPROLIFERATIVE DISORDERS AND MIXED CRYOGLOBULINEMIA - (04/26/17)
     
  2084. EASL: Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. ANRS CO12 CirVir Cohort - (04/26/17)
     
  2085. EASL: Incidence of and predictors for direct acting antiviral treatment failure among 4099 hepatitis C genotype 1 infected adults: Real world outcomes from HCV TARGET - (04/26/17)
     
  2086. EASL: Elbasvir/Grazoprevir effectiveness in patients with Chronic Hepatitis C and Chronic Kidney Disease: Real-world experience from the TRIO Network - (04/26/17)
     
  2087. EASL: The Safety and Tolerability of SOF/VEL/VOX for 8 or 12 Weeks in >1000 Patients Treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 Studies: an Integrated Analysis - (04/26/17)
     
  2088. EASL: Real-world use of elbasvir/grazoprevir and outcomes in patients with Chronic Hepatitis C: Retrospective data analyses from the TRIO Network. - (04/26/17)
     
  2089. EASL: Utilization of DAA therapies ledipasvir/sofosbuvir and sofosbuvir/velpatasvir in patients with genotype 1 HCV: Real-world experience from the TRIO Network. - (04/26/17)
     
  2090. EASL: EASL-ILC 2017: Viral Hepatitis Debreif by Heiner Wedemeyer - (04/26/17)
     
  2091. EASL: Among Cirrhotic Patients with a Hepatitis C Sustained Viral Response, the Risk of De-novo Hepatocellular Carcinoma Relates to Baseline Factors and Not the Use of Direct Acting Antivirals: Results from a Nationwide Cohort - (04/26/17)
     
  2092. EASL: Among Cirrhotic Patients with a Hepatitis C Sustained Viral Response, the Risk of De-novo Hepatocellular Carcinoma Relates to Baseline Factors and Not the Use of Direct Acting Antivirals: Results from a Nationwide Cohort - (04/26/17)
     
  2093. EASL: IFN-free cure of HCV infection alters the soluble inflammatory milieu in patients with liver cirrhosis which could affect HCC surveillance by CD8+ T cells - (04/26/17)
     
  2094. EASL: No Impact of RASs on the High Efficacy of SOF/VEL/VOX for 12 Weeks in DAA-Experienced Patients: an Integrated Resistance Analysis of the POLARIS-1 and POLARIS-4 Studies - (04/26/17)
     
  2095. EASL: EASL-ILC 2017: Viral Hepatitis Debrief, Heiner Wedemeyer - (04/26/17)
     
  2096. EASL: A Phase 1 Study Evaluating Anti-PD-1 Treatment With or Without GS-4774 in HBeAg Negative Chronic Hepatitis B Patients - (04/26/17)
     
  2097. EASL: The PREVAIL Study: Intensive Models of HCV Care for People Who Inject Drugs - (04/26/17)
     
  2098. EASL: Four weeks of Ledipasvir/Sofosbuvir + Ribavirin with or without interferon give very high and sustained cure rates in difficult to reach but easy to treat injecting drug users with chronic hepatitis C. Final results of the 4WIDUC study. - (04/26/17)
     
  2099. EASL: The Safety and Tolerability of SOF/VEL/VOX for 8 or 12 Weeks in >1000 Patients Treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 Studies: an Integrated Analysis - (04/26/17)
     
  2100. EASL: Delisting of liver transplant candidates with chronic HCV infection after viral eradication and outcome after delisting. A European cohort study - (04/25/17)
     
  2101. EASL: Modelling the Impact of Targeted Interventions on the HCV Epidemic in Pakistan The Road to HCV Elimination - (04/25/17)
     
  2102. EASL: CHRONIC HEPATITIS C IN CHILDREN IN THE RUSSIAN FEDERATION: A MULTICENTER STUDY - (04/25/17)
     
  2103. EASL: SOF/VEL/VOX Results in High SVR12 Rates When Administered for 12 Weeks in DAA-Experienced Patients or for 8 Weeks in DAA-Naïve Patients: an Integrated Analysis of the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 Studies - (04/25/17)
     
  2104. EASL: High SVR Rates With Eight and Twelve Weeks of Pangenotypic Glecaprevir/Pibrentasvir: Integrated Efficacy Analysis of Genotype 1-6 Patients Without Cirrhosis - (04/25/17)
     
  2105. EASL: Elbasvir/Grazoprevir effectiveness in patients with Chronic Hepatitis C and Chronic Kidney Disease: Real-world experience from the TRIO Network - (04/25/17)
     
  2106. EASL: Safety and Efficacy of Glecaprevir/Pibrentasvir in Adults With Chronic Hepati is C Virus Infection Genotype 1-6 as a Function of Chronic Kidney Disease Stage - (04/25/17)
     
  2107. EASL: Serum Cholesterol Changes Associated with NGM282 Treatment in Obese Insulin Resistant Cynomolgus Monkeys and NASH Patients are Reversed with Lipid Lowering Agents - (04/24/17)
     
  2108. EASL: NGM282, a Novel Variant of FGF19, Significantly Reduces Hepatic Steatosis and Key Biomarkers of NASH: Results of a Phase 2, Multicenter, Randomized, Double-Blinded, Placebo Controlled Trial in Biopsy-Confirmed NASH Patients - (04/24/17)
     
  2109. EASL: BMS-986036 (pegylated FGF21) in patients with non-alcoholic steatohepatitis: A phase 2 study - (04/24/17)
     
  2110. EASL: MAGELLAN-2: SAFETY AND EFFICACY OF GLECAPREVIR/PIBRENTASVIR IN LIVER OR RENAL TRANSPLANT ADULTS WITH CHRONIC HEPATITIS C GENOTYPE 1-6 INFECTION - (04/24/17)
     
  2111. EASL: SOF/VEL/VOX for 8 or 12 Weeks Is Well Tolerated and Results in High SVR12 Rates in Patients Receiving Opioid Substitution Therapy - (04/24/17)
     
  2112. EASL: Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: The SIMPLIFY study - (04/24/17)
     
  2113. EASL: Early occurrence of hepatocellular carcinoma in patients with HCV cirrhosis treated with direct acting antivirals - (04/24/17)
     
  2114. EASL: Safety and Efficacy of the Fixed-dose Combination Regimen of Uprifosbuvir (MK-3682) / Grazoprevir / Ruzasvir in Cirrhotic or Non-cirrhotic Patients with Chronic HCV GT1 Infection Who Previously Failed a Direct-acting Antiviral Regimen (C-SURGE) - (04/24/17)
     
  2115. EASL: MAGELLAN-1, PART 2: GLECAPREVIR/PIBRENTASVIR FOR 12 OR 16 WEEKS IN PATIENTS WITH CHRONIC HCV GENOTYPE 1 OR 4 AND PRIOR DIRECT-ACTING ANTIVIRAL TREATMENT FAILURE - (04/24/17)
     
  2116. EASL: Short Duration Treatment with AL-335 and Odalasvir, with or without Simeprevir, in Treatment Naïve Patients with Hepatitis C Infection with or without Cirrhosis - (04/24/17)
     
  2117. EASL: Ledipasvir/Sofosbuvir for 12 Weeks Is Safe and Effective in Patients with Chronic Hepatitis C and Hepatitis B Coinfection: A Phase 3 Study in Taiwan - (04/24/17)
     
  2118. EASL: Sofosbuvir/velpatasvir compared to existing Standards of Care in GT2-6 HCV Real-world experience from the TRIO Network - (04/24/17)
     
  2119. EASL: Ledipasvir/Sofosbuvir ï Ribavirin for 12 or 24 Weeks Is Safe and Effective in Children 6-11 years old with Chronic Hepatitis C Infection - (04/24/17)
     
  2120. EASL: Gilead Announces Scientific Presentations Demonstrating Efficacy of Harvoni® (Ledipasvir/Sofosbuvir) in Special Patient Populations With HCV Infection - (04/24/17)
     
  2121. EASL: Real-World Observational Study in the U.S. Veterans Affairs System Evaluating Use of Merck's ZEPATIER® (Elbasvir and Grazoprevir) Shows High Sustained Virologic Response Rates in Patients with Chronic Hepatitis C - (04/24/17)
     
  2122. EASL: Real-World Observational Study in the U.S. Veterans Affairs System Evaluating Use of Merck's ZEPATIER® (Elbasvir and Grazoprevir) Shows High Sustained Virologic Response Rates in Patients with Chronic Hepatitis C - (04/24/17)
     
  2123. EASL: Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection: An Integrated Analysis - (04/24/17)
     
  2124. EASL: Pooled Resistance Analysis in HCV Genotype 1-6 Infected Patients Treated With Glecaprevir/Pibrentasvir in Phase 2 and 3 Clinical Trials - (04/24/17)
     
  2125. EASL: Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy - (04/24/17)
     
  2126. EASL: Elbasvir/Grazoprevir Plus Sofosbuvir ï Ribavirin in Treatment-Naive And Treatment-Experienced People With Hepatitis C Virus Genotype 3 Infection and Compensated Cirrhosis: SVR24 Results of the C-ISLE Study - (04/21/17)
     
  2127. EASL: Among Cirrhotic Patients with a Hepatitis C Sustained Viral Response, the Risk of De-novo Hepatocellular Carcinoma Relates to Baseline Factors and Not the Use of Direct Acting Antivirals: Results from a Nationwide Cohort - (04/21/17)
     
  2128. EASL: Nivolumab in Sorafenib-Experienced Patients With Advanced Hepatocellular Carcinoma With or Without Chronic Viral Hepatitis: CheckMate 040 Study - (04/21/17)
     
  2129. EASL: ENDURANCE-3: SAFETY AND EFFICACY OF GLECAPREVIR/PIBRENTASVIR COMPARED TO SOFOSBUVIR PLUS DACLATASVIR IN TREATMENT-NAÏVE HCV GENOTYPE 3-INFECTED PATIENTS WITHOUT CIRRHOSIS - (04/21/17)
     
  2130. EASL: EXPEDITION-I: Efficacy and Safety of Glecaprevir/Pibrentasvir for Treatment of Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection in Adults with Compensated Cirrhosis - (04/21/17)
     
  2131. EASL: Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis - (04/21/17)
     
  2132. EASL: A Phase 3 Study Comparing Tenofovir Alafenamide to Tenofovir Disoproxil Fumarate in Patients With HBeAg-Positive, Chronic Hepatitis B: Efficacy and Safety Results at Week 96 - (04/21/17)
     
  2133. EASL: EASL Launches Major New Funding Initiative: HCV education/public awareness/elimination - (04/21/17)
     
  2134. EASL: Treatment With SOF/VEL or SOF/VEL/VOX Is Well Tolerated and Results in High SVR12 in Genotype 1-6 HCV-Infected Patients With Minimal Fibrosis: a Retrospective Analysis of the ASTRAL and POLARIS Clinical Studies - (04/21/17)
     
  2135. EASL: High Sustained Virologic Response Rates at 24 Weeks in Participants With Chronic HCV GT1, 2, or 3 Infection Following 16 Weeks of Grazoprevir/Ruzasvir/Uprifosbuvir (MK-3682) Plus Ribavirin After Having Failed 8 Weeks of a Triple Drug Regimen (Part C of C-CREST-1 & 2) - (04/20/17)
     
  2136. EASL: Efficacy and Safety of the Fixed-Dose Combination Regimen of Grazoprevir/Ruzasvir/Uprifosbuvir (MK-3682) With or Without Ribavirin in Non-cirrhotic or Cirrhotic Participants With Chronic HCV GT1, 2, 3, 4, or 6 Infection (Parts A & B of C-CREST-1 & 2) - (04/20/17)
     
  2137. EASL: Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected With Hepatitis C Virus and Human Immunodeficiency Virus-1: The EXPEDITION-2 Study - (04/20/17)
     
  2138. EASL: No Impact of RASs on the High Efficacy of SOF/VEL/VOX for 8 Weeks in DAA-Naïve Patients: an Integrated Resistance Analysis of the POLARIS-2 and POLARIS-3 Studies - (04/20/17)
     
  2139. EASL: ILC 2017: Is direct-acting antiviral therapy for Hepatitis C associated with an increased risk of liver cancer? The debate continues - (04/20/17)
     
  2140. EASL: Arrowhead Pharmaceuticals Announces Presentations at The International Liver Congress™ - (04/20/17)
     
  2141. Acute Hepatitis C infection in lower risk MSM [London/BHIVA]: an evolving picture. 20% of HIV+ MSM Reported Condomless Sex as Sole Risk Factor. 33% for HIV-Neg MSM. - (04/13/17)
     
  2142. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment - (04/13/17)
     
  2143. Experience and Outcomes of Hepatitis C Treatment in a Cohort of Homeless and Marginally Housed Adults - (04/12/17)
     
  2144. Prevalence of HIV, HCV and HBV among Homeless and Non-homeless United States Veterans - (04/12/17)
     
  2145. Sofosbuvir and Velpatasvir for the Treatment of HCV in Patients Coinfected with HIV-1: an Open-Label, Phase 3 Study - (04/12/17)
     
  2146. Treat HCV Early - Increased mortality among persons with chronic hepatitis C with moderate or severe liver disease: a cohort study - (04/10/17)
     
  2147. U.S. FDA Approves New Indications for Harvoni® and Sovaldi® in Pediatric Patients 12 Years and Older with Chronic Hepatitis C Infection - (04/10/17)
     
  2148. Merck to Present New Data on ZEPATIER® (elbasvir and grazoprevir) and Investigational Combination Therapy MK-3682B for the Treatment of Chronic Hepatitis C Infection at The International Liver Congress™ 2017 - (04/07/17)
     
  2149. CROI: CROI 2017 HCV/HBV Reports - - (04/05/17)
     
  2150. APASL: Safety and Efficacy of Nivolumab in Patients With Advanced Hepatocellular Carcinoma: Interim Analysis of the Phase 1/2 CheckMate 040 Study - (04/04/17)
     
  2151. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012 - (04/03/17)
     
  2152. CROI: Acute HCV Drops Sharply in HIV-Positive Dutch MSM After DAA Rollout - Mark Mascolini - (03/31/17)
     
  2153. CROI: IFN-FREE THERAPY IS EFFECTIVE AND SAFE FOR HCV RECURRENCE IN LT HCV/HIV CO-INFECTION - (03/23/17)
     
  2154. CROI: Effectiveness of DAAs In HIV/HCV-coinfected Patients with Decompensated Cirrhosis - (03/23/17)
     
  2155. CROI: Efficacy and Safety of Direct Antiviral Agents in Cirrhotic HCV-HIV Coinfected Patients - (03/23/17)
     
  2156. CROI: Cost of noninfectious comorbidities in patients with HIV - Cost of HIV CARE Increases 5 fold Due to Cost for Comorbidities from <40 to >60 - (03/23/17)
     
  2157. CROI: High Efficacy of IFN-free Anti-HCV Regimens for Individuals on Opiate Agonist Therapy - (03/22/17)
     
  2158. APASL: Improvement in Fibrosis Parameters Following Treatment With Fixed-Dose Daclatasvir/Asunaprevir/Beclabuvir in Japanese Patients With Chronic HCV GT 1 Infection - (03/22/17)
     
  2159. CROI: Frailty Status and Risk of Falls in HIV-Infected Older Adults in the ACTG A5322 Study - (03/22/17)
     
  2160. CROI: Summary from CROI 2017 for viral Hepatitis HCV - elimination on its way: dream or emerging reality? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/22/17)
     
  2161. CROI: High Efficacy of IFN-free Anti-HCV Regimens for Individuals on Opiate Agonist Therapy - (03/22/17)
     
  2162. CROI: REAL-LIFE TREATMENT RATES FOR HEPATOCELLULAR CARCINOMA IN HIV-INFECTED PATIENTS - (03/21/17)
     
  2163. CROI: High Efficacy of IFN-free Anti-HCV Regimens for Individuals on Opiate Agonist Therapy - (03/21/17)
     
  2164. CROI: High Efficacy of IFN-free Anti-HCV Regimens for Individuals on Opiate Agonist Therapy - (03/21/17)
     
  2165. CROI: 95% SVR Rates Using Imported Generic DAAs for Patients With Hepatitis C - (03/21/17)
     
  2166. CROI: Delivering HCV Cures in the FQHC Medical Home: Training a New Generation of Providers - (03/21/17)
     
  2167. CROI: Strategies for Utilizing Electronic Health Record to Improve Birth Cohort Testing In the Hospital Setting - (03/21/17)
     
  2168. CROI: Implementation of an EHR Prompt Reveals Low Adherence to HCV Birth Cohort Testing Recommendations - (03/21/17)
     
  2169. CROI: Similar SVR12 cure rates for patients treated for hepatitis C in FQHCs with behavioral health conditions compared to those without - (03/21/17)
     
  2170. CROI: HCV TREATMENT IN PEOPLE WHO INJECT DRUGS CO-LOCATED WITHIN A NEEDLE SYRINGE PROGRAM - (03/21/17)
     
  2171. CROI: Cost-effectiveness of HCV Screening and Linkage in MMT: Relevance of HIV Co-infection - (03/20/17)
     
  2172. CROI: Real-world outcomes of HCV treatment in homeless and marginally housed adults - (03/20/17)
     
  2173. CROI: HCV REINFECTION AFTER SUCCESFUL DAA TREATMENT -A GECCO ANALYSIS - 11% HIV+ MSM - (03/20/17)
     
  2174. CROI: Direct-Acting Antivirals Improve Access to Care and Cure for Patients with HIV and chronic Hepatitis C Virus from 2011-2015 - (03/20/17)
     
  2175. CROI: High rates of hepatitis C virus cure among black and non-black persons with HIV-infection receiving care in an urban center - (03/20/17)
     
  2176. CROI: Same same but different? Risk of DAA therapy failure in real-life HCV/HIV coinfection: The GECCO Cohort - (03/20/17)
     
  2177. CROI: HIV-HCV Coinfection in the DAA Era: "En Route for Eradication" ? - (03/20/17)
     
  2178. CROI: Effectiveness of All-Oral DAAs for HCV Genotype 3 In HIV/HCV-Coinfected Patients - (03/20/17)
     
  2179. APASL: C-EDGE CO-STAR: Interim Results From the 3-year Follow-up Trial on Risk Factors and Rate of Reinfection in Patients on Opiate Agonist Therapy Previously Treated With Elbasvir/Grazoprevir for 12 Week - (03/15/17)
     
  2180. APASL: HIGH EFFICACY IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1b INFECTION TREATED WITH ELBASVIR/GRAZOPREVIR FOR 12 WEEKS: AN INTEGRATED ANALYSIS - (03/15/17)
     
  2181. APASL: EFFICACY AND SAFETY OF ELBASVIR/GRAZOPREVIR IN TREATMENT-NAïVE PATIENTS WITH CHRONIC HCV GT 1, GT 4 AND GT 6 INFECTION (C-CORAL): A PHASE III RANDOMIZED MULTINATIONAL CLINICAL TRIAL - (03/15/17)
     
  2182. APASL: Safety of Sofosbuvir-Based Regimens for the Treatment of Chronic HCV Infection in Patients With Mild or Moderate Renal Impairment - (03/15/17)
     
  2183. APASL: A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir (LDV/SOF), with or without Ribavirin (RBV), in HCV Infected Subjects Who Have Failed Prior Treatment with Non-NS5A, SOF-based Therapies (RESCUE) - (03/15/17)
     
  2184. APASL: Sofosbuvir/Velpatasvir for 12 Weeks Results in High SVR12 Rates with a Favorable Safety Profile in Asian Patients: an Integrated Subgroup Analysis of From the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies - (03/15/17)
     
  2185. APASL: Prevalence of Pretreatment NS5A and NS5B NI-Resistance Associated Substitutions in HCV-Infected Patients Enrolled in Clinical Trials in Asia - (03/15/17)
     
  2186. APASL: Ledipasvir/Sofosbuvir in Egyptian Patients With Chronic Genotype 4 HCV Infection - (03/15/17)
     
  2187. APASL: Long-term Follow-up of Patients With Chronic HCV Infection and Compensated or Decompensated Cirrhosis Following Treatment With Sofosbuvir-Based Regimens - (03/15/17)
     
  2188. APASL: Ledipasvir/Sofosbuvir in Patients with Chronic HCV and HIV/HCV Coinfection and in SOF-Experienced Patients - (03/15/17)
     
  2189. APASL: Impact of a 12-Week Oral Regimen of Elbasvir/Grazoprevir (EBR/GZR) On Health-Related Quality of Life (HRQOL) and Fatigue in Treatment-Naïve Patients With Chronic Hepatitis C Virus (HCV) Genotype (GT) 1, 4, or 6 Infection: Data From the C-CORAL Study - (03/15/17)
     
  2190. APASL: Elbasvir/Grazoprevir + Sofosbuvir ï Ribavirin in Treatment-Naive and Treatment-Experienced Patients with Hepatitis C Virus Genotype 3 Infection and Compensated Cirrhosis: The C-ISLE Study - (03/15/17)
     
  2191. APASL: Prevention of Liver-Related Complications in Patients With Chronic Hepatitis C Receiving Elbasvir/Grazoprevir Compared With Pegylated Interferon/Ribavirin andNo Treatment in Vietnam - (03/15/17)
     
  2192. AbbVie Granted Priority Review in Japan for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C - (03/14/17)
     
  2193. APASL: ONYX-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Asian Adults with Genotype 1b Chronic Hepatitis C Virus Infection - A Randomized, Double-Blind, Placebo-Controlled Study - (03/14/17)
     
  2194. APASL: GARNET: High SVR Rates Following 8-Week Treatment With Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir in Patients With HCV Genotype 1b Infection - (03/14/17)
     
  2195. APASL: Safety, Efficacy, and Clinical Outcomes in Hepatitis C Virus Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ï Ribavirin in the TOPAZ-I and TOPAZ-II Trials - (03/13/17)
     
  2196. APASL: Long-Term Evaluation of Liver Stiffness and Blood Markers in Hepatiti s C Virus Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ï Ribavirin: Interim Results from TOPAZ-I and TOPAZ-II - from Jules: TREAT EARLY - (03/13/17)
     
  2197. Understanding Barriers to HCV Treatment: the clinical, Financial and Policy Issues that Impact Patient Access TRIO Webinar - (03/10/17)
     
  2198. APASL: Elbasvir/Grazoprevir Does Not Worsen Renal Function in Patients With Hepatitis C Virus Infection and Pre-existing Renal Disease - (03/08/17)
     
  2199. FDA GT4 Label/TECHNIVIE Indication Expanded - (03/08/17)
     
  2200. CROI: A Systematic HCV-RNA Screening in HIV+ MSM Reveals a High Number of Potential Transmitters: 5% HCV Prevalence, 17% acute HCV incidence, higher rates of condomless sex, IDU, syphillis - (03/07/17)
     
  2201. CROI: High and Rising HCV Incidence in San Diego Study of 2395 MSM With HIV - Mark Mascolini (03/07/17)
     
  2202. CROI: The Association Between HCV And Comorbid Conditions In 2 Large Patient Cohorts - Mark Mascolini - (03/02/17)
     
  2203. CROI: High prevalence of hepatitis C virus among HIV negative MSM in the Amsterdam PrEP project - (03/02/17)
     
  2204. CROI: HCC DEVELOPMENT IN HCV PATIENTS AFTER DAA: THE EXPERIENCE OF THE SCOLTA PROJECT - (03/02/17)
     
  2205. CROI: Liver Cancer Cases Rise After SVR With All-DAA Therapy in Spanish HCV/HIV Cohort...... "our study has not found evidence for an increased HCC incidence with DAA use" - Mark Mascolini - (03/02/17)
     
  2206. CROI: Unrestricted Dutch Athena Cohort (HIV+/MSM/IDU) DAA Access Leads to Speedy Uptake, High Cure Rates ....'51% decrease in acute HCV, increased STD rates/syphillis' - Mark Mascolini - (03/02/17)
     
  2207. CROI: High and Rising HCV Incidence in San Diego Study of 2395 MSM With HIV - Mark Mascolini - (03/02/17)
     
  2208. APASL: Clinical Pharmacokinetics and Antiviral Activity of CC-31244, a Pan-genotypic, Potent Nonnucleoside NS5B Polymerase Inhibitor (NNI) for the Treatment of Hepatitis C - (02/21/17)
     
  2209. CROI: INCIDENCE OF HEPATITIS C AMONG HIV-INFECTED MEN WHO HAVE SEX WITH MEN IN SAN DIEGO, 2000-2015 - (02/24/17)
     
  2210. APASL: Sofosbuvir-Containing Regimens Are Safe and Effective in Adolescents With Chronic Hepatitis C Infection - (02/21/17)
     
  2211. APASL: Sofosbuvir/Velpatasvir in Combination With Ribavirin for 24 Weeks Is Effective Retreatment for Patients Who Failed Prior NS5A-Containing DAA Regimens: Results of the Retreatment Study - (02/21/17)
     
  2212. APASL: ONYX-II: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Coadministered with Ribavirin in Asian Adults with Genotype 1b Chronic Hepatitis C Virus Infection and Compensated Cirrhosis - (02/21/17)
     
  2213. APASL: PROJECTED IMPACT OF ELBASVIR/GRAZOPREVIR IN TREATMENT-NAÏVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 AND CHRONIC KIDNEY DISEASE IN VIETNAM - (02/21/17)
     
  2214. APASL: Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study - (02/21/17)
     
  2215. APASL: Clinical Pharmacokinetics and Antiviral Activity of CC-31244, a Pan-genotypic, Potent Nonnucleoside NS5B Polymerase Inhibitor (NNI) for the Treatment of Hepatitis C - (02/21/17)
     
  2216. CROI: Correlation of Renal Biomarkers and Tenofovir AUC in the ION-4 Study Cohort - (02/20/17)
     
  2217. CROI: GLECAPREVIR AND PIBRENTASVIR INTERACTIONS WITH COMBINATION ANTIRETROVIRAL REGIMENS - (02/20/17)
     
  2218. CROI: Correlation of Renal Biomarkers and Tenofovir AUC in the ION-4 Study Cohort - (02/19/17)
     
  2219. Gilead Sciences, Inc. Medical Affairs HIV/HCV NoCo program: Toward Elimination of HCV in HIV-Infected Populations - $ 3 Million in Grants - (02/14/17)
     
  2220. United HealthCare HCV Settlement Upheld / Dropping Restrictions - (02/14/17)
     
  2221. New HCV Patient Treatment Starts - (02/13/17)
     
  2222. Hepatitis C drugs top Medicaid spending, highlighting larger concerns - (02/08/17)
     
  2223. NYS HCV Summit - (02/08/17)
     
  2224. U.S. FDA Grants Priority Review to AbbVie for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) - (02/06/17)
     
  2225. Eradication of HCV and non-liver-related non-AIDS-related events (CVD/diabetes/kidney/cancers) in HIV/HCV coinfection - (02/01/17)
     
  2226. Liver Cancer Mortality & Incidence Nationally Increased by 87% - NYC, NYS, Oregon - (01/30/17)
     
  2227. NS5A Resistance-Associated Substitutions in Patients with Genotype 1 Hepatitis C Virus: Prevalence and Effect on Treatment Outcome - (01/30/17)
     
  2228. The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection - (01/30/17)
     
  2229. Nonalcoholic steatohepatitis and the intestinal microbiota - Editorial - (01/30/17)
     
  2230. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications..... - (01/26/17)
     
  2231. Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial - (01/26/17)
     
  2232. New Genotype 3 Treatments - New HCV Treatments - (01/26/17)
     
  2233. The HCV care continuum does not end with cure: A call to arms for the prevention of reinfection - Editorial - (01/26/17)
     
  2234. UK NICE NHS Recommends Epclusa - (01/25/17)
     
  2235. Zepatier Accepted by SMC - Scottish Medicines Consortium - (01/24/17)
     
  2236. AbbVie Submits New Drug Application to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C - (01/24/17)
     
  2237. European Medicines Agency Grants Accelerated Assessment, Validates Marketing Authorization Application for AbbVie's Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) - (01/24/17)
     
  2238. Effect of interferon-free therapy on cognition in HCV and HCV/HIV infection: A pilot study - (01/24/17)
     
  2239. European Medicines Agency Validates Gilead's Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) - (01/24/17)
     
  2240. IDSA: Direct Acting Anti-Viral Therapy for Chronic Hepatitis C Virus Infection Is Associated with Regression of Liver Fibrosis, Assessed by Serial Transient Elastography (Fibroscan) - (01/11/16)
     
  2241. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial - (01/11/16)
     
  2242. Long-term safety and efficacy of [RG-101] microRNA-targeted therapy in chronic hepatitis C patients - (01/11/16)
     
  2243. Achillion Announces Initiation of Patient Dosing by Janssen in a Global, Short Treatment-Duration Phase 2b Study of JNJ-4178 in Chronic HCV - (01/11/16)
     
  2244. Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) for Chronic Hepatitis C Achieved High SVR[12] Rates in Genotype 1 Japanese Patients - (01/11/16)
     
  2245. EASL Recommendations on Treatment of Hepatitis C 2016 - (01/11/16)
     
  2246. Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? - (01/11/16)
     
  2247. HCV Universal Treatment Access /Global Elimination - Targeted direct-acting antiviral treatment for chronic hepatitis C: A financial reality or an obstacle to elimination? - Editorial - (01/11/16)
     
  2248. Liver injury from herbal and dietary supplements - NIH Report - (01/10/16)
     
  2249. Serum biomarkers for nonalcoholic fatty liver disease: Are we there yet? Editorial - (01/10/16)
     
  2250. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease - (01/10/16)
     
  2251. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population - (12/21/16)
     
  2252. Global genotype distribution of hepatitis C viral infection among people who inject drugs - (12/21/16)
     
  2253. Does the liver accelerate ageing: Talking muscles and liver? - (12/21/16)
     
  2254. Zepatier/Trial Underway for Hep C-Positive Kidney Transplants - (12/16/16)
     
  2255. AASLD: Hepatitis B reactivation after interferon-based therapy versus pan-oral direct acting antiviral agents in chronic hepatitis C patients co-infected with hepatitis B virus: a systematic review and meta-analysis - (12/15/16)
     
  2256. AASLD: Hepatitis B Reactivation Associated with Direct Acting Antiviral Therapy for Hepatitis C: A review of Spontaneous Post-Marketing Cases - (12/06/16)
     
  2257. AASLD: SVR12 rates under DAA-based HCV therapy from the National German Cohort Study: Does HIV co-infection impair the response to DAA combination therapy? - (12/15/16)
     
  2258. AASLD: A Phase 2 Study of BMS-986036 (PegylatedFGF21) in Obese Adults with Type 2 Diabetes and a High Prevalence of Fatty Liver - (12/15/16)
     
  2259. AASLD: Retreatment with Sofosbuvir + Grazoprevir + Elbasvir + Ribavirin of Patients with Hepatitis C Virus Genotype 1 or 4 with RASs at Failure of a Sofosbuvir + Ledipasvir or + Declatasvir or + Simeprevir Regimen - (12/15/16)
     
  2260. AASLD: 8 Weeks Treatment Under Real Life Conditions with Ledipasvir/Sofosbuvir in HIV Co-Infected Treatment-Naïve HCV Genotype 1 Infected Patients with Similar Results to Mono-Infected HCV Patients: data from the German Hepatitis C-Registry (DHC-R) - (12/15/16)
     
  2261. AASLD: Effectiveness and Safety of DAA Combination Therapies for Treatment of HCV in Elderly Patients (> 70 yrs): Results from the German Hepatitis C-Registry (DHC-R) - (12/15/16)
     
  2262. AASLD: Treatment of HCV in the Department of Corrections in the Era of oral Direct Acting Antivirals - (12/15/16)
     
  2263. AASLD: Four Weeks Treatment of Injection Drug Users with Chronic Hepatitis C - (12/15/16)
     
  2264. AASLD: Risk of Incident Liver Cancer Following HCV Treatment With Sofosbuvir-Containing Regimens - (12/15/16)
     
  2265. AASLD: Hepatitis B reactivation after interferon-based therapy versus pan-oral direct acting antiviral agents in chronic hepatitis C patients co-infected with hepatitis B virus: a systematic review and meta-analysis - (12/15/16)
     
  2266. EASL: Summary from EASL 2016 for Hepatitis C Highly efficacious pan-genotypic DAA combinations on their way: the last gaps in difficult-to-treat patient populations are going to be closed soon. - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany
     
  2267. AASLD: Summary for AASLD 2016 for Hepatitis C - New HCV two and three drug regimens on their way: what do they promise? And what do clinicians need to look out for under DAA combination therapy and beyond SVR? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany
     
  2268. AASLD: Summary for AASLD 2016 for Hepatitis C - New HCV two and three drug regimens on their way: what do they promise? And what do clinicians need to look out for under DAA combination therapy and beyond SVR? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (12/13/16)
     
  2269. Hepatic Steatosis [fatty liver] is Highly Prevalent in HIV and Significantly Associated with Diabetes Risk - (12/09/16)
     
  2270. Gilead Submits New Drug Application to U.S. Food and Drug Administration for the Investigational Single Tablet Regimen Sofosbuvir/Velpatasvir/Voxilaprevir - (12/09/16)
     
  2271. AASLD: Treatment outcomes for hepatitis C genotype 1 infection with direct acting antivirals (DAA): Data from the German Hepatitis C-Registry (DHC-R) - (12/01/16)
     
  2272. AASLD: EFFECTIVENESS OF DACLATASVIR PLUS SOFOSBUVIR IN HCV-GT3 PATIENTS RESULTS FROM THE GERMAN HEPATITIS C REGISTRY (DHC-R) - (12/01/16)
     
  2273. AASLD: Are risk factors still relevant for HCV treatment with directly-acting agents against HCV in HIV-HCV-coinfection? Results from the German hepatitis C cohort (GECCO) - (12/01/16)
     
  2274. AASLD: Are risk factors still relevant for HCV treatment with directly-acting agents against HCV in HIV-HCV-coinfection? - Results from the German hepatitis C cohort (GECCO) - (12/08/16)
     
  2275. AASLD: High Cure Rates after Directly Acting Antivirals in Patients with Chronic Hepatitis C and Psychiatric Disorders - (12/08/16)
     
  2276. HCV/HIV Children / Young Adults in Europe - Sofosbuvir, Ledipasvir/sofosbuvir PK in aged <6 to <12 Years Old - (12/07/16)
     
  2277. AASLD: Sofosbuvir + Ribavirin for 12 or 24 Weeks Is Safe and Effective in Adolescents With Genotype 2 or Genotype 3 Chronic Hepatitis C Infection - (12/07/16)
     
  2278. AASLD: Efficacy and safety of DAA-based oral therapy in a large cohort of HCV patientstreated in clinical practice in Italy and monitored by the NAVIGATORE web-platform - (12/05/16)
     
  2279. EASL: FXR AGONISM BY GS-9674 DECREASES STEATOSIS AND FIBROSIS IN A MURINE MODEL OF NASH - (12/02/16)
     
  2280. EASL: RG-101 DEMONSTRATES FAVORABLE IN VITRO ANTIVIRAL ACTIVITY AND CROSS RESISTANCE PROFILE TO SUPPORT CLINICAL COMBINATION STUDIES IN HCV PATIENTS - (12/02/16)
     
  2281. Nonalcoholic Fatty Liver Disease in HIV-Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors - (12/01/16)
     
  2282. Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes of Chronic Hepatitis C - (12/01/16)
     
  2283. Shedding of Hepatitis C Virus Into the Rectum of HIV-infected Men Who Have Sex With Men - (11/30/16)
     
  2284. Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with Nitto Denko for Targeted siRNA Therapy in Advanced Non-alcoholic Steatohepatitis (NASH) and Cirrhosis Due to NASH - (12/15/16)
     
  2285. Nonalcoholic Fatty Liver Disease in HIV-Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors - (12/01/16)
     
  2286. Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes of Chronic Hepatitis C - (12/01/16)
     
  2287. AASLD: A Prospective Study of The Association of Body Morphometry With Hepatic Steatosis and Fibrosis in HIV-HCV Coinfected Patients - (11/30/16)
     
  2288. AASLD: Sofosbuvir-Based Regimens for Patients with Chronic Hepatitis C Genotype 3 Infection: Integrated Analysis of Five Clinical Studies - (11/30/16)
     
  2289. AASLD: Real-world Outcomes With New HCV Antivirals in HIV/HCV-coinfected Subjects:Madrid Coinfection Registry (Madrid-CoRE) Findings - (11/30/16)
     
  2290. AASLD: HCV at AASLD / New HCV Drugs / New NASH Drugs - (11/30/16)
     
  2291. AASLD: HCC Risk/DAAs - Long Term Followup SVR / SVR Durability - (11/30/16)
     
  2292. AASLD: Sofosbuvir-Based Regimens for Patients with Chronic Hepatitis C Genotype 3 Infection: Integrated Analysis of Five Clinical Studies - (11/30/16)
     
  2293. AASLD: Safety of Sofosbuvir-Based Regimens for the Treatment of Chronic HCV Infection in Patients With Mild or Moderate Renal Impairment - (11/30/16)
     
  2294. AASLD: DIAGNOSTIC PATTERN AND DISEASE ACTIVITY ARE RELATED TO DISEASE PROGRESSION AND REGRESSION IN NONALCOHOLIC FATTY LIVER DISEASE - (11/29/16)
     
  2295. AASLD: Evaluation of the Safety and Pharmacokinetics of the Oral, Nonsteroidal Farnesoid X Receptor Agonist GS-9674 in Healthy Volunteers - (11/29/16)
     
  2296. AASLD: Ledipasvir/Sofosbuvir + Ribavirin for 12 Weeks in Decompensated HCV Genotype 1 Patients: SOLAR-1 and SOLAR-2 Studies Compared to a Real-World Dataset - (11/29/16)
     
  2297. AASLD: Optimal Timing of Hepatitis C Treatment for Patients on the Liver Transplant Waiting List - (11/29/16)
     
  2298. AASLD: Predictors of Improvement in Glomerular Filtration Rate Among Patients Treated With Ombitasvir/Paritaprevir/r and Dasabuvir With or Without Ribavirin - (11/29/16)
     
  2299. AASLD: Improved Hepatic Profile in Hepatitis C Virus (HCV) Genotype (GT) 4-Infected Egyptian Patients With Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/Ritonavir With Ribavirin (AGATE-II) - (11/29/16)
     
  2300. AASLD: Regulus Expands Clinical Trial Collaboration with GSK ....."potential single-visit cure" - (11/29/16)
     
  2301. AASLD: A Single Subcutaneous Dose of 2 mg/kg or 4 mg/kg of RG-101, a Galnac-Conjugated Oligonucleotide with Antagonist Activity against miR-122, Results in Significant Viral Load Reductions in Chronic Hepatitis C Patients - (11/29/16)
     
  2302. AASLD: Poor Adherence to Hepatocellular Carcinoma (HCC) Surveillance in a U.S. Cohort of 2,917 Patients with Chronic Hepatitis C (CHC) and Cirrhosis - (11/28/16)
     
  2303. AASLD: Real-world Outcomes With New HCV Antivirals in HIV/HCV-coinfected Subjects: Madrid Coinfection Registry (Madrid-CoRE) Findings - (11/28/16)
     
  2304. AASLD: GEODE-II: Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Patients With Genotype 1a Chronic Hepatitis C Virus Infection Without Cirrhosis - (11/28/16)
     
  2305. AASLD: Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, and Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir Antiviral Regimens for Hepatitis C In 17,847 Patients in the Veterans Affairs National Healthcare System - (11/28/16)
     
  2306. AASLD: Impact of all-oral antiviral therapy on portal pressure and hemodynamics on HCV-infected cirrhotic patients. - (11/28/16)
     
  2307. ID Week: Effectiveness of DAA Regimens in Genotype 1 HIV/HCV Coinfected Patients: An Analysis of the VA National Clinical Case Registry - (11/28/16)
     
  2308. AASLD: Predictors of Sustained Virologic Response in 21,242 Genotype 1 Patients Treated with Ledipasvir/SofosbuvirïRibavirin or Ombitasvir/Paritaprevir/Ritonavir+DasabuvirïRibavirin in Routine Medical Practice - (11/28/16)
     
  2309. AASLD: Safety, Tolerability, Pharmacokinetics (PK) and Antiviral Activity of EDP-494, a Potent Pan-Genotypic Cyclophilin (Cyp) Inhibitor for Chronic Hepatitis C Infection (CHC), in Healthy Subjects (HS) and in CHC Genotype 1 and 3 Patients: Preliminary Results - (11/28/16)
     
  2310. AASLD: Hepatitis B Reactivation in Patients Receiving Interferon-Free Direct Acting Antiviral Agents for Chronic Hepatitis C Virus Infection - (11/23/16)
     
  2311. AASLD: Ledipasvir/Sofosbuvir in Egyptian Patients With Chronic Genotype 4 HCV Infection - (11/21/16)
     
  2312. AASLD: Safety and Tolerability of Direct Acting Antiviral Agents (DAAs) Used in Usual Clinical Practice: HCV-TARGET International Consortium - (11/21/16)
     
  2313. AASLD: Non-adherence is the most important risk factor for ledipasvir/sofosbuvir HCV treatment failure in the real world - (11/21/16)
     
  2314. AASLD: Effect of Ethnicity on HCV Patient Outcomes and Access to Therapy in Era of All DAA Regimens: Real-World Experience From the Trio Network - (11/21/16)
     
  2315. AASLD: Assessment of risk of acute kidney injury associated with exposure to sofosbuvir-containing HCV treatment regimens and HCV infection - (11/21/16)
     
  2316. AASLD: Towards a Single Treatment Cure for HCV: Reformulation of the Pangenotypic NS5B NNI GSK2878175 as a Long Acting Parenteral (LAP) - (11/21/16)
     
  2317. AASLD: HCV Screening and Infection awareness in a cohort of HIV infected & Uninfected and Marginally Housed Women in San Francisco..... - (11/21/16)
     
  2318. AASLD: The Increased Mortality and the Medicare Disability Eligibility Status of the HCV Population in the US - (11/21/16)
     
  2319. AASLD: Real World Effectiveness of Ledipasvir/Sofosbuvir in Patients Coinfected With HCV and HIV-1: A Comparative Analysis of Clinical Trials with Four Real World Cohorts - (11/21/16)
     
  2320. AASLD: GS-4997, an Inhibitor of Apoptosis Signal-Regulating Kinase (ASK1), Alone or in Combination with Simtuzumab for the Treatment of Nonalcoholic Steatohepatitis (NASH): A Randomized, Phase 2 Trial - (11/21/16)
     
  2321. AASLD: EIGHT WEEKS TREATMENT DURATION WITH LEDIPASVIR/SOFOSBUVIR (LDV/SOF) IS EFFECTIVE FOR APPROPRIATELY SELECTED PATIENTS WITH GENOTYPE 1 HEPATITIS C VIRUS (HCV) INFECTION: AN ANALYSIS OF MULTIPLE REAL WORLD COHORTS TOTALING >6,500 PATIENTS - (11/21/16)
     
  2322. AASLD: ELEVATED HCV REINFECTION INCIDENCE AFTER SUCCESSFUL TREATMENT AMONG HIV-INFECTED MEN WHO HAVE SEX WITH MEN IN SAN DIEGO - (11/21/16)
     
  2323. AASLD: Impact of Drug Use and Opioid Substitution Therapy on Hepatitis C Reinfection: The BC Hepatitis Testers Cohort - (11/21/16)
     
  2324. AASLD: New HCV Drugs at AASLD - (11/21/16)
     
  2325. AASLD: The impact of sustained virological response to HCV infection on long term risk of hepatocellular carcinoma: The BC Hepatitis Testers Cohort - (11/17/16)
     
  2326. AASLD: Ledipasvir/Sofosbuvir for 8 Weeks Results in High SVR Rates in Treatment-Naïve Patients With Chronic HCV Infection and HIV/HCV Coinfection - in Russia - (11/17/16)
     
  2327. AASLD: INTERIM ANALYSIS OF A 3-YEAR FOLLOW-UP STUDY OF NS5A AND NS3 RESISTANCE-ASSOCIATED VARIANTS AFTER TREATMENT WITH GRAZOPREVIR-CONTAINING REGIMENS IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION - (11/17/16)
     
  2328. AASLD: Ledipasvir/Sofosbuvir for 8 Weeks Results in High SVR Rates in Treatment-Naïve Patients With Chronic HCV Infection and HIV/HCV Coinfection - in Russia - (11/17/16)
     
  2329. AASLD: "Incidence and pattern of "de novo" hepatocellular carcinoma in HCV patients treated with oral DAAs" - (11/17/16)
     
  2330. AASLD: ELBASVIR/GRAZOPREVIR PLUS SOFOSBUVIR ï RIBAVIRIN IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 3 INFECTION AND COMPENSATED CIRRHOSIS: THE C-ISLE STUDY - (11/17/16)
     
  2331. AASLD: High Rates of Medical and Psychiatric Comorbidities in HIV/HCV-Coinfected Patients Treated With Sofosbuvir-Containing Regimens in Registrational Clinical Trials - Harvoni / Epclusa - (11/17/16)
     
  2332. AASLD: QUARTZ II-III: Final Efficacy and Safety Results in Patients With HCV Genotype 2 or 3 Infection - Abbvie 2D + Sofosbuvir in Gt3 [12 weeks] & Gt2 (6, 8 weeks) - treatment experienced & naive - (11/17/16)
     
  2333. AASLD: ONYX-II: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Coadministered With Ribavirin in Asian Adults With Genotype 1b Chronic Hepatitis C Virus Infection and Compensated Cirrhosis - (11/17/16)
     
  2334. AASLD: Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ï Ribavirin: First Interim Safety and Efficacy Results From TOPAZ-I - (11/17/16)
     
  2335. AASLD: An Open-Label, Multicenter Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Infection: Efficacy and Safety Results of TOPAZ-VA.... .49% had ongoing psych disorders - (11/17/16)
     
  2336. AASLD: SURVEYOR-II, Part 4: Glecaprevir/Pibrentasvir [ABT493+ABT530] Demonstrates High SVR Rates in Patients With HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis Following an 8-Week Treatment Duration - (11/17/16)
     
  2337. AASLD: Six weeks of sofosbuvir/ledipasvir treatment of acute hepatitis C virus genotype 1 mono-infection: Final results of The German HepNet Acute HCV IV Study......55% were sexual transmission including 5 MSM - (11/17/16)
     
  2338. AASLD: ONYX-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Asian Adults With Genotype 1b Chronic Hepatitis C Virus Infection - A Randomized, Double-Blind, Placebo-Controlled Study - (11/17/16)
     
  2339. AASLD: Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection - (11/17/16)
     
  2340. AASLD: AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease - (11/16/16)
     
  2341. AASLD: Healthy Eating Patterns - Eat Your Way to a Healthy Liver / NASH-Fatty Liver - (11/16/16)
     
  2342. AASLD: RUBY-II: Efficacy and Safety of a Ribavirin-Free Ombitasvir/Paritaprevir/Ritonavir ï Dasabuvir Regimen in Patients With Severe Renal Impairment or End-Stage Renal Disease and HCV Genotype 1a or 4 Infection - (11/16/16)
     
  2343. AASLD: RG-101 + DAAs - New Combination Therapy Could Cure Hepatitis C With Only 4 Weeks of Treatment - (11/16/16)
     
  2344. AASLD: Impact of treatment induced vs. spontaneous HCV clearance on the long term risk of hepatocellular carcinoma: BC Hepatitis Testers Cohort - (11/16/16)
     
  2345. AASLD: Nivolumab in Patients With Advanced Hepatocellular Carcinoma: the CheckMate 040 Study - (11/16/16)
     
  2346. AASLD: SURVEYOR-II, Part 4: Glecaprevir/Pibrentasvir Demonstrates High SVR Rates in Patients With HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis Following an 8-Week Treatment Duration - (11/16/16)
     
  2347. AASLD: The Safety and Tolerability of Sofosbuvir/Velpatasvir With Weight-Based Ribavirin in Patients With Child-Pugh Turcotte Class B Cirrhosis in the ASTRAL-4 Study - (11/15/16)
     
  2348. AASLD: RUBY-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection With Severe Renal Impairment or End-Stage Renal Disease - (11/15/16)
     
  2349. AASLD: RUBY-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection With Severe Renal Impairment or End-Stage Renal Disease - (11/15/16)
     
  2350. AASLD: A Randomized, Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study - (11/15/16)
     
  2351. AASLD: A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naïve Genotype 1-6 HCV Infected Patients: The POLARIS-2 Study - (11/15/16)
     
  2352. AASLD: ENDURANCE-1: A Phase 3 Evaluation of the Efficacy and Safety of 8- versus 12-week Treatment with Glecaprevir/Pibrentasvir (formerly ABT-493/ABT-530) in HCV Genotype 1 Infected Patients with or without HIV-1 Co-infection and without Cirrhosis - (11/15/16)
     
  2353. AASLD: EXPEDITION-4: EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR (ABT-493/ABT-530) IN PATIENTS WITH RENAL IMPAIRMENT AND CHRONIC HEPATITIS C VIRUS GENOTYPE 1 - 6 INFECTION - (11/15/16)
     
  2354. AASLD: Cenicriviroc Versus Placebo for the Treatment of Nonalcoholic Steatohepatitis with Liver Fibrosis: Results from the Year 1 Primary Analysis of the Phase 2b CENTAUR Study - (11/29/16)
     
  2355. AASLD: Distinct evolutionary pathways of NS5A inhibitor resistance in patients with genotype 1a versus 1b infection during monotherapy with MK-8742 (Elbasvir) - (11/15/16)
     
  2356. AASLD: Sofosbuvir/Velpatasvir/Voxilaprevir for 12 Weeks as a Salvage Regimen in NS5A Inhibitor-Experienced Patients With Genotype 1-6 Infection: The Phase 3 POLARIS-1 Study - (11/15/16)
     
  2357. AASLD: Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682 / Grazoprevir / MK-8408 (Ruzasvir) in Cirrhotic or Non-cirrhotic Patients with Chronic HCV GT1 Infection who Previously Failed a Direct-acting Antiviral Regimen (C-SURGE) - (11/15/16)
     
  2358. AASLD: Long-term follow-up of patients with chronic HCV infection & treated with daclatasvir-based regimens in phase 2 and 3 studies - (11/15/16)
     
  2359. AASLD: Integrated Analysis of Sofosbuvir +Ribavirin, Ledipasvir/Sofosbuvir or Sofosbuvir/Velpatasvir for the Treatment of Genotype 4 Chronic HCV Infection - (11/15/16)
     
  2360. AASLD: Triple Combination Drug Interaction Studies of the Nucleotide Analog, AL-335, in Combination with Simeprevir and Odalasvir Demonstrate Significant Synergy in the Hepatitis C Virus (HCV) Subgenomic Replicon System - (11/15/16)
     
  2361. AASLD: Pharmacokinetics (PK), safety and tolerability of the 2-and 3-direct acting antiviral (DAA) combination of AL-335, odalasvir (ODV) and simeprevir (SMV) administered once-daily (QD) in healthy volunteers (HVs) - (11/15/16)
     
  2362. AASLD: Safety of Sofosbuvir-Based Regimens for the Treatment of Chronic HCV Infection in Patients With Mild or Moderate Renal Impairment - (11/14/16)
     
  2363. AASLD: ENDURANCE-4: Efficacy and Safety of Glecaprevir/Pibrentasvir (Formerly ABT-493/ABT-530) Treatment in Patients with Chronic HCV Genotype 4, 5, or 6 Infection - (11/14/16)
     
  2364. AASLD: SURVEYOR-II, PART 3: EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR (ABT-493/ABT-530) IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 3 INFECTION WITH PRIOR TREATMENT EXPERIENCE AND/OR CIRRHOSIS - (11/14/16)
     
  2365. AASLD: High Sustained Virologic Response Rates in Patients with Chronic HCV GT1, 2 or 3 Infection Following 16 Weeks of MK-3682/Grazoprevir/MK-8408 (Ruzasvir) Plus Ribavirin After Failure of 8 Weeks of Therapy (Part C of C-CREST-1 & 2) - (11/14/16)
     
  2366. AASLD: A Randomized, Controlled, Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir or Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Patients With Genotype 1-6 HCV Infection: The POLARIS-4 Study - (11/14/16)
     
  2367. AASLD: Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 (Ruzasvir) With or Without Ribavirin in Non-cirrhotic or Cirrhotic Patients with Chronic HCV GT1, 2 or 3 Infection (Part B of C-CREST-1 & -2) - (11/14/16)
     
  2368. AASLD: EFFICACY AND SAFETY OF ELBASVIR/GRAZOPREVIR IN TREATMENT-NAïVE PATIENTS WITH CHRONIC HCV GT 1, GT 4 AND GT 6 INFECTION (C-CORAL): A PHASE III RANDOMIZED MULTINATIONAL CLINICAL TRIAL - (11/14/16)
     
  2369. AASLD: ELBASVIR/GRAZOPREVIR PLUS SOFOSBUVIR ï RIBAVIRIN IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 3 INFECTION AND COMPENSATED CIRRHOSIS: THE C-ISLE STUDY - (11/14/16)
     
  2370. AASLD: ENDURANCE-2: Safety and Efficacy of Glecaprevir/Pibrentasvir in Hepatitis C Virus Genotype 2-infected Patients without Cirrhosis: a Randomized, Double-Blind, Placebo-Controlled Study - (11/14/16)
     
  2371. AASLD: Pharmacokinetics of Once-Daily Sofosbuvir and Ledipasvir/Sofosbuvir in HCV-Infected Pediatrics Aged 6 to <12 Years Old - (11/14/16)
     
  2372. AASLD: Long-term Follow-up of Patients With Chronic HCV Infection and Compensated or Decompensated Cirrhosis Following Treatment With Sofosbuvir-Based Regimens - (11/14/16)
     
  2373. AASLD: Real World Effectiveness of Ledipasvir/Sofosbuvir in Patients Coinfected With HCV and HIV-1:A Comparative Analysis of Clinical Trials with Four Real World Cohorts - (11/14/16)
     
  2374. AASLD: C-EDGE CO-STAR: Interim Results From the 3-year Follow-up Trial on Risk Factors and Rate of Reinfection in Patients on Opiate Agonist Therapy Previously Treated With Elbasvir/Grazoprevir for 12 Weeks - (11/14/16)
     
  2375. AASLD: Integrated Resistance Analyses of HCV-Infected Patients Treated With Sofosbuvir, Velpatasvir, and Voxilaprevir for 8 and 12 Weeks From Phase 2 Studies - (11/14/16)
     
  2376. AASLD: Final Results From Phase 3 Portion in Phase 2/3 Study of Elbasvir/Grazoprevir in Hepatitis C Genotype 1-Infected Japanese Patients - (11/14/16)
     
  2377. AASLD: High Efficacy in Patients With Chronic Hepatitis C Virus (HCV) Genotype 1b Infection Treated with Elbasvir/Grazoprevir for 12 Weeks: An Integrated Analysis - (11/14/16)
     
  2378. AASLD: Elbasvir/Grazoprevir Does Not Worsen Renal Function in Patients With Hepatitis C Virus Infection and Pre-existing Renal Disease - (11/14/16)
     
  2379. AASLD: Prevalence and Impact of Baseline Resistance-Associated Variants on the Efficacy of Elbasvir/Grazoprevir in Hepatitis C Genotype 1-Infected Japanese Patients - (11/14/16)
     
  2380. AASLD: Concomitant Proton Pump Inhibitor Use Does Not Reduce the Efficacy of Elbasvir/Grazoprevir - (11/14/16)
     
  2381. AASLD: Chronic Hepatitis C Virus Infection and Cancer Risks: A Population-Based Cohort Study - (11/14/16)
     
  2382. AASLD: The Impact of Hepatitis C Viral Cure on Progression of Renal Disease - (11/14/16)
     
  2383. AASLD: Merck Announces Presentation of New Findings for ZEPATIER™ (Elbasvir and Grazoprevir) in Patients with Chronic Hepatitis C at The Liver Meeting® - (11/14/16)
     
  2384. HCV Resistance, DAA Failures, and Other difficult situations - Excerpts - (11/10/16)
     
  2385. IDSA: [Barriers to HCV Care] Expanded HCV Testing and Linkage to Care: Program Implementation to Overcome Barriers to Engagement in Care ....7% SVR rate..... from Jules: there remain persistent difficult barriers to HCV care in inner cities, very strong support services related to linkage to care are needed. - (11/09/16)
     
  2386. Cocrystal Announces Positive Interim Data from an Ongoing Phase 1 Study with CC-31244 for the Treatment of Chronic Hepatitis C Infection - (11/07/16)
     
  2387. Sofosbuvir/Velpatasvir Plus Voxilaprevir for 6, 8, or 12 Weeks in Genotype 1-6 HCV-infected Patients: An Integrated Analysis of Safety and Efficacy from Two Phase 2 Studies - (11/03/16)
     
  2388. GLASGOW: Outcomes of Cabotegravir (CAB) Treatment in HIV-1 ART-Naive Patients With Chronic or Acute Hepatitis C Virus (HCV) Co-infection: Data From the Phase IIbProgramme - (11/02/16)
     
  2389. NYS Durb Final Report - Sept 15 2016 Meeting - (10/30/16)
     
  2390. GLASGOW: Sofosbuvir/Velpatasvir Single Tablet Regimen in HCV Monoinfected and HIV/HCV Coinfected Patients: Comparison of Efficacy and Safety Data from Phase 3 Clinical Trials - (10/26/16)
     
  2391. Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertension (PAH) and Diabetic Kidney Disease (DKD) - (10/21/16)
     
  2392. Gilead Announces SVR12 Rates From Four Phase 3 Studies of a Once-Daily, Fixed-Dose Combination of Sofosbuvir, Velpatasvir and Voxilaprevir in Treatment-Naïve and Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients - (10/21/16)
     
  2393. EASL HCV Recommendations Updated - (10/19/16)
     
  2394. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis - (10/17/16)
     
  2395. HCV Extrahepatic Diseases / Manifestations - kidney, cardiovascular, bone - inflammation - brain - increased mortality - (10/17/16)
     
  2396. Prisoners With Hep C Get Cured In Some States But Not Others - (10/14/16)
     
  2397. NYC Hepatitis C 2015 Surveillance Update - by age group, by Neighborhoods, by poverty, by Race, Country of Origin - (10/14/16)
     
  2398. The Changing Face of the Hepatitis C Epidemic New York State (Excluding NYC) - new HCV Case Reports Increased for Young IDUs & Females - (10/12/16)
     
  2399. HHS HCV/Opioid Rural RFPs-Funding Opportunity Title - (10/08/16)
     
  2400. HCV post-exposure prophylaxis in the healthcare worker: Why DAAs don't change a thing - (10/08/16)
     
  2401. NYS DURB Recommendations - Sept 15 2016 - (10/05/16)
     
  2402. NEW HCV DRUGS Development - (10/05/16)
     
  2403. Merck to Present New Data on ZEPATIER™ (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting® 2016 - (10/05/16)
     
  2404. ABT-493+ABT-530 - AbbVie's Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation - (10/05/16)
     
  2405. Cluster of Sexually Transmitted Hepatits C Virus Among the MSM Population in Southeast Michigan [Detroit] - (09/28/16)
     
  2406. Special EASL: Barriers To HCV Treatment in Methadone Users / Philadelphia Study-Temple University - (09/27/16)
     
  2407. Special EASL: Meta-Analysis of the Real-World Effectiveness of Ombitasvir/Paritaprevir ritonavir ï Dasabuvir ï Ribavirin in Patients With HCV Genotype 1 or 4 Infection - (09/26/16)
     
  2408. Special EASL: Ribavirin Management in HCV Genotype 4 Patients Receiving Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in the Phase 3 AGATE-I Study - (09/26/16)
     
  2409. Special EASL: Analysis of Baseline Variants in GT1a-Infected Pati ents Treated With 3D With and Without RBV, and Cirrhotic GT1a Patients Treated With 3D Plus RBV for 12 or 24 Weeks - (09/26/16)
     
  2410. Special EASL: GEODE-II: Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Patients With Genotype 1a Chronic Hepatitis C Virus Infection Without Cirrhosis - (09/26/16)
     
  2411. Special EASL: GARNET: High SVR Rates Following 8-Week Treatment With Ombitasvir/ Paritaprevir/Ritonavir + Dasabuvir in Patients With HCV Genotype 1b Infection - (09/26/16)
     
  2412. Special EASL: Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen's Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV - (09/26/16)
     
  2413. Special EASL: Short duration treatment with AL-335 and odalasvir (ODV), with or without simeprevir (SMV), in treatment naïve patients with hepatitis C virus (HCV) genotype (GT) 1 infection - (09/26/16)
     
  2414. Special EASL: AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C - (09/26/16)
     
  2415. Women & HCV - Screen & Treat Early / Screen Pregnant Women to Prevent Transmission to Children / Philadelphia Report - (09/23/16)
     
  2416. NICE / Europe - Hepatitis C (chronic) - sofosbuvir and velpatasvir [ID921] - (09/23/16)
     
  2417. NYS HCV DURB Hearing Sept 15 2016 - (09/23/16)
     
  2418. New perspectives for preventing hepatitis C virus liver graft infection / Entry Inhibitors - (09/22/16)
     
  2419. HCV reinfection incidence [high in Europe] and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe - (09/22/16)
     
  2420. Comparison of Hepatitis C Treatment Costs - (09/22/16)
     
  2421. ACLU Files Class Action Lawsuit Against Colorado Medicaid Over Unlawful Hepatitis C Treatment Restrictions - (09/19/16)
     
  2422. Updated AASLD/IDSA HCV Guidelines - (09/19/16)
     
  2423. IWCADRH: Future challenges for clinical care of an ageing population infected with HIV: a "geriatric-HIV" modelling study - [Healthcare Costs].... Very Sobering Analysis go Aging in HIV+....60% frail - (09/15/16)
     
  2424. United Health Expands Hepatitis C Drug Coverage to Settle National Class Action - (09/15/16)
     
  2425. Women & HCV - Screen & Treat Early / Screen Pregnant Women to Prevent Transmission to Children / Women & HCV in Philadelphia / Vertical Transmission in Kentucky Up 200% & Nationally Up 68%.... public health policies needed - (09/14/16)
     
  2426. Veterans: barriers to care - stigma, drug abuse - HCV Screening Rate 51%, HCV RNA Positivity 5.4%, 8.1% HCV Antibody Positivity vs HCV RNA in general population of 2.4% - (09/14/16)
     
  2427. HCV Treatment In Prisons / Drug Users - Good Opportunity to Treat & to Elimnate HCV - (09/14/16)
     
  2428. NICE /EU Issues Guidance Recommending Zepatier - (09/14/16)
     
  2429. HCV Treatment IS AS Effective For Drug Users / Drug Users Should Have Equal Access to Treatment - (09/13/16)
     
  2430. Drug Users Should Have Access to New Hepatitis C Therapies or Disease Won't Be Eradicated, Experts Say - (09/13/16)
     
  2431. Achillion Announces 100% SVR Reported in Janssen's Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCV - (09/13/16)
     
  2432. VA estimates 107,000 vets have undiagnosed or untreated hepatitis C.... - (09/07/16)
     
  2433. The Economic and Clinical Burden of Non-alcoholic Fatty Liver Disease (NAFLD) in the United States and Europe - (09/07/16)
     
  2434. Evaluation of Proton Pump Inhibitor Use on Treatment Outcomes with Ledipasvir and Sofosbuvir in a Real-World Cohort Study - (09/07/16)
     
  2435. Colorado Expands HCV HCV Frmulary Coverage - Colorado Department of Health Care Policy and Financing Preferred Drug List (PDL) - Effective October 1, 2016 - (09/07/16)
     
  2436. New HCV Drugs - Helicase Inhibitor - Cocrystal Pharma - (09/07/16)
     
  2437. Hepatocellular Carcinoma and Viral Hepatitis in New York City - (09/07/16)
     
  2438. CDC - 23-27% with HCV Have Advanced Fibrosis or Cirrhosis - The Burden of Hepatitis C Infection-Related Liver Fibrosis in the United States - (09/07/16)
     
  2439. HCV Treatment IS AS Effective For Drug Users / Drug Users Should Have Equal Access to Treatment - (09/09/16)
     
  2440. Transmission of HCV NS5A Inhibitor-Resistant Variants Among HIV-Infected Men Who Have Sex With Men - (09/06/16)
     
  2441. Reasons for missed appointments with a hepatitis C outreach clinic: a qualitative study - (09/06/16)
     
  2442. Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study - (09/06/16)
     
  2443. Epclusa / Patients on OST-Equally Effective 96% SVR - Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of Phase 3 ASTRAL trials - (09/06/16)
     
  2444. Harvoni Equally Effective in Patients Receiving Opoid Substitution [OST] AND Illicit Drug Users on OST - Phase 3 ION Trials - (09/02/16)
     
  2445. HCV Resistance, DAA Failures, and Other difficult situations - Excerpts - (09/02/16)
     
  2446. Trek's HCV DAAs - MIV-802 / TD-6450 - (09/02/16)
     
  2447. Trek Therapeutics buys rights to Medivir's hep C candidate MIV-802 - (09/02/16)
     
  2448. Georgia Launches New National Strategy to Eliminate Hepatitis C - (09/02/16)
     
  2449. ACLU threatens to sue Colorado over hepatitis C drug restrictions - (09/02/16)
     
  2450. CDC: Hepatitis C Kills More Americans than Any Other Infectious Disease - (08/15/16)
     
  2451. The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma - (08/15/16)
     
  2452. VA Extends New Hepatitis C Drugs to All Veterans in Its Health System - (08/15/16)
     
  2453. Disparities in hepatitis C testing in U.S. veterans born 1945-1965.....(51%) had HCV testing with 8.1% HCV antibody and 5.4% RNA positive. - (08/15/16)
     
  2454. Epclusa PI - FDA product insert - (08/15/16)
     
  2455. Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming? - (08/12/16)
     
  2456. Hepatitis skyrockets in Ky women, drugs blamed......"strongly recommends all pregnant women be tested and everyone get educated about the disease" - (08/12/16)
     
  2457. The Rhode Island Department of Health (RIDOH) and the Rhode Island Public Health Institute (RIPHI) announced Thursday in a new report that there has been a significant increase in Hepatitis C virus-related hospitalizations and deaths in Rhode Island. - (08/12/16)
     
  2458. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial - (08/10/16)
     
  2459. Cocrystal Pharma Updates New HCV Drugs Development - - (08/10/16)
     
  2460. 3rd International HIV/Viral Hepatitis Co-Infection Meeting HIV/Viral Hepatitis: Improving Diagnosis, Antiviral Therapy and Access 17 July 2016, Durban, South Africa - (08/10/16)
     
  2461. IAC: Rapidly falling costs for new hepatitis C direct-acting antivirals (DAAs): potential for universal access - (08/03/16)
     
  2462. IAC: Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study - (08/03/16)
     
  2463. IAC: TURQUOISE-I Part 2: safety and efficacy of ombitasvir + paritaprevir/r ï dasabuvir with or without RBV in patients with HIV-1 and HCV GT1 or GT4 co-infection - (08/03/16)
     
  2464. European Commission Grants Marketing Authorisation for MSD's ZEPATIER™ (elbasvir/grazoprevir) for the Treatment of Chronic Hepatitis C Infection - (08/01/16)
     
  2465. Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution - (08/01/16)
     
  2466. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution - (08/01/16)
     
  2467. Urgent action to fight hepatitis C in people who inject drugs in Europe..... - (07/27/16)
     
  2468. Is Europe ready to eliminate viral hepatitis? Is the US ready to eliminate HCV? - (07/27/16)
     
  2469. IAC: Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study - (07/26/16)
     
  2470. CDC, Severe Increase in for mother-to-child transmission of HCV - (07/26/16)
     
  2471. AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C - (07/26/16)
     
  2472. CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A) - (07/25/16)
     
  2473. IAC: HCV Coinfection Not Tied to Higher HIV Load in Meta-Analysis - Mark Mascolini - (07/22/16)
     
  2474. IAC: TURQUOISE-I Part 2: safety and efficacy of ombitasvir + paritaprevir/r ï dasabuvir with or without RBV in patients with HIV-1 and HCV GT1 or GT4 co-infection - (07/20/16)
     
  2475. IAC: Drug-Drug Interactions Studies between HCV Antivirals Sofosbuvir/Velpatasvir and HIV Antiretrovirals in Healthy Volunteers - (07/20/16)
     
  2476. IAC: Sofosbuvir/Velpatasvir Yields 95% SVR12 in Patients With HCV/HIV - Mark Mascolini - (07/20/16)
     
  2477. IAC: Drug-Drug Interactions Studies between HCV Antivirals Sofosbuvir/Velpatasvir and HIV Antiretrovirals in Healthy Volunteers-2 - Mark Mascolini - (07/20/16)
     
  2478. Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance - (07/19/16)
     
  2479. Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients - (07/18/16)
     
  2480. Lack of Evidence of Recurrent HCC After SVR: "we focused on HCC patients who underwent curative procedures before DAA treatment" - (07/18/16)
     
  2481. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees - (07/15/16)
     
  2482. Gilead receives approval in Canada for EPCLUSA™ (sofosbuvir/velpatasvir), the first once-daily pan-genotypic (genotypes 1-6) single tablet regimen for the treatment of chronic hepatitis C - (07/11/16)
     
  2483. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment with Ledipasvir and Sofosbuvir - (07/11/16)
     
  2484. Epclusa European Commission - SUMMARY OF PRODUCT CHARACTERISTICS  - (07/11/16)
     
  2485. New Obama Medical Project - Genetics, not HCV - (07/10/16)
     
  2486. European Commission Grants Marketing Authorization for Gilead's Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C - (07/10/16)
     
  2487. HCV Drives Increased Mortality to Ranking of 7th Globally in US, Europe, Russia, Australia, Central/South America/North Africa....."a greater proportion of mortality in Europe, the Middle East, the Americas, and north Africa is attributed to HCV than to HBV" - (07/10/16)
     
  2488. The Medicines Patent Pool Signs New Round of Generic Manufacturing Licences for HIV and Hepatitis C Treatments - (07/10/16)
     
  2489. HCV Guidelines Update July 6 2016 - (07/07/16)
     
  2490. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013..... - (07/07/16)
     
  2491. SOF/velpatasvir DDIs - (07/06/16)
     
  2492. Sof/Velpatasvir in India - (07/06/16)
     
  2493. Hold middlemen's feet to the fire to cauterize specialty drug spending - (07/06/16)
     
  2494. Massachusetts Cuts Deal with Drugmakers to Pay for HCV Drugs: "enhance access/lifting restrictions" - (07/01/16)
     
  2495. Letter to Providers: Mass Director of Pharmacy Referred HCV Drugs - (07/01/16)
     
  2496. Global Distribution & Prevalence of HCV Genotypes - (07/01/16)
     
  2497. Sofosbuvir/Velpatasvir - (07/01/16)
     
  2498. Gilead [BMS too] and Massachusetts agree to rebates for hep C drugs - (07/01/16)
     
  2499. Pharm: Pharmacokinetics of Darunavir, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin in Adults Infected with Hepatitis C Virus (HCV) Genotype 1 and Human Immunodeficiency Virus (HIV) - (06/29/16)
     
  2500. Regulus Reports Clinical Hold of RG-101 - (06/29/16)
     
  2501. UNRESTRICTED MEDICAID ACCESS TO NOVEL HEPATITIS C THERAPIES MAY REDUCE OVERALL COSTS, IMPROVE OUTCOMES - (06/29/16)
     
  2502. Sofosbuvir/Valpatasvir FDA Product Label - (06/29/16)
     
  2503. FDA approves Epclusa for treatment of chronic Hepatitis C virus infection - (06/29/16)
     
  2504. U.S. Food and Drug Administration Approves Gilead's Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C - (06/29/16)
     
  2505. DDW:Cost per Sustained Virological Response 4 (SVR 4) in Genotype 1 Patients Treated With Sofosbuvir and Ledipasvir With and Without Ribavirin. A Detailed Cost-Mapping Study - (06/08/16)
     
  2506. HIV & HCV Highlights from Recent Conferences: ASM/ICAAC - Pharmacology Workshop - DDW New HIV & HCV Drugs / Inflammation-Heart Disease-Statin, TDF PrEP new studies / Cabotegravir Update: Long-Acting Treatment & Prevention / CMV-Aging - (06/27/16)
     
  2507. Pharm: The 17th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy Report by Courtney Fletcher, PharmD/Jennifer Kiser, PharmD - (06/27/16)
     
  2508. Florida Blue Settles Lawsuit by Covering Hepatitis C Drug - (06/23/16)
     
  2509. Florida Blue To Provide Costly Hep C Drug After Lawsuits - (06/23/16)
     
  2510. Health Department Highlights New Preliminary Data on Hepatitis B and C in Recognition of Hepatitis Awareness Month - press release May 16 2016 from NYC DOH / NYC Project INSPIRE - (06/22/16)
     
  2511. Enanta Pharmaceuticals Initiates Proof-of-Concept Study with Pan-genotypic Cyclophilin Inhibitor EDP-494 in Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Virus - (06/21/16)
     
  2512. New Florida Medicaid FFS Formulary After Threatened Lawsuit - (06/21/16)
     
  2513. Delaware HCV Medicaid Prior Authorization Forms After Threatened Lawsuit Regarding Restrictions. - (06/21/16)
     
  2514. HCV CDC Grant Opportunity - (06/21/16)
     
  2515. DAAs /Restrictions-Denials - New Article: Cost Pushback Limiting Hepatitis C Drug Utilization - (06/20/16)
     
  2516. Pharm: No Clinically Significant Interaction of MK-3682 With the HIV Medications Dolutegravir, Raltegravir, Rilpivirine, and Tenofovir Disoproxil Fumarate - (06/17/16)
     
  2517. Pharm: No Clinically Significant Interaction of MK-8408 With the HIV Medications Dolutegravir, Raltegravir, Rilpivirine, and Tenofovir Disoproxil Fumarate - (06/16/16)
     
  2518. Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma - (06/17/16)
     
  2519. Pharm: Efficacy of once-weekly MK-8591 in SIV infected rhesus macaques - (06/17/16)
     
  2520. Pharm: Rifampin (RIF) Decreases Cabotegravir (CAB) Exposure following Oral Coadministration - (06/17/16)
     
  2521. Pharm: Pharmacokinetics and Exploratory Interactions of HIV Maturation Inhibitor BMS-955176 in Healthy Subjects: Single- and Multiple-Ascending Dose Studies - (06/17/16)
     
  2522. Pharm: Open-Label, Drug-Drug Interaction Study between Second-generation HIV-1 Maturation Inhibitor BMS-955176 and Tenofovir in Healthy Subjects - (06/17/16)
     
  2523. Pharm: Open-Label, Drug-Drug Interaction Study between HIV-1 Attachment Inhibitor BMS-663068 and Maraviroc in Healthy Subjects - (06/17/16)
     
  2524. Pharm: Pharmacokinetics, safety and efficacy of atazanavir, dolutegravir and lamivudine as maintenance regimen in HIV-infected patients: a pilot study - (06/17/16)
     
  2525. SVR Reduces Comorbidities; IDUs Have Greater Immune Activation & Thus are at Greater Risk for Comorbidities & All-Cause Death, and of course HCV & HIV+ are at double the risk - (06/16/16)
     
  2526. CDC HCV Grant Opportunity: hepatitis screening, linkage-to-care - (06/16/15)
     
  2527. Pharm: MK-3682, a HCV NS5B Inhibitor with a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotypes -1,-2, and -3 HCV-Infected Patients - (06/16/16)
     
  2528. Pharm: Coadministration of ZEPATIER™ (Grazoprevir/Elbasvir) With Tenofovir Disoproxil Fumarate Resulted in No Clinically Meaningful Drug-Drug Interaction in Healthy Subjects - (06/16/16)
     
  2529. Pharm: Lack of an Effect of Ledipasvir on CYP3A Activity in Healthy Volunteers - (06/16/16)
     
  2530. Pharm: Population Pharmacokinetic Analysis of Velpatasvir, a Pangenotypic HCV NS5A Inhibitor,in Healthy and Hepatitis C Virus-Infected Subjects - (06/16/16)
     
  2531. SVR - Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension - (06/15/16)
     
  2532. Washington State HCV Formulary After Federal Court Order - (06/15/16)
     
  2533. Pharm: Clinical, biological and Pharmacological relevance of Ledipasvir/Sofosbuvir drug interaction with TDF containing Regimen in HCV/HIV co-infected patients. - (06/14/16)
     
  2534. Pharm: A CLINICALLY MEANINGFUL DRUG-DRUG INTERACTION OBSERVED BETWEEN ZEPATIERTM (GRAZOPREVIR/ELBASVIR) AND STRIBILD® HIV FIXED-DOSE COMBINATION IN HEALTHY SUBJECTS - (06/14/16)
     
  2535. Pharm: Clinical, biological and Pharmacological relevance of Ledipasvir/Sofosbuvir drug interaction with TDF containing Regimen in HCV/HIV co-infected patients. - (06/14/16)
     
  2536. Pharm: LEDIPASVIR/SOFOSBUVIR and TENOFOVIR in HIV-HCV co-infected PATIENTS: IMPACT on TENOFOVIR Ctrough and RENAL SAFETY - (06/14/16)
     
  2537. HHS Bill flat funds HCV.........prioritizes screening, minorities - (06/13/16)
     
  2538. Pharm: NS5B HCV Inhibitor Strong in 7-Day Monotherapy Trial - Mark Mascolini - (06/13/16)
     
  2539. Pharm: High risk on drug-drug interactions during hepatitis C treatment: a nationwide cohort - (06/13/16)
     
  2540. Pharm: Phosphoramidate prodrugs of uridine analogs, including sofosbuvir, are metabolized to both uridine and cytidine triphosphates in Huh7 cells and primary human hepatocytes - (06/13/16)
     
  2541. Pharm: High risk on drug-drug interactions during hepatitis C treatment: a nationwide cohort - (06/13/16)
     
  2542. Pharm: Increased Tenofovir Diphosphate in Cells, but Not Tenofovir in Plasma, with Sofosbuvir and Ribavirin - (06/10/16)
     
  2543. Pharm: Evaluation of Drug-Drug Interaction Between Sofosbuvir/Velpatasvir and Rifaximin in HCV-Infected Subjects with Moderate Hepatic Impairment - (06/10/16)
     
  2544. Pharm: Effect of daclatasvir/asunaprevir/beclabuvir in fixed-dose combination on the pharmacokinetics of CYP450/ transporter substrates in healthy subjects - (06/10/16)
     
  2545. DDW:Integrated Analysis Of Studies Evaluating The Treatment of Chronic Hepatitis C Genotype 4 With Interferon-Free Sofosbuvir-Based Regimens - (06/08/16)
     
  2546. DDW:High Efficacy of Ledipasvir/Sofosbuvir Plus Ribavirin Among Patients With Decompensated Cirrhosis Who Underwent Liver Transplant During Participation in the SOLAR-1 and SOLAR-2 Studies - (06/08/16)
     
  2547. DDW:The Tolerability of Sof/VEL for 12 Weeks in >1000 Patients Treated in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies: An Integrated Safety Analysis - (06/08/16)
     
  2548. The Need to Expand Access to Hepatitis C Virus Drugs in the Indian Health Service - (06/08/16)
     
  2549. SOLAR-2: the sun also rises for cirrhotics - Comment - (06/08/16)
     
  2550. Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-naïve or Previously Treated Patients with HCV Genotype 1 or 3 Infections - (06/08/16)
     
  2551. Zepatier - (06/07/16)
     
  2552. Sofosbuvir/velpatasvir - (06/07/16)
     
  2553. DDW:Baseline Clinical and Laboratory Parameters Associated With Clinical Benefits of Successful HCV Treatment With Sofosbuvir/Velpatasvir in Decompensated Cirrhotic Patients - (06/06/16)
     
  2554. DDW:Sofosbuvir/Velpatasvir for 12 Weeks Results in High SVR12 Rates in Patients With Negative Predictors of Response to Treatment: an Integrated Analysis of Efficacy From the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies - (06/06/16)
     
  2555. DDW:Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Weeks in Genotype 1 Treatment-Naïve Non-Cirrhotic Patients with HCV Viral load <6 million IU/ml; A Comparative Analysis of the Phase-3 ION-3 Data to Real World Effectiveness - (06/06/16)
     
  2556. DDW:Real World Effectiveness of Ledipasvir/Sofosbuvir in Treatment-Experienced Cirrhotic Genotype 1 Patients with Chronic HCV: A Comparative Analysis of Gilead Sponsored Trials with 4 Real-World Cohorts - (06/06/16)
     
  2557. Baseline HCV NS5A Resistance / Retreatment - (06/02/16)
     
  2558. French Govt Announces Universal HCV Drug Access Plan - (06/02/16)
     
  2559. New Medicaid Changes to Restrictions - (06/01/16)
     
  2560. Sofosbuvir+Valpatasvir FDA Approval is expected.... - (06/01/16)
     
  2561. EASL: Summary from EASL 2016 for Hepatitis C Highly efficacious pan-genotypic DAA combinations on their way: the last gaps in difficult-to-treat patient populations are going to be closed soon. - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany Correspondence: Prof. Dr. J.K. Rockstroh Department of Medicine I University of Bonn Sigmund-Freud-Str. 25 53105 Bonn Germany - (06/01/16)
     
  2562. EASL: HCV DAAs Resistance / New HCV Drugs - Direct antiviral combination treatment according to presence of baseline RAVs in NS3, NS5A and NS5B leads to high SVR rates in non-cirrhotic and cirrhotic genotype 1 infected patients - (05/31/16)
     
  2563. EASL: A NOVEL TASK SHIFTING MODEL TO EXPAND THE HCV CARE CONTINUUM: THE ASCEND INVESTIGATION - (05/31/16)
     
  2564. EASL: EFFECTIVENESS AND SAFETY OF DAA COMBINATION THERAPIES FOR TREATMENT OF HCV IN ELDERLY PATIENTS (>70 YRS.): RESULTS FROM THE GERMAN HEPATITIS C-REGISTRY (DHC-R) - (05/31/16)
     
  2565. News Coverage: Fed Judge Orders Restriction Removal in Washington State - (05/31/16)
     
  2566. Lawsuit Successful in Washington State to Remove HCV Restrictions: federal district court Judge Orders State Medicaid to Cover HCV Drugs - (05/31/16)
     
  2567. EASL: Six weeks of sofosbuvir/ledipasvir (SOF/LDV) are sufficient to treat acute hepatitis C virus genotype 1 monoinfection: The HepNet Acute HCV IV Study - (05/27/16)
     
  2568. Zepatier - ELBASVIR/GRAZOPREVIR FDA Package Insert - (05/27/16)
     
  2569. Renal Conf: ELBASVIR/GRAZOPREVIR TREATMENT OF HCV INFECTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 4/5: CLINICAL, VIROLOGIC, AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN THE C-SURFER STUDY - (05/27/16)
     
  2570. DDW: Failure with All-oral DAA Regimens: Real-World Experience from the Trio Network - (05/27/16)
     
  2571. EASL: Retreatment of Patients who failed DAA-Combination Therapies: Real-World Experience from a Large Hepatitis C Resistance Database - (05/27/16)
     
  2572. European CHMP Adopts Positive Opinion for Gilead's Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C - (05/27/16)
     
  2573. Merck Receives Positive CHMP Opinion for ZEPATIER™ (elbasvir and grazoprevir) in the European Union - (05/27/16)
     
  2574. DDW: HIGH SVR RATES WITH THE COMBINATION OF ABT-493 + ABT-530 FOR 8 WEEKS IN NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1 OR 2 INFECTION - (05/26/16)
     
  2575. DDW: SURVEYOR-I: 100% SVR12 AND FAVORABLE SAFETY OF ABT-493 + ABT-530 ADMINISTERED FOR 12 WEEKS IN NON-CIRRHOTIC PATIENTS WITH GENOTYPES 4, 5, OR 6 INFECTION - (05/26/16)
     
  2576. DDW: DDW/2016: Access to Therapy in Era of All DAA Regimens: Real World Experience from the TRIO Network - (05/26/16)
     
  2577. DDW: DDW/2016: Ledipasvir/Sofosbuvir+/-Ribavirin in Patients Co-infected with HCV and HIV: Real-world Heterogeneous Population from the TRIO Network - Academic and community treatment of a real-world, heterogeneous population - (05/26/16)
     
  2578. DDW: DDW/2016: A New Digital Health Feedback Offering to Keep Patients Adherent to Oral Hepatitis C Therapy - (05/26/16)
     
  2579. DDW: DDW/2016: Barriers to [Veterans] Hepatitis C Treatment in the DAA era - (05/26/16)
     
  2580. DDW: QUARTZ-I: OMBITASVIR/PARITAPREVIR/R, DASABUVIR, AND SOFOSBUVIR TREATMENT OF PATIENTS WITH HCV GENOTYPE 1-INFECTION WHO FAILED A PRIOR COURSE OF DAA THERAPY - (05/26/16)
     
  2581. DDW: DDW/2016: Factors Affecting Approval Rates of Direct Acting Antivirals (DAA) for Hepatitis C Infection: A Single Center Experience - (05/25/16)
     
  2582. DDW 5/2016: Trends in Health Care Utilization for Hepatitis C Virus Infection in the United States: "HCV related Cirrhosis and HCC increased significantly..... Hepatitis C related hospitalizations and associated are increasing over the past 15 years" - (05/24/16)
     
  2583. DDW/5-2016: Development of a Community-Based Testing (San Diego), Linkage, and Hepatitis C Treatment Program: ....."high prevalence of HCV exposure (20%) and chronic HCV (14%).....Less than half of HCV Ab+ patients had insurance coverage .....SVR12 rates were comparable to large 'real world cohorts'..." - (05/24/16)
     
  2584. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen - (05/23/16)
     
  2585. NYS DURB Webcast: Medicaid Pharmacy Prior Authorization Program Updates - (05/23/16)
     
  2586. HCV Highlights / EASL - (05/23/16)
     
  2587. NYS Medicaid Pharmacy Prior Authorization Program Updates - (05/20/16)
     
  2588. EASL: Daclatasvir+SOF at EASL 2016 - (05/18/16)
     
  2589. EASL: Pharmacokinetics, Safety, and Tolerability of Next Generation Direct Acting Antivirals ABT-493 and ABT-530 in Subjects with Renal Impairment - (05/18/16)
     
  2590. Streamlining Screening to Treatment: The Hepatitis C Cascade of Care at Kaiser Permanente Mid-Atlantic States - (05/18/16)
     
  2591. Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV - Letter to the Editor - (05/18/16)
     
  2592. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis; Direct acting antivirals for decompensated cirrhosis. Efficacy and safety are now established - Editorial - (05/18/16)
     
  2593. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.... Treated hepatitis C virus (HCV) cirrhotic patients can have normal life expectancy - (05/18/16)
     
  2594. The increasing burden of nonalcoholic fatty liver disease among young adults in the United States: A growing epidemic - (05/18/16)
     
  2595. Neurodegeneration and Ageing in the HAART Era....... - (05/18/16)
     
  2596. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+) - (05/18/16)
     
  2597. EASL: Pharmacokinetics, Safety, and Tolerability of Next Generation Direct Acting Antivirals ABT-493 and ABT-530 in Subjects with Hepatic Impairment - (05/10/16)
     
  2598. Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) or AL-335 and ODV in the Treatment of Chronic Hepatitis C Infection - new phase 2 study - (05/10/16)
     
  2599. Janssen readies mid-stage study of short duration HCV combo regimen for genotypes 1-6 - (05/10/16)
     
  2600. Hepatitis C is Killing Americans in Record Numbers while Patients Cannot Access Life Saving Medicine - (05/10/16)
     
  2601. Association of Hepatitis C Virus With Alcohol Use Among U.S. Adults: NHANES 2003-2010, CDC - (05/10/16)
     
  2602. High HCV Reinfection Rates Reported in HIV+, MSM (25%), IDUs at EASL: multiple reinfections reported - (05/10/16)
     
  2603. FDA Draft Guidance May 2016 - Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs for Treatment Guidance for Industry - (05/10/16)
     
  2604. Neurodegeneration and Ageing in the HAART Era....... - (05/10/16)
     
  2605. Cocoa Flavanols Improve the Brain ? - (05/10/16)
     
  2606. EASL: ABT-493 AND ABT-530 COMBINATION DEMONSTRATED MINIMAL POTENTIAL FOR CYP-MEDIATED DRUG-DRUG INTERACTIONS - (05/10/16)
     
  2607. CDC - "acute HCV infection increased more than 2.5 times from 2010-2014 - (05/09/16)
     
  2608. Increasing prevalence of cirrhosis among U.S. adults aware or unaware of their chronic hepatitis C virus infection...17% 2012 - (05/09/16)
     
  2609. Hepatitis C reinfection after sustained virological response/PWID....Sweden, Norway and Denmark (NORTH-C) - (05/09/16)
     
  2610. EASL: Sustained Virologic Response Predicts Fibrosis Regression Measured by FibroTest in HCV-Infected Patients - 'Earliest Treatment Provides Most Regression' *** - (05/09/16)
     
  2611. EASL: Reductions in Lifetime Risks of Liver-Related Morbidity and Mortality Associated with Novel Direct-Acting Antiviral Regimens Recommended for Treating Genotype 4 Non-Cirrhotic Hepatitis C Patients in the United States - (05/09/16)
     
  2612. EASL: Improvement in Markers of Liver Fibrosis and Function in HCV Genotype 4-Infected Patients With Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/Ritonavir With Ribavirin (AGATE-I) - (05/09/16)
     
  2613. EASL: HIV Coinfection Impairs the Response to DAA-based HCV Therapy - (05/09/16)
     
  2614. EASL: Improvement in Markers of Liver Fibrosis and Function in HCV Genotype 4-Infected Patients With Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/Ritonavir With Ribavirin (AGATE-I) - (05/09/16)
     
  2615. EASL: HIV Coinfection Impairs the Response to DAA-based HCV Therapy - (05/09/16)
     
  2616. EASL: DAA-induced HCV clearance does not restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C.... from Jules: is HCC recurrence associated with lack of benefit associated with Interferon-based therapy? and cytokine response? - (05/09/16)
     
  2617. EASL: Decreasing incidence of cancer after liver transplantation - A Nordic population-based study - (05/09/16)
     
  2618. Viral hepatitis: HCV compartmentalization in HCC: driver, passenger or both? - Diminished viral replication and compartmentalization of hepatitis C virus in hepatocellular carcinoma tissue - (05/06/16)
     
  2619. J&J HCV Update: AL335+ACH3102+Simeprevir Phase 2 Study - (05/06/16)
     
  2620. Cocrystal Pharma Receives Health Canada Approval to Conduct Phase I Clinical Study for CC-31244 in Healthy and HCV-Infected Subjects - (05/06/16)
     
  2621. AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirrhosis - (05/06/16)
     
  2622. Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy Review - (05/06/16)
     
  2623. Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy Review - (05/06/16)
     
  2624. NYS Report HCV Testing Law Evaluation Report Jan 2016, excerpts listed below, pdf attached - (05/06/16)
     
  2625. Association Between Hepatitis C Virus and Head and Neck Cancers - (05/06/16)
     
  2626. Evaluation of the Centers for Disease Control and Prevention Recommendations for Hepatitis C Virus Testing in an Urban Emergency Department......CDC Guidelines miss 25% with HCV - (05/06/16)
     
  2627. Bristol-Myers Squibb to Support AmeriCares and the Clinton Health Access Initiative, Inc. in a New Program Aimed at Treating Patients Co-infected with Hepatitis C and HIV - (05/06/16)
     
  2628. EASL: The effect of sofosbuvir containing regimens in patients with HCV genotype 3 - A Scandinavian real-life experience. [effect of cirrhosis/CP-A/B/C - (05/05/16)
     
  2629. EASL: The presence of diabetes mellitus is a strong risk factor for hepatocellular carcinoma in hepatitis C infected patients with advanced fibrosis or cirrhosis who have achieved sustained virological response. - (05/05/16)
     
  2630. EASL: PREVALENCE AND CLINICAL IMPORTANCE OF HEPATITIS C VIRUS GENOTYPE 2K/1B CHIMERAS - (05/05/16)
     
  2631. EASL: EFFECTIVENESS AND SAFETY OF OMBITASVIR, PARITAPREVIR, RITONAVIR AND DASABUVIR PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C VIRUS INFECTION: RESULTS FROM THE SPANISH REAL WORLD COHORT - (05/05/16)
     
  2632. EASL: ABT-493 + ABT-530 at EASL - (05/05/16)
     
  2633. EASL: Sofosbuvir / Velpatasvir.... + GS-9857 - (05/05/16)
     
  2634. EASL: Newest HCV Drugs at EASL - (05/05/16)
     
  2635. EASL: Analysis of HCV Genotype 2 and 3 Variants in Patients Treated With Combination Therapy of Next Generation HCV Direct-Acting Antiviral Agents ABT-493 and ABT-530 - (05/05/16)
     
  2636. EASL: Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without ribavirin, in adults treated with the regimen approved in Australia, Canada, New Zealand and Switzerland .....Global Cohorts/ABT493+ABT530 - (05/05/16)
     
  2637. EASL: Efficacy and Safety of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir Without Ribavirin in Patients with HCV Genotype 1b With or Without Compensated Cirrhosis: Pooled Analysis Across 5 Clinical Trials - (05/05/16)
     
  2638. EASL: Sustained Virologic Response to Daclatasvir and Sofosbuvir, With or Without Ribavirin, Among Patients in the French Daclatasvir ATU programme Infected With HCV Genotypes 4, 5 and 6 - (05/02/16)
     
  2639. EASL: Effectiveness of Daclatasvir-Based Therapy in Patients With Chronic Hepatitis C in Europe: Experience From the Named Patient Program - (05/02/16)
     
  2640. EASL: Factors Impacting SVR12 for Patients With Advanced Cirrhosis Receiving Daclatasvir and Sofosbuvir With Ribavirin in the ALLY-1 Study - (05/02/16)
     
  2641. EASL: Pharmacokinetic Analyses of Ledipasvir/Sofosbuvir in HCV-Infected Subjects With Advanced Liver Disease and/or Following Liver Transplantation - (05/02/16)
     
  2642. EASL: Ledipasvir/Sofosbuvir With Ribavirin for 12 Weeks Is Effective and Safe in Treatment-Naïve Genotype 3 HCV-Infected Patients in Canada - (05/02/16)
     
  2643. EASL: On-Treatment Illicit Drug Use Did Not Impact Treatment Outcome During Therapy With Ledipasvir/Sofosbuvir With or Without Ribavirin in the Phase 3 ION-1 Study - (04/29/16)
     
  2644. EASL: An Integrated Safety and Efficacy Analysis of Sofosbuvir-Based Regimens in Patients With Hereditary Bleeding Disorders - (04/29/16)
     
  2645. EASL: Final SVR24 Data from the Phase 3 C-EDGE Treatment-Naïve Study of Elbasvir/Grazoprevir in Patients With Chronic HCV Genotype 1, 4, or 6 Infection - (04/29/16)
     
  2646. EASL: EUROPEAN RAVS DATABASE: FREQUENCY AND CHARACTERISTICS OF RAVS IN TREATMENT-NAïVE AND DAA-EXPERIENCED PATIENTS - (04/29/16)
     
  2647. EASL: OMBITASVIR/PARITAPREVIR/R, DASABUVIR, AND SOFOSBUVIR TREATMENT OF PATIENTS WITH HCV GENOTYPE 1-INFECTION WHO FAILED A PRIOR COURSE OF DAA THERAPY: THE QUARTZ-I STUDY....95-100% SVR - (04/29/16)
     
  2648. EASL: C-SWIFT RETREATMENT FINAL RESULTS: HIGHLY SUCCESSFUL RETREATMENT OF GT1-INFECTED PATIENTS WITH 12 WEEKS OF ELBASVIR/GRAZOPREVIR PLUS SOFOSBUVIR AND RIBAVIRIN AFTER FAILURE OF SHORT-DURATION ALL-ORAL THERAPY - (04/29/16)
     
  2649. EASL: C-EDGE CO-STAR: Favorable Impact of Elbasvir and Grazoprevir on Health-Related Quality of Life in Treatment-Naïve HCV-Infected Persons Who Inject Drugs Receiving Opioid Agonist Therapy - (04/28/16)
     
  2650. EASL: C-EDGE CO-STAR: Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 12 Weeks in HCV-infected Persons Who Inject Drugs on Opioid Agonist Therapy - (04/28/16)
     
  2651. EASL: An Integrated Safety and Efficacy Analysis of Sofosbuvir-Based Regimens in Patients With Hereditary Bleeding Disorders - (04/28/16)
     
  2652. EASL: C-EDGE IBLD: Efficacy and Safety of Elbasvir/Grazoprevir in Patients With Chronic Hepatitis C Virus Infection and Inherited Blood Disorders - (04/28/16)
     
  2653. EASL: The Additional Impact of Chronic Kidney Disease on Cardiovascular Outcomes and Death Among HCV Patients - (04/28/16)
     
  2654. EASL: BASELINE CLINICAL AND LABORATORY PARAMETERS ASSOCIATED WITH CLINICAL BENEFITS OF SUCCESSFUL HCVTREATMENT WITH SOFOSBUVIR/VELPATASVIR IN DECOMPENSATED CIRRHOTIC PATIENTS - (04/27/16)
     
  2655. EASL: LEDIPASVIR/SOFOSBUVIR+/-RIBAVIRIN IN HCV POST-TRANSPLANT PATIENTS: REAL-WORLD HETEROGENEOUS POPULATION FROM THE TRIO NETWORK - (04/27/16)
     
  2656. EASL: HCV ERADICATION RESULTS IN REDUCTION OF HEPATIC VENOUS PRESSURE GRADIENT 48 WEEKS AFTER END OF TREATMENT; FINAL RESULTS OF THE STUDY OF SOFOSBUVIR PLUS RIBAVIRIN IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION - (04/27/16)
     
  2657. EASL: Cost-Effectiveness of Elbasvir (EBR, MK-8742)/Grazoprevir (GZR, MK-5172) Use in Treatment-Naïve and Treatment-Experienced Patients with Hepatitis C Virus (HCV) Genotype 1 Infection and Chronic Kidney Disease (CKD) in the Unites States - (04/27/16)
     
  2658. EASL: CHARACTERISTICS AND PREVALENCE OF CHRONIC KIDNEY DISEASE AMONG PATIENTS WITH HEPATITIS C WHO ARE TREATED WITH INTERFERON-FREE DIRECT-ACTING ANTIVIRAL REGIMENS - (04/27/16)
     
  2659. EASL: ANALYSIS OF THE IMPACT OF HIV CO-INFECTION ON HEPATITIS C TREATMENT EFFECTIVENESS FOR PATIENTS USING NEW DIRECT-ACTING ANTIVIRALS - (04/27/16)
     
  2660. EASL: ANALYSIS OF THE REAL-WORLD EFFECTIVENESS OF DIRECT ACTING ANTIVIRAL TREATMENTS FOR HEPATITIS C IN A LARGE POPULATION - (04/27/16)
     
  2661. EASL: EFFECTIVENESS AND SAFETY OF SOFOSBUVIR/LEDIPASVIR TREATMENT FOR MONOINFECTED GENOTYPE 1 HCV PATIENTS IN REAL-LIFE CLINICAL PRACTICE: RESULTS FROM SPANISH HEPA-C COHORT - (04/27/16)
     
  2662. EASL: High sustained virological response rates using generic direct antiviral treatment for Hepatitis C REDEMPTION-1 - (04/27/16)
     
  2663. EASL: The Effect of Sustained Virologic Response on Cerebral Metabolism and Neurocognition in Patients With Chronic Genotype 1 HCV Infection - (04/27/16)
     
  2664. EASL: NVR 3-778, a First-in-class HBV Core Inhibitor, Alone and in Combination with Pegylated-interferon (peg-IFN alpha-2a), in Treatment-naïve HBeAg-positive Patients: Early Reductions in HBV DNA and HBeAg - (04/27/16)
     
  2665. NY AG: "Will do everything to ensure treatment availability so patients can be cured", Lisa Landau's Office did investigation - (04/27/16)
     
  2666. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis - (04/27/16)
     
  2667. New York Insurers to Change Coverage of Hepatitis C Drugs - (04/26/16)
     
  2668. EASL: The Effect of Sustained Virologic Response on Cerebral Metabolism and Neurocognition in Patients With Chronic Genotype 1 HCV Infection - (04/26/16)
     
  2669. EASL: On-Treatment HCV RNA as a Predictor of SVR12 in Patients With Genotype 1-6 HCV Infection Treated With Sofosbuvir/Velpatasvir for 12 Weeks: An Analysis of the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies - (04/26/16)
     
  2670. EASL: Sofosbuvir/Velpatasvir for 12 Weeks in HCV-Infected Patients Previously Treated With Placebo: Results of the Deferred Treatment Study - (04/26/16)
     
  2671. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis - (04/27/16)
     
  2672. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution - (04/27/16)
     
  2673. EASL: Development of Hepatocellular Carcinoma in HCV Cirrhotic Patients Treated with Direct Acting Antivirals - (04/25/16)
     
  2674. EASL: Baseline Clinical and Laboratory Parameters Associated With Clinical Benefits of Successful HCV Treatment With Sofosbuvir/Velpatasvir in Decompensated Cirrhotic Patients - (04/25/16)
     
  2675. EASL: TREATMENT OF HEPATITIS C VIRUS IN PATIENTS WITH ADVANCED CIRRHOSIS: ALWAYS JUSTIFIED? ANALYSIS OF THE HEPA-C REGISTRY - (04/25/16)
     
  2676. EASL: INTERFERON (INF)-FREE ANTIVIRAL THERAPY IN CIRRHOTIC PATIENTS INFECTED WITH HEPATITIS C ON THE WAITING LIST FOR LIVER TRANSPLANTATION. EFFICACY AND IMPACT ON DELISTING AND LIVER FUNCTION - (04/25/16)
     
  2677. EASL: Clinical outcomes in HCV-infected patients treated with direct acting antivirals - 18-month post-treatment follow-up in the French ANRS CO22 HEPATHER Cohort study. - (04/25/16)
     
  2678. EASL: Safety and Efficacy of DAAs in 2432 HCV Patients with advanced Fibrosis: An interim analysis of the Lombardia Regional Network for Viral Hepatitis - (04/25/16)
     
  2679. EASL: UK EAP - Antiviral treatment in patients with advanced HCV cirrhosis using sofosbuvir and ledipasvir/ daclatasvir, with or without ribavirin - outcomes compared to untreated patients and long term outcomes....... ANTIVIRAL TREATMENT IN PATIENTS WITH ADVANCED HCV CIRRHOSIS USING SOFOSBUVIR AND LEDIPASVIR/ DACLATASVIR WITH OR WITHOUT RIBAVIRIN - 6 AND 12 MONTH OUTCOMES COMPARED TO UNTREATED PATIENTS - (04/22/16)
     
  2680. EASL: Short-Duration Treatment With Sofosbuvir/Velpatasvir Plus GS-9857 in Treatment-Naïve Genotype 1-6 HCV-Infected Patients With or Without Cirrhosis - (04/22/16)
     
  2681. EASL: High Efficacy of Ledipasvir/Sofosbuvir Plus Ribavirin Among Patients With Decompensated Cirrhosis Who Underwent Liver Transplant During Participation in the SOLAR-1 and -2 Studies - (04/22/16)
     
  2682. EASL: High SVR Rates in Patients With Genotype 4 Chronic Hepatitis C Infection and Compensated Cirrhosis Treated With Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin (AGATE-I) - (04/22/16)
     
  2683. EASL: Ombitasvir/Paritaprevir/Ritonavir With Ribavirin Achieves High Sustained Virologic Response (SVR) Rates in Egypti an Adults With Chronic HCV Genotype 4 Infection (AGATE-II) - (04/22/16)
     
  2684. EASL: High SVR Rates in Patients With Genotype 4 Chronic Hepatitis C Infection and Compensated Cirrhosis Treated With Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin (AGATE-I) - (04/22/16)
     
  2685. EASL: Impact of direct anti-viral agents on inactivation/de-listing of liver transplant candidates listed for decompensated C cirrhosis: a European study - (04/22/16)
     
  2686. EASL: The Tolerability of Sofosbuvir/Velpatasvir for 12 Weeks in >1000 Patients Treated in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies: An Integrated Safety Analysis - (04/22/16)
     
  2687. EASL: Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Weeks in Genotype 1 Treatment-Naïve Non-Cirrhotic Patients with HCV Viral load (VL) <6 million IU/ml; A Comparative Analysis of the Phase-3 ION-3 Data to Real-World Effectiveness - (04/22/16)
     
  2688. EASL: On-Treatment Illicit Drug Use Did Not Impact Treatment Outcome During Therapy With Ledipasvir/Sofosbuvir With or Without Ribavirin in the Phase 3 ION-1 Study - (04/22/16)
     
  2689. EASL: Sofosbuvir/Velpatasvir for 12 Weeks Is Well Tolerated and Results in High SVR12 Rates in People Receiving Opioid Substitution Therapy - (04/22/16)
     
  2690. EASL: Ledipasvir/Sofosbuvir+/-Ribavirin in Patients Co-infected with HCV and HIV: Real-world Heterogeneous Population from the TRIO Network - (04/21/16)
     
  2691. EASL: FINAL RESULTS OF THE PYRAMID 1 STUDY, A PHASE 3 REGISTRATIONAL TRIAL OF RAVIDASVIR (PPI-668) AND SOFOSBUVIR IN HCV GENOTYPE-4 PATIENTS: HIGH RATES OF SUSTAINED VIRAL CLEARANCE IN CIRRHOTIC AND NON-CIRRHOTIC PATIENTS - (04/21/16)
     
  2692. EASL: No Effect of Proton Pump Inhibitor (PPI) Use on SVR with Ledipasvir/ Sofosbuvir(LDV/SOF): Real-World Data from 2034 Genotype 1 Patients in the TRIO Network - (04/21/16)
     
  2693. EASL: Prevalence and Impact of Baseline Resistance-Associated Variants (RAVs) on the Efficacy of Ledipasvir/Sofosbuvir or Simeprevir/Sofosbuvir Against GT1 HCV Infection: HCV-TARGET Interim Analysis - (04/21/16)
     
  2694. EASL: Real World Effectiveness of Ledipasvir/Sofosbuvir in Treatment-Experienced Cirrhotic Genotype 1 Patients with Chronic HCV: A Comparative Analysis of Gilead Sponsored Trials with 4 Real-World Cohorts - (04/21/16)
     
  2695. EASL: Real-World Data on the Use of Ribavirin With Ombitasvir/Paritaprevir/r With or Without Dasabuvir in HCV Genotype 1- or 4-Infected Pati ents From the German Hepatitis C Registry - (04/21/16)
     
  2696. EASL: Sofosbuvir/Velpatasvir+GS9857 & Sofosbuvir/Velpatasvir Retreatment / Resistance - (04/21/16)
     
  2697. EASL: Drug-Drug Interaction Profile of Sofosbuvir/Velpatasvir Fixed-Dose Combination - (04/21/16)
     
  2698. EASL: Daclatasvir and Sofosbuvir Therapy for Patients with Decompensated Cirrhosis or Post-Liver Transplant HCV Recurrence and Advanced Fibrosis or Cirrhosis: United States Multicentre Treatment Protocol - (04/21/16)
     
  2699. EASL: Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Patients With HCV Infection and Decompensated Cirrhosis: Interim Analysis of a French Multicentre Compassionate Use Programme - (04/20/16)
     
  2700. EASL: All-Oral Treatment with Daclatasvir Plus Sofosbuvir ï Ribavirin in HCV Genotype 3-Infected Patients With Advanced Fibrosis or Cirrhosis: An Analysis of ALLY-3 and ALLY-3+ - (04/20/16)
     
  2701. EASL: Daclatasvir Plus Sofosbuvir With or Without Ribavirin for Treatment of Chronic HCV Infection in Patients With Advanced Liver Disease: Results of a European Compassionate Use Programme - (04/20/16)
     
  2702. EASL: High Sustained Virologic Response Rates in Patients Infected With HCV genotype 2 With Baseline NS5A Polymorphisms Treated With Daclatasvir-Based Regimens - (04/20/16)
     
  2703. EASL: Daclatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Chronic HCV Infection in Patients With Decompensated Cirrhosis: Results of a European Multicentre Compassionate Use Programme - (04/20/16)
     
  2704. EASL: Next-Generation Sequencing Analysis of NS5A and NS5B Minor Resistance-Associated Variants in Patients with HCV Genotype 3 Infection who Failed Treatment with Daclatasvir Plus Sofosbuvir - (04/20/16)
     
  2705. EASL: Daclatasvir Plus Sofosbuvir Plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients with HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis - (04/20/16)
     
  2706. EASL: INCIDENCE OF HCV REINFECTION AMONG TREATED INDIVIDUALS WITH RECENTLY ACQUIRED INFECTION ....MSM & IDUs, HIV+ - (04/20/16)
     
  2707. EASL: Evidence of impressive real world SVR from the Portuguese ledipasvir/sofosbuvir and sofosbuvir universal coverage program to erradicate (eliminate) hepatitis C - (04/19/16)
     
  2708. EASL: Resistance Analyses for Ledipasvir/Sofosbuvir-Containing Regimens in Patients Infected With Chronic HCV Who Have Advanced Liver Disease Or Are Post Liver Transplant (SOLAR-1 and -2 Studies) - (04/19/16)
     
  2709. EASL: High Rate of SVR in Adolescents Treated With the Combination of Ledipasvir/Sofosbuvir - (04/19/16)
     
  2710. EASL: 100% SVR12 WITH ABT-493 AND ABT-530 WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAÏVE HCV GENOTYPE 3-INFECTED PATIENTS WITH CIRRHOSIS - (04/19/16)
     
  2711. EASL: Ledipasvir/Sofosbuvir (LDV/SOF) for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients With Chronic Genotype 1 or 4 HCV Infection - (04/19/16)
     
  2712. EASL: High Efficacy of an 8-Week, 3-Drug Regimen of MK-3682/Grazoprevir/MK-8408 in HCV Genotype 1, 2, or 3-Infected Patients: SVR24 Data from the Phase 2 C-CREST 1 and 2 Studies - (04/19/16)
     
  2713. EASL: Ledipasvir/Sofosbuvir (LDV/SOF) for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients With Chronic Genotype 1 or 4 HCV Infection - (04/18/16)
     
  2714. EASL: High Efficacy and Favourable Safety of ABT-493 + ABT-530 Co-Administration for 12 Weeks in HCV Genotype 1-Infected Patients With Cirrhosis (SURVEYOR-I) - (04/18/16)
     
  2715. EASL: 100% SVR4 and Favorable Safety of ABT-493 + ABT-530 Administered for 12 Weeks in Non-Cirrhotic Patients With Genotypes 4, 5, or 6 Infection (SURVEYOR-I) - (04/18/16)
     
  2716. EASL: Safety of ABT-493 + ABT-530 Co-Administered in Patients With HCV Genotype 1-6 Infection: Results From the SURVEYOR-I and SURVEYOR-II Studies - (04/18/16)
     
  2717. EASL: High SVR Rates With the Combination of ABT-493 + ABT-530 for 8 Weeks in Non-Cirrhotic Patients With HCV Genotype 1 or 2 Infection - (04/18/16)
     
  2718. EASL: Sofosbuvir/Velpatasvir for 12 Weeks in Patients Coinfected With HCV and HIV-1: The ASTRAL-5 Study - (04/18/16)
     
  2719. EASL: Gilead Announces Multiple Scientific Presentations Demonstrating Broad Utility of Sofosbuvir-Based Hepatitis C Therapies - (04/18/16)
     
  2720. EASL: HIGH SVR RATES WITH ABT-493 + ABT-530 CO-ADMINISTERED FOR 8 WEEKS IN NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 3 INFECTION - (04/18/16)
     
  2721. EASL: AbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals - (04/18/16)
     
  2722. EASL: Gilead Presents New Data Highlighting Progress in Liver Fibrosis (NASH, primary sclerosing cholangitis) - (04/18/16)
     
  2723. EASL: AbbVie Presents New Phase 2 Data for Investigational, Once-Daily, Ribavirin-Free, Pan-Genotypic Regimen of ABT-493 and ABT-530 for Hepatitis C Genotypes 1-6 - (04/18/16)
     
  2724. EASL: Merck Announces Results From Phase 3 Studies of ZEPATIER™ (Elbasvir and Grazoprevir) in Chronic Hepatitis C Patient Populations at The International Liver Congress™ - (04/18/16)
     
  2725. EASL: In a 5-day Monotherapy Trial, MK-8408 Demonstrated Potent Antiviral Activity and Improved Resistance Profile in HCV Patients With Genotypes 1, 2, and 3 Infections - (04/18/16)
     
  2726. EASL: PAN-GENOTYPIC EVALUATION OF AL-335, A CLINICAL STAGE URIDINE ANALOG INHIBITOR OF HEPATITIS C VIRUS POLYMERASE - (04/18/16)
     
  2727. EASL: AL-335, A ONCE-DAILY PANGENOTYPIC NUCLEOTIDE HCV POLYMERASE INHIBITOR, DEMONSTRATES POTENT ANTIVIRAL ACTIVITY OVER 7 DAYS IN TREATMENT-NAïVE GENOTYPE 1-4 PATIENTS - (04/18/16)
     
  2728. EASL: Effect of Baseline Resistance-Associated Variants on SVR With the 3D Regimen Plus RBV - (04/18/16)
     
  2729. EASL: REAL-WORLD SAFETY AND EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/R ï DASABUVIR ï RIBAVIRIN IN THE GERMAN HEPATITIS C REGISTRY (clear version) - (04/15/16)
     
  2730. EASL: Long-Term Follow-up of Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antiviral Regimens: Maintenance of SVR, Persistence of Resistance Mutations, and Clinical Outcomes - (04/15/16)
     
  2731. EASL: Resistance Analysis of Genotype 1 or 3 HCV-Infected Patients Treated With Sofosbuvir/Velpatasvir + GS-9857 for 6 or 8 Weeks - (04/15/16)
     
  2732. EASL: The Real-World Israeli experience of treating chronic hepatitis C (CHC), genotype 1 (GT1) patients with advanced fibrosis with paritaprevir/ritonavir/ombitasvir, dasabuvir with or without ribavirin (3DïR): a large multi-center cohort - (04/15/16)
     
  2733. EASL: Resistance Analysis in 1284 Patients With Genotype 1-6 HCV Infection Treated With Sofosbuvir/Velpatasvir in the Phase 3 ASTRAL-1, ASTRAL-2, ASTRAL-3, and ASTRAL-4 Studies - (04/15/16)
     
  2734. EASL: RG-101 IN COMBINATION WITH 4 WEEKS OF ORAL DIRECT ACTING ANTIVIRAL THERAPY ACHIEVES HIGH VIROLOGIC RESPONSE RATES IN TREATMENT NAïVE GENOTYPE 1 AND 4 CHRONIC HEPATITIS C PATIENTS: INTERIM RESULTS FROM A RANDOMISED, MULTI-CENTER, PHASE 2 STUDY - (04/15/16)
     
  2735. EASL: HIGH EFFICACY OF ABT-493 AND ABT-530 IN HCV GENOTYPE 1-INFECTED PATIENTS WHO HAVE FAILED DIRECT-ACTING ANTIVIRAL-CONTAINING REGIMENS: THE MAGELLAN-I STUDY - (04/15/16)
     
  2736. EASL: Hepatitis C virus reinfection incidence and outcomes among HIV-positive MSM in Western Europe - (04/15/16)
     
  2737. EASL: Sofosbuvir/Velpatasvir in Combination With Ribavirin for 24 Weeks Is Effective Retreatment for Patients Who Failed Prior NS5A-Containing DAA Regimens: Results of the Retreatment Study - (04/15/16)
     
  2738. EASL: High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated With Direct-Acting Antivirals - (04/15/16)
     
  2739. EASL: C-EDGE: HEAD 2 HEAD - Efficacy and Safety of Elbasvir/Grazoprevir versus Sofosbuvir /Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and Prior PR Treatment Failure Subjects with Chronic HCV GT1 or 4 Infection - (04/15/16)
     
  2740. EASL: High Efficacy of Sofosbuvir/Velpatasvir/GS-9857 With or Without Ribavirin for 12 Weeks in Direct-Acting Antiviral-Experienced Patients With Genotype 1 HCV Infection - (04/15/16)
     
  2741. EASL: AbbVie Announces High SVR Rates with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) Regardless of the Presence of Resistance-Associated Variants Prior to Treatment in Genotype 1 Chronic Hepatitis C Patients - (04/14/16)
     
  2742. EASL: Merck's ZEPATIER™ (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial - (04/14/16)
     
  2743. EASL: Pre-EASL Notes from Jules - (04/14/16)
     
  2744. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population - (04/13/16)
     
  2745. HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir - Response Guided HCV Therapy - (04/13/16)
     
  2746. Shedding of Hepatitis C Virus in Semen of HIV-infected Men...33% shed in semen - (04/13/16)
     
  2747. Gilead Sciences Announces Acquisition of Nimbus Therapeutics' Acetyl-CoA Carboxylase (ACC) Program for NASH and Other Liver Diseases - (04/13/16)
     
  2748. Rising Mortality Associated With Hepatitis C Virus in the United States, 2003-2013.....CDC....Hepatitis C Deaths Up Sharply Over Past Decade - (04/13/16)
     
  2749. The spread of hepatitis C virus genotype 1a in North America: a retrospective phylogenetic study - (04/13/16)
     
  2750. APASL: SOF/Velpatasvir, +GS-9857 - Sofosbuvir/Velpatasvir Fixed-Dose Combination for the Treatment of HCV in Patients With Decompensated Liver Disease: the Phase 3 ASTRAL-4 Study - (04/12/16)
     
  2751. Hepatitis C virus as a systemic disease: reaching beyond the liver - cancers/kidney/diabetes/CVD/Brain - (04/08/16)
     
  2752. 70% of Baby Boomers Did not Know They Had Increased Risk for HCV; 48% Did Not Know HCV is Curable - (04/08/16)
     
  2753. HCV Death Rates Doubled Predominantly Among Middle-Aged People BUT Underestimate ....73% of HCV Related Deaths in ages 45-54 & 55-64 CDC - "Rising Mortality Associated with Hepatitis C in the United States 2003-2013" - CDC - (04/08/16)
     
  2754. Liver Cancers/Deaths Increased CDC Reports / Testing & Access to Care are Keys: AASLD - (04/08/16)
     
  2755. With More Funding ($1 Bill), VA to Cover Vets Requiring Hepatitis C Treatments - (04/08/16)
     
  2756. Increased Liver Cancer Deaths - new report from CDC - (04/08/16)
     
  2757. Hepatitis C Disease Burden in the United States in the Era of Oral Direct-Acting Antivirals......despite DAAs - Unless Screening & Linkage To Care is Expanded 700,000 Will Die or get Very Advanced Disease - (04/08/16)
     
  2758. 12 Weeks of Daclatasvir in Combination with Sofosbuvir for HIV-HCV Coinfection (ALLY-2 study): Efficacy and Safety by HIV Combination Antiretroviral Regimens - (04/08/16)
     
  2759. CDC - Liver Disease Ranked 5th/6th As Leading Cause of Death Among 25-65 Ages - (04/08/16)
     
  2760. AbbVie Receives CHMP Positive Opinion for VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) Without Ribavirin for the Treatment of Chronic Hepatitis C in Genotype 1b Patients with Compensated Cirrhosis (Child-Pugh A) in - (04/08/16)
     
  2761. EASL: Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016 - (04/07/16)
     
  2762. EASL: AbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) and Investigational, Pan-Genotypic Regimen at The International Liver Congress™ 2016 - new HCV Drug Pipeline ABT493+ABT530 - (04/07/16)
     
  2763. CROI: HCV at CROI 2016 - (04/4/16)
     
  2764. CROI: Hepatitis C and the Risk of Non-Liver-Related Morbidity and Mortality in HIV+ Persons....kidney, bone, cardiovascular - (04/4/16)
     
  2765. CROI: Understanding the Relative Contributions of IDU and HCV on Systemic Immune Activation...... .....HCV should be aggressively treated in current IDUs even more if HIV and/or HCV positive - (04/4/16)
     
  2766. APASL: Sofosbuvir and Ledipasvir/Sofosbuvir for the Treatment of Patients With Chronic Genotype 6 Hepatitis C Virus Infection: Integrated Analysis of Phase 2 and Phase 3 Studies - (04/01/16)
     
  2767. APASL: Sofosbuvir/Velpatasvir Fixed-Dose Combination for the Treatment of HCV in Patients With Decompensated Liver Disease: the Phase 3 ASTRAL-4 Study - (04/01/16)
     
  2768. Breaking HCV Drug Pricing News - (03/30/16)
     
  2769. AbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) and Investigational, Pan-Genotypic Regimen at The International Liver Congress 2016 [ABT-493+ABT-530] - (03/30/16)
     
  2770. New 2016 Hepatology Textbook by Drs Mauss, Berg, Sarrazin, Rockstroh and Wedemeyer - (03/30/16)
     
  2771. FDA approves expanded use of Roche hepatitis C virus RNA test as aid in diagnosis - (03/30/16)
     
  2772. Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfected men who have sex with men (Swiss Cohort)....Deferring Therapy Increased 10-fold mortality & morbidity - (03/30/16)
     
  2773. Liver Cancers/Deaths Increased CDC Reports / Testing & Access to Care are Keys: AASLD - (03/30/16)
     
  2774. HCV VA Memo" "Funding & Prioritization Status Update" dated Feb 24 2016 - (03/30/16)
     
  2775. With More Funding ($1 Bill), VA to Cover Vets Requiring Hepatitis C Treatments - (03/30/16)
     
  2776. Merck Applauds the U.S. Department of Veterans Affairs (VA) for Broadening Treatment Access for Veterans with Chronic Hepatitis C Infection .....Zepatier added to VA formulary - (03/30/16)
     
  2777. New York Said to Investigate Insurers Over Hepatitis C Drugs - (03/30/16)
     
  2778. NEW RECOMMENDATIONS IN THE UPDATED WHO: GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION - (03/30/16)
     
  2779. AbbVie Receives CHMP Positive Opinion for VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) Without Ribavirin for the Treatment of Chronic Hepatitis C in Genotype 1b Patients with Compensated Cirrhosis (Child-Pugh A) in - (03/30/16)
     
  2780. CROI: Hepatitis C in Egypt: A National Approach to Treatment, Manal El-Sayed MD - (03/24/16)
     
  2781. CROI: Real-life renal safety of "boosted TDF" in HIV/HCV-patients on SOF/LDV - (03/24/16)
     
  2782. CROI: HCV resistance to the daclatasvir/sofosbuvir combination across different HCV genotypes in the real life French Cohort - (03/24/16)
     
  2783. CROI: Lower Ribavirin Exposures in HIV+ Patients that Relapsed to Acute HCV Treatment: SWIFT-C - (03/24/16)
     
  2784. CROI: Response to DAA-based regimens in HIV-HCV co-infected patients in real-life, France....patients with avg Fibroscan of 14.2 kPa / 67% of patients cirrhotic - (03/24/16)
     
  2785. CROI: Summary from CROI 2016 for Hepatitis C Feedback from real-life: how is HCV therapy working outside of clinical trials? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/23/16)
     
  2786. CROI: Summary from CROI 2016 for Hepatitis C Feedback from real-life: how is HCV therapy working outside of clinical trials? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany Correspondence: Prof. Dr. J.K. Rockstroh Department of Medicine I University of Bonn Sigmund-Freud-Str. 25 53105 Bonn Germany - (03/23/16)
     
  2787. CROI: SOF/Rbv SWIFT-C Study Acute HCV Treatment: low RBV levels & relapse; Acute HCV - studies of 4, 6, 8 & 12 weeks - (03/23/16)
     
  2788. CROI: Directly Acting Agents Against HCV - Results From the German Hepatitis C Cohort (GECCO) in HIV+, 8 weeks SOF/LDV - (03/18/16)
     
  2789. CROI: HCV in Egypt: History/Epidemiology, Care/Access/Treatment.... more than 90% Egyptian HCV is genotype 4 - (03/18/16)
     
  2790. CROI: SOF/Rbv SWIFT-C Study Acute HCV Treatment: low RBV levels & relapse; Acute HCV - studies of 4, 6, 8 & 12 weeks - (03/18/16)
     
  2791. CROI: "Chemsex" and High-Risk Sexual Behaviours in HIV-Positive Men Who Have Sex With Men...increased risk for HCV & STIs - (03/11/16)
     
  2792. CROI: Sexual Behaviour is Associated with Recently Acquired HCV in HIV/HCV Co-infected MSM - (03/11/16)
     
  2793. CROI: Prevalence & Factors of HCV Infection Among HIV-Negative & HIV-Positive MSM - (03/11/16)
     
  2794. CROI: Incidence of Hepatitis C Virus Infection in the HIV Outpatient Study (HOPS) Cohort: 2000-2013.... from 2011-2023 MSM HCV hazard ratio was 4.5 times greater vs IDUs (Table 2) - (03/11/16)
     
  2795. CROI: Hepatitis C Screening and Linkage to Care [Cascade of Care] at a Comprehensive Health System (Detroit/Henry Ford health System)...78% not screened for HCV - (03/11/16)
     
  2796. CROI: Residual risk of disease progression after hepatitis C cure in HIV-HCV co-infected patients - (03/11/16)
     
  2797. CROI: Liver Cancer in Patients Cured of HCV: Less Cirrhosis and Less Fat than Expected - (03/11/16)
     
  2798. CROI: Genotypic and Phenotypic Characterization of Clinical HCV NS5A Drug Resistance - (03/11/16)
     
  2799. CROI: HCV Treatment in Groups at Risk for Reinfection - talk at CROI by Oluwaseun Falade-Nwulia - (03/11/16)
     
  2800. CROI: NEW RECOMMENDATIONS IN THE UPDATED WHO: GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION - (03/07/16)
     
  2801. CROI: Ledipasvir/Sofosbuvir Controls Acute HCV in HIV+ Without Highest HCV Loads - Mark Mascolini (03/07/16)
     
  2802. CROI: Project INSPIRE: a Comprehensive Care Coordination Program for HCV-Infection Preliminary Year 1 Results - (03/07/16)
     
  2803. CROI: HCV Guidelines Updated Feb 24 2016 - (03/07/16)
     
  2804. CROI: Resistance Associated Variants: Data From the NIAID SYNERGY Trial / Harvoni-Retreating Short Duration Therapy - (03/07/16)
     
  2805. CROI: Immediate ART Initiation Reduces Risk of Infection-Related Cancer in HIV Infection/START Study - (03/07/16)
     
  2806. CROI: Ledipasvir/Sofosbuvir Controls Acute HCV in HIV+ Without Highest HCV Loads - Written by Mark Mascolini (03/07/16)
     
  2807. CROI: Ravidasvir/Sofosbuvir Yields Quick SVRs in Largest Genotype 4 Trial - (03/05/16)
     
  2808. CROI: Statin Dose and Type Tied to Lower Fibrosis Progression and Liver Cancer Incidence - (03/05/16)
     
  2809. CROI: TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/r + Dasabuvir + RBV for HCV/HIV Co-Infection - (03/05/16)
     
  2810. CROI: Safety and Tolerability of Elbasvir/Grazoprevir in Patients With Chronic Hepatitis C: An Integrated Analysis of Phase 2-3 Trials - (03/05/16)
     
  2811. CROI: CROI 2016 - Themed Discussion: Rants About HCV RAVS - (03/05/16)
     
  2812. CROI: Retreatment of HCV/HIV-Coinfected Patients Who Failed 12 Weeks of LDV/SOF - (03/05/16)
     
  2813. CROI: High HCV Cure Rates for Drug Users Treated with DAAs at an Urban Primary Care Clinic - (03/05/16)
     
  2814. CROI: Ledipasvir/Sofosbuvir for 6 Weeks in HIV-Infected Patients with Acute HCV Infection - (03/01/16)
     
  2815. CROI: Interactions Between ABT-493 plus ABT-530 combination and Rilpivirine or Raltegravir - (03/01/16)
     
  2816. CROI: Protective Effect of Coffee Intake on Mortality of French HIV-HCVInfected Patients (ANRS CO13 HEPAVIH Cohort) - (03/01/16)
     
  2817. CROI: Atorvastatin and Fluvastatin are Associated with Dose-Dependent Reductions in Cirrhosis and HCC Among Patients with HCV: Results from ERCHIVES - (03/01/16)
     
  2818. CROI: Poorly Controlled HIV Infection is a Risk Factor for Liver Fibrosis in the CNICS Cohort ...CD4 & Viral load predict progression to advanced fibrosis - (03/01/16)
     
  2819. CROI: More Coffee Tied to Lower Mortality in French HIV/HCV Group - Mark Mascolini - (02/24/16)
     
  2820. CROI: Primary Providers as Successful as Specialists in Treating HCV Infection - Mark Mascolini - (02/24/16)
     
  2821. CROI: Effect of Baseline Resistance-Associated Variants on SVR With the 3D Regimen Plus RBV - (02/24/16)
     
  2822. CROI: Drug Interaction Studies Between Sofosbuvir/Velpatasvir and Boosted HIV ARV Regimens - (02/24/16)
     
  2823. APASL: Data Presented at APASL from First Completed Phase 3 Trial of All-oral Chronic Hepatitis C Regimen in Chinese Patient Population Shows Daclatasvir and Asunaprevir DUAL Therapy Demonstrated High Cure Rates Among HCV Genotype 1b Patients - (02/23/16)
     
  2824. APASL: SAFETY AND EFFICACY OF ORAL REGIMENS FOR THE TREATMENT OF HEPATITIS C GENOTYPE 1b INFECTION: HCV---TARGET INTERIM ANALYSIS OF A PROSPECTIVE, OBSERVATIONAL STUDY HCV-TARGET Study Group - (02/23/16)
     
  2825. APASL: Integrated Safety and Tolerability of DCV + ASV in Patients with Chronic HCV Genotype 1b Infection - (02/23/16)
     
  2826. APASL: All-Oral Daclatasvir/Asunaprevir/Beclabuvir Fixed-Dose Combination Therapy for HCV Genotype 1..... Enrolled in South Korea, Taiwan, and Russia.....mostly HCV GT 1b infection, up to 20% with compensated cirrhosis - (02/23/16)
     
  2827. APASL: Daclatasvir/Asunaprevir/Beclabuvir Fixed-Dose Combination in Treatment-Naive and Interferon-Experienced Japanese Patients With HCV Genotype 1 Infection: UNITY-3 Study - (02/23/16)
     
  2828. APASL: DCV + ASV in IFN (ï RBV) Ineligible/Intolerant Non-Japanese Asian Patients With Chronic HCV Genotype 1b Infection - (02/23/16)
     
  2829. APASL: Safety and Tolerability of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C: An Integrated Analysis of Phase 2-3 Trials - (02/23/16)
     
  2830. APASL: Predictors of Response to Elbasvir/Grazoprevir Among HCV Genotype 1 (GT1)-Infected Patients: Integrated Analysis of Phase 2-3 Trials - (02/23/16)
     
  2831. APASL: GIFT-I: DURABILITY OF RESPONSE OF OMBITASVIR/PARITAPREVIR/RITONAVIR IN HCV GT1B JAPANESE PATIENTS - (02/23/16)
     
  2832. APASL: GIFT-I: ALT CHANGES WITH OMBITASVIR/PARITAPREVIR/RITONAVIR AND CONCOMITANT USE OF HEPATOPROTECTIVES - (02/22/16)
     
  2833. APASL: High Efficacy of the Combination HCV Regimen Grazoprevir and Elbasvir for 8 or 12 weeks with or without Ribavirin in Treatment-NaÏve, Non-Cirrhotic HCV GT1b Infected Patients: an Integrated Analysis - (02/22/16)
     
  2834. APASL: Elbasvir/Grazoprevir in Cirrhotic Patients With HCV Infection - (02/22/16)
     
  2835. APASL: Sofosbuvir, Ledipasvir in IBD treated patients with advanced biologics including Ribavirineradicating Chronic Hepatitis C: SOLATAIRE CTrial. A multi-center clinical prospectivepilot study - (02/22/16)
     
  2836. APASL: GIFT-I: OMBITASVIR/PARITAPREVIR/RITONAVIR SAFETY AND EFFICACY IN RENALLY-IMPAIRED JAPANESE PATIENTS - (02/22/16)
     
  2837. APASL: GIFT-I: SAFETY AND EFFICACY OF OMBITASVIR/PARITAPREVIR/RITONAVIR IN ELDERLY JAPANESE PATIENTS - (02/22/16)
     
  2838. APASL: Evaluation of Daclatasvir and Asunaprevir Exposures in Japanese, Non Japanese Asians, and Non-Asians - (02/22/16)
     
  2839. APASL: EQ-5D Results in Asian Patients with HCV Genotype 1b Receiving Daclatasvir plus Asunaprevir who are Interferon Intolerant/Ineligible - (02/22/16)
     
  2840. APASL: FSS and SF-36 in Asian Patients with HCV Genotype 1b Receiving Daclatasvir and Asunaprevir and who are Interferon plus Ribavarin Intolerant or Ineligible - (02/22/16)
     
  2841. APASL: Daclatasvir+Asunaprevir versus Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Genotype 1 in Japanese Patients: A Matching-Adjusted Indirect Comparison - (02/22/16)
     
  2842. APASL: High SVR Rates With ABT-493 + ABT-530 in Non-Cirrhotic Patients With HCV Genotypes 1, 2, 3 Infection - (02/22/16)
     
  2843. APASL: SLAM C study Sofosbuvir and Ledipasvir versus Sofosbuvir and Simeprevir combination therapy in the management of acute hepatitis C: A randomized open label prospective clinical pilot study. (drug rehabs in NYC] - (02/22/16)
     
  2844. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial - (02/19/16)
     
  2845. Hepatitis C-free Europe is possible by 2030 / EU HCV Summit Brussels Webcast 2/17/2016 - (02/19/16)
     
  2846. RG-101 Interim Analysis Shows 97% Response at 8 Week Follow-Up - (02/19/16)
     
  2847. Global epidemiology and genotype (genotype 1b) distribution of the hepatitis C virus infection - (02/19/16)
     
  2848. FDA Harvoni Updated Label Feb 12 2016 - (02/16/16)
     
  2849. U.S. FDA APPROVES TWO SUPPLEMENTAL INDICATIONS FOR HARVONI® IN CHRONIC HEPATITIS C PATIENTS WITH ADVANCED LIVER DISEASE - press release, for Immediate release - (02/16/16)
     
  2850. FDA Harvoni Updated Label Feb 12 2016 - (02/16/16)
     
  2851. Illinois Puts HCV DAA Drugs on ADAP Formulary Feb 9 2016 - (02/15/16)
     
  2852. Obama Releases FY 2017 Budget: [HHS] drug pricing, PrEP, HCV in HIV+ - (02/11/16)
     
  2853. Public health clinic-based hepatitis C testing and linkage to care in baltimore - (02/11/16)
     
  2854. HCV/HIV Coinfection New $9 Milion Federal Funded Program - (02/10/16)
     
  2855. HIV & HCV Excerpts from HHS/CDC 2017 Budget: ".....$17.5 billion on healthcare for people living with HIV in 2015" - (02/10/16)
     
  2856. HCV 2017 Federal Budget Disgraceful $5 Mill Increase for HCV - (02/10/16)
     
  2857. 2 HCV lawsuits in Washington State - (02/10/16)
     
  2858. GT-3 - Here are several studies - (02/10/16)
     
  2859. U.S. FDA Approves Expanded Use of Bristol-Myers Squibb's Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C - (02/10/16)
     
  2860. Daclatasvir, Sofosbuvir, and Ribavirin for Hepatitis C Virus Genotype 3 and Advanced Liver Disease: A Randomized Phase III Study (ALLY-3+) - (02/09/16)
     
  2861. Merck Zepatier Pricing - (02/09/16)
     
  2862. Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries - (02/09/16)
     
  2863. FDA Hepatitis Update - Approval of Zepatier for treatment of chronic hepatitis C genotypes 1 and 4 - (02/09/16)
     
  2864. FDA Hepatitis Update - Approval of Zepatier for treatment of chronic hepatitis C genotypes 1 and 4 - (02/05/16)
     
  2865. Resistance Testing is Recommended Prior to Merck Zepatier Treatment Only for Genotype 1a - (02/05/16)
     
  2866. Merck HCV Drug Zepatier / FDA Product Insert - (02/05/16)
     
  2867. Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review - (02/05/16)
     
  2868. FDA approves [Merck's] Zepatier for treatment of chronic hepatitis C genotypes 1 and 4 - (02/05/16)
     
  2869. CDC Urging Dialysis Providers and Facilities to Assess and Improve Infection Control Practices to Stop Hepatitis C Virus Transmission in Patients Undergoing Hemodialysis - HCV transmission reported at dialysis centers - (02/05/16)
     
  2870. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks - (02/05/16)
     
  2871. NYS Gov Cuomo Plan to Cap Drug Prices - (02/05/16)
     
  2872. European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV - (01/28/16)
     
  2873. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population - (01/27/16)
     
  2874. HCV, HIV, IDUs - Local, state, groups meet to combat alarming drug rise in NC - (01/27/16)
     
  2875. Failure to Test and Identify Perinatally Infected Children Born to Hepatitis C-Positive Women - (01/27/16)
     
  2876. Harvoni for Genotype 5 - (01/27/16)
     
  2877. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study - (01/27/16)
     
  2878. New HCV Treatments coming - (01/27/16)
     
  2879. New HCV Drug RG-101 - (01/25/16)
     
  2880. Challenge to HCV Restrictions in Missouri - Letter from Legal Services to Missouri State Officials - (01/25/16)
     
  2881. NYC HCV Plan NYC DOH: HEPATITIS C in NEW YORK CITY - (01/25/16)
     
  2882. AASLD: Sofosbuvir and ledipasvir for 8 weeks (SL8) in patients with hepatitis C virus (HCV) mono-infection and human immunodeficiency virus (HIV)-HCV co-infection with genotype (GT) 1 and 4 in clinical practice - results from the German hepatitis C cohort (GECCO) - (01/20/16)
     
  2883. AASLD: Sofosbuvir-based treatments for patients with hepatitis C virus (HCV) mono-infection and human immunodeficiency virus (HIV)-HCV co-infection with genotype 3 in clinical practice - Results from the GErman hepatitis C COhort (GECCO) - (01/20/16)
     
  2884. AASLD: Sofosbuvir-based treatments for patients with hepatitis C virus (HCV) mono-infection and human immunodeficiency virus (HIV)-HCV co-infection with genotype 3 in clinical practice - Results from the GErman hepatitis C COhort (GECCO) - (01/20/16)
     
  2885. AASLD: No Clinically Meaningful Pharmacokinetic Interactions Between HCV Inhibitors Grazoprevir/Elbasvir With Tacrolimus, Mycophenolate Mofetil, and Prednisone, But Cyclosporine Increases Grazoprevir/Elbasvir Exposures in Healthy Subjects - (01/20/16)
     
  2886. AASLD: No Pharmacokinetic Interaction Between HCV NS5A Inhibitor Elbasvir and Buprenorphine/Naloxone in Healthy Volunteers - C-EDGE C-Star Study: Grazoprevir/Elbasvir in IDUs on Opioid Antagonist Therapy - (01/20/16)
     
  2887. AASLD: No Pharmacokinetic Interaction Between HCV Inhibitors Grazoprevir/Elbasvir With Famotidine and Pantoprazole - (01/20/16)
     
  2888. HCV Update: New Therapies / Conference Summary, Reports, Highlights - (01/19/16)
     
  2889. AASLD: Baseline HCV NS5A Resistance-Associated Variants Do Not Impact SVR12 Rates in Non-Cirrhotic and Post-Liver Transplant Patients With Genotype 1 Infection Treated With Daclatasvir and Sofosbuvir With or Without Ribavirin for 12 Weeks: An Integrated Analysis - (01/15/16)
     
  2890. Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/HCV-coinfected patients with advanced liver disease....Response Guided Therapy - (01/15/16)
     
  2891. A Cross-sectional Study of the Association Between Chronic Hepatitis C Virus Infection and Subclinical Coronary Atherosclerosis Among Participants in the Multicenter AIDS Cohort Study - (01/13/16)
     
  2892. AASLD: Merck at AASLD / HepDart 2015 - (01/14/16)
     
  2893. Aetna HCV Drug Criteria - (01/13/16)
     
  2894. AASLD: Gilead at AASLD / HepDart - Harvoni, Sofosbuvir/Velpatasvir, Sofosbuvir/Velpatasvir+GS9857 (6-8 weeks), Harvoni + Vedroprevir - (01/13/16)
     
  2895. AASLD: Abbvie at AASLD / Hep Dart 2015 - (01/13/16)
     
  2896. AASLD: BMS at AASLD - (01/13/16)
     
  2897. AASLD: Data from ALLY-3+ Trial Investigating Daklinza (daclatasvir) in Combination with Sofosbuvir and Ribavirin in Chronic Hepatitis C Genotype 3 Patients with Advanced Fibrosis or Cirrhosis Presented at AASLD - BMS press release - (01/13/16)
     
  2898. AASLD: The Association of Sustained Virological Response and Mortality After Interferon-based Therapy for Chronic Hepatitis C (HCV) in a Large U.S. Community-based Health Care Delivery System....SVR Reduces Mortality a Lot/Treating Early Before Cirrhosis Reduced Mortality vs in Cirrhotics - (01/13/16)
     
  2899. AbbVie Initiates Enrollment of Six Global Phase 3 Clinical Studies for Once-Daily, Pan-Genotypic Hepatitis C Regimen - (01/11/16)
     
  2900. United HealthCare Removes Fibrosis Restriction - (01/11/16)
     
  2901. Genotype 3 at AASLD - (01/11/16)
     
  2902. HCV Highlights: HepDart/AASLD - Current HCV Treatments - New HCV Treatments in Development - (01/11/16)
     
  2903. AASLD: Predictors of Response to Elbasvir/Grazoprevir Among HCV Genotype 1 (GT1)-Infected Patients: Integrated Analysis of Phase 2-3 Trials -2 - (01/08/16)
     
  2904. HIV & HCV & Parkinsons Disease: is there an increased risk - undecided yet with mixed opinions and suggestive data - (01/08/16)
     
  2905. FDA Grants Priority Review to AbbVie for Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chronic Hepatitis C Virus Patients with Compensated Cirrhosis - (01/08/16)
     
  2906. Mylan Launches Generic Harvoni® (Ledipasvir/Sofosbuvir) Under the Brand Name MyHep LVIR™ in India - (01/08/16)
     
  2907. Cigna & Restrictions - (01/08/16)
     
  2908. Hepatitis C virus infection as a risk factor for Parkinson disease - (01/08/16)
     
  2909. Development of hyperdynamic circulation and response to ß-blockers in compensated cirrhosis with portal hypertension - (01/07/15)
     
  2910. Hepatitis C virus infection as a risk factor for Parkinson disease - (01/07/15)
     
  2911. HCV in New Jersey Young Suburban Heroin Users - (01/06/15)
     
  2912. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial - (01/06/15)
     
  2913. Development of hyperdynamic circulation and response to ß-blockers in compensated cirrhosis with portal hypertension - (01/06/15)
     
  2914. Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort - (01/06/15)
     
  2915. Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir/Velpatasvir for Treatment of All Genotypes of Chronic Hepatitis C Infection - (01/05/15)
     
  2916. Maribel Rodriguez-Torres, MD, Scientist, Puerto Rico Passes - (01/05/15)
     
  2917. AASLD: Efficacy, Safety and Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Hepatitis C Genotype 1 Infected Non-cirrhotic Japanese Patients (Phase 2 Portion in Phase 2/3 Combined Study) - (01/04/16)
     
  2918. AASLD: C-EDGE TN: Impact of 12-Week Oral Regimen of Elbasvir (EBR, MK-8742) / Grazoprevir (GZR, MK-5172) on Patient-Reported Outcomes (PROs) in Treatment-Naïve Patients With Chronic Hepatitis C Virus (HCV) Genotype (GT) 1, 4, or 6 Infection - (01/04/16)
     
  2919. AASLD: C-EDGE Co-infection: Impact of 12-Week Oral Regimen of Elbasvir (EBR, MK-8742)/Grazoprevir (GZR, MK-5172) on Patient-Reported Outcomes (PROs) in Treatment- Naïve Patients With HCV/HIV Co-infection - (01/04/16)
     
  2920. AASLD: High Efficacy of the Combination HCV Regimen Elbasvir and Grazoprevir for 8 or 12 Weeks With or Without Ribavirin in Treatment-Naive, Non-Cirrhotic HCV GT1b-Infected Patients: An Integrated Analysis - (01/04/16)
     
  2921. AASLD: Safety and Tolerability of Elbasvir/Grazoprevir in Patients With Chronic Hepatitis C: An Integrated Analysis of Phase 2-3 Trials - (01/04/16)
     
  2922. AASLD: Safety and Tolerability of Grazoprevir/Elbasvir in Patients With Chronic Hepatitis C (HCV) Infection: Integrated Analysis of Phase 2-3 Trials - (01/04/16)
     
  2923. AASLD: Predictors of Response to Elbasvir/Grazoprevir Among HCV Genotype 1 (GT1)-Infected Patients: Integrated Analysis of phase 2-3 Trials - (01/04/16)
     
  2924. hepDART: Optimizing Outcomes in HCV Patients: Elbasvir/Grazoprevir: kidney disease/IDUs/resistance (01/04/16)
     
  2925. AASLD: Summary from AASLD 2015 for Hepatitis C Beyond 95% SVR cure rates: still room for improvement? Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (12/29/15)
     
  2926. hepDART: (HepDart) Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients (12/22/15)
     
  2927. hepDART: High Efficacy of Ledipasvir/Sofosbuvir With Ribavirin In HCV Genotype-1 Infected Patients with Decompensated Liver Disease: Analysis by MELD Score from the SOLAR-1 and SOLAR-2 Trials (12/22/15)
     
  2928. hepDART: Retreatment of Patients Who Failed Sofosbuvir-Based Regimens with Ledipasvir/Sofosbuvir Regimens (12/22/15)
     
  2929. hepDART: (HepDart) PREVALENCE AND IMPACT OF BASELINE NS5A RESISTANCE ASSOCIATED VARIANTS (RAVS) IN HCV GT1A PATIENTS TREATED WITH ELBASVIR/GRAZOPREVIR (EBR/GZR) (12/22/15)
     
  2930. hepDART: (HepDart) SURVEYOR-II: High SVR4 Rates Achieved With the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 In Non-Cirrhotic Treatment-Naïve and Treatment-Experienced Patients With HCV Genotype 3 Infection (12/22/15)
     
  2931. hepDART: PREVALENCE AND IMPACT OF BASELINE NS5A RESISTANCE ASSOCIATED VARIANTS (RAVS) IN HCV GT1A PATIENTS TREATED WITH ELBASVIR/GRAZOPREVIR (EBR/GZR) (12/22/15)
     
  2932. Harvoni FDA Label Update- HIV/GT-4/5/6 PK/DDIs - (12/22/15)
     
  2933. AASLD: Dual-Combination Therapy (NASH) Directed Against Lysyl Oxidase-Like-2 and Apoptosis Signal-Regulating Kinase 1 Potently Inhibits Fibrosis and Portal Hypertension in a New Mouse Model of PSC-Like Liver Disease/NASH - (12/22/15)
     
  2934. AASLD: The Antiviral Response to the Toll-Like Receptor 7 Agonist GS-9620 in Preclinical Models of Chronic Hepatitis B Is Associated With an Intrahepatic Cytotoxic T Cell Transcriptional Signature - (12/22/15)
     
  2935. AASLD: Effect of Chronic Kidney Disease on the Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir in Subjects with HCV Genotype 1 Infection - (12/22/15)
     
  2936. AASLD: TURQUOISE-III: 12-Week Ribavirin-Free Regimen of Ombitasvir/Paritaprevir/r and Dasabuvir for Patients With HCV Genotype 1b and Cirrhosis - (12/22/15)
     
  2937. AASLD: (VA) Effectiveness of Ledipasvir/Sofosbuvir in Treatment Naïve Genotype 1 Patients Treated in Routine Medical Practice - (11/16/15)
     
  2938. AASLD: Failure with All-Oral DAA Regimens:Academic and Community Treatment of a Real-World Population from the TRIO Network - (12/16/15)
     
  2939. AASLD: (HCV-TARGET) - Treatment Outcomes With 8, 12 and 24 Week Regimens of Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Infection: Analysis of a Multicenter Prospective, Observational Study - (12/03/15)
     
  2940. EASL: The Pharmacokinetics of GS-5816, a Pangenotypic HCV-Specific NS5A Inhibitor, in HCV-Uninfected Subjects With Severe Renal Impairment - (12/21/15)
     
  2941. AASLD: Population Pharmacokinetics of Sofosbuvir and Its Major Metabolite (GS-331007) in Healthy and HCV-Infected Adult Subjects - (12/21/15)
     
  2942. NICE, UK, Hep C patients to get NHS access to three new therapies - (12/21/15)
     
  2943. Cirrhosis May Persists Despite SVR - (12/21/15)
     
  2944. HCV Drug Pricing Models - (12/21/15)
     
  2945. Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir - (12/21/15)
     
  2946. 2016 Congress Spending Bill Disses HCV Again - (12/21/15)
     
  2947. 2016 Congressional Spending Bill: "expand services that address prescription drug abuse and heroin use in high-risk communities" - (12/21/15)
     
  2948. HCV Solution in Egypt / Standoff in USA - (12/21/15)
     
  2949. HCV Pay for Cure in Scotland - (12/21/15)
     
  2950. Portugal / Georgia Deals for HCV Drugs - (12/21/15)
     
  2951. Daclatasvir (Daklinza) FDA Product Information - (12/21/15)
     
  2952. Hetero gets DCGI approval to market Hepatitis C drug Harvoni Generic - (12/21/15)
     
  2953. HCV Drug spending Actually Drives Down Healthcare Costs...... "The Impact Of New Hepatitis C Drugs On National Health Spending" - (12/21/15)
     
  2954. NYS Nov 19, 2015 HCV DURB Hearing - (12/21/15)
     
  2955. AASLD: Hepatitis C Cure Leads to a Durable Decrease in Liver Stiffness..... "cirrhosis persisted in 58%" - (12/18/15)
     
  2956. AASLD: Ombitasvir/Paritaprevir/r and Dasabuvir With or Without Ribavirin for Patients With Post-Transplant HCV Recurrence - (12/18/15)
     
  2957. AASLD: Better Work Productivity and Activity in Patients On Ombitasvir/Paritaprevir/Ritonavirand Dasabuvir With or Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 (GT1) Chronic Hepatitis C - 2 - (12/18/15)
     
  2958. AASLD: Resistance Analysis of Treatment-Naïve and DAA-Experienced Genotype 1 Patients With and Without Cirrhosis Who Received Short-Duration Treatment With Sofosbuvir/Velpatasvir + GS-9857 - (12/18/15)
     
  2959. AASLD: Characterization of HCV Resistance From a 3-Day Monotherapy Study of GS-9857, a Novel Pangenotypic NS3/4A Protease Inhibitor - (12/18/15)
     
  2960. AASLD: Asian Patients With Chronic Genotype 2 HCV Infection Achieve 98% Sustained Virologic Response Following 12-Week Administration of Sofosbuvir in Combination With Ribavirin: Integrated Analysis of Phase 3 Multicenter Studies - (12/18/15)
     
  2961. AASLD: Preliminary Safety and Efficacy Results From TOPAZ-II: A Phase 3b Study Evaluating Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ï Ribavirin - (12/18/15)
     
  2962. AASLD: Long-Term Efficacy of Ombitasvir/Paritaprevir/r and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Patients With or Without Cirrhosis - (12/18/15)
     
  2963. AASLD: Safety, efficacy and tolerability in the treatment of patients with Chronic Hepatitis C and Severe Renal Impairment - (12/18/15)
     
  2964. AASLD: Safety, efficacy and tolerability in the treatment of patients with Chronic Hepatitis C and Severe Renal Impairment - (12/16/15)
     
  2965. AASLD: Hepatitis C cure could avoid liver transplant in some Cirrhotic patients on Dialysis listed for simultaneous liver-kidney transplantation - (12/16/15)
     
  2966. AASLD: Effect of Renal Function on the Pharmacokinetics of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir and Ribavirin in Over 2000 Subjects with HCV GT1 Infection - (12/16/15)
     
  2967. AASLD: Efficacy and Safety of Ombitasvir/Paritaprevir/r and Dasabuvir ï Ribavirin in HCV Genotype 1-Infected Patients With a History of Bleeding Disorders: Results From Phase 3 Trials - (12/16/15)
     
  2968. AASLD: RUBY-I: Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ï Ribavirin in Non-Cirrhotic HCV Genotype 1-Infected Patients With Severe Renal Impairment or End-Stage Renal Disease - (12/16/15)
     
  2969. AASLD: Projected Long-term Impact of Grazoprevir (GZR, MK-5172)/Elbasvir (EBR, MK-8742) in Treatment-naïve and Treatment-experienced Patients With Hepatitis C Virus Genotype 1 Infection and Chronic Kidney Disease - (12/16/15)
     
  2970. AASLD: Hepatitis C and Renal Disease: Differences in Patient Characteristics and Clinical Outcomes in the United States - (12/16/15)
     
  2971. AASLD: Failure with All-Oral DAA Regimens:Academic and Community Treatment of a Real-World Population from the TRIO Network - (12/16/15)
     
  2972. AASLD: Effectiveness of 8 or 12 week LDV-SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network - (12/16/15)
     
  2973. AASLD: Effectiveness of 12 or 24 week LDV-SOF and 12 week LDV-SOF + RBV in Treatment-Experienced Patients with Cirrhotic, Genotype 1 Hepatitis C: Real-world Experience from the TRIO Network - (12/16/15)
     
  2974. Cost of NOT Treating HCV - (12/14/15)
     
  2975. hepDART: High Efficacy of Sofosbuvir/Velpatasvir In HCV Genotypes 1-6 Infected Patients With Cirrhosis: Pooled Data From the ASTRAL 1, 2 and 3 Trials (12/14/15)
     
  2976. hepDART: High Efficacy of Sofosbuvir/Velpatasvir Across 7 HCV Genotypes and 46 Subtypes: Pooled Data From the ASTRAL1, 2 and 3 Trials (12/14/15)
     
  2977. hepDART: Development of Potent Novel Oral Pan-genotypic HCV Nucleotide, NS5A, NS5B Non-nucleoside, and Helicase Inhibitors (12/14/15)
     
  2978. hepDART: Phase 2, Randomized, Open-Label Clinical Trials of the Efficacy and Safety of Grazoprevir and MK-3682 (NS5B Polymerase Inhibitor) with Either Elbasvir or MK-8408 (NS5A Inhibitor) in Patients with Chronic HCV GT1, 2 or 3 Infection (Part A of C-CREST 1 & 2) (12/14/15)
     
  2979. hepDART: (HepDart) Treatment With Ombitasvir/Paritaprevir/r Plus Dasabuvir With Ribavirin Was Not Associated With Changes in Renal Function: An Analysis of 1211 Patients Enrolled in Four Phase 2 and 3 Trials (12/14/15)
     
  2980. hepDART: (HepDart) Efficacy and Safety of Ombitasvir/Paritaprevir/r + Dasabuvir ï Ribavirin According to Baseline Renal Function: Analysis of 2005 Patients Enrolled in Six Phase 3 Trials (12/14/15)
     
  2981. hepDART: Risk of cardiomyopathy and cardiac failure among patients with evidence of hepatitis C virus infection: an administrative claims database analysis (12/14/15)
     
  2982. hepDART: (HepDart) Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Weeks in Genotype 1 (GT1) Treatment-Naïve (TN) Non-Cirrhotic (NC) Patients with HCV Viral load (VL) <6 million IU/ml (6M); A Comparative Analysis of the Phase-3 ION-3 Efficacy Data to Real World Effectiveness (RWE) (12/14/15)
     
  2983. AbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) to Treat Genotype 1 Chronic Hepatitis C Virus Infection - (12/11/15)
     
  2984. India approves sale of generic Hepatitis C drugs - (12/11/15)
     
  2985. Hepatitis C cure may cost as low as Rs 67k - (12/11/15)
     
  2986. Hep C patients to get NHS access to three new therapies....with or without cirrhosis - (12/11/15)
     
  2987. AbbVie's TECHNIVIE Receives Health Canada Approval for Genotype 4 Chronic Hepatitis C Infection - (12/11/15)
     
  2988. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons....."saves $750 Million" - (12/11/15)
     
  2989. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population - '$58 Bill to treat all' - (12/11/15)
     
  2990. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection - (12/11/15)
     
  2991. AASLD: Safety and Efficacy of Treatment With Daily Sofosbuvir 400 mg + Ribavirin 200 mg for 24 Weeks in Genotype 1 or 3 HCV-Infected Patients With Severe Renal Impairment - (12/09/15)
     
  2992. AASLD: Safety, Antiviral Efficacy, and Pharmacokinetics of Sofosbuvir in Patients With Severe Renal Impairment - (12/09/15)
     
  2993. AASLD: Sofosbuvir+GS-5816 GT 1-6: ASTRAL-1, ASTRAL-2, ASTRAL-3, ASTRAL-4 - (12/09/15)
     
  2994. AASLD: The Pharmacokinetics of Ledipasvir, an HCV-Specific NS5A Inhibitor, in HCV-Uninfected Subjects With Severe Renal Impairment - (12/09/15)
     
  2995. AASLD: Current Trends in Liver Transplantation among HCV-Infected Baby Boomer Generation in the United States: A Case for Birth-Cohort Screening - (12/09/15)
     
  2996. AASLD: HCV Infection in Aging Baby Boomers is an Independent Predictor of Poor Outcome in Liver Transplant Recipients: An Analysis of the UNOS database - (12/09/15)
     
  2997. AASLD: Wait Time of <6 and >18 Months Predicts HCC Recurrence after Liver Transplantation: A Multicenter Study Suggesting a Wait Time "Sweet Spot" - (12/09/15)
     
  2998. AASLD: Curing Decompensated Wait-Listed HCV Patients with the New DAAs: Potential Significant Impact on Liver Transplant Wait List and Organ Allocation - (12/09/15)
     
  2999. AASLD: Safety and Efficacy of Treatment With Daily Sofosbuvir 400 mg + Ribavirin 200 mg for 24 Weeks in Genotype 1 or 3 HCV-Infected Patients With Severe Renal Impairment - (12/09/15)
     
  3000. AASLD: Treatment with the Anti-miRNA122 Oligonucleotide RG-101 Results in a Decrease in IP-10 but Does Not affect the levels of other Cytokines in Patients with chronic Hepatitis C - (12/08/15)
     
  3001. AASLD: A Single Dose of RG-101, a GalNAc-Conjugated Oligonucleotide Targeting miR-122, Results in Undetectable HCV RNA Levels in Chronic Hepatitis C Patients at Week 28 of Follow-up - (12/08/15)
     
  3002. AASLD: Ledipasvir/Sofosbuvir With Ribavirin in Patients With Decompensated Cirrhosis or Liver Transplantation and HCV Infection: SOLAR-1 and -2 Trials - (12/08/15)
     
  3003. AASLD: Sofosbuvir and Ledipasvir/Sofosbuvir for the Treatment of Patients With Chronic Genotype 6 Hepatitis C Virus Infection: Integrated Analysis of Phase 2 and Phase 3 Studies - (12/08/15)
     
  3004. AASLD: Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir and Velpatasvir (GS-5816) and HIV Antiretoviral Therapies - (12/07/15)
     
  3005. AASLD: Cascade of Care for Hepatitis C Virus (HCV) Infection within the U.S. Department of Veterans Affairs (VA) - (12/07/15)
     
  3006. AASLD: Safety, efficacy & Tolerability in the Treatment of Patients with Chronic HCV & Severe Renal Impairment - Hepatitis C Cure Could Avoid Liver Transplant In Some Cirrhotic Patients On Dialysis Listed for Simultaneous Liver Kidney Transplantation - (12/07/15)
     
  3007. AASLD: Impact of Sofosbuvir-Based Regimens on Renal Function in Liver Transplant Recipients: Results of a Multicenter Study - (12/07/15)
     
  3008. AASLD: A Novel HCV Antigen Test System for One-step Screening and Diagnosing Viremic HCV Infection Using Serum or Urine Specimens - (12/07/15)
     
  3009. AASLD: Costs per Diagnosed Liver Disease Stage Among Individuals with Chronic Hepatitis C Virus in the Veterans Health Administration - (12/07/15)
     
  3010. AASLD: The Cost of Making Hepatitis C a Rare Disease in the United States - (12/07/15)
     
  3011. AASLD: Presence of Hepatitis C (HCV) Infection in Baby Boomers with Medicare Is Independently Associated with Mortality and Resource Utilization - (12/07/15)
     
  3012. AASLD: Efficacy, Change in MELD Score, and Safety by Baseline MELD Score in Patients With Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/r and Dasabuvir Plus Ribavirin in the Phase 3 TURQUOISE-II Trial - (12/07/15)
     
  3013. AASLD: Better Work Productivity and Activity in Patients On Ombitasvir/Paritaprevir/Ritonavirand Dasabuvir With or Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 (GT1) Chronic Hepatitis C - (12/07/15)
     
  3014. AASLD: Evolution Of Resistance Associated Variants During Initial Treatment, Viral Failure, And Re-Treatment With Directly Acting Antiviral Therapy NIH SYNERGY Trial - (12/04/15)
     
  3015. AASLD: TELAPREVIR IN THE TREATMENT OF ACUTE HCV INFECTION IN HIV-INFECTED MEN - (12/04/15)
     
  3016. AASLD: Sofosbuvir and Ledipasvir versus Sofosbuvir and Simeprevir combination therapy in the management of acute hepatitis C: A randomized open label prospective clinical pilot study. SLAM C study - (12/04/15)
     
  3017. AASLD: Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals: SWIFT-C....Harvoni 8 weeks enrolling - (12/04/15)
     
  3018. AASLD: SOFOSBUVIR IN THE TREATMENT OF ACUTE HCV INFECTION IN HIV-INFECTED MEN - (12/04/15)
     
  3019. AASLD: Activation of Hepatic Stellate Cells Drives the Rapid Development of Liver Fibrosis During Acute HCV Infection in HIV-infected Men - (12/04/15)
     
  3020. AASLD: Daclatasvir Exposure Does Not Explain Lower Sustained Virologic Response Rates in Cirrhotic Patients With HCV Genotype 3 Following 12 Weeks of Daclatasvir Plus Sofosbuvir Treatment - (12/04/15)
     
  3021. AASLD: Short-Duration Therapy With Daclatasvir/Asunaprevir/Beclabuvir Fixed-Dose Combination Plus Sofosbuvir in Patients With Chronic Hepatitis C Genotype 1 (FOURward Study) - (12/04/15)
     
  3022. AbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) to Treat Genotype 1 Chronic Hepatitis C Virus Infection - (12/04/15)
     
  3023. European Medicines Agency Validates Gilead's Marketing Application for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for the Treatment of Hepatitis C - (12/04/15)
     
  3024. AASLD: Failure with All-oral DAA Regimens: Real-world experience from the TRIO Network. Academic and community treatment of a real-world, heterogeneous population - (12/03/15)
     
  3025. AASLD: (HCV-TARGET) - Treatment Outcomes With 8, 12 and 24 Week Regimens of Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Infection: Analysis of a Multicenter Prospective, Observational Study - (12/03/15)
     
  3026. AASLD: Integrated Safety Analysis of Daclatasvir Plus Sofosbuvir, With or Without Ribavirin, in Patients With HCV Genotype 3 Infection - (12/03/15)
     
  3027. AASLD: An Integrated Safety Analysis of Daclatasvir + Sofosbuvir, With or Without Ribavirin, in Patients With Chronic HCV Infection - (12/03/15)
     
  3028. AASLD: Daclatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Chronic HCV in Patients Coinfected With HIV: Interim Results of a Multicenter European Compassionate Use Program (advanced liver disease) - (12/03/15)
     
  3029. AASLD: Cost-effectiveness of Combination Daclatasvir-Sofosbuvirfor Genotype 3 Chronic Hepatitis C Infection in the United States - (12/03/15)
     
  3030. AASLD: Impact of Daclatasvir-Sofosbuvir Combination Treatment on Avoided Medical Events and Costs in Patients Infected with Genotype 3 Hepatitis C Virus - (12/03/15)
     
  3031. AASLD: Improvement in Liver Disease Parameters Following Treatment with Daclatasvir + Sofosbuvir and Ribavirin in Patients With Chronic HCV Infection and Advanced Cirrhosis - (12/03/15)
     
  3032. AASLD: Efficacy of Elbasvir (EBR) and Grazoprevir (GZR) in Black HCV-Infected Patients: Results of a Pooled Analysis of Phase 2/3 Studies - (12/03/15)
     
  3033. AASLD: Value of A Cure To Society: "$256.9 Bill relative to No Treatment" - (12/03/15)
     
  3034. AASLD: Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir and Velpatasvir (GS-5816) and HIV Antiretoviral Therapies 2 - (12/02/15)
     
  3035. AASLD: Improving liver function and delisting of patients awaiting liver transplantation for HCV cirrhosis: do we ask too much to DAAs? - (12/01/15)
     
  3036. AASLD: Daclatasvir and Sofosbuvir in Patients with Recurrent HCV Following Liver Transplantation with Advanced Fibrosis or Cirrhosis: United States Multicenter Treatment Protocol - (12/01/15)
     
  3037. AASLD: Response-guided therapy leads to complete cure after three weeks of all-oral triple-direct acting antiviral regimens in non-cirrhotic chronic hepatitis C genotype 1b Chinese subjects (SODAPI study) - (12/01/15)
     
  3038. AASLD: Increasing Prevalence of Cirrhosis among US Adults with Chronic HCV Infection: Results from NHANES 1988-1994 and 1999-2012 - (12/01/15)
     
  3039. AASLD: High Efficacy of Elbasvir and grazoprevir With or Without Ribavirin in 103 Treatment-Naive and Experienced Patients With HCV Genotype 4 Infection: A Pooled Analysis - (12/01/15)
     
  3040. AASLD: Daclatasvir in Combination With Sofosbuvir With Or Without Ribavirin Is Safe and Efficacious in Liver Transplant Recipients With HCV Recurrence: Interim Results of a European Multicenter Compassionate Use Program - (12/01/15)
     
  3041. AASLD: High Rates of SVR in Treatment-Experienced Patients With Genotype 1 HCV Infection and Cirrhosis After Treatment With Ledipasvir/Sofosbuvir and Vedroprevir With or Without Ribavirin for 8 Weeks - (12/01/15)
     
  3042. AASLD: SURVEYOR-II: High SVR4 Rates Achieved With the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 in Non-Cirrhotic Treatment-Naïve and Treatment-Experienced Patients With HCV Genotype 2 Infection - (12/01/15)
     
  3043. AASLD: SURVEYOR-II: High SVR4 Rates Achieved With the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 in Non-Cirrhotic Treatment-Naïve and Treatment-Experienced Patients With HCV Genotype 3 Infection - (12/01/15)
     
  3044. AASLD: Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Patients With HCV Genotype 3 Infection: Interim Analysis of a French Multicenter Compassionate Use Program - (12/01/15)
     
  3045. AASLD: Regression of Advanced Fibrosis or Cirrhosis Measured by Elastography in Patients with Chronic Hepatitis C who Achieve Sustained Virologic Response after Treatment for HCV - (12/01/15)
     
  3046. AASLD: Highly Successful Retreatment With LDV/SOF in HCV Gt-1 Patients Who Failed Short Course LDV/SOF-Based Therapy: The NIH SYNERGY Trial - (12/01/15)
     
  3047. HCV at EACS: Mortality/SVR; 8 Weeks Harvoni COinfected & mono infected; HCC increasing; Abbvie 3D in Coinfected; ChemSex & HCV in London - (11/30/15)
     
  3048. (SOF/GS5816 ASTRAL Studies) Editorial by John Ward - Simple, Effective, but Out of Reach? Public Health Implications of HCV Drugs - (11/30/15)
     
  3049. AASLD: Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection - (11/30/15)
     
  3050. AASLD: Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection - (11/30/15)
     
  3051. AASLD: Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis (ASTRAL-4) - (11/30/15)
     
  3052. AASLD: Sofosbuvir/Velpatasvir Fixed-Dose Combination for the Treatment of HCV in Patients With Decompensated Liver Disease: the Phase 3 ASTRAL-4 Study / ASTRAL 1, 2 and 3 - (11/30/15)
     
  3053. AASLD: Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 24 Weeks in Genotype 3 HCV-Infected Patients: The Randomized Controlled Phase 3 ASTRAL-3 Study - (11/30/15)
     
  3054. AASLD: A Randomized Controlled Trial of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 12 Weeks in Genotype 2 HCV-Infected Patients: The Phase 3 ASTRAL-2 Study - (11/30/15)
     
  3055. AASLD: C-EDGE Co-Infected: final results from Phase 3 Study of elbasvir / grazoprevir in Patients with HCV/HIV - (11/30/15)
     
  3056. AASLD: High Rates of SVR in Patients With HCV Genotype 2 or 3 Infection Treated With Ombitasvir/Paritaprevir/r and Sofosbuvir With or Without Ribavirin - (11/30/15)
     
  3057. AASLD: Treating Hepatitis C in the US: Measuring impact and value in the context of other major health interventions - (11/23/15)
     
  3058. AASLD: Hepatitis C Disease Burden in the United States in 2015 and Beyond - (11/23/15)
     
  3059. AASLD: Daclatasvir and Asunaprevir in Non-Japanese Asian Patients with Chronic HCV Genotype 1b Infection who are Ineligible for or Intolerant to Interferon-alfa Therapies with or without Ribavirin: Phase 3 SVR12 Interim Results - (11/23/15)
     
  3060. AASLD: Incidence and Determinants of Denial of DAA Therapy by Type of Insurance During the First 6 Months of the Modern HCV Treatment Era - (11/23/15)
     
  3061. AASLD: High Virologic Response Rate in Egyptian HCV-Genotype 4 Patients Treated with Ravidasvir (PPI-668) and Sofosbuvir: Results of a Large Multicenter Phase 3 Registrational Trial - (11/23/15)
     
  3062. AASLD: All-Oral Treatment With Daclatasvir Plus Sofosbuvir Plus Ribavirin for 12 or 16 Weeks in HCV Genotype 3-Infected Patients With Advanced Fibrosis or Cirrhosis: The ALLY-3+ Phase 3 Study - (11/23/15)
     
  3063. AASLD: Sofosbuvir and Velpatasvir [GS5816] for HCV Genotype 1, 2, 4, 5, and 6 Infection ASTRAL-1 - (11/23/15)
     
  3064. AASLD: Preclinical characterization of CC-31244, a pan-genotypic, potent NS5B non-nucleoside inhibitor for the treatment of chronic hepatitis C - (11/23/15)
     
  3065. AASLD: Detecting Drug-Induced Liver Injury in Patients With Decompensated Chronic Hepatitis C: A Review of the SOLAR-1 and SOLAR-2 Studies - (11/23/15)
     
  3066. AASLD: Incidence and Predictors of Hepatocellular Carcinoma after Sustained Viral Response in Veterans with HCV-infection - (11/23/15)
     
  3067. AASLD: C-SWIFT Retreatment (Part B): 12 Weeks of Elbasvir/Grazoprevir with Sofosbuvir and Ribavirin Successfully Treated G1-Infected Subjects who Failed Short-Duration All-Oral Therapy - (11/23/15)
     
  3068. AASLD: Prevalence and Impact of Baseline NS5A Resistance-Associated Variants (RAVs) on the Efficacy of Elbasvir/Grazoprevir (EBR/GZR) Against GT1a Infection - 16 Weeks vs 12 weeks - (11/23/15)
     
  3069. AASLD: High Rates of SVR in Patients With HCV Genotype 2 or 3 Infection Treated With Ombitasvir/Paritaprevir/r and Sofosbuvir With or Without Ribavirin - (11/23/15)
     
  3070. AASLD: Phase 2, Randomized, Open-Label Clinical Trials of the Efficacy and Safety of Grazoprevir and MK-3682 (NS5B Polymerase Inhibitor) with Either Elbasvir or MK-8408 (NS5A Inhibitor) in Patients with Chronic HCV GT1, 2 or 3 1nfection (Part A of C-CREST-1 & 2) - (11/23/15)
     
  3071. AASLD: Reduced Work Productivity, Absenteeism and Presenteeism of Patients Infected with HCV are Independently Predicted by Physical Component of Patient-Reported Outcomes - (11/23/15)
     
  3072. The Medicines Patent Pool Signs Licence with Bristol-Myers Squibb to Increase Access to Hepatitis C Medicine Daclatasvir - (11/23/15)
     
  3073. AASLD: ABBVIE ANNOUNCES HIGH SUSTAINED VIROLOGIC RESPONSE RATES IN PHASE 2 STUDIES WITH PAN-GENOTYPIC, INVESTIGATIONAL REGIMEN IN PATIENTS WITH CHRONIC HEPATITIS C - (11/19/15)
     
  3074. AASLD: The Risk of Developing Liver Cancer Even After Being Cured from Hepatitis C - (11/19/15)
     
  3075. AASLD: Multiple Scientific Presentations at The Liver Meeting 2015 Further Highlight the Utility of Sofosbuvir-Based Hepatitis C Therapies - (11/19/15)
     
  3076. AASLD: Prevalence and Impact of Baseline NSA Resistance Associated Variants (RAVs) on the Efficacy of Elbasvir/Grazoprevir (EBR/GZR) Against GT1a Infection - (11/19/15)
     
  3077. AASLD: Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting® - (11/19/15)
     
  3078. AASLD: Effect of HCV treatment on hospitalization rate: Chronic Hepatitis Cohort Study (CHeCS) - (11/19/15)
     
  3079. AASLD: AN INTEGRATED ANALYSIS OF 402 COMPENSATED CIRRHOTIC PATIENTS WITH HCV GENOTYPE (GT) 1, 4 or 6 INFECTION TREATED WITH Elbasvir/GRAZOPREVIR - (11/19/15)
     
  3080. AASLD: Ombitasvir/Paritaprevir/r and Dasabuvir With Ribavirin for HCV Genotype 1 Patients With Decompensated Cirrhosis - (11/18/15)
     
  3081. AASLD: No Pharmacokinetic Interaction Between HCV NS5A Inhibitor Elbasvir and Buprenorphine/Naloxone in Healthy Volunteers - (11/18/15)
     
  3082. AASLD: Clinicians Have Multiple First-line Options for Treating HCV; Challenge is Implementation: all patients have right to be treated - (11/18/15)
     
  3083. AASLD: Baseline HCV NS5A Resistance-Associated Variants Do Not Impact SVR12 Rates in Non-Cirrhotic and Post-Liver Transplant Patients With Genotype 1 Infection Treated With Daclatasvir and Sofosbuvir With or Without Ribavirin for 12 Weeks: An Integrated Analysis - (11/18/15)
     
  3084. AASLD: Daclatasvir Exposure Alone Does Not Explain HCV Relapse in HIV-HCV Coinfected Patients Receiving Daclatasvir Plus Sofosbuvir with Ritonavir-Boosted Darunavir in the ALLY-2 Study - (11/18/15)
     
  3085. AASLD: Daclatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Chronic HCV in Patients Coinfected With HIV: Interim Results of a Multicenter European Compassionate Use Program - (11/18/15)
     
  3086. AASLD: Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting® - (11/18/15)
     
  3087. AASLD: Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy - (11/18/15)
     
  3088. AASLD: Drug-Drug Interactions Between Next Generation Direct Acting Antivirals ABT-493 and ABT-530 with Cyclosporine or Tacrolimus in Healthy Subjects - (11/18/15)
     
  3089. AASLD: Absence of Significant Drug-Drug Interactions Between Next Generation Direct Acting Antivirals ABT-493 and ABT-530 and Methadone or Buprenorphine/Naloxone in Subjects on Opioid Maintenance Therapy ..... "no dose adjustments required" - (11/18/15)
     
  3090. AASLD: Analysis of HCV Genotype 1 Variants Detected During Monotherapy and Combination Therapy With Next Generation HCV Direct-Acting Anti viral Agents ABT-493 and ABT-530 "........COMBINATION THERAPY (SURVEYOR-I PART 1, PHASE 2 DOSE-RANGING STUDY) .....All patients with baseline NS3 or NS5A variants achieved SVR12 (Study SVR12: 99%)" - (11/18/15)
     
  3091. AASLD: Efficacy and Safety of Co-Formulated Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Chronic HCV Genotype 4 Infection Without Cirrhosis and With Compensated Cirrhosis in Egypt (AGATE-II) - (11/18/15)
     
  3092. AASLD: Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Infection and Cirrhosis (AGATE-I) - (11/18/15)
     
  3093. AASLD: Eliminate Restrictions to Substance Users/Injection Drug Users - SVR Rates the Same in New Study as in Non-IDUs 96% - Routine HCV Testing is needed - (11/18/15)
     
  3094. AASLD: Eliminate Restrictions to Substance Users/Injection Drug Users - SVR Rates the Same in New Study as in Non-IDUs 96% - Routine HCV Testing is needed - (11/17/15)
     
  3095. AASLD: 100% SVR4 in HCV Genotype 1 Non-Cirrhotic Treatment-Naïve or -Experienced Patients With the Combination of ABT-493 and ABT-530 for 8 Weeks (SURVEYOR-I)....[8 weeks] - (11/17/15)
     
  3096. AASLD: QUARTZ-I: Retreatment of HCV Genotype 1 DAA-failures With Ombitasvir/Paritaprevir/r, Dasabuvir, and Sofosbuvir - (11/17/15)
     
  3097. AASLD: A Phase 3 Double-Blind Placebo-Controlled Evaluation of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Genotype 1, 2, 4, 5, 6 HCV-Infected Patients: Results of the ASTRAL-1 Study - (11/17/15)
     
  3098. AASLD: The Combination of Elbasvir and Grazoprevir ï RBV Is Highly Effective for the Treatment of GT1a-Infected Patients - (11/17/15)
     
  3099. AASLD: High Prevalence of co-morbidities and complex polyharmacy with drug-drug interaction (DDI) potential in patients with chronic Hepatitis C - (11/17/15)
     
  3100. AASLD: Sofosbuvir With Velpatasvir (GS-5816) in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial - (11/17/15)
     
  3101. AASLD: Sofosbuvir Plus Velpatasvir (GS-5816) Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial - (11/17/15)
     
  3102. AASLD: AbbVie Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis - (11/16/15)
     
  3103. AASLD: AbbVie Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis - (11/16/15)
     
  3104. AASLD: Multiple Scientific Presentations at The Liver Meeting 2015 Further Highlight the Utility of Sofosbuvir-Based Hepatitis C Therapies - (11/16/15)
     
  3105. AASLD: Gilead Presents New Data at The Liver Meeting 2015 - (11/16/15)
     
  3106. AASLD: Safety and Efficacy of Daclatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Chronic HCV Genotype 3 Infection: Interim Results of a Multicenter European Compassionate Use Program - (11/16/15)
     
  3107. AASLD: Sofosbuvir/Velpatasvir + GS-9857 for 6 or 8 Weeks in Genotype 1 or 3 HCV-Infected Patients - (11/16/15)
     
  3108. AASLD: C-EDGE CO-STAR: efficacy of grazoprevir / elbasvir Fixed Dose Combination for 12 Weeks in HCV-infected Persons Who Inject Drugs on Opioid Agonist Therapy - (11/16/15)
     
  3109. AASLD: SVR12 results from the Phase II, open-label IMPACT study of simeprevir (SMV) in combination with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1/4 infection and decompensated liver disease - (11/16/15)
     
  3110. AASLD: SURVEYOR-I: 98% - 100% SVR4 in HCV Genotype 1 Non-Cirrhotic Treatment-Naïve or Pegylated Interferon/Ribavirin Null-Responders with the Combination of the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 - (11/16/15)
     
  3111. AASLD: Prevalence of Pre-Treatment NS5A Resistance Associated Variants in Genotype 1 Patients Across Different Regions Using Deep Sequencing and Effect on Treatment Outcome with LDV/SOF - (11/16/15)
     
  3112. AASLD: Treatment Outcomes With 8, 12 and 24 Week Regimens of Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Infection: Analysis of a Multicenter Prospective, Observational Study - (11/16/15)
     
  3113. AASLD: (VA) Effectiveness of Ledipasvir/Sofosbuvir in Treatment Naïve Genotype 1 Patients Treated in Routine Medical Practice - (11/16/15)
     
  3114. AASLD: Rectal Shedding of HCV in HIV/HCV co-infected Men - (11/16/15)
     
  3115. AASLD: Pharmacokinetic Analyses of Ledipasvir/Sofosbuvir and HIV Antiretroviral Regimens in Subjects With HCV/HIV Coinfection - (11/16/15)
     
  3116. U.S. FDA Approves New Indications for Harvoni®, Gilead's Once-Daily Single Tablet Regimen for Chronic Hepatitis C - (11/13/15)
     
  3117. Treat HCV Early, Deferral to Cirrhosis Increases Risk for NOT Regression & Developing HCC, Death - (11/13/15)
     
  3118. The Medicines Patent Pool Expands Mandate to Hepatitis C and Tuberculosis Treatment - (11/10/15)
     
  3119. National Medicaid Officials Dismiss CMS HCV Letter - (11/10/15)
     
  3120. HCV Cost Burden: medical costs; treatment costs; work productivity losses & savings; HCC mortality has tripled, cirrhosis has doubled. NYS Restrictions below. CMS/Feds Letter to Medicaids - (11/10/15)
     
  3121. HIV, Hepatitis C outbreak continues in Indiana - HCV Snowballing - (11/06/15)
     
  3122. Administration wades further into drug price debate - (11/06/15)
     
  3123. CMS Sends Letter of Guidance to State Medicaid Programs & Letters to Pharma - (11/06/15)
     
  3124. Study suggests unprecedented 3-week hepatitis C cure - (11/05/15)
     
  3125. Extrahepatic Morbidity and Mortality of Chronic Hepatitis C Review - SVR Clears/Reduces Extrahepatic Manifestations - (11/05/15)
     
  3126. Trends in Burden of Cirrhosis and Hepatocellular Carcinoma by Underlying Liver Disease in US Veterans, 2001-2013 - Cirrhosis Doubled; Deaths Due to Cirrhosis increased 50%; HCC incidence increased 2.5 fold; HCC mortality tripled - (11/05/15)
     
  3127. Rapid Resolution of Hepatitis C Virus-Associated Cryoglobulin Rash With Use of Direct-Acting Antivirals - (11/05/15)
     
  3128. Bradyarrhythmias Associated with Sofosbuvir Treatment - Correspondence - (11/05/15)
     
  3129. Therapy With Direct-Acting Antivirals for Genotype 3 Patients: Interferon's Last Gasp? Commentary - (11/04/15)
     
  3130. NATAP HCV Fall 2015 Current Reports / Reading List/Conference Reports: ICAAC, IDSA, EACS - (11/04/15)
     
  3131. EACS: ChemSex: Data on Recreational Drug Use and Sexual Behaviour in Men Who Have Sex with Men (MSM) from a Busy Sexual Health Clinic in London, UK - (11/03/15)
     
  3132. Harvoni for Acute HCV Study Enrolling - (11/03/15)
     
  3133. Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for Treatment of All Six Genotypes of Hepatitis C - (11/03/15)
     
  3134. EACS: Trends in incidences and risk factors for hepatocellular carcinoma & other liver events in HIV/HCV co-infected individuals from 2001 to 2014: a multi-cohort study - (10/30/15)
     
  3135. EACS: No decline in hepatitis C incidence among HIV-positive MSM; an update from the CASCADE Collaboration - (10/30/15)
     
  3136. FDA - Hepatitis C Treatments Viekira Pak and Technivie: Drug Safety Communication - Risk of Serious Liver Injury - (10/28/15)
     
  3137. Mortality in HCV/HIV Coinfected Drug Users in Amsterdam Twice that of Drug Users - Temporal trends in mortality among people who use drugs compared with the general Dutch population differ by hepatitis C virus and HIV infection status - (10/28/15)
     
  3138. "Treatment is recommended for all patients with chronic HCV infection" - HCV Guidelines Updated Oct 22 2015 - (10/28/15)
     
  3139. EACS: TURQUOISE-I STUDY: USE OF OMBITASVIR/PARITAPREVIR/RITONAVIR + DASABUVIR + RIBAVIRIN IN PATIENTS WITH HCV/HIV-1 CO-INFECTION ON STABLE DARUNAVIR-CONTAINING ANTIRETROVIRAL THERAPY (10/27/15)
     
  3140. EACS: Sofosbuvir plus ledipasvir for 8 weeks in HCV-mono- and HIV-HCV-coinfected patients - Results from the German hepatitis C cohort (GECCO) (10/27/15)
     
  3141. EACS: Near-100% SVR12 With 8 Weeks of Sofosbuvir/Ledipasvir in German HIV+/HIV- Cohort - Written by Mark Mascolini (10/27/15)
     
  3142. EACS: Is Response to Anti-HCV Treatment Predictive of Mortality in HCV/HIV Co-infected Patients?..... "SVR -reduced incidence of liver-related death and improved overall survival" (10/27/15)
     
  3143. IDSA: HCV at IDSA, Treatment Study Results in HIV/HCV Coinfected, Cascade & Barriers to Care (10/23/15)
     
  3144. IDSA: HCV Cascade/Barriers in Philadelphia - "Meet the Professor: Overcoming barriers to HCV care" (10/21/15)
     
  3145. IDSA: DAA Cure Rate 75% in HCV/HIV Cohort With Ongoing Barriers to Care - Mark Mascolini (10/21/15)
     
  3146. HCV Hospitalizations Costs Increase 291%, estimated healthcare system burden by study at $15 billion/year... - (10/21/15)
     
  3147. Bristol-Myers Squibb to Present Data from Multiple Studies of Difficult-to-Treat Chronic Hepatitis C Patients at AASLD - (10/21/15)
     
  3148. Risk of Deferring HCV Treatment - CDC CheCS: "All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus" - (10/20/15)
     
  3149. NICE Recommends Daklinza (daclatasvir) for Treatment of Certain Patients with Chronic Hepatitis C Genotypes 1, 3 and 4 - (10/20/15)
     
  3150. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis - (10/20/15)
     
  3151. IDSA: Exploring the Benefits of an Enhanced Social Work Intervention within the HCV Cascade of Care (10/19/15)
     
  3152. IDSA: HCV Cascade/Denver - Impact of Interferon-Era HCV Treatment Restrictions on Current Referral and Treatment Trends (10/19/15)
     
  3153. IDSA: Gender, Ethnicity, IDU, and Risk for HCV Among New York City Jail Inmates (10/19/15)
     
  3154. IDSA: Diagnosed, staged and untreated: Hepatitis C fibrosis severity by transient elastography (TE) in an inner city clinic (10/19/15)
     
  3155. IDSA: Linkage to Care for Hepatitis C: Creating a Cascade of Care to Identify Gaps at the Individual Hospital Level (Bellevue Hospital-NYC) (10/19/15)
     
  3156. IDSA: Hepatitis C Virus (HCV) In Young Suburban Heroin Users In New Jersey; Part Of The Second Wave Of Hepatitis C (10/19/15)
     
  3157. IDSA: C-EDGE: INTEGRATED ANALYSIS FROM THE PHASE 2/3 STUDIES OF ELBASVIR / GRAZOPREVIR IN PATIENTS WITH HCV/HIV (2) (10/19/15)
     
  3158. IDSA: Continued Rising Mortality from Hepatitis C Virus in the United States, 2003-2013 (10/19/15)
     
  3159. IDSA: Pharmacy-based Resource Requirements to Obtain HCV Therapy for HIV/HCV Co-Infected Patients (10/15/15)
     
  3160. IDSA: C-EDGE: INTEGRATED ANALYSIS FROM THE PHASE 2/3 STUDIES of ELBASVIR / GRAZOPREVIR in HIV PATIENTS WITH HCV/HIV (10/15/15)
     
  3161. IDSA: 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens (10/15/15)
     
  3162. IDSA: 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by Black Race (10/15/15)
     
  3163. IDSA: Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients (10/15/15)
     
  3164. IDSA: Lack of Drug Interactions Between Boosted and Unboosted TAF-Based Antiretroviral Single-Tablet Regimens (E/C/F/TAF, R/F/TAF) and the anti-HCV Single-Tablet Regimen Ledipasvir/Sofosbuvir (10/13/15)
     
  3165. IDSA: SVR12 Similar in HCV-1 Patients With or Without HIV in Four LDV/SOF Trials - written by Mark Mascolini - (10/13/15)
     
  3166. Daklinza/sofosbuvir - Indian Drugmakers Engineer Hep C Cocktails Impossible in West - (10/09/15)
     
  3167. HCV USA/Prevalence 8-9 Million?? - (10/09/15)
     
  3168. Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugs - Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries - (10/09/15)
     
  3169. Excluding people who use drugs or alcohol from access to hepatitis C treatments - Is this fair, given the available data? - EDITORIAL - (10/09/15)
     
  3170. The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study - (10/09/15)
     
  3171. Results from Merck's Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir in Patients with Advanced Chronic Kidney Disease - (10/07/15)
     
  3172. U.S. FDA Grants Priority Review For Daklinza (daclatasvir) sNDAs - (10/07/15)
     
  3173. HCV Prevalence Underestimated, Screening Programs Needed; Immigrant Populations; IDUs; Neighborhood-Based Screening/Linkage-To-Care - (10/07/15)
     
  3174. Why We Should Be Willing to Pay for Hepatitis C Treatment...... - (10/07/15)
     
  3175. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study - (10/07/15)
     
  3176. Treatment of Chronic HCV With Sofosbuvir and Simeprevir in Patients With Cirrhosis and Contraindications to Interferon and/or Ribavirin..... Decompensated Child class B or C cirrhosis was present in 33% of the patients - (10/07/15)
     
  3177. AbbVie Demonstrates Commitment to Hepatitis C Patients with New Data on VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) and Ongoing Clinical Development Program at The Liver Meeting® 2015 - (10/02/15)
     
  3178. UAE-wide hepatitis C awareness campaign launched - (10/02/15)
     
  3179. Enanta Pharmaceuticals Announces Data Presentations at The Liver Meeting® 2015 - (10/02/15)
     
  3180. On the origin of liver regeneration - (10/02/15)
     
  3181. Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department - HCV Screening of Baby Boomers 4 Times Greater than Estimated - (09/30/15)
     
  3182. Toward a more accurate estimate of the prevalence of hepatitis C in the United States - (09/30/15)
     
  3183. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice - Review - (09/30/15)
     
  3184. Hepatocellular Carcinoma and Lifestyles - alcohol, coffee, diet, exercise, smoking - (09/30/15)
     
  3185. ICAAC: New HCV NS5A Inhibitor - (09/30/15)
     
  3186. ICAAC: Pharmacokinetics, Safety and Tolerability of EDP-239, a Novel Hepatitis C (HCV) NS5A inhibitor, in Patients with HCV Infection - (09/30/15)
     
  3187. ICAAC: Pharmacokinetics, Safety, and Tolerability of EDP-239, a novel Hepatitis C NS5A inhibitor, in Healthy Volunteers - (09/30/15)
     
  3188. Hepatitis and the Sustainable Development Goals: time for an end run - (09/28/15)
     
  3189. AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype 1 Chronic Hepatitis C - (09/28/15)
     
  3190. New Millman HCV Report - The Cost of HCV - (09/25/15)
     
  3191. HCV Transmission & Dialysis - (09/25/15)
     
  3192. HCV VA Funding Needs Support: One senator's push to fund hepatitis C treatment for veterans - (09/25/15)
     
  3193. ICAAC: Safety of Ledipasvir/Sofosbuvir with and without Ribavirin for the Treatment of Patients with Chronic HCV Genotype 1 Infection: An Analysis of the Phase 3 ION trials - (09/25/15)
     
  3194. ICAAC: No Difference in Safety Profiles Comparing 12- and 24-Week HCV Treatment Durations in HCV Genotype 1 and HIV-1 Co-Infected Patients: Results From TURQUOISE-I - (09/25/15)
     
  3195. Excluding people who use drugs or alcohol from access to hepatitis C treatments - Is this fair, given the available data? - EDITORIAL - (09/24/15)
     
  3196. Hepatitis C Virus Infection is Associated With Increased Cardiovascular Mortality: A Meta-analysis of Observational Studies - (09/22/15)
     
  3197. Hepatitis C virus infection: a risk factor for Parkinson's disease - (09/22/15)
     
  3198. Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes - (09/22/15)
     
  3199. ICAAC: FIB-4 Linked to All-Cause Mortality in Large Italian HIV/HCV Cohort - Written by Mark Mascolini - - (09/21/15)
     
  3200. Achillion Reports 100% SVR12 From Second Cohort of Patients in the Previously-Completed Six Week Phase 2 Trial Evaluating Odalasvir (ACH-3102) and Sofosbuvir for Genotype 1 HCV ("Proxy Study") - (09/18/15)
     
  3201. Sofosbuvir plus Simeprevir Treatment of Recurrent Genotype 1 Hepatitis C after Liver Transplant - (09/18/15)
     
  3202. Harvoni in Advanced Liver Disease - (09/18/15)
     
  3203. Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010 - (09/18/15)
     
  3204. Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment - (09/18/15)
     
  3205. Daclatasvir Active in GT 5 & 6 - (09/17/15)
     
  3206. Incidence of sexually transmitted hepatitis C virus infection in HIV-positive MSM: a systematic review and meta-analysis - HCV in MSM High-Risk Groups - need for targeted hepatitis C prevention and testing campaigns for this group - (09/17/15)
     
  3207. Harvoni GT-6 - (09/17/15)
     
  3208. Genotypic Distribution of Hepatitis C Virus in Thailand and Southeast Asia - (09/17/15)
     
  3209. Efficacy and safety of Paritaprevir/r/Ombitasvir/Dasabuvir ïRibavirin in GT1 HCV infected patients treated in real life settings (AMBER study - interim analysis) - (09/17/15)
     
  3210. HCV Guidelines - Genotype 1b.....Abbvie Granted Orphan Drug Designation for pedisatric patients - (09/17/15)
     
  3211. Genotype 3 - A Special Genotype - (09/16/15)
     
  3212. Incidence of sexually transmitted hepatitis C virus infection in HIV-positive MSM: a systematic review and meta-analysis - HCV in MSM High-Risk Groups - need for targeted hepatitis C prevention and testing campaigns for this group - (09/14/15)
     
  3213. GS-9857 in Genotypes 1-6 - (09/14/15)
     
  3214. HCV genotype 3 - the new treatment challenge - "HCV-3 has become the more difficult genotype to treat" - (09/14/15)
     
  3215. SVR Improves Steatosis in GT-3..... Associations of chronic hepatitis C with metabolic and cardiac outcomes - (09/14/15)
     
  3216. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis - IDUs are not engaged in care resulting in increased infectiousness/costs/disease progression - (09/14/15)
     
  3217. Incidence of sexually transmitted hepatitis C virus infection in HIV-positive MSM: a systematic review and meta-analysis: HCV in MSM Increasing / need for targeted hepatitis C prevention and testing campaigns for this group - (09/14/15)
     
  3218. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent - (09/14/15)
     
  3219. GT 6 & 5 SVRs Harvoni & Future Gilead Therapies (daclatasvir Gt5 in vitro activity) - (09/14/15)
     
  3220. HCV in MSM in NY, London, SF, MACS - (09/14/15)
     
  3221. Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus - (09/14/15)
     
  3222. Sub-Par SVR Rates in "Real-World, why? VA Study - (09/11/15)
     
  3223. Monogram NS5A Resistance Test - (09/11/15)
     
  3224. Updated HCV Guidelines: treatment update & "supports treatment for all HCV-infected persons" - (09/11/15)
     
  3225. Daktari Enters Collaboration Agreement with Merck to Develop (Point-of-Care Screening) Test for Hepatitis C Virus - (09/11/15)
     
  3226. New Cholesterol Drugs Estimated Costs $10 to $150 Billion A Year - (09/11/15)
     
  3227. Economic burden associated with diagnosed diabetes (all ages) and undiagnosed diabetes, GDM, and prediabetes (adults) is estimated to be $322 billion - (09/11/15)
     
  3228. Randomized trials of ombitasvir/paritaprevir/r+dasabuvir ï ribavirin vs telaprevir+pegIFN/ribavirin in adults with genotype 1 HCV - published - (09/10/15)
     
  3229. PACHA Letter on HCV to HHS - (09/10/15)
     
  3230. Updated Label for Daklinza (daclatasvir) for the 12-week Treatment of Non-cirrhotic Patients with Chronic Hepatitis C Genotype 3 Approved by the European Commission - (09/10/15)
     
  3231. US HCV Guidelines Recommendations GT1/2/3/4/5/6 Aug 2015 - (09/10/15)
     
  3232. EASL Recommendations Gt1-6 April 2015 - (09/10/15)
     
  3233. Sub-Par SVR Rates in "Real-World, why? VA Study Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans - (09/09/15)
     
  3234. Sub-Par SVR Rates in "Real-World, why? VA Study Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans - (09/09/15)
     
  3235. Hepatitis C in [high-risk] men who have sex with men in London - a community survey - (09/09/15)
     
  3236. Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease - (09/09/15)
     
  3237. Randomized trials of ombitasvir/paritaprevir/r+dasabuvirïribavirin vs telaprevir+pegIFN/ribavirin in adults with genotype 1 HCV - published - (09/09/15)
     
  3238. Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade - (09/09/15)
     
  3239. Emerging trends in hepatocellular carcinoma incidence and mortality - HCC incidence continues to increase in the U.S. population - (09/09/15)
     
  3240. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits - (09/09/15)
     
  3241. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes - 75% reduced liver mortality & severe liver morbidity - (09/09/15)
     
  3242. EASL: SURVIVAL OF PATIENTS INFECTED BY CHRONIC HEPATITIS C AND F0F1 FIBROSIS AT BASELINE AFTER A 15 YEARS FOLLOW-UP - (09/08/15)
     
  3243. Center for Health Economics of Treatment for Substance Users Established (HCV, HIV) - (09/04/15)
     
  3244. California Invokes New HCV Drug Restrictions - (09/04/15)
     
  3245. Merck GT4 - (09/04/15)
     
  3246. Harvoni GT4/5 - EASL/2015-GS9857/GS5816 - (09/04/15)
     
  3247. Abbvie GT4 - FDA Approved 7/28/15 - (09/04/15)
     
  3248. Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade - (09/04/15)
     
  3249. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits - (09/04/15)
     
  3250. New Study - SVR Reduces Liver Mortality & Morbidity by 75% and CVD Hospitaliztion by 30% - (09/04/15)
     
  3251. Ledipasvir-sofosbuvir for hepatitis C genotype 4 infection - Comment - (09/04/15)
     
  3252. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study - (09/04/15)
     
  3253. Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4 - (09/04/15)
     
  3254. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection - (09/04/15)
     
  3255. Optimism for patients with genotype 4 HCV infection: Clinical trials with direct-acting antivirals finally available - Editorial - (09/03/15)
     
  3256. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry - (09/03/15)
     
  3257. UK/NICE - Hepatitis C (chronic)-daclatasvir [ID766] - (09/03/15)
     
  3258. Daclatasvir/GT3 Canada Approves After England Denies & US Approves & EASL Recommends - (09/03/15)
     
  3259. Liver Damage in Hepatitis C Patients Significantly Underestimated and Underreported - (09/03/15)
     
  3260. Prevalence of Cirrhosis in Hepatitis C Patients in the Chronic Hepatitis Cohort Study (CHeCS): A Retrospective and Prospective Observational Study....."may be significantly underestimated, underdiagnosedm, underdocumented, underreported" - (09/02/15)
     
  3261. IAS: HCV Co-infection Report by David Shepp MD - David H Shepp, MD Associate Professor of Medicine Hofstra-North Shore LIJ School of Medicine - (09/02/15)
     
  3262. IAS: Fibrosis Regression is Possible after Successful Treatment of Hepatitis C, Even with Cirrhosis - Patients with F4 don't regress as often as those with earlier disease - (09/02/15)
     
  3263. African American women have 19 times higher rates of HIV diagnosis.....44% of women retained in care....Viral Suppression 33% to 53% in Women Depending on Age with Younger women 33-36% vs 42-53% for Older Women - (08/17/15)
     
  3264. Hepatitis C patients in England denied lifesaving liver drug .....daclatasvir - (08/17/15)
     
  3265. New "Recommendations for the management of hepatitis C virus infection among people who inject drugs" but not new......"HCV Test & Treat" / Routine HCV Screening - (08/17/15)
     
  3266. Many hepatitis C patients with serious liver disease to be denied a chance of a cure* as NICE announces decision to restrict use of the daily oral pill, Daklinza® (daclatasvir)1,2 - (08/17/15)
     
  3267. IAS: The risk of cardiovascular disease and death over 10 years in HIV/HCV co-infected patients with and without steatosis ....mortality was high .....high rates of cardiovascular disease - (08/14/15)
     
  3268. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus Aug 4 2015 - (08/14/15)
     
  3269. Incident Hepatitis C Virus Infections Among Users of HIV Preexposure Prophylaxis in a Clinical Practice Setting - (08/14/15)
     
  3270. Recent Approval Holds Promise for Genotype 3, but Hurdles Anticipated - Editorial - (08/14/15)
     
  3271. Chronic Hepatitis C Virus Infection Is Associated with Subclinical Coronary Atherosclerosis in the Multicenter AIDS Cohort Study (MACS): a Cross-Sectional Study - (08/13/15)
     
  3272. Linoleic Acid Induced Acute Hepatitis: A Case Report and Review of the Literature - (08/13/15)
     
  3273. National Health expenditures Not Increasing says CMS Paper / White House Supports Payment for $178,000 Cancer Drug - (08/10/15)
     
  3274. HCV Emergency Room Testing Study in Oakland, CA - 10% prevalence - 38% among IDUs / 25% among homeless / 13% in Birth cohort - 24% attended follow-up visits - highest among Blacks - (08/07/15)
     
  3275. Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5 - (08/06/15)
     
  3276. GT1-5 Sofosbuvir/Harvoni / GS5816 / GS9857 Future Pangenotypic Protease Inhibitor - (08/06/15)
     
  3277. GS-5816 / GS9857 Genotypes 1-6 - (08/06/15)
     
  3278. Transportation Bill Allows for $500 Mill for HCV for Vets - (08/06/15)
     
  3279. Achillion Announces That Janssen Has Initiated a Phase I Study to Evaluate the Effect of Simeprevir and Odalasvir (ACH-3102) on AL-335 Pharmacokinetics - (08/03/15)
     
  3280. HCV DRUG Wars - The Federal & State Medicaid Deceit, Lies & Scandal..... Compare Prices - HCV Drug Pricing vs New Cholesterol Drugs - (08/03/15)
     
  3281. Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection - (07/31/15)
     
  3282. New Millman Report - Aging Will Affect Medicare's Hepatitis C Mortality and Cost - (07/31/15)
     
  3283. Why We Should Be Willing to Pay for Hepatitis C Treatment - (07/31/15)
     
  3284. Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection - (07/30/15)
     
  3285. Aging will affect Medicare's Hepatitis C mortality and cost - (07/30/15)
     
  3286. Launch of a Nationwide Hepatitis C Elimination Program - Georgia, April 2015 - (07/30/15)
     
  3287. Georgia sets sights on eliminating hepatitis C - (07/30/15)
     
  3288. TAF-Harvoni Drug Interaction ..... Drug Interactions Between Anti-HCV Antivirals Ledipasvir/Sofosbuvir and Integrase Strand Transfer Inhibitor-Based Regimens......"LDV/SOF may be coadministered with E/C/F/TAF without monitoring" - (07/30/15)
     
  3289. IAS: HCV/HIV Coinfection at IAS Vancouver 2015 July 19-23 - (07/30/15)
     
  3290. IAS: Treat HCV Early or you are at risk of cirrhosis & then not achieving regression of fibrosis which increases death rate & liver-related complications.....study finds fibrosis regression is required even with an SVR to reduce all-cause death & liver-related death.....THUS, early HCV treatment is crucial, waiting until cirrhosis is tantamount to a 50% chance of a death sentence - (07/29/15)
     
  3291. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine - (07/28/15)
     
  3292. FDA Approves Daklinza (daclatasvir) for the Treatment of Patients with Chronic Hepatitis C Genotype 3 - (07/28/15)
     
  3293. Daclatasvir FDA Prescribing Information/Label - (07/28/15)
     
  3294. TECHNIVIE™ (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA Approval as the First and Only All-Oral, Interferon-Free Treatment for Genotype 4 Chronic Hepatitis C in the U.S. - (07/28/15)
     
  3295. Abbvie GT4 FDA Label/PI - (07/28/15)
     
  3296. FDA approves Technivie (Abbvie 2D) for treatment of chronic hepatitis C genotype 4 - (07/28/15)
     
  3297. FDA Announcement Daclatasvir GT3 - (07/28/15)
     
  3298. IAS: Janssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral, Once-Daily OLYSIO® (Simeprevir) in Combination with Sofosbuvir - (07/28/15)
     
  3299. IAS: Frequent Fibrosis Regression With SVR in HCV/HIV+, Cutting Death Risk - (07/28/15)
     
  3300. IAS: Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1 - (07/24/15)
     
  3301. IAS: Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1 - (07/24/15)
     
  3302. IAS: More Diabetes and CVD, Shorter Survival, in HIV/HCV-Positives With Steatosis - written by Mark Mascolini - (07/22/15)
     
  3303. IAS: Abbvie 3D in HCV/HIV Update ......HIGH SVR RATES IN HCV/HIV-1 CO-INFECTED PATIENTS REGARDLESS OF BASELINE CHARACTERISTICS........(note IDUs had 100% SVR) - (07/22/15)
     
  3304. IAS: DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HIV-HCV COINFECTION: INTERIM ANALYSIS OF A FRENCH MULTICENTER COMPASSIONATE USE PROGRAM (AI444-258) - (07/22/15)
     
  3305. IAS: Ledipasvir/sofosbuvir for 12 Weeks in Patients Coinfected With HCV and hiv-1: ION-4 - (07/22/15)
     
  3306. CDC Report: Increased Heroin Use in USA - "Demographic and Substance Use Trends Among Heroin Users - United States, 2002-2013" - - (07/17/15)
     
  3307. Impact of hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy - (07/17/15)
     
  3308. HCV at VA - "$500 MILLION SHORTFALL IN FY 2015" - "New VA Shutdown Threat Documents Revealed"..... - (07/17/15)
     
  3309. EASL: INTERFERON AND RIBAVIRIN-FREE THERAPY WITH SOFOSBUVIR AND DACLATASVIR IN A REAL-LIFE COHORT OF DIFFICULT-TO-TREAT HIV/HCV-COINFECTED PATIENTS WITH AND WITHOUT PORTAL HYPERTENSION - (07/13/15)
     
  3310. EASL: Safety, efficacy and tolerability of half-dose Sofosbuvir plus Simeprevir in treatment of Hepatitus C in patients with end stage renal disease - (07/13/15)
     
  3311. Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection - (07/13/15)
     
  3312. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans......early treatment equals higher SVR - (07/13/15)
     
  3313. Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease - (07/13/15)
     
  3314. AbbVie's Investigational Chronic Hepatitis C Treatment Granted Priority Review in Japan - (07/13/15)
     
  3315. Abbvie GT1b GIFT-1/TURQUOISE-III - (07/13/15)
     
  3316. Treatment of hepatitis C in patients with HIV - Comment - (07/10/15)
     
  3317. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial - (07/10/15)
     
  3318. HCV Reinfections Among MSM - Triple Reinfections Reported in 1 Study - (07/10/15)
     
  3319. HCV Tripled Among HIV+ MSM in NYC, Earlier Death Reported by NYC - (07/10/15)
     
  3320. "Acute HCV infection of HIV-infected MSM in New York City is sexually transmitted"......"HCV epidemic in both HIV-infected and -uninfected MSM has been ongoing for decades" - (07/10/15)
     
  3321. NS5A Mutations/HCV Drug Resistance - (07/08/15)
     
  3322. Japan's Ministry of Health, Labour and Welfare Approves Gilead's Harvoni®, the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C - (07/06/15)
     
  3323. ISVHLD: REAL-WORLD EFFECTIVENESS OF LEDIPASVIR/SOFOSBUVIR 8 WEEKS CHRONIC HEPATITIS C TREATMENT - (07/02/15)
     
  3324. ISVHLD: HCV-TARGET International Registry Do Phase III Trials Translate into Real World ...... /GT2-3/Harvoni 8 Wks/SIM-SOF.....Sof/Rbv, Peg/Rbv/Sof - (07/02/15)
     
  3325. ISVHLD: Ledipasvir/Sofosbuvir Single Tablet Regimen Is Effective in Patients With HCV Genotype 2 Infection - (07/02/15)
     
  3326. Acute HCV Underreported, Time for Routine HCV Testing in USA... - (07/02/15)
     
  3327. Genotype 3 Report - Treatment history, 3 Guidelines (EASL, UK, AASLD/IDSA/IAS), prevalence, after disease progression - (07/01/15)
     
  3328. Restrictions [illegal] for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States - (07/01/15)
     
  3329. Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs - Opinion - (07/01/15)
     
  3330. Hepatitis C Virus Treatment and Injection Drug Users: It Is Time to Separate Fact From Fiction - Opinion - (07/01/15)
     
  3331. Underascertainment of Acute Hepatitis C Virus Infections in the U.S. Surveillance System: A Case Series and Chart Review - Opinion - (07/01/15)
     
  3332. Sofosbuvir-Based Regimens Are Associated With High SVR Rates Across Genotypes and Among Patients With Multiple Negative Predictive Factors - (07/01/15)
     
  3333. Genotype 3 - prevalence, treatment - (06/30/15)
     
  3334. What's behind fatigue, elevated liver enzymes? - (06/30/15)
     
  3335. [FDA] Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs - (06/30/15)
     
  3336. HEPATITIS C GUIDANCE: AASLD-IDSA [IAS] RECOMMENDATIONS FOR TESTING, MANAGING, AND TREATING ADULTS INFECTED WITH HEPATITIS C VIRUS - (WHEN AND IN WHOM TO INITIATE HCV THERAPY) - - (06/30/15)
     
  3337. CE: Viral Hepatitis: New U.S. Screening Recommendations, Assessment Tools, and Treatments ".....focusing on the role of nurses in prevention and treatment" - (06/30/15)
     
  3338. Direct-Acting Antivirals Cure Innate Immunity in Chronic Hepatitis C - EDITORIAL ......"Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function" - (06/30/15)
     
  3339. DDW: Effect of Baseline Factors on Response to the Fixed-Dose Combination of Daclatasvir, Asunaprevir, and Beclabuvir, With or Without Ribavirin, in Patients With HCV Genotype 1 Infection and Cirrhosis - (06/29/15)
     
  3340. DDW: The Effect of Renal Impairment on Multiple-dose Pharmacokinetics of the Fixed-dose Combination of Daclatasvir/Asunaprevir/Beclabuvir - (06/29/15)
     
  3341. DDW: On-treatment HCV RNA as a Predictor of Sustained Virologic Response in HCV Genotype 3-Infected Patients Treated With Daclatasvir and Sofosbuvir: Analysis of the Phase 3 ALLY-3 Study - (06/29/15)
     
  3342. TURQUOISE-III: SAFETY AND EFFICACY OF 12-WEEK RIBAVIRIN-FREE TREATMENT FOR PATIENTS WITH HCV GENOTYPE 1B AND CIRRHOSIS - (06/26/15)
     
  3343. Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration - (06/26/15)
     
  3344. The Cost-effectiveness, Health Benefits, and Financial Costs of New Antiviral Treatments for Hepatitis C Virus- new study, commentary "virtually every patient with chronic HCV should be treated [2]. Now." - (06/26/15)
     
  3345. AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis - 100% SVR - (06/24/15)
     
  3346. Continuum of hepatitis C testing and care [in Philadelphia] - HCV Screening/Linkage to Care Programs/funding Needed/Should be the FOCUS - (06/24/15)
     
  3347. DDW: The Natural History of Chronic Hepatitis C. An Updated Look at the Rate of Progression to Cirrhosis and the Incidence of Decompensation in a Large U.S. Health Maintenance Organization - (06/24/15)
     
  3348. Legal Threats to Connecticut Removes HCV Restrictions - (06/23/15)
     
  3349. PCSK-9 inhibitors achieve next milestone, plus 4 more FDA actions, $150 Billion Annual Cost projected Dwarfing HCV - (06/22/15)
     
  3350. HCV Call To Action - (06/22/15)
     
  3351. New HCV Restrictions Proposed for Vets....still no federal solution - (06/22/15)
     
  3352. VA to outsource care for 180,000 vets with hepatitis C & Impose Restrictions - (06/22/15)
     
  3353. ACH-3102 (NS5A) + Ribavirin - (06/22/15)
     
  3354. VA to outsource care for 180,000 vets with hepatitis C - (06/22/15)
     
  3355. Retreatment with an interferon-free combination of simeprevir-sofosbuvir in patients who had previously failed on HCV NS5A inhibitor-based regimens - (06/22/15)
     
  3356. Hepatitis C Bill Awaits Governor's Signature.....would require doctors to provide a hepatitis C screening for patients who are baby boomers - born from 1945 to 1965 - (06/19/15)
     
  3357. Towards interferon-free treatment for all HCV genotypes (gt4) - Editorial - (06/19/15)
     
  3358. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial - (06/19/15)
     
  3359. Genotype 4 Treatment - (06/19/15)
     
  3360. Clinical Pharm of HIV & Hepatitis: The 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy - written by Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center Jennifer J. Kiser, Pharm.D. Assistant Professor School of Pharmacy University of Colorado at Denver - (06/17/15)
     
  3361. EASL: SPONTANEOUS CLEARANCE RATES INCREASE WITH HCV REINFECTION EPISODE IN HIV-POSITIVE MEN WHO HAVE SEX WITH MEN (MSM) INDEPENDENT OF HCV SUBTYPE - (06/17/15)
     
  3362. Mass Prisoners Sue for HCV Treatment Access with Class Action Lawsuit - (06/17/15)
     
  3363. Retreatment with an interferon - free combination of simeprevir - sofosbuvir in patients who had previously failed on HCV NS5A inhibitor - based regimens - (06/17/15)
     
  3364. DDW: The Impact of Sustained Viral Eradication on the Work Productivity of Patients with Chronic Hepatitis C (CHC) from the Five Western European Countries and the United States - (06/16/15)
     
  3365. Acute hepatitis C infection in HIV-negative men who have sex with men [in London].....low HCV screening rate - (06/15/15)
     
  3366. Where next for hepatitis B and C surveillance?....."Hepatitis C Surveillance programmes are often weak" - (06/15/15)
     
  3367. HCV Drug Interactions & Switching Patient's ART Regimen in order to take HCV Therapy - Clin Pharm Workshop - (06/15/15)
     
  3368. Roche cuts Hepatitis C drug cost by 65% for government institutions - (06/15/15)
     
  3369. UK Announces Funding Increased to Treat HCV Cirrhotics Only - (06/15/15)
     
  3370. Global Distribution & Prevalence of HCV Genotypes (GT3) - (06/15/15)
     
  3371. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis - (06/15/15)
     
  3372. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study....genotype 3 was found in 20.8% - (06/15/15)
     
  3373. Genotype 3 Numbers in USA - (06/15/15)
     
  3374. Genotypes, Genotype 3 (GT3) in VA, Global - (06/15/15)
     
  3375. HCV Genotype 3 Is Associated With an Increased Risk of Cirrhosis and Hepatocellular Cancer in a National Sample of U.S. Veterans With HCV - (06/15/15)
     
  3376. GT3 Progress quickly - HCV/HIV Coinfected Patients & Switching ARTs - GT3 Daclatasvir/SOF 24 Weeks Model 95% SVR - (06/15/15)
     
  3377. HCV Genotype 3 Treatment: Daclatasvir+Sofosbuvir, Sofosbuvitr+Peg/Rbv / EASL-Abbvie/Gilead/J&J/Merck/BMS/Achillion/African-Americans/New Drugs - (06/15/15)
     
  3378. Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial - (06/11/15)
     
  3379. DDW: Cascade of Care for Hepatitis C Virus (HCV) Infection within the U.S. Department of Veterans Affairs (VA) - (06/11/15)
     
  3380. The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients - (06/11/15)
     
  3381. The All Wales Medicines Strategy Group (AWMSG) has recommended Daklinza® (daclatasvir) for the treatment of adult patients with chronic hepatitis C virus (HCV) infection - (06/11/15)
     
  3382. Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013...68% HCV Prevalence - (06/11/15)
     
  3383. Estimates on HCV disease burden worldwide - filling the gaps - (06/09/15)
     
  3384. Enhanced surveillance of hepatitis C in the EU, 2006 - 2012..... injecting drug use was the most common route of transmission....... dearth of research on hepatitis B and C testing in many European countries...... do not yet have enough information to plan effective public health responses in Europe - (06/09/15)
     
  3385. SVRs/Opioid Replacement Therapy, African-Americans - (06/09/15)
     
  3386. Abbott India launches Hepatitis C awareness,diagnosis programme - (06/09/15)
     
  3387. Clinical Pharm of HIV & Hepatitis No Pharmacokinetic Interaction Between HCV Inhibitors Grazoprevir/Elbasvir with Rilpivirine - (06/08/15)
     
  3388. Clinical Pharm of HIV & Hepatitis Coadministration of HCV Protease Inhibitor Grazoprevir With HCV NS5A Inhibitor Elbasvir Has No Effect On Pravastatin But Increases Rosuvastatin Exposure In Healthy Subjects - (06/08/15)
     
  3389. Clinical Pharm of HIV & Hepatitis Drug-Drug Interactions of Ombitasvir/Paritaprevir/r plus Dasabuvir with Dolutegravir or Abacavir plus Lamivudine - (06/08/15)
     
  3390. Clinical Pharm of HIV & Hepatitis Drug-Drug Interactions of Commonly Used Medications with Direct Acting Antiviral HCV Combination Therapy of Paritaprevir/r, Ombitasvir and Dasabuvir - (06/08/15)
     
  3391. Clinical Pharm of HIV & Hepatitis Effect of Comedications on Paritaprevir, Ritonavir, Ombitasvir, Dasabuvir and Ribavirin Pharmacokinetics - (06/08/15)
     
  3392. Clinical Pharm of HIV & Hepatitis Pharmacokinetics of Dasabuvir when Administered with Ombitasvir, Paritaprevir and Ritonavir in Healthy Volunteers - (06/08/15)
     
  3393. Clinical Pharm of HIV & Hepatitis Drug Interactions with Direct Acting Antiviral Combination of Paritaprevir/Ritonavir + Ombitasvir - (06/08/15)
     
  3394. Kirk Joins American Legion to Raise Hepatitis C Awareness for Veterans.....$900 mill for HCV drugs Bill passes Senate Appropriations Committee - (06/03/15)
     
  3395. Sovaldi Medical Tourism - Patients Get Extreme to Obtain Hepatitis Drug That's 1% the Cost Outside U.S. - (06/03/15)
     
  3396. Cancer/HCC Immunotherapies/PD1 Inhibitors - Nivolumab targets a protein called the programmed death-1 (PD-1) receptor & for HCC/Liver Cancer - (06/03/15)
     
  3397. DDW: Issues in Hepatitis C: Identification, Access to Care, and Cost - (06/03/15)
     
  3398. DDW: The Seroprevalence of Hepatitis C in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis - (06/03/15)
     
  3399. Clinical Pharm of HIV & Hepatitis Drug Interactions Between the Anti-HCV Regimen Ledipasvir/Sofosbuvir and Antiretrovirals - (06/03/15)
     
  3400. Clinical Pharm of HIV & Hepatitis Drug Interactions Between Anti-HCV Antivirals Ledipasvir/Sofosbuvir and Integrase Strand Transfer Inhibitor-Based Regimens......"LDV/SOF may be coadministered with E/C/F/TAF without monitoring" - (06/03/15)
     
  3401. Clinical Pharm of HIV & Hepatitis Drug-Drug Interactions with Grazoprevir/Elbasvir: Practical Considerations for the Care of HIV/HCV Co-Infected Patients - (06/03/15)
     
  3402. Clinical Pharm of HIV & Hepatitis Assessment of Drug-Drug Interactions Between Daclatasvir and Darunavir/Ritonavir or Lopinavir/Ritonavir - (06/03/15)
     
  3403. DDW: Predictors of Inpatient Mortality and Resource Utilization of Elderly Patients with Chronic Hepatitis C (CH-C) in the United States - (06/02/15)
     
  3404. DDW: A COST-EFFECTIVENESS ANALYSIS OF LDV/SOF+RBV FOR 12 WEEKS VS. LDV/SOF 24 WEEK VS. SOF+SMV 24 WEEKS IN CHC GT1 TE CIRRHOTIC PATIENTS - (06/02/15)
     
  3405. Clinical Pharm of HIV & Hepatitis Standard Daclatasvir Dose OK With Darunavir/RTV or Lopinavir/RTV - written by Mark Mascolini - (06/01/15)
     
  3406. Clinical Pharm of HIV & Hepatitis Possible Dose Adjustments With Four Drugs and Abbvie 3D HCV Regimen - written by Mark Mascolini - (06/01/15)
     
  3407. Clinical Pharm of HIV & Hepatitis Triple-DAA Combo Cuts SSRI Levels by One Third, But No Dose Adjustment Needed - written by Mark Mascolini - (06/01/15)
     
  3408. Clinical Pharm of HIV & Hepatitis Almost Three Quarters of HIV/HCV Group May Have DAA-ARV Interactions - written by Mark Mascolini - (06/01/15)
     
  3409. Clinical Pharm of HIV & Hepatitis DAAs Grazoprevir and Elbasvir Boost Levels of Rosuvastatin But Not Pravastatin - written by Mark Mascolini - (06/01/15)
     
  3410. Clinical Pharm of HIV & Hepatitis Readying HIV/HCV Coinfected Patients for HCV Treatment: Occurrence and Management of Antiviral Interactions....[can patients switch their HIV regimen?] - (06/01/15)
     
  3411. Clinical Pharm of HIV & Hepatitis Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir: Drug Interactions with Antiretroviral Agents - (06/01/15)
     
  3412. Clinical Pharm of HIV & Hepatitis Therapeutic drug monitoring of daclatasvir in HIV/HCV co-infected patients receiving darunavir/ritonavir 800/100mg once-daily - (06/01/15)
     
  3413. Clinical Pharm of HIV & Hepatitis Population Viral Kinetic Modeling: SVR Prediction in HCV GT-3 Cirrhotic Patients With 24 Weeks of Daclatasvir + Sofosbuvir Administration - (05/29/15)
     
  3414. AASLD: Predicted Future HCV Liver Disease Burden - "Predicting Utilization of Liver Transplantation for Hepatitis C-related Liver Disease in the United States" - (05/29/15)
     
  3415. Merck Submits U.S. New Drug Application for Grazoprevir/Elbasvir, an Investigational Once-Daily, Single Tablet Combination Therapy, for Treatment of Chronic Hepatitis C Genotypes 1, 4, and 6 Infection - (05/29/15)
     
  3416. Clinical Pharm of HIV & Hepatitis Evaluation of Drug Interactions between Dolutegravir and Daclatasvir in Healthy Subjects - (05/29/15)
     
  3417. DDW: Cost Effectiveness of Hepatitis C Treatment - (05/28/15)
     
  3418. DDW: Effectiveness of Sofosbuvir-Based Hepatitis C (HCV) Antiviral Regimens in a Large U.S. Veteran Cohort - (05/28/15)
     
  3419. DDW: CANCER RATES IN PATIENTS WITH CHRONIC HEPATITIS C IN A LARGE U.S. HEALTH MAINTENANCE ORGANIZATION - (05/28/15)
     
  3420. Clinical Pharm of HIV & Hepatitis Evaluation of PK/PD Relationships Between Ribavirin and Sustained Virologic Response in HCV-Genotype 3 Infected Subjects in the Sofosbuvir Phase 3 Program - (05/29/15)
     
  3421. Clinical Pharm of HIV & Hepatitis Model Predicts Higher SVR With 24- vs 12-Week Daclatasvir/Sofosbuvir for HCV-3 Cirrhotics - written by Mark Mascolini - (05/29/15)
     
  3422. DDW: The Cost per Cure of Chronic Hepatitis C (HCV). A Cost Mapping Study of Direct Costs Associated With the Treatment of HCV In A Large U.S. Health Maintenance Organization - (05/28/15)
     
  3423. DDW: Eradication of Hepatitis C: India as a Model for Resource Limited Settings - (05/28/15)
     
  3424. DDW: Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus in Various US Practice Settings: Interim Analysis of the SONET Study - (05/28/15)
     
  3425. DDW: Sustained Virologic Response (SVR) and Liver Disease Progression after Hepatitis C Virus (HCV) treatment initiation: a Real World Analysis using a Large electronic Health record (EHR) Database..... ......SVR reduced progression to cirrhosis or end-stage liver disease by 63-65% - (05/28/15)
     
  3426. DDW: Patient and Clinical Characteristics of Chronic Hepatitis C (CHC) Patients Treated With Newer Direct-Acting Antiviral (DAA)-based Regimens From a Large US Payer Perspective - (05/28/15)
     
  3427. DDW: Safety and Efficacy of Ledipasvir/Sofosbuvir for the Treatment of Genotype 1 Hepatitis C in Patients Aged 65 Years or Older: A Retrospective Analysis of International Phase 3 Studies - (05/28/15)
     
  3428. DDW: Sofosbuvir-Based Regimens for Patients with Hepatitis C Virus Genotype 3 Infection: Summary Results from the VALENCE, BOSON, LONESTAR-2, and ELECTRON-2 Studies - (05/28/15)
     
  3429. DDW: Plasma Interferon-γ-Inducible Protein 10 (IP-10) and Response to Interferon-Free Direct-Acting Antiviral Therapy in HCV Genotype 1-Infected Patients With and Without Cirrhosis - Abbvie Analysis - (05/22/15)
     
  3430. DDW: High Rates of Adherence to Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients With Cirrhosis: Data From the TURQUOISE-II Study - (05/22/15)
     
  3431. DDW: Evaluation of access to care in patients prescribed sofosbuvir-containing regimens; data from the TRIO network - (05/22/15)
     
  3432. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial - (05/28/15)
     
  3433. Bristol-Myers Squibb Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen - (05/28/15)
     
  3434. From the big three to the big four [Hepatitis] / little HCV Funding Comment - (05/27/15)
     
  3435. AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis - (05/27/15)
     
  3436. Liver Fibrosis Non-Invasive Testing - Staging Liver Disease in 2015 - combining elastography + blood tests - (05/22/15)
     
  3437. Merck at EASL 2015 - (05/22/15)
     
  3438. EASL: Summary from EASL 2015 for Hepatitis C All oral HCV DAA therapy on its way to optimization: still much to learn. - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany (05/22/15)
     
  3439. Routine HCV Screening Project in Philadelphia finds High HCV-Infection Rate, 8.6% infected with HCV: CDC Report - "Identification and Linkage to Care of HCV-Infected Persons in Five Health Centers - Philadelphia, Pennsylvania, 2012-2014" - (05/20/15)
     
  3440. Connecticut is making a new class of hepatitis C drugs more accessible to those on Medicaid - (05/20/15)
     
  3441. Blue Cross Withholds Cure from Hepatitis C Patients, Lawsuit Claims - (05/20/15)
     
  3442. Staging Liver Disease in Clinical Practice 2015: Focus on Hepatitis C......"Combine elastography and blood tests when possible" - (05/20/15)
     
  3443. Blue Cross Withholds Cure from Hepatitis C Patients, Lawsuit Claims - (05/20/15)
     
  3444. Achillion Enters Into Worldwide Collaboration for Hepatitis C With Janssen - (05/20/15)
     
  3445. Janssen Enters into a Worldwide Collaboration with Achillion Pharmaceuticals, Inc. to Combat Hepatitis C Virus - (05/20/15)
     
  3446. Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection: A Systematic Review - (05/20/15)
     
  3447. Noninvasive Methods to Assess Liver Disease in Patients With Hepatitis B or C - (05/20/15)
     
  3448. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®) - (05/20/15)
     
  3449. FIB-4 and Liver Stiffness Measurement Predict Death - "Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C" - (05/20/15)
     
  3450. CDC Hepatitis C section Under Fire - "Centers for Disease Control and Prevention: protecting the private good?" - (05/20/15)
     
  3451. Combining Fibroscan+Serum Fibrosis Test for Staging - "Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive" - (05/18/15)
     
  3452. Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients - (05/18/15)
     
  3453. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography - (05/18/15)
     
  3454. EASL: PRECLINICAL CHARACTERISATION OF MIV-802, A NOVEL URIDINE NUCLEOTIDE HCV NS5B POLYMERASE INHIBITOR, FOR TREATMENT OF HEPATITIS C VIRUS INFECTION - (05/18/15)
     
  3455. EASL: IDUs/Intervention Model Global - What is needed to control Hepatitis C (HCV) in different epidemiological settings? - (05/18/15)
     
  3456. EASL: UNDERSTANDING AND PREVENTING THE HCV EPIDEMIC AMONG MEN WHO HAVE SEX WITH MEN IN THE UK: A MATHEMATICAL MODELLING ANALYSIS - (05/18/15)
     
  3457. EASL: The Impact of Ribavirin on Real World Adherence and Discontinuation Rates in HCV Patients Treated with Sofosbuvir + Simeprevir - (05/18/15)
     
  3458. EASL: Exposure-Response Analyses for Efficacy (SVR12) for the Direct Acting Antiviral Regimen of Paritaprevir/r, Ombitasvir with Dasabuvir ï Ribavirin in Subjects with HCV Genotype 1 Infection - (05/18/15)
     
  3459. EASL: PHARMACOKINETICS OF PARITAPREVIR, OMBITASVIR, DASABUVIR, RITONAVIR AND RIBAVIRIN IN SUBJECTS WITH HCV GENOTYPE 1 INFECTION IN PHASE 3 STUDIES - (05/18/15)
     
  3460. EASL: Adherence to Ombitasvir/Paritaprevir/r, Dasabuvir, and Ribavirin is >98% in the SAPPHIRE-I and SAPPHIRE-II Trials - (05/18/15)
     
  3461. EASL: Public Health Impact of HCV Screening and Treatment in the French Baby-Boomer Population - (05/18/15)
     
  3462. SVR Improves Health / Cost Outcomes - (05/15/15)
     
  3463. EASL: How should scale up of HCV antiviral treatment be prioritized? A cost-effectiveness analysis including individual and population prevention benefits - (05/15/15)
     
  3464. EASL: Achillion at EASL 2015 - (05/15/15)
     
  3465. EASL: HEALTHCARE ECONOMICS / SVR Improves Health, Mortality / Early HCV Therapy Prefer - (05/14/15)
     
  3466. EASL: Cohort Studies at EASL 2015 - (05/14/15)
     
  3467. EASL: Gilead at EASL 2015 - (05/12/15)
     
  3468. EASL: NS5A Mutations/Resistance - (05/11/15)
     
  3469. EASL: GS-9857 Pangenotypic Protease Inhibitor + SOF/GS5816 for 6/8 Weeks - (05/11/15)
     
  3470. EASL: ABT530+ABT493 Pangenotypic in Phase 2B - (05/11/15)
     
  3471. EASL: WHO moves to improve access to lifesaving medicines for hepatitis C, drug-resistant TB and cancers - (05/11/15)
     
  3472. EASL: Harvoni Post-Transplant - (05/11/15)
     
  3473. EASL: Safety and efficacy of Sofosbuvir-containing regimens in the French cohort- ANRS CO22 HEPATHER - (05/11/15)
     
  3474. EASL: Negative impact of HBV/HCV coinfection on HBV or HCV monoinfection: data from the French cohort- ANRS CO22 HEPATHER - (05/11/15)
     
  3475. EASL: Abbvie at EASL 2015 - Healthcare Economics, Clinical Trials - (05/11/15)
     
  3476. EASL: J&J at EASL - (05/11/15)
     
  3477. EASL: BMS at EASL - (05/11/15)
     
  3478. The Cost-Effectiveness of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Virus Genotype 2 or 3 Infection - (05/11/15)
     
  3479. The VA's Hepatitis C Problem - (05/11/15)
     
  3480. Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis - (05/11/15)
     
  3481. EASL: New HCV Drugs new nukes-NS5A/Protease Inhibitors - (05/08/15)
     
  3482. CDC Reports 350% Surge in HCV Infections Among Young in Apalachia; federal ineptitude & refusal to respond to HCV persists - (05/06/15)
     
  3483. Pricing Expensive New Drugs - (05/06/15)
     
  3484. Saudi Arabia approves groundbreaking hepatitis treatment Viekira Pak - (05/06/15)
     
  3485. Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis - (05/06/15)
     
  3486. Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection - (05/06/15)
     
  3487. Editorial - Continued Progress Against Hepatitis C Infection - (05/06/15)
     
  3488. EASL: Merck HCV Nuk MK3682 7-Day Monotherapy - (05/05/15)
     
  3489. EASL: Preclinical Characterization of AL-335, a Potent Uridine Based Nucleoside Polymerase Inhibitor for the Treatment of Chronic Hepatitis C - (05/05/15)
     
  3490. EASL: Derisking the Potential for Mitochondrial Toxicity of Nucleoside Analogs - (05/05/15)
     
  3491. EASL: Effect of Baseline Factors on Response to the Fixed-Dose Combination Of Daclatasvir, Asunaprevir and Beclabuvir in Non-Cirrhotic Patients with HCV Genotype 1 Infection - (05/05/15)
     
  3492. EASL: Effect of Baseline Factors on Response to the Fixed-Dose Combination of Daclatasvir, Asunaprevir, and Beclabuvir, With or Without Ribavirin, in Patients With HCV Genotype 1 Infection and Cirrhosis - (05/05/15)
     
  3493. EASL: The Pharmacokinetics of Beclabuvir (BMS-791325) When Administered in Combination With Daclatasvir and Asunaprevir in Treatment-naive Patients With or Without Cirrhosis Infected With HCV Genotype 1 - (05/05/15)
     
  3494. EASL: The Effect of Renal Impairment on Multiple-dose Pharmacokinetics of the Fixed-dose Combination of Daclatasvir/Asunaprevir/Beclabuvir - (05/05/15)
     
  3495. EASL: Safety and Efficacy of Sofosbuvir-Containing Regimens in Hepatitis C Infected Patients with Reduced Renal Function: Real-World Experience from HCV-TARGET - (05/05/15)
     
  3496. EASL: Evaluation of Drug-Drug Interactions Between the Fixed-Dose Combination of Daclatasvir/Asunaprevir/Beclabuvir and Methadone or Buprenorphine/Naloxone - (05/05/15)
     
  3497. EASL: Steady-State Pharmacokinetics and Safety of Co-administration of Pan-Genotypic Direct Acting Protease Inhibitor ABT-493 with Pan-Genotypic NS5A Inhibitor ABT-530 in Healthy Adult Subjects - (05/04/15)
     
  3498. EASL: Advanced Fibrosis is Common in Individuals whose Hepatitis C Has Not Been Diagnosed: Results from the National Health and Nutrition Examination Survey 2001-2012 - (05/04/15)
     
  3499. EASL: Pharmacokinetics of ABT-493 and ABT-530 is Similar in Healthy Caucasian, Han Chinese, and Japanese Adult Subjects - (05/04/15)
     
  3500. EASL: 8 HCV DAA Studies in African-Americans - (05/04/15)
     
  3501. EASL: No Evidence of Pharmacokinetic Drug-Drug Interaction in Healthy Subjects Between Coadministered Grazoprevir (MK-5172)/Elbasvir (MK-8742) and Sofosbuvir - (05/04/15)
     
  3502. EASL: Resistance Analysis of Virologic Failures in Hepatitis C Genotype 1-Infected Patients Treated With Grazoprevir + Elbasvir ï Ribavirin: the C-WORTHY Study - (05/04/15)
     
  3503. EASL: The ASTRAL Studies: Evaluation of SOF/GS-5816 Single-Tablet Regimen for the Treatment of Genotype 1-6 HCV Infection - (05/04/15)
     
  3504. EASL: Early versus delayed use of sofosbuvir plus peginterferon/ribavirin therapy in fibrosis patients with hepatitis C virus: a cost-effectiveness analysis - (05/04/15)
     
  3505. EASL: Resistance Analysis of Treatment-Experienced Genotype 1 and 3 HCV-Infected Patients Treated With Sofosbuvir in Combination With GS-5816 ï Ribavirin for 12 Weeks - (05/04/15)
     
  3506. EASL: Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of Fibrosing Cholestatic Hepatitis C After Liver Transplantation - (05/04/15)
     
  3507. EASL: Early Viral Kinetics in Patients With Varying Degrees of Fibrosis and Cirrhosis in the SOLAR-1 Trial - (05/04/15)
     
  3508. EASL: Potent Antiviral Activity of ABT-493 and ABT-530 With 3-Day Monotherapy in Patients With and Without Compensated Cirrhosis With Hepatitis C Virus (HCV) Genotype 1 Infection - (05/04/15)
     
  3509. NY City Council Moves to Require Hepatitis Reporting - (04/31/15)
     
  3510. EASL: SVR Reduces Morbidity/Deaths by 5-10 Fold - Abbvie Analysis - Percent of Subjects Experiencing Liver Morbidity Over a Lifetime Horizon with AbbVie 3D (Abt-450/Ritonavir/Ombitasvirand Dasabuvir) Versus No treatment - (04/31/15)
     
  3511. EASL: Sustained Virologic Response After ACH-3102 and Sofosbuvir Treatment for 8 or 6 Weeks: a Phase 2 "Proxy" Study - (04/31/15)
     
  3512. EASL: ACH-3422, a Novel Nucleotide Prodrug Inhibitor of HCV NS5B Polymerase - (04/31/15)
     
  3513. EASL: ACHIEVEMENT OF SVR24 DESPITE THE PRESENCE OF HCV VARIANTS RESISTANT TO FIRST-GENERATION NS5A INHIBITORS IN GENOTYPE-1 HEPATITIS C PATIENTS AFTER 8-WEEK THERAPY OF ACH-3102 IN COMBINATION WITH SOFOSBUVIR - (04/31/15)
     
  3514. EASL: Relationship between HCV genotype, liver co-morbidities and fibrosis in the French cohort ANRS CO22 HEPATHER - (04/31/15)
     
  3515. EASL: Cost-Effectiveness of Treating Different Stages of Genotype 1 Hepatitis C Virus (GT1-HCV) With Viekira Pak (Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir) ï Ribavirin Compared to No Treatment in the United States - (04/31/15)
     
  3516. EASL: 100% SVR12 With Ledipasvir/Sofosbuvir ï Ribavirin for 12 Weeks in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Who Previously Failed Protease Inhibitor + Pegylated Interferon-a + Ribavirin Therapy - (04/31/15)
     
  3517. EASL: 98% SVR12 in Korean and Taiwanese Patients With Chronic Genotype 2 HCV Infection Receiving 12 Weeks of Sofosbuvir Plus Ribavirin: Results From an International, Multicenter Phase 3 Study - (04/31/15)
     
  3518. EASL: Final evaluation of HCV patients treated with 12 week regimens containing sofosbuvir +/- simeprevir in the TRIO network: academic and community treatment of a real-world, heterogeneous population - (04/30/15)
     
  3519. EASL: Efficacy evaluation of 24 week SOF + RBV in a heterogeneous, real-world population of Genotype 3 HCV; data from the TRIO network - (04/30/15)
     
  3520. EASL: Comparison of sofosbuvir +/- simeprevir in heterogeneous, real-world populations of HCV patients over 70 years; data from the TRIO network - (04/30/15)
     
  3521. EASL: Prevalence of Pretreatment NS5A and NS5B Resistance-Associated Variants and Genetic Variation Within HCV Subtypes Across Different Countries/Gilead-Study - (04/30/15)
     
  3522. EASL: Ledipasvir/Sofosbuvir With Ribavirin Is Safe in >600 Decompensated and Post-Liver Transplantation Patients With HCV Infection: An Integrated Safety Analysis of the SOLAR-1 and SOLAR-2 Trials - (04/29/15)
     
  3523. EASL: The Prevalence and the Effect of HCV NS5A Resistance-Associated Variants in Patients With Compensated Cirrhosis Treated With Ledipasvir/Sofosbuvir ï RBV - (04/29/15)
     
  3524. EASL: Time Course of Hepatic Improvement using the HepQuant® (HQ)-SHUNT Function Test during and after Treatment with Ledipasvir/Sofosbuvir in Liver Transplant Recipients with Allograft Fibrosis or Cirrhosis and Patients with Decompensated Cirrhosis who have not undergone Transplantation - (04/29/15)
     
  3525. EASL: Effect of Long-Term Viral Suppression With Sofosbuvir + Ribavirin on Hepatic Venous Pressure Gradient in HCV-Infected Patients With Cirrhosis and Portal Hypertension - (04/29/15)
     
  3526. EASL: Daclatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of HCV in Patients With Severe Liver Disease: Interim Results of a Multicenter Compassionate Use Program - (04/29/15)
     
  3527. EASL: A Systematic Review of Viral Hepatitis B and C Testing in Europe: shortage of hepatitis screening studies across Europe/barrier to diagnosis, early treatment & prevention - (04/29/15)
     
  3528. EASL: Evaluation of the Pangenotypic HCV NS3/4A Protease Inhibitor GS-9857 in Healthy Volunteers - (04/29/15)
     
  3529. EASL: Preclinical Profile of the Pangenotypic HCV NS3/4A Protease Inhibitor GS-9857 - (04/29/15)
     
  3530. EASL: Ledipasvir/Sofosbuvir for the Treatment of Patients With Chronic Genotype 4 or 5 HCV Infection - (04/29/15)
     
  3531. EASL: HCV Reinfection in Phase 3 Studies of Sofosbuvir - (04/29/15)
     
  3532. EASL: Long-Term Persistence of HCV NS5A Variants After Treatment With NS5A Inhibitor Ledipasvir - (04/29/15)
     
  3533. EASL: A Phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2 - (04/29/15)
     
  3534. EASL: EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE TO PREVENT VERTICAL TRANSMISSION IN MOTHERS WITH LAMIVUDINE-RESISTANT HBV - (04/29/15)
     
  3535. EASL: A Phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1 - (04/28/15)
     
  3536. EASL: Real World Effectiveness and Cost of Simeprevir- and/or Sofosbuvir-based HCV Treatments - (04/28/15)
     
  3537. EASL: PREDICTORS OF SUSTAINED VIRAL RESPONSE TO 4-6 WEEK DURATION THERAPY WITH LEDIPASVIR + SOFOSBUVIR + GS-9451 +/- GS-9669 IN EARLY AND ADVANCED FIBROSIS (NIH/UMD SYNERGY TRIAL) - (04/28/15)
     
  3538. EASL: HIGH EFFICACY OF RETREATMENT WITH LEDPASVIR AND SOFOSBUVIR IN HCV PATIENTS WHO FAILED INITIAL SHORT COURSE THERAPY WITH COMBINATION DAA REGIMENS (NIH SYNERGY TRIAL) - (04/28/15)
     
  3539. EASL: Safety and efficacy of all-oral DAA regimens in HIV-HCV coinfected cirrhotic patients from the prospective ANRS CO13 - HEPAVIH cohort - (04/28/15)
     
  3540. EASL: Efficacy of the oral Sofosbuvir-based combination in HCV genotype 4-monoinfected patients from the French observational cohort ANRS CO22 HEPATHER - (04/28/15)
     
  3541. EASL: CAN HEPATITIS C TREATMENT BE SAFELY DELAYED?: EVIDENCE FROM THE VETERANS ADMINISTRATION HEALTHCARE SYSTEM - (04/28/15)
     
  3542. EASL: The Value of Survival Benefits from Treating Hepatitis C at Different Fibrosis Stages with All-Oral, Interferon-Free Therapy Relative to 'Watchful Waiting' - (04/28/15)
     
  3543. EASL: Reduction in Annual Medical Costs with Early Treatment of HCV Using Abbvie 3D (AbT-450/Ritonavir/Ombitasvir and Dasabuvir) ï Ribavirin in the United States - (04/28/15)
     
  3544. EASL: Grazoprevir/Elbasvir plus Ribavirin For Chronic HCV Genotype-1 Infection After Failure of Combination Therapy Containing a Direct-Acting Antiviral Agent - (04/28/15)
     
  3545. EASL: EFFICACY OF AN 8-WEEK REGIMEN OF GRAZOPREVIR PLUS ELBASVIR WITH AND WITHOUT RIBAVIRIN IN TREATMENT-NAIVE, NONCIRRHOTIC HCV GENOTYPE 1B INFECTION - (04/28/15)
     
  3546. EASL: A Single-Tablet Regimen of Ledipasvir/Sofosbuvir for 12 Weeks in HCV Genotype 1- or 4-Infected Patients With HIV-1 Coinfection: the Phase 3 ION-4 Study - (04/28/15)
     
  3547. EASL: Merck Phase 3 clinical trials evaluating grazoprevir/elbasvir, C-EDGE program, - (04/28/15)
     
  3548. EASL: Real-world effectiveness of Ledipasvir/Sofosbuvir 8 weeks chronic HCV treatment - (04/28/15)
     
  3549. EASL: Ledipasvir/Sofosbuvir With Ribavirin Is Safe in >600 Decompensated and Post-Liver Transplantation Patients With HCV Infection: An Integrated Safety Analysis of the SOLAR-1 and SOLAR-2 Trials - (04/28/15)
     
  3550. EASL: OMBITASVIR/PARITAPREVIR/RITONAVIR FOR TREATMENT OF HCV GENOTYPE 1B IN JAPANESE PATIENTS WITH OR WITHOUT CIRRHOSIS: RESULTS FROM GIFT-I - (04/28/15)
     
  3551. EASL: ALL-ORAL 12-WEEK COMBINATION TREATMENT WITH DACLATASVIR AND SOFOSBUVIR IN TREATMENT-EXPERIENCED PATIENTS INFECTED WITH HCV GENOTYPE 3: A SUBANALYSIS OF THE ALLY-3 PHASE 3 STUDY - (04/28/15)
     
  3552. EASL: Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients with Advanced Cirrhosis or Post-transplant Recurrence: ALLY-1 Phase 3 Study - (04/28/15)
     
  3553. EASL: On-Treatment HCV RNA as a Predictor of Sustained Virologic Response in HCV Genotype 3-Infected Patients Treated With Daclatasvir and Sofosbuvir: A Subanalysis of the Phase 3 ALLY-3 Study - (04/28/15)
     
  3554. EASL: Daclatasvir Plus Sofosbuvir for Treatment of HCV Genotypes 1-4 in HIV-HCV Coinfection: The ALLY-2 Study - (04/28/15)
     
  3555. EASL: CANCER RATES IN PATIENTS WITH CHRONIC HEPATITIS C IN A LARGE U.S. HEALTH MAINTENANCE ORGANIZATION (Kaiser)....HCV Linked to Increased Cancer Risks/Not just liver cancer - (04/27/15)
     
  3556. EASL: Sofosbuvir Plus Peg-IFN/RBV for 12 Weeks vs Sofosbuvir/RBV for 16 or 24 Weeks in Genotype 3 HCV-Infected Patients and Treatment-Experienced Cirrhotic Patients With Genotype 2 HCV: The BOSON Study - (04/27/15)
     
  3557. EASL: SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR FOR TREATING HCV GT1 INFECTION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT OR END-STAGE RENAL DISEASE: THE RUBY-I STUDY - (04/27/15)
     
  3558. EASL: Malachite-I Phase 3b Trial of Ombitasvir/Paritaprevir/r and Dasabuvir ï Ribavirin or Telaprevir + Peginterferon/Ribavirin in Treatment-Naïve Adults With Hc v Genotype 1 - (04/27/15)
     
  3559. EASL: Malachite-II : Phase 3b Trial of Ombitasvir/Paritaprevir/r and Dasabuvir + Ribavirin or Telaprevir + Peginterferon/Ribavirin in Peginterferon/Ribavirin Treatment-Experienced Adults With Hcv Genotype 1 - (04/24/15)
     
  3560. EASL: The association of Sofosbuvir and Daclatasvir for treating severe recurrence of HCV infection after liver transplantation - (04/27/15)
     
  3561. EASL: No Significant Interaction Among Ombitasvir/Paritaprevir/Ritonavir ï Dasabuvir and Sofosbuvir - (04/27/15)
     
  3562. EASL: Healthcare Costs by Stage of Liver Disease in Chronic Hepatitis C Patients in the United States - (04/27/15)
     
  3563. EASL: THE GLOBAL AND REGIONAL BURDEN OF LIVER DISEASE, 2013: deaths due to HCV doubled from 1990 to 2013 - (04/27/15)
     
  3564. EASL: HCV Screening/treatment in UK Prisons Can be Cost-Effective - IS INCREASED HCV CASE-FINDING COMBINED WITH 8 OR 12 WEEK INTERFERON-FREE DIRECT-ACTING ANTIVIRAL TREATMENT COST EFFECTIVE IN UK PRISONS? A COST UTILITY ANALYSIS INCLUDING TREATMENT AS PREVENTION BENEFITS - (04/27/15)
     
  3565. EASL: SAFETY AND EFFICACY OF THE COMBINATION DACLATASVIR-SOFOSBUVIR IN HCV GENOTYPE 1-MONO-INFECTED PATIENTS FROM THE FRENCH OBSERVATIONAL COHORT ANRS CO22 HEPATHER - (04/27/15)
     
  3566. EASL: Phase 3b Studies (5 Years post-treatment) to Assess Long-Term Clinical Outcomes in HCV GT1-Infected Patients Treated With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin - (04/27/15)
     
  3567. EASL: A Single Subcutaneous Dose of 2 mg/kg or 4 mg/kg of RG-101, a Galnac-Conjugated Oligonucleotide with Antagonist Activity against miR-122, Results in Significant Viral Load Reductions in Chronic Hepatitis C Patients - (04/27/15)
     
  3568. EASL: Pharmacokinetics of Miravirsen, a miR-122 Inhibitor, Predict the Prolonged Viral Load Reduction in Treatment Naive Genotype 1 HCV-Infected Patients - (04/27/15)
     
  3569. EASL: CANCER RATES IN PATIENTS WITH CHRONIC HEPATITIS C IN A LARGE U.S. HEALTH MAINTENANCE ORGANIZATION.....cancer rate 2.5 times higher among HCV+, even when liver cancer is excluded rate is almost 2 times higher - (04/27/15)
     
  3570. EASL: LONG-TERM FOLLOW-UP OF TREATMENT-EMERGENT RESISTANCE-ASSOCIATED VARIANTS IN NS3, NS5A AND NS5B WITH PARITAPREVIR/r-, OMBITASVIR- AND DASABUVIR-BASED REGIMENS - (04/24/15)
     
  3571. EASL: Safety and Efficacy of Short-Duration Treatment With GS-9857 Combined With Sofosbuvir/GS-5816 in Treatment-Naïve and DAA-Experienced Genotype 1 Patients With and Without Cirrhosis - (04/24/15)
     
  3572. EASL: Implications of Baseline HCV RNA Level and Intrapatient Viral Load Variability on OBV/PTV/r + DSV 12-Week Treatment Outcomes - (04/24/15)
     
  3573. EASL: An Open-Label Study to Evaluate the Efficacy and Safety of Co-Formulated Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults with Chronic HCV Genotype 4 Infection in Egypt (AGATE-II) - (04/24/15)
     
  3574. EASL: Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV Genotypes 1 and 3 - (04/24/15)
     
  3575. EASL: DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 3 INFECTION: INTERIM ANALYSIS OF A FRENCH MULTICENTER COMPASSIONATE USE PROGRAM - (04/24/15)
     
  3576. EASL: DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HIV-HCV COINFECTION: INTERIM ANALYSIS OF A FRENCH MULTICENTER COMPASSIONATE USE PROGRAM - (04/24/15)
     
  3577. EASL: Malachite-I Phase 3b Trial of Ombitasvir/Paritaprevir/r and Dasabuvir ï Ribavirin or Telaprevir + Peginterferon/Ribavirin in Treatment-Naïve Adults With Hcv Genotype 1 - (04/24/15)
     
  3578. EASL: Simeprevir plus daclatasvir and sofosbuvir in treatment-naïve and treatment-experienced patients with chronic hepatitis C virus genotype 1 or 4 infection and decompensated liver disease: interim results from the Phase II IMPACT study - (04/24/15)
     
  3579. EASL: THE PHASE 3 C-EDGE TREATMENT-NAIVE (TN) STUDY OF A 12-WEEK ORAL REGIMEN OF GRAZOPREVIR (GZR, MK-5172)/ELBASVIR (EBR, MK-8742) IN PATIENTS WITH CHRONIC HCV GENOTYPE (GT) 1, 4, OR 6 INFECTION - (04/24/15)
     
  3580. EASL: U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C - (04/24/15)
     
  3581. EASL: Ledipasvir/Sofosbuvir With Ribavirin is Safe and Efficacious in Decompensated and Post-Liver Transplantation Patients With HCV Infection: Preliminary Results of the SOLAR-2 Trial - (04/24/15)
     
  3582. EASL: Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir/Sofosbuvir-Based Regimens With Ledipasvir/Sofosbuvir for 24 Weeks - (04/24/15)
     
  3583. EASL: Gilead Announces Data for Investigational, All-Oral, Pan-Genotypic Three-Drug Regimen of Sofosbuvir, GS-5816 and GS-9857 for Chronic Hepatitis C - (04/24/15)
     
  3584. EASL: Gilead's Harvoni and Sovaldi Demonstrate Efficacy and Safety among Chronic Hepatitis C Patients with Advanced Liver Disease - (04/24/15)
     
  3585. EASL: ELECTRON-2 - Ledipasvir/Sofosbuvir Fixed-Dose Combination Is Safe and Effective in Difficult-to-Treat Populations Including GT 3 Patients, Decompensated GT 1 Patients, and GT 1 Patients With Prior Sofosbuvir Experience  - (04/24/15)
     
  3586. EASL: Improvement in Liver Function and Non-Invasive Estimates of Liver Fibrosis 48 Weeks after Treatment With Ombitasvir/Paritaprevir/r, Dasabuvir, and Ribavirin in HCV Genotype 1 Patients With Cirrhosis - (04/24/15)
     
  3587. EASL: High SVR Rates Despite Multiple Negative Predictors in Genotype 1 Patients Receiving Ombitasvir/Paritaprevir/r, Dasabuvir With or Without Ribavirin For 12 and 24 Weeks: Integrated Analysis of Six Phase 3 Trials - (04/24/15)
     
  3588. EASL: A Randomized, Open-Label Study to Evaluate Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Infection and Cirrhosis (AGATE-I) - (04/23/15)
     
  3589. EASL: SAFETY AND EFFICACY OF SHORT-DURATION TREATMENT WITH GS-9857 COMBINED WITH SOFOSBUVIR/GS-5816 IN TREATMENT-NAIVE AND DAA-EXPERIENCED GENOTYPE 1 PATIENTS WITH AND WITHOUT CIRRHOSIS - (04/23/15)
     
  3590. EASL: All Oral HCV Therapy is Safe and Effective in Patients with Decompensated Cirrhosis: Report from HCV-TARGET - (04/23/15)
     
  3591. EASL: Daclatasvir Plus Sofosbuvir for Treatment of HCV Genotypes 1-4 in HIV-HCV Coinfection: The ALLY-2 Study - (04/23/15)
     
  3592. EASL: EFFICACY AND SAFETY OF GRAZOPREVIR AND ELBASVIR IN HEPATITIS C GENOTYPE 1-INFECTED PATIENTS WITH CHILD-PUGH CLASS B CIRRHOSIS (C-SALT PART A) - (04/23/15)
     
  3593. EASL: On-treatment virologic response and tolerability of simeprevir, daclatasvir and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation (OLT): interim data from the Phase II SATURN study - (04/23/15)
     
  3594. EASL: C-SWIFT: GRAZOPREVIR/ELBASVIR + SOFOSBUVIR IN CIRRHOTIC AND NONCIRRHOTIC, TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION, FOR DURATIONS OF 4, 6 OR 8 WEEKS AND GENOTYPE 3 INFECTION FOR DURATIONS OF 8 OR 12 WEEKS - (04/23/15)
     
  3595. EASL: C-SURFER: GRAZOPREVIR PLUS ELBASVIR IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION AND CHRONIC KIDNEY DISEASE - (04/23/15)
     
  3596. EASL: Merck Announces Results from Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease - (04/23/15)
     
  3597. EASL: Janssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis - (04/23/15)
     
  3598. EASL: C-EDGE COINFECTION: PHASE 3 STUDY OF GRAZOPREVIR/ELBASVIR IN PATIENTS WITH HCV/HIV - (04/23/15)
     
  3599. EASL: C-SCAPE: EFFICACY AND SAFETY OF 12 WEEKS OF GRAZOPREVIR ï ELBASVIR ï RIBAVIRIN IN PATIENTS WITH HCV GT2, 4, 5, OR 6 INFECTION - (04/23/15)
     
  3600. EASL: A Phase 1 Study to Evaluate the Interaction of HCV NS5B Inhibitor MK-3682 With HCV NS3/4A Protease Inhibitor MK-5172 and HCV NS5A Inhibitor MK-8408 in Healthy Subjects - (04/23/15)
     
  3601. EASL: EFFICACY AND SAFETY OF GRAZOPREVIR/ELBASVIR +/- RBV FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV G1, G4 OR G6 INFECTION WHO PREVIOUSLY FAILED PEGINTERFERON/RBV: C-EDGE TREATMENT-EXPERIENCED - (04/23/15)
     
  3602. EASL: C-SALVAGE: GRAZOPREVIR (GZR; MK-5172), ELBASVIR (EBR; MK-8742) AND RIBAVIRIN (RBV) FOR CHRONIC HCV-GENOTYPE 1 (GT1) INFECTION AFTER FAILURE OF DIRECT-ACTING ANTIVIRAL (DAA) THERAPY - (04/23/15)
     
  3603. EASL: EASL Recommendations on Treatment of Hepatitis C 2015 - (04/22/15)
     
  3604. EASL: AbbVie to Present New Data from Hepatitis C Clinical Development Program at The International Liver Congress™ 2015 - (04/22/15)
     
  3605. FDA approved changes to the Olysio (simeprevir) package insert to include two new Warnings and Precautions; - (04/20/15)
     
  3606. Risk Factors for HCV Acquisition Among HIV-Positive MSM in Belgium - (04/20/15)
     
  3607. Global HCV: The case for keeping viral hepatitis in the SDGs (UN's Sustainable Development Goals) - (04/15/15)
     
  3608. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study - (04/15/15)
     
  3609. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study - SVR - majority of patients symptoms persistently disappeared - (04/15/15)
     
  3610. Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure - HCV traces in PBMC of 3/54 SVRs disappear after 9 yrs - (04/15/15)
     
  3611. Federal Healthcare Solution Needed - Specialty drugs cost increasing for cancers, diabetes, heart disease, autoimmune diseases which are not curable - (04/15/15)
     
  3612. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study - (04/13/15)
     
  3613. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study - SVR - majority of patients symptoms persistently disappeared - (04/13/15)
     
  3614. Pricing of Drugs and Formulary Placement: Making Sense of Hepatitis C Treatment Camilla S. Graham, MD, MPH - Co-Director, Viral Hepatitis Center, Division of Infectious Disease Beth Israel Deaconess Medical Center and Harvard Medical School Boston, Massachusetts - (04/08/15)
     
  3615. Janssen Highlights Hepatitis C Virus Development Program at The International Liver Congress 2015 of the European Association for the Study of the Liver (EASL) - (04/08/15)
     
  3616. Grazoprevir/Elbasvir, Merck's Investigational Chronic Hepatitis C Therapy, Granted FDA Breakthrough Therapy Designations; New Phase 2 and 3 Data in Multiple HCV Patient Types to be Presented at The International Liver CongressTM 2015 - (04/08/15)
     
  3617. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS) - (04/08/15)
     
  3618. United HealthCare Buys PBM Catamaran - How the nation's biggest health insurer is fighting higher drug costs - (04/06/15)
     
  3619. What is a 'Pharmacy Benefit Manager?' - (04/06/15)
     
  3620. 4 HCV Cost-Effectiveness Studies Just Published; Costs for New Cancer/Cholesterol, Diabetes Drugs - New Model to Fund Healthcare - (04/01/15)
     
  3621. APASL: Sofosbuvir Plus Ribavirin for the Treatment of Russian Patients With Chronic HCV Genotype 1 or 3 Infection - (04/01/15)
     
  3622. APASL: Sofosbuvir Plus Ribavirin, an Interferon-Free Regimen, in the Treatment of Egyptian Patients With Chronic Genotype 4 HCV Infection - (03/27/15)
     
  3623. CROI: INCIDENCE OF EXTRAHEPATIC COMPLICATIONS IN HIV/HCV PATIENTS WHO ACHIEVED SVR - (03/27/15)
     
  3624. CROI: Modeling the Impact of Deferring HCV Treatment [to F3/F4 vs F2 or sooner: 1 month/year after diagnosis) on Liver-Related Events in HIV+ Patients....outcomes: liver-related events & infectious duration....by Swiss HIV & HCV Cohort....model finds delay in treatment increased 2-times to 5 times risk in developing decompensation, HCC & liver-related death - (03/27/15)
     
  3625. New kids on the block [Merck]-step by step to an ideal HCV therapy - (03/27/15)
     
  3626. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial - (03/27/15)
     
  3627. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial - (03/27/15)
     
  3628. Cipla launches generic drug Sofosbuvir in India - (03/27/15)
     
  3629. CROI: Majority of HCV/HIV-co-infected patients in the Netherlands remain in need of effective HCV treatment - (03/26/15)
     
  3630. CROI: Non-Risk Based HCV Screening Among Baby Boomers in Surveillance-Identified HIV Risk Areas....30% HCV+ - (03/26/15)
     
  3631. CROI: Successful Treatment with Direct Acting Antivirals in HIV/HCV Patients ....95% SVR with Sim/Sof in real-world clinic setting/support services - (03/25/15)
     
  3632. CROI: Real-world Data on HIV-Positive Patients with HCV Treated with Sofosbuvir and/or Simeprevir - (03/25/15)
     
  3633. CROI: Simeprevir and Sofosbuvir Regimens for Hepatitis C: Decompensation and Serious Adverse Events - (03/25/15)
     
  3634. CROI: Drug-Drug Interaction Between HCV Inhibitors Grazoprevir/Elbasvir With Dolutegravir - (03/25/15)
     
  3635. CROI: German cohort on sofosbuvir based therapy for HCV/HIV- and HCV-infection (GECOSO) - (03/25/15)
     
  3636. CROI: Sofosbuvir/Daclatasvir in HIV/HCV Co-infected Patients With Extensive Liver Fibrosis - (03/25/15)
     
  3637. CROI: Modeling the Impact of Deferring HCV Treatment [to F3/F4 vs F2 or sooner: 1 month/year after diagnosis) on Liver-Related Events in HIV+ Patients....outcomes: liver-related events & infectious duration....by Swiss HIV & HCV Cohort - (03/25/15)
     
  3638. CROI: Majority of HIV/HCV Co-Infected Patients Require Antiretroviral Therapy Switch Prior to Use of Simeprevir .....15% cant switch for resistance etc...31% on boosted PI cant switch - (03/25/15)
     
  3639. CROI: Hematologic Analysis of Paritaprevir(ABT-450)/r/Ombitasvir and Dasabuvir + RBV in TURQUOISE-I - (03/25/15)
     
  3640. CROI: Summary from CROI 2015 for Hepatitis C HIV/HCV coinfected patients are no longer a difficult to treat special patient population. What can we learn from new clinical phase III studies and feedback from real-life cohorts receiving modern DAA-based therapy? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/24/15)
     
  3641. FDA Hepatitis Update - Important safety information: Harvoni , and Sovaldi coadministration of amiodarone with ither Harvoni or with Sobvaldi in combination with another DAA - (03/23/15)
     
  3642. FDA Safety Notice/amiodarone+Harvoni or Sovaldi in combination with another direct acting antiviral.....Gilead Issued Doctor Letter....re: symptomatic bradycardia ....It was in the Label - (03/23/15)
     
  3643. CROI: Statins Improve SVR, Reduce Fibrosis Progression and HCC Among HCV+ Persons. Statins Reduce Plaque/Halt Carotid Artery Wall Thickening/Improve Kidney - (03/23/15)
     
  3644. CROI: Marijuana Use Does Not Accelerate Liver Fibrosis in HCV/HIV-Coinfected Women - (03/20/15)
     
  3645. CROI: Portal Pressure Changes After HCV Eradication in HIV/HCV+ Patients With Cirrhosis - (03/20/15)
     
  3646. CROI: Impact of SVR on Liver Decompensation and Hepatic Fibrosis Markers in HIV/HCV - (03/20/15)
     
  3647. CROI: Impact of Integrating EMR HCV Testing Prompts in a Difficult to Navigate EMR System - (03/20/15)
     
  3648. CROI: Characterization of Naturally Occurring Resistance to HCV NS5A Inhibitors - (03/20/15)
     
  3649. CROI: One Year Results of a Community-Based Hepatitis C Testing and Linkage to Care Program - (03/18/15)
     
  3650. APASL: Efficacy, safety and pharmacokinetics of 12 weeks of simeprevir in combination with TMC647055 and ritonavir with or without ribavirin in genotype 1 hepatitis C virus-infected patients - (03/18/15)
     
  3651. APASL: Simeprevir plus peginterferon/ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection: Results from the Phase III TIGER study conducted in East Asian patients living in China and Korea - (03/18/15)
     
  3652. APASL: All-oral Dual Combination of Daclatasvir plus Asunaprevir Compared with Telaprevir plus Peginterferon Alfa/Ribavirin in Treatment-naive Japanese Patients Chronically infected with HCV Genotype 1b: The AI447031 Study - (03/18/15)
     
  3653. APASL: All-Oral 12-Week Combination Treatment With Daclatasvir and Sofosbuvir in Patients Infected With HCV Genotype 3: ALLY-3 Phase 3 Study - (03/18/15)
     
  3654. APASL: Exposure-Efficacy Analysis for Daclatasvir and Asunaprevir in DUAL Combination in Non-Japanese and Japanese Subjects with Genotype 1b Hepatitis C Virus Infection - (03/18/15)
     
  3655. APASL: Characterization of Resistance in HCV Genotype 1b-Infected Japanese and Western Patients Treated With an Interferon- and Ribavirin-Free Regimen of Ombitasvir and Paritaprevir/Ritonavir - (03/18/15)
     
  3656. APASL: LONG-TERM EFFICACY AND SAFETY OF THE INTERFERON- AND RIBAVIRIN-FREE REGIMEN OF PARITAPREVIR/RITONAVIR AND OMBITASVIR IN HCV GENOTYPE 1B-INFECTED TREATMENT-EXPERIENCED JAPANESE PATIENTS - (03/18/15)
     
  3657. APASL: Elderly and Cirrhotic Patients Without Baseline NS5A Polymorphisms in HCV Genotype 1b Have Very High Sustained Virologic Responses to Daclatasvir Plus Asunaprevir - (03/18/15)
     
  3658. Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States - (03/18/15)
     
  3659. NYS DURB HCV Feb 26 2015 Hearing Summary Posted - (03/16/15)
     
  3660. Bristol-Myers Squibb Announces Acceptance of New Drug Application for Investigational Daclatasvir for FDA Review for the Treatment of Hepatitis C Genotype 3 - (03/16/15)
     
  3661. Hetero Received Generic Sofosbuvir (Gilead's Sovaldi) Approval From Drug Controller General of India (DCGI) - (03/16/15)
     
  3662. Natco Sofosbuvir Approved in India Too - (03/16/15)
     
  3663. NYS DURB Mtg Feb 26 Viekira Pak Declared Preferred Drug for FFS Medicaid - Summary/Video - (03/16/15)
     
  3664. Expensive Cancer, Heart Disease, Diabetes Drugs over the long run more expensive than HCV - (03/16/15)
     
  3665. The Cost-effectiveness, Health Benefits, and Financial Costs of New Antiviral Treatments for Hepatitis C Virus and Editorial - (03/16/15)
     
  3666. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease - (03/16/15)
     
  3667. CROI: Risk Factors for Transmission of HCV among HIV-Infected MSM: a Case-Control Study - (03/13/15)
     
  3668. CROI: Risk of late relapse or re-infection with Hepatitis C after Sustained Virological Response: meta-analysis of 66 studies in 11,071 patients - (03/11/15)
     
  3669. Natco Pharma ties up with Gilead on hepatitis C drugs for Generic - (03/10/15)
     
  3670. Videocast at DURB Feb 26 Medicaid NYS Hearing - (03/10/15)
     
  3671. HCV & Women - several key reports - (03/10/15)
     
  3672. CROI: Chronic Hepatitis B and C Infection and Risk for Non-Hodgkin Lymphoma in HIV Infected Patients - (03/09/15)
     
  3673. CROI: Sofosbuvir, Simeprevir, +/- Ribavirin in HCV G1 Protease Inhibitor-Experienced Patients [14/15 SVR 93%] - (03/09/15)
     
  3674. CROI: Real-World Cost-per-SVR with Simeprevir/Sofosbuvir ï Ribavirin.... 88% SVR/76% SVR in PI-Experienced - (03/09/15)
     
  3675. CROI: Effectiveness of Sofosbuvir/Simeprevir for HIV/HCV Patients in Clinical Practice - (03/09/15)
     
  3676. CROI: Low HCV Testing Uptake of the Current Birth Cohort Guidelines....HCV Cascade - (03/09/15)
     
  3677. CROI: Utility of Hepatitis C Viral Load Monitoring with Ledipasvir ! and Sofosbuvir Therapy ! (week 4 testing in Harvoni NIH study) - (03/09/15)
     
  3678. CROI: Effect of HIV Co-infection on Adherence to a 12-week regimen of HCV Therapy with Ledipasvir/Sofosbuvir - (03/06/15)
     
  3679. CROI: SVR Durability: HCV Patients Treated with IFN-Free DAA Regimens - (03/06/15)
     
  3680. CROI: ALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected with HIV After Ribavirin-Free Investigational 12-Week Regimen of Daclatasvir and Sofosbuvir - (03/06/15)
     
  3681. CROI: Hepatitis C infection and Cognition in Older HIV+ Adults: Data from the Center of Excellence on Disparities in HIV and Aging (CEDHA) - (03/06/15)
     
  3682. CROI: The Burden of Liver Disease among Persons with Hepatitis C in the United States...."the need is urgent to identify HCV-infected persons & link them to management & care" screening - (03/06/15)
     
  3683. CROI: Has Modern ART Reduced Endstage Liver Disease Risk in HIV-Hepatitis Coinfection? ...... "No clear reduction in ESLD risk was observed over the 3 time periods" - (03/06/15)
     
  3684. CROI: Chronic Kidney Disease Progression after HCV Seroconversion - (03/06/15)
     
  3685. CROI: Impact of SVR on Liver Decompensation and Hepatic Fibrosis Markers in HIV/HCV ...... "SVR Associated with reduced risks of decompensation and death..... No decompensations were observed in HIV/HCV patients who achieved SVR" - (03/06/15)
     
  3686. HCV Medicaid DURB Hearing Outcome, Feb 26, 2015 - (03/04/15)
     
  3687. CROI: CROI Big Stories: new HIV ARTs attachment & maturation inhibitors; new HCV drugs study results in HIV/HCV coinfected - Harvoni, daclatasvir+sofosbuvir, Abbvie 3D - (Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin ) - written by Mark Mascolini - (03/02/15)
     
  3688. CROI: Daclatasvir in Combination With Sofosbuvir for HIV/HCV Coinfection: ALLY-2 Study - (02/27/15)
     
  3689. CROI: Ledipasvir/sofosbuvir for 12 Weeks in Patients Coinfected With HCV and hiv-1: ION-4 - (02/27/15)
     
  3690. CROI: GILEAD ANNOUNCES SVR12 RATES FROM PHASE 3 STUDY EVALUATING HARVONI® FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS CO-INFECTED WITH HIV - (02/27/15)
     
  3691. CROI: HIGH SVR REGARDLESS OF TIME TO SUPPRESSION WITH OMBITASVIR/PARITAPREVIR/R & DASABUVIR + RBV - (02/27/15)
     
  3692. CROI: SVR12 in over 90% of HCV/HIV null responders stating daclatasvir/asunaprevir plus PR - written by Mark Mascolini - (03/02/15)
     
  3693. CROI: Drug Interactions Between the anti-HCV Regimen Ledipasvir/Sofosbuvir and Ritonavir Boosted Protease Inhibitors plus Emtricitabine/Tenofovir DF - (02/23/15)
     
  3694. CROI: HCV recurrence after SVR 20 times more frequent with HIV/HCV than HCV alone - written by Mark Mascolini - (02/23/15)
     
  3695. Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection - (02/24/15)
     
  3696. Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1 A Randomized Trial - (02/24/15)
     
  3697. Hepatitis C and HIV Co-infection Closing the Gaps - Editorial - (02/24/15)
     
  3698. Results from AbbVie's Study of VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) Published Online in JAMA; Sub-analyses to be Presented at the Annual Conference on Retroviruses and Opportunistic Infections (CROI) - (02/24/15)
     
  3699. AASLD: ACH-3422, A Novel HCV NS5B RNA Polymerase Nucleotide Inhibitor, Demonstrates Improved Potency Over Sofosbuvir Against HCV Genotype-3 Replicons In Vitro - (02/19/15)
     
  3700. New Lower Prices for Gilead Hepatitis C Drugs Reach CTAF Threshold for High Health System Value - (02/18/15)
     
  3701. New Philadelphia Study Highlights Need for HCV Community-Based Screening ($200 million needed) - (02/18/15)
     
  3702. Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program - (02/17/15)
     
  3703. Predictors of Poor Mental and Physical Health Status Among Patients With Chronic Hepatitis C Infection: The Chronic Hepatitis Cohort Study (CHeCS) - (02/17/15)
     
  3704. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study - - (02/17/15)
     
  3705. The Hepatitis C treatment experience: patients' perceptions of the facilitators of and barriers to uptake, adherence and completion - (02/13/15)
     
  3706. Achillion Achieves 100% SVR12 in Phase 2 Trial Evaluating 6-Week Combination Treatment With ACH-3102 - press release - (02/13/15)
     
  3707. microRNA-122 new HCV drug - All HCV Patients Treated with a Single SC Administration of 4 mg/kg of RG-101 Responded with Mean Viral Load Reduction of 4.8 log10 at Day 29 and 9/14 Patients are Below the Limit of Quantification at Day 57 - press release - (02/13/15)
     
  3708. $5M Hepatitis C strategy announced by P.E.I. government (Canada) - (02/13/15)
     
  3709. AbbVie Submits New Drug Application in Japan for its Investigational, All-Oral, Treatment for Chronic Hepatitis C - (02/13/15)
     
  3710. Gilead agrees 41,000 euro hep-C drug price for 12 week treatment - (02/13/15)
     
  3711. Cigna Signs Agreement with Gilead to Improve Affordability of Hepatitis C Treatment for Customers and Clients - (02/05/15)
     
  3712. HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus-coinfected patients - (02/04/15)
     
  3713. AbbVie Announces Top-line Results from Phase 3 Study of All-Oral Treatment for Hepatitis C in Japan - (02/04/15)
     
  3714. Catamaran Introducing Innovative Clinical Outcomes-Based Program for Hepatitis C Treatment - (02/04/15)
     
  3715. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis - (02/04/15)
     
  3716. All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase 3 Study - (02/02/15)
     
  3717. Daclatasvir in Spain - (02/02/15)
     
  3718. Daclatasvir EMA Summary of Product Characteristics/Label - (02/02/15)
     
  3719. Enanta Announces 95 percent SVR12 rate in AbbVie's Phase 3 Study of All-Oral Treatment for Hepatitis C Virus in Japanese Patients - (02/02/15)
     
  3720. European Commission Approves Bristol-Myers Squibb's Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection - (02/02/15)
     
  3721. Quest Diagnostics and CDC Expand Public Health Collaboration to Improve Hepatitis Diagnosis and Treatment - (01/29/15)
     
  3722. Harvard Pilgrim negotiates discount on pricey hepatitis drug - (01/29/15)
     
  3723. Abbvie Medicaid HCV Deal with 25 State Medicaids - (01/28/15)
     
  3724. PBM EnvisionRx chooses Gilead hepatitis C drugs for its formulary - (01/28/15)
     
  3725. NJ Advances HCV Testing Bill - (01/28/15)
     
  3726. Missouri, as part of 25-state consortium, designates new Hepatitis C drug for Medicaid patients; reaches agreement that will save taxpayers millions of dollars in Fiscal Year 2016 - (01/28/15)
     
  3727. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late - (01/28/15)
     
  3728. NYS DURB HCV Mtg Feb 26 - (01/28/15)
     
  3729. Mylan Expands Hepatitis C Licensing Agreement with Gilead to Include Investigational Pan-Genotypic Agent - (01/26/15)
     
  3730. Gilead cuts hepatitis C drug prices in Germany - (01/26/15)
     
  3731. Gilead Expands Generic Sovaldi Pact to Add Investigational Pill GS-5816; Sovaldi India Launch by June - (01/26/15)
     
  3732. Gilead Expands Hepatitis C Generic Licensing Agreements to Include Investigational Pan-Genotypic Agent GS-5816 - (01/26/15)
     
  3733. AASLD: J&J New HCV Nucleotides - AL-335 & AL-516 - (01/23/15)
     
  3734. First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 - (01/23/15)
     
  3735. Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt - New Study - (01/23/15)
     
  3736. SVR Rates the Same in Studies in African-Americans & for those on Opioid Substitution Therapy (methadone) - (01/23/15)
     
  3737. New Drug Slows HCC Progression in Phase 2 Study - (01/23/15)
     
  3738. UK Delays Sofosbuvir Access Blaming Unprepared Infrastructure Despite EMA Approval - (01/23/15)
     
  3739. Seven years of chronic hepatitis C virus infection in an HIV-infected man without detectable antibodies - (01/23/15)
     
  3740. Merck Voluntarily Discontinues Victrelis in USA - (01/21/15)
     
  3741. Merck Voluntarily Discontinuing VICTRELIS in USA - Dear Health Professional Letter - (01/21/15)
     
  3742. EMA Viekirax Label/Product Insert - (01/21/15)
     
  3743. CROI: Liver-related death among HIV/HCV coinfected individuals, implications for the era of directly acting antivirals: CD4 & > F2 Associated with Liver Related Deaths in EuroSIDA - (01/20/15)
     
  3744. HCV/Vertical Transmission: pregnant women unaware of HCV/in opoid dependent pregnant women/viral load/HIV - Reducing Risk for Mother-to-Infant Transmission of Hepatitis C Virus: A Systematic Review for the U.S. Preventive Services Task Force - (01/20/15)
     
  3745. Vertical Transmission of Hepatitis C Virus: Systematic Review and Meta-analysis - "5.8%-10.8%" - (01/20/15)
     
  3746. Vertical transmission of hepatitis C virus: Current knowledge and perspectives [global] - (01/20/15)
     
  3747. Aetna and Gilead agree to discount pricing for hepatitis C drugs - (01/20/15)
     
  3748. India approved for marketing sofosbuvir - (01/20/15)
     
  3749. AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir) and EXVIERA® (dasabuvir) Licensed for Use in the UK for the Treatment of Chronic Hepatitis C - (01/20/15)
     
  3750. Is screening baby boomers for HCV enough? A call to screen for hepatitis C virus in persons from countries of high endemicity - (01/20/15)
     
  3751. Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: a prospective analysis from the UFO Study cohort - (01/20/15)
     
  3752. Novel 'Pay If You Clear' scheme introduced in England for new hepatitis C treatment OLYSIO® (simeprevir) - (01/16/15)
     
  3753. Janssen statement in response to the NICE FAD on the use of Olysio™ for hepatitis C - press release - (01/16/15)
     
  3754. ADAP Crisis Task Force Announces Groundbreaking Agreement with AbbVie for Hepatitis C Treatment Viekira Pak™ - (01/16/15)
     
  3755. European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Chronic Hepatitis C - (01/16/15)
     
  3756. NICE recommends simeprevir (Olysio) in combination with peginterferon alfa and ribavirin for treating hepatitis C in final draft guidance - (01/16/15)
     
  3757. NHS postpone breakthrough 660-a-day hepatitis C drug [sofosbuvir] over cost fears - (01/16/15)
     
  3758. Prisoners Treated for Hepatitis C with Protease Inhibitor, New York, USA, 2012 - (01/16/15)
     
  3759. HCV Screening Controversy - (01/15/15)
     
  3760. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study - (01/14/15)
     
  3761. (new Study) Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-9857 (pan-genotypic protease) in Subjects With Chronic Hepatitis C Virus Infection - (01/14/15)
     
  3762. Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics - (01/12/15)
     
  3763. Plan of Action for the Prevention, Care & Treatment of Viral Hepatitis, Egypt 2014-2018 - (01/12/15)
     
  3764. Gilead Strikes Hepatitis C Deal With Anthem - (01/12/15)
     
  3765. Anthem Strikes Deal With Gilead On Hep C Rx, But Still Restricts Coverage - (01/12/15)
     
  3766. Merck HCV FDA Submission in 1st Half 2015 - (01/12/15)
     
  3767. [Calif] Brown's Budget Proposal Allocates Millions [$300 mill] For Hepatitis C Drugs - (01/12/15)
     
  3768. APASL: Clinical Characteristics of Patients Who Developed HCC While Receiving Tenofovir Disoproxil Fumarate (TDF) Up to 336 Weeks of Therapy - (01/08/15)
     
  3769. microRNA, antimiR New HCV Drug, Subcutaneous Dose - interim new study results - (01/08/15)
     
  3770. Safety and Efficacy Study of Daclatasvir 60mg, Sofosbuvir 400mg, and Ribavirin (Dosed Based Upon Weight) in Subjects With Chronic Genotype 3 Hepatitis C Infection With or Without Prior Treatment Experience and Compensated Advanced Cirrhosis for 12 or 16 Weeks - new study - (01/08/15)
     
  3771. AbbVie Receives Health Canada Approval of HOLKIRA™ PAK for the Treatment of Chronic Genotype 1 Hepatitis C - (01/08/15)
     
  3772. Gilead fights back: CVS to cover its hepatitis C drugs exclusively - (01/08/15)
     
  3773. Gilead Sciences Announces Acquisition of Phenex Pharmaceuticals' Development Program for Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases - (01/08/15)
     
  3774. 2nd report-Gilead Sciences Announces Acquisition of Phenex Pharmaceuticals' Development Program for Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases - (01/08/15)
     
  3775. CVS to cover Gilead hepatitis C treatment over AbbVie regimen - update - (01/07/15)
     
  3776. Gilead fights back: CVS to cover its hepatitis C drugs exclusively - (01/07/15)
     
  3777. AASLD: Pharmacokinetics of Cyclosporine and Tacrolimus, Following Coadministration with the Direct Acting Antiviral Combination, ABT-450/r, Ombitasvir and Dasabuvir, in Liver Transplant Patients with Genotype-1 HCV Infection - (12/22/14)
     
  3778. Abbvie HCV Therapy 'VIEKIRA PAK' - FDA Product Insert - (12/22/14)
     
  3779. FDA approves [Abbvie] Viekira Pak to treat hepatitis C - FDA News Release - (12/22/14)
     
  3780. Express Scripts and AbbVie Make Hepatitis C Cure Available to Millions of Patients in Need - (12/22/14)
     
  3781. Express Scripts Shuns Gilead in Hepatitis C Deal With AbbVie - (12/22/14)
     
  3782. AbbVie Deal Heralds Changed Landscape for Hepatitis Drugs - (12/22/14)
     
  3783. The continuum of hepatitis C testing and care...... "Many patients are lost at each stage, highlighting the need to raise awareness among health care professionals and at-risk populations about appropriate hepatitis testing, referral, support, and care" - (12/22/14)
     
  3784. HCV Disrupts Immune System - (12/22/14)
     
  3785. Despite High Costs, Specialty Drugs May Offer Value For Money Comparable To That Of Traditional Drugs - (12/22/14)
     
  3786. OLYSIO™ (simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C - (12/22/14)
     
  3787. Achillion Shows Potential for "Best-in-Disease" HCV Regimen - 100% SVR4 Following a Dual 6-Week ACH-3102-Based Regimen and Separately a 4.8 Log10 Reduction With ACH-3422 - (12/22/14)
     
  3788. Update to HCV Guidelines Dec 19 2014 - (12/22/14)
     
  3789. Strategies to manage hepatitis C virus (HCV) infection disease burden ......."active screening programs & active management with antiviral therapy" - (12/19/14)
     
  3790. Historical epidemiology of hepatitis C virus (HCV) in select countries - (12/19/14)
     
  3791. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - (12/19/14)
     
  3792. HCV/HIV DART: Daclatasvir: Overview of Drug-Drug Interactions With Antiretroviral Agents and Other Common Concomitant Drugs - (12/17/14)
     
  3793. AASLD: Simeprevir+Sofosbuvir at AASLD - (12/17/14)
     
  3794. AASLD: Time to Viral Suppression [week 2/4] Is Not Related to Achievement of SVR12 in HCV GT1-infected Patients Treated With ABT-450/Ritonavir/Ombitasvir and Dasabuvir With or Without Ribavirin - (12/17/14)
     
  3795. AASLD: Abbvie 3D in Depression-Bipolar/Opoid Replacement/Transplant/HIV Coinfection/African-Americans - (12/17/14)
     
  3796. AASLD: Identification and Treatment of Multiple Subtypes of HCV Genotype 4 in the PEARL-I Study With Ombitasvir and ABT-450/r ï Ribavirin - (12/17/14)
     
  3797. AASLD: TURQUOISE-II: Trends in Liver Fibrosis Testing, Hepatic Synthetic Function, and Platelet Counts at Baseline and 12 Weeks After Treatment With ABT-450/r/Ombitasvir and Dasabuvir With Ribavirin in HCV Genotype 1-Infected Patients With Cirrhosis - (12/17/14)
     
  3798. AASLD: Early Improvement in the HepQuant® (HQ)-SHUNT Function Test during Treatment with Ledipasivir/Sofosbuvir in Liver Transplant Recipients with Allograft Fibrosis or Cirrhosis and Patients with Decompensated Cirrhosis who have not undergone Transplantation - (12/17/14)
     
  3799. AASLD: Characteristics of HCV-Infected Patients With Cirrhosis Requiring Ribavirin Dose Reduction During Treatment With Direct-Acting Antivirals - (12/17/14)
     
  3800. PCORI Board Approves Providing Up to $50 Million for CER on Hepatitis C, Also Approves $150.7 Million for PCORnet Phase II and Reviews Plans for Research Funding Shift - (12/16/14)
     
  3801. TORONTO DECLARATION: STRATEGIES TO CONTROL AND ELIMINATE VIRAL HEPATITIS GLOBALLY - (12/16/14)
     
  3802. HCV Different than Specialty/Oncology Drugs-new report - (12/16/14)
     
  3803. Hepatitis C Surveillance among Youth and Young Adults in New York City, 2009-2013 - (12/16/14)
     
  3804. Daclatasvir+Sofosbuvir-new studies, VX135, Daclatasvir Phase 3 IFN-free, EMA Compassionate Use, Accelerated EMA Marketing Review Recommendation
     
  3805. HCV/HIV DART: Daclatasvir: Overview of Drug-Drug Interactions With Antiretroviral Agents and Other Common Concomitant Drugs - (12/16/14)
     
  3806. AASLD: Safety of ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients ≥65 Years of Age: Results From Phase 2 and 3 Trials - (12/15/14)
     
  3807. AASLD: Resistance Analysis of Treatment-Experienced HCV Genotype 1-Infected Patients Re-treated With Sofosbuvir - (12/15/14)
     
  3808. AASLD: The Pharmacokinetics of Ledipasvir, an HCV-Specific NS5A Inhibitor, in HCV-Uninfected Subjects With Severe Renal Impairment - (12/15/14)
     
  3809. AASLD: SVR12 Rate of 96.2% in 209 HCV Genotype 1-infected Null Responders Treated With ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin - (12/15/14)
     
  3810. AASLD: Safety of ABT-450/Ritonavir/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients: Results From Phase 2 and 3 Trials - (12/15/14)
     
  3811. AASLD: Baseline and Post-Baseline Resistance Analyses of Phase 2/3 Studies of Ledipasvir/Sofosbuvir ï RBV - (12/15/14)
     
  3812. AASLD: Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin for the Treatment of Patients With Chronic HCV Genotype 1 Infection: An Analysis of the Phase 3 ION Trials - (12/15/14)
     
  3813. HCV Drug Adherence, Discontinuations - (12/12/14)
     
  3814. Liver Fibrosis Progression in Hepatitis C Virus Infection After Seroconversion: FIB-4 scores doubled in the first 4 years after infection and more than 18% of them developed cirrhosis within 10 years after infection, our data would suggest treating early - (12/12/14)
     
  3815. AASLD: Summary from AASLD 2014 for Hepatitis C Boston 7-11 November 2014 - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (12/11/14)
     
  3816. AASLD: Performance and Cost -Effectiveness of Simeprevir and Sofosbuvir Based HCV treatment in Real World Clinical Practice - 2014 at Mt Sinai Hospital NY - (12/11/14)
     
  3817. AASLD: Efficacy and Safety of Sofosbuvir and Simeprevir in Patients with Advanced HCV Cirrhosis - (12/11/14)
     
  3818. AASLD: Interferon Ineligible subjects treated with Simeprevir in special population (Schizophrenic, severe major depression, severe bipolar and schizoaffective disorder) in genotype 1 subjects with Ribavirin Effecr; in naive chronic hepatitis C (CHC) genotype 1 subjects. An open label prospective clinical pilot study; INSPIRE C study - (12/11/14)
     
  3819. AASLD: Single Center Experience with Simeprevir / Sofosbuvir Combination Therapy for Recurrent Hepatitis C Virus Infection in Liver Transplant Recipients - (12/11/14)
     
  3820. AASLD: Successful treatment of post liver transplant patients with genotype 1 hepatitis C virus with sofosbuvir and simeprevir - (12/11/14)
     
  3821. AASLD: Multicenter Experience using Sofosbuvir and Simeprevir with/without Ribavirin to Treat HCV Genotype 1 after Liver Transplantation - (11/10/14)
     
  3822. AASLD: Post-Liver Transplant Treatment of Hepatitis C with a Combination of Sofosbuvir, Simeprevir +/- Ribavirin at a High Volume Academic Transplant Center - (12/11/14)
     
  3823. AASLD: Time to Viral Suppression [week 2/4] Is Not Related to Achievement of SVR12 in HCV GT1-infected Patients Treated With ABT-450/Ritonavir/Ombitasvir and Dasabuvir With or Without Ribavirin - (12/09/14)
     
  3824. AASLD: On-Treatment HCV RNA as a Predictor of Virologic Response in the Ledipasvir/Sofosbuvir Phase 3 Program for HCV Genotype 1 Infection: Analysis of the ION-1, ION-2, and ION-3 Studies - (12/09/14)
     
  3825. AASLD: Evaluation of efficacy of sofosbuvirand simeprevir-based regimens in a real-life population of HCV patients with cirrhosis; data from the TRIO network - (12/09/14)
     
  3826. AASLD: Efficacy of sofosbuvir and simeprevir-based regimens for HCV treatment-experienced GT1 patients in a real-life setting; data from the TRIO network - (12/09/14)
     
  3827. AASLD: Rapid Normalization of Pro-Inflammatory Cytokine Levels During Potent Antiviral Therapy With Sofosbuvir Plus Ribavirin in Patients With Genotype 2 and 3 HCV Infection - (12/09/14)
     
  3828. AASLD: 97% Sustained Virologic Response in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection Receiving Sofosbuvir in Combination With Ribavirin for 12 Weeks: Results From a Phase 3 Multicenter Study - (12/09/14)
     
  3829. AASLD: 100% SVR12 in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection Receiving Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks: Results From a Multicenter Phase 3 Study - (12/09/14)
     
  3830. 'India Cries Out for HCV Services/Treatment' - Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study - (12/08/14)
     
  3831. HCV in people who inject drugs: a neglected epidemic - (12/08/14)
     
  3832. AASLD: Concordance Between SVR4, SVR12, and SVR24 in Genotype 1 HCV-Infected Patients Who Received All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir With or Without Ribavirin in Phase 3 Clinical Trials - (12/05/14)
     
  3833. AASLD: The Global Burden of Viremic HCV Infection - (12/05/14)
     
  3834. AASLD: Disease Burden of Chronic Hepatitis C Virus (HCV) Infection in India - (12/05/14)
     
  3835. AASLD: CLINICAL EFFICACY OF HIGHLY EFFECTIVE INTERFERON-FREE THERAPY IN PATIENTS WITH CHRONIC HCV INFECTION AND COMPENSATED ADVANCED HEPATIC FIBROSIS - Life Expectancy in Patients With Chronic HCV Infection and Cirrhosis Compared With a General Population - (12/03/14)
     
  3836. AASLD: High Rates of SVR in Patients With Genotype 1 HCV Infection and Cirrhosis After Treatment With Ledipasvir/Sofosbuvir + Ribavirin or Ledipasvir/Sofosbuvir + GS-9669 for 8 Weeks - (12/03/14)
     
  3837. AASLD: No Differences in the Efficacy of Fixed-Dose Combination Ledipasvir/Sofosbuvir in Patients According to Fibrosis Stage Determined by Liver Biopsy or Laboratory Biomarker in Phase 3 Clinical Trials - (12/03/14)
     
  3838. Sovaldi in Pakistan - (12/03/14)
     
  3839. Hospitalizations And Costs Associated With Hepatitis C And Advanced Liver Disease Continue To Increase - HCV/Aging Hospitalizations/Costs Tripled in 6 Years - (12/03/14)
     
  3840. National Estimates of Healthcare Utilization by Individuals With Hepatitis C Virus Infection in the United States - (12/03/14)
     
  3841. Fixed Dose Ledipasvir/Sofosbuvir Harvoni Phase 3 Data New Drug Application Submitted to Japan for Genotype 1 - (12/03/14)
     
  3842. Life Expectancy in Patients With Chronic HCV Infection and Cirrhosis Compared With a General Population - (12/03/14)
     
  3843. AASLD: Urgent Treatment With Sofosbuvir Based Regimen For Hepatitis C Genotype 1 Patients With Severe Renal Insufficiency (GFR <30ml/min) - (12/03/14)
     
  3844. AASLD: Safety, Antiviral Efficacy, and Pharmacokinetics of Sofosbuvir in Patients With Severe Renal Impairment - (12/03/14)
     
  3845. Health Economics/Cost Effectiveness: AASLD: Cost-Effectiveness of Novel Hepatitis C Drug Regimens Among Treatment-Experienced U.S. Veterans - (12/02/14)
     
  3846. Health Economics/Cost Effectiveness: AASLD: Direct Costs of Care for Hepatocellular Carcinoma in patients with Hepatitis C cirrhosis - (12/02/14)
     
  3847. AASLD: Interferon-Free Regimens of Ombitasvir and ABT-450/r With or Without Ribavirin in Patients With HCV Genotype 4 Infection: PEARL-I Study Results - (12/01/14)
     
  3848. AASLD: Adherence to Prescribed Doses of ABT-450/r/Ombitasvir, Dasabuvir, and Ribavirin in the Phase 3 PEARL-II, PEARL-III, and PEARL-IV Trials - (12/01/14)
     
  3849. AASLD: Preliminary results of a Daclatasvir (DCV) based treatment protocol (DCV+Sof, DCV+Simeprevir) in LT recipients with severe recurrent HCV - (12/01/14)
     
  3850. AASLD: SVR12 Rate of 98.6% in 992 HCV Genotype 1b-Infected Patients Treated With ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin - (12/01/14)
     
  3851. AASLD: HCV infection in opioid dependent pregnant women - (12/01/14)
     
  3852. AASLD: Effects of Sustained Virological Response on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 34,563 patients with Hepatitis C infection - (12/01/14)
     
  3853. AASLD: Treatment of Hepatitis C Genotype 4 with Ledipasvir and Sofosbuvir for 12 weeks: Results of the SYNERGY Trial - (12/01/14)
     
  3854. AASLD: Summary from AASLD 2014 for Hepatitis C Boston 7-11 November 2014 - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany
     
  3855. HCV, Illinois, Medicaid Costs Projected - (11/25/14)
     
  3856. Connecticut Restricts HCV Drug Access to F4 - (11/25/14)
     
  3857. AASLD/EASL NY HCV Special Conference: Open Label Study to Evaluate Safety, Tolerability, and Efficacy of Telaprevir (TVR) in Combination with Sofosbuvir (SOF) in Treatment-naïve Patients with Genotype 1 Hepatitis C Virus Infection - (11/24/14)
     
  3858. NYS DURB Hearing on Harvoni Criteria Nov 20 2014 in Albany, NY - (11/21/14)
     
  3859. Health Economics/Cost Effectiveness: AASLD: AASLD: Health Economics/Cost-Effectiveness - (11/21/14)
     
  3860. CHMP Grants Positive Opinions of AbbVie's VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe - (11/21/14)
     
  3861. European Commission Grants Marketing Authorization for Gilead's Harvoni® (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4 - EU Harvoni Label/Product Characteristics - (11/21/14)
     
  3862. AASLD/EASL NY HCV Special Conference: Changes in Intrahepatic, Endogenous Interferon Expression in Chronic HCV, Genotype-1 Patients Treated with Interferon-free, Ribavirin-Free DAA Regimens - (11/20/14)
     
  3863. Health Economics/Cost Effectiveness: AASLD: Estimating the Number of Patients with Chronic Hepatitis C (HCV) Infection Meeting 'Highest' or 'High' Priority Treatment Criteria in the United States - (11/20/14)
     
  3864. Health Economics/Cost Effectiveness: AASLD: Improving HCV care cascade outcomes in a community-based testing program by providing same day confirmatory testing and patient navigation - (11/20/14)
     
  3865. AASLD: Retreatment of Patients Who Failed Prior Sofosbuvir-Based Regimens With All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir Plus Ribavirin for 12 Weeks - (11/20/14)
     
  3866. European Commission Grants Marketing Authorization for Gilead's Harvoni® (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4 - (11/19/14)
     
  3867. HCV Treatment for Post-Transplant - (11/18/14)
     
  3868. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory - (11/18/14)
     
  3869. CTAF Report: Newest Treatments for Hepatitis C, Genotype 1: next public meeting of the California Technology Assessment Forum (CTAF) on Thursday, December 18, 2014 in Oakland, California. - (11/18/14)
     
  3870. AASLD: Effectiveness of Hepatitis C Virus Testing for Persons Born during 1945-1965: Summary Results from Three Randomized Controlled Trials - (11/17/14)
     
  3871. AASLD: Virologic Response Rates to All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir Regimens Are Similar in Patients With and Without Traditional Negative Predictive Factors in Phase 3 Clinical Trials - (11/17/14)
     
  3872. AASLD: All-oral Dual Combination of Daclatasvir plus Asunaprevir Compared with Telaprevir plus Peginterferon Alfa/Ribavirin in Treatment-naive Japanese Patients Chronically infected with HCV Genotype 1b: Results from a Phase 3 Study - (11/17/14)
     
  3873. Health Economics/Cost Effectiveness: AASLD: FIB4 Score and Gender Predict the Incidence of Hepatocellular Carcinoma (HCC) among Patients with Chronic Hepatitis C Virus (HCV) Infection: Chronic Hepatitis Cohort Study (CHeCS) - (11/17/14)
     
  3874. Health Economics/Cost Effectiveness: AASLD: Increased All-cause Hospitalization among Hepatitis C Virus Infected Persons: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010 - (11/17/14)
     
  3875. Health Economics/Cost Effectiveness: AASLD: Evaluation Of The Long-Term Health Outcomes Of Ledipasivir-Sofosbuvir (LDV/SOF) And Sofosbuvir-Based Regimens For Patients With Chronic Hepatitis C And Liver Cirrhosis Across Genotypes 1 To 4 - (11/17/14)
     
  3876. Health Economics/Cost Effectiveness: AASLD: Treatment with Interferon- and Ribavirin-Free Regimens with Ledipasvir and Sofosbuvir Improves Patient-Reported Outcomes for Patients with Genotype 1 Chronic Hepatitis C: Results from the ION-1, 2 and 3 Clinical Trials - (11/17/14)
     
  3877. Health Economics/Cost Effectiveness: AASLD: Evaluation of the Health Outcomes for Ledipasvir / Sofosbuvir in Early vs. Delayed Treatment According to the Fibrosis Stage of Patients with Chronic Hepatitis C Virus (HCV) Genotype 1 Infection: Results from a Decision-Analytic Markov Model....... "initiating earlier LDV/SOF treatment at F0-2 vs F3/4 reduced liver disease progression/sequalae by 66-82% & rests in lower lifetime costs by 14.3-15.9%" - (11/17/14)
     
  3878. Health Economics/Cost Effectiveness: AASLD: A Decision-Analytic Markov Model to Evaluate the Health Outcomes of Ledipasvir/Sofosbuvir for Patients with Chronic Hepatitis C Genotype 1 Infection - (11/17/14)
     
  3879. Health Economics/Cost Effectiveness: AASLD: LEDIPASVIR/SOFOSBUVIR SINGLE-TABLET REGIMEN FOR CHRONIC HEPATITS C (CHC) INFECTION: INSIGHTS FROM A WORK PRODUCTIVITY ECONOMIC MODEL - (11/17/14)
     
  3880. Health Economics/Cost Effectiveness: AASLD: Projected Health and Economic Impact of Hepatitis C on the United States Medicare System From 2010 to 2024 - (11/17/14)
     
  3881. Updates to the HCV/HIV Section in HHS ART Adult/Adolescent Guidelines Nov 13 2014 - (11/14/14)
     
  3882. Treatment for Key Groups: HIV Coinfection, African-Americans, Cirrhosis/Treatment Experiencec-PI-Failures, Decompensated Cirrhosis, Genotype 3, Post-Transplant - (11/14/14)
     
  3883. HIV/HCV Coinfection SVR Rates The Same as in Monoinfected - (11/14/14)
     
  3884. AASLD: The Pharmacokinetics and Safety of the Direct Acting Antiviral Regimen of ABT-450/r, Ombitasvir with/without Dasabuvir in Subjects with Mild, Moderate and Severe Renal Impairment Compared to Subjects with Normal Renal Function - (11/14/14)
     
  3885. AASLD: An Interferon-free Antiviral Regimen for HCV after Liver Transplantation Abbvie 3D - (11/14/14)
     
  3886. AASLD: Pharmacokinetics and Safety of Pan-Genotypic, Direct Acting Protease Inhibitor, ABT-493, and NS5A Inhibitor, ABT-530, Following 3 Day Monotherapy in HCV Genotype-1 Infected Subjects With or Without Compensated Cirrhosis - (11/14/14)
     
  3887. AASLD: A Next Generation HCV DAA Combination: Potent, Pangenotypic Inhibitors ABT-493 and ABT-530 With High Barriers to Resistance - (11/14/14)
     
  3888. AASLD: Efficacy by Race or Geographic Region in HCV Genotype 1-Infected Patients Treated With ABT-450/Ritonavir/Ombitasvir and Dasabuvir With or Without Ribavirin - (11/14/14)
     
  3889. AASLD: Drug-Drug Interaction Profile of the Fixed-Dose Combination Tablet Ledipasvir/Sofosbuvir - (11/14/14)
     
  3890. AASLD: Mortality and progression to decompensated cirrhosis in chronic hepatitis C patients with liver biopsy confirmed fibrosis in the Chronic Hepatitis Cohort Study (CHeCS) - (11/14/14)
     
  3891. AASLD: Mortality and progression to decompensated cirrhosis in chronic hepatitis C patients with liver biopsy confirmed fibrosis in the Chronic Hepatitis Cohort Study (CHeCS) - (11/13/14)
     
  3892. AASLD: Interim Sustained Virologic Response (SVR), Safety And Tolerability Results Of 8-Week Treatment With ACH-3102 And Sofosbuvir In Chronic Hepatitis C (HCV), Genotype-1 (GT-1), Treatment-Naïve Patients: A Phase 2 "Proxy" Study - (11/13/14)
     
  3893. AASLD: Antiviral Activity and Resistance Emergence: Combinations of the NS5B Nucleotide Inhibitor ACH-3422 with Other Antiviral Agents in Vitro - (11/13/14)
     
  3894. AASLD: PEARL-IV Trial: Subgroup Analysis of Genotype 1a-infected Patients Treated With Dasabuvir Plus Ombitasvir/ABT-450/r With or Without Ribavirin - (11/13/14)
     
  3895. AASLD: ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients With History of Depression or Bipolar Disorder: Pooled Analysis of Efficacy and Safety in Phase 3 Trials - (11/13/14)
     
  3896. AASLD: ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Patients Receiving Stable Opioid Substitution Treatment: Pooled Analysis of Efficacy and Safety in Phase 2 and Phase 3 Trials - (11/13/14)
     
  3897. AASLD: The Combination of Grazoprevir (MK-5172), an NS3 Inhibitor, and MK-8408, an NS5A Inhibitor, Presents a High Genetic Barrier to Resistance in HCV Genotypes 1a and 3a - (11/14/14)
     
  3898. AASLD: MK-8408, a Potent and Selective NS5A Inhibitor With a High Genetic Barrier to Resistance and Activity Against HCV Genotypes 1-6 - (11/12/14)
     
  3899. AASLD: Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial - (11/14/14)
     
  3900. AASLD: Efficacy and safety of MK-5172 and MK-8742 ï RIBAVIRIN IN Hcv Gt1 Infected Patients with cirrhosis or previous null reSPonse: FINAL RESULTS OF the C-WORTHY Study (PARTS A AND B) - (11/12/14)
     
  3901. AASLD: Efficacy and safety of MK-5172 and MK-8742 ï RIBAVIRIN IN Hcv Gt1 Infected Patients with cirrhosis or previous null reSPonse: FINAL RESULTS OF the C-WORTHY Study (PARTS A AND B) - (11/12/14)
     
  3902. AASLD: Efficacy and safety of MK-5172 + MK-8742ï ribavirin in HCV mono-infected and HIV/HCV co-infected treatment-naïve, non-cirrhotic patients with hCV gT1 infection: The C-WORTHY study (Final results, Parts A and B) - (11/12/14)
     
  3903. AASLD: Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of HCV in Patients With Decompensated Cirrhosis: Preliminary Results of a Prospective, Multicenter Study - (11/12/14)
     
  3904. AASLD: HIGH SUSTAINED VIROLOGIC RESPONSE RATES IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HCV GENOTYPE 1 INFECTION RECEIVING ABT-450/r/OMBITASVIR + DASABUVIR PLUS RIBAVIRIN CORAL-1 Study - (11/12/14)
     
  3905. AASLD: A Phase I/IIa Study Assessing 7-Day Dosing of MK-3682 (formerly IDX21437)in Subjects Infected With Hepatitis C Virus (HCV) - (11/12/14)
     
  3906. AASLD: Sofosbuvir and Ribavirin Therapy for the Treatment of HIV/HCV Coinfected Patients With HCV GT 1-4 Infection: The PHOTON-1 and -2 Trials - (11/12/14)
     
  3907. AASLD: High Efficacy of Treatment With Sofosbuvir + GS-5816 ï Ribavirin for 12 Weeks in Treatment-Experienced Patients With Genotype 1 or 3 HCV Infection - (11/12/14)
     
  3908. AASLD: Safety and Efficacy of LDV/SOF in African Americans: A Retrospective Analysis of Phase 3 Data - (11/12/14)
     
  3909. AASLD: Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C - (11/12/14)
     
  3910. AASLD: Hepatitis Debrief AASLD 2014 - (11/12/14)
     
  3911. AASLD: TURQUOISE-I: 94% SVR12 in HCV/HIV-1 Co-infected Patients Treated With ABT-450/r/Ombitasvir and Dasabuvir and Ribavirin - (11/12/14)
     
  3912. AASLD: (ELECTRON-2) Regimens for 12 Weeks for Patients With HCV Genotype 3 or 6 Infection - (11/12/14)
     
  3913. AASLD: All-Oral, Fixed-Dose Combination Therapy With Daclatasvir/Asunaprevir/Beclabuvir for Non-Cirrhotic Patients With Chronic HCV Genotype 1 Infection: UNITY-1 Phase 3 SVR12 Results - (11/12/14)
     
  3914. AASLD: Janssen at AASLD 2014 - (11/11/14)
     
  3915. AASLD: Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis - (11/11/14)
     
  3916. AASLD: All-Oral Fixed-Dose Combination Therapy With Daclatasvir/Asunaprevir/Beclabuvir, ïRibavirin, for Patients With Chronic HCV Genotype 1 Infection and Compensated Cirrhosis: UNITY-2 Phase 3 SVR12 Results - (11/11/14)
     
  3917. AASLD: All-Oral 12-Week Combination Treatment With Daclatasvir and Sofosbuvir in Patients Infected With HCV Genotype 3: ALLY-3 Phase 3 Study - (11/11/14)
     
  3918. AASLD: Regimens for 12 Weeks for Patients With HCV Genotype 3 or 6 Infection - (11/11/14)
     
  3919. AASLD: Ledipasvir/Sofosbuvir Fixed-Dose Combination Is Safe and Efficacious in Cirrhotic Patients Who Have Previously Failed Protease-Inhibitor Based Triple Therapy SIRIUS Trial - (11/11/14)
     
  3920. AASLD: Safety and Efficacy of New DAA---based Therapy for Hepatitis C Post---Transplant: Interval Results from the HCV---TARGET Longitudinal, Observational Study - (11/11/14)
     
  3921. AASLD: ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients - (11/11/14)
     
  3922. AASLD: Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD) - (11/11/14)
     
  3923. AASLD: Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of HCV in Patients With Post- Transplant Recurrence: Preliminary Results of a Prospective, Multicenter Study - (11/11/14)
     
  3924. AASLD: An Integrated Safety and Efficacy Analysis of >500 Patients With Compensated Cirrhosis Treated With Ledipasvir/Sofosbuvir With or Without Ribavirin - (11/11/14)
     
  3925. AASLD: Alios/J&J HCV Nucleotides Preclinical Data at AASLD - (11/11/14)
     
  3926. AASLD: Once-Daily Sofosbuvir With GS-5816 for 8 Weeks With or Without Ribavirin in Patients With HCV Genotype 3 Without Cirrhosis Result in High Rates of SVR12: The ELECTRON-2 Study - (11/10/14)
     
  3927. AASLD: Safety and Efficacy of Treatment with Sofosbuvir + GS-5816 ï Ribavirin for 8 or 12 Weeks in Treatment-Naïve Patients with Genotype 1-6 HCV Infection - (11/10/14)
     
  3928. AASLD: C-SWIFT: Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Sofosbuvir in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection, With and Without Cirrhosis, for Durations of 4, 6, or 8 Weeks (Interim Results) - (11/10/14)
     
  3929. AASLD: Safety and Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C: Real-World Experience in a Diverse, Longitudinal Observational Cohort HCV-TARGET - (11/10/14)
     
  3930. AASLD: Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network - Academic and community treatment of a real-world, heterogeneous population - (11/10/14)
     
  3931. AASLD: Burden of Side Effects Associated with Treatment of Hepatitis C - (11/10/14)
     
  3932. AASLD: Cerebral MR spectroscopy and patient reported mental health outcomes in hepatitis C genotype 1 naïve patients treated with ledipasvir and sofosbuvir (from Jules: these results found treatment with ledipasvir+sofosbuvir improved neuronal function) - (11/10/14)
     
  3933. AASLD: L159F and V321A Sofosbuvir Treatment-Emergent HCV NS5B Substitutions - (11/10/14)
     
  3934. AASLD: C-SWIFT: Grazoprevir (MK-5172) + Elbasvir (MK-8472) + Sofosbuvir in Treatment-Naïve Patients with Hepatitis C Virus Genotype 1 Infection, With and Without Cirrhosis, for Durations of 4, 6 or 8 Weeks (Interim Results) - (11/10/14)
     
  3935. AASLD: INTEGRATED EFFICACY ANALYSIS OF FOUR PHASE 3 STUDIES IN HCV GENOTYPE 1A-INFECTED PATIENTS TREATED WITH ABT-450/R/OMBITASVIR AND DASABUVIR WITH OR WITHOUT RIBAVIRIN - (11/10/14)
     
  3936. AASLD: TURQUOISE-II: REGIMENS OF ABT-450/r/OMBITASVIR AND DASABUVIR WITH RIBAVIRIN ACHIEVE HIGH SVR12 RATES IN HCV GENOTYPE 1-INFECTED PATIENTS WITH CIRRHOSIS, REGARDLESS OF BASELINE CHARACTERISTICS - (11/10/14)
     
  3937. AASLD: Use of Ledipasvir/Sofosbuvir Fixed Dose Combination for Treatment of HCV Genotype-1 Infection in Patients Coinfected with HIV - (11/10/14)
     
  3938. OLYSIO® (simeprevir) Gains Additional FDA Approval as Once-Daily, All-Oral Interferon- and Ribavirin-Free Treatment Option in Combination with Sofosbuvir for Adults with Genotype 1 Chronic Hepatitis C Infection - (11/06/14)
     
  3939. Glasgow - TURQUOISE-I: SAFETY AND EFFICACY OF OMBITASVIR/ABT-450/R, DASABUVIR AND RIBAVIRIN IN HCV/HIV-1 CO-INFECTED PATIENTS RECEIVING ATAZANAVIR OR RALTEGRAVIR ART REGIMENS - (11/05/14)
     
  3940. Association of Opioid Agonist Therapy With Lower Incidence of Hepatitis C Virus Infection in Young Adult Injection Drug Users - (11/05/14)
     
  3941. New Federal HCV Policy Direction Needed...'find new champions in White House, Congress, funding for screening, open access to treatment' - (11/04/14)
     
  3942. Bristol-Myers Squibb Announces Global HCV Strategy - (11/03/14)
     
  3943. Here are key HCV Reports - Harvoni was FDA Approved Oct 10, Abbvie 3D is expected to be FDA approved by Dec 21, Simeprevir+Sofosbuvir Approval Expected by Dec 20, Daclatasvir+Sofosbuvir expected in mid 2015 - (11/03/14)
     
  3944. Sovaldi FDA Label - Prescribing Information - (11/03/14)
     
  3945. UnitedHealthCare - F3/F4 - AASLD/IDSA Guidance - (10/31/14)
     
  3946. Hepatitis C beware-the end is nigh - (10/31/14)
     
  3947. AASLD/EASL NY HCV Special Conference: AASLD/IDSA Guidelines Improves Restrictions Language - (10/31/14)
     
  3948. Locking up Savings? Sovaldi Could be Cost Effective for Prisons: Study - (10/30/14)
     
  3949. Factors associated with medical resource utilisation and related costs in treatment-experienced patients with genotype 1 chronic hepatitis C virus - SVR "consumes less medical resources"...F3-F4 predicts costs more to treat - (10/30/14)
     
  3950. Key HCV & AGING Reports - 6 Conference Reports-ICAAC/IDSA/ Aging WK-Baltimore / Adverse Events Comorbidities WK-Philadelphia / American Congress of Gastroenterology - 2 HCV Conference in Vienna & Germany - (10/29/14)
     
  3951. New AASLD HCVGuidelines Restriction Language Posted Oct 24 - (10/29/14)
     
  3952. NAMD (Medicaid Association) Letter Urges Congress to Address Break Through Drugs - (10/29/14)
     
  3953. IDSA: Evaluation of Drug-Drug Interaction between Daclatasvir and Methadone or Buprenorphine/Naloxone - (10/28/14)
     
  3954. IDSA: Evaluation of Drug-Drug Interaction Between Asunaprevir and Methadone or Buprenorphine/Naloxone - (10/28/14)
     
  3955. IDSA: Predictors of Sustained Virological Response in Cancer Survivors with Hepatitis C Virus Infection Receiving Antiviral Therapy. Cancer Patients are a "special population" of HCV-infected & should be prioritized for treatment. - (10/27/14)
     
  3956. IDSA: One in 5 With HIV in US Never Tested for HCV, Prevalence 21% in Tested - Mark Mascolini - (10/25/14)
     
  3957. IDSA: Hip Fracture Rate Higher With HIV/HBV Than HIV Alone in Medicaid Analysis - Mark Mascolini - (10/25/14)
     
  3958. HCV in Australia "it is the Dallas Buyers Club scenario"...HCV therapy is much less expensive than HIV HAART...... "Australia is on the verge of a catastrophic death spiral from Hepatitis C" (10/25/14)
     
  3959. Harvoni Criteria Anthem/Express Scripts - (10/24/14)
     
  3960. ACG: Abbvie 3D at ACG - (10/20/14)
     
  3961. ACG: MANAGEMENT OF HEMOGLOBIN DECREASE IN PATIENTS TREATED WITH ABT-450/RITONAVIR/OMBITASVIR AND DASABUVIR WITH OR WITHOUT RIBAVIRIN IN HCV GENOTYPE-1 INFECTED PATIENTS - (10/20/14)
     
  3962. New HCV Oral Interferon-Free Regimens - (10/23/14)
     
  3963. ACA/59% Use Specialty Meds Prescriptions: HIV/HCV Prominent-Express Scripts Report - (10/23/14)
     
  3964. United Healthcare Criteria for Harvoni - (10/22/14)
     
  3965. IDSA: HCV at ID Week-2 2014 David H Shepp, MD Associate Professor of Medicine Hofstra-North Shore LIJ School of Medicine - (10/22/14)
     
  3966. Prevalence of the Hepatitis C Virus Polymorphism Q80K in a Pooled Analysis of Genotype 1 Patients from Telaprevir and Simeprevir Phase II/III Clinical Trials - (10/20/14)
     
  3967. Renal Function in HCV Genotype 1-infected Treatment-naïve Patients Receiving Simeprevir in Combination with Peg-IFN and Ribavirin: A Post-hoc Analysis - (10/20/14)
     
  3968. NYS HCV Criteria Hearing Nov 20 2014 - (10/20/14)
     
  3969. HCV - Medicaid Pharmacy Program Criteria & Prior Authorization (PA) Update - (10/20/14)
     
  3970. ACG: NORMALIZATION OF LIVER-RELATED LABORATORY PARAMETERS IN HCV GENOTYPE 1-INFECTED PATIENTS WITH CIRRHOSIS AFTER TREATMENT WITH ABT-450/R/OMBITASVIR, DASABUVIR AND RIBAVIRIN - (10/20/14)
     
  3971. ACG: Sustained Virologic Response 12 Weeks Post-treatment With ABT-450/Ritonavir/Ombitasvir and Dasabuvir With Ribavirin (SAPPHIRE I and II) Is Independent of Patient Subgroups - (10/20/14)
     
  3972. ACG: Low Incidence of Hyperbilirubinaemia With Ombitasvir-ABT-450/r and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Patients - (10/20/14)
     
  3973. ACG: Results From the Phase 2 PEARL-I Study: Interferon-free Regimens of ABT-450/r + ABT-267 With or Without Ribavirin in Patients With HCV Genotype 4 Infection - (10/20/14)
     
  3974. ACG: Safety Comparison of 12- and 24-Week Treatments in HCV Genotype 1-Infected Patients With Cirrhosis: Results From TURQUOISE-II - (10/20/14)
     
  3975. IDSA: HCV at IDSA - Bone Disease Greater in HIV+ HCV or HBV Coinfected / Barriers to Care / Hi Prevalence 7% at STD Clinic in Baltimore / 20% of HIV+ Never Tested for HCV / New HCV Therapies: Ledipasvir/Sofosbuvir & Abbvie 3D Data Summaries - (10/17/14)
     
  3976. IDSA: Characterization of Patients with Viral Hepatitis at an Urban Hospital in Washington, DC 2009-2013 - (10/17/14)
     
  3977. IDSA: HCV at ID Week 2014 Written by David H Shepp, MD Associate Professor of Medicine Hofstra-North Shore LIJ School of Medicine - (10/17/14)
     
  3978. Novel 'Pay If You Clear' guarantee offered in Scotland as SMC approves new hepatitis C treatment OLYSIO® (simeprevir) for use within NHS Scotland1 - (10/16/14)
     
  3979. AASLD/EASL NY HCV Special Conference: Preclinical Characterization of AL-335, a Potent Uridine Based Nucleoside Polymerase Inhibitor for the Treatment of Chronic Hepatitis C - (10/15/14)
     
  3980. IDSA: ABT-450/R/OMBITASVIR AND DASABUVIR WITH RIBAVIRIN ACHIEVES HIGH SUSTAINED VIROLOGIC RESPONSE RATES REGARDLESS OF BASELINE CHARACTERISTICS: POOLED ANALYSES OF THE SAPPHIRE-I AND SAPPHIRE-II STUDIES - (10/15/14)
     
  3981. IDSA: Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis - (10/15/14)
     
  3982. IDSA: HCV Treatment 2014 and Beyond - New Era of Hepatitis C Management - (10/15/14)
     
  3983. IDSA: Hepatitis C Care among HIV Infected Patients in a Community Based Clinic (Ryan White Clinic/Baltimore) - (10/15/14)
     
  3984. IDSA: Sexually Transmitted Diseases Clinic Based Hepatitis C Testing and Linkage to care - Hi prevalence 7%, low attendance at offsite HCV specialist appointments - (10/15/14)
     
  3985. IDSA: Prevalence of and Factors Associated with Hepatitis C Virus Testing and Infection Among HIV-infected Adults Receiving Medical Care in the United States .... 20% Never Tested/21% HCV+/MSM Lo % Tested/Homelessness associated with HCV+ - (10/15/14)
     
  3986. IDSA: Optimization of the HCV Testing and Care Continuum in an Urban Federally Qualified Health Center in Denver - (10/15/14)
     
  3987. IDSA: Safety of ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Patients, by Baseline Demographics - (10/15/14)
     
  3988. NYS Advocates Protest Harsh Restrictive HCV Drug Criteria - (10/15/14)
     
  3989. Alios BioPharma Presents Data on its Anti-HCV Nucleotide AL-335 at Special Conference on Hepatitis C - (10/15/14)
     
  3990. Johnson & Johnson Announces Agreement To Acquire Alios BioPharma's HCV Nukes - (10/15/14)
     
  3991. IDSA: Structural Bone Deficits in HIV/HCV, HCV-Monoinfected, and HIV-Monoinfected Women - (10/14/14)
     
  3992. IDSA: Non-Genotype 1 HCV Predicts Sustained Virologic Response in Cancer Survivors - written by Mark Mascolini - (10/14/14)
     
  3993. Hepatitis C core antigen testing: a reliable, quick and potentially cost-effective alternative to Hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection - (10/14/14)
     
  3994. Janssen's Olysio 'pay if you clear' deal.....NHS in Scotland is to be reimbursed for the cost of a new hepatitis drug if sufferers fail to clear the virus - (10/14/14)
     
  3995. Olysio/Simeprevir COSMOS, ATTAIN Study - (10/14/14)
     
  3996. Harvoni FDA Product Info/Label, Patient Info - (10/11/14)
     
  3997. U.S. Food and Drug Administration Approves Gilead's Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C - (10/11/14)
     
  3998. FDA approves first combination pill to treat hepatitis C - Harvoni: sofosbuvir/ledipasvir fixed dose combination (FDC) - (10/11/14)
     
  3999. Sovaldi Cost-Effectiveness/Disease Outcome Analysis - (10/10/14)
     
  4000. IDSA: HCV Treatment Cascade: Is Eradication Possible? - (10/10/14)
     
  4001. IDSA: Evaluation of Drug-Drug Interaction between Daclatasvir and Methadone or Buprenorphine/Naloxone - (10/10/14)
     
  4002. Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir (MK-5172/MK-8742) at the 65th American Association for the Study of Liver Diseases Annual Meeting - (10/08/14)
     
  4003. Bristol-Myers Squibb Statement about Asunaprevir in the U.S. - (10/08/14)
     
  4004. The Prevalence of HCV NS5A, Nucleoside and Protease Inhibitor Resistance Associated Variants and the Effects on Treatment with Ledipasvir/Sofosbuvir ï RBV in the Phase 3 ION Studies - (10/08/14)
     
  4005. Medicaid/HCV in Texas - (10/08/14)
     
  4006. Sovaldi\ledipasvir+vedroprevir Study in treatment-experienced gt1 cirrhotics - 8 weeks - (10/08/14)
     
  4007. Bristol-Myers Squibb Presents Data from Multiple New Studies at IDWeek 2014™ Showcasing Continued Innovation in Virology - (10/02/14)
     
  4008. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients - (10/06/14)
     
  4009. NYC/US HCV Mortality Data/HIV-Coinfection - (10/06/14)
     
  4010. NYS Medicaid Sovaldi Criteria. Are they discriminatory & illegal, a lawsuit in the making? Comment Period Open Now - (10/05/14)
     
  4011. Abbvie:  Research in Hepatitis C with Investigational Data from Clinical Program Being Presented at The Liver Meeting (AASLD) - (10/05/14)
     
  4012. Bristol-Myers Squibb Presents Data from Multiple New Studies at IDWeek 2014™ Showcasing Continued Innovation in Virology - (10/02/14)
     
  4013. Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection 12, 24 weeks GT1/2/3, FDA Approvals Oct 10 thru Dec This Fall - (10/02/14)
     
  4014. HCV & HIV African-American/Latino Disparities of Care.... - (10/01/14)
     
  4015. HCV Epidemiology Changing - HCV & Youth: Increasing New Infections - (09/30/14)
     
  4016. Eliminating HCV " Test & Treat" - HCV is a Disease of the Marginalized: homeless, IDUs, immigrants, African-Americans, Latinos - (09/30/14)
     
  4017. HCV Screening in HIV is Poorly Implemented, MSM don't get screened adequately, only 55% get screened again after initial screen - (09/29/14)
     
  4018. Sovaldi/Rbv Study in Adolescents Children Gt2/3 - (09/29/14)
     
  4019. Sovaldi studies Child-Pugh B Cirrhosis/Advanced Liver Disease/Post-Transplant - (09/29/14)
     
  4020. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network - (09/29/14)
     
  4021. The relationship between hepatitis C virus infection and diabetes: Time for a divorce? - Editorial - (09/29/14)
     
  4022. Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response - (09/29/14)
     
  4023. AASLD/EASL NY HCV Special Conference: Most patients with HCV-associated lymphoma present with mild liver disease at cancer diagnosis: A call to revise indications for HCV treatment - (09/26/14)
     
  4024. AASLD/EASL NY HCV Special Conference: Outcome analysis of ledipasvir/sofosbuvir (LDV/SOF) for the treatment of chronic hepatitis C infected genotype 1 patients in the UK. - (09/26/14)
     
  4025. HCVguidelines Update - Hepatitis C Treatment: Guidance on Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy Posted - (09/26/14)
     
  4026. European CHMP Adopts Positive Opinion for Gilead's Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults - (09/26/14)
     
  4027. Gilead Submits New Drug Application to Japan's Pharmaceutical and Medical Devices Agency for Fixed-Dose Combination of Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 1 Infection - (09/24/14)
     
  4028. NICE consults on draft guidance on the drug simeprevir (Olysio) for treating hepatitis C - (09/23/14)
     
  4029. NICE Simeprevir Report - (09/23/14)
     
  4030. Rhode Island HCV Medicaid Imposes Harsh Restrictions - (09/23/14)
     
  4031. Pennsylvania Harsh HCV Medicaid Restrictions TOO - (09/22/14)
     
  4032. Broadly neutralizing antibodies abrogate established hepatitis C virus infection....."perhaps a vaccine" - (09/22/14)
     
  4033. Treatment of Hepatitis C Virus Infection: Is It Time for the Internist to Take the Reins?......"cure of individual patients is eminently feasible and communitywide eradication is conceivable" - (09/22/14)
     
  4034. OLYSIO (simeprevir) label revisions - (pdf of new simeprevir label included) - (09/22/14)
     
  4035. AASLD/EASL NY HCV Special Conference: The Optimal HCV All-Oral Cocktail HCV genotypes 4,5 & 6 and Mixology - (09/19/14)
     
  4036. (NY) State health officials issue Sovaldi recommendations - (09/19/14)
     
  4037. NYS HCV Drug Criteria, NYS Hearing Sept 18 - (09/19/14)
     
  4038. Generic Sovaldi/ledipasvir Licensed by Gilead - (09/17/14)
     
  4039. $6 million grant to improve hepatitis C treatment in King County (Seattle) - (09/17/14)
     
  4040. HCV Key Topics - IDUs/African-Americans/Latinos/treatment-experienced cirrhotics 24 weeks - (09/17/14)
     
  4041. Abbvie 3D at ICAAC, Sovaldi/ledipasvir, Daclatasvir+SOF, Simeprevir+SOF, Merck's triple - (09/17/14)
     
  4042. ION-1 NAIVES & ION-2 Treatment-Exp SVR Rates - RBV Cirrhotics/Ethnicity/ baseline NS5A resistance - (09/17/14)
     
  4043. ICAAC: Serum levels of soluble cellular adhesion molecules are associated with survival and liver-related events in adults coinfected with HIV/HCV - (09/16/14)
     
  4044. HCV Treatment Access Restrictions - HCV Can Be Eradicated ! - (09/16/14)
     
  4045. IDSA, HIVMA Call for State Medicaid Programs to Lift Hepatitis C Prescribing Restrictions from ID and HIV Doctors -IDSA/HIVMA - (09/16/14)
     
  4046. HCV Infection/Drug Use in Rural Appalachian/Kentucky: 54% HCV+, 31% were aware of status, 94% white, age 31, prescription opoids (OxyContin/illicit methadone or hydrocodone more common) - (09/16/14)
     
  4047. AASLD/EASL NY HCV Special Conference: Changing Epidemiology of HCV Infection: Unsafe Injections and Other Modes of Transmission (prevention/screening/heroin/cascade of care/IDUs - (09/15/14)
     
  4048. AASLD/EASL NY HCV Special Conference: Therapeutic Challenges: Decompensated Cirrhosis and Liver Transplantation - (09/15/14)
     
  4049. AASLD/EASL NY HCV Special Conference: Real World Experience with DAA Regimens - Phase 4 HCV TARGET Study - (09/15/14)
     
  4050. ICAAC: Over Half of MSM in Swiss Study Group Don't Know About HCV Infection - Mark Mascolini - (09/15/14)
     
  4051. Gilead Close To Sending Sovaldi to Poor Countries - (09/11/14)
     
  4052. Britain Has No Problem Paying for Expensive Hepatitis C Drugs/Different Healthcare Systems - (09/11/14)
     
  4053. Medicaid HCV Treatment Restrictions Denying Care & Treatment, which HCV Guidelines Committee Supported - (09/11/14)
     
  4054. Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza® (daclatasvir) and Sunvepra® (asunaprevir) Dual Regimen - (09/10/14)
     
  4055. Iowa Prisons Use Sovaldi - (09/10/14)
     
  4056. ICAAC: Drug-Drug Interactions of the Direct Acting Antiviral Regimen of ABT-450/r, Ombitasvir and Dasabuvir with HIV Protease Inhibitors - (09/08/14)
     
  4057. ICAAC: Drug-Drug Interactions with Direct Acting Antiviral Combination Therapy of ABT-450/r, Ombitasvir and Dasabuvir - (09/08/14)
     
  4058. ICAAC: Drug-Drug Interactions of the Direct Acting Antiviral Regimen of ABT-450/r, Ombitasvir and Dasabuvir with Emtricitabine + Tenofovir, Raltegravir, Rilpivirine and Efavirenz - (09/08/14)
     
  4059. ICAAC: Transient Indirect Bilirubin Elevations Associated With ABT-450/r/Ombitasvir and Dasabuvir With Ribavirin - (09/08/14)
     
  4060. ICAAC: Adverse Event Profile of the Interferon-free All-oral ABT-450/r/Ombitasvir, Dasabuvir, and Ribavirin Regimen in HCV Patients - (09/08/14)
     
  4061. ICAAC: TURQUOISE-I: SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN PATIENTS CO-INFECTED WITH HEPATITIS C AND HIV-1 - (09/08/14)
     
  4062. ICAAC: High SVR12 Rates in HCV Genotype 1b-Infected Patients Receiving Ombitasvir/ABT-450/r and Dasabuvir With or Without Ribavirin Regardless of Baseline Characteristics - (09/08/14)
     
  4063. ICAAC: Risky Sex and Drug Use Common in HIV-Negative MSM With Acute HCV - Written by Mark Mascolini - (09/08/14)
     
  4064. HIV Medical Associations Challenge Insurer Restrictions to HCV Treatment - IDSA/ HIVMA/AAHIVM - (09/03/14)
     
  4065. HCV Subgroup Analyses: Cirrhosis/African-Americans/Opoid Replacement/Comorbidities - (09/03/14)
     
  4066. Abbvie 3D HIV/HCV Coinfection Study - 300 enrollment - (09/03/14)
     
  4067. Ledipasvir/Sofosbuvir HIV/HCV Coinfection Phase 3 Study Ongoing - (09/03/14)
     
  4068. HCV Subgroup Analyses: Cirrhosis/African-Americans/Opoid Replacement/Comorbidities - Abbvie 3D, Ledipasvir/Sofosbuvir - (09/03/14)
     
  4069. HCV Prevalence, Diagnosed in US, Western Europe, Japan Gt 1/2/3/4-5-6 - (09/03/14)
     
  4070. Racial Differences in the Progression to Cirrhosis and Hepatocellular Carcinoma in HCV-Infected Veterans....."Hispanics with HCV had a 28 and 61% increased risk of developing both cirrhosis and HCC" - (09/03/14)
     
  4071. SVR Rates: predictors/liver disease stage(cirrhosis) - Abbvie 3D, Gilead's LDV/SOF, JNJ's SIM/SOF, BMS's Daclatasvir+Sofosbuvir  - (09/03/14)
     
  4072. Florida Medicaid HCV Criteria for Olysio (simeprevir) - (08/30/14)
     
  4073. Florida-Medicaid HCV Criteria/Sovaldi .....August 8, 2014 pdf attached - (08/30/14)
     
  4074. Florida Medicaid Adds $1,000-a-Pill Drug - (08/30/14)
     
  4075. FLorida Medicaid Limits Hep C Drug - (08/30/14)
     
  4076. New California HCV Treatment Restrictions.....requires urine-analysis/denies access to drug users unless abstinent for 6 months/requires advanced disease to be treated - (08/28/14)
     
  4077. Australia's PBAC, Pharmacy Benefits Program, akin to Medicaid in USA, Rejects Sofosbuvir, here is their language - (08/25/14)
     
  4078. Increased plasma concentration of ribavirin as a result of renal dysfunction in hepatitis C virus patients treated with telaprevir - (08/25/14)
     
  4079. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C....... "treat all" - (08/25/14)
     
  4080. IAC: HCV at IAC/2014-Melbourne - (08/22/14)
     
  4081. HCV/Medicaid Law Suits Coming - (08/22/14)
     
  4082. Increased Intake of Vegetables, but not Fruit, Reduces Risk for Hepatocellular Carcinoma: A Meta-analysis - (08/22/14)
     
  4083. Increased plasma concentration of ribavirin as a result of renal dysfunction in hepatitis C virus patients treated with telaprevir - (08/22/14)
     
  4084. SVR Rates Are The Same in HIV/HCV Coinfected as in Mono-infected Patients ! - (08/20/14)
     
  4085. Emerging Epidemic of Hepatitis C Virus Infections Among Young Non-Urban Persons who Inject Drugs in the United States, 2006-2012 - (08/20/14)
     
  4086. Medicaids/ Feds Deny HCV Treatment to Poor/Disenfranchised, Those Most Affected by HCV- - (08/19/14)
     
  4087. HCV Treatment & Barriers To Care in HIV/HCV-Coinfected - (08/18/14)
     
  4088. UK NICE Sovaldi Guidance - "We are pleased to be able to provisionally recommend sofosbuvir as a clinically and cost effective treatment for some people with chronic hepatitis C" - (08/18/14)
     
  4089. Oregon Sovaldi Decision Tabled - (08/18/14)
     
  4090. Medicaid Restrictions, Opoid Replacement Therapy, African-Americans, Depression/Comorbidities....is this legal? A lawsuit- "swift overturn in courts" - (08/18/14)
     
  4091. Medicaids Restrictions Based on Misleading Information: African-Americans/ Opoid Replacement (Methadone) Users SVR Rates, comorbidities - (08/18/14)
     
  4092. Vertex to stop selling hepatitis C drug Incivek - (08/15/14)
     
  4093. PegLambda Discontinued by BMS - (08/15/14)
     
  4094. Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study") - (08/15/14)
     
  4095. DDW: VA Patients Are Good Candidates for Early HCV Treatment - (08/13/14)
     
  4096. EASL: The Impact of Fibrosis on the Risk of Long-Term Morbidity & Mortality in Chronic Hepatitis C Patients Treated in the US Veterans Health Administration Health Care System - advanced HCV disease correlated with risk for hospitalization/events/death - (08/13/14)
     
  4097. EASL: Resource Utilization During Hepatitis C Treatment With Boceprevir- or Telaprevir-Based Triple Therapy vs Dual Therapy In A Large Health Maintenance Organization - low treatment rates & high resource utilization rate too with IFN-based therapies boceprevir or telaprevir or INF-based Double Therapy In A Large Health Maintenance Organization - (08/13/14)
     
  4098. EASL: Comorbidities Associated with Not Being Treated for HCV - (08/13/14)
     
  4099. Earlier HCV Treatment Reduces Serious Liver Disease Outcomes - (08/12/14)
     
  4100. HCV Guidelines Questionably Prioritize The Sickest To Be Treated, New Guidelines Section- "WHEN AND IN WHOM TO INITIATE HCV THERAPY" - commentary - (08/12/14)
     
  4101. HCV Guidelines-AASLD/IDSA New Recommendations-'Whom & When To Initiate Therapy' issued Aug 11 2014 - (08/12/14)
     
  4102. Hepatitis C can be cured globally, but at what cost? - (08/11/14)
     
  4103. Viral hepatitis more deadly than HIV, but unfunded - (08/11/14)
     
  4104. HCV Treatment, HIV Treatment: public & personal health denied - HCV Cost Burden - commentary - (08/11/14)
     
  4105. Interview with Illinois Medicaid Medical Director Re: their new restrictions on Sovaldi Access - (08/08/14)
     
  4106. IAC: Antifibrotic activity of dual CCR5/CCR2 antagonist cenicriviroc in a mouse model of renal fibrosis - (08/08/14)
     
  4107. HCV Positivity in Ukraine - (08/08/14)
     
  4108. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C - (08/08/14)
     
  4109. HCV Treatment Cost-Effectiveness/ SOF/PR SVR Reduces Liver Disease vs PI/PR Treatments - (08/08/14)
     
  4110. HCV positive injection drug users and linkage to care: a missed opportunity........Of the 188 past or current PWID who completed our questionnaire, 95% reported having received at least 1 HCV test in the past......66% reported their HCV status as positive. Of the HCV positive participants, 36% were uninsured, 62% had never seen an HCV specialist, and only 15% had ever received treatment. Multiple subjective access to care barriers were reported by participants. - (08/08/14)
     
  4111. Treating HCV Earlier vs at Cirrhosis Reduces Serious Liver Disease Outcomes - (08/08/14)
     
  4112. New Hepatitis-C drug 99% cheaper in India - (08/08/14)
     
  4113. New Models for Healthcare Funding Needed - (08/06/14)
     
  4114. HCV Could be a "Rare Disease" by 2026, "1-time HCV screening for all/test & treat"..... need for more aggressive screening strategies and higher treatment capacity.....1-time universal screening - new study projects - (08/06/14)
     
  4115. IAC: The HCV Care "Cliff": High burden of HCV disease and poor access to HCV services among people who inject drugs in India - (08/06/14)
     
  4116. Oregon Medicaid Restricts HCV Therapy Access....A Symptom of a Failing Healthcare System That Denies Human Dignity & Life - (08/05/14)
     
  4117. IAC: IAC Plenary on HIV/Aging & NATAP Reports on HIV/Aging-Complications / HCV /Activation / Inflammation/Kidney/Anal Cancer-HSIL clearance/COPD/Neuro-Cognitive Disorders - (08/04/14)
     
  4118. IAC: Does the Addition of HCV Testing to a Rapid HIV Testing Program Impact HIV Test Acceptance? A Randomized Controlled Trial - (08/04/14)
     
  4119. Medicare Premiums/ HCV - New Millman Report - (08/01/14)
     
  4120. IAC: Lack of Clinically Relevant Drug Interactions Between Elvitegravir plus Ritonavir Boosted-Atazanavir and Telaprevir (07/30/14)
     
  4121. Around 4 million Vietnamese people suffer hepatitis C - (07/30/14)
     
  4122. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study - (07/30/14)
     
  4123. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study - (07/30/14)
     
  4124. Global Distribution & Prevalence of HCV Genotypes - (07/30/14)
     
  4125. HCC Risk - (07/30/14)
     
  4126. NHANES: "non-Hispanic blacks bore the greatest burden of HCV infection in the United States... IDU remains Strongest Risk Factor for HCV infection" - (07/30/14)
     
  4127. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study - (07/28/14)
     
  4128. IAC: Improvement of kidney function after anti HCV therapy in hepatitis C/HIV coinfection - (07/28/14)
     
  4129. IAC: Efficacy and Safety of Dolutegravir (DTG) in Hepatitis (HBV or HCV) Co-infected Patients: Results From the Phase 3 Program - (07/28/14)
     
  4130. IAC: SAPPHIRE-II Subgroup Analysis: ABT-450/r/Ombitasvir (ABT-267), Dasabuvir (ABT-333), and Ribavirin Regimen Achieves High Sustained Virologic Response Rates 12 Weeks Post-treatment in Treatment-experienced Patients With Chronic HCV GT 1 Infection, Regardless of Baseline Characteristics - (07/25/14)
     
  4131. IAC: Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis - (07/25/14)
     
  4132. IAC: SAPPHIRE-I Subpopulation Analysis: ABT-450/r/Ombitasvir (ABT-267), Dasabuvir (ABT-333), and Ribavirin Regimen Achieves High Sustained Virologic Response Rates 12 Weeks Post-treatment in Treatment-naïve Patients With Chronic HCV GT 1 Infection, Regardless of Baseline Characteristics - (07/25/14)
     
  4133. IAC: Low Frequency of Anemia in Phase 3 Trials of ABT-450/r/ABT-267 and ABT-333 With Ribavirin in Treatment-naïve (SAPPHIRE-I) and Treatment-experienced (SAPPHIRE-II) Patients - (07/25/14)
     
  4134. IAC: TURQUOISE-I: SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN PATIENTS CO-INFECTED WITH HEPATITIS C AND HIV-1 (07/21/14)
     
  4135. IAC: TURQUOISE-I: SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN PATIENTS CO-INFECTED WITH HEPATITIS C AND HIV-1 (07/21/14)
     
  4136. IAC: Abbvie 3D Regimen in HCV Genotype 1-Infected Patients on Methadone or Buprenorphine (07/21/14)
     
  4137. IAC: High Response Rates With Triple-DAA Regimen in People With HCV and HIV: Abbvie 3D - ABT-450/ritonavir, ombitasvir, and dasabuvir, with ribavirin - written by Mark Mascolini - (07/21/14)
     
  4138. IAC: SVR12 Rate 97% With 3 DAAs Plus Ribavirin in People on Opioid Replacement - written by Mark Mascolini - (07/21/14)
     
  4139. IAC: High SVR12 With Sofosbuvir/Ribavirin in HCV/HIV-Coinfected: PHOTON-2 (07/21/14)
     
  4140. Stabilizing Incidence of Hepatitis C Virus Infection Among Men Who Have Sex With Men in Amsterdam - (07/21/14)
     
  4141. CDC: IDUs in the United States continue to engage in sexual and drug-use behaviors that increase their risk for HIV infection - (07/21/14)
     
  4142. U.S. FDA has granted Priority Review for OLYSIO® in combination with sofosbuvir supplementary New Drug Application - (07/21/14)
     
  4143. IAC: All-Oral Therapy with Sofosbuvir Plus Ribavirin for the Treatment of HCV Genotype 1, 2,3 and 4 Infection in Patients Coinfected with HIV (PHOTON-2) (07/21/14)
     
  4144. IAC: Prenatal Exposure to Zidovudine and Risk for Ventricular Septal Defects and Congenital Heart Defects: Data From the Antiretroviral Pregnancy Registry (APR) (07/21/14)
     
  4145. IAC: FIB-4 Predicts Major Liver Complications and Death in HCV+ People Starting ART (07/21/14)
     
  4146. GT4 Abbvie/ GS5816+Sofosbuvir - (07/16/14)
     
  4147. Gilead Submits New Drug Application to Japan's Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C Genotype 2 - (07/16/14)
     
  4148. Global HCV Report HCV/IDUs/PWID - HCV in the USA [New NHANES HCV report] (27% African-Americans, that is double the 13% in the US population), PWIDs in the USA (6.6 million ever - 770,00 in last year injected drugs). Latest Report on Latinos in USA with HCV: men and women of Puerto Rican background in the Bronx had the highest HCV prevalence (14.2% and 4.1%, respectively) - (07/16/14)
     
  4149. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV - (07/16/14)
     
  4150. Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta-analysis - (07/16/14)
     
  4151. Regional and global summary estimates of antibody to hepatitis C virus prevalence in detainee populations: Seeing the forest and the trees? - Editorial - (07/16/14)
     
  4152. Sofosbuvir Approval- Australia/New Zealand - (07/15/14)
     
  4153. Gilead Submits New Drug Application to Japan's Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C - (07/15/14)
     
  4154. AbbVie files New Drug Submission to Health Canada for its investigational, all-oral, interferon-free therapy for the treatment of hepatitis C - (07/15/14)
     
  4155. Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza® (daclatasvir) and Sunvepra® (asunaprevir) Dual Regimen - (07/15/14)
     
  4156. 75%, 97%/100%+ Greater Kidney Risk for HCV+ vs HIV-neg, study reports - (07/15/14)
     
  4157. The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis - (07/15/14)
     
  4158. The Burden of Untreated Hepatitis C Virus Infection: A US Patients' Perspective....... - (07/15/14)
     
  4159. HCV/NHANES April 2014 - The changing epidemiology of hepatitis C virus infection in the United States: National health and nutrition examination survey 2001 through 2010 - (07/15/14)
     
  4160. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: Modelling the predicted impact of treatment under different scenarios - '17% treated' so far - (07/15/14)
     
  4161. India/ISG appeals to govt to offer free treatment for Hepatitis C - (06/30/14)
     
  4162. Utilization of FibroScan in Clinical Practice..... - (06/30/14)
     
  4163. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases - (06/30/14)
     
  4164. Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection - (06/30/14)
     
  4165. HCV & Kidney Disease, Extra-hepatic Manifestations of HCV - (06/30/14)
     
  4166. Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza® (daclatasvir) for Treatment of Chronic Hepatitis C in the European Union - (06/27/14)
     
  4167. European Medicines Agency recommends approval of Daklinza in chronic hepatitis C - (06/27/14)
     
  4168. Short Duration (4, 6 weeks) Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study) - (06/27/14)
     
  4169. WHO Global Partner's Meeting on Hepatitis - convened by WHO March 2014 Geneva - Call To Action - Screening, care, treatment - (06/27/14)
     
  4170. HCV DAA Drugs' Discounts - (06/26/14)
     
  4171. HCV Treatment Cost-Effective Unitedhealthcare's OPTUMRx PBM says - (06/25/14)
     
  4172. HCV/Women - "menopausal state was independently associated with accelerated fibrosis progression.... Long-term benefit of estrogen exposure" - (06/25/14)
     
  4173. Fighting for Their Lives: Economist Intelligence Unit Report Finds Patient Groups Lead Global Efforts to Address Hepatitis C - (06/25/14)
     
  4174. HCV Costs/Access - (06/25/14)
     
  4175. HCV Cures Result in Long-Term Savings & Improved Quality of Life - (06/25/14)
     
  4176. Forgotten In The Sovaldi Price Debate: Hep-C Patients And Healthcare Savings. Drug Research Innovation. Do insurers have correct model? - (06/25/14)
     
  4177. HCV Treatment Access - (06/25/14)
     
  4178. Even With Sovaldi And ACA Costs, Health Inflation To Rise 'Modest' 6.8% In 2015 - (06/24/14)
     
  4179. Building Capacity to Test, Treat and Cure Hepatitis C (CDC HCV Meeting in Atlanta June 17-18, 2014) - (06/23/14)
     
  4180. Using Electronic Medical Record Decision Support to Increase Testing for Hepatitis C (CDC HCV meeting in Atlanta June 17-18 2014) - (06/23/14)
     
  4181. Sovaldi Pakistan Distribution: Ferozsons Lab, Gilead Sciences sign agreement - (06/23/14)
     
  4182. New Published Study Discusses Global Epidemiology of PWID, People Who Inject Drugs, & HIV & HCV Prevalence - (06/23/14)
     
  4183. Daclatasvir+Sofosbuvir 4 Wks Study by BMS - (06/23/14)
     
  4184. 4 weeks/4 Drugs-Daclatasvir/Sofosbuvir/Asunaprevir/BMS325 - (06/23/14)
     
  4185. HCV Health Services Utilization "Large", Increasing Healthcare Burden......new study - (06/23/14)
     
  4186. Boehringer ingelheim HCV Statement - (06/19/14)
     
  4187. EUROPEAN MEDICINES AGENCY VALIDATES MARKETING AUTHORIZATION APPLICATIONS FOR ABBVIE'S INVESTIGATIONAL, ALL-ORAL, INTERFERON-FREE THERAPY FOR THE TREATMENT OF GENOTYPE 1 CHRONIC HEPATITIS C - (06/17/14)
     
  4188. 15th Intl Wrkshp Clinical Pharm HIV Therapy A novel microdose approach to assess bioavailability, intestinal absorption, gut metabolism, and hepatic clearance of simeprevir in healthy volunteers - (06/16/14)
     
  4189. 15th Intl Wrkshp Clinical Pharm HIV Therapy PBPK modeling to characterize the interplay between metabolism and transport in the disposition of simeprevir in healthy volunteers and HCV infected patients - (06/16/14)
     
  4190. U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C - (06/16/14)
     
  4191. Hispanics & Liver Disease/Fatty Liver, Liver Cancer & Mortality Rates Increasing Particularly Among Blacks & Hispanics - (06/16/14)
     
  4192. A Multicenter Compassionate Use Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C - Europe - (06/16/14)
     
  4193. A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C - USA Expanded Access Open - (06/16/14)
     
  4194. Gilead Announces Phase 3 Data Showing That the Fixed-Dose Combination of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) Among Patients with Chronic Hepatitis C in Japan - (06/16/14)
     
  4195. 15th Intl Wrkshp Clinical Pharm HIV Therapy The 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy - written by Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center Jennifer J. Kiser, Pharm.D. Assistant Professor School of Pharmacy University of Colorado at Denver - (06/11/14)
     
  4196. OraSure Technologies Announces New Co-Promotion Agreement for OraQuick(R) HCV Rapid Antibody Test - (06/12/14)
     
  4197. 'Oregon wants to deny access to HCV Drugs for Some, while "Other states by law must cover the drugs for their Medicaid programs. And private insurers are under pressure from Medicare to do the same.......the scientific evidence for ....[new drugs] is 'still poor"' - (06/12/14)
     
  4198. OraSure Technologies Announces New Co-Promotion Agreement for OraQuick(R) HCV Rapid Antibody Test - (06/12/14)
     
  4199. 15th Intl Wrkshp Clinical Pharm HIV Therapy Antiviral Quantification in Paired Blood and Liver Tissue or Hepatocytes - (06/11/14)
     
  4200. Achillion Announces Initiation of ACH-3422 Dosing in HCV-Infected Patients and Ability to Resume Sovaprevir Clinical Program for the Treatment of Chronic HCV - (06/11/14)
     
  4201. WHO World Health Assembly approves resolution on hepatitis and mechanism to coordinate noncommunicable disease response - (06/11/14)
     
  4202. Scotland.....Hepatitis C drug is approved.... - (06/11/14)
     
  4203. FDA HCV Submissions / HCV Update - (06/11/14)
     
  4204. NHS England agrees funding for life-saving hepatitis C drug(s) sofosbuvir, daclatasvir - (06/09/14)
     
  4205. Intl Wrkshp on Antiviral Drug Resistance: The Prevalence of HCV NS5A, Nucleoside and Protease Inhibitor Resistance Associated Variants and the Effects on Treatment with Ledipasvir/Sofosbuvir ï RBV in the Phase 3 ION Studies (06/09/13)
     
  4206. Intl Wrkshp on Antiviral Drug Resistance: Persistence of Resistance-Associated Variants in Hepatitis C Virus (HCV) Genotype 1-4 Infected Subjects Following 3-day Samatasvir Monotherapy (06/09/13)
     
  4207. Merck to Acquire Idenix - (06/09/14)
     
  4208. Medicare (CMS) Announces 'Covers HCV Screenings' - (06/04/14)
     
  4209. Heart Disease in HCV+....... - (06/03/14)
     
  4210. FDA Approval DAA IFN-free Regimens Expected This Fall 2014 & Future Ongoing New Drug Development - (06/03/14)
     
  4211. CMS on HCV DAAs - (06/01/14)
     
  4212. HCV Extrahepatic Mortality-kidney/heart/cancers - (06/01/14)
     
  4213. "Medicaid Evidence-Based Decisions Project at OHSU" Report Questions Sofosbuvir Research & the AASLD Guidelines & Medicaid Director (NAMD) Comments - (06/01/14)
     
  4214. Burden of disease and cost of chronic hepatitis C virus infection in Canada.......New Analysis Reveals the Escalating Costs Associated with Untreated Chronic Hepatitis C - (06/01/14)
     
  4215. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection - (06/01/14)
     
  4216. How does coffee prevent liver fibrosis? biological plausibility for recent epidemiological observations - Editorial - (06/01/14)
     
  4217. Estimating the Number of Persons Who Inject Drugs in the United States by Meta-Analysis to Calculate National Rates of HIV and Hepatitis C Virus Infections - (05/30/14)
     
  4218. 15th Intl Wrkshp Clinical Pharm HIV Therapy Pharmacokinetics and Safety of Tenofovir Alafenamide in Subjects With Mild or Moderate Hepatic Impairment - (05/29/14)
     
  4219. HCV Barriers to Care/IDUs-HIV-coinfected/Marginalized Patient Populations/IDUs - (05/29/14)
     
  4220. Report on new HCV drugs from Optum, a consulting subsidiary of United Healthcare - (05/29/14)
     
  4221. Injection Drug Users & HCV - a series of publications on IDUs & HCV treatment: reducing prevalence; prevention & management; cost-effectiveness: HCV eradication, by noted experts in HCV & IDUs - (05/28/14)
     
  4222. HCV in Pakistan....and India...."new era in Hepatitis-C Virus (HCV) therapy ......time for government to make new options available at affordable price" - (05/28/14)
     
  4223. 15th Intl Wrkshp Clinical Pharm HIV Therapy Bristol-Myers Squibb HCV DAAs: Review of Interactions Involving Transporters - (05/28/14)
     
  4224. 15th Intl Wrkshp Clinical Pharm HIV Therapy DDIs (drug-drug interactions) in the evolving HCV treatment landscape - (05/28/14)
     
  4225. 15th Intl Wrkshp Clinical Pharm HIV Therapy Pharmacokinetics and Safety of Hepatitis C Virus Nonstructural Protein 5A Inhibitor MK-8742 in Cirrhotic Patients With Mild and Moderate Hepatic Insufficiency - (05/27/14)
     
  4226. 15th Intl Wrkshp Clinical Pharm HIV Therapy Pharmacokinetics of Hepatitis C Virus Protease Inhibitor MK-5172 in Volunteers With Mild and Moderate Hepatic Impairment - (05/27/14)
     
  4227. 15th Intl Wrkshp Clinical Pharm HIV Therapy Age and Gender Effects on the Pharmacokinetics of HCV NS5A Inhibitor MK-8742 - (05/27/14)
     
  4228. 15th Intl Wrkshp Clinical Pharm HIV Therapy Pharmacokinetic Interaction of HCV NA5A Inhibitor MK-8742 and Ketoconazole in Healthy Subjects - (05/27/14)
     
  4229. 15th Intl Wrkshp Clinical Pharm HIV Therapy Effect of Food and Acid Reducing Agents on the Relative Bioavailability and Pharmacokinetics of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet - (05/27/14)
     
  4230. 15th Intl Wrkshp Clinical Pharm HIV Therapy Population Pharmacokinetic Analysis of Ledipasvir (GS-5885) in Healthy and Hepatitis C Virus-Infected Subjects - (05/27/14)
     
  4231. 15th Intl Wrkshp Clinical Pharm HIV Therapy Evaluation of the Effect of Ledipasvir on the QT/QTc Interval in Healthy Subjects - (05/27/14)
     
  4232. 15th Intl Wrkshp Clinical Pharm HIV Therapy Drug Interactions Between Direct-Acting anti-HCV Antivirals Sofosbuvir and Ledipasvir and HIV Antiretrovirals - (05/27/14)
     
  4233. Daclatasvir-ART Interactions/FDA review/Phase 3 Studies - (05/23/14)
     
  4234. 15th Intl Wrkshp Clinical Pharm HIV Therapy Evaluation of Transporter and Cytochrome P450-Mediated Drug-Drug Interactions Between Pan-Genotypic HCV NS5A Inhibitor GS-5816 and Phenotypic Probe Drugs - Mark Mascolini - (05/23/14)
     
  4235. 15th Intl Wrkshp Clinical Pharm HIV Therapy The Effect of Steady-state BMS-791325, a Non-nucleoside HCV NS5B Polymerase Inhibitor, on the Pharmacokinetics of Midazolam in Healthy Japanese and Caucasian Males - (05/23/14)
     
  4236. 15th Intl Wrkshp Clinical Pharm HIV Therapy Assessment of Correlation of Asunaprevir With Polymorphisms in Liver Uptake Transporters (OATP1B1 and 2B1): Results of an Integrated Population PK Analyses - (05/23/14)
     
  4237. 15th Intl Wrkshp Clinical Pharm HIV Therapy Asunaprevir Does Not Have an Effect on QTcF Interval in Healthy Subjects - (05/23/14)
     
  4238. 15th Intl Wrkshp Clinical Pharm HIV Therapy Resistance Analysis in Patients Receiving Daclatasvir in Combination With Asunaprevir and BMS-791325: Hepatitis C Virus Genotype 1 Infection - (05/23/14)
     
  4239. 15th Intl Wrkshp Clinical Pharm HIV Therapy No Clinically Meaningful Effect of Single- and Multiple-Dose Administration of Peginterferon Lambda-1a on the QTc Interval - (05/23/14)
     
  4240. 15th Intl Wrkshp Clinical Pharm HIV Therapy Translational Studies to Understand the Mechanism of Liver Delivery by Sofosbuvir - (05/23/14)
     
  4241. 15th Intl Wrkshp Clinical Pharm HIV Therapy Gilead - Transporters: Role in Clinical Development of HCV Compounds - (05/23/14)
     
  4242. Hepatology - A Clinical Textbook edition 2014 - Mauss, Berg, Rockstroh, Sarrazin, Wedemeyer - (05/22/14)
     
  4243. 15th Intl Wrkshp Clinical Pharm HIV Therapy Clinically Relevant Interactions Between GS5816 HCV NS5A Inhibitor and Probe Drugs - Mark Mascolini - (05/22/14)
     
  4244. 15th Intl Wrkshp Clinical Pharm HIV Therapy PHARMACOKINETICS OF SIMEPREVIR, JNJ-56914845 AND RITONAVIR-BOOSTED TMC647055 WHEN CO-ADMINISTERED IN HEALTHY VOLUNTEERS - (05/22/14)
     
  4245. 15th Intl Wrkshp Clinical Pharm HIV Therapy The Effect of Renal Impairment on Single-Dose Pharmacokinetics of Daclatasvir, an HCV NS5A Inhibitor - (05/22/14)
     
  4246. 15th Intl Wrkshp Clinical Pharm HIV Therapy Drug Interactions Between Direct-Acting anti-HCV Antivirals Sofosbuvir and Ledipasvir and HIV Antiretrovirals - (05/22/14)
     
  4247. 15th Intl Wrkshp Clinical Pharm HIV Therapy ABT-450/Ritonavir +Ombitasvir + Dasabuvir: Drug Interactions Mediated by Transporters - (05/21/14)
     
  4248. 15th Intl Wrkshp Clinical Pharm HIV Therapy No Critical Interactions Between Ledipasvir/Sofosbuvir and Certain Key Antiretrovirals - written by Mark Mascolini - (05/21/14)
     
  4249. 15th Intl Wrkshp Clinical Pharm HIV Therapy Pharmacokinetics and Safety of IDX21437, a Novel HCV Nucleotide Prodrug, in Healthy Volunteers and HCV-Infected Subjects: Results of a First-In-Human Study - (05/21/14)
     
  4250. 15th Intl Wrkshp Clinical Pharm HIV Therapy Idenix IDX437/IDX719 Development Program - (05/21/14)
     
  4251. 15th Intl Wrkshp Clinical Pharm HIV Therapy No Critical Interactions Between Ledipasvir/Sofosbuvir and Certain Key Antiretrovirals - written by Mark Mascolini - (05/21/14)
     
  4252. 15th Intl Wrkshp Clinical Pharm HIV Therapy Impact of Food and Antacids on Levels of Ledipasvir and Sofosbuvir - written by Mark Mascolini - (05/20/14)
     
  4253. 'Super-Frequent Hospital Emergency Dept Users' have a Substance Abuse Addiction-New Study, HCV Screening in Emergency Depts - study at AASLD - (05/19/14)
     
  4254. Hepatitis C Virus-Related Knowledge and Willingness to Receive Treatment Among Patients on Methadone Maintenance - (05/19/14)
     
  4255. About 15m Pakistanis suffering from hepatitis - (05/19/14)
     
  4256. HCC Tripled in USA/Treatment Normalized Survival, would Reduce HCC by 60%-new studies - (05/19/14)
     
  4257. Simeprevir approved in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection - (05/16/14)
     
  4258. AbbVie Submits for EU Marketing Authorization its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Chronic Hepatitis C - (05/16/14)
     
  4259. OLYSIO™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection - (05/16/14)
     
  4260. Rapid Hepatitis C Testing Among Persons at Increased Risk for Infection - Wisconsin, 2012-2013 - (05/15/14)
     
  4261. Effects of a Sustained Virologic Response on Outcomes of Patients With Chronic Hepatitis C - (05/15/14)
     
  4262. AASLD: Comparison of the overall survival between patients with HCV-induced advanced hepatic fibrosis and the general population - (05/15/14)
     
  4263. Responding to Hepatitis C through the Criminal Justice System - Perspective - (05/15/14)
     
  4264. Phase III HIV/HCV Co-Infection Daclatasvir (DCV)+ Sofosbuvir (SOF) (ALLY 2) [treatment-naive & treatment-experienced - (05/15/14)
     
  4265. Efficacy and Safety of MK-5172, MK-8742, and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074) - (05/15/14)
     
  4266. Is there sufficient evidence to recommend antiviral therapy in hepatitis C? - (05/14/14)
     
  4267. SVR, Mortality & cost burden- Study Reports SVR Normalizes Survival in Advanced Disease - (05/14/14)
     
  4268. DDW: Projected Health and Economic Impact of Hepatitis C on the United States Veterans Administration Health System From 2014 To 2024 - (05/13/14)
     
  4269. New VA HCV Treatment Guidelines March 2014 - (05/13/14)
     
  4270. Safety & Efficacy of Boceprevir/Peginterferon/Ribavirin for HCV G1 Compensated Cirrhotics: Meta-Analysis of 5 Trials - (05/13/14)
     
  4271. HCV & the Affordable Care Act, New HCV Study Results, HCV Cascade of Care, Undiagnosed HCV, Access to Care Barriers, Quality of Life for HCV+, HCV+ & HIV/HCV Coinfected Die 20 Years Earlier, more.... - (05/13/14)
     
  4272. HCV Expanded Access Daclatasvir+Sofosbuvir in Europe - (05/12/14)
     
  4273. Emrates National Oil Company (ENOC) joins hands with MSD (Merck) to provide all employees with free Hepatitis C screening - (05/12/14)
     
  4274. HCV/Coinfection in NYC-HCV+ Die 20 Yrs Earlier/HCV Among HIV+ MSM Tripled - (05/12/14)
     
  4275. Curing Chronic Hepatitis C - The Arc of a Medical Triumph - (05/12/14)
     
  4276. EASL: HCV in India at EASL: IDUs, Burden, Limited Access - (05/09/14)
     
  4277. Daclatasvir+Sofosbuvir - (05/09/14)
     
  4278. DDW: Intake of Coffee and Caffeine are Associated with Decreased Risk of Hepatitis C-related Hepatic Fibrosis - (05/09/14)
     
  4279. HCV Cascade of Care for mono & HIV coinfected - (05/09/14)
     
  4280. Janssen Submits Supplemental New Drug Application to U.S. FDA for OLYSIO™ (Simeprevir) for Once-Daily Use in Combination with Sofosbuvir for 12 Weeks for the Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C - (05/08/14)
     
  4281. AbbVie Submits for EU Marketing Authorization its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Chronic Hepatitis C - (05/08/14)
     
  4282. Merck CEO Weighs in on HCV - (05/08/14)
     
  4283. DDW: The Tip of an Iceberg - Who Is Known to Have Hepatitis C? - 'majority remain undiagnosed, especially in younger men outside the birth cohort....birth-cohort & risk based screening needed.....30-49 age.....88-65% remain undiagnosed....less than 33% overall were diagnosed with HCV.....prevalence 1-3.3%' - (05/08/14)
     
  4284. DDW: Bridging the Gap between HCV Screening and Access to Care: Insights from National Health and Nutrition HCV Follow-up Study, 2001-2010 - (05/08/14)
     
  4285. DDW: Comorbid Conditions Associated with Decision-Making Regarding Treating or Not Treating Chronic Hepatitis C in a Large U.S. Health Maintenance Organization - (05/07/14)
     
  4286. DDW: PEARL-II: RANDOMIZED PHASE 3 TRIAL OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333 WITH OR WITHOUT RIBAVIRIN IN HEPATITIS C VIRUS GENOTYPE 1B-INFECTED, TREATMENT-EXPERIENCED PATIENTS - (05/07/14)
     
  4287. Gilead says has discounted hepatitis C drug for some health plans - (05/07/14)
     
  4288. Relationship Between Alcohol Use Categories and Noninvasive Markers of Advanced Hepatic Fibrosis in HIV-Infected, Chronic Hepatitis C Virus-Infected, and Uninfected Patients....findings suggest a little alcohol in HCV/HIV coinfected increased risk for advanced liver fibrosis, and among HCV or HIV monoinfected as well. - (05/07/14)
     
  4289. Gilead aims to license hepatitis C drug to 3-4 Indian firms - (05/07/14)
     
  4290. DDW: Comorbid Conditions Associated with Decision-Making Regarding Treating or Not Treating Chronic Hepatitis C in a Large U.S. Health Maintenance Organization - (05/06/14)
     
  4291. DDW: Quality of Life, Productivity, and Activity Impairment Among US Survey Respondents With Hepatitis C: An Evaluation of HCV and Six Select Medical Conditions - (05/06/14)
     
  4292. DDW: All-Oral Therapy With Daclatasvir in Combination With Asunaprevir and BMS-791325 for Treatment-Naive Patients With Chronic HCV Genotype 4 Infection - (05/06/14)
     
  4293. DDW: Resource Utilization During Hepatitis C Treatment With Boceprevir- or Telaprevir-Based Triple Therapy vs Dual Therapy In A Large Health Maintenance Organization - (05/05/14)
     
  4294. DDW: Low treatment rates and suboptimal treatment completion rates to HCV therapy: A real world analysis of a large US cohort - (05/05/14)
     
  4295. DDW: Treatment Satisfaction in Clinical Trial (AVIATOR) Patients Treated with Interferonfree, Oral DAA Regimens: External Validation of the Hepatitis C Virus (HCV) Treatment Satisfaction (HCVTSat) Instrument - (05/05/14)
     
  4296. DDW: PEARL-IV: A 12-week Regimen of ABT-450/r/ABT-267 and ABT-333, With or Without Ribavirin Achieves SVR12 Rates ≥90% in Treatment-naïve Adults Infected With Hepatitis C Virus Genotype 1a - (05/05/14)
     
  4297. Germany IQWIG Issues Sovaldi Statement - (05/05/14)
     
  4298. Potential impacts of the Affordable Care Act on the clinical practice of hepatology - (05/05/14)
     
  4299. The Rapid Evolution of Treatment Strategies for Hepatitis C....Current AASLD/IDSA Treatment Guidelines - (05/05/14)
     
  4300. EASL: Effect of alisporivir (ALV) on the pharmacokinetics (PK), safety, and tolerability of methadone in healthy subjects and opioid-dependent patients on stable methadone maintenance therapy (MMT) - (05/05/14)
     
  4301. Changing Hepatocellular Carcinoma Incidence and Liver Cancer Mortality Rates in the United States..... "US liver cancer mortality rates increased with age in all racial/ethnic groups..... Among individuals aged 50-64 years, blacks had the highest mortality rate (18.6), followed by Hispanics (13.5), Asians/Pacific Islanders (13.0), and whites (7.7)." - (05/05/14)
     
  4302. EASL: Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM.......Eleven persons were re-infected......The cumulative incidence was 33% within 2 years - (05/02/14)
     
  4303. EASL: Trends in hepatitis C virus infections among MSM attending a sexually transmitted infection clinic; 1995-2010 "appears to level off in recent years" in Amsterdam Clinic - (05/02/14)
     
  4304. EASL: Stabilizing Incidence of Hepatitis C Virus Infection among Men who have Sex with Men in Amsterdam - (05/02/14)
     
  4305. Vertex to Out-license VX135 - (05/03/14)
     
  4306. Impact of New Hepatitis C Treatments in Different Regions of the World - (05/02/14)
     
  4307. New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges - (05/02/14)
     
  4308. Achillion Advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, Into Clinical Trial; Initiates Phase 2 Pilot Study With ACH-3102, NS5A Inhibitor (+sofosbuvir), for HCV - (05/01/14)
     
  4309. EASL: High Burden of Fibrosis and Metabolic Cofactors in a Cohort of Predominantly Genotype 3-Infected Injection Drug Users in Southern India - (05/01/14)
     
  4310. Breaking the Silence on Viral Hepatitis - opinion - (04/30/14)
     
  4311. EASL: Limited Access to HCV Testing and Treatment among Injection Drug Users across India - (04/30/14)
     
  4312. EASL: Hepatocellular Carcinoma (HCC) incidence in Chronic Hepatitis C patients (CHC) according to Sustained Virologic Response (SVR) and baseline characteristics - (04/30/14)
     
  4313. EASL: High Burden of HCV & HIV/HCV Coinfection among Injection Drug Users in India: Need for Integration of HIV & HCV Services - (04/28/14)
     
  4314. New VA HCV Guidelines 3-2014 / DAA HIV-Coinfection Studies / Sovaldi Update-Launch - (04/25/14)
     
  4315. EASL: Ledipasvir and Sofosbuvir Combination Improves Patient-Reported Outcomes During Treatment of Chronic Hepatitis C: The Result from ION-1 Clinical Trial - (04/24/14)
     
  4316. EASL: Health-Related Quality of Life (HRQL) and Patient-Reported Outcomes (PROs) Assessment in Chronic Hepatitis C (CH-C) Treated with Sofosbuvir (SOF) and Ribavirin (RBV): The VALENCE Study (Gt2/3)....extending treatment to 24 weeks - (04/24/14)
     
  4317. EASL: Independent Predictors of Patient-Reported Outcomes (PROs) and Quality of Life (QOL) in Chronic Hepatitis C Patients Receiving Interferon (IFN) -Free versus IFN-Containing Regimens with Sofosbuvir (SOF) - (04/24/14)
     
  4318. EASL: Estimating Health Status Using EQ-5D for Chronic Hepatitis C (CH-C) Patients Treated with Sofosbuvir Containing Regimens - (04/24/14)
     
  4319. EASL: Improvement of Central Fatigue is Associated with Sustained Virologic Response (SVR) Following Sofosbuvir-Containing Regimens - (04/24/14)
     
  4320. EASL: INDEPENDENT PREDICTORS OF PATIENT-REPORTED OUTCOMES (PROS) AND QUALITY OF LIFE (QOL) IN CHRONIC HEPATITIS C PATIENTS RECEIVING INTERFERON (IFN)-FREE VERSUS IFN-CONTAINING REGIMENS WITH SOFOSBUVIR (SOF) - (04/23/14)
     
  4321. EASL: Quality of Life Improved by SVR, Ifn-Free Therapy Improves Better - (04/23/14)
     
  4322. EASL: IMPACT OF NEW DAA-CONTAINING REGIMENS ON HCV TRANSMISSION AMONG INJECTING DRUG USERS (IDUS): A MODEL-BASED ANALYSIS (ANRS 12376)...."Test & Treat", Eliminating HCV - (04/21/14)
     
  4323. AbbVie Submits New Drug Application to U.S. FDA for its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C - (04/22/14)
     
  4324. UnitedHealth: New hepatitis C drug costs far more than forecast - (04/21/14)
     
  4325. Clue for hepatitis C survival, avoids elimination, potential therapeutic target - 'Hepatitis C virus triggers mitochondrial fission and attenuates apoptosis to promote viral persistence' - (04/21/14)
     
  4326. EASL: New DAA Phase 3 Studies for genotype 1 at EASL - in both Treatment-naives, treatment-experienced; simultaneous publications - (04/21/14)
     
  4327. EASL: Peginterferon Lambda for the Treatment of Chronic Hepatitis B (CHB): A Phase 2b Comparison With Peginterferon Alfa in Patients With HBeAg-Positive Disease (LIRA-B) - (04/21/14)
     
  4328. EASL: SVR IS ASSOCIATED WITH NO RISK REDUCTION OF HCC DEVELOPMENT IN PATIENTS WITH HCV-RELATED CIRRHOSIS. A PROSPECTIVE, UP-TO 23 YEARS, COHORT FOLLOW-UP STUDY - (04/21/14)
     
  4329. EASL: Prolonged therapy of hepatitis delta for 96 weeks with PEG-IFNa-2a plus tenofovir or placebo does not prevent HDV RNA relapse: The HIDIT-2 study. - (04/21/14)
     
  4330. EASL: Resistance Analysis of HCV Genotype 1 Patients Treated With Sofosbuvir in Combination With Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669: The ELECTRON Study - (04/21/14)
     
  4331. EASL: Long-term Follow-up of Patients Treated With Sofosbuvir in the Phase 3 Studies FISSION, POSITRON, FUSION, and NEUTRINO - (04/21/14)
     
  4332. EASL: Early Viral Kinetics Do Not Predict Treatment Outcome With Sofosbuvir + Ribavirin for 12 or 24 Weeks in HCV Genotype 2/3 Patients in the VALENCE Trial - (04/21/14)
     
  4333. EASL: Integrated Safety Analysis of Sofosbuvir-Based HCV Treatment Regimens From Phase 3 Studies - (04/21/14)
     
  4334. EASL: Modeling Predicts Clinically Meaningful SVR Rates in Genotype 1 Treatment-Experienced Patients Based on Results in Genotype 1 Treatment-Naïve Patients Treated With Sofosbuvir + Peginterferon + Ribavirin for 12 Weeks - (04/21/14)
     
  4335. EASL: Ledipasvir/Sofosbuvir Retreating Prior Failures Phase 3 - (04/21/14)
     
  4336. EASL: Abbvie 3-D in Cirrhosis Phase 3/Liver Transplants Phase 2 - (04/21/14)
     
  4337. EASL: Low Persistence of Resistance-Associated Variants After 3 Days of Monotherapy With NS5B NNI Site II Inhibitor GS-9669 in Genotype 1 HCV Patients - (04/21/14)
     
  4338. EASL: Efficacy and Safety of MK-5172 Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection: Final Results of the C-SPIRIT Study - (04/21/14)
     
  4339. EASL: Safety and Efficacy of MK-5172 Plus Peginterferon Alfa-2b and Ribavirin (PR) in Cirrhotic and Noncirrhotic Treatment-Naive Patients With Hepatitis C Virus (HCV) Genotype (G)1 Infection - (04/21/14)
     
  4340. EASL: Comparative Resistance Analysis Between Cirrhotic and Non-cirrhotic Treatment Experienced Patients Who Failed Treatment With a Combination of Vaniprevir (MK-7009) and Pegylated Interferon and Ribavirin (P/R) - (04/21/14)
     
  4341. EASL: Futility Testing at Treatment Week 8 in Patients With Hepatitis C Virus (HCV) Genotype 1 Infection Receiving Boceprevir: A Post Hoc Analysis - (04/21/14)
     
  4342. The patent system, Hepatitis C drugs not reaching poor - "access to drugs will depend on the development of cheap diagnostics"...... "Major donors have not yet signalled their intention to pay for the drugs"..... "It's possible it's really going to be up to the countries to fund their own programmes"...... - (04/17/14)
     
  4343. NHS England agrees funding for life-saving hepatitis C drugs - (04/17/14)
     
  4344. APASL: A Single Direct-acting Anti-viral Agent, ACH-3102, with Ribavirin is Able to Achieve a Robust Anti-viral Response in Subjects with Genotype 1b Chronic Hepatitis C Infection - (04/17/14)
     
  4345. APASL: ACH-3102 and Ribavirin in Genotype-1b Hepatitis C Patients: Confirmation of the High Barrier to Viral Breakthrough in Genotype-1b HCV - (04/17/14)
     
  4346. APASL: SVR4 Results for the Combination of ACH-3102 and Sovaprevir, With Ribavirin, in Patients With Genotype 1 Chronic Hepatitis C Infection - (04/17/14)
     
  4347. EASL: Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in European patients who relapsed after previous interferon-based therapy: the PROMISE trial - (04/17/14)
     
  4348. EASL: Virology analyses of simeprevir in Phase 2b and 3 studies - (04/17/14)
     
  4349. EASL: Deep sequencing analyses of minority baseline polymorphisms and persistence of emerging mutations in HCV genotype 1-infected patients treated with simeprevir - (04/17/14)
     
  4350. EASL: Comorbid Conditions Associated With Decision-Making Regarding Treating or Not Treating Chronic Hepatitis C In A Large U.S. Health Maintenance Organization - (04/17/14)
     
  4351. EASL: RESULTS FROM THE PHASE 2 PEARL-I STUDY: INTERFERON-FREE REGIMENS OF ABT-450/r + ABT-267 WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 4 INFECTION - (04/16/14)
     
  4352. EASL: PEARL-III: 12 Weeks of ABT-450/r/267 + ABT-333 Achieved SVR in >99% of 419 Treatment-naïve HCV Genotype 1b-Infected Adults With or Without Ribavirin - (04/16/14)
     
  4353. EASL: An Interferon- and Ribavirin-Free 12-Week Regimen of Once-Daily VX-135 and Daclatasvir in Treatment-Naïve Patients With Genotype 1 HCV Infection - (04/16/14)
     
  4354. EASL: Sofosbuvir Plus Ribavirin, an Interferon-Free Regimen, in the Treatment of Treatment-Naïve and -Experienced Patients With Chronic Genotype 4 HCV Infection - (04/16/14)
     
  4355. EASL: Sofosbuvir and Ribavirin for the Treatment of Recurrent Hepatitis C Infection After Liver Transplantation: Results of a Prospective, Multicenter Study - (04/16/14)
     
  4356. EASL: Sofosbuvir and Daclatasvir for Recurrent Hepatitis C After Liver Transplantation: Potent Antiviral Activity But Lack of Clinical Benefit if Treatment is Given Too Late - (04/16/14)
     
  4357. EASL: Pharmacokinetic (PK) Drug-Drug Interaction between Samatasvir (IDX719), a Pan-Genotypic NS5A Inhibitor, and Simeprevir in Healthy Volunteers and HCV-Infected Subjects - (04/16/14)
     
  4358. EASL: A Phase II Study of Samatasvir (IDX719) in Combination with Simeprevir and Ribavirin in Treatment-Naïve HCV-Infected Subjects with Genotypes 1b and 4 (HELIX-1 Study) - (04/16/14)
     
  4359. EASL: Favorable Preclinical Profile of IDX21437, a Novel Uridine Nucleotide Prodrug, for Use in a Direct-Acting Antiviral (DAA) Regimen for HCV - (04/16/14)
     
  4360. Gilead Announces U.S. FDA Priority Review Designation for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Chronic Hepatitis C Genotype 1 Infection - (04/15/14)
     
  4361. EASL: EASL Coverage: 6 phase 3 studies; Simeprevir+Sofosbuvir Update; HIV Coinfection: 2 studies reported - (04/15/14)
     
  4362. EASL: 2 HIV/HCV Coinfection Studies at EASL - (04/15/14)
     
  4363. EASL: Bristol-Myers Squibb Presents Phase III Data Demonstrating that Investigational All-oral Daclatasvir and Asunaprevir Therapy Achieved SVR12 Rates of up to 90% Among Broad Range of Genotype 1b Hepatitis C Patients - (04/15/14)
     
  4364. EASL: EASL Recommendations (Guidelines) on Treatment of Hepatitis C 2014 - (04/15/14)
     
  4365. Sovaldi Global Access - (04/14/14)
     
  4366. Rapid Hepatitis C Testing Among Persons at Increased Risk for Infection - Wisconsin, 2012-2013 - (04/14/14)
     
  4367. EASL: Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype-1 prior null responders with METAVIR F0-2: COSMOS study subgroup analysis - (04/14/14)
     
  4368. EASL: Efficacy and Safety of Daclatasvir in Combination With Asunaprevir in Cirrhotic and Non-Cirrhotic Patients With HCV Genotype 1b: Results of the HALLMARK-DUAL Study - (04/14/14)
     
  4369. EASL: SAFETY AND EFFICACY OF THE ALL-ORAL REGIMEN OF MK-5172 / MK-8742 ï RIBAVIRIN IN TREATMENT-NAIVE, NONCIRRHOTIC PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION: THE C-WORTHy STUDY - (04/14/14)
     
  4370. EASL: Successful Retreatment of HCV Genotype-1 Infected Patients Who Failed Prior Therapy with Peg-interferon + Ribavirin Plus 1 or 2 Other Direct-Acting Antiviral Agents with Sofosbuvir - (04/14/14)
     
  4371. EASL: Sofosbuvir Compassionate Use Program for Patients with Severe Recurrent Hepatitis C Including Fibrosing Cholestatic Hepatitis Following Liver Transplantation - (04/14/14)
     
  4372. EASL: Gilead's Sovaldi® Demonstrates Efficacy and Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease - press release - (04/14/14)
     
  4373. EASL: Final Data from the Phase 2 COSMOS Study of Janssen's Once-Daily Simeprevir in Combination with Sofosbuvir Presented at the International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) - (04/14/14)
     
  4374. EASL: Sofosbuvir-Based Regimens Are Associated With High SVR Rates Across Genotypes and Among Patients With Multiple Negative Predictive Factors - (04/14/14)
     
  4375. EASL: Successful Retreatment With Sofosbuvir-containing Regimens for HCV Genotype 2 or 3 Infected Patients who Failed Prior Sofosbuvir Plus Ribavirin Therapy - (04/14/14)
     
  4376. EASL: HIGH RATE OF SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH HCV GENOTYPE-1A INFECTION: A PHASE 2 TRIAL OF FALDAPREVIR, DELEOBUVIR AND PPI-668, WITH AND WITHOUT RIBAVIRIN - (04/14/14)
     
  4377. EASL: All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir With Or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: the Phase 3 ION-1 Study - (04/14/14)
     
  4378. EASL: Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection - (04/14/14)
     
  4379. EASL: Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection - (04/14/14)
     
  4380. EASL: All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Experienced Genotype 1 HCV-Infected Patients: The Phase 3 ION-2 Study - (04/14/14)
     
  4381. EASL: RESULTS OF THE PHASE 2 STUDY M12-999: INTERFERON-FREE REGIMEN OF ABT-450/r/ABT-267 + ABT-333 + RIBAVIRIN IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HCV GENOTYPE 1 INFECTION - (04/14/14)
     
  4382. EASL: Safety and Efficacy of Treatment With Interferon-Free, Ribavirin-Free Combination of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Naïve Patients With Genotypes 1-6 HCV Infection - (04/14/14)
     
  4383. EASL: All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir With Or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: the Phase 3 ION-1 Study - (04/14/14)
     
  4384. EASL: TURQUOISE-II: SVR12 RATE OF 92-96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/r/ABT-267 AND ABT-333 PLUS RIBAVIRIN - (04/14/14)
     
  4385. EASL: Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype-1 prior null-responder / treatment-naïve patients (COSMOS study): primary endpoint (SVR12) results in patients with METAVIR F3-4 (Cohort 2) - (04/14/14)
     
  4386. EASL: All-Oral Dual Therapy With Daclatasvir and Asunaprevir in Patients With HCV Genotype 1b Infection: Phase 3 HALLMARK-DUAL Study Results - (04/14/14)
     
  4387. EASL: ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis - Phase 3 TURQUOISE-II - (04/14/14)
     
  4388. EASL: Ledipasvir/Sofosbuvir Fixed-Dose Combination Is Safe and Effective in Difficult-to-Treat Populations Including GT 3 Patients, Decompensated GT 1 Patients, and GT 1 Patients With Prior Sofosbuvir Experience - (04/11/14)
     
  4389. EASL: EFFICACY AND SAFETY OF THE ALL-ORAL REGIMEN, MK-5172/MK-8742 +/- RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDY - (04/11/14)
     
  4390. EASL: Efficacy and safety of MK-5172 and MK-8742 ï RIBAVIRIN IN Hepatitis C Genotype 1 Infected Patients with cirrhosis or previous null response: the C-WORTHY Study - (04/11/14)
     
  4391. EASL: Effect of Baseline NS5A Polymorphisms on Virologic Response to the All-Oral Combination of Daclatasvir + Sofosbuvir ï Ribavirin in Patients With Chronic HCV Infection - (04/11/14)
     
  4392. EASL: Sofosbuvir and Ribavirin for the Treatment of Chronic HCV With Cirrhosis and Portal Hypertension With and Without Decompensation: Early Virologic Response and Safety - (04/11/14)
     
  4393. EASL: Effect of Baseline NS5A Polymorphisms on Virologic Response to the All-Oral Combination of Daclatasvir + Sofosbuvir ï Ribavirin in Patients With Chronic HCV Infection - (04/11/14)
     
  4394. EASL: SVR AND SAFETY OF LOWER DOSES OF MK-5172 25 MG AND 50 MG DAILY FOR 12 WEEKS IN HCV GENOTYPE (G)1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS - (04/11/14)
     
  4395. EASL: Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Naïve Patients with Genotype 1 Infection - (04/11/14)
     
  4396. EASL: EFFICACY AND SAFETY OF THE ALL-ORAL REGIMEN, MK-5172/MK-8742 +/- RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDY - (04/11/14)
     
  4397. EASL: Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis - (04/11/14)
     
  4398. EASL: AbbVie to Present Detailed Phase III Results from SAPPHIRE-I and SAPPHIRE-II Studies in Chronic Hepatitis C Patients at the 2014 International Liver Congress™ - (04/11/14)
     
  4399. EASL: Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin (in previously untreated patients with HCV genotype 1 infection and no cirrhosis) - (04/11/14)
     
  4400. EASL: SAPPHIRE-I: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/r/ABT-267, ABT-333, AND RIBAVIRIN IN 631 TREATMENT-NAïVE ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 - (04/11/14)
     
  4401. EASL: Ledipasvir/Sofosbuvir With and Without Ribavirin for 8 Weeks Compared to Ledipasvir/Sofosbuvir for 12 Weeks in Treatment-Naïve Noncirrhotic Genotype-1 HCV-Infected Patients: The Phase 3 ION-3 Study - (04/11/14)
     
  4402. EASL: RESULTS FROM THE PHASE 2 PEARL-I STUDY: INTERFERON-FREE REGIMENS OF ABT-450/r + ABT-267 WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 4 INFECTION - (04/11/14)
     
  4403. EASL: Dose-dependent Pharmacokinetics for MK-5172 25 mg, 50 mg, and 100 mg Once Daily for 12 Weeks in HCV Genotype 1 Treatment-naïve Non-cirrhotic Patients - (04/11/14)
     
  4404. EASL: SOFOSBUVIR/LEDIPASVIR IN RETREATMENT OF HCV GENOTYPE-1 PATIENTS WHO PREVIOUSLY FAILED SOFOSBUVIR/RIBAVIRIN THERAPY - (04/10/14)
     
  4405. EASL: Bristol-Myers Squibb Presents Phase III Data Demonstrating that Investigational All-oral Daclatasvir and Asunaprevir Therapy Achieved SVR12 Rates of up to 90% Among Broad Range of Genotype 1b Hepatitis C Patients - (04/10/14)
     
  4406. EASL: USE OF SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION FOR TREATMENT OF HCV GENOTYPE-1 INFECTION IN PATIENTS COINFECTED WITH HIV (Interim results) - (04/10/14)
     
  4407. EASL: Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin - (04/10/14)
     
  4408. EASL: SAPPHIRE-II: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/r/ABT-267, ABT-333, AND RIBAVIRIN IN 394 TREATMENT-EXPERIENCED ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 - (04/10/14)
     
  4409. EASL: AASLD Preparing Providers for Hepatitis Patients: Online Hepatitis Program for Primary Care Providers - (04/10/14)
     
  4410. EASL: WHO Guidelines for the screening, care and treatment of persons with hepatitis C infection - (04/09/14)
     
  4411. Bristol-Myers Squibb Submits NDAs for Daclatasvir and Asunaprevir to US FDA for the Treatment of Hepatitis C - (04/08/14)
     
  4412. Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan - (04/07/14)
     
  4413. Idenix Announces Promising Clinical Data and Continued Progress in Nucleotide Prodrug Development Programs for the Treatment of Hepatitis C - (04/07/14)
     
  4414. Preparing for the uncertain yet inevitable: Off-label combinations of antiviral agents in hepatitis C virus - (04/04/14)
     
  4415. Updated Action Plan to Combat Viral Hepatitis Released - (04/04/14)
     
  4416. CROI: Ritonavir-Boosted Atazanavir, Lopinavir, & Darunavir Increase HCV NS5A Inhibitor MK-8742 Levels - (04/05/14)
     
  4417. CROI: Pharmacokinetic Interactions Between the HCV NS5A Inhibitor MK-8742 and Tenofovir (TDF), Raltegravir (RAL), and Efavirenz (EFV) - (04/05/14)
     
  4418. Preparing for the uncertain yet inevitable: Off-label combinations of antiviral agents in hepatitis C virus - (04/04/14)
     
  4419. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 HCV in interferon ineligible/intolerant individuals, or Daclatasvir+Sofosbuvir - (04/04/14)
     
  4420. Janssen Initiates Phase 3 OPTIMIST Trials of Once-Daily Simeprevir in Combination with Once-Daily Sofosbuvir for the Treatment of Genotype 1 Chronic Hepatitis C - (04/03/14)
     
  4421. CROI: Daclatasvir Pharmacokinetics in Healthy Subjects: No Clinically Relevant Drug-Drug Interaction With Either Cyclosporine or Tacrolimus - (04/03/14)
     
  4422. CROI: CD4:CD8 Ratio Remains Significantly Depressed Despite Viral Suppression With Effective ART - (04/02/14)
     
  4423. CROI: Favorable Adverse Event Profile of Sofosbuvir/Ribavirin Versus Standard of Care for Hepatitis C - (04/02/14)
     
  4424. Simeprevir receives positive CHMP opinion for the treatment of adults with chronic hepatitis C in the European Union - (03/25/14)
     
  4425. Janssen to Present New Simeprevir Data at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) - (03/25/14)
     
  4426. Merck to Present New Data for Investigational Hepatitis C Treatments MK-5172 and MK-8742 at EASL Annual Meeting/The International Liver Congress™ 2014 - (03/25/14)
     
  4427. Simeprevir has now been approved in Russia - (03/25/14)
     
  4428. Bristol-Myers Squibb to Present Data for Daclatasvir in Multiple Investigational All-oral Combinations across Hepatitis C Genotypes at The International Liver Congress™ - (03/25/14)
     
  4429. AbbVie to Present Detailed Results from Phase III Studies in Patients with Chronic Hepatitis C at the 2014 International Liver Congress™ - (03/25/14)
     
  4430. APASL: Simeprevir with Peginterferon/Ribavirin for Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Treatment-Experienced Patients: Interim Results of a Phase III Rollover Trial - (03/25/14)
     
  4431. APASL: Simeprevir (TMC435) with peginterferon-α-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy in patients with genotype 1b HCV in the PROMISE Phase III trial - (03/25/14)
     
  4432. CROI: The CORE HCV Cascade a Decade Later: Looking Ahead to an IFN-free Era - (03/24/14)
     
  4433. CROI: High Hepatitis C Infection Rate in Birth Cohort Testing of an Urban, Primary Care Clinic Population: HCV Cascade, 8.2% Prevalence - (03/24/14)
     
  4434. CROI: Impact of Rapid Hepatitis C testing on Receipt of Hepatitis C Results in a Public STD Clinic - (03/24/14)
     
  4435. CROI: The burden of hepatitis C infection in Pennsylvania state prisons and implications for treatment - (03/24/14)
     
  4436. CROI: Hepatitis C Virus Incidence in the Amsterdam Cohort Study among Men who have Sex with Men; 1984-2011 - (03/24/14)
     
  4437. CROI: The Treatment Cascade for People with Chronic Hepatitis C Virus Infection in the United States - (03/24/14)
     
  4438. CROI: Implementation of a Hepatitis C testing program in a network of Federally Qualified Health Centers: initial results of an Academic-Community partnership - (03/24/14)
     
  4439. CROI: The Hepatitis C Cascade of Care Among HIV Infected Patients Following Diagnosis of HCV Infection - (03/24/14)
     
  4440. CROI: CROI 2014 March 3 - Martin Delaney Panel: Hepatitis C Virus: From Trials and Tribulation to Triumph - (03/24/14)
     
  4441. CROI: Safety and Efficacy of IFN-free, Sofosbuvir/RBV Therapy in HIV/HCV Liver Transplanted Patients - (03/24/14)
     
  4442. CROI: Safety and Efficacy of IFN-free, Sofosbuvir/RBV Therapy in HIV/HCV Liver Transplanted Patients - (03/24/14)
     
  4443. CROI: Liver-related death among HIV/HCV coinfected individuals, implications for the era of directly acting antivirals - (03/24/14)
     
  4444. CROI: Level of Alcohol Use and Advanced Hepatic Fibrosis in HIV-Infected and Uninfected Patients...."there may be no safe level of alcohol use among HIV+ & HCV+" - (03/24/14)
     
  4445. CROI: Pill Burden and Treatment Duration Reduce Adherence to IFN-Free Hepatitis C Therapy in an Urban Cohort - (03/24/14)
     
  4446. CROI: Telaprevir in Treatment-Experienced HIV-HCV G1 Coinfected Patients (ANRS HC26 TelapreVIH) - (03/24/14)
     
  4447. CROI: Boceprevir for Previously Treated HCV-HIV Coinfected Patients: The ANRS-HC27 BocepreVIH Trial - (03/24/14)
     
  4448. CROI: Boceprevir/Telaprevir-Based Therapy in HIV-Infection: Interim Analysis of a Multicenter Cohort - (03/24/14)
     
  4449. CROI: Telaprevir Increases Ribavirin Toxicity Through eGFR Decrease in HIV-HCV Coinfected Patients - (03/24/14)
     
  4450. CROI: PHARMACOKINETICS OF FALDAPREVIR AND ANTIRETROVIRALS IN PATIENTS WITH HIV/HCV CO-INFECTION - (03/21/14)
     
  4451. CROI: EFFECT OF FALDAPREVIR ON ATAZANAVIR PHARMACOKINETICS IN PATIENTS WITH HIV/HCV CO-INFECTION - (03/21/14)
     
  4452. CROI: EFFECT OF FALDAPREVIR ON RALTEGRAVIR PHARMACOKINETICS IN HEALTHY VOLUNTEERS - (03/21/14)
     
  4453. CROI: FIB-4 Alone Proves Best Predictor of ESLD in People With HCV/HIV - written Mark Mascolini - (03/21/14)
     
  4454. CROI: Post-SVR Liver Decompensation Rate Similar With HCV/HIV and HCV Alone - written Mark Mascolini - (03/21/14)
     
  4455. CROI: Summary from CROI 2014 for Hepatitis HCV direct acting antivirals (DAAs) in HCV and HIV/HCV coinfection: same outcome? Which DAA regime will allow for the shortest treatment duration? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany (03/20/14)
     
  4456. Fracture risk in hepatitis C virus infected persons: results from the DANVIR cohort study; HIV & HCV/HIV Bone Loss - (03/19/14)
     
  4457. Simeprevir+Sovaldi Access - Getting free hepatitis C drugs a boon for needy Travis County residents - (03/19/14)
     
  4458. Hepatic Decompensation in Antiretroviral-Treated Patients Co-Infected With HIV and Hepatitis C Virus Compared With Hepatitis C Virus-Monoinfected Patients: A Cohort Study - (03/19/14)
     
  4459. APASL: High Efficacy and Safety of the All-Oral Combination Regimen, MK-5172 / MK-8742 ï RBV for 12 Weeks in HCV Genotype 1 Infected Patients: The C-WORTHY Study - (03/19/14)
     
  4460. APASL: Sofosbuvir Plus Ribavirin For HCV Genotype 1-3 Infection in HIV Co-infected Patients (PHOTON-1) - (03/19/14)
     
  4461. APASL: Once-Daily Sofosbuvir/Ledipasvir Fixed-Dose Combination With or Without Ribavirin Resulted in 97% Sustained Virologic Response in Patients With HCV Genotype 1, Including Patients With Cirrhosis: The LONESTAR Trial - (03/19/14)
     
  4462. APASL: A Phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir vs telaprevir in combination with pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1 treatment-experienced patients: the ATTAIN study - (03/19/14)
     
  4463. APASL: Simeprevir (TMC435) with peginterferon-α/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve patients: efficacy in patients with genotype 1b HCV in the QUEST-1 and -2 Phase III trials - (03/19/14)
     
  4464. APASL: High Efficacy and Safety of the All-Oral Combination Regimen, MK-5172 / MK-8742 ï RBV for 12 Weeks in HCV Genotype 1 Infected Patients: The C-WORTHY Study - (03/17/14)
     
  4465. APASL: Efficacy and Safety of an Interferon-Free Regimen of MK-5172 + Ribavirin for 12 Weeks or 24 Weeks in Treatment-Naive, Noncirrhotic Subjects With HCV GT1 Infection: The C-SPIRIT Study - (03/17/14)
     
  4466. APASL: Faldaprevir Plus Pegylated Interferon α-2a/Ribavirin in HIV/HCV Co infection: STARTVerso4 - (03/17/14)
     
  4467. APASL: Interferon- and Ribavirin-Free Regimen of ABT-450/r and ABT-267 in Treatment-Experienced Japanese Patients Infected With HCV Genotype 1b or Genotype 2 - (03/17/14)
     
  4468. APASL: Pharmacokinetics of ABT-450/r and ABT-267 in Treatment-Experienced HCV Subgenotype 1b- and Genotype 2-Infected Japanese Subjects - (03/17/14)
     
  4469. APASL: Concordance of SVR12 With SVR4 and SVR24 in Patients With Chronic HCV Genotype 1b Treated With the Interferon- and Ribavirin-free ABT-450/r and ABT-267 Regimen - (03/17/14)
     
  4470. APASL: Once Daily Sofosbuvir/Ledipasvir Fixed-Dose Combination With Ribavirin in Patients With Inherited Bleeding Disorders and HCV Infection - (03/17/14)
     
  4471. APASL: High Sustained Response Rates With Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patients With HCV Genotype 2 or 3 Infection: The VALENCE Trial - (03/17/14)
     
  4472. APASL: Sofosbuvir in Combination With Pegylated Interferon-alfa and Ribavirin for 12 Weeks Provides High SVR Rates in HCV-Infected Genotype 2 or 3 Treatment-Experienced Patients With and Without Compensated Cirrhosis: Results From the LONESTAR-2 Study - (03/17/14)
     
  4473. APASL: Once Daily Sofosbuvir/Ledipasvir Fixed-Dose Combination With or Without Ribavirin: Data From the ELECTRON Trials - (03/17/14)
     
  4474. APASL: Cross-Study Analysis of the Efficacy of the All-Oral Combination of Daclatasvir (DCV) and Asunaprevir (ASV) in Patients with HCV Genotype 1b Infection - (03/17/14)
     
  4475. APASL: On-Treatment Predictors of Response to Daclatasvir (DCV) in Combination With Asunaprevir (ASV) in Japanese Patients With Genotype 1b Infection - (03/17/14)
     
  4476. APASL: Investigating treatment strategies to optimise clinical outcomes associated with emerging therapies for HCV - (03/17/14)
     
  4477. APASL: Efficacy and Safety of Daclatasvir (DCV) in Combination With Asunaprevir (ASV) in Cirrhotic and Non-Cirrhotic Patients With Hepatitis C Virus (HCV) Genotype 1b Infection - (03/17/14)
     
  4478. APASL: Effect of Demographic and Baseline Disease Characteristics on the Efficacy and Safety of Daclatasvir in Combination With Asunaprevir in Japanese Patients With HCV Genotype 1b Infection - (03/17/14)
     
  4479. CROI: Post-Transplant Survival Lower With HIV and HCV-1 Than With HCV-1 Alone - written by Mark Mascolini - (03/12/14)
     
  4480. CROI: HCV Coverage at CROI - (03/10/14)
     
  4481. Medicare proposes coverage for hepatitis C screening - (03/07/14)
     
  4482. CROI: Abbvie IFN-free 3 DAA Regimen in HCV Genotype 1-infected Patients on Methadone or Buprenorphine - (03/06/14)
     
  4483. CROI: On-treatment Viral Response to MK-5172/MK-8742 ï RBV for 12 Weeks in HCV/HIV Co-infected Patients: The C-WORTHY Study - (03/06/14)
     
  4484. CROI: Boehringer Ingelheim Announces Phase 3 SVR12 Results in HCV/HIV Co-Infected Patients Treated with Faldaprevir; New Drug Application Accepted by FDA - (03/06/14)
     
  4485. Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010 - (03/05/14)
     
  4486. CROI: Bristol-Myers Squibb Presents Promising Phase IIb Data for Novel, Investigational Attachment Inhibitor for HIV-1 Infected Treatment-Experienced Patients - press release - (03/05/14)
     
  4487. CROI: Sofosbuvir With Ribavirin in Gt1/2/3 HCV/HIV Coinfected Patients - written by Mark Mascolini - (03/05/14)
     
  4488. CROI: HIV Transmission Bottleneck Offers Clue to HCV Epidemic in HIV+ MSM - written by Mark Mascolini - (03/05/14)
     
  4489. CROI: ABT-493, a Potent HCV NS3/4A Protease Inhibitor With Broad Genotype Coverage - (03/05/14)
     
  4490. CROI: ABT-530, an HCV NS5A Inhibitor With Potent Pangenotypic Activity and High Genetic Barrier to Resistance - (03/05/14)
     
  4491. CROI: Triple-DAA Combo (a Possible 3-in-1 Pill) Yields SVRs Over 90% After 12 Weeks - written by Mark Mascolini - (03/05/14)
     
  4492. CROI: All-Oral Combination of Daclatasvir, Asunaprevir, and BMS-791325 for HCV Genotype 1 Infection - (03/04/14)
     
  4493. CROI: Daclatasvir in Combination With Simeprevir With or Without Ribavirin for Hepatitis C Virus Genotype 1 Infection - (03/04/14)
     
  4494. CROI: All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, and 3 Infection in Patients Co-infected With HIV (PHOTON-1) - (03/04/14)
     
  4495. CROI: Three-DAA Regimen (Abbvie) Achieves 99% SVR12 Rates in HCV Genotype 1b Naives - written by Mark Mascolini - (03/04/14)
     
  4496. CROI: Simeprevir Plus PegIFN/RBV Yields 74% SVR12 in HCV/HIV Patients - written by Mark Mascolini - (03/04/14)
     
  4497. CROI: SVR12 72% With Faldaprevir Plus PegIFN/RBV in Naives With HCV/HIV - written by Mark Mascolini - (03/04/14)
     
  4498. CROI: Combination Oral, Hepatitis C Antiviral Therapy for 6 or 12 Weeks: Results of the SYNERGY Trial - (03/04/14)
     
  4499. CROI: Simeprevir plus PegIFN/ribavirin in HCV genotype-1/HIV-1 co-infection (Study C212) - (03/04/14)
     
  4500. CROI: Double or Triple DAA Therapy for HCV-1 Yields 95-100% SVRs in 6 or 12 Weeks (SYNERGY Study) - written by Mark Mascolini - (03/04/14)
     
  4501. CROI: PEARL III: SVR ≥99% AFTER 12 WKS OF ABT-450/R/267 + ABT-333 ï RBV IN TREATMENT-NAIVE HCV GT1B INFECTION - (03/04/14)
     
  4502. CROI: PEARL III: SVR ≥99% AFTER 12 WKS OF ABT-450/R/267 + ABT-333 ï RBV IN TREATMENT-NAIVE HCV GT1B INFECTION - (03/04/14)
     
  4503. HCV in India, New Study Reporting High Rates in Younger People - (03/03/14)
     
  4504. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2: new research insight into HCV entry in developing HCV vaccine and inhibitors - (02/27/14)
     
  4505. HCV Sex Transmission, Early Reports from 1995/2002 Among Men, Women at Johns Hopkins STD Clinics & other Studies, HIV+ MSM from the Netherlands - (02/24/14)
     
  4506. Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for All-Oral Daclatasvir Dual Investigational Regimen for Chronic Hepatitis C - (02/24/14)
     
  4507. Mapping Diverse Global HCV Genotype Distribution- Europe/1b in Far East - (02/21/14)
     
  4508. Gilead's Hepatitis C Pill Takes Off Like A Rocket - (02/21/14)
     
  4509. Genotype 3 - (02/21/14)
     
  4510. European Medicines Agency advises on compassionate use of a new combination therapy for chronic hepatitis C: sofosbuvir+ledipasvir  - (02/21/14)
     
  4511. Active at night, sleepy all day - Sleep disturbances in patients with hepatitis C virus infection - (02/20/14)
     
  4512. HCV Treatment Costs Benefit/Cost Ratio - (02/19/14)
     
  4513. DAA Combinations - (02/19/14)
     
  4514. WHO Reports Liver Disease Deaths #2 Globally now among Cancers - (02/14/14)
     
  4515. Heroin Resurgence/Youth, Heroin's Small-Town Toll, and a Mother's Grief - (02/14/14)
     
  4516. The global AIDS response can help in fighting hepatitis C - problems/solutions - (02/14/14)
     
  4517. Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Hepatitis C - (02/11/14)
     
  4518. Gilead/Abbvie/BMS/Janssen/Merck Latest Data/study results - (02/11/14)
     
  4519. Cincinnati Area's first needle exchange program targets AIDS, hepatitis C - (02/11/14)
     
  4520. Poor Nations Seek New Hepatitis C Drug - (02/11/14)
     
  4521. Sustained drug use changes following hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study - (02/11/14)
     
  4522. Mortality among Persons in Care with Hepatitis C Virus Infection--The Chronic Hepatitis Cohort Study (CHeCS), 2006-2010: liver disease deaths 12 times higher - (02/11/14)
     
  4523. (premature) Deaths among People with Hepatitis C in New York City, 2000 - 2011 - (02/11/14)
     
  4524. Determining the Effect of Hepatitis C on Mortality: Sorting the Signal From the Noise - Editorial - (02/11/14)
     
  4525. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial - (02/10/14)
     
  4526. Georgia Govt Launches Treatment Programme to Curb Hepatitis - (02/10/14)
     
  4527. Experts warn of rise in gay 'slamming' in London: increased HIV & HCV transmission risk - (02/07/14)
     
  4528. Injection behaviors among injection drug users in treatment: The role of hepatitis C awareness - (02/07/14)
     
  4529. HIV & HCV Share Transmission Networks - Implications for Domestic HCV transmission Among HIV+ MSM in Swiss Cohort - close link, HIV & HCV sexual transmission linked Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV - (02/07/14)
     
  4530. HOW DOES COFFEE PREVENT LIVER FIBROSIS? BIOLOGICAL PLAUSIBILITY FOR RECENT EPIDEMIOLOGICAL OBSERVATIONS - Editorial - (02/07/14)
     
  4531. Sticker Shock and the Price of New Therapies for Hepatitis C: Is it worth it? - (02/07/14)
     
  4532. The Relationship of Hepatitis C Virus Infection with Diabetes in the United States Population: HCV & Diabetes Not Associated, same for Pre-Diabetes - NHANES - (02/07/14)
     
  4533. Patient Advocate Foundation Announces Co-Pay Relief (CPR) Support for Patients Living with Hepatitis C - (02/05/14)
     
  4534. Gilead, local generic players in talks to bring hepatitis C drug into India - (02/05/14)
     
  4535. Injection behaviors among injection drug users in treatment: The role of hepatitis C awareness - Does HCV+ Awareness Among IDUs Reduce Needle Sharing? - (02/05/14)
     
  4536. HCV Survives/Maintains Infectivity in Syringe/On Surfaces- 2 studies - (02/03/14)
     
  4537. HIV/HCV Coinfection Treatment Options - including new Abbvie Study and BMS Daclatasvir+Sofosbuvir Study - (02/03/14)
     
  4538. Vertex Announces Sustained Viral Response Rate (SVR4) Data from All-Oral Study of VX-135 in Combination with Daclatasvir in Hepatitis C - (01/31/14)
     
  4539. Does Eltrombopag Really ENABLE SVR? Editorial - (01/31/14)
     
  4540. Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection - (01/31/14)
     
  4541. New Recommendations for Testing, Managing, and Treating Hepatitis C from AASLD/IDSA Panel. And newer developments in HCV therapy - (01/31/14)
     
  4542. AbbVie Completes Largest Phase III Program of an All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C Genotype 1 - (01/31/14)
     
  4543. hepDART: HepDART December 2013 Selected Slide Presentations (01/24/14)
     
  4544. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: Prospective analysis of 435 liver biopsy pairs - 'HIV/HCV Coinfected's Liver Disease Can Progress Quickly' - (01/24/14)
     
  4545. Eradication of hepatitis C infection: The importance of targeting people who inject drugs - (01/24/14)
     
  4546. Statins for prevention of hepatocellular cancer: One step closer? Commentary - (01/24/14)
     
  4547. Only just the beginning of the end of hepatitis C - (01/24/14)
     
  4548. UNITAID can address HCV/HIV co-infection - (01/24/14)
     
  4549. New HCV Screening Bill in Florida - Mia Jones' bill would require doctors to offer Hepatitis C tests to Baby Boomers - (01/22/14)
     
  4550. NS5A Samatasvir(IDX719) Monotherapy in Gt1/2/3/4 - (01/22/14)
     
  4551. HCV in Latinos/Puerto Ricans - (01/22/14)
     
  4552. New York State HCV Screening Law Frequently Asked Questions Latest Version - (01/22/14)
     
  4553. Low rates of hepatitis C testing among people who inject drugs in Thailand: implications for peer-based interventions - new publication - (01/22/14)
     
  4554. Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection - (01/17/14)
     
  4555. Abbvie HCV - Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1 - (01/17/14)
     
  4556. Boehringer Ingelheim HCV Announcement - (01/17/14)
     
  4557. European Commission Grants Marketing Authorization for Gilead's Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection - (01/17/14)
     
  4558. HCV: who/how to screen-HCV is a Disease of the Marginalized - (01/16/14)
     
  4559. CDC/NYS HCV: Screen Baby Boomers/IDUs-New HCV Treatments - (01/15/14)
     
  4560. Update on CDC's Response to the HCV Epidemic Among Persons Born From 1945-1965 -- Dec 16 2013 - (01/15/14)
     
  4561. HCV in Republic of Georgia & in Russia - (01/15/14)
     
  4562. HCV New drugs Latest Updates - (01/15/14)
     
  4563. HCV in India: Doctors plan to launch a foundation to make government and community pay greater attention to the problem..... - (01/15/14)
     
  4564. CUPIC & Adverse Events Study & Commentary - (01/15/14)
     
  4565. HCV Global/USA "Test & Treat"...."Eradication/Access" - (01/15/14)
     
  4566. Daclatasvir+Sofosbuvir-new studies, VX135, Daclatasvir Phase 3 IFN-free, EMA Compassionate Use, Accelerated EMA Marketing Review Recommendation - (01/15/14)
     
  4567. Update on CDC's Response to the HCV Epidemic Among Persons Born From 1945-1965 -- Dec 16 2013 - (01/15/14)
     
  4568. HCV in Republic of Georgia & in Russia - (01/15/14)
     
  4569. HCV New drugs Latest Updates - (01/15/14)
     
  4570. HCV in India: Doctors plan to launch a foundation to make government and community pay greater attention to the problem..... - (01/15/14)
     
  4571. CUPIC & Adverse Events Study & Commentary - (01/15/14)
     
  4572. HCV Global/USA "Test & Treat"...."Eradication/Access" - (01/15/14)
     
  4573. [HCV Heterogeneity among various Latino groups] Prevalence of Hepatitis C Virus Infection in US Hispanic/Latino Adults: Results from the NHANES 2007-2010 and HCHS/SOL Studies - (01/15/14)
     
  4574. HCV in Pakistan-2 - (01/14/14)
     
  4575. New Abbvie HCV Drugs Study - (01/14/14)
     
  4576. Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by the European Medicines Agency - (01/14/14)
     
  4577. How Many/Who HAS HCV in USA - (01/14/14)
     
  4578. [HCV Heterogeneity among various Latino groups] Prevalence of Hepatitis C Virus Infection in US Hispanic/Latino Adults: Results from the NHANES 2007-2010 and HCHS/SOL Studies - (01/14/14)
     
  4579. New NHANES: The Changing Epidemiology of Hepatitis C Virus Infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010 - (01/13/14)
     
  4580. Treatment as prevention and cure towards global eradication of hepatitis C virus - (01/13/14)
     
  4581. Global HCV Prevalence/WGO Guidelines April/13/Sofosbuvir - (01/13/14)
     
  4582. A Silent Storm: Hepatitis C in Pakistan - (01/13/14)
     
  4583. Pre & Post Liver Transplant Treatment- Recent Studies - New DAAs, Boceprevir, Telaprevir - "Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience" and Editorial - (01/13/14)
     
  4584. Antisense therapy for hepatitis C virus infection -Commentary - (01/13/14)
     
  4585. [new survey] The Changing Epidemiology of Hepatitis C Virus Infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010 - (01/13/14)
     
  4586. Minimum costs for producing Hepatitis C Direct Acting Antivirals, for use in large-scale treatment access programs in developing countries - (01/13/14)
     
  4587. UNMC Part Of International Hepatitis C Registry To Improve Treatment (HCV-TARGET) - (01/13/14)
     
  4588. Minimum costs for producing Hepatitis C Direct Acting Antivirals, for use in large-scale treatment access programs in developing countries - (01/13/14)
     
  4589. Achillion (Update) Reports HCV Pipeline Progress and Outlines 2014 HCV Milestones - (01/13/14)
     
  4590. Idenix Pharmaceuticals Reports Sustained Virologic Response Rate (SVR4) for Phase II All-Oral Combination Study of Samatasvir (IDX719), a Potent, Pan-Genotypic HCV NS5A Inhibitor, and Simeprevir - (01/13/14)
     
  4591. Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: Results from the ANRS CO13 HEPAVIH cohort study. Association of Coffee Consumption With All-Cause and Cardiovascular Disease Mortality - 2 new studies - (12/31/13)
     
  4592. HCV in HIV+ MSM in SF: "Epidemiology of the Viral Hepatitis-HIV Syndemic in San Francisco: A Collaborative Surveillance Approach" - (12/27/13)
     
  4593. Pilot Program Integrating HCV Screening Into HIV Screening in Incarcerated in Massachusetts: 37.8% (n=531) had an HCV-related test result reported to MAVEN after release, indicating linkage to care - (12/27/13)
     
  4594. HCV+ Died 23 Yrs Earlier Than Persons without HCV. Blacks Have Double the Rate vs Whites-CDC Study - (12/27/13)
     
  4595. Nigeria: 40 Million Have Hepatitis Virus and May Not Know, Inaugurates Technical Committee Hepatitis - (12/27/13)
     
  4596. Changes in Testing for Human Immunodeficiency Virus, Sexually Transmitted Infections, and Hepatitis C Virus in Opioid Treatment ProgramsÉ HCV testing declined by 13% in for-profit programs and increased by 14% in nonprofit programs. - (12/27/13)
     
  4597. Barriers to HCV Screening/Care among IDUs: "Perceptions of drug users regarding Hepatitis C screening and care: a qualitative study" - (12/27/13)
     
  4598. Simeprevir (Olysio) J & J Patient Access Programs
     
  4599. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir - (12/27/13)
     
  4600. HIV/HCV Coinfection -Psych/Social Issues, Screening for HCC, Pathogenesis of Accelerated Fibrogenesis, excerpts from meeting - (12/27/13)
     
  4601. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience - (12/27/13)
     
  4602. Healthcare reform and Hepatitis C: A convergence of risk and opportunity - report from Millman supported by Janssen - (12/23/13)
     
  4603. AASLD: Pharmacokinetics and Safety of Co-administered ABT-450 plus Ritonavir (ABT 450/r), ABT-267 and ABT-333 as a Single Dose in Subjects with Normal Hepatic Function and in Subjects with Mild, Moderate and Severe Hepatic Impairment (DAAs PK; Sofosbivur+Daclatasvir in Liver transplant; and "Pharmacologic Considerations when using DAAs in Cirrhosis" - at 2013 1st Intl Wkp on the Optimal Use of DAAs in Liver Transplantation April 23, by Jennifer Kiser PharmD - (12/23/13)
     
  4604. AASLD: Minimum costs to produce Hepatitis C Direct Acting Antivirals for access programs in developing countries - (12/20/13)
     
  4605. hepDART: High Sustained Virologic Response Rates With Sofosbuvir Regimens Irrespective of Ribavirin Dose Reductions (12/20/13)
     
  4606. hepDART: In Vitro Activation of Sofosbuvir in Primary Human Hepatocytes (12/20/13)
     
  4607. hepDART: High Sustained Virologic Response Rates With Sofosbuvir Regimens Irrespective of Ribavirin Dose Reductions - slide talk (12/18/13)
     
  4608. hepDART: A Fixed-Dose Combination of Sofosbuvir and Ledipasvir Is Highly Effective in Treatment-Naïve and Treatment-Experienced Genotype 1 HCV-Infected Patients: Results from the LONESTAR and ELECTRON Phase 2 Studies (12/18/13)
     
  4609. hepDART: A Fixed-Dose Combination of Sofosbuvir and Ledipasvir Is Highly Effective in Treatment-Naïve and Treatment-Experienced Genotype 1 HCV-Infected Patients: Results From the LONESTAR and ELECTRON Phase 2 Studies - poster (12/18/13)
     
  4610. hepDART: Daclatasvir: Present and Future DAA Combinations (12/18/13)
     
  4611. hepDART: Simeprevir Overview: From IFN-Containing to IFN-Free Regimens (12/18/13)
     
  4612. GILEAD ANNOUNCES SVR12 RATES FROM THREE PHASE 3 STUDIES EVALUATING A ONCE-DAILY FIXED-DOSE COMBINATION OF SOFOSBUVIR AND LEDIPASVIR FOR GENOTYPE 1 HEPATITIS C PATIENTS - For Immediate Release - (12/18/13)
     
  4613. ABBVIE DEMONSTRATES 96 PERCENT SVR(12) IN ITS PHASE III STUDY OF TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE 1 HEPATITIS C - (12/18/13)
     
  4614. AbbVie Releases First of Six Phase III Results from Investigational All-Oral, Interferon-Free, 12-week Regimen, Showing 96 Percent SVR12 in Genotype 1 Hepatitis C Patients New to Therapy - (11/18/13)
     
  4615. Health Canada Issues Notice of Compliance for Sovaldi™ (Sofosbuvir) for the Treatment of Chronic Hepatitis C - (12/16/13)
     
  4616. hepDART: NS3/4A BASELINE POLYMORPHISMS AND TREATMENT-EMERGENT VARIANTS IN HCV GENOTYPE-1-INFECTED, TREATMENT-NAIVE PATIENTS FROM THE PHASE III STARTVerso 1 AND 2 CLINICAL STUDIES OF FALDAPREVIR PLUS PEGYLATED INTERFERON -2A AND RIBAVIRIN - (12/16/13)
     
  4617. hepDART: TD-6450, a Heterodimeric HCV NS5A Inhibitor with a High Barrier to Resistance and Pan-Genotypic Potency - (12/16/13)
     
  4618. hepDART: Impact of Chronic Hepatitis C (CHC) Treatment on Post Therapy Healthcare Cost: HCV Therapy Completers Had Significantly Reduced Post Therapy Healthcare Costs - (12/16/13)
     
  4619. hepDART: No Pharmacokinetic Interaction Between the Hepatitis C Virus Non-Structural Protein 5A Inhibitor MK-8742 and Ethinyl Estradiol and Levonorgestrel - (12/16/13)
     
  4620. hepDART: No Meaningful Pharmacokinetic Interaction Between Hepatitis C Virus Protease Inhibitor MK-5172 and Ethinyl Estradiol and Levonorgestrel - (12/16/13)
     
  4621. hepDART: Lack of PK Interaction Between the Hepatitis C Virus Non-Structural Protein 5A Inhibitor MK-8742 and Methadone in Subjects on Stable Opiate Maintenance Therapy - (12/16/13)
     
  4622. hepDART: Pharmacokinetic Interaction Of HCV Protease Inhibitor MK-5172 and Ritonavir in Healthy Subjects - (12/16/13)
     
  4623. An all-oral phase IIa study combining Simeprevir, TMC647055 and JNJ56914845 in hepatitis C patients to be initiated - (12/16/13)
     
  4624. Sofosbuvir Access Ex-USA - (12/16/13)
     
  4625. AASLD: Anti-Fibrotic and Anti-Inflammatory Activity of the Dual CCR2 and CCR5 Antagonist Cenicriviroc in a Mouse Model of NASH - (12/11/13)
     
  4626. Anti-Fibrotic Activity of Oral, Dual CCR2 and CCR5 Antagonist Cenicriviroc in a Mouse Model of NASH and a Rat Model of TAA-Induced Liver Fibrosis - (12/11/13)
     
  4627. Simeprevir is now available for Hepatitis C patients in Japan, USA and Canada - (12/10/13)
     
  4628. FDA approves Sovaldi for chronic hepatitis C- FDA NEWS RELEASE - (12/09/13)
     
  4629. Hepatitis C Virus Serosorting in People Who Inject Drugs - (12/09/13)
     
  4630. Interferon-stimulated genes and their role in controlling hepatitis C virus - (12/09/13)
     
  4631. U.S. Food and Drug Administration Approves Gilead's Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C - (12/06/13)
     
  4632. Does Chemotherapy Cause Viral Relapse in Cancer Patients with Hepatitis C Infection Successfully Treated with Antivirals? - (12/06/13)
     
  4633. AASLD: Telaprevir combination therapy in treatment-naïve and experienced patients co-infected with HCV and HIV - (12/06/13)
     
  4634. Hepatitis C Virus Maintains Infectivity for Weeks after Drying on Inanimate Surfaces at Room Temperature: Implications for Risks of Transmission - (12/05/13)
     
  4635. Treat HCV in Drug Rehab in Helsinki: Hepatitis C spreading among drug users - (12/05/13)
     
  4636. MassBiologics gets FDA orphan drug designation for MBL-HCV1 antibody to prevent HCV recurrence post liver transplant - (12/05/13)
     
  4637. AASLD: Using Laboratory Data to Predict Long-Term Morbidity and Mortality in Chronic Hepatitis C (& treatment affect) Patients in the U.S. Veterans Health Administration - (12/04/13)
     
  4638. AASLD: 2 Screening Studies - (12/04/13)
     
  4639. AASLD: Effect of Hepatic Impairment on the Pharmacokinetics of Asunaprevir (BMS-650032, ASV) - (12/04/13)
     
  4640. AASLD: Safety Profile of Peginterferon Lambda for Treatment of Chronic Hepatitis B (CHB) or Chronic Hepatitis C (CHC): Cross-Study Analysis of Patients Treated in Three Phase 2 Studies - (12/04/13)
     
  4641. AASLD: New HCV Protease Inhibitor:a phase 1/2a Study of Safety, Tolerability and Pharmacokinetic Profiles of TG-2349, a Pan-Genotypic HCV Protease Inhibitor, in Healthy East Asian and Caucasian Subjects, and its Antiviral Activity in Chronic Hepatitis C patients. - (12/04/13)
     
  4642. AASLD: Twice Daily Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in Genotype 1 HCV Liver Transplant Recipients: Interim Week 16 Calcineurin Inhibitor, Telaprevir, and Ribavirin Pharmacokinetics From the Prospective Multicenter REFRESH Study - (12/04/13)
     
  4643. AASLD: Telaprevir in the Treatment of Acute HCV in HIV-infected Men - (12/04/13)
     
  4644. AASLD: Efficacy, Treatment Duration and Safety of boceprevir/peginterferon/ribavirin in Treatment naive Patients With Hepatitis C Virus Genotype 1 Infection: relationship to baseline fibrosis score - (12/04/13)
     
  4645. AASLD: Asunaprevir Pharmacokinetics and Safety in Subjects With Impaired Renal Function - (12/04/13)
     
  4646. AASLD: Shifting scales: comparing viral hepatits and HIV/AIDS mortality in the Global Burden of Disease Study 2010 - (12/04/13)
     
  4647. AASLD: New Monogram HCV Protease Inhibitor Resistance Test: "Cross-sectional Assessment of 1500 Clinical Samples Submitted for HCV NS3/4A Protease Inhibitor Drug Resistance Testing in the US" - (12/04/13)
     
  4648. AASLD: High End-Of-Treatment (EOT) Response Rate with Telaprevir-PegIFN-RBV in Treatment-Experienced HIV Coinfected Patients with HCV genotype 1: ANRS HC26 TelapreVIH Study - (12/04/13)
     
  4649. AASLD: W48 Response Rate of Boceprevir-PegIFN-RBV in Treatment-Experienced HIV Coinfected Patients with HCV genotype 1: ANRS-HC27 BocepreVIH Study - (12/04/13)
     
  4650. Simeprevir (Olysio) J & J Patient Access Programs - (12/04/13)
     
  4651. Hepatitis C: Boehringer Ingelheim's faldaprevir granted accelerated assessment from European Medicines Agency - press release - (12/03/13)
     
  4652. HCV in Pakistan....US based Pakistan doctors mark Hepatitis C Day....2-8% prevalence....9 mill with HCV ....5.6 mill with HBV - (12/03/13)
     
  4653. (Cost Effectiveness) Impact of Interferon Free Regimens on Clinical and Cost Outcomes for Chronic Hepatitis C Genotype 1 Patients - (12/03/13)
     
  4654. Mediterranean Diet and Hepatocellular Carcinoma - (12/03/13)
     
  4655. Hepatitis C Testing, Infection, and Linkage to Care Among Racial and Ethnic Minorities in the United States, 2009-2010 - (12/03/13)
     
  4656. HELIX-2, a phase II all-oral combination study of Simeprevir, TMC647055 and Samatasvir (IDX719) for the treatment of hepatitis C has been initiated - (12/03/13)
     
  4657. Idenix Pharmaceuticals Announces Initiation of Enrollment in a Phase II All-Oral Combination Study of Samatasvir (IDX719), Simeprevir, and TMC647055 for the Treatment of Hepatitis C Virus (HCV) Infection - (12/03/13)
     
  4658. AASLD: Daclatasvir Pharmacokinetics in Healthy Subjects: No Clinically Relevant Drug-Drug Interaction With Either Cyclosporine or Tacrolimus - (12/02/13)
     
  4659. AASLD: Post-Treatment Viral Evolution Assessment Using Ultra-Deep Pyrosequencing in Samples from Patients with Hepatitis C Virus Infection: The EXTEND Study - (12/02/13)
     
  4660. AASLD: Genome-wide Association Analysis to Evaluate Genetic Variations Associated with Rash Development in Telaprevir Phase 2 and 3 Studies - (12/02/13)
     
  4661. AASLD: High Efficacy at Lower Doses of MK-5172 25 mg and 50 mg Daily for 12 Weeks in HCV Genotype (Gt)1 Treatment-Naive Noncirrhotic Patients - (12/02/13)
     
  4662. AASLD: Vaniprevir (MK-7009) Demonstrates Higher Exposures in Treatment-Experienced Genotype (GT) 1 Cirrhotic Than Non-cirrhotic HCV-Infected Patients - (12/02/13)
     
  4663. AASLD: Costs of Telaprevir-based Triple Therapy Including Adverse Event Management at the Mount Sinai Medical Center, NY $189,000 per SVR - (12/02/13)
     
  4664. Roche at AASLD - (11/26/13)
     
  4665. NYS DEPARTMENT OF HEALTH AIDS INSTITUTE PRESENTS STATEWIDE STAKEHOLDER MEETINGS NYS Hepatitis C Testing Law - (11/26/13)
     
  4666. Olysio (Simeprevir): FDA (preliminary prescribing information; summary of the basis of approval and highlights from the prescribing information - (11/26/13)
     
  4667. HCC (Liver cancer) Screening Improves Survival - (11/26/13)
     
  4668. European Medicines Agency recommends approval of sofosbuvir for the treatment of chronic hepatitis C - (11/25/13)
     
  4669. European CHMP Adopts Positive Opinion for Gilead Sciences' Sovaldi(R) for the Treatment of Chronic Hepatitis C Infection - (11/25/13)
     
  4670. OLYSIO™ (simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C - (11/25/13)
     
  4671. New HCV Treatments - (11/25/13)
     
  4672. European Medicines Agency advises on compassionate use of daclatasvir - (11/25/13)
     
  4673. FDA Warning letter to Kadmon Pharmaceuticals - (11/25/13)
     
  4674. Drug-drug interactions with oral anti-HCV agents and Idiosyncratic Hepatotoxicity in the Liver Transplant setting - (11/25/13)
     
  4675. Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C - (11/25/13)
     
  4676. Simeprevir, New Treatment for Hepatitis C Approved by Health Canada Priority Review Gives Physicians and Patients an Effective and Tolerable Treatment Choice - (11/20/13)
     
  4677. Vertex Sells INCIVO ® Product Royalty Rights for $152 Million to Janssen - (11/20/13)
     
  4678. AASLD: Summary from AASLD 2013 for Hepatitis C Washington 1-5 November 2013 - Written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany -
     
  4679. AASLD: New Phase II Data from All-Oral Regimens - Fred Poordad, MD VP, Academic and Clinical Affairs The Texas Liver Institute Professor of Medicine University of Texas Health Science Center San Antonio, Texas - (11/18/13)
     
  4680. AASLD: Risk Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis: The ADRESS-HCC Risk Model - (11/18/13)
     
  4681. AASLD: HCV Treatment Reduces Liver Disease/Death/Transplant - (11/18/13)
     
  4682. AASLD: Ending the Silent Epidemic of Viral Hepatitis in the U.S. - Ronald Valdiserri MD HHS - (11/18/13)
     
  4683. AASLD: Sustained Virological Response After Protease Inhibitor-based Therapy For Hepatitis C Recurrence After Liver Transplantation: A Multicentric European Experience - (11/18/13)
     
  4684. AASLD: Hepatitis C Screening & Prevalence among Veterans in Dept of Veterans Affairs Care in 2012 - (11/18/13)
     
  4685. AASLD: Gilead at AASLD: Sofosbuvir for GT 3, 2 and 1 - (11/18/13)
     
  4686. AASLD: Gilead at AASLD: 2 - (11/18/13)
     
  4687. AASLD: BMS at AASLD - (11/18/13)
     
  4688. AASLD: Boehringer Ingelheim - (11/18/13)
     
  4689. AASLD: Merck at AASLD - (11/18/13)
     
  4690. AASLD: Janssen at AASLD - (11/18/13)
     
  4691. AASLD: Abbvie at AASLD - (11/18/13)
     
  4692. AASLD: 96 weeks of pegylated-interferon-alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HiDiT-2 study - (11/18/13)
     
  4693. AASLD: Screening in the Emergency Department Identifies a Large Cohort of Unrecognized Chronic HCV Infection Among Baby Boomers - (11/14/13)
     
  4694. HCV Viral Load Suppression Reduced Death, Risk for Liver Events: new study - (11/14/13)
     
  4695. AASLD: Pharmacokinetics of MK-8742, an HCV NS5A Inhibitor, Following Single and Multiple Oral Doses of MK-8742 in Healthy Subjects - (11/14/13)
     
  4696. AASLD: Impact of Treatment on Long-Term Morbidity and Mortality in Chronic Hepatitis C Patients Receiving Care Through the U.S. Veterans Health Administration - (11/14/13)
     
  4697. AASLD: Interferon-free Regimen Containing Setrobuvir in Combination with Ritonavir-boosted Danoprevir and Ribavirin with or without Mericitabine in HCV Genotype 1 Treatment-naive Patients: Interim Results from the ANNAPURNA Study - (11/14/13)
     
  4698. AASLD: Lack of a Clinically Significant Pharmacokinetic Drug-Drug Interaction Between Sofosbuvir and GS-5816 in Healthy Volunteers - (11/14/13)
     
  4699. AASLD: On-Treatment HCV RNA as a Predictor of Virologic Response in Sofosbuvir-Containing Regimens for Genotype 2/3 HCV Infection: Analysis of the FISSION, POSITRON, and FUSION Studies - (11/14/13)
     
  4700. AASLD: Targeting lysyl oxidase like 2 (LOXL2) inhibits collagen cross-linking and accelerates reversal of pre-established liver fibrosis - (11/14/13)
     
  4701. AASLD: Sofosbuvir Selects the NS5B S282T Mutation In Vitro in Genotype 1-6 Replicons and Is Not Cross-Resistant to Resistance-Associated Variants Selected by Other Classes of Antiviral Inhibitors - (11/14/13)
     
  4702. AASLD: Population Pharmacokinetics of Sofosbuvir and Its Major Metabolite (GS-331007) in Healthy and HCV-Infected Adult Subjects - (11/14/13)
     
  4703. AASLD: Nucleotide Analog Levels in Liver Explants From HCV Infected Subjects Undergoing Liver Transplantation After Up to 24 Weeks Sofosbuvir (GS-7977) With Ribavirin Treatment - (11/14/13)
     
  4704. AASLD: HCV TARGET - Impact of Age on Safety and Treatment Response in Patients with Hepatitis - (11/14/13)
     
  4705. AASLD: Responsible Use of New DAAs in 2014 and Beyond - David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville, USA - (11/14/13)
     
  4706. AASLD: Virologic Response Rates to Sofosbuvir-Containing Regimens Are Similar in Patients With and Without Traditional Negative Predictive Factors: a Retrospective Analysis of Phase 3 Data - (11/13/13)
     
  4707. AASLD: PRECLINICAL CHARACTERISTICS OF ACH-3422: A POTENT URIDINE NUCLEOTIDE PRODRUG FOR INHIBITION OF HEPATITIS C VIRUS NS5B RNA POLYMERASE - (11/13/13)
     
  4708. AASLD: Selective inhibition of lysyl oxidase like 2 (LOXL2) using a therapeutic monoclonal antibody suppresses the progression of biliary fibrosis in novel PSC-like mouse model - (11/13/13)
     
  4709. AASLD: Safety and Efficacy of BMS-791325, a Non-Nucleoside NS5B Polymerase Inhibitor, Combined With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients Infected with Hepatitis C Virus Genotype 1 - (11/13/13)
     
  4710. AASLD: Lack of Pharmacokinetic Interaction Between HCV Protease Inhibitor MK-5172 and HCV NS5A Inhibitor Daclatasvir in Healthy Volunteers - (11/13/13)
     
  4711. AASLD: Virological Outcomes and Adherence to Treatment Algorithms in a Longitudinal Study of Patients with Chronic Hepatitis C Treated with Boceprevir or Telaprevir in the U.S. (HCV-TARGET) - (11/13/13)
     
  4712. AASLD: STARTVerso4 PHASE III TRIAL OF FALDAPREVIR PLUS PEGYLATED INTERFERON α-2a AND RIBAVIRIN IN PATIENTS WITH HIV AND HCV GENOTYPE-1 CO-INFECTION - (11/11/13)
     
  4713. AASLD: MASS BALANCE, METABOLIC PROFILE, AND THE ROLE OF HEPATIC AND BACTERIAL ENZYMES IN THE METABOLISM OF THE HCV POLYMERASE INHIBITOR, DELEOBUVIR - (11/11/13)
     
  4714. AASLD: PHARMACOKINETIC INTERACTIONS OF FALDAPREVIR AND DELEOBUVIR AND THEIR INDIVIDUAL AND COMBINED EFFECT ON SELECTED CYTOCHROME P450 PROBE SUBSTRATES IN PATIENTS INFECTED WITH GENOTYPE-1 HCV - (11/11/13)
     
  4715. AASLD: INTERFERON-FREE TREATMENT WITH FALDAPREVIR, DELEOBUVIR, AND RIBAVIRIN IN SOUND-C3: 95% SVR12 IN HCV GENOTYPE-1b - (11/11/13)
     
  4716. AASLD: Sofosbuvir Plus Ribavirin in the Treatment of Chronic HCV Genotype 4 Infection in Patients of Egyptian Ancestry - (11/11/13)
     
  4717. AASLD: Lack of a Clinically Important Pharmacokinetic Interaction Between Norgestimate/Ethinyl Estradiol and Sofosbuvir (SOF) or Ledipasvir (LDV) in HCV-Uninfected Female Subjects - (11/11/13)
     
  4718. AASLD: Pharmacokinetics of Ledipasvir, an HCV-Specific NS5A Inhibitor, in HCV-Uninfected Subjects With Moderate or Severe Hepatic Impairment - (11/11/13)
     
  4719. AASLD: Efficacy and Safety of Sofosbuvir in Patients According to Fibrosis Stage: An Analysis of Phase 3 Data - (11/11/13)
     
  4720. AASLD: Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve patients: efficacy in difficult-to-treat patient sub-populations in the QUEST-1 and 2 Phase III trials - (11/10/13)
     
  4721. AASLD: Simeprevir (TMC435) with pegylated interferon-a-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy and safety in patient sub-populations in the PROMISE Phase III trial - (11/10/13)
     
  4722. AASLD: Resistance analyses of HCV isolates from patients treated with simeprevir in Phase IIB/III studies - (11/10/13)
     
  4723. AASLD: A POOLED ANALYSIS OF TWO RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIALS (STARTVerso1 AND 2) OF FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE-1 INFECTIONBACKGROUND - (11/10/13)
     
  4724. AASLD: STARTVerso4 PHASE III TRIAL OF FALDAPREVIR PLUS PEGYLATED INTERFERON α-2a AND RIBAVIRIN IN PATIENTS WITH HIV AND HCV GENOTYPE-1 CO-INFECTION - (11/10/13)
     
  4725. AASLD: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF FALDAPREVIR IN COMBINATION WITH PEGYLATED INTERFERON α-2a AND RIBAVIRIN IN TREATMENT-EXPERIENCED PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION - (11/10/13)
     
  4726. AASLD: SUBGROUP ANALYSES AND BASELINE PREDICTORS OF RESPONSE WITH FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE-1 INFECTION: A POOLED ANALYSIS OF STARTVerso1 AND 2 - (11/10/13)
     
  4727. AASLD: EFFECT OF STEADY-STATE FALDAPREVIR ON THE PHARMACOKINETICS OF STEADY-STATE METHADONE AND BUPRENORPHINE/NALOXONE IN SUBJECTS ON STABLE ADDICTION MANAGEMENT THERAPY - (11/10/13)
     
  4728. AASLD: EFFECT OF MULTIPLE ORAL DOSES OF FALDAPREVIR ON THE MULTIPLE DOSE PHARMACOKINETICS OF A COMBINATION ORAL TABLET OF ETHINYLESTRADIOL AND LEVONORGESTREL IN HEALTHY PREMENOPAUSAL FEMALE VOLUNTEERS - (11/10/13)
     
  4729. AASLD: PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF FALDAPREVIR IN PATIENTS WITH DIFFERENT LEVELS OF RENAL IMPAIRMENT - (11/10/13)
     
  4730. AASLD: Hepatitis Debrief by Mark Sulkowski MD - Professor of Medicine Division of Infectious Diseases and Gastroenterology/Hepatology Johns Hopkins University School of Medicine Baltimore, MD. - (11/08/13)
     
  4731. AASLD: THE RISK FOR HCC AMONG PATIENTS WITH CHRONIC HCV INFECTION AND ADVANCED HEPATIC FIBROSIS FOLLOWING SVR - (11/08/13)
     
  4732. AASLD: The global burden of liver disease attributable to hepatitis B, hepatitis C, and alcohol: increasing mortality, differing causes - (11/08/13)
     
  4733. AASLD: Increases in HCV Hospital Liver-Related Admissions, Charges, Days-in-Hospital: aged 50-59 demonstrated the largest increases between 2002 and 2010 in the number of liver-related admissions (164%), liver-related hospital days (133%), and liver-related hospital charges (341%), Patients Aged 60+ Had 2nd Largest Increases.....ages 20-29 too - (11/07/13)
     
  4734. AASLD: No Resistance Detected in Four Phase 3 Clinical Studies in HCV Genotypes 1-6 of Sofosbuvir + Ribavirin With or Without Peginterferon - (11/07/13)
     
  4735. AASLD: HCV RNA "Target Detected" After "Target Not Detected" During IFN-free Treatment: Time to Worry or Not? - (11/07/13)
     
  4736. AASLD: All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, and 3 Infection in Patients Co-infected With HIV (PHOTON-1) - (11/06/13)
     
  4737. AASLD: All-Oral Combination of Daclatasvir Plus Asunaprevir in Interferon-Ineligible Naïve/Intolerant and Nonresponder Japanese Patients Chronically Infected With HCV Genotype 1b: Results From a Phase 3 Trial - (11/06/13)
     
  4738. AASLD: Sofosbuvir and Ledipasvir Fixed-Dose Combination with and without Ribavirin in Treatment-Naïve and Previously Treated Patients with Genotype 1 Hepatitis C: The LONESTAR Study - (11/06/13)
     
  4739. AASLD: Pretransplant Sofosbuvir and Ribavirin to Prevent Recurrence of HCV Infection After Liver Transplantation - (11/06/13)
     
  4740. AASLD: Combination Oral, Ribavirin Free, Antiviral Therapy to Optimize Treatment Outcomes for Hepatitis C Treatment Naïve Patients: Interim Results from the NIAID SYNERGY Trial (6 & 12 weeks therapy) - (11/06/13)
     
  4741. AASLD: Initial Evaluation of the Sofosbuvir Compassionate Use Program for Patients With Severe Recurrent HCV Following Liver Transplantation - (11/06/13)
     
  4742. AASLD: Safety of Ribavirin-containing Regimens of ABT-450/r, ABT-333, and ABT-267 for the Treatment of HCV Genotype 1 Infection and Efficacy in Subjects With Ribavirin Dose Reductions - (11/06/13)
     
  4743. AASLD: High Medication Adherence in HCV-Infected Patients Taking a Triple-DAA Regimen for 12 Weeks - (11/06/13)
     
  4744. AASLD: Low Relapse Rate Leads to High Concordance of SVR4 and SVR12 With SVR24 After Treatment With ABT-450/r, ABT-267, ABT-333 + Ribavirin in Patients With Chronic HCV Genotype 1 Infection in the AVIATOR Study - (11/06/13)
     
  4745. AASLD: Phase 2b Study of the Interferon-Free and Ribavirin-Free Combination of Daclatasvir, Asunaprevir, and BMS-791325 for 12 Weeks in Treatment-Naive Patients With Chronic HCV Genotype 1 Infection - (11/05/13)
     
  4746. AASLD: SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study - (11/05/13)
     
  4747. AASLD: Sofosbuvir in Combination With PegIFN and Ribavirin for 12 Weeks Provides High SVR Rates in HCV-Infected Genotype 2 or 3 Treatment- Experienced Patients with and without Compensated Cirrhosis: Results from the LONESTAR-2 Study - (11/05/13)
     
  4748. AASLD: Sofosbuvir and Ribavirin for the Treatment of Established Recurrent Hepatitis C Infection After Liver Transplantation: Preliminary Results of a Prospective, Multicenter Study - (11/05/13)
     
  4749. AASLD: INCIVO® (TELAPREVIR) DATA TO BE PRESENTED AT AASLD AND ISPOR, TWO MAJOR INTERNATIONAL CONGRESSES, ON THE ANTI-VIRAL RESPONSE, SAFETY, TOLERABILITY AND COST-EFFECTIVENESS OF AN INCIVO® (TELAPREVIR) BASED REGIMEN IN THE TREATMENT OF GENOTYPE-1 CHRONIC HEPATITIS C - (11/05/13)
     
  4750. AASLD: MK-8742, an HCV NS5A Inhibitor With a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotype-1 and -3 HCV-Infected Patients - (11/05/13)
     
  4751. AASLD: Deep Sequencing of HCV NS5A From a 3-Day Study of GS-5816 Monotherapy Confirms the Potency of GS-5816 Against Pre-Existing Genotype 1-3 NS5A Resistance-Associated Variants - (11/05/13)
     
  4752. AASLD: PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF FALDAPREVIR IN PATIENTS WITH DIFFERENT LEVELS OF RENAL IMPAIRMENT - (11/05/13)
     
  4753. AASLD: Resistance Analysis [and activity] of Genotype-1 and -3 HCV-Infected Patients Receiving MK-8742, an HCV NS5A Inhibitor With Potent Antiviral Activity, in a Ph1b Monotherapy Study - (11/05/13)
     
  4754. AASLD: High Efficacy and Safety of the All-Oral Combination Regimen, MK-5172 / MK-8742 ï RBV for 12 Weeks in HCV Genotype 1 Infected Patients: The C-WORTHY Study - (11/05/13)
     
  4755. AASLD: Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patients With HCV Genotype 2 or 3: the VALENCE Trial - (11/04/13)
     
  4756. AASLD: VX-135, A Once-daily Nucleotide HCV Polymerase Inhibitor, Was Well Tolerated And Demonstrated Potent Antiviral Activity When Given With Ribavirin In Treatment-naïve Patients With Genotype 1 HCV - (11/04/13)
     
  4757. AASLD: GS-5816, a Once-Daily NS5A Inhibitor, Demonstrates Potent Antiviral Activity in Patients With Genotype 1-4 HCV Infection in a 3 Day Monotherapy Study - (11/04/13)
     
  4758. AASLD: Once Daily Sofosbuvir/Ledipasvir Fixed-Dose Combination With or Without Ribavirin: Data From the ELECTRON Trials - (11/04/13)
     
  4759. AASLD: Interferon- and Ribavirin-free Regimen of ABT-450/r + ABT-267 in HCV Genotype 1b-infected Treatment-naïve Patients and Prior Null Responders - (11/04/13)
     
  4760. AASLD: Efficacy and Safety of an Interferon-Free Regimen of MK-5172 + Ribavirin for 12 Weeks or 24 Weeks in Treatment-Naive, Noncirrhotic Subjects With HCV GT1 Infection: The C-SPIRIT Study - (11/04/13)
     
  4761. AASLD: Rapid and Consistent Virologic Responses in a Phase 2 Trial of a New All-Oral Combination of Faldaprevir, Deleobuvir and PPI-668, with and without Ribavirin, in Patients with HCV Genotype-1a Infection - (11/04/13)
     
  4762. AASLD: BMS Submits First All-Oral, Interferon-Free and Ribavirin-Free Treatment Regimen for Regulatory Review in Japan for Patients with Chronic Hepatitis C Infection - (11/02/13)
     
  4763. AASLD: Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Naïve and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients - (11/02/13)
     
  4764. AASLD: Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation - (11/02/13)
     
  4765. AASLD: Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation - (11/02/13)
     
  4766. AASLD: GILEAD ANNOUNCES PHASE 3 RESULTS FOR AN ALL-ORAL, SOFOSBUVIR-BASED REGIMEN FOR THE TREATMENT OF HEPATITIS C IN PATIENTS CO-INFECTED WITH HIV - (11/02/13)
     
  4767. AASLD: Presidio Pharmaceuticals Announces a High Rate of Virologic Response in an Ongoing Phase 2 Hepatitis C Trial of a New All-Oral Combination of Presidio's PPI-668 With Boehringer Ingelheim's Faldaprevir - (11/02/13)
     
  4768. AASLD: Boehringer Ingelheim's interferon-free hepatitis C treatment portfolio strengthened by promising Phase II data - (11/02/13)
     
  4769. AASLD: Phase III data show Boehringer Ingelheim's faldaprevir* was highly effective in a broad range of patients with genotype-1 hepatitis C - (11/02/13)
     
  4770. Idenix Nucleotide/NS5A Update - (10/31/13)
     
  4771. United States to approve potent oral drugs for hepatitis C/Nature article - (10/30/13)
     
  4772. New HIV & HCV Rapid Tests - (10/30/13)
     
  4773. HCV at EACS - (10/30/13)
     
  4774. EACS: Treatment of Chronic Hepatitis C: The Revolution! - (10/29/13)
     
  4775. Vertex Announcements - (10/29/13)
     
  4776. EACS: PI Use, Female Gender, HCV, Detectable Sub-50 Viral load Predict Rebound From Under 50 Copies in Italian Group - Written by Mark Mascolini - (10/28/13)
     
  4777. EACS: Differing Effects of Low- and High-Fat Meals on New Raltegravir Formulation - Written by Mark Mascolini - (10/28/13)
     
  4778. EACS: PI Use, Female Gender, HCV, Detectable Sub-50 Viral load Predict Rebound From Under 50 Copies in Italian Group - Written by Mark Mascolini - (10/28/13)
     
  4779. EACS: One Percent in Stribild and Cobicistat Trials Pick Up HCV--Treatment Response Good - Written by Mark Mascolini - (10/28/13)
     
  4780. European Medicines Agency advises on compassionate use of sofosbuvir - (10/28/13)
     
  4781. FDA panel backs Gilead hepatitis C drug sofosbuvir - (10/28/13)
     
  4782. FDA Advisory Committee Recommends Approval of Simeprevir for Combination Treatment of Genotype 1 Chronic Hepatitis C in Adult Patients - press release - (10/28/13)
     
  4783. FDA panel unanimously approves simeprevir for HCV genotype 1 - (10/28/13)
     
  4784. Merck Receives Breakthrough Therapy Designation for MK-5172/MK-8742, an Investigational Oral Combination Regimen for the Treatment of Chronic Hepatitis C Virus (HCV) Infection - (10/28/13)
     
  4785. Governor Cuomo Signs Bill to Require Hospitals to Offer Hepatitis C Testing - (10/25/13)
     
  4786. the FDA & the Janssen Briefing Documents Oct 24 Hearing - (10/23/13)
     
  4787. Sofosbuvir Briefing Documents/Hearing Oct 25 - (10/23/13)
     
  4788. EACS: 'Acute HCV BUT No HBV Reported' - Reports of Viral Hepatitis B and C in HIV Patients Participating in Clinical Trials of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF and Cobicistat-boosted Atazanavir plus Emtricitabine/Tenofovir DF - (10/21/13)
     
  4789. EACS: Substantial rates of Acute Hepatitis C Reinfection in European HIV-positive Patients - (10/21/13)
     
  4790. EACS: STARTVerso 4 Phase iii trial of faldaprevir once-daily plus peg interferon α -2a and ribavirin (PR) in patients with HiV and HCV genotype-1 co-infection - (10/20/13)
     
  4791. EACS: Simeprevir (TMC435) in combination with peginterferon/ribavirin in patients co-infected with HCV genotype-1 and HIV-1: Primary analysis of the C212 study - (10/20/13)
     
  4792. EACS: Simeprevir with peginterferon/ribavirin in treatment-naïve or experienced patients with chronic HCV genotype 4 infection: Interim results of a Phase III trial - (10/20/13)
     
  4793. EACS: Summary of pharmacokinetic drug-drug interactions for simeprevir (TMC435), a hepatitis C virus Ns3/4A protease inhibitor - (10/20/13)
     
  4794. EACS: Low Bone Mineral Density is Associated with Increased Risk of Incident Fracture in HIV-infected Adults - (10/20/13)
     
  4795. EACS: Bristol-Myers Squibb Launches Initiative to support search for a cure in chronic viral diseases (HIV/HBV/HCV) - (10/16/13)
     
  4796. ID Week: Acute HCV Treatment/HIV+ MSM/HCV Screening/New HCV Therapies: "Determinants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus" - (10/16/13)
     
  4797. ID Week: Polypharmacy in HIV: "Differences in calculated adherence rates of ART and non-ART medications among HIV positive veterans" - (10/16/13)
     
  4798. ID Week: ID Week 2012: Hepatitis C - Report written for NATAP by David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (10/15/13)
     
  4799. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users - (10/13/13)
     
  4800. HCV Economics 101 - (10/13/13)
     
  4801. ID Week: (CDC) Differences in Demographic, Behavioral and Clinical Characteristics between HCV Mono-infected and HCV/HIV Co-infected Adults in Outpatient Primary Care - (10/11/13)
     
  4802. ID Week: Clinicians May Overlook CD4 Percent in HIV+ When Deciding on PCP Prophylaxis - Written by Mark Mascolini - (10/11/13)
     
  4803. ID Week: Barriers to Effective Antenatal Hepatitis C Virus (HCV) Screening - (10/11/13)
     
  4804. ID Week: Effects of aging and antiretroviral therapy on B Cell phenotypes in HIV infected subjects - (10/11/13)
     
  4805. ID Week: (72% of women had Vit D Deficiency) Vitamin D supplementation increases Vitamin D levels but does not improve inflammatory markers in HIV Infected Women; a Chicago Women's Interagency HIV study (WIHS) study - (10/11/13)
     
  4806. HCV Reinfection - (10/11/13)
     
  4807. HCV at IDSA & ICAAC - 23 Reports - (10/11/13)
     
  4808. Increasing Mortality Due to End-Stage Liver Disease in Patients with Human Immunodeficiency Virus Infection - (10/11/13)
     
  4809. IDSA: Hospitalization among Persons with Chronic Hepatitis C Virus Infection in the United States: The Chronic Hepatitis Cohort Study (CHeCS), 2006-2010 - (10/11/13)
     
  4810. IDSA: Mortality among Persons in Care with Hepatitis C Virus Infection-Chronic Hepatitis Cohort Study (CHeCS), 2006 -2010: HCV deaths grossly Underreported mortality rate 12 times higher than the general population, average age of death is 59 for HCV & 74 for general population, a 15 year difference - (10/11/13)
     
  4811. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine - (10/10/13)
     
  4812. Spontaneous Control of Primary Hepatitis C Virus Infection and Immunity Against Persistent Reinfection - (10/10/13)
     
  4813. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users - (10/10/13)
     
  4814. Hepatitis C virus reinfection in injection drug users - (10/10/13)
     
  4815. A Canadian screening program for hepatitis C: Is now the time? - pdf attached - (10/10/13)
     
  4816. Investigational interferon-free regimen demonstrates undetectable hepatitis C virus in all patients reaching end of treatment in ongoing Phase II trial: BI/Presidio Faldaprevir + PPI-668 + Deleobuvir - (10/10/13)
     
  4817. Janssen Acquires Investigational NS5A Inhibitor for the Treatment of Hepatitis C from GlaxoSmithKline - (10/10/13)
     
  4818. HCV superinfection and reinfection - Review - (10/10/13)
     
  4819. IDSA: Sustained Virologic Response With Daclatasvir Plus Sofosbuvir ï Ribavirin (RBV) in Chronic HCV Genotype (GT) 1-Infected Patients Who Previously Failed Telaprevir (TVR) or Boceprevir (BOC) - (10/10/13)
     
  4820. IDSA: Interim Analysis of an Interferon (IFN)- and Ribavirin (RBV)-Free Regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 in Treatment-Naive, Hepatitis C Virus Genotype 1-Infected Patients - (10/10/13)
     
  4821. IDSA: DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 2 OR 3 INFECTION: COMMAND GT 2/3 STUDY - (10/10/13)
     
  4822. IDSA: Causes of Death among People with Hepatitis C in NYC, 2000-2011 - (10/10/13)
     
  4823. IDSA: HIV/Hepatitis C (HCV) Co-infection among Men who have Sex with Men (MSM) in New York City (NYC), 2000-2010 - (10/10/13)
     
  4824. IDSA: Colorectal Cancer Screening 20% Less Likely With HIV in Large Medicaid Population - (10/10/13)
     
  4825. IDSA: Lack of HCV Genetic Diversity Tied to Higher Liver Disease Risk in Women With HIV - (10/07/13)
     
  4826. IDSA: High Referral of HCV Patients to Specialists But Low Treatment Initiation Rate - Barriers to Care & Treatment - (10/07/13)
     
  4827. IDSA: CDC Figures Annual US Mortality in People With HCV Could Top 80,000: HCV Mortality Under-reported, Mortality Rate 12 Times Higher than General Population, HCV+ Die 15 Years Younger than General Population - (10/07/13)
     
  4828. IDSA: Sofosbuvir and Peginterferon Alfa-2a/Ribavirin for Treatment-Naïve Genotype 1-4 HCV-Infected Patients Who Are Coinfected With HIV - (10/07/13)
     
  4829. IDSA: Optimization of an Interferon-free Hepatitis C Virus Therapy Regimen Containing the HCV NS3/4A Protease Inhibitor Faldaprevir, the Non-nucleoside NS5B Inhibitor Deleobuvir, and Ribavirin for Genotype-1b-infected Patients - (10/07/13)
     
  4830. IDSA: Barriers to Hepatitis C Treatment in an HIV-HCV Co- Infected Cohort - (10/07/13)
     
  4831. IDSA: Telaprevir-based triple therapy for elderly patients with genotype 1 chronic hepatitis C - (10/07/13)
     
  4832. IDSA: Does Knowledge Influence Reporting Practices when Screening for Hepatitis C in Pregnant Women? - (10/07/13)
     
  4833. ICAAC: Tumor Characteristics and Survival in HIV-Infected Patients with Hepatocellular Carcinoma: the Impact of Surveillance - (10/02/13)
     
  4834. Bristol-Myers Squibb to Present Range of New Hepatitis C Data at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting - (10/02/13)
     
  4835. Pivotal Phase 3 Data from Boehringer Ingelheim Hepatitis C Portfolio to be Presented at 64th Annual AASLD Meeting - (10/02/13)
     
  4836. Data from Merck's Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study of Liver Diseases Annual Meeting - (10/02/13)
     
  4837. Idenix Pharmaceuticals Announces Nucleotide Prodrug Program Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting - (10/02/13)
     
  4838. Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) - (10/02/13)
     
  4839. Achillion News- Provides Pipeline Update - (09/30/13)
     
  4840. Achillion News - FDA PI hold continues, future plans: Achillion's other protease ACH-2684 and their NS5A ACH3102 - (09/30/13)
     
  4841. Simeprevir has been approved in Japan for the treatment of genotype 1 chronic hepatitis C infection - (09/30/13)
     
  4842. China Non-governmental groups launch program against hepatitis - (09/30/13)
     
  4843. ICAAC: Acute C hepatitis in Japanese HIV-infected patients in this decade - (09/31/13)
     
  4844. Roche/Genentech HCV Survey in Miami, Washington DC & Philadelphia Reports Data on Stigma, Lack of Awareness, Not Being Tested or Spoken to a Doctor About HCV - (09/24/13)
     
  4845. (MACS Study) Incident Hepatitis C Virus Infection in Men Who Have Sex With Men: A Prospective Cohort Analysis, 1984-2011 'HIV-infection (6-fold), unprotected receptive anal intercourse (3-fold) increase risk for HCV acquisition, low CD4, syphils' - (09/20/13)
     
  4846. ICAAC: CLINICAL CHARACTERIZATION OF HIV/HCV CO-INFECTED PATIENTS TREATED WITH DIRECT ACTING ANTIVIRAL AGENTS - (09/18/13)
     
  4847. ICAAC: Worse Response to PegIFN/RBV for HCV After Transplant in HIV/HCV+ vs HCV+ - Written by Mark Mascolini - (09/18/13)
     
  4848. ICAAC: HIV Does Not Affect Chance of HCV Genotype 2 or 3 Responding to PegIFN/RBV - Written by Mark Mascolini - (09/17/13)
     
  4849. ICAAC: Faster Bone Turnover With Atripla Than With Dolutegravir/ABC/3TC in 48 Weeks - Written by Mark Mascolini - (09/16/13)
     
  4850. ICAAC: SVR Tied to Lower Progression, Mortality in HIV/HCV+ With Moderate Fibrosis - the importance of treating coinfected patients - Written by Mark Mascolini - (09/16/13)
     
  4851. ICAAC: Lack of Clinically Relevant Drug Interactions Between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Telaprevir - (09/12/13)
     
  4852. ICAAC: Hepatitis C Eradication Reduces Liver Decompensation, HIV progression, and Death in HIV/HCV-coinfected Patients with non-Advanced Liver Fibrosis - (09/12/13)
     
  4853. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial - (09/11/13)
     
  4854. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial - (09/11/13)
     
  4855. Boehringer Ingelheim HCV Drug Development Program - (09/11/13)
     
  4856. Boehringer Ingelheim broadens efforts for interferon-free hepatitis C treatments through clinical collaboration with Presidio Pharmaceuticals - (09/11/13)
     
  4857. Abbvie HCV Drug Development Program - (09/04/13)
     
  4858. BMS HCV Drug Development Program, Collaborations for IFN-free All Oral HCV Regimens: Daclatasvir+TMC435, Daclatasvir+VX-135 - (09/04/13)
     
  4859. FDA/HCV-TARGET Collaborate - (09/04/13)
     
  4860. Abbvie (formerly Abbott) HCV Drug Program - (09/03/13)
     
  4861. Boehringer Ingelheim completes patient enrolment of two pivotal Phase III interferon-free hepatitis C clinical trials - (08/29/13)
     
  4862. Interim results from Cohort 2 of the COSMOS study evaluating Simeprevir and Sofosbuvir in HCV patients with METAVIR scores F3-F4 - (08/29/13)
     
  4863. Boehringer Ingelheim completes patient enrolment of two pivotal Phase III interferon-free hepatitis C clinical trials - (08/28/13)
     
  4864. Ribavirin Dose Reduction: 3 Reports; Boceprevir; Abbvie All-Oral IFN-free Regimen; Telaprevir - (08/28/13)
     
  4865. Telaprevir Activity in Treatment-Naive Patients Infected Hepatitis C Virus Genotype 4: A Randomized Trial - (08/28/13)
     
  4866. Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft - (08/28/13)
     
  4867. African-Americans & HIV Study Participation - (08/28/13)
     
  4868. Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics: A Randomized Clinical Trial - (08/28/13)
     
  4869. Gilead HCV Program, GS-7977 - (08/19/13)
     
  4870. Faldaprevir and Deleobuvir for HCV Genotype 1 Infection - (08/19/13)
     
  4871. Janssen HCV Drug Research & Development 2 - (08/19/13)
     
  4872. TMC435, Janssen HCV Program - (08/19/13)
     
  4873. Boehringer Ingelheim HCV R&D Mono and HIV Coinfection: Faldaprevir, Non-nuc Deleobuvir (BI127) - Mono- and HCV/HIV Coinfection, NS5A PPI-668 - (08/16/13)
     
  4874. Medivir Makes Strategic Decision to Focus Proprietary Hepatitis C R&D Efforts Exclusively on Nucleotide-Based Polymerase Inhibitors - (08/16/13)
     
  4875. SVR Improved Neurocognitive Function After SVR - (08/16/13)
     
  4876. Risk of QTc prolongation in a cohort of opioid-dependent HIV-infected patients on methadone maintenance therapy - (08/16/13)
     
  4877. Heroin Makes a Comeback - (08/14/13)
     
  4878. HCV SVR Improved Neurocognitive Function After SVR - (08/14/13)
     
  4879. To date 25% received HCV therapy in EuroSIDA - Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA - (08/09/13)
     
  4880. Hepatitis C in men who have sex with men in London - a community survey - (08/09/13)
     
  4881. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2013 Financial Results - (08/09/13)
     
  4882. Achillion HCV Update Achillion Reports Second Quarter and Six Month 2013 Financial Results - (08/09/13)
     
  4883. New HCC Risk Score System Hepatitis C: New points system helps with disease prognosis - (08/05/13)
     
  4884. Janssen HCV Drug Research & Development - (07/30/13)
     
  4885. Philadelphia Celebrates World Hepatitis Day, Hepatitis C Allies of Philadelphia HEPCAP - (07/30/13)
     
  4886. World Hepatitis Day July 26 2013: Globally....... governments fail to tackle viral hepatitis - (07/30/13)
     
  4887. Variations at multiple genes improve interleukin 28b genotype predictive capacity for response to therapy against hepatitis c genotype 1 or 4 infection - (07/30/13)
     
  4888. Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral - (07/30/13)
     
  4889. GSK receives positive CHMP opinion for REVOLADETM in thrombocytopenia associated with chronic hepatitis C infection - (07/30/13)
     
  4890. IDSA + AASLD - Leading Liver and ID Experts to Develop Hepatitis C Practice Recommendations - (07/30/13)
     
  4891. Liver Cancer deaths Double Over last 20 Years & Deaths Due to Cirrhosis Increased 43% - (07/30/13)
     
  4892. Hepatitis C on the rise among boomers in Broward, Palm Denial, fear and ignorance keeps boomers from getting hep C tests - (07/29/13)
     
  4893. Prevention and Management of Hepatitis C Virus Infection Among People Who Inject Drugs: Moving the Agenda Forward - (07/26/13)
     
  4894. IAS: Hepatitis C Re-infection Among HIV+ MSM in London & Prisoners in Spain - (07/24/13)
     
  4895. U.S. Congress Moves Closer to Lifting Ban on Transplanting Organs From HIV-Positive Donors - (07/22/13)
     
  4896. IAS: Telaprevir Regimen for HIV/HCV Patients With PegIFN/RBV Failure and Cirrhosis - written by Mark - (07/20/13)
     
  4897. Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV: A Randomized Trial - (07/18/13)
     
  4898. Report from a Viral Hepatitis Policy Forum on Implementing the WHO Framework for Global Action on Viral Hepatitis in North Asia - (07/16/13)
     
  4899. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C - (07/16/13)
     
  4900. Achillion Provides Update on Sovaprevir Development Program - FDA Clinical Hold - (07/10/13)
     
  4901. IAS: Access to HCV triple therapy with telaprevir or boceprevir in real-life setting in HIV-HCV co-infected patients - ANRS CO13 Hepavih Cohort (France) - (07/09/13)
     
  4902. IAS: SAFETY OF RIBAVIRIN-CONTAINING REGIMENS OF ABT-450/r, ABT-333, AND ABT-267 FOR THE TREATMENT OF HCV GENOTYPE 1 INFECTION AND EFFICACY IN SUBJECTS WITH RIBAVIRIN DOSE REDUCTIONS - (07/03/13)
     
  4903. Preclinical and In Vitro Resistance Profile of Potent Nucleotide Polymerase Inhibitors of HCV: ALS-2200 and its Single Diastereomer, VX-135 - (06/28/13)
     
  4904. A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment - (06/27/13)
     
  4905. APASL: Vaniprevir (MK-7009) in Treatment-Experienced Genotype (GT) 1 HCV-Infected Patients Demonstrates Time-Dependent Pharmacokinetics (PK) - (06/27/13)
     
  4906. APASL: SVR Reduces HCC, decompensated cirrhosis, transplant, death by 50% & more: Projected Long-Term Impact of Vaniprevir (MK-7009) for Previously Treated Chronic HCV Genotype 1 Infection - (06/27/13)
     
  4907. APASL: Hepatitis C Virus Infection in Western Region of China - (06/27/13)
     
  4908. Cost-Effectiveness Analysis of Direct-Acting Antiviral Therapy for Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Infection in the Veterans Health Administration - (06/26/13)
     
  4909. NY State Senate Passes HCV Screening Bill for "Baby Boomers" - NY Baby Boomers Could Avoid Serious Disease With New Hep C Test Requirement - (06/25/13)
     
  4910. USPSTF Recommends Screening Baby Boomers for HCV with a "B", Upgraded from the "C" in the Draft Recommendations from November 2012 - (06/25/13)
     
  4911. (USPSTF) Expanded Hepatitis C Virus Screening Recommendations Promote Opportunities for Care and Cure - Editorial - (06/25/13)
     
  4912. FDA approves first genotyping test for patients with hepatitis C virus - (06/25/13)
     
  4913. Cost-Effectiveness Analysis of Direct-Acting Antiviral Therapy for Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Infection in the Veterans Health Administration - (06/25/13)
     
  4914. Presentation, Outcomes, and Response to Therapy Among Patients with Acute Exacerbation of Chronic Hepatitis C - spikes in ALTs in chronic infection - (06/25/13)
     
  4915. APASL: ELECTRON: All-Oral Sofosbuvir-Based 12-Week Regimens for the Treatment of Chronic HCV GT 1 Infection - (06/25/13)
     
  4916. APASL: Treatment with Sofosbuvir+Ribavirin for 12 Weeks Achieves SVR12 of 78% in GT2/3 Interferon-Ineligible, -Intolerant, or -Unwilling Patients: The POSITRON Trial - (06/25/13)
     
  4917. APASL: All-Oral Therapy With Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment-Experienced Genotype 2/3 HCV-Infected Patients: Results of the Phase 3 FUSION Trial - (06/25/13)
     
  4918. APASL: Interim analysis of An INTERFERON (IFN)- AND RIBAVIRIN (RBV)-FREE REGIMEN of DACLATASVIR (DCV), ASUNAPREVIR (ASV), AND BMS-791325 IN TREATMENT-NAIVE, HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS - (06/25/13)
     
  4919. APASL: Sustained Virologic Response With Daclatasvir Plus Sofosbuvir ï Ribavirin (RBV) in Chronic HCV Genotype (GT) 1-Infected Patients Who Previously Failed Telaprevir (TVR) or Boceprevir (BOC) - (06/25/13)
     
  4920. APASL: ALS-2200, A Novel Once-daily Nucleotide HCV Polymerase Inhibitor, Demonstrated Potent Antiviral Activity In Treatment-naïve Patients with Compensated Cirrhosis or Genotype 2-4 Chronic Hepatitis C - (06/23/13)
     
  4921. APASL: VX-135 FOR THE TREATMENT OF CHRONIC HEPATITIS - In Vitro Safety/Potency/Mechanism - (06/23/13)
     
  4922. HCV & HBV Therapy Reverses Fibrosis & Cirrhosis, several studies in HCV monoinfection, HCV/HIV coinfection & in HBV - (06/23/13)
     
  4923. HCV Care in VA Debated - (06/24/13)
     
  4924. Primary Efficacy and Safety Findings from Four Phase 3 Japanese Studies of Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Adult Patients - (06/24/13)
     
  4925. Lou Reed Gets Liver Transplant - (06/24/13)
     
  4926. Idenix sees delay in human trials for hep C drug as FDA seeks more data - (06/24/13)
     
  4927. Emerging Therapeutic Targets for Hepatitis C Virus Infection - (06/24/13)
     
  4928. APASL: Boehringer Ingelheim's investigational all-oral interferon-free combination achieved 95% viral cure rates in genotype-1b hepatitis C patients - press release, link to presentation - (06/23/13)
     
  4929. APASL: Boehringer Ingelheim's investigational faldaprevir+ achieved viral cure in 88% of treatment-naïve hepatitis C patients in Asia - press release, link to presentation - (06/23/13)
     
  4930. APASL: Up to 91% SVR rates with ritonavir-boosted danoprevir (DNVr) plus PegIFN alfa-2a (40KD)/ribavirin (P/R) in HCV genotype (G)1b-infected prior partial/null responders - (06/20/13)
     
  4931. APASL: Low rate of danoprevir resistance with ritonavir-boosted danoprevir (DNVr) plus PegIFN alfa-2a/ribavirin (P/R) in HCV G1b-infected treatment-naive and treatment-experienced patients - (06/20/13)
     
  4932. APASL: High Rate of Sustained Virologic Response With the All-Oral Combination of Daclatasvir (NS5A Inhibitor) Plus Sofosbuvir (Nucleotide NS5B Inhibitor), With or Without Ribavirin, in Treatment-Naive Patients Chronically Infected With HCV GT 1, 2, or 3 (updated SVR12 reported, previously at AASLD/2012 SVR4 was reported for 12-week regimen) - (06/20/13)
     
  4933. New HCV Treatments and Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial - (06/17/13)
     
  4934. HCV reinfection incidence and treatment outcome among HIV-positive MSM in London - (06/17/13)
     
  4935. APASL: Reasons for Treatment Discontinuation Among Hepatitis C Patients Treated in Clinical Practice - (06/17/13)
     
  4936. APASL: N-CORE: sustained virological response rates with peginterferon alfa-2a/ribavirin (PegIFN alfa 2a/RBV) in HCV G2 or 3 patients without rapid virological response - (06/17/13)
     
  4937. APASL: Baseline viral load thresholds predicting virological response to peginterferon alfa-2a/ribavirin in HCV G2 and G3 patients: PROPHESYS cohort sub-analysis - (06/17/13)
     
  4938. APASL: Interim analysis of An INTERFERON (IFN)- AND RIBAVIRIN (RBV)-FREE REGIMEN of DACLATASVIR (DCV), ASUNAPREVIR (ASV), AND BMS-791325 IN TREATMENT-NAIVE, HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS - (06/14/13)
     
  4939. APASL: Sustained Virologic Response in Chronic HCV Genotype (GT) 1-Infected Null Responders With Combination of Daclatasvir (DCV; NS5A Inhibitor) and Asunaprevir (ASV; NS3 Inhibitor[protease]) With or Without Peginterferon Alfa-2a/Ribavirin (PEG/RBV)....and triple all-oral Daclatasvir+Asunaprevir+Rbv (gt1a/1b) - (06/14/13)
     
  4940. APASL: Peginterferon Lambda-1a (Lambda) is Associated With Less Autoimmune Thyroid Disease and Serious Autoimmune Disease Than Peginterferon Alfa-2a (Alfa) When Used in Combination With Ribavirin (RBV) for the Treatment of Chronic Hepatitis C Virus Infection - (06/14/13)
     
  4941. APASL: Robust and Persistent Replication of Genotype 6a Hepatitis C Virus Replicon in Cell Culture - (06/12/13)
     
  4942. ResisWksp: Subtyping Analysis of Hepatitis C Virus Using the INNO-LiPA assay and NS5B Sequencing (06/12/13)
     
  4943. Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease - (06/11/13)
     
  4944. BioLineRx Enters into Collaboration to Develop and Commercialize Hepatitis C Drug with CTTQ, Leading Chinese Pharma Company for Liver Disease Therapeutics - (06/11/13)
     
  4945. HCV NY State Screening Bill would provide Hep-C testing for more NY'ers - (06/11/13)
     
  4946. APASL: INTERFERON-FREE TREATMENT WITH FALDAPREVIR, DELEOBUVIR (BI 207127) AND RIBAVIRIN IN SOUND-C3: 95% SVR12 IN HCV-GT1B - (06/10/13)
     
  4947. APASL: HCV in China....Extrahepatic Diseases HCV R.E.V.E.A.L. Study in Taiwan - (06/10/13)
     
  4948. APASL: No Ethnic Differences in the Pharmacokinetics of Sofosbuvir or Sofosbuvir/Ledipasvir Fixed Dose Combination in Japanese and Caucasian Subjects - (06/10/13)
     
  4949. ResisWksp: Evolution of the HCV Viral Population from the One Patient with S282T Detected at Relapse after Sofosbuvir Monotherapy (06/09/13)
     
  4950. ResisWksp: In Vitro Efficacy and Resistance Profiling of Protease Inhibitors Against a Novel HCV Genotype 3a Replicon (06/09/13)
     
  4951. APASL: Hepatitis C Disease Awareness and Access to Care in India: a Multicenter, National Survey - (06/09/13)
     
  4952. APASL: High SVR24 rates with ritonavir-boosted danoprevir (DNVr) plus PegIFN alfa-2a/ribavirin (P/R) in HCV genotype (G)1/4-infected treatment-naive patients: the DAUPHINE study - (06/09/13)
     
  4953. APASL: FALDAPREVIR PLUS PEGYLATED-INTERFERON AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAïVE PATIENTS: SUBANALYSIS OF PATIENTS FROM JAPAN, TAIWAN AND SOUTH KOREA - (06/09/13)
     
  4954. APASL: Ritonavir boosting of the HCV protease inhibitor danoprevir (DNVr) significantly reduces reactive metabolite formation in vitro and in vivo - (06/09/13)
     
  4955. APASL: A 12-Week Trial of Interferon-free Regimens Containing ABT-450/r and ABT-267 ï Ribavirin (RBV) in Treatment-naïve Patients With HCV Genotypes 1-3 - (06/09/13)
     
  4956. APASL: INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/- RIBAVIRIN ACHIEVE HIGH SVR12 AND SVR24 RATES IN PATIENTS WITH CHRONIC HCV GENOTYPE 1b - (06/07/13)
     
  4957. Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir for the Treatment of Hepatitis C - (06/07/13)
     
  4958. In Mouse Models, New Agent Inhibits HCV Replication - (06/05/13)
     
  4959. Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis C - (06/04/13)
     
  4960. Fibroscan Performance/FDA Approved - (06/04/13)
     
  4961. Fibroscan (ultra-sound hepatic elastography) Review - (06/04/13)
     
  4962. Noninvasive Assessment of Liver Fibrosis and Portal Hypertension With Transient Elastography - (06/04/13)
     
  4963. Idenix Pharmaceuticals Announces Initiation of Phase II All-Oral Combination Study of Samatasvir (IDX719) and Simeprevir (TMC435) for the Treatment of Hepatitis C Virus (HCV) Infection - (06/02/13)
     
  4964. Medivir: An all-oral combination phase II study of Simeprevir and Samatasvir (IDX719) for the treatment of hepatitis C virus infection initiated - (06/02/13)
     
  4965. INCIVO® (TELAPREVIR) RECEIVES EUROPEAN COMMISSION APPROVAL FOR TWICE DAILY DOSING FOR TREATMENT OF GENOTYPE-1 CHRONIC HEPATITIS C VIRUS (HCV) - (06/02/13)
     
  4966. Global drug policy fuels hepatitis C epidemic, report warns - (06/02/13)
     
  4967. ClinPharm: Clinical Pharmacology Workshop in HIV (and HCV) Presentations on New DAAs (oral HCV drugs in phase 3 development now) by Boehringer Ingelheim, Gilead & BMS, by Janssen for telaprevir - (05/31/13)
     
  4968. EASL: Simtuzumab, an Antifibrotic Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2) Enzyme, Is Safe and Well Tolerated in Patients With Liver Disease - (05/30/13)
     
  4969. War on drugs 'driving hepatitis C pandemic' - (05/30/13)
     
  4970. Achillion Nominates ACH-3422 as Nucleotide for the Treatment of Chronic HCV - (05/30/13)
     
  4971. The Hidden Global Hepatitis C Epidemic - New Report - Access Needed - (05/30/13)
     
  4972. Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in HCV mono-infected and HCV/HIV co-infected adults - (05/29/13)
     
  4973. A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C-Associated Liver Cirrhosis - (05/29/13)
     
  4974. Sustained Virologic Response for Patients With Hepatitis C-Related Cirrhosis: A Major Milestone, but Not Quite a Cure - Commentary - (05/29/13)
     
  4975. European Medicines Agency Validates Gilead's Marketing Application for Sofosbuvir for the Treatment of Hepatitis C - (05/29/13)
     
  4976. As Hepatitis C Spreads, Scotland Steps In: HCV Action Plan by Scotland - (05/22/13)
     
  4977. Twice Daily Telaprevir in Combination With Peginterferon Alfa-2a/Ribavirin in HCV Genotype 1 Liver Transplant Recipients: Interim Pharmacokinetics of the REFRESH Study - (05/22/13)
     
  4978. European Medicines Agency Validates Gilead's Marketing Application for Sofosbuvir for the Treatment of Hepatitis C - (05/22/13)
     
  4979. Twice-Daily Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV Genotype 1 Liver Transplant Recipients: Interim Safety/Efficacy of the REFRESH Study - (05/22/13)
     
  4980. FDA Approves FibroScan® for Non-invasive Liver Diagnosis - (05/22/13)
     
  4981. DDW: Simeprevir with Peginterferon/ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients Who Relapsed After Previous Interferon-based Therapy: Results from PROMISE, a Phase III Trial - (05/22/13)
     
  4982. DDW: Response to 3 DAAs + RBV by Patient Characteristics: INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333, AND RIBAVIRIN ACHIEVE HIGH SUSTAINED VIROLOGIC RESPONSE 12 WEEKS POST-TREATMENT (SVR12) RATES IN PATIENTS WITH CHRONIC HCV GENOTYPE 1 REGARDLESS OF RACE, ETHNICITY, OR OTHER BASELINE CHARACTERISTICS - (05/21/13)
     
  4983. DDW: Key Drivers and Barriers to Treatment Initiation and Adherence in Individuals with Hepatitis C - (05/21/13)
     
  4984. DDW: Prevalence, Treatment, and Comorbidities of Hepatitis C Infection (HCV) Among Patients With Commercial and Medicaid Insurance - (05/21/13)
     
  4985. DDW: Final Results PROVIDE Study: Boceprevir in null-responders   - (05/21/13)
     
  4986. DDW: An Analysis of Response Rates by Fibrosis Stage in Patients Treated With Faldaprevir, BI 207127, and Ribavirin in the SOUND-C2 Study - (05/20/13)
     
  4987. EASL: An analysis of response rates by fibrosis stage in patients treated with faldaprevir, BI 207127 and ribavirin in the SOUND-C2 study - (05/19/13)
     
  4988. EASL: The relationship between sustained virological response and plasma concentrations of faldaprevir or BI 207127 in HCV GT-1-infected patients in SOUND-C2 - (05/19/13)
     
  4989. EASL: ITPA gene variants predict haemolytic ribavirin-induced anaemia in patients treated with the interferon-free regimen of faldaprevir, BI 207127 and ribavirin in SOUND-C2 - (05/19/13)
     
  4990. EASL: A MULTICENTER STUDY OF PROTEASE INHIBITOR-TRIPLE THERAPY IN HCV-INFECTED LIVER TRANSPLANT RECIPIENTS: REPORT FROM THE CRUSH-C GROUP - (05/18/13)
     
  4991. EASL: Predictors of Mortality among United States Veterans with Hepatitis C Virus Infection: 'almost double mortality rate in HCV+ vs HCV- HCV treatment reduced mortality by 50%' - (05/18/13)
     
  4992. EASL: HCV-TARGET: A Longitudinal, Observational Study of North American Patients with Chronic Hepatitis C Treated with Boceprevir or Telaprevir - (05/18/13)
     
  4993. Help on Wheels for Philly's Public Health 'Time Bomb,' Hepatitis C, HIV too - (05/16/13)
     
  4994. Hepatitis C in the United States Perspective (screening/care) - (05/16/13)
     
  4995. Current and Future Therapies for Hepatitis C Virus Infection, from NIH - (05/16/13)
     
  4996. EASL: Summary from EASL 2013 for Hepatitis C - New HCV DAAs on their way soon: what do the phase III studies tell us? - written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (05/16/13)
     
  4997. EASL: NS5A BMS052 + nuc GS-7977 100% or 95% SVR for Patients Who Did Not Achieve SVR with Boceprevir/Telaprevir Triple Therapy, Resistance & Gt3 - (05/15/13)
     
  4998. Gilead-Bristol Hepatitis C Drug Combo Cures All in Study: GS7977+BMS052 in naives & boceprevir/telaprevir experienced - (05/13/13)
     
  4999. Hepatitis C Virus Seromarkers (viral load) and Subsequent Risk of Hepatocellular Carcinoma: Long-Term Predictors From a Community-Based Cohort Study - (05/13/13)
     
  5000. New antiviral treatment could significantly reduce global burden of hepatitis C - New Study - (05/13/13)
     
  5001. AbbVie's Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration - PRESS RELEASE - (05/13/13)
     
  5002. Half of Hepatitis C patients face major health risks because of incomplete testing, CDC Report - (05/13/13)
     
  5003. Health care costs associated with hepatocellular carcinoma: A population-based study - (05/13/13)
     
  5004. HCV & Immigrants - (05/13/13)
     
  5005. 'HCV Test & Treat': Routine HCV Screening for All, Rapid HCV Test in Clinic. Baby Boomers, High Risk Populations. - (05/13/13)
     
  5006. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C - (05/13/13)
     
  5007. EASL: NS5A BMS052 + nuc GS-7977 100% or 95% SVR for Patients Who Did Not Achieve SVR with Boceprevir/Telaprevir Triple Therapy, Resistance & Gt3 - (05/11/13)
     
  5008. EASL: Hepatitis C Treatment Outcomes and Predictors of Response in Treatment-naive Patients Treated with Peginterferon Alfa/Ribavirin in Real-world Italian Clinics Compared with Other Countries: PROPHESYS Sub-analysis - (05/11/13)
     
  5009. EASL: 48 Weeks of Peginterferon Alfa-2a/Ribavirin Improves SVR24 and Decreases Relapse across HCV Genotype 2/3 Patient Subgroups Not Achieving a Rapid Virological Response: N-CORE Study - (05/11/13)
     
  5010. EASL: Correlation of IL28B Polymorphism with Degree of Fibrosis: Analysis of Treatment-naïve and Treatment-experienced Caucasian Patients Infected with HCV Genotype 1 in the Gen-C Study - (05/11/13)
     
  5011. EASL: High Concordance of SVR4, SVR12, and SVR24 in Patients With HCV Infection Who Have Received Treatment With Sofosbuvir - (05/11/13)
     
  5012. EASL: FOLLOW-UP AFTER CESSATION OF THERAPY WITH THE DIRECT ACTING ANTIVIRALS IN CHRONIC HEPATITIS C PATIENTS - WHO IS AT THE RISK OF LATE RELAPSE? - (05/11/13)
     
  5013. EASL: IMPACT OF HIGHLY EFFECTIVE ANTIVIRAL THERAPY ON THE BURDEN OF HEPATOCELLULAR CARCINOMA IN HEPATITIS C CIRRHOSIS - (05/11/13)
     
  5014. EASL: A Clinical Trial Evaluating Low HCV RNA Viremia in Patients Treated with Triple Therapy Including Telaprevir: Implications for Management Using Different Assays in Clinical Practice - (05/11/13)
     
  5015. EASL: BL-8030: A Novel, Potent, Selective, Orally Available Inhibitor of Hepatitis C Virus NS3/4A Protease - (05/11/13)
     
  5016. EASL: BioLineRx Enrolls First Patient in Phase I/II Clinical Trial for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C - press release - (05/11/13)
     
  5017. EASL: New HCV Drugs - EASL & Beyond - (05/11/13)
     
  5018. EASL: No Clinically Significant Pharmacokinetic Interaction Between Sovaprevir and ACH-3102 in Healthy Volunteers - (05/09/13)
     
  5019. EASL: ACH-3102, A Second Generation NS5A Inhibitor, Demonstrates Potent Antiviral Activity in Patients with Genotype 1A HCV Infection Despite the Presence of Baseline NS5A-Resistant Variants - (05/09/13)
     
  5020. EASL: FINDINGS FROM CLINICAL VIROLOGY STUDIES ON ACH-3102 ARE CONSISTENT WITH PRECLINICAL OBSERVATIONS ON ITS IMPROVED POTENCY AGAINST GENOTYPE-1A HCV AND RESISTANT VARIANTS - (05/09/13)
     
  5021. EASL: No Clinically Significant Pharmacokinetic Interaction Between Sovaprevir and ACH-3102 in Healthy Volunteers - (05/09/13)
     
  5022. EASL: Findings from Clinical Virology Studies on Sovaprevir, a Phase 2 HCV NS3 Protease Inhibitor, Indicate a High Pharmacological Barrier to Viral Resistance - (05/09/13)
     
  5023. EASL: Viral Kinetics Modeling to Predict cEVR and Aid in Dose Selection Decisions for Phase-2/3 Clinical Trials: ACH3102+ Sovaprevir, ACH2684 - (05/09/13)
     
  5024. EASL: ACH-2684 Demonstrates Potent Viral Suppression in Genotype 1 Hepatitis C Patients With and Without Cirrhosis: Safety, Pharmacokinetic, and Viral Kinetic Analysis - (05/09/13)
     
  5025. EASL: ACH-2684: HCV NS3 PROTEASE INHIBITOR WITH POTENT ACTIVITY AGAINST MULTIPLE GENOTYPES AND KNOWN RESISTANT VARIANTS - (05/09/13)
     
  5026. EASL: Efficacy and Safety of Peginterferon Alfa-2a (40KD) in HBeAg-Positive Chronic Hepatitis B PatientsParticipating in a Response-Guided Therapy Study: An Interim Analysis at Week 72 - (05/09/13)
     
  5027. EASL: S-collate cohort 'real-life' study: efficacy and safety of peginterferon alfa-2a (40KD) in 1233 patients with chronic hepatitis B according to Asian and Caucasian race - (05/09/13)
     
  5028. EASL: Direct and indirect cost burden is higher in HCV infection compared with a matched non-HCV infected cohort in a privately-insured population - (05/07/13)
     
  5029. EASL: Patient characteristics and utilization of protease inhibitors in hepatitis C virus (HCV) patients in a large payer database - (05/07/13)
     
  5030. EASL: Relationship Between Transaminase Levels and Plasma Pharmacokinetics Following Administration of MK-5172 With Pegylated Interferon Alfa-2b and Ribavirin to HCV Genotype 1 Treatment-Naïve Patients - (05/07/13)
     
  5031. EASL: Pharmacokinetics of simeprevir (TMC435) in volunteers with moderate or severe hepatic impairment - (05/07/13)
     
  5032. EASL: Sofosbuvir Safety and Tolerability in 778 Patients Treated for Up to 24 Weeks in Four Phase 2 Studies - (05/07/13)
     
  5033. EASL: Clinical Impact of Viral Load on the Development of Hepatocellular Carcinoma and Liver-related Mortality in Patients with Chronic Hepatitis C Virus Infection - (05/07/13)
     
  5034. EASL: Efficacy of Telaprevir Dosed Twice Daily versus Every 8 Hours by IL28B Genotype: Results from the Phase III OPTIMIZE Study - (05/07/13)
     
  5035. EASL: High SVR Rates (SVR4) for 12-Week Total Telaprevir Combination Therapy in IL28B CC Treatment-Naïves and Prior Relapsers With G1 Chronic Hepatitis C: CONCISE Interim Analysis - (05/07/13)
     
  5036. EASL: Treatment with Telaprevir-based Therapy after Exposure to Peg-IFN/RBV in the REALIZE Study: Results from the Phase IIIb C219 Rollover Study - (05/07/13)
     
  5037. EASL: Treatment with Telaprevir/Peg-IFN/RBV After 14-day Telaprevir Exposure in Phase I Studies: Results from the Phase IIIB C219 Rollover Study - (05/07/13)
     
  5038. EASL: Telaprevir - Health-related Quality of Life Among Genotype 1 Treatment Experienced Chronic Hepatitis C Patients: Post-hoc Analyses of Data From the Realize Clinical Trial - (05/06/13)
     
  5039. EASL: Sustained Viral Response and Safety of Vaniprevir (MK-7009) in Cirrhotic, Treatment-Experienced Patients with Genotype 1 HCV Infection Who Have Failed Previous Pegylated Interferon and Ribavirin - (05/06/13)
     
  5040. EASL: VIROLOGIC RESPONSE RATES ARE SIMILAR IN PREVIOUSLY UNTREATED AND PREVIOUSLY TREATED AND RELAPSED PATIENTS RECEIVING BOCEPREVIR TRIPLE THERAPY: A RETROSPECTIVE ANALYSIS - (05/06/13)
     
  5041. EASL: PHARMACOKINETIC INTERACTIONS BETWEEN THE HCV PROTEASE INHIBITOR BOCEPREVIR AND SIROLIMUS IN HEALTHY SUBJECTS - (05/06/13)
     
  5042. EASL: Resistance Analysis of Cirrhotic Treatment-Experienced Genotype 1 Patients in a Study of MK-7009 in Combination With Pegylated Interferon/Ribavirin - (05/06/13)
     
  5043. EASL: Sustained Viral Response and Safety of Vaniprevir (MK-7009) in Cirrhotic, Treatment-Experienced Patients with Genotype 1 HCV Infection Who Have Failed Previous Pegylated Interferon and Ribavirin - (05/06/13)
     
  5044. EASL: Clinical Impact of Viral Load on the Development of Hepatocellular Carcinoma and Liver-related Mortality in Patients with Chronic Hepatitis C Virus Infection - (05/03/13)
     
  5045. EASL: End Of Treatment Response After Protease Inhibitor-based Therapy For Hepatitis C Recurrence After Liver Transplantation: A Multicentric European Experience - (05/03/13)
     
  5046. EASL: Adherence with Telaprevir bid versus Every 8 Hour Dosing in Treatment-naïve HCV-infected Patients: Results from the Phase III OPTIMIZE Study - (05/03/13)
     
  5047. EASL: Safety and Efficacy of Twice Daily versus Every 8 Hour Telaprevir with Peginterferon/Ribavirin in Patients with Cirrhosis - (05/03/13)
     
  5048. EASL: Anemia and its Management in Patients Treated with Telaprevir Twice-daily versus Every 8 Hours in the Phase III OPTIMIZE Study - (05/03/13)
     
  5049. EASL: Safety & Efficacy of Boceprevir/PegInterferon/Ribavirin (BOC/P/R) Combination Therapy for Chronic HCV G1 Patients with Compensated Cirrhosis: A Meta-Analysis of Five Phase 3 Clinical Trials - (05/03/13)
     
  5050. EASL: New Oral HCV Drugs at EASL - Report 7A - (05/03/13)
     
  5051. Gilead Reports Interim Data From Phase 2 LONESTAR Study - (05/03/13)
     
  5052. EASL: EASL NEW Oral HCV Drugs - Report 1 of 3 - (04/30/13)
     
  5053. EASL: New HCV Drugs: Report 2 - (04/30/13)
     
  5054. EASL: HCV New Drugs - Report 3 (ELECTRON Study phase 2: GS7977+Rbv GT1) - (04/30/13)
     
  5055. EASL: Resistance Analyses Using Deep and Population Sequencing After 3 Day Monotherapy With GS-9669, a Novel Non-Nucleoside NS5B Inhibitor in Genotype 1 HCV Patients - (04/30/13)
     
  5056. EASL: Exposure-Response Analyses of Asunaprevir in Combination With Daclatasvir ï Peginterferon Alfa/Ribavirin Among Patients With Genotype 1 Chronic HCV Infection: Dose Selection for Phase 3 Clinical Trials - (04/30/13)
     
  5057. EASL: Combination Therapy of TMC647055 With Simeprevir (TMC435) in Genotype 1 HCV Patients - (04/30/13)
     
  5058. EASL: VAST MAJORITY OF DETECTED NS5A RESISTANT VARIANTS ARE NOT AMPLIFIED IN HCV PATIENTS DURING 3-DAY MONOTHERAPY WITH THE OPTIMIZED NS5A INHIBITOR PPI-668 - (04/29/13)
     
  5059. EASL: SAFETY OF TRIPLE THERAPY WITH TELAPREVIR OR BOCEPREVIR IN HEPATITIS C PATIENTS WITH ADVANCED LIVER DISEASE - PREDICTIVE FACTORS FOR SEPSIS - (04/29/13)
     
  5060. EASL: Study of ABT-267 2-Day Monotherapy Followed By 12-Week Combination Therapy In Treatment-Naïve Patients With Chronic HCV Genotype 1 Infection - (04/29/13)
     
  5061. EASL: VX-135, A POTENT SINGLE DIASTEREOMER OF ALS-2200, FOR THE TREATMENT OF CHRONIC HEPATITIS - (04/29/13)
     
  5062. EASL: In Vitro Resistance to ALS-2200, a Potent Nucleotide Polymerase Inhibitor for the Treatment of Chronic Hepatitis - (04/29/13)
     
  5063. EASL: No S282T Mutation Detected by Deep Sequencing in a Large Number of HCV Patients Who Received Sofosbuvir With RBV and/or GS-0938: the Quantum Study - (04/29/13)
     
  5064. EASL: GS-5816, a Second-Generation HCV NS5A Inhibitor With Potent Antiviral Activity, Broad Genotypic Coverage, and a High Resistance Barrier - (04/29/13)
     
  5065. EASL: Healthy Volunteer First-in-Human Evaluation of GS-5816, a Novel Second Generation Broad-Genotypic NS5A Inhibitor With Potential for Once-Daily Dosing - (04/29/13)
     
  5066. EASL: Once-Daily Sofosbuvir Plus Ribavirin Given for 12 or 24 Weeks in Treatment-Naïve Patients With HCV Infection: the QUANTUM Study - (04/28/13)
     
  5067. EASL: ELECTRON: All-Oral Sofosbuvir-Based 12-Week Regimens for the Treatment of Chronic HCV GT 1 Infection - (04/27/13)
     
  5068. EASL: Asunaprevir With Peginterferon-Alfa and Ribavirin in Treatment-Naive Patients With Genotype-1 or -4 Chronic Hepatitis C: SVR24 Results From a Randomized Phase 2b Study (AI447-016) - (04/27/13)
     
  5069. EASL: Treatment With Sofosbuvir + Ribavirin for 12 Weeks Achieves SVR12 of 78% in GT 2/3 Interferon-Ineligible, -Intolerant, or -Unwilling Patients: Results of the Phase 3 POSITRON Trial - (04/27/13)
     
  5070. EASL: High Sustained Viral Response of MK-5172 with Pegylated Interferon Alfa-2b and Ribavirin in HCV Genotype 1 Treatment-Naive Non-Cirrhotic Patients - (04/27/13)
     
  5071. EASL: 6-Week Treatment With Ledipasvir (NS5A Inhibitor) Plus GS-9451 (NS3 Inhibitor) With Peg-IFN/RBV in Naïve IL28B CC Subjects With Genotype 1 CHC: High Rates of Sustained Virological Response - (04/27/13)
     
  5072. EASL: Antiviral Efficacy of the Once Daily NS3 Protease Inhibitor GS-9451, the Non-Nucleoside NS5B Inhibitor Tegobuvir (GS-9190), and Pegylated Interferon + Ribavirin in Treatment-Naïve Patients With Genotype 1 Hepatitis C Infection - (04/27/13)
     
  5073. EASL: Synergistic Interactions of HCV NS5A Replication Complex Inhibitors Sensitize Resistant Variants and Enhance the Efficacy of Daclatasvir (DCV, BMS-790052) In Vitro and In Vivo - (04/27/13)
     
  5074. EASL: Sustained Virologic Response With Daclatasvir Plus Sofosbuvir ï Ribavirin (RBV) in Chronic HCV Genotype (GT) 1-Infected Patients Who Previously Failed Telaprevir (TVR) or Boceprevir (BOC) - (04/27/13)
     
  5075. EASL: FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAIVE PATIENTS - (04/27/13)
     
  5076. EASL: DACLATASVIR COMBINED WITH PEGINTERFERON ALFA 2A ALFA-AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 2 OR 3 INFECTION: COMMAND GT 2/3 STUDY - (04/27/13)
     
  5077. Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection: 2 phase 3 studies - FISSION (gt2/3), NEUTRINO (gt1) - (04/29/13)
     
  5078. EASL: Treatment With Sofosbuvir + Peginterferon + Ribavirin for 12 Weeks Achieves 90% SVR12 in Treatment-Naïve Genotype 1, 4, 5, and 6 HCV-Infected Patients: The NEUTRINO Study - (04/27/13)
     
  5079. EASL: Simeprevir (TMC435) with peginterferon-α2a or -α2b and ribavirin in treatment-naïve HCV genotype 1 patients: QUEST-2, a randomised Phase III trial - (04/27/13)
     
  5080. EASL: ALS-2200, A Novel Once-daily Nucleotide HCV Polymerase Inhibitor, Demonstrated Potent Antiviral Activity In Treatment-naïve Patients with Compensated Cirrhosis or Genotype 2-4 Chronic Hepatitis C - (04/27/13)
     
  5081. EASL: SVR12 rates and safety of triple therapy including telaprevir or boceprevir in 485 cirrhotic non responders treated in the French Early Access Program (ANRS CO20-CUPIC) - (04/27/13)
     
  5082. PPI-383, gt3/Pan-genotypic Non Nuc - (04/25/13)
     
  5083. EASL: SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/- RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY - (04/25/13)
     
  5084. EASL: Phase 3 Randomized Controlled Trial of All-Oral Treatment With Sofosbuvir + Ribavirin for 12 Weeks Compared to 24 Weeks of PEG + Ribavirin in Treatment-Naïve GT 2/3 HCV-Infected Patients (FISSION) - (04/25/13)
     
  5085. EASL: All Oral Therapy With Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment-Experienced Genotype 2/3 HCV-Infected Patients: Results of the Phase 3 FUSION Trial - (04/25/13)
     
  5086. EASL: Interim Analysis of an Interferon (IFN)- and Ribavirin (RBV)-Free Regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 in Treatment-Naive, Hepatitis C Virus Genotype 1-Infected Patients - (04/25/13)
     
  5087. EASL: Evaluation of Pharmacokinetic Drug-Drug Interaction (DDI) Between BMS-791325, an NS5B Non-Nucleoside Polymerase Inhibitor, Daclatasvir and Asunaprevir in Triple Combination in HCV Genotype 1-Infected Patients - (04/25/13)
     
  5088. EASL: Simeprevir (TMC435) with peginterferon/ribavirin for chronic hCV genotype 1 infection in treatment-naïve patients: results from QUEST-1, a Phase III trial - (04/25/13)
     
  5089. Sofosbuvir: the final nail in the coffin for hepatitis C? Commentary - (04/24/13)
     
  5090. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial - (04/24/13)
     
  5091. EASL: Vertex Announces New Data that Showed High Viral Cure Rates with a Total of 12 and 24 Weeks of Telaprevir Combination Treatment Among People with Genotype 1 Hepatitis C Who Have the IL28B CC Genotype - press release - (04/24/13)
     
  5092. 13th Intrntnl Wrkshp Clinical Pharm HIV Therapy Ribavirin Levels 50% Higher With Than Without Telaprevir - written by Mark Mascolini - (04/24/13)
     
  5093. EASL: Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options - (04/24/13)
     
  5094. Merck-Bristol-Myers' Phase II Trial To Check Hepatitis C Candidates' Combination - (04/23/13)
     
  5095. EASL: ALS-2200 (VX-135) Viral Kinetic Study Shows Significant Reduction in HCV RNA in People with Genotype 1 Hepatitis C Virus Infection and Cirrhosis, and in People with Genotypes 2, 3 or 4 HCV Infection - (04/23/13)
     
  5096. EASL: Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress™ - (04/23/13)
     
  5097. EASL: Findings from Two Phase 3 Studies of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients - (04/23/13)
     
  5098. EASL: Boehringer Ingelheim announces results from one of its HCV Phase III trials: Investigational compound faldaprevir+ shows high viral cure and early treatment success in treatment-naïve patients with genotype-1 hepatitis C - press release - (04/23/13)
     
  5099. EASL: New Data from AbbVie's Phase IIb Aviator Trial Demonstrate High Sustained Viral Response Rates Across Multiple Patient Types with HCV Genotype 1 - press release - (04/23/13)
     
  5100. EASL: DATA FROM PHASE 3 STUDIES OF GILEAD'S SOFOSBUVIR FOR HEPATITIS C TO BE PRESENTED AT 48TH ANNUAL EASL MEETING; FINDINGS PUBLISHED ONLINE TODAY IN THE NEW ENGLAND JOURNAL OF MEDICINE - Press Release - (04/23/13)
     
  5101. EASL: High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection - press release - (04/23/13)
     
  5102. Silymarin for HCV infection - Review - (04/22/13)
     
  5103. Effect of Silymarin (Milk Thistle) on Liver Disease in Patients With Chronic Hepatitis C Unsuccessfully Treated With Interferon TherapyA Randomized Controlled Trial - (04/22/13)
     
  5104. Effect of HIV on Liver Fibrosis Among HCV-Infected African Americans - (04/20/13)
     
  5105. New HCV Screening Project in Rhode Island Rhode Island Foundation names winners of Innovation Fellowships - (04/18/13)
     
  5106. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence - "requires a global response" - (04/18/13)
     
  5107. A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care - (04/18/13)
     
  5108. Achillion Initiates Phase 2 Interferon-Free Trial of Sovaprevir and ACH-3102 for Genotype 1 HCV - (04/16/13)
     
  5109. Danoprevir HCV Protease Roche China Deal - (04/16/13)
     
  5110. The impact of lifetime alcohol use on hepatitis C treatment outcomes in privately insured members of an integrated health care plan - (04/16/13)
     
  5111. MicroRNAs: New tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? - (04/16/13)
     
  5112. Bristol-Myers Squibb to Present New Data on Hepatitis C and Hepatitis B Compounds at The International Liver CongressTM (ILC) 2013 - (04/09/13)
     
  5113. Janssen Announces Data from Simeprevir in Hepatitis C Patients Will Be Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL) - (04/09/13)
     
  5114. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress - (04/09/13)
     
  5115. GILEAD SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR SOFOSBUVIR FOR THE TREATMENT OF HEPATITIS C - (04/08/13)
     
  5116. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective: HCV costs double comparison non-HCV patient group - (04/05/13)
     
  5117. Direct Economic Burden of Chronic Hepatitis C Virus in a United States Managed Care Population: 'HCV costs 4 times control group, SVR reduced costs' - (04/05/13)
     
  5118. Pharmacokinetic Interaction Between Boceprevir and Etravirine in HIV/HCV Seronegative Volunteers - (04/04/13)
     
  5119. Medivir Press Release: New Drug Application has been filed with FDA for Simeprevir (TMC435) for combination treatment of adult patients with genotype 1 chronic hepatitis C - (04/03/13)
     
  5120. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial - (04/01/13)
     
  5121. Gilead Announces Update on Phase 3 Study of Oral Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients - (04/01/13)
     
  5122. CROI: Predictors of Mortality among United States Veterans with Human Immunodeficiency Virus and Hepatitis C Virus (HIV/HCV) Co-Infection - (04/01/13)
     
  5123. CROI: Hepatitis C Co-infection and the Risk of Chronic Kidney Disease in HIV-infected Individuals: Does Hepatitis C Viremia Matter? - (04/01/13)
     
  5124. CROI: Impact of Hepatitis Serostatus on Hospitalization Rates and Reasons for Admission in a Multi Center Cohort of Persons Living with HIV in the U.S Multi-Center Cohort of persons Living with HIV in the US - (04/01/13)
     
  5125. CROI: Does persistent hepatitis C viremia lead to advanced liver fibrosis progression early after acute hepatitis C infection in HIV coinfection? - (04/01/13)
     
  5126. CROI: Incidence and Progression to Cirrhosis of HCV Superinfection in Persons Living with HIV (PLHIV): accelerated progression risk 'not as dramatic' - (04/01/13)
     
  5127. Research Published in the New England Journal of Medicine Demonstrates Marked and Long-Lasting Antiviral Activity Against HCV for Santaris Pharma A/S' Miravirsen, the First MicroRNA-Targeted Drug to Enter Clinical Trials - (03/31/13)
     
  5128. Treatment of HCV Infection by Targeting MicroRNA - (03/31/13)
     
  5129. Micromanaging Hepatitis C Virus microRNA mIR-122 Editorial - (03/31/13)
     
  5130. New Hepatitis C Drug, RNAi drugs: microRNA-122 - (03/31/13)
     
  5131. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C - (03/31/13)
     
  5132. HCV "One-Shot-Cure" ddRNAi Therapy Study Starting - (03/22/13)
     
  5133. CROI: Triple Combination Therapy Telaprevir vs Boceprevir, in Spain, Early Results, in Mono- and Coinfected - (03/29/13)
     
  5134. CROI: Absence of a Significant Pharmacokinetic Interaction Between the HCV Protease Inhibitor Boceprevir and HIV-1 NNRTI Rilpivirine - (03/29/13)
     
  5135. CROI: Increased Plasma and Intracellular Ribavirin Concentrations Associated With Telaprevir Use - (03/29/13)
     
  5136. CROI: On-treatment and Sustained Virologic Response Rates of Telaprevir-based HCV Treatments Do Not Differ Between HIV/HCV Co-infected and HCV Mono-infected Patients - (03/29/13)
     
  5137. CROI: Intra- and Extra-Hepatic Correlates of Plasma Viral Clearance in Patients with Chronic Hepatitis C Genotype 1 Treated with GS-7977 and Ribavirin - (03/29/13)
     
  5138. CROI: Summary from CROI 2013 for Hepatitis Co-infection HCV direct acting antivirals (DAAs) in HIV/HCV coinfection: More drugs on their way. What are the implications? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/29/13)
     
  5139. Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C - (03/19/13)
     
  5140. Roche's Pegasys receives EU approval for the treatment of chronic hepatitis C in children five years of age and older - (03/18/13)
     
  5141. Treating Hepatitis C: Are Children the Same as Adults? Editorial - (03/18/13)
     
  5142. CROI: HCV at CROI - (03/17/13)
     
  5143. CROI: The Effect of Hepatic Fibrosis and HCV viremia on Serum Inflammatory Mediators in HIV Infection - a Women's Interagency HIV Study - (03/16/13)
     
  5144. Study Results For PPI668 NS5A, BI335 protease, BI127 non-nuc polymerase - new collaboration between Presidio & Boerhinger Ingelheim - (03/15/13)
     
  5145. CROI: Hepatic Fibrosis and Immune Phenotypes Vary by Hepatitis C Viremia in HIV Infection: A Women's Interagency HIV Study.....[from Jules: HCV Viremia Increased Fibrosis/Immune-Dysregulation; HIV Drives Immune Activation but HCV Contributes to Immune Activation] - (03/15/13)
     
  5146. CROI: The Effect of Hepatic Fibrosis and HCV viremia on Serum Inflammatory Mediators in HIV Infection - a Women's Interagency HIV Study - (03/15/13)
     
  5147. Presidio Pharmaceuticals Announces Collaboration with Boehringer Ingelheim - (03/14/13)
     
  5148. CROI: Treatment of Acute HCV in HIV-infected MSM Incorporating Telaprevir - (03/13/13)
     
  5149. CROI: Telaprevir Combination Treatment in Hard-to-treat African American, Null Responder G1 Chronic Hepatitis C Patients: Early Data From the OUTLOOK Study - (03/09/13)
     
  5150. CROI: Telaprevir, Peginterferon and Ribavirin Combination Therapy for Chronic HCV Genotype 1 in HCV/HIV Co-infected Patients: Early Response and Viral Resistance - (03/09/13)
     
  5151. CROI: High Early Virological Response with Telaprevir-PegIFN-RBV in treatment-experienced, HCV genotype 1, HIV coinfected patients: ANRS HC26 TelapreVIH Study - (03/08/13)
     
  5152. CROI: ANRS-HC27 BocepreVIH Interim Analysis: High EVR with Boceprevir+peg-IFN+ RBV in HCV/HIV-co-infected Patients with Previous Failure to peg-IFN+RBV - (03/08/13)
     
  5153. FDA approves new Roche test to evaluate response to hepatitis C therapy - (03/07/13)
     
  5154. CROI: Simeprevir (TMC435) with peginterferon/ribavirin in patients co-infected with chronic genotype-1 HCV and HIV-1: Week-24 interim analysis of the TMC435-C212 study - (03/07/13)
     
  5155. CROI: High Efficacy of Sofosbuvir in Combination with Weight Based Ribavirin for 24 weeks in Difficult to Treat HCV Infected Genotype-1 Patients - (03/06/13)
     
  5156. CROI: COSMOS Study: SVR4 results of a once daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 null responders - (03/06/13)
     
  5157. Regulatory Application has now been filed for Simeprevir (TMC435) in Japan for the treatment of genotype 1 hepatitis C patients - (03/05/13)
     
  5158. CROI: First interim results from a phase IIa study evaluating an all-oral regimen of Simeprevir and Sofosbuvir in prior null responder Hepatitis C patients - press release - (03/04/13)
     
  5159. CROI: ELECTRON: 100% SVR Rate for Once-Daily Sofosbuvir Plus Ledipasvir Plus Ribavirin Given for 12 Weeks in Treatment-Naïve and Previously Treated Patients With HCV GT 1 - (03/04/13)
     
  5160. CROI: RISK OF VIROLOGIC RELAPSE IN HEPATITIS C, GENOTYPE 1-INFECTED SUBJECTS AFTER 8, 12, OR 24 WEEKS OF TREATMENT WITH ABT-450/r + ABT-267 + ABT-333 + RBV: IDENTIFYING OPTIMAL TREATMENT DURATION - (03/04/13)
     
  5161. CROI: 12 WEEKS OF ABT-450/r, NON-NUCLEOSIDE INHIBITOR AND RBV ACHIEVED SVR24 IN >90% OF TREATMENT-NAìVE HCV GT1 PATIENTS AND 47% OF PRIOR NONRESPONDERS - (03/04/13)
     
  5162. CROI: Pharmacokinetic interactions of darunavir/ritonavir, efavirenz, and tenofovir with the HCV protease inhibitor faldaprevir in healthy volunteers - (03/04/13)
     
  5163. CROI: STARTVerso 4: High rates of early virologic response in HCV genotype 1/HIV-co-infected patients treated with faldaprevir plus pegIFN and RBV - (03/04/13)
     
  5164. CROI: Boerhinger Ingelheim Announes Interim Results Evaluating Virologic Response Rates in HCV/HIV Coinfected Patients Treated with HCV Protease BI201335, and Drug Drug Interaction Studies with HIV ARTs - (03/04/13)
     
  5165. Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3 - (03/01/13)
     
  5166. Influence of Human Immunodeficiency Virus Infection on the Course of Hepatitis C Virus Infection: A Meta-Analysis - (02/26/13)
     
  5167. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients - (02/26/13)
     
  5168. HIV, Age, and the Severity of Hepatitis C Virus-Related Liver Disease: A Cohort Study - HIV, aging, CD4 count, HIV viral load & HCV viral load are associated with accelerated HCV disease progression - (02/26/13)
     
  5169. HIV/Aging/Viral Infections: HCV Leading Cause of Death in HIV? - (02/26/13)
     
  5170. Idenix News- Drug Development, Pharmaceuticals Reports Fourth Quarter and Year Ended 2012 Financial Results - (02/26/13)
     
  5171. Victrelis (boceprevir) label updates/Null Responders - (02/25/13)
     
  5172. Dose Ranging of NS5A GSK2336805 (vs telaprevir) in Combination Therapy - (02/25/13)
     
  5173. NS5A Review - Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein - (02/25/13)
     
  5174. New FDA Approval Process: "Breakthrough therapy" - (02/22/13)
     
  5175. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life - BMS052/declatasvir kinetics/viral load reduction - (02/21/13)
     
  5176. Achillion HCV Update - (02/21/13)
     
  5177. GILEAD'S SOFOSBUVIR FOR HEPATITIS C MEETS PRIMARY ENDPOINT IN FOURTH PIVOTAL PHASE 3 STUDY - (02/20/13)
     
  5178. Sustained virologic response rates with telaprevir by response after 4weeks of lead-in therapy in patients with prior treatment failure - (02/20/13)
     
  5179. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis - (02/20/13)
     
  5180. Republic of Georgia plagued by hepatitis C - (02/20/13)
     
  5181. Thousands get a cure as Hep C drugs make PBS list in Australia - (02/20/13)
     
  5182. Effect of HCV Infection on Cause-Specific Mortality After HIV Seroconversion, Before and After 1997- in CART Era HIV/AIDS mortality & hepatitis/Liver disease deaths higher among coinfected/routine screening & accelerated treatment needed - (02/19/13)
     
  5183. Silibinin: An old drug in the high tech era of liver transplantation, & for non-responders - (02/19/13)
     
  5184. Hepatitis C infection and presence of advanced fibrosis: Wait or treat? Why wait? There is no time to lose, is there? - (02/19/13)
     
  5185. The natural history of compensated HCV-related cirrhosis: A prospective long-term study - pdf attached - (02/19/13)
     
  5186. Biomarkers of Inflammation and Coagulation Are Associated With Mortality and Hepatitis Flares in Persons Coinfected With HIV and Hepatitis Viruses - (02/19/13)
     
  5187. GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus (and HCV) in Chronically Infected Chimpanzees - (02/19/13)
     
  5188. Statins Are Associated With a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis - (02/19/13)
     
  5189. Roche Polymerase Nuc Mericitabine, study results reported from JUMP-C - (02/12/13)
     
  5190. New Oral HCV Drugs/DAAs - (02/11/13)
     
  5191. Prevalent and Incident Hepatitis C Virus Infection among HIV-Infected Men Who Have Sex with Men Engaged in Primary Care in a Boston Community Health Center....'Worrisome Trend' - (02/07/13)
     
  5192. Idenix Pharmaceuticals Provides Update on IDX184 and IDX19368 Development Programs, stops 2 drugs' development, starts another - (02/05/13)
     
  5193. Hepatitis C scare in Valley village (India), 300 test positive - (02/04/13)
     
  5194. Telaprevir to Boceprevir Switch Highlights Lack of Cross-Reactivity - (02/04/13)
     
  5195. IDUs - HCV 'Super-Spreaders' Are Key to Prevention: Early Diagnosis & Treatment, new study - (02/04/13)
     
  5196. Gilead Announces Sustained Virologic Response Rates from Two Phase 3 Studies of Sofosbuvir for Hepatitis C - (02/04/13)
     
  5197. Antiviral and Preclinical Profiles of HCV NS5A Inhibitors IDX380 and IDX719 - (02/01/13)
     
  5198. The pharmacological properties of IDX19368, a novel nucleotide prodrug, highlight its potential for use in a low-dose DAA regimen for HCV - (02/01/13)
     
  5199. Safety, Pharmacokinetic and Preliminary Antiviral Activity Results from a First-in-Human Study of IDX719, a Pan-Genotypic Novel HCV NS5A Inhibitor - (02/01/13)
     
  5200. The pharmacological properties of IDX19368, a novel nucleotide prodrug, highlight its potential for use in a low-dose DAA regimen for HCV - (02/01/13)
     
  5201. Potent HCV Diamidate Pronucleotide Inhibitors: In Vitro Antiviral Activity Optimization (Idenix) - (02/01/13)
     
  5202. AASLD: IDX719, HCV NS5A Inhibitor, Demonstrates Pan-Genotypic Activity after Three Days of Monotherapy in Genotype 1, 2, 3 or 4 HCV-Infected Subjects - (01/31/13)
     
  5203. Phase II all-oral combination studies of Simeprevir (TMC435), TMC647055 (non nuc polymerase inhibitor) and IDX719 (NS5A) for the treatment of Hepatitis C to be initiated shortly - 4 articles below - (01/31/13)
     
  5204. Hepatitis C cases climbing in NKY......Almost 88 percent (of those tested) had a history of IV drug use......Many of those tested have been in the age group of 20-29 - (01/31/13)
     
  5205. AASLD: GS-7977 & HIV ARTs PK - No Clinically Significant Pharmacokinetic Interactions Between Sofosbuvir (GS-7977) and HIV Antiretrovirals Atripla, Rilpivirine, Darunavir/Ritonavir, or Raltegravir in Healthy Volunteers - (01/31/13)
     
  5206. Community Access National Network Launches New Hepatitis Initiative; The "HEPATITIS: Education, Advocacy & Leadership" Project (HEAL) will promote awareness, with a particular focus on HIV and HCV co-infection - (01/25/13)
     
  5207. New Study: GS-7977 and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation - (01/25/13)
     
  5208. When Did Phase 3 Studies Begin for TMC435, BI201335, GS7977, BMS790052, and PegLambda and when will they finish & receive FDA approval. - (01/25/13)
     
  5209. Association of tattooing and hepatitis C virus infection: A multicenter case-control study....authors suggest HCV screening for those with tattoos - (01/25/13)
     
  5210. HCV Treat Now or Wait?? What's Currently in Phase 3 Now, Drug Development Timeline; Liver Transplant Treatment/Studies; New study in advanced hepatic fibrosis: TMC435+GS7977 (+/-RBV) for treatment-naives & null responders - (01/22/13)
     
  5211. TMC435+GS7977 (Rbv) New Study in Advanced Hepatic Fibrosis- Null Responders & Naives - (01/22/13)
     
  5212. How Long Can HCV Survive Outside The Body - "Transmission of Hepatitis C Virus Among People Who Inject Drugs: Viral Stability and Association With Drug Preparation Equipment" - (01/22/13)
     
  5213. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin....previous reports on telaprevir & boceprevir stopping rules - (01/22/13)
     
  5214. The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries - (01/17/13)
     
  5215. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program - (01/17/13)
     
  5216. Screening for Hepatitis C Virus Infection in Adults: A Systematic Review for the U.S. Preventive Services Task Force - (01/16/13)
     
  5217. Comparative Effectiveness of Antiviral Treatment for Hepatitis C Virus Infection in Adults: A Systematic Review - (01/16/13)
     
  5218. "Hepatitis C may be the serious disease that most combines widespread prevalence with widespread ignorance." - New HCV Policy Paper: "Economist Intelligence Unit Report Calls for Global Policy Innovation to Tackle the 'Silent Pandemic' that is Hepatitis C" from Janssen - (01/16/13)
     
  5219. Economist Intelligence Unit Report Calls for Global Policy Innovation to Tackle the 'Silent Pandemic' that is Hepatitis C - new global HCV policy paper - (01/15/13)
     
  5220. 3rd Intl Wrkshp on HIV & Women: Risk of Progression to Fibrosis Twice Higher in Women Than Men With HCV/HIV - written by Mark Mascolini - (01/15/12)
     
  5221. 3rd Intl Wrkshp on HIV & Women: Lower Cognitive Scores in Women With HCV/HIV Than With HIV Alone - written by Mark Mascolini - (01/15/12)
     
  5222. Patients with HCV and F1 and F2 fibrosis stage: treat now or wait? - (01/13/13)
     
  5223. AASLD: First ever successful use of Daclatasvir and GS-7977 (Sofosbuvir) , an IFN-free regimen, in a Liver Transplant recipient with severe recurrent Hepatitis C - (01/12/13)
     
  5224. Scientists Discover New Gene That Affects Clearance of Hepatitis C Virus........A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus - (01/10/13)
     
  5225. Interferon free therapy with direct acting antivirals for HCV - (01/08/13)
     
  5226. GS-7977 Liver Transplant Studies - (01/08/13)
     
  5227. AASLD: The Pharmacokinetic Interaction Between the Investigational NS3/4A HCV Protease Inhibitor TMC435 and Methadone - (01/08/13)
     
  5228. AASLD: No clinically significant interaction between the investigational HCV protease inhibitor simeprevir (TMC435) and the immunosuppressive agents cyclosporine and tacrolimus - (01/07/13)
     
  5229. AASLD: No pharmacokinetic interaction between the investigational HCV protease inhibitor simeprevir (TMC435) and an oral contraceptive containing ethinylestradiol and norethindrone - (01/07/13)
     
  5230. Interferon free therapy with direct acting antivirals for HCV - (01/07/13)
     
  5231. AASLD: No Clinically Significant Pharmacokinetic Drug-Drug Interactions Between Sofosbuvir (GS-7977) and the Immunosuppressants Cyclosporine A or Tacrolimus in Healthy Volunteers - (01/07/13)
     
  5232. GILEAD PROVIDES UPDATE ON HEPATITIS C DEVELOPMENT PROGRAMS - update on GS-7977+GS-5885+Rbv in null responders in Electron - (01/07/13)
     
  5233. CHRONIC HEPATITIS C VIRUS (HCV) DISEASE BURDEN AND COST IN THE UNITED STATES - (01/07/13)
     
  5234. Rapid Progression to Decompensated Cirrhosis, Liver Transplantation, and Death in HIV-infected Men after Primary HCV Infection - (01/04/13)
     
  5235. Effect Of HCV Infection On Cause-Specific Mortality Following HIV Seroconversion Before And After 1997 - (01/04/13)
     
  5236. Nucleotide Polymerase Inhibitor Sofosbuvir (GS-7977) plus Ribavirin for Hepatitis C - new published study - (01/04/13)
     
  5237. Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C (ABT-450/r + ABT-333 + Rbv) - new published study - (01/04/13)
     
  5238. Determinants of Hepatitis C Virus Treatment Completion and Efficacy in Drug Users Assessed by Meta-analysis: "we observed that the availability of support services during HCV treatment significantly increased the treatment completion rates among DUs......involvement of multidisciplinary team led to higher SVR rates among DUs." - (01/04/13)
     
  5239. Improved Inflammatory Activity With Peginterferon Alfa-2b Maintenance Therapy in Non-cirrhotic Prior Nonresponders: a Randomized Study - (01/04/13)
     
  5240. Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis: "In conclusion, our study indicates that SVR was associated with improved overall survival in patients with chronic HCV infection and advanced hepatic fibrosis." - (01/02/13)
     
  5241. Lack of a Clinically Significant Drug-Drug Interaction in Healthy Volunteers Between the Hepatitis C Virus Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir - (01/02/13)
     
  5242. Telaprevir FDA Label Change Report - (01/02/13)
     
  5243. Achillion Provides Update on Clinical HCV Development Programs - (01/02/13)
     
  5244. New GS7977+GS5885 Studies/Phase 3 - (01/02/13)
     
  5245. HCV IFN-Free Therapies/Regimens - (01/02/13)
     
  5246. USPSTF Scrutiny, Controversy - (01/02/13)
     
  5247. Vertex Announces Update to U.S. Prescribing Information for INCIVEK® (telaprevir) - (12/19/12)
     
  5248. INCIVEK™ (telaprevir) Now Funded in Alberta and New Brunswick for People with Hepatitis C - (12/19/12)
     
  5249. An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients - (12/19/12)
     
  5250. FDA Drug Safety Communication/Data Summary: Serious skin reactions after combination treatment with the Hepatitis C drugs Incivek (telaprevir), peginterferon alfa, and ribavirin - (12/19/12)
     
  5251. Differential cognitive impairment in HCV coinfected men with controlled HIV compared to HCV monoinfection - (12/18/12)
     
  5252. HCV Screening Cost Effective vs Direct HCV Patient Care Costs - (12/18/12)
     
  5253. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions - (12/18/12)
     
  5254. HCV, Who Should Be Treated Now? - (12/18/12)
     
  5255. Telaprevir & Boceprevir in Liver Transplantation - (12/15/12)
     
  5256. Telaprevir therapy required tacrolimus dose reduction in liver transplant recipients with HCV - (12/15/12)
     
  5257. GS-7977 HCV Transplant Studies - (12/15/12)
     
  5258. Telaprevir Post Liver Transplant - (12/15/12)
     
  5259. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: A 12-week pilot study providing safety and efficacy data - (12/15/12)
     
  5260. Boceprevir HCV Liver Transplant - (12/15/12)
     
  5261. New therapies against HCV: Expected risks and challenges associated with their use in the liver transplant setting - (12/15/12)
     
  5262. Hepatitis C screening - getting it right - (12/14/12)
     
  5263. Economic model of a birth cohort screening program for hepatitis C virus: 3 Studies- Cost Effectiveness HCV Screening Baby Boomers & General Population - (12/14/12)
     
  5264. 14th Intl Wrkshp Adverse Reactions & Comorbidities HIV: Clinically Significant Drug Interaction Between Colchicine and Ritonavir in Healthy Adults - (12/14/12)
     
  5265. EASL: Telaprevir French Cohort Authorization for Temporary Use in Genotype 1 Hepatitis C Cirrhotic Patients with Prior Partial Response or Relapse - (12/13/12)
     
  5266. Preliminary Results of Twice Daily Dosing (Q12 hr) Of Telaprevir (TVR) for Treatment Naïve and Previously Treated Patients with Genotype 1 HCV: Comparable RVR, eRVR and SVR12 to Standard Daily Dosing at Q8 hr - (12/13/12)
     
  5267. HCV Barriers to Care & Treatment, New Study - Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations - (12/11/12)
     
  5268. Infection with concurrent multiple hepatitis C virus genotypes is associated with faster HIV disease progression - (12/07/12)
     
  5269. The high comorbidity burden of the hepatitis C virus infected population in the United States - (12/07/12)
     
  5270. Multiple infections with different HCV genotypes: prevalence and clinical impact - (12/07/12)
     
  5271. Multiple HCV genotypes: Emergence of occult minority genotype 2b hepatitis C infection in an HIV-1-co-infected patient treated for genotype 5a HCV infection with 48 weeks of pegylated-interferon- 2b and ribavirin - (12/07/12)
     
  5272. Projected future increase in aging HCV-infected liver transplant candidates: A potential effect of HCC - (12/07/12)
     
  5273. Projected future increase in aging HCV-infected liver transplant candidates: A potential effect of HCC - (12/06/12)
     
  5274. Hepatitis C Reaching Crisis Levels; Requires Coverage for Routine Screenings - (12/05/12)
     
  5275. Sexual transmission of HCV among monogamous heterosexual couples: The HCV partners study - (12/04/12)
     
  5276. Increasing Incidence of Hepatocellular Carcinoma in HIV-Infected Patients in Spain - (12/03/12)
     
  5277. History of Injection Drug Users: both CDC & HHS Recommend HCV Screening and Services - (12/03/12)
     
  5278. Risk of hip fracture associated with hepatitis c virus infection and hepatitis C/human immunodeficiency virus coinfection - (12/03/12)
     
  5279. Dual Oral Therapy with Daclatasvir and Asunaprevir for Patients with HCV Genotype 1b Infection and Limited Treatment Options - (12/03/12)
     
  5280. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial - (12/03/12)
     
  5281. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection - "Mean PPPM [per-month-per patient] all-cause healthcare costs were 32% and 247% higher for patients with CC and ESLD" - (12/03/12)
     
  5282. CDC HIV & Hepatitis C Screening & Services Guidelines / Recommendations - IDUs Highlighted - (11/30/12)
     
  5283. GILEAD ANNOUNCES SUSTAINED VIROLOGIC RESPONSE RATE OF 78% FROM PHASE 3 STUDY OF SOFOSBUVIR FOR GENOTYPE 2/3 HEPATITIS C INFECTED PATIENTS - (11/28/12)
     
  5284. HCV Screening USPSTF Draft Recommendations Open for Public Comment - (11/28/12)
     
  5285. HCV Screening USPSTF Draft Recommendations OPEN for PUBLIC COMMENT for 27 Days Explained - (11/28/12)
     
  5286. Improvement in the Health of HIV-Infected Persons in Care: Reducing Disparities - HIV & HCV Health Disparities, HIV Life Expectancy/Aging, Hopkins Moore Clinic, Ryan White Care Act future - (11/28/12)
     
  5287. HCV in MSM, ex-US vs USA Politics/Inner City HCV - Hepatitis C Virus Infections in the Swiss HIV Cohort Study: A Rapidly Evolving Epidemic - (11/28/12)
     
  5288. AASLD: Sustained Virological Response (SVR) Rate of 67% in HCV Genotype 1-Infected Prior Null Responders Treated with Danoprevir/Ritonavir (DNVr) in Combination with Peginterferon Alfa-2a (40KD) plus Ribavirin (PegIFN Alfa-2a/RBV) - (11/26/12)
     
  5289. AASLD: No Impact of Cirrhosis on Mericitabine (MCB) Pharmacokinetics and Early Antiviral Activity in Hepatitis C-Infected Patients Receiving MCB plus Peginterferon Alfa-2A (40KD)/Ribavirin (P/R) - (11/26/12)
     
  5290. AASLD: Lack of Mericitabine Resistance Mutation NS5B S282T and Detection and Characterization of a Novel Mericitabine Double Resistance Mutation NS5B L159F+L320F in Patients Treated with Mericitabine Plus Peginterferon Alfa-2a (40KD)/Ribavirin Provides Further Evidence for the High Resistance Barrier to Mericitabine - (11/26/12)
     
  5291. AASLD: Ritonavir-boosted Danoprevir plus PegIFN Alfa-2a/Ribavirin (P/R) Demonstrates up to 100% SVR24 with 12 or 24 Weeks of Total Treatment in Treatment-Naive Patients with HCV Genotype 4 Infection in the DAUPHINE Study - (11/26/12)
     
  5292. AASLD: Everolimus-Facilitated Reduction of Tacrolimus Provides Comparable Efficacy and Superior Renal Function versus Standard Tacrolimus in De Novo Liver Transplant Recipients: 24-month Results of a Randomized Trial - (11/26/12)
     
  5293. AASLD: Coadministration of Ritonavir with the HCV Protease Inhibitor Danoprevir Substantially Reduces Reactive Metabolite Formation Both In Vitro and In Vivo - (11/26/12)
     
  5294. AASLD: The outcome of 24 vs. 48 weeks of peginterferon alfa-2a (40KD) plus ribavirin on sustained virologic response rates in patients infected with genotype 2 or 3 hepatitis C virus who do not achieve a rapid viral response: the N-CORE study - (11/26/12)
     
  5295. AASLD: Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 497 cirrhotic non responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting) - (11/20/12)
     
  5296. AASLD: Daclatasvir, an NS5A Replication Complex Inhibitor, Combined With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive HCV-Genotype 1 or 4 Patients: Phase 2b COMMAND-1 SVR12 Results - (11/20/12)
     
  5297. AASLD: Twelve- or 16-Week Treatment With Daclatasvir Combined With Peginterferon Alfa and Ribavirin for Hepatitis C Virus Genotype 2 or 3 Infection: COMMAND GT 2/3 Study - (11/20/12)
     
  5298. AASLD: Treatment of Hepatitis C Genotype 1 Patients with Severe Fibrosis or Compensated Cirrhosis: The International Telaprevir Early Access Program - (11/19/12)
     
  5299. FDA approves new indication for PROMACTA® (eltrombopag) - (11/19/12)
     
  5300. AASLD: Week 24 and End of Treatment Response for Direct Acting Antiviral (DAA)-Based Therapy in Veterans With Chronic Hepatitis C - (11/19/12)
     
  5301. AASLD: Peginterferon Lambda-1a (Lambda) Compared With Peginterferon Alfa-2a (Alfa) in Treatment-Naive Patients With HCV Genotypes 1 or 4: SVR24 Results From EMERGE Phase 2b - (11/15/12)
     
  5302. AASLD: First Report of Peginterferon Lambda/Ribavirin in Combination With Either Daclatasvir or Asunaprevir in HCV Genotype 1 Japanese Patients: Early Sustained Virologic Response (SVR4) Results From the D-LITE Japanese Substudy - (11/15/12)
     
  5303. AASLD: Timing and Magnitude of Ribavirin Dose Reduction do not impact SVR with Boceprevir + Peginterferon / Ribavirin in the Anemia Management Study in HCV G1 Patients - (11/15/12)
     
  5304. AASLD: PPI-668, A Potent New Pan-Genotypic HCV NS5A Inhibitor: Phase 1 Efficacy and Safety - (11/15/12)
     
  5305. AASLD: Alisporivir (ALV) plus Peg-interferon/Ribavirin (P/R) Achieves High On-Treatment Undetectable HCV RNA Levels Among the Most Difficult to Treat HCV G1 Patients. Results of a Planned Treatment Week 24 Interim Analysis of a Randomized, Double Blind, Placebo Controlled Trial (FUNDAMENTAL study) - (11/15/12)
     
  5306. AASLD: Alisporivir plus Ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: Final results from VITAL-1 study - (11/15/12)
     
  5307. AASLD: Once Daily Sofosbuvir (GS-7977) Regimens in HCV Genotype 1-3: The ELECTRON Trial - (11/14/12)
     
  5308. AASLD: GILEAD ANNOUNCES 100 PERCENT SUSTAINED VIROLOGIC RESPONSE RATE (SVR4) FOR AN INTERFERON-FREE REGIMEN OF SOFOSBUVIR (GS-7977), GS-5885 AND RIBAVIRIN IN TREATMENT-NAïVE GENOTYPE 1 HEPATITIS C INFECTED PATIENTS - (11/14/12)
     
  5309. AASLD: Abbott Presents Promising Phase 2b Interferon-free Hepatitis C Results at 2012 Liver Meeting® - (11/14/12)
     
  5310. AASLD: Data from Viral Kinetic Study Showed Rapid Reduction of HCV RNA with ALS-2200 (VX-135), Vertex's Oral Nucleotide Analogue in Development for the Treatment of Hepatitis C - (11/14/12)
     
  5311. AASLD: Vertex Presents New Phase 3 Data that Showed People with Hepatitis C Treated with Twice-Daily Telaprevir Achieved Viral Cure (SVR12) Rates Similar to Those Treated Three Times Daily - (11/14/12)
     
  5312. AASLD: Boehringer Ingelheim's interferon-free all-oral hepatitis C treatment+ shows up to 85% viral cure in Phase II study including patients with advanced liver disease - (11/14/12)
     
  5313. AASLD: Investigational Hepatitis C Dual DAA Regimen of Daclatasvir and Asunaprevir Achieved SVR12 in 78% of Difficult-to-Treat Genotype 1b Prior Null Responders In Expanded Phase II Study - (11/14/12)
     
  5314. AASLD: Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 Achieved SVR12 of 94% in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection in Phase II Trial - (11/14/12)
     
  5315. AASLD: Bristol-Myers Squibb's Investigational Hepatitis C Compounds Lambda and Daclatasvir Plus Ribavirin Achieved SVR12 in 93% of Genotype 1b Treatment-Naive Patients In Phase IIb Study - (11/14/12)
     
  5316. AASLD: Gilead Announces 100 Percent Sustained Virologic Response Rate (SVR4) for an Interferon-Free Regimen of Sofosbuvir (GS-7977), GS-5885 and Ribavirin in Treatment-Naïve Genotype 1 Hepatitis C Infected Patients - (11/14/12)
     
  5317. AASLD: Once Daily Sofosbuvir (GS-7977) plus PEG/RBV In Treatment-Naïve Patients With HCV Genotype 1, 4, and 6 Infection: The ATOMIC Study - (11/14/12)
     
  5318. AASLD: INTERFERON (IFN)-FREE COMBINATION TREATMENT WITH THE HCV NS3/4A PROTEASE INHIBITOR FALDAPREVIR (BI 201335) AND THE NON-NUCLEOSIDE NS5B INHIBITOR BI 207127 ï RIBAVIRIN: FINAL RESULTS OF SOUND-C2 AND PREDICTORS OF RESPONSE - (11/14/12)
     
  5319. AASLD: EFFICACY AND SAFETY OF THE INTERFERON-FREE COMBINATION OF FALDAPREVIR (BI 201335) + BI 207127 ï RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH HCV GT-1 AND COMPENSATED LIVER CIRRHOSIS: RESULTS FROM THE SOUND-C2 STUDY - (11/14/12)
     
  5320. AASLD: Efficacy and tolerability of simeprevir (TMC435) 150 mg once daily with peginterferon and ribavirin for treatment of HCV genotype 1 infection in patients with Metavir score F3 and F4 (PILLAR and ASPIRE trials) - (11/13/12)
     
  5321. AASLD: OPTIMIZE Trial: Noninferiority of Twice-daily Telaprevir Versus Administration Every 8 Hours inTreatment-naïve, Genotype 1 HCV-infected Patients - (11/13/12)
     
  5322. AASLD: Safety and tolerability of simeprevir (TMC435) in combination with peginterferon a-2a and ribavirin for treatment of HCV genotype 1 infection in treatment-naïve and -experienced patients (Phase IIb PILLAR and ASPIRE Trials) - (11/13/12)
     
  5323. AASLD: Sustained Virologic Response in Chronic HCV Genotype (GT) 1-Infected Null Responders With Combination of Daclatasvir (DCV; NS5A Inhibitor) and Asunaprevir (ASV; NS3 Inhibitor) With or Without Peginterferon Alfa-2a/Ribavirin (PEG/RBV) - (11/13/12)
     
  5324. AASLD: Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine and ribavirin with or without peginterferon alfa-2a (40KD) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study - (11/13/12)
     
  5325. AASLD: Safety and efficacy of ritonavir-boosted danoprevir (DNVr), peginterferon alfa-2a (40KD), and ribavirin with or without mericitabine in HCV genotype 1-infected treatment-experienced patients with advanced hepatic fibrosis: the MATTERHORN study - (11/13/12)
     
  5326. AASLD: ALS-2200, A Novel Once-daily Nucleotide HCV Polymerase Inhibitor, Demonstrates Potent Antiviral Activity Over 7 Days in Treatmentnaïve Genotype 1 (GT1) Patients - (11/13/12)
     
  5327. AASLD: Safety and Sustained Viral Response of MK-5172 for 12 Weeks in Combination With Pegylated Interferon Alfa-2b and Ribavirin for 24 Weeks in HCV Genotype 1 Treatment-Naive Noncirrhotic Patients - (11/13/12)
     
  5328. AASLD: A Combination Containing MK-5172 (HCV NS3 protease inhibitor) and MK-8742 (HCV NS5A inhibitor) Demonstrates High Barrier to Resistance in HCV Replicon - (11/13/12)
     
  5329. AASLD: A 12-week Interferon-free Treatment Regimen With ABT-450/r, ABT 267, ABT-333, and Ribavirin Achieves SVR12 Rates (Observed Data) of 99% in Treatment-naïve Patients and 93% in Prior Null Responders With HCV Genotype 1 Infection - (11/13/12)
     
  5330. AASLD: High Efficacy of GS-7977 in Combination with Low or Full dose Ribavirin for 24 weeks in Difficult to Treat HCV Infected Genotype 1 Patients - (11/13/12)
     
  5331. AASLD: An Interferon-Free, Ribavirin-Free 12-Week Regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 Yielded SVR4 of 94% in Treatment-Naïve Patients with Genotype (GT) 1 Chronic Hepatitis C Virus (HCV) Infection - (11/13/12)
     
  5332. AASLD: High Rate of Sustained Virologic Response With the All-Oral Combination of Daclatasvir (NS5A Inhibitor) Plus Sofosbuvir (Nucleotide NS5B Inhibitor), With or Without Ribavirin, in Treatment-Naive Patients Chronically Infected With HCV GT 1, 2, or 3 - (11/13/12)
     
  5333. AASLD: Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Co-infected Patients: SVR24 Final Study Results - (11/13/12)
     
  5334. AASLD: The NS5A Inhibitor GS-5885 Is Safe and Well Tolerated in More Than 1000 Patients Treated in Phase 2 Studies - (11/13/12)
     
  5335. AASLD: Comprehensive Resistance Testing in Patients Who Relapsed After Treatment With Sofosbuvir (GS-7977)-Containing Regimens in Phase 2 Studies - (11/13/12)
     
  5336. AASLD: In Vitro Analyses of Hepatitis C Virus NS5B S282T Mutants in Multiple HCV Genotypes Show Low Levels of Reduced Susceptibility to Sofosbuvir (GS-7977), No Cross Resistance to Other Classes of Direct-Acting Antivirals, and Hypersensitivity to Ribavirin - (11/13/12)
     
  5337. AASLD: Six Weeks of an NS5A Inhibitor (GS-5885) and a Protease Inhibitor (GS-9451) Plus Peginterferon+Ribavirin Achieves High SVR4 Rates in Genotype 1 IL28B CC Treatment-Naïve Hepatitis C Virus Patients: Interim Results of a Prospective, Randomized Trial - (11/13/12)
     
  5338. Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? - (11/07/12)
     
  5339. Merck Will Initiate Interferon-Free Phase II Clinical Trials for MK-5172, an Investigational, Once-Daily, Oral Treatment for Chronic Hepatitis C Virus - (11/08/12)
     
  5340. Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers Review - (11/08/12)
     
  5341. ABT-450/ABT-267 in Genotypes 2/3 - (11/03/12)
     
  5342. IDSA: National trends in hospitalization and mortality for patients with HIV, HCV, or HIV/HCV co-infection: HCV Hospitalization Rates Increasing - (10/23/12)
     
  5343. IDSA: Describing the Burden of Hepatitis C (HCV) in a large public health care system (Chicago); Initial response to the National Viral Hepatitis Action Plan - (10/23/12)
     
  5344. HCV Protease Sales/Vertex ALS2200 Future - (10/23/12)
     
  5345. New Meta-Analysis Study: Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials: HCC incidence is diminished in both virological responders and non-responders -- see new study below these links to other recent studies also showing SVR reduces cancer, mortality - (10/23/12)
     
  5346. New Rapid And Point Of Care Hepatitis C Tests May Be Worldwide Game Changers - (10/22/12)
     
  5347. IDSA: Correlates of HIV, HCV and HIV/HCV Co-Infection in a Northeastern Inner City Population - (10/22/12)
     
  5348. Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus-Infected Patients Following TMC435 Monotherapy - (10/20/12)
     
  5349. BioCryst Pharmaceuticals and Presidio Pharmaceuticals to Merge - (10/19/12)
     
  5350. IDSA: The Pharmacokinetic Interactions of the HCV Protease Inhibitor Simeprevir (TMC435) With HIV Antiretroviral Agents in Healthy Volunteers - (10/19/12)
     
  5351. IDSA: The Pharmacokinetics of Telaprevir and Selected ART Medications in HCV/HIV Coinfected Patients - (10/19/12)
     
  5352. IDSA: [poor] Quality of Hepatitis C care at an urban tertiary medical center - (10/19/12)
     
  5353. 2 Studies on IV Silibinin & Liver Transplants in HCV - (10/17/12)
     
  5354. Abbott Phase 3 Study - (10/17/12)
     
  5355. HCV Therapy 95-100% SVR Rates: new HCV drug data at AASLD next week - (10/16/12)
     
  5356. Bristol-Myers Squibb to Present New Data Demonstrating Company's Continuing Commitment to Research and Development in Liver Disease at The American Association for the Study of Liver Diseases (AASLD) Annual Meeting - - (10/16/12)
     
  5357. Abbott's Investigational Interferon-Free Hepatitis C Treatment Regimen Achieved SVR12 (Observed Data) Rates in 99 Percent of Treatment-Naïve and 93 Percent in Prior Null Responders for Genotype 1 Patients in Phase 2b Study - Press Release - (10/15/12)
     
  5358. New hepatitis C initiative in New Zealand - (10/11/12)
     
  5359. The burden of viral hepatitis C in Europe: a propensity analysis of patient outcomes - (10/11/12)
     
  5360. HCV Screening/Baby Boomers, a misleading characterization - (10/10/12)
     
  5361. HCV - Whats Coming - (10/10/12)
     
  5362. Santa Fe New Mexico Care center offers hepatitis C testing, support - (10/09/12)
     
  5363. Seroprevalence of hepatitis C, hepatitis B virus and syphilis in HIV-1 infected patients in Shandong, China: HCV/HIV coinfection rate; HCV sexual transmission - (10/09/12)
     
  5364. ICAAC: HCV/HIV co-infection and the degree of liver fibrosis as risk factors of HAART-associated nephrotoxicity - (10/09/12)
     
  5365. EASL Prague Special Conference on Therapy of Hepatitis C: Clinical Application and Drug Development Sept 14-16 - (10/02/12)
     
  5366. Data to Guide the "Test and Treat Era" of Hepatitis C: CDC Editorial - (10/02/12)
     
  5367. Predicted Effects of Treatment for HCV Infection Vary Among European Countries: 'Future HCV Therapies Can Reduce Cirrhosis & Death by 50-280% in Europe with Screening & Access Policies' - (10/02/12)
     
  5368. Vertex Announces New Data on ALS-2200 in People With Hepatitis C, Supporting Advancement into Phase 2 All-Oral Studies in 2012; Ends Development of ALS-2158 - (10/01/12)
     
  5369. Achillion Announces Positive Proof-of-Concept Data With ACH-3102 - (10/01/12)
     
  5370. Vertex Nuke Program ALS-2200 - (10/01/12)
     
  5371. Better Hepatitis C Treatment Is Costly for Prisons - (09/20/12)
     
  5372. A Phase IIa Interferon Free Combination Hepatitis C Trial of Simeprevir (TMC435) and TMC647055 Will Commence Shortly - (09/20/12)
     
  5373. Fatigue before, during and after antiviral therapy of chronic hepatitis C: Results from the Virahep-C study - (09/19/12)
     
  5374. All-cause and liver-related mortality in HIV positive subjects compared to the general population: Differences by HCV co-infection......'HCV/HIV Coinfected Death Rates 11 Times Higher than in the general population in Spain' - (09/13/12)
     
  5375. ICAAC: HIV/HCV Coinfected and HCV Monoinfected Patients Have Similar Early Hepatitis C Viral Kinetics with the Potent HCV Nucleotide Polymerase Inhibitor Sofosbuvir (SOF) - (09/13/12)
     
  5376. ICAAC: Safety & Efficacy of Raltegravir Over 3-5 Years in Patients Co-infected With HIV and Hepatitis B and/or C Virus - (09/11/12)
     
  5377. HCV BMS Phase 3: QUAD-Nulls/DUAL-IFN-Free - (09/7/12)
     
  5378. BMS032 HCV Protease in Phase 3 Now - (09/7/12)
     
  5379. Early treatment could clear Hepatitis C - (09/4/12)
     
  5380. 3 & 4 Oral IFN-Free Roche HCV Regimens Studies, Treatment Naïve or Null Responders: setrobuvir+mericitabine+danoprevir/r+rbv. ANNAPURNA Study... - (09/4/12)
     
  5381. Hepatitis Testing Saves Lives: CDC HCV Risk Assessment - (08/31/12)
     
  5382. Hepatitis C Virus Infections in the Swiss HIV Cohort Study: A Rapidly Evolving Epidemic: increasing incidence rate among HIV+ MSM - (08/30/12)
     
  5383. Bristol Drops Hepatitis Drug, Takes Charge - (08/27/12)
     
  5384. Effect on HCV Replication by Combinations of Direct Acting Antivirals Including NS5A Inhibitor Daclatasvir - (08/27/12)
     
  5385. Incivek (telaprevir) product labeling revised - (08/27/12)
     
  5386. Hepatitis C Drug (BMS nucleotide) Halted After Patient Death - (08/27/12)
     
  5387. Peginterferon Lambda: new interferon in phase 3 now - (08/27/12)
     
  5388. GS-7977 HCV Nucleotide in Phase 3 Now - (08/27/12)
     
  5389. Early-Onset Liver Fibrosis Due to Primary Hepatitis C Virus Infection Is Higher Over Time in HIV-Infected Men - (08/23/12)
     
  5390. Prevalence of tuberculosis, hepatitis C virus, and HIV in homeless people: a systematic review and meta-analysis - (08/21/12)
     
  5391. A case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis c following liver retransplantation - (08/20/12)
     
  5392. Relationship of Liver Disease Stage and Antiviral Therapy With Liver-Related Events and Death in Adults Coinfected With HIV/HCV - (08/20/12)
     
  5393. CDC HCV Screening Guidelines/Biggest Global Screening Project - (08/17/12)
     
  5394. Idenix Shares Plunge on Hepatitis C Treatment Heart Fears: IDX184 On Hold by FDA - (08/17/12)
     
  5395. Hepatitis C Virus Testing of Persons Born During 1945 to 1965: Recommendations From the Centers for Disease Control and Prevention FREE ONLINE FIRST - (08/17/12)
     
  5396. Hepatitis B and C Virus Infection Among 1.2 Million Persons With Access to Care: Factors Associated With Testing and Infection Prevalence- 1 in 5 were tested for HBV infection and 1 of 8 for HCV infection in 4 US HCOs - (08/17/12)
     
  5397. Achillion Announces Positive SVR4 Results From Phase 2 Study of Sovaprevir (Formerly ACH-1625) and Advancement of ACH-3102 - (08/09/12)
     
  5398. 3rd UPDATE: Bristol-Myers Halts Hepatitis C Study on Safety Issue - (08/02/12)
     
  5399. BMS Suspends Study of Nucleotide BMS094 Formerly INX189 - (08/02/12)
     
  5400. Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding - (08/01/12)
     
  5401. IAC: HCV/HIV Coinfection Higher Rates of Hepatic Decompnsation, Liver Cancer & Severe Liver Events - (08/01/12)
     
  5402. Vertex Nucleotide Analysis - (08/01/12)
     
  5403. Vertex Announces Positive Results from Viral Kinetic Study of the Nucleotide Analogue ALS-2200 in People with Hepatitis C - (07/30/12)
     
  5404. IAC: Differences in CD4+ T-cell Immune Activation in HIV, Hepatitis C (HCV), and HIV/HCV Coinfection are Influenced by HIV and HCV Infection Status - (07/30/12)
     
  5405. IAC: HCV viremia affects immune phenotypes in Elite controllers of HIV infection- A Women's Interagency HIV Study - (07/30/12)
     
  5406. N.H. hep C cluster not the first: stealing syringes in hospitals & infecting patients with HCV - (07/30/12)
     
  5407. Gilead Begins Single Pill Hepatitis C Study for 2014 Approval - (07/27/12)
     
  5408. IAC: Adding Nitazoxanide to PEG/RBV Does Not Improve SVR With HIV/HCV Genotype 1 - Written by Mark Mascolini - (07/26/12)
     
  5409. The Impact of Chronic Hepatitis C Virus Infection on Mortality - Editorial - (07/19/12)
     
  5410. Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study - (R.E.V.E.A.L.)-HCV study - (07/19/12)
     
  5411. ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: A prospective study - (07/17/12)
     
  5412. HCV RNA levels in a multiethnic cohort of injection drug users: Human genetic, viral and demographic associations - (07/17/12)
     
  5413. A stealthy killer, hepatitis C needs wider screening - (07/17/12)
     
  5414. HCV Research: new HCV drugs coming; interferon-free therapy - (07/13/12)
     
  5415. Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3, and GT1 - (07/13/12)
     
  5416. Hepatitis C Treatment Highlights From the 2011 American Association for the Study of Liver Disease Meeting - (07/12/12)
     
  5417. Medivir announces an interferon-free phase II combination trial with TMC435 and daclatasvir to commence shortly - (07/10/12)
     
  5418. HCV Viral Load Reduction Improved Inflammation, Fibrosis, Clinical Outcomes with PegIFn Lead-In Maintenance therapy in HALT-C - (07/10/12)
     
  5419. Overcoming Barriers to Care for Hepatitis C - Perspective - (07/10/12)
     
  5420. Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/HCV co-infected patients - "routine screening for insulin resistance among co-infected persons may be warranted" - (07/10/12)
     
  5421. Presidio Pharmaceuticals Successfully Completes Phase 1 Proof-of-Concept for PPI-668, its Potent HCV NS5A Inhibitor, in Hepatitis C Patients with Genotype-1 Infection - press release - (06/26/12)
     
  5422. Open-Label Study of GS-7977 + Ribavirin Pre-Transplant - (06/22/12)
     
  5423. Interferon responses and spontaneous HCV clearance: Is it all a matter of fat? Editorial - (06/20/12)
     
  5424. Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States - (06/20/12)
     
  5425. Hepatitis C Virus and the Infectious Diseases Community - (06/20/12)
     
  5426. Recent Successes and Noteworthy Future Prospects in the Treatment of Chronic Hepatitis C: TOWARD AN INTERFERON-FREE FUTURE? - (06/20/12)
     
  5427. HIV Coinfection With Hepatitis C Virus: Evolving Epidemiology and Treatment Paradigms - (06/20/12)
     
  5428. Idenix Announces Positive Clinical Data for HCV Drug Candidates IDX184 and IDX719(NS5A) - (06/20/12)
     
  5429. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C - (06/20/12)
     
  5430. Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin - (06/20/12)
     
  5431. All-cause and liver-related mortality in HIV-positive subjects compared to the general population: differences by HCV co-infection (in Spain) - (06/20/12)
     
  5432. USE OF TELAPREVIR PLUS PEG INTERFERON/RIBAVIRIN FOR NULL RESPONDERS POST OLT WITH ADVANCED FIBROSIS/CHOLESTATIC HEPATITIS C - (06/12/12)
     
  5433. Can Dietary Fish Intake Prevent Liver Cancer? Editorial - (06/12/12)
     
  5434. More Than 27% of LA Homeless Adults Have Hepatitis C, and Nearly Half Don't Know It - new study - (06/12/12)
     
  5435. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis: "HBV, HCV, HPV, and H pylori were together responsible for 1·9 million cases worldwide" - (06/05/12)
     
  5436. Gilead HCV SVR Registries - (06/03/12)
     
  5437. Mortality Due to HCV-Related Disease in HIV+ - (06/03/12)
     
  5438. Bristol urges combo hepatitis C study with Gilead - (06/01/12)
     
  5439. GSK files Revolade (eltrombopag) in hepatitis C in Europe and US - (06/01/12)
     
  5440. All-oral hep. C combos threaten interferon - (06/01/12)
     
  5441. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care - review - (06/01/12)
     
  5442. UAB Checking Baby Boomers for HCV - (05/30/12)
     
  5443. DDW: Fatty Liver Disease on Rise in Teens - (05/30/12)
     
  5444. Medivir announces TMC435 in an expanded clinical collaboration: TMC435+BMS NS5A, TMC435+INX189 - (05/30/12)
     
  5445. CDC recommends hepatitis C tests for all baby boomers: Hepatitis C is an unrecognized health crisis in the United States - (05/23/12)
     
  5446. PPHF 2012 Viral Hepatitis Early Identification and Linkage to Care FOA - May 17, 2012 - (05/24/12)
     
  5447. DDW: Hepatitis Patients at Risk for Accidental Acetaminophen Toxicity - (05/23/12)
     
  5448. HCV Patients May Be Able to Delay Therapy - (05/23/12)
     
  5449. Herbal, Dietary Supplements Take Toll on Liver - (05/23/12)
     
  5450. Current and Future Disease Progression of HCV-Infected Patients Among Different Age Groups - (05/23/12)
     
  5451. Achillion Announces Additional Proof-of-Concept Data With ACH-2684 for the Treatment of Hepatitis C - (05/23/12)
     
  5452. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study - (05/23/12)
     
  5453. "HCV and the ID physician: A perfect match" - (05/23/12)
     
  5454. EASL: Results of ENABLE-2, a Phase 3, Placebo-controlled, Multicenter Study of Eltrombopag, Peginterferon Alfa-2b, and Ribavirin Treatment in Patients with Hepatitis C and Thrombocytopenia - (05/23/12)
     
  5455. EASL: Summary from EASL 2012 for Hepatitis C Will there be an interferon-free HCV therapy for all: upcoming reality or just a vision? written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (05/22/12)
     
  5456. Achillion Advances Second Generation Pan-Genotypic NS5A Inhibitor, ACH-3102, Into Clinical Development - (05/09/12)
     
  5457. EASL: HCV Reinfection - (05/09/12)
     
  5458. Pakistan Hep C & IV Heroin Use - (05/08/12)
     
  5459. OraSure Technologies' CEO Presents at Deutsche Bank AG Health Care Conference (Transcript): "We believe that the market opportunity here in the United States for rapid hepatitis C test is in excess of $250 million."......"We believe the market opportunity for on a self test or HIV sold OTC is an excess of $500 million." - (05/08/12)
     
  5460. A review of hepatitis viral infections in Pakistan - (05/08/12)
     
  5461. Mortality in HCV-infected Patients with a Diagnosis of AIDS in the Era of Combination Anti-retroviral Therapy: 50% Higher Mortality in HIV/HCV Coinfected with AIDS (<200 cd4s) vs HIV monoinfected....30% unaware of diagnosis....HCV+ more likely black, women....among women being black associated with lack of awareness of HCV diagnosis.....better screening needed - (05/07/12)
     
  5462. Meta-Analysis: Increased Mortality Associated with Hepatitis C in HIV-Infected Persons Is Unrelated to HIV Disease Progression - (05/07/12)
     
  5463. Expanding Access to Treatment for Hepatitis C in Resource-Limited Settings: Lessons From HIV/AIDS - (05/07/12)
     
  5464. Hepatitis C a latent legacy of baby boomers' youth - (05/04/12)
     
  5465. May Is Hepatitis Awareness Month - (05/04/12)
     
  5466. Hepatitis Testing Day Saturday May 19 2012 - (05/04/12)
     
  5467. EASL: Cost Effectiveness of HCV Treatment in Genotype 1 Naïve Patients in 2012 in France - (05/04/12)
     
  5468. EASL: Use of Telaprevir Plus Peg Interferon/Ribavirin for Null Responders Post OLT With Advanced Fibrosis/Cholestatic Hepatitis C - (05/04/12)
     
  5469. EASL: Ribavirin Dose Modification in Treatment-naïve and Previously Treated Patients Who Received Telaprevir Combination Treatment: No Impact on Sustained Virologic Response in Phase 3 Studies - (05/04/12)
     
  5470. EASL: Early versus delayed treatment of acute hepatitis C: The German HEP - NET Acute HCV - III Study-a randomized controlled trial- - (05/04/12)
     
  5471. EASL: Low rate of on-treatment resistance to danoprevir bosted by ritonavir (DNVr) combined with peginterferon alfa-2a (40KD)/ribavirin: 12 week interim analysis from the DAUPHINE study - (05/04/12)
     
  5472. EASL: GS-6620, A Liver-Targeted Nucleotide Prodrug, Exhibits Antiviral Activity and Favorable Safety Profile Over 5 Days in Treatment Naïve Chronic HCV Genotype 1 Subjects - (05/04/12)
     
  5473. EASL: PRECLINICAL CHARACTERISTICS OF ACH-3102: A NOVEL HCV NS5A INHIBITOR WITH IMPROVED POTENCY AGAINST GENOTYPE-1A VIRUS AND VARIANTS RESISTANT TO 1ST GENERATION NS5A INHIBITORS - (05/02/12)
     
  5474. EASL: NOVEL NS5A INHIBITOR ACH-2928 PHASE 1 RESULTS IN HEALTHY VOLUNTEERS AND HCV GT-1 PATIENTS - (05/02/12)
     
  5475. EASL: CHARACTERIZATION OF HCV NS3 PROTEASE VARIANTS FROM PATIENTS ENROLLED IN A 28-DAY PHASE 2A TRIAL OF ACH-1625 DAILY DOSING PLUS PEG-IFN-ALPHA 2A/RBV - (05/02/12)
     
  5476. EASL: CONTINUED HIGH VIROLOGIC RESPONSE RATES WITH ACH-1625 DAILY DOSING PLUS PEGIFN-ALPHA 2A IN A 28-DAY AND 12-WEEK PHASE 2A TRIAL - (05/02/12)
     
  5477. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir - (04/27/12)
     
  5478. FDA Drug Safety Communication: Updated information on drug interactions between Victrelis (boceprevir) and certain boosted HIV protease inhibitor drugs - (04/27/12)
     
  5479. EASL: Triple Therapy With Daclatasvir (DCV; BMS-790052), Peginterferon Alfa-2a and Ribavirin in HCV-Infected Prior Null and Partial Responders: 12-Week Results of Phase 2b COMMAND-2 Trial - (04/27/12)
     
  5480. EASL: ABT-450/ritonavir (ABT-450/r) Combined With Pegylated Interferon Alpha-2a/Ribavirin (P/R) After 3-Day Monotherapy in HCV Genotype 1 (GT1)-Infected Treatment-Naïve Subjects: 12-Week Sustained Virologic Response (SVR12) and Safety Results - (04/27/12)
     
  5481. EASL: ABT-072 or ABT-333 Combined With Pegylated Interferon/Ribavirin After 3-Day Monotherapy in HCV Genotype 1 (GT1)-Infected Treatment-Naïve Subjects: 12-Week Sustained Virologic Response (SVR12) and Safety Results - (04/27/12)
     
  5482. EASL: FINAL RESULTS: Randomized, Double-blind, Placebo-controlled Safety, Anti-viral, Proof of Concept Study of Miravirsen, an Oligonucleotide Targeting miR-122, in Treatment-Naïve Patients with Genotype 1 Chronic HCV Infection - (04/27/12)
     
  5483. EASL: Closing Summary by Jean-Michel Pawlotsky: New HCV Drug Development, Goodbye Interferon?, Triple, QUAD, IFN-Free, Adherence, New HCV Drugs - (04/26/12)
     
  5484. EASL: Closing Summary by Jean-Michel Pawlotsky Part 3: New data on telaprevir & boceprevir, post-transplant telaprevir/boceprevir treatment in patients with severe recurrence - (04/26/12)
     
  5485. EASL: Closing Summary by Jean-Michel Pawlotsky Part 2: New HCV Models - (04/26/12)
     
  5486. EASL: Closing Summary by Jean-Michel Pawlotsky Part 1 Genetics, HBV Clinical Guidelines, HBV, HCV Fibrosis Progression, HBC Nucleotides, Alisporivir for HBV - (04/26/12)
     
  5487. EASL: Resistance: Meeting the Challenge: A- Telaprevir, B- Boceprevir Christophe Sarrazin - (04/26/12)
     
  5488. EASL: CUPIC: French Early Access Program - Compassionate Use of Protease Inhibitors in Viral C Cirrhosis - (04/26/12)
     
  5489. EASL: Asunaprevir (ASV; BMS-650032), an NS3 Protease Inhibitor, in Combination With Peginterferon and Ribavirin in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C Infection - (04/25/12)
     
  5490. Province of Quebec funds Vertex hepatitis C drug Telaprevir - (04/25/12)
     
  5491. Abbott HCV Boosted Protease ABT450 Blocks Protease Mutations/155 Similar as in HIV - (04/25/12)
     
  5492. Two Hepatitis C Treatments (Boceprevir, Telaprevir) Win U.K. Health-Cost Agency Backing - (04/25/12)
     
  5493. EASL: Safety and Antiviral Activity of ABT-267, a Novel NS5A Inhibitor, During 3-Day Monotherapy: First Study in HCV Genotype-1 (GT1)-Infected Treatment-Naïve Subjects - (04/25/12)
     
  5494. EASL: ABT-267 Combined With Pegylated Interferon Alpha-2a/ribavirin in Genotype 1 (GT1) HCV-Infected Treatment-Naïve Subjects: 12-Week Antiviral and Safety Analysis - (04/25/12)
     
  5495. EASL: Antiviral Activity and Resistance Profile of the Novel HCV NS5A Inhibitor GS-5885 - (04/25/12)
     
  5496. EASL: Persistence of NS5A Drug Resistance Mutations Following 3 Days of GS-5885 Monotherapy in Genotype-1 HCV Patients is Dependent on the HCV Subtype and Specific Mutation - (04/25/12)
     
  5497. EASL: A Phase 2a Study of BMS-791325, an NS5B Polymerase Inhibitor, With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C Virus Infection - (04/25/12)
     
  5498. EASL: IDENTIFICATION AND CHARACTERIZATION OF PPI-383, A NEXT GENERATION HCV NS5BNON-NUCLEOSIDE INHIBITOR WITH POTENT ACTIVITY AGAINST ALL MAJORHCV GENOTYPES - (04/25/12)
     
  5499. EASL: Presidio Pharmaceuticals Announces Phase 1a-1b Clinical Results with PPI-668, a Potent Pan-genotypic HCV NS5A Inhibitor - (04/25/12)
     
  5500. EASL: Presidio Pharmaceuticals Announces a New Clinical Candidate, PPI-383, a Novel Pan-Genotypic Non-Nucleoside Polymerase Inhibitor for HCV - (04/25/12)
     
  5501. EASL: The Effect of Renal Impairment and End Stage Renal Disease on the Single-Dose Pharmacokinetics of GS-7977 - (04/25/12)
     
  5502. EASL: GS-7977 400 mg QD Safety and Tolerability in the Over 500 Patients Treated for at Least 12 Weeks - (04/25/12)
     
  5503. EASL: Persistence of NS5A Drug Resistance Mutations Following 3 Days of GS-5885 Monotherapy in Genotype-1 HCV Patients is Dependent on the HCV Subtype and Specific Mutation - (04/25/12)
     
  5504. EASL: Patients of all IL28B Genotypes have High SVR Rates when Treated with VX-222 in Combination with Telaprevir/Peginterferon/Ribavirin in the ZENITH Study - (04/24/12)
     
  5505. EASL: INTERFERON-FREE TREATMENT WITH A COMBINATION OF MERICITABINE AND DANOPREVIR/R WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED PATIENTS - (04/24/12)
     
  5506. EASL: SVR24 AMONG G1/4 TREATMENT-NAIVE PATIENTS RECEIVING MERICITABINE IN COMBINATION WITH PEG-IFNα-2A/RBV: FINAL ANALYSIS FROM THE JUMP-C STUDY - (04/24/12)
     
  5507. EASL: Interferon-Free Regimens at EASL - (04/24/12)
     
  5508. EASL: Patients of all IL28B Genotypes have High SVR Rates when Treated with VX-222 in Combination with Telaprevir/Peginterferon/Ribavirin in the ZENITH Study - (04/24/12)
     
  5509. EASL: GS-9669, A Novel NS5B Non-Nucleoside Thumb Site II Inhibitor, Demonstrates Potent Antiviral Activity, Favorable Safety Profile and Potential for Once-Daily - (04/24/12)
     
  5510. EASL: The Effect of Hepatic Impairment on the Safety, Pharmacokinetics, and Antiviral Activity of GS-7977 in Hepatitis C Infected Subjects Treated for Seven Days - (04/24/12)
     
  5511. EASL: In Vitro Resistance Analysis of Merck's HCV NS5a Inhibitor MK-8742 Demonstrates Increased Potency AgainstClinical Resistance Variants and Improved Resistance Profile - (04/23/12)
     
  5512. Collaboration on Hepatitis Drugs Lags - (04/23/12)
     
  5513. EASL: Gilead, Bristol Hep C Drug Data Arrives at EASL: 100% Cure Rate with Bristol's phase II study of daclatasvir plus Gilead's GS-7977 in patients with genotypes 1, 2, and 3: SVR4 (early cure) rate in the genotype 1 patients: 100%. In genotype 2/3 patients, the SVR4 rate was 91%. - (04/23/12)
     
  5514. EASL: Futility Rules in Telaprevir Combination Treatment - (04/23/12)
     
  5515. EASL: 100% SVR in IL28B SNP rs12979860 C/C patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the PROVE2 trial - (04/23/12)
     
  5516. EASL: A RANDOMIZED TRIAL COMPARING RIBAVIRIN DOSE REDUCTION VERSUS ERYTHROPOIETIN FOR ANEMIA MANAGEMENT IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC HEPATITIS C RECEIVING BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN - (04/23/12)
     
  5517. EASL: A 12-Week Interferon-Free Regimen of ABT-450/r + ABT-333 + Ribavirin Achieved SVR12 in More Than 90% of Treatment-Naïve HCV Genotype-1-Infected Subjects and 47% of Previous Non-Responders - (04/23/12)
     
  5518. EASL: Pancreatitis Forces Halt to HCV Drug Trial - (04/22/12)
     
  5519. EASL: Sustained Virologic Response (SVR) in Prior PegInterferon/Ribavirin (PR) Treatment Failures After Retreatment with Boceprevir (BOC) + PR: PROVIDE Study Interim Results - (04/22/12)
     
  5520. EASL: SVR4 and SVR12 with an interferon-free regimen of BI 201335 AND BI 207127, +/- ribavirin, in treatment-naïve patients with chronic genotype-1 HCV infection: Interim results of SOUND-C2 - (04/22/12)
     
  5521. EASL: Alisporivir (ALV) plus Peg-interferon/Ribavirin (PR) in HCV G1 Treatment-experienced Patients Achieves Primary Endpoint with Superior Efficacy at Treatment Week 12 Compared to Retreatment with PR - (04/22/12)
     
  5522. EASL: Alisporivir plus ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-G2 or G3 patients: SVR12 results from VITAL-1 Phase 2b study - (04/22/12)
     
  5523. EASL: RAPID AND SUSTAINED ACHIEVEMENT OF UNDETECTABLE HCV RNA DURING TREATMENT WITH RITONAVIR-BOOSTED DANOPREVIR/PEG-IFNα-2A/RBV IN HCV GENOTYPE 1 OR 4 PATIENTS: DAUPHINE WEEK 36 INTERIM ANALYSIS - (04/22/12)
     
  5524. EASL: RITONAVIR SUBSTANTIALLY REDUCES REACTIVE METABOLITE FORMATION OF THE HCV PROTEASE INHIBITOR DANOPREVIR BOTH IN VITRO AND IN VIVO - (04/21/12)
     
  5525. EASL: Once Daily GS-7977 Plus Ribavirin in HCV Genotypes 1-3: The ELECTRON Trial - (04/21/12)
     
  5526. EASL: Gilead: Interim Sustained Virologic Response Rates in Treatment-Naïve HCV Genotype 1a and 1b Patients Treated for 12 or 24 Weeks with an Interferon-Free All-Oral Quad Regimen - (04/21/12)
     
  5527. Vertex Advances INCIVEK™ (telaprevir) and Broad Portfolio of Medicines in Development With Goal of Further Expanding and Improving Treatment for People With Hepatitis C - (04/19/12)
     
  5528. Vertex at EASL 2012 - (04/19/12)
     
  5529. New Data Analyses for VICTRELIS (boceprevir) Will Be Presented at The International Liver Congress / 2012 EASL Annual Meeting - (04/19/12)
     
  5530. EASL: The efficacy and safety of the interferon-free combination of BI 201335 and BI 207127 in genotype 1 HCV patients with cirrhosis: Interim analysis from SOUND-C2 - (04/20/12)
     
  5531. EASL: GS-7977 + PEG/RBV in HCV Genotype 1: The ATOMIC Trial An End To Response-Guided Therapy - (04/20/12)
     
  5532. EASL: GS-7977 Phase 2 Trials: Concordance of SVR4 with SVR12 and SVR24 in HCV Genotypes 1-3 - (04/20/12)
     
  5533. EASL: Peginterferon Lambda-1A (Lambda) Compared With Peginterferon Alfa-2A (Alfa) in Treatment- Naive Patients With HCV Genotypes 2 or 3: First SVR24 Results From EMERGE Phase IIb - (04/20/12)
     
  5534. EASL: Dual Oral Therapy with NS5A Inhibitor Daclatasvir (BMS-790052) and NS3 Protease Inhibitor Asunaprevir (BMS-650032) in HCV Genotype 1b-Infected Null Responders or Patients Ineligible/Intolerant to Peginterferon/Ribavirin - (04/19/12)
     
  5535. EASL: TMC435 with peginterferon and ribavirin in treatment-experienced HCV genotype 1 patients: the ASPIRE study, a randomised Phase IIb trial - (04/19/12)
     
  5536. EASL: TMC435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon / ribavirin treatment: Virologic analyses of the ASPIRE trial - (04/19/12)
     
  5537. EASL: Potent Viral Suppression With the All-Oral Combination of Daclatasvir (NS5A Inhibitor) and GS-7977 (Nucleotide NS5B Inhibitor), +/- Ribavirin, in Treatment-Naive Patients With Chronic HCV GT1, 2, or 3 (100% SVR gt1, 91% gt2) - (04/19/12)
     
  5538. EASL: A 12-Week Interferon-Free Regimen of ABT-450/r, ABT-072, and Ribavirin was Well Tolerated and Achieved Sustained Virologic Response in 91% Treatment-Naïve HCV IL28B-CC Genotype-1-Infected Subjects - (04/19/12)
     
  5539. EASL: All-Oral Combination of Investigational Hepatitis C (HCV) Compounds Daclatasvir and GS-7977 Achieved Sustained Virologic Response (SVR4) in 100% of Genotype 1 and 91% of Genotype 2 and 3 Treatment-Naïve Patients in Phase II Study - press release - (04/19/12)
     
  5540. EASL: Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Naïve Hepatitis C Patients - press release - (04/19/12)
     
  5541. EASL: Gilead Announces Sustained Virologic Response Data for 12-Week Regimen of GS-7977 Plus Pegylated Interferon and Ribavirin in Genotype 1 Hepatitis C Patients - press release - (04/19/12)
     
  5542. EASL: Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Naïve Hepatitis C Patients - press release - (04/19/12)
     
  5543. EASL: Viral cure achieved without interferon in up to 82% of hepatitis C patients (GT-1a & -1b*): protease inhibitor BI 201335 and the polymerase inhibitor BI 207127, both with and without ribavirin (Boerhinger Ingelheim) - press release - (04/19/12)
     
  5544. EASL: First ever data investigating interferon-free treatment in hepatitis C patients who have liver cirrhosis shows high viral cure rate: protease inhibitor BI 201335 plus the polymerase inhibitor BI 207127 plus ribavirin (Boerhinger Ingelheim) - (04/19/12)
     
  5545. EASL: Confirmation That Quadruple Therapy With Daclatasvir (NS5A Inhibitor), Asunaprevir (NS3 Inhibitor) and Peginterferon/Ribavirin Results in a High Rate of SVR4 in HCV Genotype 1 Null Responders - (04/19/12)
     
  5546. EASL: Abbott Presents Positive Results from Interferon-Free Phase 2 "Co-Pilot" Study for the Treatment of Hepatitis C - Press Release - (04/19/12)
     
  5547. Gilead Sciences to Present New Hepatitis B and C Data at European Conference on Liver Disease This Week - (04/18/12)
     
  5548. BMS/Medivir Announces TMC435 in an Expanded Clinical Collaboration - press release - (04/18/12)
     
  5549. 13th Intrntl Wrkshp Clinical Pharm HIV: No Relevant Interactions Between Telaprevir and Two Newest Nonnucleosides Rilpivirine & Etravirine - written by Mark Mascolini - (04/18/12)
     
  5550. Abbott HCV Drug Development Update - (04/13/12)
     
  5551. GS-7977 Phase 3 in Genotype 2/3 Started, in Gt1 Soon waiting for QUANTUM results, nucleotides & Other HCV Drugs - CORRECTED - (04/13/12)
     
  5552. EASL Brief Preview, liver conference next week in Barcelona: interferon-free therapies - (04/11/12)
     
  5553. Bristol-Gilead Hep C Drug EASL Data Leaks - CORRECTED - (04/10/12)
     
  5554. New DAA FDA Guidance March 2012 - (04/10/12)
     
  5555. Medivir Announces Final Results from TMC435 Phase IIb ASPIRE (C206) Study - (04/10/12)
     
  5556. DAA Update - (04/10/12)
     
  5557. Estimates of the Population Prevalence of Injection Drug Users among Hispanic Residents of Large US Metropolitan Areas - (04/04/12)
     
  5558. Abbott hepatitis C combo impressive in small study: is the new standard of care 95% in naives? - (04/04/12)
     
  5559. Abbott to Present Positive Phase 2 Results from Multiple Interferon-Free Studies of Combination Regimens for the Treatment of Hepatitis C - press release - (04/04/12)
     
  5560. Economic burden of hepatitis C-associated diseases in the United States - (04/04/12)
     
  5561. Bristol-Myers Squibb to Present New Data Demonstrating Company's Commitment to Research and Development in Liver Disease at The International Liver CongressTM / European Association for the Study of the Liver (EASL) Annual Meeting - (04/04/12)
     
  5562. CROI: HIV/HCV Co-Infection: Untreated Epidemic in Urban Miami - (04/02/12)
     
  5563. CROI: In HIV/HCV Co-infected Patients, Higher Levels of 25infected 25-Hydroxyvitamin D Were Not Associated with HCV Treatment Responses, but Were Associated wit with Ritonavir Use - (04/02/12)
     
  5564. CROI: Augmentation of Interferon signaling pathway by Nitazoxanide: A therapeutic strategy for HIV/HCV Coinfected Relapsers to Peg-interferon and Ribavirin therapy. - (04/02/12)
     
  5565. CROI: Nitazoxanide (NTZ) may Mitigate the Unfavorable Association between IL28B Genotype and Hepatitis C Virus (HCV) Treatment Response to Pegylated Interferon- based (PEG) therapy - (04/02/12)
     
  5566. CROI: Safety and Anti Anti-HCV Activity of Rescue Therapy with Intravenous Silibinin (LEGALON ) in Cirrhotic HIV/HCV-infected Subjects - (04/02/12)
     
  5567. VICTRELIS™ Now Available for Eligible Patients in British Columbia - (03/29/12)
     
  5568. 2 to 5 % diagnosed with hepatitis C' in Kuwait - (03/29/12)
     
  5569. Screening for HCV Infection in Jails - Viewpoint - (03/28/12)
     
  5570. HCV CO-infection Guidelines Updated- New HCV Treatment - (03/28/12)
     
  5571. Okairos announces initiation of Phase I/II clinical trial for potential first-in-class hepatitis C vaccine - (03/21/12)
     
  5572. Expanding Access to Treatment for Hepatitis C in Resource-Limited Settings: Lessons From HIV/AIDS - pdf attached - (03/21/12)
     
  5573. CROI: Early On-treatment Responses to Telaprevir Are Lower, but Do Not Differ Significantly between HIV/HCV Co-infected and HCV Mono-infected Patients - (03/20/12)
     
  5574. CROI: Summary from CROI 2012 for Hepatitis Co-infection HCV direct acting antivirals (DAAs) demonstrated to work in HIV/HCV coinfection: so how are treatment paradigms in HIV/HCV coinfection changing now? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/19/12)
     
  5575. Cost-Effectiveness and Population Outcomes of General Population Screening for Hepatitis C: significantly reducing HCV-related morbidity and mortality would also require improved rates of referral, treatment, and cure improved referral and treatment could approximately double the impact of broadened screening strategies - (03/16/12)
     
  5576. Hepatitis C in Miami/Ft Lauderdale: Hepatitis C targets baby boomers - (03/14/12)
     
  5577. CROI: IFN/RBV Treatment for HCV is Associated with Development of Hypophosphatemia in HIV/HCV Co-Infected Patients! - (03/14/12)
     
  5578. CROI: HEPATITIS C INCIDENCE IN THE SWISS HIV COHORT STUDY: A CHANGING EPIDEMIC - Increased 18-fold among MSM, decreased in IDUs - (03/14/12)
     
  5579. CROI: Assessment of HIV Antiretroviral Drug Interactions With the HCV NS5A Replication Complex Inhibitor Daclatasvir Demonstrates a PK Profile Which Supports Coadministration With Tenofovir, Efavirenz and Atazanavir/r - (03/9/12)
     
  5580. CROI: GS-7977 + Ribavirin in HCV Genotype 1 Null Responders: Results from the ELECTRON Trial - (03/7/12)
     
  5581. CROI: PHARMACOKINETIC INTERACTION BETWEEN THE HCV PROTEASE INHIBITOR BOCEPREVIR AND RITONAVIR-BOOSTED HIV-1 PROTEASE INHIBITORS ATAZANAVIR, LOPINAVIR, AND DARUNAVIR - (03/7/12)
     
  5582. CROI: The Pharmacokinetic Interactions of HCV Protease Inhibitor TMC435 with Rilpivirine, Tenofovir, Efavirenz or Raltegravir in Healthy Volunteers - (03/7/12)
     
  5583. CROI: Evaluation of NS3 Amino Acid Variants in a Phase 1b Study of GT 1 Infection with the HCV Protease Inhibitor, MK-5172 - (03/7/12)
     
  5584. CROI: Influence of the HCV Protease Inhibitor Boceprevir on the Pharmacokinetics of the HIV Integrase Inhibitor Raltegravir - (03/7/12)
     
  5585. CROI: Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Co-infected Patients: SVR12 Interim Analysis - (03/7/12)
     
  5586. CROI: Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co-Infected Patients - (03/7/12)
     
  5587. CROI: HCV PI Boceprevir Lowers Levels of Three Key HIV PIs - written by Mark Mascolini - (03/7/12)
     
  5588. Ultrasound Elastography Fibrosis/Cirrhosis Diagnosis of HCV Effective in Liver Transplant - (03/03/12)
     
  5589. Liver-induced inflammation hurts the brain - (03/02/12)
     
  5590. TMC435-TiDP16-C212 - Trial of TMC435 in Genotype 1 Hepatitis C and Human Immunodeficiency Virus Co-Infected Patients - (03/02/12)
     
  5591. Is HCV Infection a Neurologic Disorder? - (03/02/12)
     
  5592. TMC435HPC2002 - Phase II Trial of TMC435 in Combination With PSI-7977 in Prior G1 Null Responders to Peg-IFN/RBV, Hepatitis C-Infected Patients - (02/29/12)
     
  5593. HCV Therapy for African-Americans - (02/29/12)
     
  5594. Stanford scientists model hepatitis C treatment options, Cost-Effectiveness - (02/28/12)
     
  5595. APASL: HCV in China: HCV Viral and Host Genotypes Distribution among Han Ethnic Chinese in China - (02/28/12)
     
  5596. APASL: Estimating the incidence and prevalence of hepatitis C infection in Taiwan using backprojection methods - (02/28/12)
     
  5597. Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C - (02/27/12)
     
  5598. APASL: Antiviral Activity of GS-9451, an HCV Specific NS3 Protease Inhibitor, in a Three-Day, Dose-Ranging, Monotherapy Study in Patients with Genotype 1 Hepatitis C Infection - (02/27/12)
     
  5599. APASL: Antiviral Activity and Characterization of Resistance in a Three Day Dose Ranging Study of GS-5885, a Novel HCV NS5A inhibitor - (02/27/12)
     
  5600. APASL: PEGINTERFERON LAMBDA-1a(LAMBDA) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGINTERFERON ALFA-2a(ALFA-2a) IN PATIENTS WITH CHRONIC HCV INFECTION (G1/2/3/4): EMERGE PHASE 2bTHROUGH WEEK 12RESULTS - (02/27/12)
     
  5601. APASL: SAFETY AND EFFICACY OF PEGINTERFERON LAMBDA-1a (LAMBDA) COMPARED WITH PEGINTERFERON ALFA-2a (ALFA-2a) IN HCV-INFECTED PATIENTS (G1/2/3) WITH COMPENSATED CIRRHOSIS: EMERGE PHASE 2b EFFICACY AND SAFETY RESULTS THROUGH WEEK 12 - (02/27/12)
     
  5602. APASL: Hepatitis B Surface Antigen (HBsAg) Loss in HBeAg+ Patients with Chronic Hepatitis B (CHB) Treated with Tenofovir Disoproxil Fumarate (TDF) - (02/25/12)
     
  5603. APASL: DACLATASVIR (BMS-790052), AN NS5A REPLICATION COMPLEX INHIBITOR, COMBINED WITH PEGINTERFERON-ALFA-2a AND RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1 OR 4 SUBJECTS: PHASE 2B AI444010 STUDY INTERIM WEEK 24 RESULTS - (02/25/12)
     
  5604. APASL: DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR (BMS-790052) AND THE NS3 PROTEASE INHIBITOR ASUNAPREVIR (BMS-650032) IN HCV GENOTYPE 1b-INFECTED NULL RESPONDERS OR PATIENTS INELIGIBLE/INTOLERANT TO PEGINTERFERON/RIBAVIRIN - (02/25/12)
     
  5605. APASL: DACLATASVIR (BMS-790052), AN NS5A REPLICATION COMPLEX INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2B AND RIBAVIRIN IN JAPANESE TREATMENT-NAIVE AND NONRESPONDER PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION - (02/25/12)
     
  5606. APASL: COMBINATION THERAPY OF TREATMENT-NAIVE AND NONRESPONDER PATIENTS WITH HCV GENOTYPE 1 INFECTION WITH DACLATASVIR (DCV; BMS-790052), AN NS5A REPLICATION COMPLEX INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN - (02/25/12)
     
  5607. APASL: BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN IN THE TREATMENT OF CHRONIC HEPATITIS C VIRUS GENOTYPE-1 INFECTED ASIAN PATIENTS IN THE SPRINT-1, SPRINT-2, AND RESPOND-2 TRIALS - (02/23/12)
     
  5608. APASL: Response-guided danoprevir (DNV; RG7227) plus Peg-IFNα-2a and ribavirin (RBV) in ATLAS: High sustained virological response (SVR24) rates in treatment -naive hepatitis C virus (HCV) genotype 1 (G1) patients - (02/23/12)
     
  5609. APASL: INTERFERON (IFN)-FREE TREATMENT WITH ONCE-DAILY ALISPORIVIR (ALV) ACHIEVES AND MAINTAINS HIGH RATES OF UNDETECTABLE HCV RNA IN A GLOBAL POPULATION OF TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPE (G) 2 OR 3 (VITAL-1 STUDY) - (02/23/12)
     
  5610. Vertex Announces 12-Week On-Treatment Data and SVR4 From Phase 2 Study of Interferon-Free (All-Oral) Treatment Regimen of INCIVEK®, VX-222 and Ribavirin in People with Genotype 1 Hepatitis C - (02/23/12)
     
  5611. Baby Boomers' Drug Use Pushes U.S. Hepatitis Deaths Past HIV, Hepatitis is Public Health Epidemic, CDC Study Finds - (02/22/12)
     
  5612. Hepatitis C Bigger Killer than HIV: 'Baby Boomers Dying from HCV & HBV - (02/22/12)
     
  5613. Hepatitis C: The End of the Beginning and Possibly the Beginning of the End - Editorial - (02/22/12)
     
  5614. The Cost-Effectiveness of Birth-Cohort Screening for Hepatitis C Antibody in U.S. Primary Care Settings - (02/22/12)
     
  5615. New Cost Effectiveness Study Published: HCV Protease Inhibitor Triple Therapy Cost Effective, Saves Lives..... Universal treatment led to greater benefit but at higher cost - (02/22/12)
     
  5616. The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007: HCV had superseded HIV as a cause of death in the United States, Hepatitis Receives Little Attention/Funding - (02/22/12)
     
  5617. Novartis Buys Enanta NS5A HCV Drug - (02/22/12)
     
  5618. APASL: Vertex QUAD Therapy Yielded 83-93% SVR with 12 weeks duration of therapy: VX-222/TELAPREVIR IN COMBINATION WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN TREATMENT-NAï VE GENOTYPE 1 HCV PATIENTS TREATED FOR 12 WEEKS: ZENITH STUDY, SVR12 INTERIM ANALYSIS - (02/22/12)
     
  5619. APASL: RETREATMENT WITH TELAPREVIR + PEGINTERFERON/RIBAVIRIN AFTER A SHORT EXPOSURE TO TELAPREVIR IN PHASE 1 STUDIES: INTERIM RESULTS FROM A PHASE 3B ROLLOVER TRIAL (C219) - (02/22/12)
     
  5620. APASL: IMPACT OF ANEMIA AND RIBAVIRIN DOSE REDUCTION ON SVR TO A TELAPREVIR-BASED REGIMEN IN PATIENTS WITH HCV GENOTYPE 1 AND PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE IN THE PHASE 3 REALIZE STUDY - (02/22/12)
     
  5621. APASL: EFFICACY AND SAFETY OF TELAPREVIR-BASED REGIMENS IN CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1 AND PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE: SUBANALYSIS OF THE REALIZE PHASE 3 STUDY - (02/22/12)
     
  5622. APASL: DRUG INTERACTION PROFILE OF TELAPREVIR - (02/22/12)
     
  5623. APASL: FOLLOW-UP OF SVR DURABILITY AND VIRAL RESISTANCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH TELAPREVIR-BASED REGIMENS: INTERIM ANALYSIS OF THE EXTEND STUDY - (02/22/12)
     
  5624. APASL: SUSTAINED VIROLOGIC RESPONSE RATES AND VIRAL RESISTANCE PROFILES WERE SIMILAR IN PATIENTS TREATED WITH A TELAPREVIR-BASED REGIMEN REGARDLESS OF LIVER FIBROSIS STAGE - (02/22/12)
     
  5625. APASL: ALISPORIVIR (ALV) PLUS Peg-IFN/RBV (PR) HAS 100% SVR IN IL28B rs12979860 CC ALLELE AND SUPERIOR EFFICACY IN CHRONIC HEPATITIS C GENOTYPE (G) 1 TREATMENT-NAIVE PATIENTS COMPARED WITH PR: THE ESSENTIAL STUDY - (02/22/12)
     
  5626. APASL: Alisporivir, a Host-targeting Antiviral, in Combination with Peg-IFNα2a and Ribavirin Results in Superior SVR and No Viral Breakthrough in HCV Genotype 1 Treatment-naïve Patients of IL28B CC Genotype: Results from the Phase IIb ESSENTIAL Study - (02/22/12)
     
  5627. APASL: DIFFERENT LIKELIHOOD OF ACHIEVING SVR ON A TELAPREVIR-CONTAINING REGIMEN AMONG NULL RESPONDERS, PARTIAL RESPONDERS AND RELAPSERS IRRESPECTIVE OF SIMILAR RESPONSESAFTER A PEGINTERFERON/RIBAVIRIN 4-WEEK LEAD-IN PHASE: REALIZE STUDY SUBANALYSIS: "When examining this population of TVR-treated patients as a whole, there was a clear relationship between Week 4 response and SVR rates" - (02/22/12)
     
  5628. Gilead Suffers First Hep C Drug Setback - (02/17/12)
     
  5629. GILEAD ANNOUNCES DATA FOR GENOTYPE 1 NULL RESPONDER HEPATITIS C PATIENTS ENROLLED IN ELECTRON STUDY - (02/17/12)
     
  5630. BioCryst Reveals Favorable Preclinical Results For Nucleotide BCX5191 For Hepatitis C - (02/16/12)
     
  5631. Hep C drug deal frenzy can't be slowed by growing doubts - (02/15/12)
     
  5632. Hep Dart Slide Presentations - (02/15/12)
     
  5633. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice - (02/15/12)
     
  5634. Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals - (02/14/12)
     
  5635. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2 to 6: TMC435-C202, a phase IIa, open-label study - Article in Press - (02/13/12)
     
  5636. A Phase 1, Randomized, Placebo-Controlled, Three-Day, Dose-Ranging Study of GS-5885, an NS5A Inhibitor, in Patients with Genotype 1 Hepatitis C - (02/13/12)
     
  5637. FDA Hepatitis Update - Victrelis (boceprevir) and Ritonavir-Boosted HIV Protease Inhibitor Drugs - Drug Interactions - (02/09/12)
     
  5638. SUBJECT: Results of Pharmacokinetic Study in Healthy Volunteers Given VICTRELIS™ (boceprevir) and Ritonavir-Boosted HIV Protease Inhibitors May Indicate Clinically Significant Drug Interactions for Patients Coinfected with Chronic Hepatitis C and HIV - (02/07/12)
     
  5639. Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C - (02/06/12)
     
  5640. Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis - (02/06/12)
     
  5641. New HCV Drug Development Programs - (02/06/12)
     
  5642. "Are we ready for IFN-free treatment regimens?" - (02/06/12)
     
  5643. Early HCV Treatment, [Cost] Effectiveness of Fibrosis Assessment Before Therapy - (02/03/12)
     
  5644. Nurse HCV Care/Treatment Adherence Support/Education Systems Improve SVR - (02/03/12)
     
  5645. A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse - (02/03/12)
     
  5646. Victrelis-New Hep C treatment available in Australia - (02/03/12)
     
  5647. Medivir/Tibotec HCV Drug Development - (02/03/12)
     
  5648. Gilead Sciences' CEO Discusses Q4 2011 Results - Earnings Call Transcript (PSI-7977 Gt1 HCV Discussion: Norbert W. Bischofberger) - (02/03/12)
     
  5649. HCV/Heroin Epidemic in Youth Nationwide: Cortland (NYS) sees spike in Hepatitis C in young drug users/new report - (02/03/12)
     
  5650. Studies Illustrate Role of HCV Infection As Risk Factor for Liver Cancer Researchers Stress Importance of Early Detection of HCV: 'HCV now is leading cause of liver cancer in US, liver cancer rates were 2-3 times higher in Mayo Clinic study than currently reported national rates, immigrants are coming into US with higher than expected rates of HCV, screening/treatment guidelines should be considered' - (02/03/12)
     
  5651. Quadruple Therapy With BMS-790052, BMS-650032 and Peg-IFN/RBV for 24 Weeks Results in 100% SVR12 in HCV Genotype 1 Null Responders: original slide presentation at EASL April 2011 Proof of Concept that SVR is Achievable Without Peg/RBV - 4/11 null responder patients achieved SVR w/o Peg/Rbv, with only BMS-790052 (NS5A inhibitor) + BMS-650032 (protease inh) - (02/03/12)
     
  5652. Triple Therapy Using Telaprevir In The Treatment of Hepatitis C Recurrence After Liver Transplantation: An Early Single Center Experience. - (02/03/12)
     
  5653. HCV SVR Improves Quality of Life & Brain Function - (01/27/12)
     
  5654. Hepatitis: Brain endothelial cells support HCV entry and replication - (01/27/12)
     
  5655. Curing HCV For Many Coming - (01/23/12)
     
  5656. HCC Rates Very Underestimated by National Data & Driven by HCV in new study by Mayo Clinic - (01/23/12)
     
  5657. Viral Hepatitis Among Somali Immigrants in Minnesota: Association of Hepatitis C With Hepatocellular Carcinoma - "our study showed high rates of anti-HCV positivity in Somalis, confirmed by HCV RNA testing" - (01/23/12)
     
  5658. Hepatitis C Virus Infection and the Rising Incidence (Triples) of Hepatocellular Carcinoma - EDITORIAL - (01/23/12)
     
  5659. Gaps in the achievement of effectiveness of HCV treatment in national VA practice - "overall effectiveness of HCV therapy is low in a national sample of veterans with chronic HCV" - (01/23/12)
     
  5660. Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing - (01/23/12)
     
  5661. Yes! Statins can be given to liver patients - Editorial pdf attached - (01/23/12)
     
  5662. First Hepatitis C Treatment Data Demonstrating Proof of Principle with Direct-Acting Antiviral-only Therapy Published - BMS press release - (01/19/12)
     
  5663. Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1: 'this was the proof-of-concept study showing SVR ('cured') could be achieved without peg/rbv & with only 2 new oral HCV drugs' - (01/19/12)
     
  5664. The protease inhibitor GS-9256 and non-nucleoside polymerase inhibitor tegobuvir alone, with RBV or peginterferon plus RBV in hepatitis C - (01/13/12)
     
  5665. Dual therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b-infected null responders - (01/13/12)
     
  5666. The end of the beginning for hepatitis C treatment - (01/13/12) Commentary
     
  5667. New Study: Alisporivir With pegIFN/RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C: Open Label - (01/19/12)
     
  5668. Study of DEB025/Alisporivir Plus Pegylated Interferon alfa2a and Ribavirin and Boceprevir Plus Pegylated Interferon alfa2a and Ribavirin in African American Chronic Hepatitis C Genotype 1 Patients That Have Never Received Treatment for Their Hepatitis C - (01/19/12)
     
  5669. Inhibitex Auction Shows Battle for Hepatitis Drugs - (01/19/12)
     
  5670. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations - (01/12/12)
     
  5671. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive - (01/12/12)
     
  5672. Liver Fibrosis Progression After Acute Hepatitis C Virus Infection in HIV-Positive Individuals - (01/12/12)
     
  5673. Merck Hepatitis C Drug May 'Anchor' Future Worldwide Regimen: 'looking to make HCV deals' - (01/10/12)
     
  5674. AASLD: Eltrombopag Therapy for HCV-Related Thrombocytopenia: Final Results of ENABLE 1, a Phase 3, Multicenter Study of Eltrombopag as an Adjunct for Antiviral Treatment of Hepatitis C Virus-Related Chronic Liver Disease Associated with Thrombocytopenia - (12/12/11)
     
  5675. IDX184 a weak nuke? - (01/10/12)
     
  5676. PSI-938 and PSI-7977 as monotherapy and in combination & INX189 Monotherapy - (01/10/12)
     
  5677. Idenix Reports Advancement of HCV Development Pipeline: new NS5A & 'next-generation' nucleotides - (01/09/12)
     
  5678. Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184 - (01/09/12)
     
  5679. Idenix Update Slides - IDX184 Nucleotide, new IDX719 NS5A (slides attached from investor call this morning), 2 new nucleotides in development (IDX19368/IDX19370) - (01/09/12)
     
  5680. Presidio Pharmaceuticals Reports Progress with Hepatitis C Antiviral Programs - press release - (01/09/12)
     
  5681. B-MS to buy HCV firm Inhibitex in $2.50 billion deal - (01/09/12)
     
  5682. Presidio Pharmaceuticals Reports Progress with Hepatitis C Antiviral Programs - press release - (01/09/12)
     
  5683. B-MS to buy HCV firm Inhibitex in $2.50 billion deal - (01/09/12)
     
  5684. Bristol-Myers Squibb to Acquire Inhibitex - (01/07/12)
     
  5685. Merck's Frazier sees partnerships, acquisitions as key to building business - (01/07/12)
     
  5686. Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons - (01/04/12)
     
  5687. Mayo study links hepatitis C to liver cancer in Somali Immigrants - 'Screen Immigrants for HCV' - (01/03/12)
     
  5688. Touching some firm ground in the epidemiology of NASH - editorial - (12/29/11)
     
  5689. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort: 'incidental abnormal ALTs (liver function test)- 25% are NAFLD(fatty liver), 7.6% with suspected advanced liver fibrosis' - (12/29/11)
     
  5690. HCV Test & Treat - (12/29/11)
     
  5691. Important updates to PegIntron labeling - (12/29/11)
     
  5692. Scottish Medicines Consortium approves INCIVO® (telaprevir), a new treatment for genotype-1 chronic hepatitis C, for use within NHS Scotland1 - (12/29/11)
     
  5693. Tyzeka (telbivudine) labeling updates re: use with pegylated interferon alfa-2a - peripheral neuropathy - (12/29/11)
     
  5694. The Cost-Effectiveness of Birth-Cohort Screening for Hepatitis C Antibody in U.S. Primary Care Settings - (12/21/11)
     
  5695. Serum MicroRNAs as Biomarkers for Hepatocellular Carcinoma in Chinese Patients with Chronic Hepatitis B Virus Infection - (12/19/11)
     
  5696. Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy - (12/19/11)
     
  5697. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection - Review - - (12/19/11)
     
  5698. Pharmasset, Gilead Say Trial Change Won't Affect Takeover - (12/17/11)
     
  5699. Pharmasset's PSI938 Discontinued; Impact on Other Nukes in Hepatitis C? - (12/17/11)
     
  5700. Hep C Nukes/Drug Development - (12/17/11)
     
  5701. Pharmasset Announces Intent to Amend QUANTUM Trial - PSI938 liver function abnormality detected - (12/16/11)
     
  5702. Merck Announces Initiation of Clinical Development Collaboration with Roche To Evaluate Investigational Combination Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Infection" boceprevir+ mericitabine and Pegasys/ribavirin in null responders - (12/16/11)
     
  5703. 2 Adherence Studies- Telaprevir & Boceprevir - (12/13/11)
     
  5704. Treatment of Chronic Hepatitis Delta: Mission Impossible? - (12/12/11)
     
  5705. Interferon-Free Treatment Regimens for Hepatitis C: Are We There Yet? Editorial - - (12/12/11)
     
  5706. Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection - - (12/12/11)
     
  5707. AASLD: A comparison of current policy needs to control hepatocellular carcinoma (HCC) in ten countries: Is there international consensus?* - (12/12/11)
     
  5708. 2 New 1st-In-Class HCV Drugs: microRNA miR-122& p7 Inhibitor BIT225 which also has HIV Activity - (12/10/11)
     
  5709. Boehringer Ingelheim completes patient entry for Phase III trial programme in Hepatitis C - (12/10/11)
     
  5710. Vertex and Alios BioPharma Begin Clinical Studies of Nucleotide Drug Candidates ALS-2200 and ALS-2158 for the Treatment of Hepatitis C - (12/10/11)
     
  5711. New HCV drugs trigger race for more tolerable therapies (Abbott & Gilead planning 4-in-1 Pills) - (12/10/11)
     
  5712. AASLD: Validation of an HCV NS3/4A Sequencing Assay for Evaluating Resistance to Boceprevir, Telaprevir and Protease Inhibitor Candidates in a Clinical Reference Laboratory Setting - (12/08/11)
     
  5713. AASLD: Alisporivir - A Host-targeting Antiviral, Provides Low Viral Breakthrough Rate and High Barrier to Resistance in HCV Genotype 1 Treatment-naïve Patients in the Phase IIb ESSENTIAL Study - (12/08/11)
     
  5714. HepDART: REAL-LIFE SAFETY OF TELAPREVIR OR BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA/RIBAVIRIN, IN CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC) (12/08/11)
     
  5715. HepDART: Characterization of Virologic Resistance in HCV Genotype 1 Null Responders Receiving a Dual Direct- Acting Antiviral Combination of NS3 Protease Inhibitor Asunaprevir (ASV; BMS-650032) and NS5A Replication Complex Inhibitor Daclatasvir (DCV; BMS-790052) (poster presentation) (12/08/11)
     
  5716. HepDART: Characterization of Virologic Resistance in HCV Genotype 1 Null Responders Receiving a Dual Direct- Acting Antiviral Combination of NS3 Protease Inhibitor Asunaprevir (ASV; BMS-650032) and NS5A Replication Complex Inhibitor Daclatasvir (DCV; BMS-790052) (oral presentation) (12/08/11)
     
  5717. HepDART: Biotron study of lead Hepatitis C drug shows virus undetectable in patients after three months: 'First-in-class, new mode of action drug, Novel p7 inhibitor with the potential to increase the potency of current anti-HCV therapy' - 'BIT225 is a novel antiviral compound that inhibits the viroporin function of HIV-1 Vpu and HCV p7.....and a potentially useful agent to target cellular viral reservoirs' (12/08/11)
     
  5718. HepDART: Antiviral activity and tolerability of BIT225 plus pegylated interferon alfa-2b and weight-based ribavirin for 28 days in HCV treatment-naïve, genotype 1, mono-infected patients (12/08/11)
     
  5719. HepDART: Host targeting antiviral (HTA) alisporivir presents a high barrier to resistance both in vitro and in HCV patients with no cross-resistance to DAAs (12/08/11)
     
  5720. AASLD: Santaris Pharma A/S Phase 2a data of miravirsen shows dose-dependent, prolonged antiviral activity of 2-3 logs HCV RNA after four-week treatment in Hepatitis C patients - press release - (12/07/11)
     
  5721. AASLD: Anti-viral Proof of Concept Study of Miravirsen, an OligonucleotideTargeting miR-122, in Treatment Naïve Patients with Genotype 1 Chronic HCV Infection - (12/07/11)
     
  5722. HepDART: Alisporivir Plus Peg-IFN_-2a/Ribavirin Treatment for Chronic Hepatitis C Genotype 1 Treatment-Naïve Patients Shows Superior Sustained Virologic Response Irrespective of IL28B Genotype and High Barrier to Resistance (12/07/11)
     
  5723. HepDART: Pharmacokinetic Evaluation of the Interaction Between the HCV Protease Inhibitor Boceprevir and the HMG-CoA Reductase Inhibitors Atorvastatin and Pravastatin (12/07/11)
     
  5724. HepDART: Pharmacokinetic Interaction Between the HCV Protease Inhibitor Boceprevir and the Calcineurin Inhibitors Cyclosporine and Tacrolimus (12/07/11)
     
  5725. HepDART: Coadministration of the HCV Protease Inhibitor Boceprevir Has No Clinically Meaningful Effect on the Pharmacokinetics of the Selective Serotonin Reuptake Inhibitor Escitalopram in Healthy Volunteers (12/07/11)
     
  5726. HepDART: Treatment Week 12/24 Stopping Rules for Boceprevir (BOC) Combination Therapy with Peginterferon+Ribavirin (PR):Exploratory Analyses of SPRINT-2 and RESPOND-2 (12/07/11)
     
  5727. HepDART: Sustained Virologic Response in Prior Null Responders to Peginterferon/Ribavirin (PR) After Retreatment With Boceprevir + PR: The PROVIDE Study (12/07/11)
     
  5728. HepDART: Safety and Antiviral Activity of MK-5172, a Next Generation HCV NS3/4A Protease Inhibitor with a Broad HCV Genotypic Activity Spectrum and Potent Activity Against Known Resistance Mutants, in genotype-1 and -3 HCV-Infected Patients: '75% (30/40) of GT-1, and 38% (9/24) of GT-3 HCV-infected patients achieved plasma HCV RNA below the limit of quantitation with a 7 day monotherapy course of MK-5172' (12/07/11)
     
  5729. HepDART: Safety and Antiviral Activity of MK-5172, a Next Generation HCV NS3/4A Protease Inhibitor with a Broad HCV Genotypic Activity Spectrum and Potent Activity Against Known Resistance Mutants, in genotype-1 and -3 HCV-Infected Patients (12/07/11)
     
  5730. HepDART: Population and Clonal Analysis of Resistance-Associated Amino Acid Variants (RAVs) in Viruses From Patients Enrolled in a Phase 2b Study of MK-7009 (Vaniprevir): 'HCV Protease Resistance Persists-Clonal Sequencing-novel double/triple mutations detected up to 300 days after stopping HCV therapy' (12/07/11)
     
  5731. EASL: The Pharmacokinetic Interaction Between Methadone and the Investigational HCV Protease Inhibitor Telaprevir - (12/07/11)
     
  5732. HepDART: MK-5172, a Second Generation HCV NS3/4A Protease Inhibitor is Active Against Common Resistance Associated Variants (RAVs) and Exhibits Cross-Genotype Activity (12/06/11)
     
  5733. HepDART: Quantification of the Effect of Adherence to Clinical Outcomes in Telaprevir-based Regimens (12/06/11)
     
  5734. HepDART: No Significant Effect of the HCV Protease Inhibitor Telaprevir on Pharmacokinetics and Pharmacodynamics of Buprenorphine in HCV-negative Volunteers (12/06/11)
     
  5735. HepDART: Drug Interaction Profile of Telaprevir (12/06/11)
     
  5736. HepDART: Futility Rules in Telaprevir Combination Treatment (12/06/11)
     
  5737. HepDART: Review Activity/Safety: Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin Increased Sustained Virologic Response in Genotype 1 Chronic HCV (12/06/11)
     
  5738. Bristol-Myers Squibb Enters Clinical Collaboration Agreement with Tibotec Pharmaceuticals for Phase II Combination Study in Patients Chronically Infected with Hepatitis C - (12/05/11)
     
  5739. HepDART: Hepatitis C, A smouldering public-health crisis, 'Silent Epidemic' in U.S. Needs More Funding, Researcher Says - (12/05/11)
     
  5740. J&J, BMS join forces in race to develop interferon-free hep C combos - (12/05/11)
     
  5741. HCV & Re-Use of Syringes, China Latest Outbreak....Prevention - (12/05/11)
     
  5742. HepDART: PSI-7977 400 mg with PEG/RBV Provides 93% SVR Across HCV GT 1, 2 and 3 - (12/05/11)
     
  5743. NS5A HCV Drug Study Results, Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations - (12/05/11)
     
  5744. Surveillance for hepatocellular carcinoma: A standard of care, not a clinical option - editorial - (12/05/11)
     
  5745. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities - (12/05/11)
     
  5746. Feasibility of conducting a randomized control trial for liver cancer screening: Is a randomized controlled trial for liver cancer screening feasible or still needed? 'informed patients prefer surveillance' - (12/05/11)
     
  5747. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry - (12/05/11)
     
  5748. Boceprevir Case Study - (12/05/11)
     
  5749. AASLD: Lack of Effect of the Nucleotide Analog Polymerase Inhibitor PSI-7977 on Methadone PK and PD - (12/05/11)
     
  5750. AASLD: PSI-7977 Has No Effect on QTcF Intervals at Therapeutic or Supratherapeutic Doses - (12/05/11)
     
  5751. HepDART: PSI-7977 400 mg with PEG/RBV Provides 93% SVR Across HCV GT 1, 2 and 3 (12/05/11)
     
  5752. HepDART: PSI-7977 with PEG/RBV Elicits Rapid Declines in HCV RNA in Patients with HCV GT-4 and GT-6 (12/05/11)
     
  5753. HepDART: Global HCV - (12/01/11)
     
  5754. OraSure Technologies Receives CLIA Waiver for OraQuick(R) HCV Rapid Test - (11/30/11)
     
  5755. New Data Reported on INX-189, HCV Nucleotide - (11/30/11)
     
  5756. AASLD: Preclinical Characterization of a Series of Highly Potent Achiral Phosphorodiamidate Nucleotide Analogue Inhibitors of Hepatitis C Polymerase - (11/30/11)
     
  5757. AASLD: Cost-Effectiveness of Boceprevir Use in Patients with Chronic Hepatitis C Genotype-1 Who Failed Prior Treatment with Peginterferon/Ribavirin - (11/28/11)
     
  5758. Achillion Is in Talks With Potential Buyers or Partners - (11/22/11)
     
  5759. Hepatitis C virus (HCV) testing and diagnosis rates in the commercially insured and Medicare populations in the U.S: 'HCV testing rates low.... 1.1% in the commercial population and 1.7% in the Medicare population.....partially explain the high percentage (75%) of undiagnosed patients' (slides below) - (11/22/11)
     
  5760. Treatment Effect and Resistance Profiles Were Similar Between Black/African American and Non-Black/African American Patients Treated with a Telaprevir Combination Regimen - (11/22/11)
     
  5761. Pharmasset Purchase - (11/22/11)
     
  5762. AASLD: Treatment Week 12/24 Stopping Rules for Boceprevir (BOC) Combination Therapy with Peginterferon+Ribavirin (PR): Exploratory Analyses of SPRINT-2 and RESPOND-2 - (11/22/11)
     
  5763. AASLD: In Vitro Assessment of Potential Drug-Drug Interactions Between Telaprevir and Cyclophilin Inhibitors in the Treatment of Chronic Hepatitis C - (11/22/11)
     
  5764. AASLD: An Evaluation of Neutropenia in the Pivotal Studies of Boceprevir Plus Peginterferon alfa-2b/Ribavirin - (11/22/11)
     
  5765. AASLD: Cost-effectiveness analysis of a multidisciplinary support program in hepatitis C treatment - (11/22/11)
     
  5766. Cost-effectiveness Assessment of Telaprevir Combination Treatment Compared to Pegylated-Interferon + Ribavirin Alone in the Management of Chronic Hepatitis C in Patients Who Failed a Prior Pegylated-Interferon + Ribavirin Treatment - (11/21/11)
     
  5767. Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion - (11/21/11)
     
  5768. Gilead Acquires Pharmasset $11 Billion - (11/21/11)
     
  5769. Estimating the prevalence of Hepatitis C cases in New York State: 'chronic HCV prevalence estimate was 1.33% (range: 0.44, 2.31%) or 197,705 cases' - (11/21/11)
     
  5770. AASLD: Impact of Anemia and Ribavirin Dose Reduction on SVR to a Telaprevir-based Regimen in Patients with HCV Genotype 1 and Prior Peginterferon/Ribavirin Treatment Failure in the Phase III REALIZE Study - (11/21/11)
     
  5771. AASLD: Boceprevir/Merck HCV Presentations - AASLD, IDSA - (11/21/11)
     
  5772. AASLD: New HCV Drugs at AASLD - (11/21/11)
     
  5773. AASLD: MicroRNA Drug Safe in Ongoing HCV Study - (11/21/11)
     
  5774. AASLD: GSK's eltrombopag Platelet Booster Aids HCV Therapy - (11/21/11)
     
  5775. AASLD: Liver Cancer Therapy Positive in Early Trials - (11/21/11)
     
  5776. AASLD: Fatty Liver May Benefit from Mediterranean Diet - (11/21/11)
     
  5777. AASLD: ITPA Deficiency is Associated with Lower Rates of Anemia and EPO use in Patients Treated with Boceprevir (BOC) plus Peginterferon/Ribavirin (PR) - (11/20/11)
     
  5778. AASLD: Telaprevir at AASLD - (11/20/11)
     
  5779. AASLD: Projections Using Decision-Analytic Modeling of Long-Term Clinical Value of Telaprevir for the Treatment of HCV Patients Who Had Failed Prior Peginterferon/Ribavirin Treatment - (11/16/11)
     
  5780. AASLD: Evaluation of Drug Interaction Potential of the HCV Protease Inhibitor Asunaprevir (ASV; BMS-650032) at 200 mg Twice Daily (BID) in Metabolic Cocktail and P-glycoprotein (P-gp) Probe Studies in Healthy Volunteers - (11/16/11)
     
  5781. AASLD: Single-Dose Pharmacokinetics of Daclatasvir (DCV; BMS-790052) in Subjects With Hepatic Impairment Compared With Healthy Subjects - (11/16/11)
     
  5782. AASLD: Daclatasvir (DCV; BMS-790052) Has No Clinically Significant Effect on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Female Subjects - (11/16/11)
     
  5783. AASLD: Prevalence of HCV Viral and Host IL28B Genotypes in China - (11/16/11)
     
  5784. AASLD: NO DETECTION OF VARIANTS BEARING NS5B S282T MERICITABINE (MCB) RESISTANCE MUTATION IN DAA TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED PATIENTS USING ULTRA-DEEP PYROSEQUENCING (UDPS) - (11/16/11)
     
  5785. AASLD: Influence of Hepatitis C Virus (HCV) Genotype-1 (G1) Subtype, Baseline Viral Load and IL28B Genotype on Peginterferon (PEG-IFN)/Ribavirin (RBV) Treatment Response: Results of the IDEAL Study - (11/16/11)
     
  5786. AASLD: Efficacy of Boceprevir in Prior Null Responders to Peginterferon/Ribavirin: The PROVIDE Study - (11/16/11)
     
  5787. AASLD: Records Show Deaths Associated with Hepatitis C Have Overtaken Deaths Caused by HIV: 'By 2007 hepatitis C-associated deaths had overtaken HIV as a cause of mortality in the United States. To achieve declines in mortality similar to those seen with HIV will require new policy directions and commitment to detect and link infected persons to care and successful treatment' - (11/16/11)
     
  5788. AASLD: Once-Daily Narlaprevir (NVR; SCH 900518) and Ritonavir (RTV) in Combination With Peginterferon Alfa-2b/Ribavirin (PR) for 12 Weeks Plus 12 Weeks PR in Treatment-Naive Patients With HCV Genotype 1 (G1): SVR Results From NEXT-1, a Phase 2 Study - (11/16/11)
     
  5789. AASLD: In vitro Assessment of Drug-Drug Interaction Potential of Boceprevir As an Inhibitor and Inducer of Drug Metabolizing Enzymes and Transporters - (11/16/11)
     
  5790. AASLD: A US-Based Cost-Effectiveness Analysis of Boceprevir-Based Regimens in Previously Untreated Adult Subjects with Chronic Hepatitis C Genotype 1 - (11/16/11)
     
  5791. AASLD: Safety and Efficacy of Vaniprevir (MK-7009) in Combination with Peg-interferon a-2a (Peg-IFN)/Ribavirin (RBV) in Genotype 1 Treatment-Experienced HCV-Infected Japanese Patients - (11/16/11)
     
  5792. AASLD: Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationship for MK-5172, a Novel Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, in Genotype 1 and Genotype 3 HCV-Infected Patients - (11/16/11)
     
  5793. AASLD: Treatment-Naïve Black Patients Treated with Boceprevir (BOC) Combined with Peginterferon alfa-2b + Ribavirin (PR): Results from HCV SPRINT-2 - (11/16/11)
     
  5794. AASLD: Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat HCV Patient Types - (11/16/11)
     
  5795. AASLD: TMC-435 New PI Effective, Safe in HCV Trial - (11/16/11)
     
  5796. AASLD: Projections Using Decision-Analytic Modeling of Long-Term Clinical Value of Telaprevir for the Treatment of HCV Patients Who Had Failed Prior Peginterferon/Ribavirin Treatment - (11/15/11)
     
  5797. AASLD: SVR and pharmacokinetics of the HCV protease inhibitor BI 201335 with PegIFN/RBV in HCV genotype-1 patients with compensated liver cirrhosis and non-response to previous PegIFN/RBV - (11/15/11)
     
  5798. AASLD: Sustained Virologic Response Rates and Viral Resistance Profiles Were Similar in Patients Treated with a Telaprevir-based Regimen Regardless of Liver Fibrosis Stage - (11/15/11)
     
  5799. AASLD: Analysis of Resistance-Associated Amino Acid Variants (RAVs) in non-SVR Patients Enrolled in a Retrospective Long-term Follow-up Analysis of Boceprevir Phase 3 Clinical Studies - (11/15/11)
     
  5800. AASLD: Analysis of Sustained Viral Response and Boceprevir Resistance Following Combination Treatment With Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in HCV Genotype 1 Prior Relapsers And Nonresponders - (11/15/11)
     
  5801. AASLD: The Effect of Using Lower Limit of Quantitation (LLQ) vs Lower Limit of Detection (LLD) for the Definition of Undetectable HCV RNA: Data from the RESPOND-2 and SPRINT-2 trials - (11/15/11)
     
  5802. AASLD: Predictors of Sustained Virologic Response Among Poor Interferon Responders When Boceprevir is Added to Peginterferon alfa-2b/Ribavirin - (11/15/11)
     
  5803. AASLD: Concomitant Medication Use (drug interactions) in Patients with Hepatitis C Genotype 1 Treated with Boceprevir Combination Therapy - (11/15/11)
     
  5804. AASLD: A Phase 2b Study of MK-7009 (vaniprevir) in Patients with Genotype 1 HCV Infection Who HaveFailed Previous Pegylated Interferon and Ribavirin Treatment - (11/15/11)
     
  5805. AASLD: The Effects of Combining Two Gilead Direct Acting Antivirals GS-9256+GS-9190, Ribavirin, and Pegylated Interferon on the Detection of Drug Resistance Mutations Early in Treatment of HCV - (11/15/11)
     
  5806. AASLD: Evaluation of Pre-Existing Levels of Y448H HCV NS5B Polymerase Mutant Using Viral Kinetics Monitored by Allele-Specific PCR in HCV Patients and Replicon Cells Treated with the HCV Non-Nucleoside Inhibitor Tegobuvir - (11/15/11)
     
  5807. AASLD: Characterization of HCV Resistance from a Multiple Dose Clinical Trial of GS-5885, a Novel HCV NS5A Inhibitor - (11/15/11)
     
  5808. AASLD: In Vitro Selection of Resistance to GS-9451, a Novel and Potent Inhibitor of HCV NS3 Protease - (11/15/11)
     
  5809. AASLD: Overall Safety Profile of Boceprevir Plus Peginterferon alfa-2a/Ribavirin in Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin - (11/15/11)
     
  5810. AASLD: Baseline Viral Voad Predicts SVR: Effect of Baseline Viral Load (VL) on Response of Boceprevir (BOC) Plus Peginterferon Alfa-2b/Ribavirin (PR) in Patients Infected With HCV Genotype 1 - (11/15/11)
     
  5811. AASLD: Disease burden in patients with chronic hepatitis C virus (HCV) infection in a United States (US) private health insurance claims database analysis from 2003 to 2010 - (11/10/11)
     
  5812. AASLD: HIGH RAPID VIROLOGIC RESPONSE (RVR) WITH ACH-1625 DAILY DOSING PLUS PEGIFN- ALPHA 2A/RBV IN A 28-DAY PHASE 2A TRIAL - (11/10/11)
     
  5813. AASLD: PHARMACOKINETIC MODELING OF ACH-2684, A HEPATOSELECTIVE PHASE I PAN-GENOTYPIC HCV NS3 PROTEASE INHIBITOR: PREDICTIONS AND CORRELATION WITH HUMAN PHARMACOKINETICS - (11/10/11)
     
  5814. AASLD: Daclatasvir (DCV; BMS-790052), an NS5A Replication Complex Inhibitor, in Combination With Peginterferon Alfa-2b and Ribavirin in Japanese Treatment-Naïve and Nonresponder Patients With Chronic HCV Genotype 1 Infection - (11/10/11)
     
  5815. AASLD: Novel Hepatitis C Virus NS5A Inhibitors with Improved Potency Against Genotype-1a Replicons and Replicons Carrying Mutations Associated With Viral Resistance to 1st Generation NS5A Inhibitors - (11/10/11)
     
  5816. AASLD: Safety and Efficacy of Peginterferon Lambda-1a (Lambda) Compared With Peginterferon Alfa-2a (Alfa-2a) in HCV-Infected Patients (G1/2/3) With Compensated Cirrhosis: EMERGE Phase 2B Efficacy and Safety Results Through Week 12 - (11/10/11)
     
  5817. AASLD: Combination Therapy of Treatment-Naïve and Nonresponder Patients With HCV Genotype 1 Infection With Daclatasvir (DCV; BMS-790052), an NS5A Replication Complex Inhibitor, in Combination With Peginterferon Alfa-2a and Ribavirin - (11/10/11)
     
  5818. AASLD: Entecavir (ETV) monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir (TDF) in nucleos(t)ide-naïve patients with chronic hepatitis B (CHB): the BE-LOW study - (11/10/11)
     
  5819. AASLD: BI HCV Protease & Other New HCV Drugs - (11/09/11)
     
  5820. AASLD: VX-222/Telaprevir in Combination With Peginterferon-alfa-2a and Ribavirin in Treatment-naïve Genotype 1 HCV Patients Treated for 12 Weeks: ZENITH Study, SVR12 Interim Analysis - (11/09/11)
     
  5821. AASLD: Once-daily alisporivir interferon (IFN)-free regimens achieve high rates of early HCV clearance in previously untreated patients with HCV genotype (G) 2 or 3 - (11/09/11)
     
  5822. AASLD: GSK2336805 HCV NS5A Inhibitor Demonstrates Potent Antiviral Activity in Chronic Hepatitis C (CHC) Genotype 1 Infection: Results from a First Time in Human (FTIH) Single and Repeat Dose Study - (11/09/11)
     
  5823. AASLD: In Null Responders 4 Week Peg/Rbv Lead-In Predicts SVR' - Different Likelihood of Achieving SVR on a Telaprevir-containing Regimen Among Null Responders, Partial Responders and Relapsers Irrespective of Similar Responses after a Peginterferon/Ribavirin 4-week Lead-in Phase: REALIZE Study Subanalysis - (11/09/11)
     
  5824. AASLD: Predictors of Virologic Response with Telaprevir-based Combination Treatment in HCV Genotype 1-infected Patients with Prior Peginterferon/ribavirin Treatment Failure: Post-hoc Analysis of the Phase III REALIZE Study - (11/09/11)
     
  5825. AASLD: Follow-up of SVR Durability and Viral Resistance in Patients with Chronic Hepatitis C Treated with Telaprevir-Based Regimens: Interim Analysis from the EXTEND Study - (11/09/11)
     
  5826. AASLD: Virologic response to an interferon-free regimen of BI 201335 and BI 207127, with and without ribavirin, in treatment-naïve patients with chronic genotype-1 HCV infection: Week 12 interim results of the SOUND-C2 study - (11/08/11)
     
  5827. AASLD: Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD - press release - (11/08/11)
     
  5828. AASLD: TMC435 in Combination with Peginterferon and Ribavirin in Treatment-naïve HCV Genotype 1 Patients: Final Analysis of the PILLAR Phase IIb Study (TMC435-C205) - (11/08/11)
     
  5829. AASLD: Treatment with the 2nd generation HCV protease inhibitor BI 201335 results in high and consistent SVR rates - results from SILEN-C1 in treatment-naïve patients across different baseline factors - (11/08/11)
     
  5830. AASLD: High SVR following IFN-free treatment of chronic HCV GT1 infection for 4 weeks with HCV protease inhibitor BI 201335, polymerase inhibitor BI 207127 and ribavirin, followed by BI 201335 and PegIFN/ribavirin - the SOUND-C1 study - (11/08/11)
     
  5831. AASLD: PROTON: PSI-7977 & Peg/RBV in Treatment-naïve Patients with HCV GT1: Sustained Virologic Response - (11/08/11)
     
  5832. AASLD: Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Co-infected Patients: A 24-Week Treatment Interim Analysis - (11/08/11)
     
  5833. AASLD: Virologic response to an interferon-free regimen of BI 201335 and BI 207127, with and without ribavirin, in treatment-naïve patients with chronic genotype-1 HCV infection: Week 12 interim results of the SOUND-C2 study - (11/08/11)
     
  5834. AASLD: Dual Oral Combination Therapy with the NS5A Inhibitor Daclatasvir(DCV; BMS-790052) and the NS3 Protease Inhibitor Asunaprevir(ASV; BMS-650032) Achieved 90% Sustained Virologic Response (SVR12) in Japanese HCV Genotype 1b-Infected Null Responders - (11/08/11)
     
  5835. Inhibitex Nucelotide INX-189 Higher Dosing Increases Viral Load Reduction - Inhibitex reports third quarter financial results and recent corporate developments - (11/07/11)
     
  5836. AASLD: Interim Data from Phase 2 Study Showed 93% of People with Hepatitis C Who Received a Total of 12 Weeks of a Combination Regimen Including INCIVEK™ (telaprevir) and VX-222 (400mg) Achieved a Viral Cure (SVR) - (11/07/11)
     
  5837. AASLD: Positive Interim Data From a Phase 2 Study of INCIVEK™ (telaprevir) Combination Therapy in People Co-Infected with Hepatitis C and HIV Presented at The Liver Meeting® - (11/07/11)
     
  5838. AASLD: High sustained virologic response (SVR24) rates with response-guided danoprevir (DNV; RG7227) plus PegIFN alfa-2a (40KD) and ribavirin (P/R) in treatment-naive HCV genotype 1 (G1) patients: results from the ATLAS study - (11/07/11)
     
  5839. AASLD: Gilead Announces Positive Five-Year Data Showing Effect of Viread(R) on Liver Fibrosis and Cirrhosis Caused by Chronic Hepatitis B - (11/07/11)
     
  5840. AASLD: Novartis DEB025 data showed viral clearance as early as six weeks and potential for interferon-free therapy in hepatitis C patients - (11/07/11)
     
  5841. AASLD: Efficacy and Safety of Telaprevir-based Regimens in Cirrhotic Patients with HCV Genotype 1 and Prior Peginterferon/Ribavirin Treatment Failure: Subanalysis of the REALIZE Phase III Study - (11/07/11)
     
  5842. AASLD: Dose-Ranging Trial of PPI-461, a Potent New Pan-Genotypic HCV NS5A Inhibitor, in Patients with HCV Genotype-1 Infection - (11/07/11)
     
  5843. AASLD: SILEN-C3: treatment for 12 or 24 weeks with BI 201335 combined with peginterferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype-1 HCV infection - (11/07/11)
     
  5844. AASLD: Retreatment with Telaprevir/Peg-IFN/RBV after a Short Exposure to Telaprevir in Phase I Studies: Interim Results from a Phase IIIb Rollover Trial (C219) - (11/07/11)
     
  5845. AASLD: PSI-7977: ELECTRON Interferon is not required for Sustained Virologic Response in Treatment-Naïve Patients with HCV GT2 or GT3 - (11/07/11)
     
  5846. AASLD: Antiviral Activity and Safety of INX-08189, a Nucleotide Polymerase Inhibitor, Following 7-Days of Oral Therapy in Naïve Genotype-1 HCV Patients - (11/07/11)
     
  5847. AASLD: Antiviral Activity/Resistance Monitoring of HCV Patients Treated for Three Days with the NS5A Inhibitor PPI-461 Reveals Rapid Emergence of Resistant HCV Variants - (11/07/11)
     
  5848. AASLD: Human safety, pharmacokinetics and antiviral activity of TMC647055, a novel HCV non-nucleoside polymerase inhibitor - (11/07/11)
     
  5849. AASLD: MK-5172, a Second Generation HCV NS3/4A Protease Inhibitor is Active Against Common Resistance Associated Variants (RAVs) and Exhibits Cross-Genotype Activity - (11/07/11)
     
  5850. AASLD: Discovery of MK-4882, a Novel Inhibitor of HCV NS5a with an Attractive Pre-clinical Profile - (11/07/11)
     
  5851. AASLD: Safety and Antiviral Activity of MK-5172, a Next Generation HCV NS3/4a Protease Inhibitor with a Broad HCV Genotypic Activity Spectrum and Potent Activity Against Known Resistance Mutants, in Genotype 1 and 3 HCV-Infected Patients - (11/07/11)
     
  5852. Inhibitex Commences Dosing of Phase 2 Clinical Trial of INX-189 in HCV Infected Genotype 2/3 Patients - (11/04/11)
     
  5853. A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189, a Nucleotide Polymerase Inhibitor, in Healthy Subjects - (11/04/11)
     
  5854. New 12 Week, Interferon-Free Treatment Arms Added to All-Oral Combination Study of PSI-7977 and Daclatasvir (BMS-790052) for HCV Genotype 1 - (11/04/11)
     
  5855. Hepatitis C Transmission in Injection Drug Users: Could Swabs Be the Main Culprit? - (11/04/11)
     
  5856. Inactivation and Survival of Hepatitis C Virus on Inanimate Surface - (11/04/11)
     
  5857. Agent, Host, and Environment: Hepatitis C Virus in People Who Inject Drugs - (11/04/11)
     
  5858. Response-guided Telaprevir Combination Treatment in Genotype 1 Chronic Hepatitis C Patients who had Prior Relapse to Peginterferon Alfa-2a/Ribavirin - (11/02/11)
     
  5859. Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin Increased Sustained Virologic Response in Genotype 1 Chronic HCV - (11/02/11)
     
  5860. IDSA: Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co-Infected Patients - (10/25/11)
     
  5861. EACS: Predictors of Hepatitis C RNA Levels in HIV Co-infected Individuals in a Prospective Cohort Study (10/25/11)
     
  5862. Simplified Explanation of the Phase 3 Studies of HCV Protease Inhibitor Boceprevir
     
  5863. Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV - (11/01/11)
     
  5864. Pharmasset Phase 3 Plan Announced: Slides Presented This Morning on Pharmasset Conference Call - (11/01/11)
     
  5865. Abbott Announces Positive Data from Mid-Stage Trial of Hepatitis C Therapy: 12 weeks duration with 2 Abbott oral HCV drugs protease inhibitor+NNRTI - (10/25/11)
     
  5866. Vertex Starts Global Phase 3b Study to Evaluate the Potential for People with Hepatitis C to Achieve a Viral Cure (SVR) with a Total Treatment Duration of 12 Weeks of INCIVEK Combination Therapy - (10/25/11)
     
  5867. Interim Phase IIb Data for Merck's VICTRELIS (boceprevir) in Patients Coinfected with Chronic Hepatitis C and HIV-1 Presented at the Infectious Diseases Society of America (IDSA) 2011 Annual Meeting - (10/20/11)
     
  5868. AASLD PRACTICE GUIDELINE: An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases - (10/20/11)
     
  5869. DEBO25 vs Boceprevir New Study in African-Americans - (10/17/11)
     
  5870. Roche Buys Anadys (ANA-598) - (10/17/11)
     
  5871. ANA-598 HCV Non-Nuke Phase 2b Study Preliminary Data Results Background to Phase IIb Study - (10/14/11)
     
  5872. Achillion Announces Nomination of Second Generation NS5A Inhibitor for the Treatment of Hepatitis C - press release - (10/13/11)
     
  5873. INCIVO® (telaprevir), a new treatment for genotype-1 chronic hepatitis C launched today in UK - (10/11/11)
     
  5874. INCIVEK (telaprevir) Now Available in Canada for People with Hepatitis C - (10/11/11)
     
  5875. Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C - shortened durations, monotherapy, INF-free - (10/10/11)
     
  5876. Medivir Announces Acceptance of Four TMC435 Abstracts for Presentation at the AASLD Meeting - (10/05/11)
     
  5877. Bristol-Myers Squibb to Present New Data Demonstrating Company's Leadership in Liver Disease at The Liver Meeting® / AASLD Annual Meeting - (10/05/11)
     
  5878. Santaris Pharma A/S to Report New Clinical Data From HCV microRNA Miravirsen Phase 2a Study to Treat Hepatitis C in Late-Breaking Oral Presentation at the AASLD 2011 Annual Meeting - press release - (10/05/11)
     
  5879. New Data from Boehringer Ingelheim HCV Portfolio to be Presented at AASLD - (10/05/11)
     
  5880. Inhbitex nucleotide in Phase 2 - (10/05/11)
     
  5881. ICAAC: TMC435 in combination with peginterferon and ribavirin for treatment of HCV genotype 1 infection: Week 24 interim analyses of Phase IIB PILLAR and ASPIRE trials - (09/30/11)
     
  5882. Updated Hepatitis C Practice Guidelines Now Available from AASLD - Guidelines pdf attached - (09/29/11)
     
  5883. ICAAC: Responder-relapser (RR) patients might obtain benefit in liver fibrosis, after anti-HCV chemotherapy, in comparison to non-responders (NR) or non-treated (control) HIV- HCV coinfected patients - (09/27/11)
     
  5884. ICAAC: Longitudinal assessment of liver fibrosis (LF) by non-invasive methods in HIV- HCV coinfected patients, after HCV chemotherapy - (09/27/11)
     
  5885. Enanta's Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover's Top 10 Infectious Disease Projects to Watch - (09/26/11)
     
  5886. Acute Hepatitis C Virus in an HIV Clinic: A Screening Strategy, Risk Factors, and Perception of Risk - (09/26/11)
     
  5887. Hepatitis C virus infection in USA: an estimate of true prevalence - 'estimated 5.2 to 7.1 million HCV+ in USA' - (09/26/11)
     
  5888. New Abbott HCV 3-Drug Regimen Study - (09/24/11)
     
  5889. ICAAC: ART-HCV Protease Inhibitor BI-201335 Interactions - (09/21/11)
     
  5890. ICAAC: The Pharmacokinetic Interaction Between Telaprevir & Raltegravir in Healthy Volunteers - (09/21/11)
     
  5891. In Memoriam: Emmet B. Keeffe, M.D. - (09/21/11)
     
  5892. ICAAC: High Rates of SVR24 for BMS-790052, an NS5A Replication Complex Inhibitor, in Combination With PegIFN-alfa-2a and Ribavirin: Phase 2a Trial in Treatment-Naive HCV Genotype 1 Subjects - (09/19/11)
     
  5893. ICAAC: BMS-790052 Plus Peginterferon Alfa and Ribavirin Demonstrated up to 83% Sustained Virologic Response 24 Weeks Post-Treatment (SVR24) in Phase II Study of Genotype 1 Hepatitis C Patients - (09/19/11)
     
  5894. Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes - (09/16/11)
     
  5895. Simplified Explanation of the Phase 3 Studies of HCV Protease Inhibitor Boceprevir - (03/21/11)
     
  5896. New HCV Drug Telaprevir Allows Shorter Hepatitis Therapy for Some - (09/16/11)
     
  5897. Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections - (09/08/11)
     
  5898. Completed Enrollment of Three Global Phase 3 Trials for TMC435 in Chronic Hepatitis C Genotype-1 Infected Patients - (09/08/11)
     
  5899. Pharmasset Announces 91% SVR12 From the PROTON Trial in Subjects With Hepatitis C Genotype 1 - (09/08/11)
     
  5900. Gilead Amends Study Design for Ongoing Hepatitis C Clinical Trials That Include GS 9190, Pegylated Interferon and Ribavirin, and Another Direct-Acting Antiviral Agent - (09/08/11)
     
  5901. Santaris Pharma A/S Showcases microRNA and mRNA Research Advancements Utilizing its Proprietary Locked Nucleic Acid Technology at Oligonucleotide Therapeutics Society Meeting - (09/08/11)
     
  5902. HCV Protease Inhibitor Resistance - New Monogram Resistance Assay: this report contains relevant information related to HCV telaprevir & boceprevir resistance and the new assay - (09/07/11)
     
  5903. Patient preferences and assessment of likely adherence to hepatitis C virus treatment - (09/07/11)
     
  5904. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response - (09/07/11)
     
  5905. PSI-938 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection - (08/24/11)
     
  5906. Evaluation of Three Rapid Screening Assays for Detection of Antibodies to Hepatitis C Virus - false positives for HIV+ persons - (08/24/11)
     
  5907. Cerebral magnetic resonance imaging reveals marked abnormalities of brain tissue density in patients with cirrhosis without overt hepatic encephalopathy - (08/19/11)
     
  5908. Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1 - (08/16/11)
     
  5909. Utilization of Surveillance for Hepatocellular Carcinoma Among Hepatitis C Virus-Infected Veterans in the United States: 'HCC surveillance low among cirrhotics despite recommendations for HCC surveillance in these high-risk patients' - (08/16/11)
     
  5910. PEGINTERFERON MAINTENANCE THERAPY IN PATIENTS WITH ADVANCED HEPATITIS C TO PREVENT HEPATOCELLULAR CARCINOMA: THE PLOT THICKENS - (08/15/11)
     
  5911. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C - (08/10/11)
     
  5912. Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER-medicare database - (08/10/11)
     
  5913. Extended Interferon-Alpha Therapy Accelerates Telomere Length Loss in Human Peripheral Blood T Lymphocytes - (08/06/11)
     
  5914. Hepatitis C virus epidemiology in Asia, Australia and Egypt - (08/06/11)
     
  5915. New Protease Inhibitor (NS3/4A) Drug Resistance Test - (08/06/11)
     
  5916. HCV in Pakistan: Around 24,000 people die of HCV - (08/03/11)
     
  5917. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa - (08/04/11)
     
  5918. Global HCV 150 Million: reused syringes, IDU, sexual transmission, HIV coinfection, China/India/Pakistan, Africa - (08/02/11)
     
  5919. High-Dose Pegylated Interferon-α and Ribavirin in Nonresponder Hepatitis C Patients and Relationship With IL-28B Genotype (SYREN Trial) - (08/01/11)
     
  5920. IAS: Microbial Translocation and Hepatitis C Disease Progression among HIV-infected Women - (07/27/11)
     
  5921. Pharmasset Announces Final SVR Data (100% 24/24) from PROTON trial with PSI-7977 in Subjects Infected with Hepatitis C Infection Genotype 2 or 3 - 12 weeks therapy - (07/28/11)
     
  5922. Care Intervention Study to Improve Eligibility for HCV Therapy for Patients with Mental Health/Substance Abuse Barriers to Treatment/Care: patients who participated in INTervention were more likely to become eligible for PegIFN treatment by the end of the 9-month trial compared to participants in SC (42% vs. 18% - (07/27/11)
     
  5923. Interim Data from Phase 2 Study of Combination Regimen Including VX-222 and INCIVEK™ Suggest Potential to Treat Genotype 1 Hepatitis C in as few as 12 Weeks and No More Than 24 Weeks - (07/26/11)
     
  5924. IAS: Progressive Histological Liver Improvement After SVR in HCV/HIV Coinfected Patients Using Transient Elastography (Fibroscan) - (07/25/11)
     
  5925. IAS: Temporal Trends in Liver-Related Mortality in a Prospective Cohort of HIV-Infected Patients in Spain 1997-2008: HCV/HIV Coinfected Death Rates Increase While Rates Decline Among HCV-/HIV+ - (07/25/11)
     
  5926. Sexual Transmission of Hepatitis C Virus Among HIV-Infected Men Who Have Sex with Men --- New York City, 2005--2010 - (07/22/11)
     
  5927. Intrntnal Wrkshp Clin Pharma HCV Therapy Meeting Report - 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy (June 22-23, 2011, Boston, MA) - (07/13/11)
     
  5928. Racial differences in hepatitis C treatment eligibility - (07/12/11)
     
  5929. Risk factors for infection in chronic hepatitis C: A high prevalence of sexual exposure among human immunodeficiency virus-coinfected women - (07/12/11)
     
  5930. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents - A potentially lethal cocktail (see article below editorial) - Editorial - (07/12/11)
     
  5931. Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1 infected patients - (07/12/11)
     
  5932. Patient acceptance of universal screening for hepatitis C virus infection - (07/08/11)
     
  5933. Pharmasset Enters into a Clinical Collaboration Agreement with Tibotec Pharmaceuticals for a Combination Study in Patients Chronically Infected with Hepatitis C - (07/07/11)
     
  5934. Medivir: TMC435 has Received Fast Track Designation from the FDA and TMC435 will be studied in combination with Pharmasset's PSI-7977 for HCV genotype-1 - (07/07/11)
     
  5935. Int'l Wrkshp HIV & HCV Resist & Curative Strategies: Report on the International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies - June 7- 11, Cabo, Mexico - (06/30/11)
     
  5936. Int'l Wrkshp HIV & HCV Resist & Curative Strategies: International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies - June 7- 11, Cabo, Mexico - (06/30/11)
     
  5937. Vertex & Merck HCV Ads HCV Disease Focused - (06/28/11)
     
  5938. Host targeting cyclophilin inhibitor alisporivir (DEB025) presents a high barrier to resistance with no cross-resistance to direct acting antivirals, in Phase 3 Now - (06/27/11)
     
  5939. Telaprevir for Retreatment of HCV Infection - NEJM published - (06/24/11)
     
  5940. Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection - (06/23/11)
     
  5941. Unmet Needs Among People Reported With Hepatitis C, New York City - (06/21/11)
     
  5942. Cocaine Inflicts 'Silent' Damage to the Heart - (06/21/11)
     
  5943. Boerhinger Ingelheim HCV Drugs Development- Protease, Polymerase - (06/14/11)
     
  5944. HBV & HCV Epidemics & Screening in USA - (06/13/11)
     
  5945. Noninvasive assessment of liver fibrosis (and Biobsy) - (06/13/11)
     
  5946. Vertex and Alios BioPharma Announce Exclusive Worldwide Licensing Agreement for Two Nucleotide Drug Candidates, Broadening Vertex's Efforts to Develop New Combinations of Medicines for Hepatitis C - Press Release - (06/13/11)
     
  5947. Telaprevir/Combination DAAs/Shortening Therapy Duration - Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: Implications for treatment duration - (06/09/11)
     
  5948. HCV Treaters Shortage Editorial - Distributive justice and the arrival of direct-acting antivirals: Who should be first in line? - (06/09/11)
     
  5949. Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C - (06/08/11)
     
  5950. Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C - (06/06/11)
     
  5951. NEW Drugs in Development for HCV - (06/06/11)
     
  5952. Chronic hepatitis C genotype 2 and 3: Are we ready for personalized medicine? (12-16 weeks therapy??) - (06/06/11)
     
  5953. Telemedicine Puts HCV Care in Hands of PCPs - (06/03/11)
     
  5954. A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C - pdf attached - (06/02/11)
     
  5955. Coffee Consumption Is Associated With Response to Peginterferon and Ribavirin Therapy in Patients With Chronic Hepatitis C - (06/02/11)
     
  5956. New Studies in Genotypes 1, 2, 3, 4 and 5 with nucleotide PSI-7977 - (06/02/11)
     
  5957. A Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject Drugs: 'HCV can be prevented-multicomponent interventions including substance abuse treatment/safe injection' - (06/02/11)
     
  5958. AASLD: BMS-824393 Is a Potent Hepatitis C Virus NS5A Inhibitor With Substantial Antiviral Activity When Given as Monotherapy in Subjects With Chronic G1 HCV Infection - (06/01/11)
     
  5959. Association of caffeine intake and histological features of chronic hepatitis C - (06/01/11)
     
  5960. Oral combination therapy: future hepatitis C virus treatment? - protease Danoprevir + polymerase R7128 - (06/01/11)
     
  5961. BMS Phase 2B Study including 4 drug regimen of NS5A BMS-790052 + protease BMS-650032 + Peglambda/Rbv: - (06/01/11)
     
  5962. 2 Roche Studies of 3 or 4 HCV drugs: 1st study is 3 drug regimen- protease danoprevir/r boosted + R7128 polymerase+ribavirin; 2nd study is 3 or 4 drug regimens including danoprevir/r boosted+R7128 & various combinations of ribavirin or Pegasys/Rbv - (06/01/11)
     
  5963. New Study of 3 Oral HCV Drugs: Study of 2 Abbott new oral HCV drugs ABT-450+NNRTI either ABT-072 or ABT-333 - (06/01/11)
     
  5964. Gilead's New HCV Study - 4 Drug Regimen - GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection - 3 new oral HCV drugs from Gilead: NS5A, protease + NNRTI + ribavirin - (06/01/11)
     
  5965. All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated + BMS NS5A BMS-790052 - (05/26/11)
     
  5966. Characteristics of Patients With Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma - (05/25/11)
     
  5967. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: A phase 1b multiple ascending dose study - (05/25/11)
     
  5968. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection - (05/25/11)
     
  5969. Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy - (05/24/11)
     
  5970. Viral Load Tied to Vertical Transmission of Hepatitis C - (05/23/11)
     
  5971. Telaprevir - Label, Storage/Handling, Food, Study results - (05/23/11)
     
  5972. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility - (05/23/11)
     
  5973. EASL: Pharmacokinetics of TMC435 in subjects with moderate hepatic impairment - (05/20/11)
     
  5974. Medivir Announces Positive 48-week Interim Data from TMC435 Hepatitis C Phase 2b ASPIRE Study in Treatment-Experienced Genotype-1 Patients - (05/20/11)
     
  5975. CHMP (Europe) Issues Positive Opinion for Merck's Victrelis (Boceprevir), Oral Hepatitis C Virus (HCV) Protease Inhibitor - (05/20/11)
     
  5976. Boceprevir Highlights from Labels - (05/19/11)
     
  5977. MK-5172 Administered With Peginterferon and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C (MK-5172-003): 500 people comparing MK5172 to boceprevir, + peg/RBV - (05/19/11)
     
  5978. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin - pdf attached - (05/19/11)
     
  5979. Merck press release: FDA Approves Merck's VICTRELIS (boceprevir), First-in-Class Oral Hepatitis C Virus (HCV) Protease Inhibitor - (05/18/11)
     
  5980. Statin Use and the Risk of Liver Cancer: A Population-Based Case-Control Study - pdf attached - (05/18/11)
     
  5981. Celebrex may curb colon cancer, but with caveats - (05/18/11)
     
  5982. Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV-hepatitis C virus-coinfected patients with prior nonresponse or relapse - pdf attached - (05/18/11)
     
  5983. Merck Announces Hope Against Hepatitis C Initiative to Support Public Awareness, Education and Research in the Fight Against Hepatitis C Virus - (05/10/11)
     
  5984. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007 - (05/09/11)
     
  5985. Histological diagnosis (markers) of early hepatocellular carcinoma - Editorial - (05/07/11)
     
  5986. Comments on the International Liver Cancer Association Fourth Annual Conference, 2010. Is there really no role for liver biopsy interpretation in liver cancer? - Comments from the Editors - (05/07/11)
     
  5987. Insurance status and treatment candidacy of hepatitis C patients: Analysis of population-based data from the United States: "only 54.3% of HCV+ treatment candidates had any type of insurance coverage, only 36.3% of HCV+ patients were potentially eligible for treatment and had health insurance" - pdf attached - (05/07/11)
     
  5988. EASL: Increasing & Peaking Cirrhosis, Decompensated Cirrhosis & HCC(liver cancer) in UK Projected - (05/07/11)
     
  5989. EASL: EASL HCV Clinical Practice Guidelines - (05/07/11)
     
  5990. Telaprevir SVR & African-Americans, Latinos & Advanced Fibrosis - (05/04/11)
     
  5991. Boceprevir & Telaprevir SVR Rates Reported at FDA Hearing - (05/03/11)
     
  5992. Telaprevir & Boceprevir SVR - Fibrosis/Ethnicity Reported at FDA Hearing - (05/02/11)
     
  5993. FDA Advisory Committee Unanimously Recommends Approval of Telaprevir for People with Hepatitis C - Vertex press release - (04/29/11)
     
  5994. Boehringer Ingelheim starts patient recruitment in HCV drug trial Phase 3 Protease Inhibitor BI201335 - (04/29/11)
     
  5995. FDA Panel Votes 18-0 Recommending Boceprevir Approval for Treatment of HCV in Genotype 1 Patients - Merck press release - (04/29/11)
     
  5996. HCV Standard of Care Controversy: report from FDA Hearing; what can new era of HCV antivirals offer by Ira Jacobson; Key Treatment Outcomes for Boceprevir & Telaprevir, Essentially Doubling SVR Rates - (04/29/11)
     
  5997. Boceprevir & Telaprevir FDA Hearing April 27/28 Briefing Documents - (04/26/11)
     
  5998. Idera Pharmaceuticals Delays Initiation of Phase 2 Clinical Trial of IMO-2125 (Toll-Like Receptor -TLR - 9 agonist) in Treatment-Naïve HCV Patients (animal tox) - (04/25/11)
     
  5999. EASL: New Approach in HBV & HCV: Gilead's TLR 7 Agonist GS-9620 at EASL - (04/09/11)
     
  6000. EASL: Cost Benefit Analysis of Response Guided Therapy: Dynamic Disease Markov Modeling for Patients with Chronic Hepatitis CVirus (HCV) by Fibrosis Stages - (04/09/11)
     
  6001. EASL: Burden of viral hepatitis C in Europe: a propensity analysis of patient outcomes - (04/09/11)
     
  6002. Bacterial Translocation in HIV-Infected Patients With HCV Cirrhosis: Implication in Hemodynamic Alterations and Mortality - 'more profound inflammatory state in those HIV-HCV patients with decompensated cirrhosis....inflammation predicts mortality in these patients' - (04/23/11)
     
  6003. EASL: New HCV Drugs at EASL - (04/19/11)
     
  6004. EASL: Boceprevir at EASL - (04/18/11)
     
  6005. New Study- Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin - (04/18/11)
     
  6006. EASL: EASL Telaprevir Report (coinfection too) - (04/18/11)
     
  6007. EASL: Pharmacokinetics, Safety and Tolerability of the HCV NS5A Inhibitor ABT-267 Following Single and Multiple Doses in Healthy Adult Volunteers - (04/18/11)
     
  6008. EASL: Utility of Historical Data Compared to Lead-In Response in Predicting Sustained Virologic Response in Nonresponders and Relapsers to Peginterferon/Ribavirin When Retreated With Boceprevir+Peginterferon Alfa-2b/Ribavirin - (04/18/11)
     
  6009. EASL: High Sustained Virologic Response Among Genotype 1 Previous Non-responders and Relapsers to Peginterferon/Ribavirin when Re-treated With Boceprevir Plus Peginterferon Alfa-2a/Ribavirin - (04/18/11)
     
  6010. Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection - (04/13/11)
     
  6011. EASL: Anemia & Telaprevir - (04/13/11)
     
  6012. EASL: Telaprevir Week 4 Response Predicts Outcome (SVR) - (04/13/11)
     
  6013. EASL: Gilead's HCV Pipeline Unveiled at EASL - (04/13/11)
     
  6014. EASL: Sustained Virologic Response and Boceprevir Resistance-Associated Variants Observed in Patients Infected With HCV Genotype 1a/1b When Treated With Boceprevir Plus Peginterferon Alfa-2b/Ribavirin: SVR rates among patients with G1b virus were consistently higher compared with G1a patients in both SPRINT-2 and RESPOND-2 - (04/12/11)
     
  6015. EASL: Frequencies of Resistance-Associated Amino Acid Variants Detected by 454 Sequencing During Combination Treatment With Boceprevir Plus Pegintron (Peginterferon Alfa-2b)/Ribavirin in HCV (GT1)-Infected Subjects - (04/12/11)
     
  6016. EASL: Overall Safety Profile of Boceprevir Plus Peginterferon Alfa-2b/Ribavirin - (04/12/11)
     
  6017. EASL: Anemia During Treatment With Peginterferon Alfa-2b/Ribavirin With or Without Boceprevir is Associated With Higher SVR Rates: Analysis of Previously Untreated and Previous Treatment-Failure Patients - (04/12/11)
     
  6018. EASL: Response-Guided Therapy With Boceprevir Plus Peginterferon Alfa-2b/Ribavirin Reduces Treatment Duration in Previously Untreated and Previous-Treatment-Failure Patients With HCV Genotype 1 - (04/12/11)
     
  6019. EASL: SVR and pharmacokinetics of the HCV protease inhibitor BI 201335 with PegIFN/RBV in HCV genotype-1 patients with compensated liver cirrhosis and non-response to previous PegIFN/RBV - (04/11/11)
     
  6020. EASL: Inhibitex Reports Positive Safety and Antiviral Data from Its Phase 1b Study of HCV Nucleotide Inhibitor INX-189 - (04/11/11)
     
  6021. EASL: A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189, a Nucleotide Polymerase Inhibitor, in Healthy Subjects - (04/11/11)
     
  6022. EASL: No resistance to IDX184 was detected in 3-day and 14-day clinical studies of IDX184 in genotype 1-infected HCV subjects - (04/11/11)
     
  6023. EASL: Idenix NS5A HCV replication inhibitors with low picomolar, pan-genotypicin vitro antiviral activity - (04/11/11)
     
  6024. EASL: CHARACTERIZATION OF NOVEL, HIGHLY POTENT NS5A INHIBITORS WITH QD DOSING POTENTIAL AND ROBUST ACTIVITY IN AN HCV CHIMERIC ANIMAL MODEL - (04/11/11)
     
  6025. EASL: GNS-227: A New Potent and Selective (2nd Gen) HCV NS3 Protease Inhibitor With a High Genetic Barrier to Resistance - (04/11/11)
     
  6026. EASL: ACH-2928: A NOVEL HIGHLY POTENT HCV NS5A INHIBITOR WITH FAVORABLE PRECLINICAL CHARACTERISTICS - (04/11/11)
     
  6027. EASL: Mechanisms of isolated unconjugated hyperbilirubinaemia induced by the HCV NS3/4A protease inhibitor BI 201335 - (04/11/11)
     
  6028. EASL: PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF ACH-1625 (HCV NS3 PROTEASE INHIBITOR) IN HCV GENOTYPE 1 INFECTION - (04/11/11)
     
  6029. EASL: CHARACTERIZATION AND IDENTIFICATION OF PPI-437, PPI-668 AND PPI-833 AS POTENT AND SELECTIVE HCV NS5A INHIBITORS WITH ACTIVITY AGAINST ALL HCV GENOTYPES - (04/11/11)
     
  6030. EASL: BI 201335 pharmacokinetics and early effect on viral load in HCV genotype-1 patients - (04/11/11)
     
  6031. EASL: Four-week Therapy With Peginterferon Alfa-2b/Ribavirin Effectively Predicts Sustained Virologic Response in Previously Untreated and Previous-Treatment-Failure Patients With HCV-1 Treated With Boceprevir Plus Peginterferon Alfa-2b/Ribavirin - (04/09/11)
     
  6032. EASL: NOVEL, POTENT, PAN-GENOTYPIC HCV NS3/4A PROTEASE INHIBITORS WITH A HIGH BARRIER TO RESISTANCE from Roche/Intermune - (04/09/11)
     
  6033. EASL: Predictors of Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-Treated With Boceprevir Plus Peginterferon Alfa-2b/Ribavirin (IL28B affect-see bargraph inside) - (04/09/11)
     
  6034. EASL: BMS-650032, an NS3 Inhibitor (protease), in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C Infection - (04/08/11)
     
  6035. EASL: Treatment outcome and resistance analysis in HCV genotype 1 patients previously exposed to TMC435 monotherapy and re-treated with TMC435 in combination with PegIFNa-2a/ribavirin - (04/08/11)
     
  6036. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon: "the high mortality rates observed, particularly in the cirrhosis stratum, confirm the poor outcomes among patients with chronic hepatitis C and advanced hepatic fibrosis." - (04/07/11)
     
  6037. EASL: In vitro profiling of GSK2336805, A Potent and Selective Inhibitor of HCV NS5A - (04/08/11)
     
  6038. EASL: Preclinical Characterization of GSK2485852A, a Novel HCV Polymerase Inhibitor - (04/08/11)
     
  6039. Increasing Prevalence of HCC and Cirrhosis in Patients With Chronic Hepatitis C Virus Infection - (04/04/11)
     
  6040. Boosted ABT-450/r HCV Protease 3-Day Monotherapy - (04/04/11)
     
  6041. Danoprevir Unboosted activity, safety & resistance - (04/04/11)
     
  6042. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN -2a/RBV in hepatitis C patients - pdf attached - (04/04/11)
     
  6043. EASL: Low prevalence of danoprevir resistance identified in genotype 1b HCV patients with prior null response treated with danoprevir plus low-dose ritonavir plus peginterferon alfa-2a (40KD)/ribavirin for 12 weeks - (04/06/11)
     
  6044. EASL: BMS-766, a Novel HCV NS5A Inhibitor With Enhanced Resistance Coverage - (04/06/11)
     
  6045. EASL: Three-Day, Dose-Ranging Study of the HCV NS5A Inhibitor GS-5885 - (04/06/11)
     
  6046. EASL: A Phase 2b Trial Comparing 24 to 48 Weeks Treatment with Tegobuvir (GS-9190)/PEG/RBV to 48 Weeks Treatment with PEG/RBV for Chronic Genotype 1 HCV Infection - (04/06/11)
     
  6047. EASL: GS-6620: A Liver Targeted Nucleotide Prodrug with Potent Pan-Genotype Anti-Hepatitis C Virus Activity In Vitro - (04/06/11)
     
  6048. EASL: Emergence and Persistence of NS5B Mutations Following Combination Treatment with Tegobuvir (GS-9190) plus Standard of Care--Long-Term follow-Up from the Phase 2b Study GS-US-196-0103 - (04/06/11)
     
  6049. EASL: Preclinical Properties of the Novel HCV NS3 Protease Inhibitor GS-9451 - (04/06/11)
     
  6050. EASL: GS-6620, A Novel Anti-Hepatitis C Virus Nucleotide Prodrug, Has A High In Vitro Barrier To Resistance - (04/06/11)
     
  6051. EASL: PSI-352938, A Novel Purine Nucleotide Analog, Exhibits Potent Antiviral Activity and No Evidence of Resistance in Patients with HCV Genotype 1 Over 7 Days - (04/06/11)
     
  6052. EASL: Nonclinical and Cross-genotypic Profiles of GS-9669, a Novel HCV NS5B Non-nucleoside Thumb Site II Inhibitor - (04/06/11)
     
  6053. EASL: Preclinical Characterization of GS-9620, A Potent and Selective Oral TLR7 Agonist - (04/06/11)
     
  6054. EASL: A Phase-I, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Escalating Oral Doses of GS-9620 In Healthy Subjects - (04/06/11)
     
  6055. EASL: Genotypic and Phenotypic Characterization of HCV Resistance From a Multiple Dose Clinical Trial of GS-9451, a Novel NS3 Protease Inhibitor - (04/06/11)
     
  6056. EASL: HCV Drug Resistance - (04/06/11)
     
  6057. EASL: Nucleotide Inhibitor Resistance Selections Using GT2a Infectious Virus: PSI-7851 and GS-6620 Select for A Novel Resistance Pathway Including Substitutions of M289V/L Followed By S282T - (04/06/11)
     
  6058. EASL: Characterization of Viral Resistance Mutations In Genotype 1 HCV Patients Receiving Combination Therapy with a Protease Inhibitor and a Polymerase Inhibitor with or without Ribavirin - (04/06/11)
     
  6059. EASL: Factors affecting HCV viral load response to the non-nucleoside polymerase inhibitors ABT-072 and ABT-333 - (04/05/11)
     
  6060. EASL: Adherence To Assigned Dosing Regimen and Sustained Virologic Response Among Hepatitis C-Genotype 1 Previously Untreated and Peginterferon/Ribavirin Treatment-Failure Patients Treated With Boceprevir Plus Peginterferon Alfa-2b/Ribavirin (patients with >80% adherence to all dosing achieved 90% cure rates. My guess is if adherence is 100% SVR rates will be higher) - (04/05/11)
     
  6061. EASL: Four-Week Treatment with GS-9256 and Tegobuvir (GS-9190) +/- RBV +/- PEG, Results in Enhanced Viral Suppression on Follow-up PEG/RBV Therapy, in Genotype 1a/1b HCV Patients - (04/05/11)
     
  6062. EASL: Genotypic and Phenotypic Characterization of NS3 Variants Selected in HCV-Infected Patients Treated with ABT-450 - (04/05/11)
     
  6063. EASL: Characterization of Virologic Escape in HCV Genotype 1 Null Responders Receiving a Combination of the NS3 Protease Inhibitor BMS-650032 and NS5A Inhibitor BMS-790052 - (04/05/11)
     
  6064. EASL: ABT-450/Ritonavir (ABT-450/r) Combined with Pegylated Interferon Alpha-2a and Ribavirin After 3-Day Monotherapy in Genotype 1 HCV-Infected Treatment-naïve Subjects: 12-Week Interim Efficacy and Safety Results - (04/04/11)
     
  6065. EASL: Boehringer Ingelheim's Lead Hepatitis C Compound Moves into Phase 3 - the First Within the BI HCV Portfolio - (04/04/11)
     
  6066. EASL: Merck, J&J's New Hepatitis C Treatments Fetch $31,000 in France - (04/04/11)
     
  6067. EASL: Anemia had No Effect on Efficacy Outcomes in Treatment-naïve Patients Who Received Telaprevir-based Regimen in the ADVANCE and ILLUMINATE Phase 3 Studies - (04/04/11)
     
  6068. EASL: Positive Phase 2 results reported with Boehringer Ingelheim's investigational HCV protease inhibitor in both previously treated and untreated patient - (04/04/11)
     
  6069. EASL: TMC435 HCV Protease - (04/04/11)
     
  6070. EASL: Hepatitis C Treatment In France: three-to four-fold increase between now and 2012 is anticipated in the number of patients treated in hospital for HCV genotype 1 infection (the most common in France) - (04/04/11)
     
  6071. EASL: Brief Recap Report from EASL Liver Conference in Berlin: state of HCV Now- policy, treatment, access - (04/04/11)
     
  6072. EASL: Anemia had No Effect on Efficacy Outcomes in Treatment-naïve Patients Who Received Telaprevir-based Regimen in the ADVANCE and ILLUMINATE Phase 3 Studies - (04/03/11)
     
  6073. EASL: BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS (RAVS) ARE OBSERVED MORE FREQUENTLY IN HCV (GT1)-INFECTED PATIENTS WITH POOR RESPONSE TO PEGINTERFERON ALFA-2B/RIBAVIRIN - (04/03/11)
     
  6074. EASL: Evolution of Treatment-Emergent Variants in Telaprevir Phase 3 Clinical Trials - (04/03/11)
     
  6075. EASL: Telaprevir Substantially Improved SVR Rates Across All IL28B Genotypes in the ADVANCE Study - (04/03/11)
     
  6076. EASL: Therapeutic HCV Vaccine - (04/03/11)
     
  6077. EASL: Investigational Compound PEG-Interferon Lambda Achieved Higher Response Rates with Fewer Flu-Like and Musculoskeletal Symptoms and Cytopenias Than PEG-Interferon Alfa in Phase IIb Study of 526 Treatment-Naive Hepatitis C Patients - BMS press release - (04/03/11)
     
  6078. EASL: First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: interim analysis from the JUMP-C trial - (04/03/11)
     
  6079. EASL: Pegylated Interferon-Lambda (PegIFN-λ) Shows Superior Viral Response With Improved Safety and Tolerability Versus PegIFN-α-2a in HCV Patients (G1/2/3/4): EMERGE Phase IIb Through Week 12 - (04/03/11)
     
  6080. EASL: HCV Cured With out Peginterferon/ribavirin with 2 oral HCV drugs BMS790052+BMS650032: Quadruple Therapy With BMS-790052, BMS-650032 and Peg-IFN/RBV for 24 Weeks Results in 100% SVR12 in HCV Genotype 1 Null Responders: "HCV infection can be cured without interferon & ribavirin: 2 orals BMS790052+BMS650032"  - (04/02/11)
     
  6081. EASL: The New England Journal of Medicine (NEJM) Publishes Pivotal Studies Showing Merck's Investigational Medicine VICTRELIS (boceprevir) in Combination Therapy Significantly Increased SVR In Patients with Chronic HCV Genotype 1 Who Failed Previous Treatment or Who Were New to Treatment Compared to Control - (04/01/11)
     
  6082. EASL: Impact of IL28B Genotype and Pre-treatment Serum IP-10 in Treatment-Naïve Genotype 1 HCV Patients Treated with TMC435 in Combination with Peginterferon alpha-2a and Ribavirin in the PILLAR Study - (04/01/11)
     
  6083. EASL: Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin Increased Sustained Virologic Response Rates in Treatment-naïve Patients Regardless of Race or Ethnicity - (04/01/11)
     
  6084. EASL: IL28B POLYMORPHISM PREDICTS VIROLOGIC RESPONSE IN PATIENTS WITH HEPATITIS C GENOTYPE 1 TREATED WITH BOCEPREVIR COMBINATION THERAPY - (04/01/11)
     
  6085. EASL: Boceprevir in Addition to Standard of Care Enhanced SVR in Hepatitis C Virus Genotype-1 With Advanced Fibrosis/Cirrhosis: Subgroup Analysis of SPRINT-2 and RESPOND-2 Studies - (04/01/11)
     
  6086. EASL: PROTON Study: PSI-7977 QD with PEG/RBV: 12-week Safety, RVR, cEVR, & SVR12 in Treatment-naïve Patients with HCV GT2 or GT3 - (04/01/11)
     
  6087. EASL: Activity of danoprevir plus low-dose ritonavir in combination with peginterferon alfa-2a (40KD) plus ribavirin in previous null responders - (04/01/11)
     
  6088. EASL: SILEN-C1: sustained virological response (SVR) and safety of BI 201335 combined with peginterferon alfa 2a and ribavirin (PegIFN/RBV) in treatment-naïve patients with chronic genotype-1 HCV infection - (04/01/11)
     
  6089. EASL: SILEN-C2: sustained virological response (SVR) and safety of BI 201335 combined with peginterferon alfa 2a and ribavirin (PegIFN/RBV) in chronic HCV genotype-1 patients with nonresponse to PegIFN/RBV - (04/01/11)
     
  6090. EASL: The ASPIRE Trial: TMC435 in treatment-experienced patients with genotype 1 HCV infection who have failed previous PegIFN/RBV treatment: Week 24 interim analysis - (04/01/11)
     
  6091. EASL: Similar SVR Rates in IL28B CC, CT or TT Prior Relapser, Partial- or Null-responder Patients Treated with Telaprevir/Peginterferon/Ribavirin: Retrospective Analysis of the REALIZE Study - (04/01/11)
     
  6092. EASL: VICTRELIS (boceprevir), Merck's Investigational Medicine, Added to Peginterferon Alfa-2a and Ribavirin Achieved Significantly Higher SVR Rates In Treatment-Failure Patients with Chronic HCV Genotype 1 Compared to Control - (04/01/11)
     
  6093. EASL: New Data Analyses with VICTRELIS (boceprevir), Merck's Investigational Medicine, Examined Possible Predictors of Sustained Virologic Response - (04/01/11)
     
  6094. EASL: REALIZE Trial Final Results: Telaprevir-based Regimen for Genotype 1 Hepatitis C Virus Infection in Patients with Prior Null Response, Partial Response or Relapse to Peginterferon/Ribavirin - (04/01/11)
     
  6095. EASL: First Report of SVR12 for a NS5A Replication Complex Inhibitor, BMS-790052, in Combination With PegIFNα-2a and RBV: Phase IIA Trial in Treatment-Naive HCV Genotype 1 Subjects - (03/31/11)
     
  6096. EASL: Data From Phase 3 Studies Showed Substantial Improvements in SVR (Viral Cure) Rates With Telaprevir-Based Therapy Compared to Currently Available Medicines in People With Hepatitis C, Regardless of Their IL28B Genotype Status - (03/31/11)
     
  6097. EASL: Interim Phase 2 Data Showed Rapid Viral Response to VX-222 in Combination with Telaprevir, Pegylated-Interferon and Ribavirin Among People With Hepatitis C - (03/31/11)
     
  6098. EASL: Results From Phase 3 REALIZE Study Showed Telaprevir-Based Therapy Significantly Improved SVR (Viral Cure) Rates in People Whose Prior Treatment For Hepatitis C Was Unsuccessful - (03/31/11)
     
  6099. EASL: Once daily alisporivir (DEB025) plus Peg-IFN-alfa-2A/ ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment-naïve patients - The ESSENTIAL study - (03/31/11)
     
  6100. EASL: Once daily alisporivir (DEB025) plus Peg-IFN-alfa-2A/ ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment-naïve patients - The ESSENTIAL study - (03/31/11)
     
  6101. EASL: ONCE DAILY DUAL-NUCLEOTIDE COMBINATION OF PSI-938 AND PSI-7977 PROVIDES 94% HCV RNA < LOD AT DAY 14: FIRST PURINE/PYRIMIDINE CLINICAL COMBINATION DATA (THE NUCLEAR STUDY) - (03/31/11)
     
  6102. EASL: PSI-7977 QD Plus PEG/RBV In HCV GT1: 98% Rapid Virologic Response, Complete Early Virologic Response: The PROTON Study - (03/31/11)
     
  6103. EASL: 4 New HCV Drugs: 1st SVR Results from NS5A BMS790052; 2 nucleotides in combination PSI938 + PSI7977; cyclophillin inhibitor Debo25; - (03/31/11)
     
  6104. New Drugs for Hepatitis C on the Horizon - (03/31/11)
     
  6105. Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection - (03/31/11)
     
  6106. Boceprevir for Untreated Chronic HCV Genotype 1 Infection - (03/31/11)
     
  6107. EASL: Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes - (03/31/11)
     
  6108. EASL: Presidio Pharmaceuticals, Inc. Announces Positive Results in a Phase 1b Clinical Trial of PPI-461, a Novel, Potent Broadly-Active Hepatitis C Virus (HCV) Inhibitor - (03/30/11)
     
  6109. EASL: Achillion Announces Positive RVR Results With ACH-1625 to Treat Chronic Hepatitis C - (03/30/11)
     
  6110. EASL: Tibotec Advances Global Clinical Research Program for TMC435 in HCV; Will Present Four Abstracts Evaluating Safety and Efficacy at EASL - (03/30/11)
     
  6111. CROI: Risk of Fractures Associated with HIV/Hepatitis C Coinfection - (03/28/11)
     
  6112. Efficacy and Safety Study of DEB025/Alisporivir Combined to Standard Therapy (Peg-IFN and Ribavirin) in Chronic Hepatitis C Genotype 1 naïve Patients PHASE 3 Study - (03/23/11)
     
  6113. CROI: Sustained Response to Anti-HCV Therapy Higher During Acute Infection in HIV Positives - written by Mark Mascolini - (03/22/11)
     
  6114. CROI: Boceprevir Boosts Sustained Virologic Response Rate With HCV Genotype 1 - written by Mark Mascolini - (03/22/11)
     
  6115. CROI: Boceprevir Improves SVR With PegIFN/RBV After Failure or Relapse With HCV-1 - written by Mark Mascolini - (03/22/11)
     
  6116. Simplified Explanation of the Phase 3 Studies of HCV Protease Inhibitor Boceprevir - (03/21/11)
     
  6117. CROI: High incidence rate of HCV reinfection after treatment of acute HCV infection in HIV-infected MSM in Amsterdam - (03/21/11)
     
  6118. CROI: Summary from CROI for Hepatitis Coinfection - New drugs for treatment of hepatitis C are becoming available: what does that mean for the HIV coinfected patient? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/19/11)
     
  6119. HCV Infection and the Incidence of CKD (pdf attached) - (03/16/11)
     
  6120. CROI: The Effect of Low-dose Ritonavir on the Pharmacokinetics of the Investigational HCV Protease Inhibitor Telaprevir in Healthy Volunteers - (03/15/11)
     
  6121. CROI: Clinical Pharmacology at CROI 2011 (HIV & HCV) - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center 986000 Nebraska Medical Center (03/14/11)
     
  6122. CROI: Telapravir Promotes Early Clearance of HCV RNA With PEG-IFN/RBV, Early Response Predicts Outcome (weeks 1,2,4) - written by Mark Mascolini - (03/8/11)
     
  6123. New Data on Multiple Bristol-Myers Squibb Investigational Hepatitis C Compounds to be Presented at The International Liver Congress 2011 (EASL) - (03/10/11)
     
  6124. CROI: Liver Death Rate Twice Higher With HBV Than HCV in Gay HIV+ Men of MACS - written by Mark Mascolini - (03/8/11)
     
  6125. CROI: Telapravir Promotes Early Clearance of HCV RNA With PEG-IFN/RBV, Early Response Predicts Outcome (weeks 1,2,4) - written by Mark Mascolini - (03/8/11)
     
  6126. CROI: Positive Phase 2 Interim Data from First Study of Telaprevir in People Co-Infected with Hepatitis C and HIV Presented at CROI Conference - (03/2/11)
     
  6127. CROI: Telaprevir + Peginterferon and Ribavirin: phase 2a study in coinfected patients on HAART Reported at CROI March 2 2011 - (03/2/11)
     
  6128. CROI: Clinical Pharmacology of Boceprevir: Metabolism, Excretion, and Drug-Drug Interactions - (03/2/11)
     
  6129. CROI: Pharmacokinetic Interactions Between Antiretroviral Agents and the Investigational HCV Protease Inhibitor Telaprevir in Healthy Volunteers - (03/2/11)
     
  6130. CROI: Positive Phase 2 Interim Data from First Study of Telaprevir in People Co-Infected with Hepatitis C and HIV Presented at CROI Conference - (03/2/11)
     
  6131. CROI: Interim Analysis of Phase 2a Study of Telaprevir + Peginterferon/Ribavirin in HCV/HIV Coinfected Patients - (03/2/11)
     
  6132. APASL: Associations between two SNPs (rs12979860, rs12980275) and complete early virological response for peginterferon alfa-2a (40KD) - based treatment in naive patients and previous non-responders - (02/28/11)
     
  6133. APASL: Retrospective pooled safety analysis of standard- versus high-dose peginterferon alfa-2a (40KD) (PEGASYS) in chronic hepatitis C genotype 1 or 4 patients - (02/28/11)
     
  6134. APASL: Intensified peginterferon alfa-2a (40KD) dosing increases sustained virological response rates in genotype 1 hepatitis C patients with elevated low-density lipoprotein - (02/25/11)
     
  6135. Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use - pdf attached - (02/24/11)
     
  6136. APASL: Can HCV Be Cured Without Peg/RBV: Combination BMS-790052, BMS-650032 and pegIFN/RBV Provides Undetectable HCV RNA Through 12 Weeks of Therapy in HCV Genotype 1 Null Responders - (02/24/11)
     
  6137. APASL: Can HCV Be Cured Without Peg/RBV: Combination BMS-790052, BMS-650032 and pegIFN/RBV Provides Undetectable HCV RNA Through 12 Weeks of Therapy in HCV Genotype 1 Null Responders - (02/24/11)
     
  6138. APASL: Phase 2 Study of Pegylated Interferon Lambda for HCV: Safety, Viral Response, and Impact of Host Genotype Through Week 12 - (02/24/11)
     
  6139. Medivir Announces Positive Phase 2b 48-week (SVR24) Interim Results of TMC435 in Treatment-Naive Patients Chronically Infected With Genotype-1 Hepatitis C Virus - (02/22/11)
     
  6140. Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 in Adults With Chronic Genotype 1 HCV - (02/22/11)
     
  6141. APASL: Burden of Viral Hepatitis C in Japan: A Propensity Analysis of Patient Outcomes - (02/21/11)
     
  6142. APASL: Antiviral Activity of Boceprevir Monotherapy inTreatment-Naive Subjects With Chronic Hepatitis C Genotype 2/3 - (02/21/11)
     
  6143. Pegasys Patient Assistance Program
     
  6144. Boceprevir & Peginterferon Patient Assistance Programs
     
  6145. APASL: 12-Week Effiacy and Safety of ABT-072 or ABT-333 with Pegylated Interferon + Ribavirin, Following 3-Day Monotherapy in Genotype 1 HCV-Infected Treatment-Naïve Subjects - (02/19/11)
     
  6146. APASL: Telaprevir-based Therapy in Genotype 1 Hepatitis C Virus-infected Patients with Prior Null Response, Partial Response or Relapse to Peginterferon/Ribavirin: REALIZE Trial Final Results - (02/18/11)
     
  6147. Medivir Kicks Off Phase 1a Trial of the Hepatitis C Polymerase Inhibitor TMC649128 - (02/17/11)
     
  6148. Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C - (02/16/11)
     
  6149. New protease inhibitors for HCV - Help is on the way - (02/16/11)
     
  6150. Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting: 'prevalence 3-7 times higher than 1.6% reported by CDC'..... - pdf attached - (02/16/11)
     
  6151. HIV and HCV health [mis]beliefs in an inner-city community - pdf attached: 'inaccurate understanding of HCV'.... - (02/16/11)
     
  6152. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients - pdf attached - (02/16/11)
     
  6153. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b in Japan- pdf attached - (02/16/11)
     
  6154. Editorial: Effect of Atorvastatin, Vitamin E and C on Nonalcoholic Fatty Liver Disease: Is the Combination Required? - (02/14/11)
     
  6155. IL28B Genomic-Based Treatment Paradigms for Patients With Chronic Hepatitis C Infection: The Future of Personalized HCV Therapies - pdf attached - (02/14/11)
     
  6156. Surveillance for hepatocellular carcinoma (HCC) in patients with cirrhosis is recommended but 17% received regular testing for HCC(liver cancer) - (02/14/11)
     
  6157. Medivir Announces Start of Phase 1a Trial of the Hepatitis C Polymerase Inhibitor TMC649128 - (02/11/11)
     
  6158. Sustained High Levels of HCV-infection Among IDUs in USA - Prevention of Hepatitis C Virus in Injecting Drug Users: A Narrow Window of Opportunity -editorial - (02/05/11)
     
  6159. Liver Cancer Triples, NO HCV Testing Funds: Aging with HCV - (02/05/11)
     
  6160. HCV Sexual Transmission among MSM HIV+ in the USA: "sexual transmission is likely to be responsible for incident HCV infection" in men - (02/05/11)
     
  6161. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients - pdf attached - (02/05/11)
     
  6162. The role of triple therapy in HCV genotype 1-experienced patients pdf attached - (02/05/11)
     
  6163. Changes in Blood-borne Infection Risk (HCV) Among Injection Drug Users - pdf attached - (02/05/11)
     
  6164. Transmission Clusters among HIV-Positive and HIV-Negative Individuals in the Australian Trial in Acute Hepatitis C - "(18%) were most likely infected through sexual exposure [men and women]" (pdf attached) - (02/05/11)
     
  6165. Gene Variants Linked to Hepatitis C Treatment-Related Anemia Identified - (01/26/11)
     
  6166. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR - pdf attached - (01/26/11)
     
  6167. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir - pdf attached - (01/26/11)
     
  6168. U.S. FDA and Health Canada Grant Priority Reviews for Telaprevir for the Treatment of Hepatitis C - (01/19/11)
     
  6169. Immune Activation & HCV-Infection: Reduced Naive CD4 T Cell Numbers and Impaired Induction of CD27 in Response to T Cell Receptor Stimulation Reflect a State of Immune Activation in Chronic Hepatitis C Virus Infection - pdf attached - (01/12/11)
     
  6170. Bristol-Myers Squibb and Pharmasset Enter into a Clinical Collaboration Agreement for Proof of Concept Combination Study in Patients Chronically Infected with Hepatitis C - (01/11/11)
     
  6171. Boceprevir, Merck's Investigational Oral Hepatitis C Protease Inhibitor, Receives FDA Priority Review and EMA Accelerated Assessment - (01/07/11)
     
  6172. Pharmasset Reports Positive Results from its HCV Clinical Programs: PSI-7977 & PSI-938 - (01/06/11)
     
  6173. Anadys Pharmaceuticals starts Phase IIb trial of ANA598 in HCV patients - (01/06/11)
     
  6174. Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3 - (01/06/11)
     
  6175. Lower Recurrence Rate for HCC Treated With Resection Than Radiofrequency Ablation - publication study article below, pdf attached - (01/04/11)
     
  6176. Liver Disease in the HIV-Infected Individual REVIEW- publication pdf attached - (01/04/11)
     
  6177. Liver Cancer in Cirrhotic Patients Effectively Treated with Radiofrequency Ablation: Full-Text journal article and pdf follows press release - (01/04/11)
     
  6178. EU drugs agency launches new guidelines for HIV testing in injecting drug users - pdf of guidelines attached - (01/03/11)
     
  6179. Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients - pdf attached - (12/30/10)
     
  6180. Pharmacodynamics of PEG-IFN alpha-2a and HCV response as a function of IL28B polymorphism in HIV/HCV co-infected patients - published pdf attached - (12/19/10)
     
  6181. Maintenance Peginterferon Therapy and Other Factors Associated with Hepatocellular Carcinoma in Patients with Advanced Hepatitis C - pdf attached - (12/19/10)
     
  6182. Early Menopause is Associated with Lack of Response to Antiviral Therapy in Women with Chronic Hepatitis C: "This suggests that CHC in women should be treated early, disregarding the fact that liver disease is milder in women of reproductive age, as this condition will last only as long as the estrogen-exposed period." - published pdf attached - (12/19/10)
     
  6183. AASLD: A Phase IIa Study of IDX184 in Combination with Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Treatment-Naïve Genotype 1 HCV-Infected Subjects - (12/13/10)
     
  6184. AASLD: Phase I Study in Healthy Volunteers and Patients with IDX375, a Novel Non-Nucleoside HCV Polymerase Inhibitor - (12/13/10)
     
  6185. AASLD: Antiviral Activity, Safety and Pharmacokinetics of IDX320, a Novel Macrocyclic HCV Protease Inhibitor, in a 3-Day Proof-of-Concept Study in Patients with Chronic Hepatitis C - (12/13/10)
     
  6186. AASLD: Steatosis, Obesity, Peg-IFN Dose Reduction & Menopause are Associated with Relapse in Chronic Hepatitis C Patients Treated with Pegylated Interferon Plus Ribavirin - (12/13/10)
     
  6187. AASLD: IL-28B Genotype is a Major Determinant of the Induction of a Virological Response by High-Dose Peginterferon and Ribavirin in Null-responders to SOC Therapy: Pegasys double-dose significantly increased early virologic response - (12/13/10)
     
  6188. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study) - published pdf attached - (12/06/10)
     
  6189. Medivir Announces Positive 24-week Interim Data of TMC435 From the ASPIRE Study (C206) in Treatment-Experienced Prior Non-responders - (12/02/10)
     
  6190. Pharmasset Initiates Dosing in a Combination Study of PSI-7977 and PSI-938 for Chronic Hepatitis C - (11/30/10)
     
  6191. Latinos & HCV: unequal opportunity for treatment - (11/30/10)
     
  6192. Irreversible inhibition of a protease central to hepatitis C infection; New HCV Protease AVL-192: Study (full text; published pdf attached) - (11/29/10)
     
  6193. AASLD: New HCV Drugs at AASLD - (11/29/10)
     
  6194. AASLD: Assessment of Hepatitis C Virus Attitudes Towards Treatment Among Methadone Maintenance Treatment Program Staff - (11/29/10)
     
  6195. AASLD: Ultra-Deep Sequencing of the NS3 and NS5B Regions Detects Pre-Existing Resistant Variants to Direct Acting Antivirals (DAA) in HCV Genotype 1 Treatment-Naïve Infected Patients - (11/29/10)
     
  6196. AASLD: Low rate of viral load rebound observed among treatment-naive genotype 1 patients with chronic hepatitis C treated with danoprevir (RG7227) plus Peg-IFN α-2a (40KD) (PEG ASYS) plus ribavirin: interim analysis - (11/21/10)
     
  6197. AASLD: Genotypic and phenotypic analysis of the NS5B polymerase region from viral isolates of HCV chronically infected patients treated with BI 207127 for 5 days' monotherapy - (11/21/10)
     
  6198. AASLD: No evidence of drug resistance or baseline S282T resistance mutation among GT 1 and GT 4 HCV infected patients on nucleoside polymerase inhibitor RG7128 and Peg-IFN/RBV combination treatment for up to 12 weeks: Interim analysis from the PROPEL study - (11/21/10)
     
  6199. AASLD: Analysis of Resistance-Associated Mutations in Patients treated with narlaprevir and subsequently standard of care - (11/21/10)
     
  6200. AASLD: Chronic Hepatitis C (HCV) Infections and the Risk of Depression and Other Adverse Events - (11/21/10)
     
  6201. AASLD: In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters - (11/21/10)
     
  6202. AASLD: Phase II randomized, partially blind, parallel-group study of oral danoprevir (RG7227) with PegIFN alfa-2a (PEGASYS) plus ribavirin (COPEGUS) in treatment-naive genotype 1 patients with CHC: Results of planned Week 12 interim analysis of the ATLAS study - (11/21/10)
     
  6203. AASLD: Impact of PegIntron (PEG) Maintenance Therapy (MT) on Fibrosis Biomarkers (FibroTest [FT]/FibroSURE) in Prior Nonresponders With METAVIR Fibrosis Scores (MFS) of F2/F3: Final Results From the EPIC3 Program - (11/21/10)
     
  6204. AASLD: No Impact of Insulin Resistance on Antiviral Efficacy of Telaprevir-based Regimen in HCV Genotype 1 Treatment-naïve Patients: Subanalysis of C208 Study - (11/21/10)
     
  6205. AASLD: Differential association of a chromosome 19 single nucleotide polymorphism (SNP: rs12979860) to outcome (early virologic response/sustained virologic response [EVR /SVR]) in naive vs. retreated HCV patients treated with IFN-based therapies - (11/21/10)
     
  6206. AASLD: Telaprevir Resistance Disappears in 89% of Patients: Long-Term Follow-up of Patients with Chronic Hepatitis C Treated with Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin: Interim Analysis from the EXTEND Study - (11/16/10)
     
  6207. Telaprevir: Phase 3 ADVANCE Study Data Presented at AASLD - (11/15/10)
     
  6208. AASLD: Coadministration of BMS-790052 and BMS-650032 Does Not Result in a Clinically Meaningful Pharmacokinetic Interaction in Healthy Subjects - (11/15/10)
     
  6209. AASLD: Gilead's New HCV Drugs Studies & HBV at AASLD - (11/15/10)
     
  6210. AASLD: 36 versus 48 weeks of treatment with peginterferon alfa-2a plus ribavirin for genotype 1/4 patients with undetectable HCV RNA at week 8: Final results of a randomized multicenter study - (11/14/10)
     
  6211. AASLD: Genotype 1b vs 1a and Peg/Rbv Lead-In - (11/12/10)
     
  6212. AASLD: The Effect of Hepatitis C Treatment Response on Medical Costs: A 5-Year Longitudinal Analysis in a Managed Care Setting - (11/12/10)
     
  6213. AASLD: Virological response and safety of 4 weeks' treatment with the protease inhibitor BI 201335combined with 48 weeks of peginterferon alfa 2a and ribavirin for treatment of HCV GT-1 patients who failed peginterferon/ribavirin - (11/12/10)
     
  6214. AASLD: BMS-790052, a First-in-Class Potent Hepatitis C Virus NS5A Inhibitor, Demonstrates Multiple-Dose Proof-of-Concept in Subjects With Chronic GT1 HCV Infection (potent, up to 5.7 log reduction) - (11/10/10)
     
  6215. AASLD: New HCV Drugs at AASLD, easy to understand report: (see links below to reports from AASLD) - (11/10/10)
     
  6216. AASLD: HCV New Drugs - (11/08/10)
     
  6217. AASLD: Pegylated Interferon Lambda (pegIFNλ) Phase 2 Dose-Ranging, Active-Controlled Study in Combination With Ribavirin (RBV) for Treatment-Naive HCV Patients (Genotypes 1, 2, 3, or 4): Safety, Viral Response, and Impact of IL28B Host Genotype Through Week 12 - (11/08/10)
     
  6218. AASLD: Initial Antiviral Activity of the HCV NS3 Protease Inhibitor ABT-450 When Given with Low-dose Ritonavir as 3-Day Monotherapy: Preliminary Results of Study M11-602 in Genotype 1 (GT1) HCV-infected Treatment-naïve Subjects - (11/08/10)
     
  6219. AASLD: Rapid Progression to Decompensated Cirrhosis and Death in HIV-infected Men with Newly-acquired HCV Infection - (11/08/10)
     
  6220. AASLD: A Phase IIa, open-label study to assess the antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6 - (11/08/10)
     
  6221. AASLD: High Rapid Virologic Response (RVR) with PSI-7977 Daily Dosing plus PEG-IFN/RBV in a 28-day Phase 2a Trial - (11/08/10)
     
  6222. AASLD: IL28B SNP Geographical Distribution and Antiviral Responses in a 28-day Phase 2a Trial of PSI-7977 Daily Dosing plus PEG-IFN/RBV - (11/08/10)
     
  6223. AASLD: Clinical Synergy of an Anti-HCV Nucleotide Analog with SOC: Viral Kinetics of PSI-7977 with SOC - (11/08/10)
     
  6224. AASLD: Pharmacokinetics, Safety, and Tolerability of PSI-352938, a Novel Nucleotide Polymerase Inhibitor for HCV, Following Single Ascending Oral Doses in Healthy Subjects - (11/08/10)
     
  6225. AASLD: Virologic analysis of genotype-1-infected patients treated with once-daily TMC435 during the Optimal Protease inhibitor Enhancement of Response to TherApy (OPERA)-1 study - (11/07/10)
     
  6226. AASLD: Three-Day, Dose-Ranging Study Of The HCV NS3 Protease Inhibitor GS-9451 - (11/07/10)
     
  6227. AASLD: Antiviral Response and Resistance Analysis of Treatment-Naïve HCV Infected Subjects Receiving Single and Multiple Doses of GS-9190 - (11/07/10)
     
  6228. AASLD: Safety, Pharmacokinetics, and Antiviral Activity of Single Oral Doses of the HCV NS3 Protease Inhibitor GS-9256 - (11/07/10)
     
  6229. AASLD: 5 New Potent HCV Protease inhibitors - (11/05/10)
     
  6230. AASLD: New HCV Drugs: R7128 nucleoside, PSI7977 nucleotide, PSI938 nucleotide, ANA598 nnrti (rash), danoprevir protease, IMO-2125, a TLR agonist - (11/05/10)
     
  6231. AASLD: IMO-2125, a TLR9 Agonist, Induces Immune ResponsesWhich Correlate With Reductions In Viral Load In Null Responder HCV Patients - (11/05/10)
     
  6232. AASLD: AASLD President's Choice Lecture: The National Strategy for the Control of Viral Hepatitis and Liver by Dr Howard Koh, HHS - (11/05/10)
     
  6233. AASLD: Frequencies of Resistance-Associated Amino Acid Variants Following Combination Treatment with Boceprevir Plus PEGINTRON (PegInterferon Alfa-2b)/Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 1 (G1) - (11/05/10)
     
  6234. AASLD: Clinical Virology Results from Telaprevir Phase 3 Study ADVANCE - (11/05/10)
     
  6235. AASLD: Dual, Triple, and Quadruple Combination Treatment with a Protease Inhibitor (GS-9256) and a Polymerase Inhibitor (GS-9190) alone and in Combination with Ribavirin (RBV) or PegIFN/RBV for up to 28 days in Treatment Naïve, Genotype 1 HCV Subjects - (11/04/10)
     
  6236. AASLD: Safety and Antiviral Activity of MK-5172, a Novel HCV NS3/4a Protease Inhibitor with Potent Activity Against Known Resistance Mutants, in Genotype 1 and 3 HCV-Infected Patients - (11/04/10)
     
  6237. AASLD: Maintenance peginterferon (pegIFN) therapy to prevent hepatocellular carcinoma (HCC) in patients with advanced chronic hepatitis C: extended follow - up results from the HALT - C Trial - (11/04/10)
     
  6238. AASLD: Effects of Ribavirin Monotherapy on ALT, HCV Viral Levels, Serum Cytokines, and Hepatic Interferon - Stimulated Gene Expression in Chronic Hepatitis C - (11/04/10)
     
  6239. AASLD: Sustained Virological Response of Antiviral Therapy and Clinical Outcomes in Elderly Patients with Compensated HCV - related Cirrhosis - (11/04/10)
     
  6240. AASLD: Strong antiviral activity and safety of IFN-sparing treatment with the protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127, and ribavirin, in patients with chronic hepatitis C: the SOUND-C1 trial - (11/04/10)
     
  6241. AASLD: Safety and Pharmacokinetics of PPI-461, a Potent New HCV NS5A Inhibitor with Pan-Genotype Activity - (11/04/10)
     
  6242. AASLD: Long Term (4 Year) Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Positive Patients (HBeAg+) with Chronic Hepatitis B (Study 103) - (11/04/10)
     
  6243. AASLD: Continued Efficacy and Safety Through 4 Years of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102) - (11/04/10)
     
  6244. AASLD: Coffee is associated with virologic response in chronic Hepatitis C: Findings from the Hepatitis C Long - Term Treatment against Cirrhosis Trial (HALT - C) . - (11/04/10)
     
  6245. AASLD: Clinical, Virological, Biochemical Outcomes After 20 Years of Sustained Virological Response (SVR) in Chronic Hepatitis C: The NIH Experience. - (11/04/10)
     
  6246. AASLD: Sustained Viral Response (SVR) Rates in Genotype 1 Treatment-naïve Patients with Chronic Hepatitis C (CHC) Infection Treated with Vaniprevir (MK-7009), a NS3/4a Protease Inhibitor, in Combination with Pegylated Interferon Alfa-2a and Ribavirin for 28 Days - (11/04/10)
     
  6247. AASLD: Telaprevir in Combination with Peginterferon alfa-2a and Ribavirin in Genotype 1 HCV Treatment-Naïve patients: Final results of Phase 3 ADVANCE Study - (11/04/10)
     
  6248. AASLD: Phase 3 - Response Guided Therapy (RGT) - Boceprevir Combined with peginterferon alfa-2b plus ribavirin for treatment-naïve patients with HCV genotype 1 (SPRINT-2 Final Results) - (11/04/10)
     
  6249. AASLD: Telaprevir Phase 3 ILLUMINATE Study - Final Results Reported at AASLD Nov 2 2010 - (11/04/10)
     
  6250. AASLD: High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PegIFN alfa-2a (40KD)/RBV: Planned Week 12 interim analysis from the PROPEL study - (11/04/10)
     
  6251. AASLD: Response-Guided Therapy with Boceprevir + Peginterferon alfa-2b/Ribavirin for Treatment-Naïve Patientswith Hepatitis C Virus Genotype 1 Was Similar to a 48-Wk Fixed-Duration Regimen with Boceprevir + Peginterferon alfa-2b/Ribavirin in SPRINT-2 - (11/04/10)
     
  6252. AASLD: Merck's Investigational Medicine Boceprevir Achieved Significantly Higher SVR Rates In Treatment-Failure And Treatment-Naïve Adult Patients With Chronic Hepatitis C Genotype 1 Compared To Control - merck press release - (11/04/10)
     
  6253. AASLD: Telaprevir in Combination with Peginterferon alfa-2a and Ribavirin in Genotype 1 HCV Treatment-Naïve patients: Final results of Phase 3 ADVANCE Study - (11/03/10)
     
  6254. AASLD: Phase 3 - Response Guided Therapy (RGT) - Boceprevir Combined with peginterferon alfa-2b plus ribavirin for treatment-naïve patients with HCV genotype 1 (SPRINT-2 Final Results) - (11/03/10)
     
  6255. AASLD: Telaprevir Phase 3 ILLUMINATE Study - Final Results Reported at AASLD Nov 2 2010 - (11/03/10)
     
  6256. AASLD: High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PegIFN alfa-2a (40KD)/RBV: Planned Week 12 interim analysis from the PROPEL study - (11/03/10)
     
  6257. AASLD: Response-Guided Therapy with Boceprevir + Peginterferon alfa-2b/Ribavirin for Treatment-Naïve Patientswith Hepatitis C Virus Genotype 1 Was Similar to a 48-Wk Fixed-Duration Regimen with Boceprevir + Peginterferon alfa-2b/Ribavirin in SPRINT-2 - (11/03/10)
     
  6258. AASLD: Merck's Investigational Medicine Boceprevir Achieved Significantly Higher SVR Rates In Treatment-Failure And Treatment-Naïve Adult Patients With Chronic Hepatitis C Genotype 1 Compared To Control - merck press release - (11/03/10)
     
  6259. AASLD: Combination Therapy With BMS-790052 and BMS-650032 Alone or With Pegylated Interferon and Ribavirin (pegIFN/RBV) Results in Undetectable HCV RNA Through 12 Weeks of Therapy in HCV Genotype 1 Null Responders - (11/03/10)
     
  6260. AASLD: Medivir Notes that Partner Tibotec Announced Week 24 Interim Results from Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD - (11/03/10)
     
  6261. AASLD: Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C at AASLD - (11/03/10)
     
  6262. AASLD: Telaprevir in Combination with Peginterferon alfa-2a and Ribavirin in Genotype 1 HCV Treatment-Naïve patients: Final results of Phase 3 ADVANCE Study - (11/02/10)
     
  6263. AASLD: HCV RESPOND-2 Final Results: High Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin when Re- Treated with Boceprevir Plus PEGINTRON (Peginterferon alfa-2b)/Ribavirin - (11/02/10)
     
  6264. AASLD: Efficacy and Safety of TMC435 in Combination With Peginterferon alfa-2a and Ribavirin in Treatment-naïve Genotype-1 HCV Patients: 24-Week Interim Results from the PILLAR Study - (11/02/10)
     
  6265. AASLD: 4-Week Virologic Response and Safety of ABT-450 Given with Low-dose Ritonavir (ABT-450/r) First As 3-Day Monotherapy Then in Combination with Pegylated Interferon Alpha-2a and Ribavirin (SOC) in Genotype 1 (GT1) HCV-infected Treatment-naïve Subjects - (11/02/10)
     
  6266. AASLD: HCV Late Breaker Posters this Morning at AASLD.....ABT450, BMS790052 NS5A+proteaseBMS650032, BI 201335+HCV polymerase inhibitor BI 207127+ribavirin - (11/02/10)
     
  6267. AASLD: Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon - (11/01/10)
     
  6268. AASLD: Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD - (11/01/10)
     
  6269. AASLD: Gilead's Investigational Hepatitis C Compounds GS 9190 and GS 9256 in Combination with Standard of Care Therapies Achieve Substantial Viral Suppression in Phase II Study - (11/01/10)
     
  6270. AASLD: Merck Announces Pivotal Phase III Data for Boceprevir will be Presented at the American Association for the Study of Liver Diseases 2010 Annual Meeting - (11/01/10)
     
  6271. AASLD: Telaprevir+pEg/RBV Based Combination Therapy in People with Hepatitis C, Regardless of Race or Stage of Liver Disease - 'up to 88% in African-Americans' Vertex press release - (11/01/10)
     
  6272. AASLD: Vertex's telaprevir and Merck's boceprevir: Compliance issues due to toxicity raise resistance concerns, physicians say - (11/01/10)
     
  6273. AASLD: Bristol-Myers, Gilead and other companies Seek AIDS Cocktail Success in Hepatitis C: '2 oral HCV drugs in combination' - (11/01/10)
     
  6274. AASLD: Black patients (& new HCV therapy) fare well on Vertex hepatitis C drug - (11/01/10)
     
  6275. Biolex Announces Locteron SVR12 Results and Safety/Tolerability Advantages in SELECT-2 Hepatitis C Trial - (10/28/10)
     
  6276. Hepatitis C Virus Infection and Increased Risk of Cerebrovascular Disease - pdf attached - (10/28/10)
     
  6277. Pharmasset Announces Results of a 28-day Phase 2a Study with PSI-7977 for the Treatment of Chronic Hepatitis C Infection - (10/28/10)
     
  6278. Pharmasset Reports Positive Preliminary Antiviral Data with PSI-938 for the Treatment of Hepatitis C - (10/28/10)
     
  6279. Vertex Pharmaceuticals Announces Start of a Phase 3b Study of Twice-Daily Telaprevir in People Not Treated Previously for Hepatitis C - (10/28/10)
     
  6280. Presidio Pharmaceuticals, Inc. to Present First Clinical Data for PPI-461, a New HCV NS5A inhibitor, at the American Association for the Study of Liver Diseases (AASLD) Meeting, Supporting Initiation of a Trial in Hepatitis C Patients - (10/28/10)
     
  6281. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin - pdf attached - (10/26/10)
     
  6282. Treatment Duration for Genotypes 2 and 3: Still Confusing After All These Years - editorial review - (10/26/10)
     
  6283. HCV Neurotoxicity & Inflammation Additive in Brain in HIV+ Person - pdf attached - (10/13/10)
     
  6284. Women Experience Higher Rates of Adverse Events During Hepatitis C Virus Therapy in HIV Infection: A Meta-Analysis - pdf attached - (10/04/10)
     
  6285. The Next Step for Taribavirin - Commentary - (09/24/10)
     
  6286. Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C - pdf attached - (09/24/10)
     
  6287. Therapeutic Silencing of MicroRNA-122 by SPC3649 in Primates with Chronic Hepatitis C Virus Infection - (09/23/10)
     
  6288. Evaluation of Versant Hepatitis C Virus Genotype Assay (LiPA) 2.0 - pdf attached - (09/21/10)
     
  6289. Concerns About HCV Genotyping: Hepatitis C Virus (HCV) Genotype 1 Subtype Identification in New HCV Drug Development and Future Clinical Practice - pdf attached - (09/20/10)
     
  6290. New Pegasys Patient Assistance Program - (09/15/10)
     
  6291. ICAAC: Safety and Pharmacokinetics of BMS-650032 Following Multiple Ascending Doses for 14 Days in Healthy Subjects (09/15/10)
     
  6292. ICAAC: Insulin Resistance Correlates With HCV Load and SVR in HCV/HIV-Coinfected - Written by Mark Mascolini - (09/15/10)
     
  6293. FDA Guidance for Industry Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Agents for Treatment - DRAFT GUIDANCE - (09/15/10)
     
  6294. Idenix Update - Hopes to Resume Course With Hepatitis C Drugs by Year's End - (09/15/10)
     
  6295. TMC-435 Update - (09/15/10)
     
  6296. 'IL28B Predicts SVR in Coinfection, Associated With 2-Fold Higher Rate of SVR' - published pdf attached - (09/07/10)
     
  6297. Proteome-Wide Anti-Hepatitis C Virus (HCV) and Anti-HIV Antibody Profiling for Predicting and Monitoring the Response to HCV Therapy in HIV-Coinfected Patients - BRIEF REPORT - (09/07/10)
     
  6298. Is sexual contact a major mode of hepatitis C virus transmission? Review, early pub from CDC - pdf attached - (09/07/10)
     
  6299. 65% of People Whose Prior Treatment for Hepatitis C Was Unsuccessful Achieved SVR (Viral Cure) with Telaprevir-Based Therapy in Phase 3 REALIZE Study (31% null responders) - (09/07/10)
     
  6300. Outcome of sustained virological responders with histologically advanced chronic hepatitis C (Early HCV Therapy?) - (08/29/10)
     
  6301. HCV Survival in Syringes - The Beginning of a New Era in Understanding Hepatitis C Virus Prevention - EDITORIAL COMMENTARY - (08/25/10)
     
  6302. Survival of Hepatitis C Virus in Syringes: Implication for Transmission among Injection Drug Users - published pdf attached - (08/25/10)
     
  6303. Pharmasset Initiates Phase 2b Clinical Trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3 - (08/25/10)
     
  6304. ZymoGenetics Announces Completion of Enrollment in Phase 2b Clinical Trial with PEG-Interferon lambda in Hepatitis C - (08/25/10)
     
  6305. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients - (08/25/10)
     
  6306. Early HCV Treatment?: Chronic and cleared hepatitis C viral infection: A nationwide cohort study - pdf attached - (08/16/10)
     
  6307. Boost for drugs against hepatitis C - (08/15/10)
     
  6308. Phase 3 ILLUMINATE Study Supports 24-Week Telaprevir-Based Therapy Within a Response-Guided Regimen for People with Hepatitis C Who Had Not Received Prior Treatment - press release from Vertex - (08/11/10)
     
  6309. Tattoos 'Strong Risk Factor for HCV Transmission' - new study - (08/10/10)
     
  6310. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection - publication pdf attached - (08/09/10)
     
  6311. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial - in the Lancet Aug 9 Epub - - (08/09/10)
     
  6312. Abnormalities of lipid metabolism in hepatitis C virus infection - (08/06/10)
     
  6313. In Pivotal Phase III Studies, Merck's Investigational Medicine Boceprevir Helped Majority of Patients with Chronic Hepatitis C Genotype 1 Infection Achieve Sustained Virologic Response, the Primary Endpoint of the Studies - Merck press release - (08/06/10)
     
  6314. Fibrosis Stage Predicts SVR Rate: cirrhotics have 10% SVR rate in CHARIOT Study - (08/06/10)
     
  6315. HCV Clearance Increased Lipids/HCV Infection Lowers Lipids - (08/06/10)
     
  6316. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-938 in Patients with Chronic Hepatitis C - (07/29/10)
     
  6317. LabCorp Gains Rights to Merck & Co.'s IL-28B Polymorphism IP for HCV Therapy Predictive Test - (07/29/10)
     
  6318. NHANES/Edlin The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 - pdf of publication attached - (07/29/10)
     
  6319. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-938 in Patients with Chronic Hepatitis C - (07/28/10)
     
  6320. CF102 Reduces HCV Viral Load in HCC Patients - (07/27/10)
     
  6321. Idenix Pharmaceuticals Research and Development Update on HCV Programs - (07/27/10)
     
  6322. IAC: HCV Co-infection is Associated with a High Risk of Osteoporotic Fractures Among HIV Patients - (07/26/10)
     
  6323. Hope Against Hepatitis C, New Drugs - 'this will be revolutionary' - (07/19/10)
     
  6324. IAC: HCV in HIV-Positives Raises Osteoporotic Fracture Risk Over 40% - written by Mark Mascolini - (07/20/10)
     
  6325. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection - Editorial Review - (07/19/10)
     
  6326. BMS HCV Study in Null Responders: 2 oral HCV Drugs Alone vs quad with peg/rbv plus 2 orals - (07/15/10)
     
  6327. HIV & Hepatitis C: Coping with Coinfection (Part 1) - (07/12/10)
     
  6328. HIV & Hepatitis C: Coping with Coinfection (Part 2) - (07/12/10)
     
  6329. Medivir Announces Phase 2b 24-week Interim Results of TMC435 in Treatment-naïve Patients Chronically Infected with Genotype-1 Hepatitis C Virus - News Releases - (07/12/10)
     
  6330. Intrntnl Wrkshp Hep C Resis New Cmpnds: HCV NS5A Targeted Antivirals (BMS-790052) - (07/12/10)
     
  6331. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta-analysis of the risk factors - (07/10/10)
     
  6332. SVR Prevents Esophageal Varices in Patients with Cirrhosis - (07/07/10)
     
  6333. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study - (07/07/10)
     
  6334. Intrn Wrkshp Pharm Hep Therapy: Meeting Report - 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy - by Jennifer Kiser PharmD - (07/05/10)
     
  6335. Hepatitis C virus infection: A "liaison a trois" amongst the virus, the host, and chronic low-level inflammation for human survival - (07/05/10)
     
  6336. Excitement grows for potential revolution in hepatitis C virus treatment - (07/02/10)
     
  6337. Discovery of a Hepatitis C-Related Virus in Bats May Reduce Outbreaks in Humans - (07/02/10)
     
  6338. Intrntnl Wrkshp Hep C Resis New Cmpnds: Telaprevir/Peginterferon/Ribavirin - (07/01/10)
     
  6339. Intrntnl Wrkshp Hep C Resis New Cmpnds: Pharmacokinetic Enhancement of HCV Protease Inhibitors with Ritonavir: More Than It Seems? - (06/30/10)
     
  6340. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes in Spain - (06/29/10)
     
  6341. IL28B polymorphism determines treatment response of patients with hepatitis C genotypes 2 or 3 who do not achieve a rapid virologic response - (06/28/10)
     
  6342. Intrntnl Wrkshp Hep C Resis New Cmpnds: New HCV Protease: Preclinical Characteristics and Microdosing Pharmacokinetics in Healthy Volunteers Support a Low-Dose, Once-Daily Dosing Regimen of the HCV NS3/4a Protease Inhibitor ITMN-8187 - (06/28/10)
     
  6343. Intrntnl Wrkshp Hep C Resis New Cmpnds: Discovery of Potent NS5A Inhibitors with Favorable Pharmacokinetics and Robust Activity in an HCV Animal Model - (06/28/10)
     
  6344. Replicated Association Between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin - full text pdf attached - (06/28/10)
     
  6345. Advanced Fibrosis Predicts SVR: Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing - Earlier HCV Peg/Rbv Therapy - (06/28/10)
     
  6346. Caffeine, a drug for all seasons - (06/28/10)
     
  6347. Reaping the Early Harvest of the Genomics Revolution - IL28B gene predicts response to Peg/Rbv SVR in Caucasians & African-Americans- Editorial - (06/28/10)
     
  6348. Intrntnl Wrkshp Hep C Resis New Cmpnds: Chronic HCV Infection: How Does Maturation of the HCV Infected Patient Population Impact Drug Development - Gary Davis MD - (06/25/10)
     
  6349. Intrntnl Wrkshp Hep C Resis New Cmpnds: Implications of host polymorphism IL28b for drug development and patient care - Mark Sulkowski MD - (06/25/10)
     
  6350. Intrn Wrkshp Pharm Hep Therapy: Regulatory Requirements for Early Clinical Testing of Novel HCV Antiviral Drugs: FDA Perspective, Jeff Murray, M.D., M.P.H. FDA, Division of Antiviral Products - (06/25/10)
     
  6351. Intrn Wrkshp Pharm Hep Therapy: A European Perspective: EMA and his critical standpoint, Prof. Jean-Michel Pawlotsky, MD, PhD - (06/23/10)
     
  6352. New HCV Antivirals in the Pipeline - (06/23/10)
     
  6353. Fatty Liver Associated with Lipids/Metabolics/VAT - (06/20/10)
     
  6354. ResisWksp: Deep sequencing analysis of baseline and on-treatment samples from HCV genotype-1 patients treated for 5 days with TMC435 monotherapy and subsequently re-treated with TMC435 in combination with PegIFN -2a/ribavirin - poster presentation - (06/14/10)
     
  6355. ResisWksp: Samples from HCV Genotype-1 Patients Treated for 5 Days with TMC435 Monotherapy and Subsequently Re-treated with TMC435 in Combination with PegIFN-2a/Ribavirin - slide talk - (06/14/10)
     
  6356. ResisWksp: Analysis of Resistance in Virologic Failures during IFN/RBV Therapy Post 28-Day Treatment with MK7009: Results through Week 24 of the Phase 2A Dosing Finding Study in Genotype 1 Patients - (06/12/10)
     
  6357. ResisWksp: Long-term Follow-up of Patients Treated with Boceprevir in Combination with PEG-Intron/Ribavirin (P/R): Durability of Responses and Rates of Reversion of Resistance Mutations - (06/12/10)
     
  6358. Idenix Pharmaceuticals Initiates Proof-of-Concept Study for Protease Inhibitor IDX320 in Hepatitis C Patients - News Release - (06/11/10)
     
  6359. Pharmasset Announces Submission of Abstracts to AASLD Liver Meeting Including an Interim Analysis of Roche's Phase 2b PROPEL Trial of RG7128 - (06/10/10)
     
  6360. New use for old drugs (metformin) in treating hepatitis C, metformin suppresses HCV in vitro -pdf full text attached - (06/08/10)
     
  6361. ANADYS ANNOUNCES COMPLETED 12-WEEK RESULTS FROM PHASE II COMBINATION STUDY OF ANA598 WITH INTERFERON AND RIBAVIRIN - (06/07/10)
     
  6362. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals - (06/07/10)
     
  6363. Evaluation of renal function in patients with cirrhosis - (05/29/10)
     
  6364. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy - (05/29/10)
     
  6365. Vertex Pharma: Five Reasons to Worry About Telaprevir - (05/25/10)
     
  6366. 23% Test for HCV, 29% for HIV, 22% for HBV at Substance Abuse Facilities: Reported by SAMSHA, National Survey of Substance Abuse Treatment Services (N-SSATS) - (05/25/10)
     
  6367. New Data: 75% of Treatment-Naïve Patients with Chronic Hepatitis C Achieve SVR (Viral Cure) with Telaprevir-Based Treatment in Phase 3 Trial - (05/25/10)
     
  6368. Hepatitis C Treatment in an Urban Population - (05/24/10)
     
  6369. Updated New York State Guidelines on HCV-HIV Coinfection: annual screening recommended for HIV+ At-Risk Individuals - (05/20/10)
     
  6370. HCV Death Rates Double in Western Countries...recent USA, Scotland studies - (05/17/10)
     
  6371. Study of Glaxo platelet drug halted due to clots - (05/07/10)
     
  6372. EASL: ANTIVIRAL ACTIVITY, COMBINATION AND RESISTANCE OF ACH-1625, A POTENT HCV NS3 PROTEASE INHIBITOR - (05/12/10)
     
  6373. EASL: CHARACTERIZATION OF THE HEPATOSELECTIVE DISTRIBUTION OF ACH-1625: A POTENT, CLINICAL STAGE HCV NS3 PROTEASE INHIBITOR - (05/12/10)
     
  6374. EASL: VIROLOGICAL RESPONSE, SAFETY, AND PHARMACOKINETIC PROFILE FOLLOWING SINGLE - AND MULTIPLE-DOSE ADMINISTRATION OF ACH-1625 PROTEASE INHIBITOR TO HEALTHY VOLUNTEERS AND HCV GENOTYPE-1 PATIENTS - (05/12/10)
     
  6375. EASL: Validation of the GeneSeq HCV NS5B Sequencing Assay for Patient-Derived HCV Subtypes 1a and 1b - (05/07/10)
     
  6376. Hepatocellular Carcinoma --- United States, 2001--2006 Weekly - (05/07/10)
     
  6377. Every 6-month HCC Screening Recommended - (05/06/10)
     
  6378. (DDW) Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide plus Peginterferon and Ribavirin in Naïve Patients with Chronic Hepatitis C Genotype 1 Infection: Final Report (24 wk SVR) - (05/06/10)
     
  6379. Drug Resistance in HCV - pdf of published article by Perelson et al attached - (05/06/10)
     
  6380. FDA HCV Hearing on Early Access to New Drugs: report from Jules Levin - (05/04/10)
     
  6381. Amino acid substitution in HCV core region and genetic variation near IL28B gene predict viral response to telaprevir with peginterferon and ribavirin - (05/03/10)
     
  6382. GlobeImmune's Hepatitis C Product Candidate Improves End of Treatment Response....."The data demonstrated a 10 percent absolute improvement in SVR for treatment-naïve patients receiving GI-5005 plus SOC versus SOC alone" - (05/03/10)
     
  6383. Presidio Pharmaceuticals, Inc. Initiates First-in-Human Clinical Trial of PPI-461, an Investigational NS5A Inhibitor for HCV - (05/03/10)
     
  6384. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection - Review - (05/03/10)
     
  6385. Sorafenib, HCC treatment: Where do we go from here? - (05/03/10)
     
  6386. IL28B CC Genotype Increases SVR Rate by 4-5 Times in Coinfection (AIDS jnl) - (05/03/10)
     
  6387. An aged T cell phenotype: A prognostic indicator in liver transplant recipients? Editorial - (05/03/10)
     
  6388. Features of immune senescence in liver transplant recipients with established grafts - (05/03/10)
     
  6389. EASL: Resistance Profile Of ABT-333 And Relationship To Viral Load Decrease In Patients Treated In Combination With Peg-interferon And Ribavirin For 28 Days. - (04/28/10)
     
  6390. EASL: Pharmacokinetics of the HCV Polymerase Inhibitor ABT-333 in US and Japanese Healthy Volunteers - (04/28/10)
     
  6391. EASL: Exposure-Viral Response Analyses of the Non-nucleoside Polymerase Inhibitor ABT-333, Following Monotherapy and ABT-333 Plus Pegylated Interferon and Ribavirin Therapy - (04/28/10)
     
  6392. EASL: Pharmacokinetics of the HCV Polymerase Inhibitor ABT-072 Following Single and Multiple Dosing in Healthy Adult Volunteers - (04/28/10)
     
  6393. EASL: Virologic Response Rates Following 4 Weeks of Filibuvir in Combination with Pegylated Interferon Alfa-2a and Ribavirin in Chronically-Infected HCV Genotype-1 Patients - (04/27/10)
     
  6394. EASL: Genotypic Characterisation of Filibuvir Resistance in Patients Receiving Four Weeks Co-administration of Filibuvir with pegIFN/RBV(12 Week Analysis) - (04/27/10)
     
  6395. EASL: Exposure-response Relationship of Filibuvir in HCV-infected Patients: Application to Dose Selection for Combination Therapy - (04/27/10)
     
  6396. EASL: Impact of Sustained Virological Response After Antiviral Treatment in Chronic Hepatitis C Patients on Life Expectancy and Quality-adjusted Life-years - (04/27/10)
     
  6397. EASL: Locteron, controlled-release interferon alpha 2b, 3 studies at EASL 2010 Vienna - 3 company press releases - (04/26/10)
     
  6398. EASL: PHASE IIB STUDY OF BALAPIRAVIR (RG1626; NUCLEOSIDE ANALOGUE INHIBITOR OF HCV POLYMERASE) PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOR CHRONIC HEPATITIS C GENOTYPE 1: FINAL RESULTS - (04/26/10)
     
  6399. AASLD: Response-Guided Therapy for Boceprevir Combination Treatment? Results from HCV SPRINT-1 - (04/26/10)
     
  6400. AASLD: High Sustained Virologic Response in Genotype 1 Null Responders to Peginterferon α-2b + Ribavirin When Treated with Boceprevir Combination Therapy - Results From HCV Sprint-1 - (04/26/10)
     
  6401. EASL: RANDOMIZED, OPEN-LABEL, 12-WEEK COMPARISON OF CONTROLLED-RELEASE INTERFERON ALPHA2B + RIBAVRIN VS. PEGYLATED-INTERFERON ALPHA2B + RIBAVRIN IN TREATMENT-NAïVE GENOTYPE1 HEPATITIS C: 4 WEEK RESULTS FROM 480STUDY (PANEL A) - (04/24/10)
     
  6402. EASL: Slow Responders Benefit From 72 Weeks Peg/Rbv - Predicting Treatment Outcome Among Slow Responders: A Retrospective Analysis of the SUCCESS Study - (04/24/10)
     
  6403. EASL: Q2week Controlled Release Interferon Alpha2b + Ribavrin Reduces Flu-like Symptoms >50% And Provides Equivalent Efficacy In Comparison To Weekly Pegylated Interferon Alpha2b + Ribavirin In Treatment-naïve Genotype-1 Chronic Hepatitis C: Results From EMPOWER, A Randomized Open-label 12-week Comparison In 133 Patients - (04/24/10)
     
  6404. EASL: Early Viral Response Of Controlled-release Interferon Alpha2b And Ribavirin Vs. Pegylated-interferon Alpha2b And Ribavirin In Treatment-naïve Genotype-1 Hepatitis C: 12 Week Results (SELECT-2 Trial) - (04/24/10)
     
  6405. EASL: IMPACT OF LOW-DOSE RITONAVIR BOOSTING ON THE PHARMACOKINETICS OF DANOPREVIR (RG7227; ITMN-191), A HIGHLY POTENT AND SELECTIVE INHIBITOR OF THE HCV NS3/4A PROTEASE - (04/23/10)
     
  6406. EASL: High Dose Pegasys/rbv can improve SVR: Impact of higher doses of peginterferon alfa-2a and ribavirin on RVR, cEVR and SVR in HCV G1 patients with viral loads ≥400 000 IU/mL weighing ≥85 kg - (04/23/10)
     
  6407. EASL: Predictors of relapse among patients treated with standard- or induction-dose peginterferon alfa-2a (40KD) combined with standard- or higher-dose ribavirin in difficult-to-cure patients - (04/23/10)
     
  6408. EASL: Pegasys vs Pegintron, Baseline characteristics and on-treatment predictors of responses from real-world patient cohorts: interim results of the multinational PROPHESYS cohorts - (04/23/10)
     
  6409. EASL: Metabolic Syndrome (MS) [glucose/diabetes] Is a Negative Predictor of Treatment Outcome in Patients With Chronic Hepatitis C: Results From the IDEAL Study - (04/23/10)
     
  6410. EASL: Improved Inflammatory Activity With Low-Dose PegIntron (PEG) Maintenance Therapy in Prior Nonresponders With METAVIR Fibrosis Scores (MFS) of F2/F3: Final Results From the EPIC3 Program - (04/23/10)
     
  6411. BMS NS5A HCV Inhibitor - chemical genetics discovery process in Nature jnl - pdf attached - (04/22/10)
     
  6412. EASL: Characterization of resistant mutants selected in vitro by the HCV NS3/4A protease inhibitor BI 201335 - (04/22/10)
     
  6413. EASL: Preclinical characterization of non-covalent HCV NS3/4A protease inhibitor BI 201335 - (04/22/10)
     
  6414. EASL: MK-5172, the 1st HCV Protease Inibitor with Potent Acyivity Against Resistance Mutations In Vitro - (04/21/10)
     
  6415. EASL: MK-5172, the 1st HCV Protease Inibitor with Potent Acyivity Against Resistance Mutations In Vitro - (04/21/10)
     
  6416. EASL: TMC435 & Drug Interactions: Evaluation of metabolic interactions for TMC435 via cytochrome P450 (CYP) enzymes in healthy volunteers - (04/21/10)
     
  6417. EASL: EARLY ON-TREATMENT RESPONSES DURING PEGYLATED INTERFERON PLUS RIBAVIRIN ARE INCREASED FOLLOWING 13 DAYS OF COMBINATION NUCLEOSIDE POLYMERASE (RG7128) AND PROTEASE (RG7227) INHIBITOR THERAPY (INFORM-1) - (04/21/10)
     
  6418. EASL: Combination of TMC435 with two novel NS5B inhibitors increases anti-HCV activity and results in a higher genetic barrier in vitro - (04/21/10)
     
  6419. EASL: 4 week therapy with the non-nucleosidic polymerase inhibitor BI 207127 in combination with peginterferon alfa2A and ribavirin in treatment naïve and treatment experienced chronic HCV GT1 patients - (04/21/10)
     
  6420. EASL: Pharmacokinetic-pharmacodynamic (PK-PD) analyses of TMC435 in treatment-naïve hepatitis C (HCV)-infected patients in the OPERA-1 study - (04/20/10)
     
  6421. EASL: Once-daily NS5A Inhibitor (BMS-790052) Plus Peginterferon-alpha-2a And Ribavirin Produces High Rates Of Extended Rapid Virologic Response In Treatment-naïve HCV-genotype 1 Subjects: Phase 2a Trial - Bristol-Myers Squibb Study AI444014 - (04/20/10)
     
  6422. EASL: SILEN-C2: Early antiviral activity and safety of BI 201335 combined with peginterferon alfa-2a and ribavirin (PegIFN/RBV) in chronic HCV genotype 1 patients with non-response to PegIFN/RBV - (04/20/10)
     
  6423. EASL: Phase 2 Randomized, Double-Blind Placebo-Controlled Study of Nitazoxanide with Peginterferon Alfa-2a and Ribavirin in Nonresponders with Chronic Hepatitis C Genotype 1: Final Report - (04/20/10)
     
  6424. EASL: Nitazoxanide + Peg/Rbv in Nonresponders - (04/20/10)
     
  6425. EASL: Combination of two complementary nucleotide analogues, PSI-7977 and PSI-938, effectively clears wild type and NS5b: S282T HCV replicons - Comparison with combinations of other antiviral compounds - (04/20/10)
     
  6426. EASL: Sustained Virologic Response following RG7128 1500 mg BID PEG-IFN/RBV for 28 days in HCV Genotype 2/3 prior non-responders - (04/20/10)
     
  6427. EASL: Vitamin D Supplement improve SVR in Chronic Hepatitis C (Genotype 1) Naïve Patients treated with Peg Interferon and Ribavirin - (04/20/10)
     
  6428. EASL: Idenix Pharmaceuticals Reports Favorable Pharmacokinetic Data for IDX320, a Potent, Multi-Genotypic Protease Inhibitor for the Treatment of Hepatitis C - (04/20/10)
     
  6429. EASL: Idenix Pharmaceuticals Reports Positive Results With IDX184 nucleoside polymerase From Interim Analysis of Phase IIa Hepatitis C Study - (04/19/10)
     
  6430. EASL: Triple Combinations of Direct-Acting Antiviral Agents Demonstrate Robust Anti-HCV Activity In Vitro - (04/19/10)
     
  6431. EASL: Antiviral Activity, Pharmacokinetics & Safety of IDX184 in Combination with Peg/Rbv in Treatment Naïve Genotype 1 - (04/19/10)
     
  6432. EASL: In Vitro Antiviral Activity of IDX320, a Novel and Potent Macrocyclic HCV Protease Inhibitor - (04/19/10)
     
  6433. EASL: ANA598 HCV Polymerase Inhititor Safety & Activity + Peg/Rbv in Genotype 1 - (04/19/10)
     
  6434. EASL: 72% OF PATIENTS RECEIVING ANA598 IN PHASE II COMBINATION STUDY WITH INTERFERON AND RIBAVIRIN ACHIEVE UNDETECTABLE LEVELS OF VIRUS AT WEEK EIGHT - (04/19/10)
     
  6435. EASL: Idenix Pharmaceuticals Reports Favorable Pharmacokinetic Data for IDX320, a Potent, Multi-Genotypic Protease Inhibitor for the Treatment of Hepatitis C - (04/19/10)
     
  6436. EASL: Discrepancies Between Definitions of Null Response to Treatment with Peginterferon Alfa-2a and Ribavirin: Implications for New HCV Drug Development - (04/18/10)
     
  6437. EASL: On-Treatment Response-Guided Therapy with Telaprevir q8h or q12h Combined with Peginterferon Alfa-2a or Alfa-2b and Ribavirin in Treatment-Naïve Genotype 1 Hepatitis C (Study C208) - (04/18/10)
     
  6438. EASL: Activity of Telaprevir Alone or in Combination with Peginterferon Alfa-2a and Ribavirin in Treatment-naïve, Genotype 2 and 3, Hepatitis C Patients: Final Results of Study C209 - (04/18/10)
     
  6439. EASL: On-Treatment Response-Guided Therapy with Telaprevir q8h or q12h Combined with Peginterferon Alfa-2a or Alfa-2b and Ribavirin in Treatment-Naïve Genotype 1 Hepatitis C (Study C208) - (04/18/10)
     
  6440. EASL: Idenix Pharmaceuticals Reports Positive Results With IDX184 From Interim Analysis of Phase IIa Hepatitis C Study - (04/18/10)
     
  6441. EASL: Silibinin as Rescue Therapy for Suboptimal Response to Peg/Rbv - (04/18/10)
     
  6442. EASL: Vitamin D Improves SVR in Naïve Genotype 1 with Peg/Rbv - (04/16/10)
     
  6443. EASL: InterMune Reports Virologic Response of Ritonavir-Boosted Danoprevir (RG7227/ITMN-191) in Patients with Chronic Hepatitis C - (04/16/10)
     
  6444. EASL: Identification and Characterization of PPI-461, a Potent and Selective HCV NS5A Inhibitor with Activity Against all HCV Genotypes - (04/16/10)
     
  6445. EASL: Dose-Ranging, Three-Day Monotherapy Study of the HCV NS3 Protease Inhibitor GS-9256 - (04/16/10)
     
  6446. EASL: Long-term Outcomes Following Combination Treatment with Boceprevir plus PegIntron/Ribavirin (P/R) in Patients with Chronic Hepatitis C, Genotype 1 (CHC-G1) - (04/16/10)
     
  6447. EASL: Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide Plus Peginterferon and Ribavirin in HCV Genotype 1 Naïve Patients: Week 12 Sustained Virologic Response Rate - (04/16/10)
     
  6448. EASL: GlobeImmune GI-5005 HCV Product Candidate Improves Sustained Virologic Response by 10 Percent, Demonstrating Potential to Be First Therapeutic Vaccine for HCV - (04/16/10)
     
  6449. EASL: Ritonavir boosting of low-dose danoprevir (RG7227; ITMN-191), HCV NS3/4A protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens - (04/15/10)
     
  6450. EASL: Telaprevir in Null-Responders & Non-Responders - (04/15/10)
     
  6451. EASL: VX-222 Vertex NNRTI Polymerase Inhibitor 3 Days Monotherapy - (04/15/10)
     
  6452. EASL: Merck HCV Protease Inhibitor For Resistance - (04/15/10)
     
  6453. New HCV Drugs EASL 2010 - (04/14/10)
     
  6454. Telaprevir for Previously Treated Chronic HCV Infection - NEJM - (04/15/10)
     
  6455. Fibrosis progression in initially mild chronic hepatitis C: 36% with F1 Progress to F3 or cirrhosis - (04/15/10)
     
  6456. Pharmasset Initiates First Time in Human Study of PSI-938 for the Treatment of Hepatitis C: unique new HCV drug, nucleotide - (04/15/10)
     
  6457. Pharmasset to Present New Data on RG7128 and PSI-7977 at the EASL Conference - (04/15/10)
     
  6458. Merck Demonstrates Continued Commitment to Advancing Hepatitis Therapy at European Association for the Study of the Liver (EASL) 2010 Annual Meeting - (04/15/10)
     
  6459. InterMune (and Roche: phase 2b RG7227/ITMN-191) Reports on Hepatitis C Treatment at EASL - (04/15/10)
     
  6460. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy - (04/07/10)
     
  6461. Low SVR Rates for Hispanics & African-Americans in Inner City Clinic in the Bronx NY - pdf attached - (03/31/10)
     
  6462. APASL: A Phase 1b Dose-Ranging Study of 4 Weeks of PEG-Interferon (IFN) Lambda (PEG-rIL-29) in Combination with Ribavirin (RBV) in Patients with Chronic Genotype 1 Hepatitis C Virus (HCV) I - (03/31/10)
     
  6463. APASL: Safety, Tolerability, Pharmacokinetics and Antiviral Activity following Single- and Multiple-Dose Administration of BMS-650032, a Novel HCV NS3 Inhibitor, in Subjects with Chronic Genotype 1 HCV Infection - (03/30/10)
     
  6464. APASL: BMS-790052 is a First-in-class Potent Hepatitis C Virus (HCV) NS5A Inhibitor for Patients with Chronic HCV Infection: Results from a Proof-of-concept Study - (03/30/10)
     
  6465. A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus: risk of these outcomes is reduced by 70%-80% for patients who achieve SVR- mortality, hepatic decompensation, HCC - pdf attached - (03/26/10)
     
  6466. The Institute of Medicine report on viral hepatitis: A call to action - (03/26/10)
     
  6467. Institute of Medicine recommendations for the prevention and control of hepatitis B and C - (03/26/10)
     
  6468. Rifaximin Treatment in Hepatic Encephalopathy - (03/26/10)
     
  6469. HUMAN GENOME SCIENCES ANNOUNCES INTERIM RESULTS OF PHASE 2B MONTHLY-DOSING TRIAL OF ZALBIN (albuferon, interferon) IN PATIENTS WITH CHRONIC HEPATITIS C - (03/24/10)
     
  6470. Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis - see attached pdf - (03/22/10)
     
  6471. Diagnosing cirrhosis non-invasively: Sense the stiffness but don't forget the nodules! - (03/22/10)
     
  6472. GSK microRNA HCV Drug Development Carlsbad Biotech Inks Deal With GlaxoSmithKline Regulus Theraputics is developing a groundbreaking treatment for hepatitis C - (03/19/10)
     
  6473. Evidence ('weak') for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews - pdf attached - (03/12/10)
     
  6474. Telaprevir Coinfection Study Open - Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV - (03/12/10)
     
  6475. Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression - (03/11/10)
     
  6476. Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients - (03/11/10)
     
  6477. FDA Hearing on HCV Oral Drugs Early Access - (03/10/10)
     
  6478. Liver Transplant Recommendations Revised - pdf of full published report attached - (03/09/10)
     
  6479. CROI: HCV/HIV Co-infection Affects Neurocognitive Performance But Not Diffusion Tensor Imaging Measures - (03/10/10)
     
  6480. CROI: IL-28 Gene & HCV Recovery - (03/10/10)
     
  6481. CROI: Strong Association of a Single Nucleotide Polymorphism Located Near the Interleukin-28b Gene with Response to Hepatitis C Therapy in HIV/HCV Co-infected Patients - (03/07/10)
     
  6482. CROI: Incidence and Predictors of Anemia in HCV/HIV Co-infected Subjects Treated with Pegylated Interferon and Ribavirin in A5178 - (03/07/10)
     
  6483. CROI: All-cause Mortality in HIV-infected Patients in Spain Compared to the General Population according to HCV Status: HIV increases death risk 2.5 times, HCV coinfection increases death risk 11 times higher - (03/07/10)
     
  6484. CROI: Evaluation of the Anti-HCV Activity and Pharmacokinetics of ATI-0810, a Novel Inhibitor of HCV Replication - (03/07/10)
     
  6485. CROI: HCV Core Protein Induces Neuroinflammation and Potentiates HIV Vpr Neurotoxicity - (03/07/10)
     
  6486. CROI: Interleukin 28 B Genotype Is a Potent Predictor of Response to Therapy with Pegylated Interferon plus Ribavirin in HIV/HCV Co-infected Patients - (03/07/10)
     
  6487. CROI: Insulin Resistance Is a Major Predictor of Sustained Virological Response to Peginterferon and Ribavirin in HIV/HCV Co-infected Patients Undergoing HCV Retreatment - (03/07/10)
     
  6488. CROI: High Rate of Hepatitis C Infection Clearance in HIV-1 Natural Viral Suppressors - (03/07/10)
     
  6489. CROI: Fast Liver Damage Progression in HIV/HCV Co-infected Patients in Spite of Effective HAART - (03/07/10)
     
  6490. CROI: Impact of Zidovudine on Hematologic Parameters during Treatment with Peginterferon alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV/HCV Co-infected Patients Enrolled in a Large Randomized Double-blind Study - (03/07/10)
     
  6491. CROI: Genetic Variability of the HCV NS3 Protease in HIV/HCV Co-infected Patients Treated with HIV Protease Inhibitors - (03/07/10)
     
  6492. CROI: Effect of Accompanying Antiretroviral Drugs on Virologic Response to PEG-IFN and Ribavirin in HIV/HCV Co-infected Patients: 'AZT not good, abacavir ok' - (03/07/10)
     
  6493. CROI: Biomarkers of Inflammation and Coagulation and Risk of Non-AIDS Death in HIV/Hepatitis Co-infected Patients in the SMART Study: inflammation associated with advanced liver disease - (03/07/10)
     
  6494. CROI: In the HAART Era, in Viral Cirrhosis Liver Transplant Candidates, HIV Co-infection Remains as an Independent Predictor of Mortality on the Waiting List with a death rate of 48% at 24 weeks), but Not after Liver Transplantation: - (03/07/10)
     
  6495. CROI: Survival of HIV-Infected Patients with Compensated Liver Cirrhosis: accelerated death rate; MELD & transient elastometry predict mortality - (03/07/10)
     
  6496. Enanta Nominates EDP-239 as Lead Development Candidate for NS5A HCV Inhibitor Program - (03/04/10)
     
  6497. ENANTA HCV PROGRAMS - (03/04/10)
     
  6498. CROI: Screening for Hepatocellular Carcinoma (HCC) in HIV/HCV-Coinfected Patients: Impact on Staging, Therapy, and Survival - (03/04/10)
     
  6499. New Abbott Study of 3 HCV Oral Drugs - Abbott and Enanta Announce Advancement of Hepatitis C Collaboration Initiation of Phase 2 Clinical Trial Investigating Three Individual HCV Antivirals - (03/03/10)
     
  6500. CROI: Summary from CROI for Hepatitis Coinfection - What are the challenges and how can we improve management of Hepatitis coinfection in HIV-Infected Patients? - written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/03/10)
     
  6501. Vertex Begins Study of 2 Oral HCV Drugs Telaprevir + VX-222 - (03/02/10)
     
  6502. Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection - (02/28/10)
     
  6503. CROI:Baseline Liver Disease is Independently Associated with Risk of Death among HIV/HCV co-infected Adults with Histologic Staging - (02/20/10)
     
  6504. Pharmasset Announces Complete Enrollment of RG7128 Phase 2b Clinical Study- Roche Initiating Additional Clinical Studies with RG7128 - INFORM Studies Delayed - (02/19/10)
     
  6505. Alcohol Use and Treatment of Hepatitis C Virus (alcohol users can be treated): Results of a National Multicenter Study - (02/17/10)
     
  6506. Retreatment Of Chronic Hepatitis C- Genotype 1-Infected Relapsers To Peginterferon/Ribavirin With Consensus Interferon/Ribavirin Or With Extended Duration Therapy Peginterferon/Ribavirin - (02/15/10)
     
  6507. Validation of a Hepatitis C Screening Tool in Primary Care - (02/11/10)
     
  6508. Debio-025 Activity/Safety in 3 Studies Over 3 Years in naives/experienced, coinfected, various genotypes - (02/10/10)
     
  6509. Randomized Study of Peginterferon-α2a Plus Ribavirin vs Peginterferon-α2b Plus Ribavirin in Chronic Hepatitis C - publication pdf attached - (02/10/10)
     
  6510. Do Differences in Pegylation of Interferon Alfa Matter? Commentary by Stefan Zeuzem - (02/10/10)
     
  6511. Peginterferon Alfa-2a Plus Ribavirin Is More Effective Than Peginterferon Alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection - pdf publication attached - (02/10/10)
     
  6512. Debio-025 Activity/Safety in 3 Studies Over 3 Years in naives/experienced, coinfected, various genotypes - (02/10/10)
     
  6513. Barriers To Retention in Care in HIV and HCV - (02/10/10)
     
  6514. Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 - (02/09/10)
     
  6515. Novartis buys rights to Debiopharm's hep C drug - (02/09/10)
     
  6516. Achillion Announces Nomination of ACH-2684 as Lead Clinical Candidate in Resistance-Focused HCV Program - (02/04/10)
     
  6517. Conatus Pharmaceuticals Initiates Phase II Clinical Trial of CTS-1027 in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV) - (02/04/10)
     
  6518. A glimpse of future hepatitis C virus treatment paradigms - telaprevir - (01/29/10)
     
  6519. We Can Cure HCV - (01/28/10)
     
  6520. Dynavax Reports Positive Phase 1b Data for SD-101 in Chronic Hepatitis C Infection - (01/27/10)
     
  6521. HCV & HBV Medicaid/Medicare Training by NYS DOH - (01/26/10)
     
  6522. HCV Drug Update for Vertex, Roche, Idenix - (01/26/10)
     
  6523. Lessons From HIV Therapy Applied to Viral Hepatitis Therapy: Summary of a Workshop - (01/26/10)
     
  6524. Liver cancer: From molecular pathogenesis to new therapies: Summary of the EASL single topic conference - (01/21/10)
     
  6525. Pharmasset Initiates Phase 2a Trial with PSI-7977, a Chirally Pure Isomer of PSI-7851 - (01/21/10)
     
  6526. Limit of Fibroscan - (01/20/10)
     
  6527. New HCV Drug IDX184 - New Data; Idenix Pharmaceuticals Highlights Progress in Three HCV Programs - (01/12/10)
     
  6528. Achillion Announces Additional Positive Phase 1b Data With ACH-1625 to Treat Hepatitis C, 5-day monotherapy - (01/12/10)
     
  6529. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C - Report from the Institute of Medicine (IOM) pdf of full report attached - (01/12/10)
     
  6530. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety - (01/06/10)
     
  6531. What is Liver Cancer? - (12/02/09)
     
  6532. What Is Cirrhosis? What Causes Cirrhosis? - (12/02/09)
     
  6533. Therapeutic Silencing of MicroRNA-122 by SPC3649 in Primates with Chronic Hepatitis C Virus Infection - (01/10/10)
     
  6534. Effects of Coffee Consumption on Fasting Blood Glucose and Insulin Concentrations Randomized controlled trials in healthy volunteers - (01/07/10)
     
  6535. Caffeine Increases Ambulatory Glucose and Postprandial Responses in Coffee Drinkers With Type 2 Diabetes - (01/07/10)
     
  6536. Coffee, Caffeine, and Risk of Type 2 Diabetes A prospective cohort study in younger and middle-aged U.S. women - (01/07/10)
     
  6537. Does Coffee Consumption Reduce the Risk of Type 2 Diabetes in Individuals With Impaired Glucose? - (01/07/10)
     
  6538. Decaffeinated coffee and glucose metabolism in young men. pdf attached - (01/07/10)
     
  6539. Does Coffee Consumption Reduce the Risk of Type 2 Diabetes in Individuals With Impaired Glucose? - (01/07/10)
     
  6540. Caffeine May Affect Blood Glucose Levels - (01/07/10)
     
  6541. Glucose Abnormalities in Patients with Hepatitis C Virus Infection Epidemiology and pathogenesis - (01/07/10)
     
  6542. Peginterferon Alfa-2a Plus Ribavirin Is More Effective Than Peginterferon Alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection - pdf publication attached - (01/06/10)
     
  6543. Liver Stiffness Measurements & Fibrosis Detection After Liver Transplant - full text of publication follows below - (01/06/10)
     
  6544. HCV & HBV National Strategy Report from the Institute of Medicine - Monday Jan 11 Release & Conference Call - (01/06/10)
     
  6545. London's teenage 'It Girl' - (12/28/09)
     
  6546. Factors Associated with HCV Transmission from Male to Female with No IDU History in WIHS - (12/23/09)
     
  6547. AASLD: Combination of IDX184, a Nucleotide Prodrug Polymerase Inhibitor, with Other Classes of HCV Inhibitors is Additive to Synergistic in the HCV Replicon in vitro - (12/21/09)
     
  6548. Scripps Research Scientists Identify Novel Hepatitis C Inhibitors: four small-molecule inhibitors of dimerization of the viral core protein - (12/17/09)
     
  6549. HepDART: The Business of HCV Antiviral Agents: 2010 and Beyond (12/17/09)
     
  6550. HepDART: Longitudinal clonal resistance analysis of treatment-naïve patients with chronic Hepatitis C (CHC) genotype 1 infection treated with MK-7009, a Novel NS3/4a Protease Inhibitor, in combination with Pegylated Interferon Alfa-2a and Ribavirin for 28 day (12/17/09)
     
  6551. Achillion Announces Positive Preliminary Phase 1b Proof of Concept Data With ACH-1625 to Treat Hepatitis C - Achieves 3.94 log10 Reduction in HCV RNA With Continued Safety and Tolerability - (12/16/09)
     
  6552. Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial -- full text pdf of published study attached - (12/14/09)
     
  6553. HepDART: Safety and Tolerability of Filibuvir, a Non nucleoside Inhibitor of HCV Polymerase (12/10/09)
     
  6554. 4th Intl Wrkshp HCV Resistance & New Compounds Analysis of antiviral resistance to MK-7009 in protocol 004, a phase 1b monotherapy study - (12/09/09)
     
  6555. HepDART: Pharmacokinetics of a Polymerase Inhibitor, ABT-333, in Treatment-naïve HCV Genotype 1-Infected Subjects Following Treatment with 2 days of ABT-333 Followed by 26 Days of ABT-333 Plus Pegylated Interferon and Ribavirin (12/08/09)
     
  6556. HepDART: Pharmacokinetics and Tolerability of the HCV Protease Inhibitor ABT-450 Following Single Ascending Doses in Healthy Adult Volunteers with and Without Ritonavir (12/08/09)
     
  6557. HepDART: Pharmacokinetics, Safety and Tolerability of the HCV Protease Inhibitor ABT-450 with Ritonavir Following Multiple Ascending Doses in Healthy Adult Volunteers (12/08/09)
     
  6558. HepDART: Safety, Tolerability, Pharmacokinetics and Antiviral Activity of the HCV Polymerase Inhibitor ABT-072 Following Single and Multiple Dosing in Healthy Adult Volunteers and Two Days of Dosing in Treatment-Naïve HCV Genotype 1-Infected Subjects (12/08/09)
     
  6559. AASLD: Asian and White Patients With Chronic Hepatitis C (CHC) Achieve Similar Response Rates With Peginterferon (PEG-IFN) Alfa-2b Plus Ribavirin (RBV) in Genotypes (G) 2 and 3: Subanalysis of the REDD 2/3 Study - (12/07/09)
     
  6560. AASLD: Identifying HCV genotype 2/3 patients who could receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin - (12/07/09)
     
  6561. AASLD: Ribavirin priming enhances efficacy of chronic hepatitis C re-treatment in patients who had not responded to previous combination therapy - (12/07/09)
     
  6562. AASLD: PREDICT Study Final Results: Efficacy and Safety of 24-Wk Regimen of Peginterferon alfa-2b Plus Weight-based Ribavirin in Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 (G1) With Low Viral Load Who Achieve Rapid Viral Response - (12/07/09)
     
  6563. Santaris Study Shows HCV Drug Inhibits miRNA Target in Chimps - (12/03/09)
     
  6564. New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C - (12/03/09)
     
  6565. Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection -Science Magazine article today - full text pdf attached - (12/03/09)
     
  6566. Vitamin D Boosts Treatment of Chronic Hepatitis C - (12/02/09)
     
  6567. HUMAN GENOME SCIENCES SUBMITS BIOLOGICS LICENSE APPLICATION TO FDA FOR ZALBIN™ (albuferon)s - (12/02/09)
     
  6568. Pharmasset HCV Drug Pipeline - (12/02/09)
     
  6569. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients -- attached is the full-text pdf - (12/02/09)
     
  6570. AASLD: Standard versus higher induction doses of peginterferon alfa-2a (40KD) and/or higher ribavirin (RBV) in HCV G1 patients with high viral load and body weight ≥85 kg: Final results of the PROGRESS study - (12/02/09)
     
  6571. AASLD: SVR Results of Weight-based Taribavirin Versus Weight-based Ribavirin, Both with Peginterferon alfa-2b, in Naïve Chronic Hepatitis C, Genotype 1 Patients - (11/30/09)
     
  6572. NS2 Protease - Multitasking may be Achilles heel for hepatitis C - (11/25/09)
     
  6573. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C - (11/23/09)
     
  6574. FDA Perspectives on Clinical Trial Design for New HCV Products, Early Access, presented by Kim Struble at EATG meeting Nov 21 2009, Brussels - (11/20/09)
     
  6575. ITMN-191 HCV Protease Study High Dose Modified Side Effect Reported - (11/20/09)
     
  6576. AASLD: Efficacy and safety of albinterferon alfa-2b in combination with ribavirin in treatment-naïve patients with chronic hepatitis C genotype 1 - (11/10/09)
     
  6577. EACS: Fatty Liver in HIV & HCV - (11/17/09)
     
  6578. EACS: Rough Group Sex--Not Just Anal Sex--May Explain HCV Epidemic in HIV+ Gays - (11/13/09)
     
  6579. AASLD: New Drug Boceprevir Boosts HCV Clearance for Nonresponders - (11/11/09)
     
  6580. AASLD: Once-Daily HCV Protease Inhibitors Show Early Promise - (11/11/09)
     
  6581. DISCOVERY OF POTENT, BIOAVAILABLE HCV NS3/4A PROTEASE INHIBITORS THAT DISPLAY UNIMPAIRED ACTIVITY AGAINST AN NS3 SEQUENCE VARIANT ASSOCIATED WITH RESISTANCE TO LINEAR TETRAPEPTIDES AND MACROCYCLIC INHIBITORS - (11/11/09)
     
  6582. AASLD: Phase 2 Study of Telaprevir Administered q8h or q12h with Peginterferon Alfa-2a or Alfa-2b and Ribavirin in Treatment-Naïve Patients with Genotype 1 Hepatitis C: Final Results - (11/10/09)
     
  6583. AASLD: Telaprevir Vertex hep C protease inhibitor drug works well in twice daily dosing - (11/10/09)
     
  6584. AASLD: More than 80% of Hepatitis C Patients Treated in Study C208 Achieved an SVR with Telaprevir-Based Regimens - press release from Vertex - (11/10/09)
     
  6585. AASLD: 2 Oral HCV Drug Combination R7227+R7128 Without Interferon/ribavirin in INFORM Study - (11/09/09)
     
  6586. AASLD: SVR Improves Survival, Risk for Liver Cancer, Decompensated Liver Disease and Liver Transplant/Death - Also, Transient Viral Suppression (breakthroughs/relapsers) Improves Clinical Outcomes Too - (11/09/09)
     
  6587. AASLD: KINETIC ANALYSIS OF VIRAL REBOUND AND DRUG-RESISTANT VIRAL VARIANT DYNAMICS IN PATIENTS TREATED WITH ITMN-191 (RG7227) MONOTHERAPY SUGGESTS A HIGH BARRIER TO VIRAL ESCAPE - (11/09/09)
     
  6588. AASLD: INCIDENCE OF VIROLOGIC ESCAPE OBSERVED DURING ITMN-191 (R7227) MONOTHERAPY IS GENOTYPE DEPENDENT, ASSOCIATED WITH A SPECIFIC NS3 SUBSTITUTION, AND SUPPRESSED UPON COMBINATION WITH PEGINTERFERON ALFA-2a/RIBAVIRIN - (11/09/09)
     
  6589. AASLD: Telaprevir, Peginterferon Alfa-2a and Ribavirin Improved Rates of Sustained Virologic Response (SVR) in "Difficult-to-Cure" Patients With Chronic Hepatitis C (CHC): a Pooled Analysis From the PROVE1 and PROVE2 Trials - (11/09/09)
     
  6590. AASLD: Telaprevir PROVE3 Final Results: treatment-experienced patients - (11/06/09)
     
  6591. AASLD: HCV Response Linked Strongly to Gene Variant IL28B - (11/06/09)
     
  6592. AASLD: HCV antibody seroconversion in a U.S. HIV-infected male clinical trials population - (11/06/09)
     
  6593. AASLD: SILEN-C1: Early Antiviral Activity and Safety of BI 201335 Combined with Peginterferon alfa-2a and Ribavirin in Treatment-naïve Patients with Chronic Genotype 1 HCV infection - (11/06/09)
     
  6594. AASLD: Treatment-naïve, genotype-1 HCV-infected subjects show significantly greater HCV RNA decreases when treated with 28 days of ABT-333 plus peginterferon and ribavirin compared to peginterferon and ribavirin alone - (11/06/09)
     
  6595. AASLD: HCV Sex Transmission Among HIV+ MSM in NYC Study Report from Mt Sinai Researchers - (11/06/09)
     
  6596. AASLD: Genotypic and Phenotypic Analysis of Samples From HCV-Infected Subjects Treated with BMS-650032 in a Single Ascending Dose Study - (11/06/09)
     
  6597. AASLD: Early Viral Response Rates in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Infection Treated with MK-7009, a Novel NS3/4a Protease Inhibitor, in Combination with Pegylated Interferon Alfa-2a and Ribavirin for 28 Days - (11/05/09)
     
  6598. AASLD: Safety and Antiviral Activity of NS5B Polymerase Inhibitor MK-3281in Genotype 1 and 3 HCV-Infected Patients - (11/05/09)
     
  6599. AASLD: COMBINATION THERAPY WITH NUCLEOSIDE POLYMERASE (RG7128) AND PROTEASE (RG7227) INHIBITORS IN GENOTYPE 1 HCV INFECTED PATIENTS: INTERIM RESISTANCE ANALYSIS OF INFORM-1 COHORTS A-D - (11/05/09)
     
  6600. AASLD: Antiviral activity and safety of TMC435 combined with pegylated interferon and ribavirin in hepatitis C patients with genotype 1 who had previous exposure to TMC435 - (11/05/09)
     
  6601. AASLD: A Phase 1b Dose-Ranging Study of 4 Weeks of PEG-Interferon (IFN) Lambda (PEG-rIL-29) in Combination with Ribavirin (RBV) in Patients with Chronic Genotype 1 Hepatitis C Virus (HCV) Infection - (11/05/09)
     
  6602. AASLD: Antiviral Activity, Pharmacokinetics, Safety, and Tolerability of PSI-7851, a Novel Nucleotide Polymerase Inhibitor for HCV, Following Single and 3 Day Multiple Ascending Oral Doses in Healthy Volunteers and Patients with Chronic HCV Infection - (11/05/09)
     
  6603. AASLD: PHARMACOKINETICS/PHARMACODYNAMICS (PK/PD) OF COMBINATION RG7227 AND RG7128 THERAPY FROM INFORM-1 DEMONSTRATES SIMILAR EARLY HCV VIRAL DYNAMICS WHEN RG7227 IS COMBINED WITH EITHER PEG-IFN/RIBAVIRIN (SOC) OR RG7128 - (11/05/09)
     
  6604. AASLD: Boceprevir in Genotype 1 Null-Responders with Peg/RBV Lead-In - (11/05/09)
     
  6605. AASLD: Merck HCV Protease MK-7009 - (11/05/09)
     
  6606. AASLD: HCV/MSM Sex Transmission in HIV+ in New York City - (11/05/09)
     
  6607. AASLD: Combination Therapy With A Nucleoside Polymerase (RG7128) And Protease (RG7227/ITMN-191) Inhibitor In HCV: Safety, Pharmacokinetics, And Virologic Results From INFORM-1 - (11/04/09)
     
  6608. AASLD: Safety, Tolerability, Pharmacokinetics and Antiviral Activity following Single- and Multiple-Dose Administration of BMS- 650032, a Novel HCV NS3 Inhibitor, in Subjects with Chronic Genotype 1 HCV Infection - (11/04/09)
     
  6609. AASLD: High Sustained Virologic Response in Genotype 1 Null Responders to Peginterferon α-2b + Ribavirin When Treated with Boceprevir Combination Therapy Results From HCV Sprint-1 - (11/04/09)
     
  6610. AASLD: Once Daily Narlaprevir (SCH 900518) in Combination with Peginterferon alfa-2b/ Ribavirin for Treatment-Naive Patients with Genotype-1 Chronic Hepatitis C: Interim Results from the NEXT-1 Study - (11/04/09)
     
  6611. AASLD: BI 207127 is a potent HCV RNA polymerase inhibitor during 5 days monotherapy in patients with chronic hepatitis C - (11/04/09)
     
  6612. AASLD: Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting - Schering Plough press release - (11/01/09)
     
  6613. AASLD: Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C - (11/01/09) Schering Plough press release
     
  6614. AASLD: GlobeImmune's Hepatitis C Therapeutic Vaccine Combined With Standard of Care Increases End of Treatment Response Rate by 15% - (11/01/09) press release
     
  6615. AASLD: Virological response and safety of BI 201335 protease inhibitor, peginterferon alfa 2a and ribavirin treatment of HCV genotype-1patients with compensated liver cirrhosis and non-response to previous peginterferon/ribavirin - (11/01/09)
     
  6616. AASLD: Schering hep C drug promising in Phase II study - (11/01/09)
     
  6617. AASLD: Telaprevir PROVE3 Final Results: treatment-experienced patients - (11/01/09)
     
  6618. AASLD: Boceprevir in Genotype 1 Null-Responders with Peg/RBV Lead-In - (11/01/09)
     
  6619. AASLD: Merck HCV Protease MK-7009 - (11/01/09)
     
  6620. HCV Drives Down Kidney Function - (11/01/09)
     
  6621. Viral Hepatitis and Liver Cancer Control and Prevention Act Introduced in Congress: call your representative to express support - (11/01/09)
     
  6622. Rep Honda Introduces Bi-Partisan Bill to End Hepatitis Epidemic in America - (10/29/09)
     
  6623. ZymoGenetics Initiates Phase 2 Clinical Trial of PEG-Interferon lambda in Hepatitis C with Bristol-Myers Squibb - (10/27/09)
     
  6624. New HCV Polymerase Drug - (10/26/09)
     
  6625. Vertex New HCV Drugs/Studies Update - (10/26/09)
     
  6626. Public health impact of antiviral therapy for hepatitis C in the United States - 50% Undiagnosed - (10/20/09)
     
  6627. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin - (10/20/09)
     
  6628. Hepatitis C drug development at a crossroads - Comments from the Editors - (10/08/09)
     
  6629. Pharmasset Nominates PSI-879 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development - (10/07/09)
     
  6630. Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-2125, a TLR9 Agonist, in Combination with Ribavirin for Chronic Hepatitis C Virus Infection - (10/07/09)
     
  6631. New Data on Four Bristol-Myers Squibb Compounds to Be Presented at AASLD 2009: new HCV NS3 inhibitor - (10/04/09)
     
  6632. Bristol-Myers Squibb and ZymoGenetics to Present Final Phase Ib Data on PEG-Interferon Lambda at AASLD 2009 - (10/04/09)
     
  6633. Hepatitis C virus infection and its clearance alter circulating lipids: Implications for long-term follow-up - (10/04/09)
     
  6634. Hepatitis C drug development at a crossroads - Comments from the Editors - (10/04/09)
     
  6635. AASLD: Viral Responses in African Americans, Latinos, and Caucasians in the US Phase 2 Study (PROVE1) of Telaprevir with Peginterferon Alfa-2a and Ribavirin in Treatment-Naive, Genotype 1-Infected Patients with Hepatitis C - (9/29/09)
     
  6636. Schering-Plough Highlights Boceprevir, Narlaprevir (SCH 900518) and PEGINTRON(R) Data at the American Association for the Study of Liver Diseases (AASLD) 2009 Annual Meeting - (10/17/09)
     
  6637. Once Monthly Interferon: Alios BioPharma Issued Broad U.S. Patent for Glyco-Engineered Interferons - (10/17/09)
     
  6638. Achillion Completes Phase 1a Trial of ACH-1625; Begins Dosing in Phase 1b Segment With HCV-Infected Patients - (09/29/09)
     
  6639. Vertex Takeover Rumors - (09/29/09)
     
  6640. New HCV Nucleotide PSI-7851 - (09/26/09)
     
  6641. ICAAC: Acute HBV & HCV Infection Among MSM: CDC Data from Population-Based Surveillance, 2006-2008 - (09/25/09)
     
  6642. The many faces of hepatitis C: Liver disease and type 2 diabetes - (09/17/09)
     
  6643. Addiction, HCV & Prisons - (09/14/09)
     
  6644. The many faces of hepatitis C: Liver disease and type 2 diabetes - (09/11/09)
     
  6645. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598 - (09/11/09)
     
  6646. CDC HCV Surveillance Study 2006-2007 Published - (09/11/09)
     
  6647. Medtronic Initiates Phase II Hepatitis C Clinical Study ''COPE-HCV'' to Determine Tolerability and Safety of Continuous Interferon Infusion for Patients with HCV - (09/03/09)
     
  6648. The model for end-stage liver disease score (MELD) is the best prognostic factor in HIV 1-infected patients with end-stage liver disease: A prospective cohort study - (09/03/09)
     
  6649. Viable strategies to facilitate liver transplantation for HIV/HCV coinfection - Editorial - (09/03/09)
     
  6650. Viral Hepatitis (HCV, HBV) Sign-On Letter: letter pdf attached
     
  6651. HEP DART December 6 2009
     
  6652. Roche, InterMune Commence Mid-Stage Trial Of Hepatitis C Protease Drug ITMN-191 and Ritonavir Boosting Study - (08/19/09)
     
  6653. Anadys HCV Drug Problems: Anadys Moves Hepatitis C Drug Ahead on its Own - (08/19/09)
     
  6654. Rate of Sustained Virologic Response in Relation to Baseline Hepatitis C Virus (HCV) RNA Level and Rapid Virologic Clearance in Persons with Acute HCV Infection: genotype 1 can achieve high SVR rate is treated during acute infection - (08/18/09)
     
  6655. Gilead Caspase Inhibitor for Liver Disease - (08/18/09)
     
  6656. Abbott HCV Protease & Polymerase Drug Development Program - (08/18/09)
     
  6657. Genes Tied to Gap in Treatment of Hepatitis C: "principal reason for the disparity between the races"....."genetic test based on the finding would be of great interest to patients and physicians" - (08/17/09)
     
  6658. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C - (08/17/09)
     
  6659. Quality of life considerations for patients with chronic hepatitis C: "SVR improves long-term prognosis & health-related quality of life - mental health, physical & general health/virality, emotional health" - (08/17/09)
     
  6660. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis - (08/17/09)
     
  6661. Community-based hepatitis B screening programs in the United States in 2008: CDC recommends HBsAg testing to identify HBV-infection for foreign-born persons from areas with HBsAg prevalence 2% or greater - (08/17/09)
     
  6662. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance; for African-Americans, Hispanics, East Asians - (08/15/09)
     
  6663. Blueberry Chemical Blocks HCV Replication - (08/15/09)
     
  6664. Telaprevir PROVE1 Study: Telaprevir with Peginterferon and Ribavirin for Chronic Genotype 1 Infection - (08/15/09)
     
  6665. PROVE2: Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection (genotype 1) - (08/15/09)
     
  6666. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a - (08/14/09)
     
  6667. Coinfection with Hepatitis C Virus and HIV: More than Double Trouble - EDITORIAL COMMENTARY - (08/14/09)
     
  6668. ANA773 HCV Toll-Receptor Reduced Viral Load, oral inducer of endogenous interferons that acts via the toll like receptor 7 (TLR7) pathway, 10-day monotherapy study - (08/14/09)
     
  6669. State Health Department Launches Media Campaign To Increase Public Awareness About Hepatitis C - (08/14/09)
     
  6670. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin - pdf of published study attached - (08/14/09)
     
  6671. PTC THERAPEUTICS ANNOUNCES ACHIEVEMENT OF MAJOR MILESTONE IN SCHERING-PLOUGH HEPATITIS C COLLABORATION - (08/14/09)
     
  6672. Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy (HCV, IVDU) - (08/12/09)
     
  6673. New Expanded Access Rules to Investigational Drugs for Treatment Use and Charging for Investigational Drugs - (08/12/09)
     
  6674. FDA Expands Access to Investigational Drugs - (08/12/09)
     
  6675. Increased liver-related mortality to hepatitis C viremia defined on the 20th anniversary of its identification- Editorial : HCV carriers had a significantly higher rate of overall mortality - (08/05/09)
     
  6676. Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study - (08/05/09)
     
  6677. Effect of hepatitis C virus and its treatment on survival: HCV associated with mortality, treatment reduces risk - dah - (08/05/09)
     
  6678. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus - (08/05/09)
     
  6679. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients - press release - (08/01/09)
     
  6680. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial -- attached is pdf and appendix with adverse events - (08/04/09)
     
  6681. New HCV Nucleotide Polymerase PSI-7851 Achieves 1 log Reduction in Viral Load in 3-Day Study - (08/01/09)
     
  6682. 5th IAS: HIV Regimens Lacking Nucleosides Tied to Higher SVR Rate With HCV Therapy - written by Mark Mascolini - (07/29/09)
     
  6683. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) - (07/25/09)
     
  6684. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the united states population - (07/15/09)
     
  6685. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam - (07/15/09)
     
  6686. Vertex Pharmaceuticals Announces Intention to Sell Its Rights to European Milestone Payments for Telaprevir - (07/12/09)
     
  6687. 4th Intrntnl Wrkshp Clncl Pharm HCV: Meeting Report - The 4th International Workshop on Clinical Pharmacology of Hepatitis Therapy - written by Jennifer J. Kiser, Pharm.D - (07/12/09)
     
  6688. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development - (07/09/09)
     
  6689. Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development - (07/08/09)
     
  6690. ELEVATE Phase III Study- for Eltrombopag To raise platelet count - (07/07/09)
     
  6691. Hepatitis C Virus Infection and the Risk of Coronary Disease - (07/03/09)
     
  6692. 4th Intrntnl Wrkshp HCV Resist: New HCV Drugs, Special Population (Coinfectio) Access: 4th International Workshop on Hepatitis C, Resistance and New Compounds 25-26 June 2009, Boston, MA U - (06/30/09)
     
  6693. Time-Released Interferon Locteron Study Enrollment Completed - (06/30/09)
     
  6694. 4th Intrntnl Wrkshp HCV Resist: FDA Loosens Up HCV Drug Development - HCV Boston Meeting June 27, 2009 - (06/30/09)
     
  6695. "Maintenance Therapy Did Not Reduce Incidence of HCC in the HALT-C Study" - (06/21/09)
     
  6696. HCC Surveillance is Needed in USA - Hepatitis C and Hepatocellular Carcinoma: Grist for the Mill EDITORIAL - (06/21/09)
     
  6697. Low-fat Diet Helps Genetically Predisposed Animals Avoid Liver Cancer - (06/15/09)
     
  6698. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients - (06/10/09)
     
  6699. Progenics Stops PRO 206 HCV Entry Inhibitor - (06/10/09)
     
  6700. CDC Updated Viral Hepatitis Surveillance - (06/05/09)
     
  6701. Liver Disease 'Shrunk' By Blood-pressure Drug - (06/05/09)
     
  6702. Liver Cancer Rates Triple: Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005 - (06/03/09)
     
  6703. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results - (06/01/09)
     
  6704. Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal - (06/01/09)
     
  6705. Causes of Liver Cancer in HCV: Hepatitis C virus-induced hepatocarcinogenesis (HCC)) - (06/01/09)
     
  6706. EASL: Early EPO Use Increased SVR Rates and Reduced Discontinuation Rate ! (05/29/09)
     
  6707. EASL: New HCV Drug Report: "Using a new palette of treatment options to paint the portrait of cure for patients infected with hepatitis C on our clinical canvas." - written by Robert Gish MD - (05/28/09)
     
  6708. Hepatitis Advocacy Update: Congressional Black Caucus Requests Federal Funding, for African-Americans The HCV Prevalence Rate is Double Compared To All Others in the USA; Congressmen Request Funding Support; Pres Obama Recognizes hepatitis with a Statement - (05/28/09)
     
  6709. EASL: EXTENDED TREATMENT DURATION TO 72 Weeks IN CHRONIC HEPATITIS C GENOTYPE 1-INFECTED SLOW RESPONDERS: FINAL RESULTS OF THE SUCCESS STUDY (SUCCESS) - (05/27/09)
     
  6710. EASL: BI 201335, a potent HCV NS3 protease inhibitor, in treatment-naïve and -experienced chronic HCV genotype-1 infection: genotypic and phenotypic analysis of the NS3 protease domain - (05/27/09)
     
  6711. EASL: Preclinical characterization of PRO 206, an orally active HCV entry inhibitor - (05/27/09)
     
  6712. Consequences of Hepatitis C Virus (HCV): Costs of a Baby Boomer Epidemic of Liver Disease MAY 2009 - (05/18/09)
     
  6713. Evidence of a Large, InternationaL Network of HCV Transmission in HIV-Positive Men Who Have Sex With Men - (05/18/09)
     
  6714. EASL: EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A 360 µg/WEEK IN COMBINATION WITH RIBAVIRIN IN HEPATITIS C GENOTYPE 1 PATIENTS - IMPACT Of CIRRHOSIS: ANALYSIS FROM THE CHARIOT STUDY - (05/14/09)
     
  6715. EASL: EASL Analysis, New Oral HCV Drugs What's Expected - (05/14/09)
     
  6716. EASL: Histologic Outcomes in Hepatitis C-Infected Patients With Breakthrough or Relapse to Interferon-Based Treatments: there was a positive correclation between viral response and improved fibrosis - (05/13/09)
     
  6717. EASL: BASELINE CHARACTERISTICS AND WEEK 4 RESPONSE AMONG CHRONIC HEPATITIS C PATIENTS INFECTED WITH HCV GENOTYPE 1, 2, 3 OR 4: INTERIM RESULTS OF THE PROPHESYS TRIAL - (05/13/09)
     
  6718. EASL: Identifying Patients Infected With HCV Genotype 1 Who May Benefit From Extended Peginterferon Alfa-2a/Ribavirin Therapy Beyond 48 Weeks - (05/13/09)
     
  6719. EASL: IDENTIFYING PATIENTS WITH A HIGH LIKELIHOOD OF ACHIEVING AN SVR FOLLOWING RE-TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN: USE OF POSITIVE PROGNOSTIC FACTORS (PPF'S) - (05/12/09)
     
  6720. EASL: Ursodeoxychic Acid Improved NASH, Not So Sure About Rosiglitazone - (05/12/09)
     
  6721. EASL: Single and Multiple-Dose Assessments of the Safety and Pharmacokinetics of SCH 900518 and Its Effect on the Pharmacokinetics of Midazolam in Healthy Subjects - (05/12/09)
     
  6722. EASL: Preclinical Characterization of SCH 900518,A Novel Mechanism-Based Inhibitor of HCV NS3 Protease - (05/12/09)
     
  6723. EASL: Individualized treatment duration with peginterferon alfa-2b and ribavirin for 24, 30 or 36 weeks in HCV genotype 1-infected patients with undetectable HCV-RNA early during therapy (INDIV-2 study) - (05/12/09)
     
  6724. EASL: A Regional Gastrointestinal Absorption Study of the HCV NS3 Protease Inhibitor SCH 900518 in Healthy Volunteers: "remote-controlled drug delivery device that delivers any form of drug to key regions of the human gastrointestinal (GI) tract." - (05/12/09)
     
  6725. EASL: Preclinical Pharmacokinetic and Safety Profile of IDX375, A Novel and Potent Non-Nucleoside HCV Polymerase Inhibitor - (05/11/09)
     
  6726. EASL: Preclinical Profiles of IDX136 and IDX316, Two Novel Macrocyclic HCV Protease Inhibitors - (05/11/09)
     
  6727. EASL: IDENTIFICATION AND PROFILE OF POTENT AND SELECTIVE INHIBITORS OF HCV NS5A PROTEIN - (05/11/09)
     
  6728. Phase 2a Study to Evaluate the Safety and Tolerability and Anti-Viral Effect of 4 Doses of a Novel, Controlled-Release Interferon Alfa-2b (LocteronTM) Given Every 2 Weeks for 12 Weeks in Treatment-Naive Patients with Chronic Hepatitis C (Genotype 1) (AASLD 2007) - (05/08/09)
     
  6729. Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection...PROVE1 in NEJM 4/2009 - (05/08/09)
     
  6730. Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection....A total of 334 patients who had chronic infection with HCV genotype 1 and had not been treated previously (PROVE2) - (05/08/09)
     
  6731. A Step Forward in Therapy for Hepatitis C EDITORIAL - NEJM 4/2009 - (05/08/09)
     
  6732. EASL: Albuferon vs Pegasys Genotype 2/3 - (05/07/09)
     
  6733. EASL: Albuferon vs Pegasys Genotype 1 - (05/07/09)
     
  6734. EASL: Co Press Release: Biolex presents Locteron US Phase 2a hepatitis C data at EASL - (05/07/09)
     
  6735. EASL: Identification and Characterization of VCH-222, a Novel Potent and Selective Non-Nucleoside HCV Polymerase Inhibitor - (05/07/09)
     
  6736. EASL: Activity & Genotypic and Phenotypic Analysis of HCV NS5B Variants Selected from Patients Treated with VCH-916 - (05/07/09)
     
  6737. EASL: Randomized Trial Comparing Systemic and Local Reactions to Controlled-release Interferon Alpha2b and Pegylated-interferon Alpha2b in Hepatitis C Patients Who Failed Prior Treatment - (05/07/09)
     
  6738. EASL: Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide with Peginterferon Alfa-2a and Ribavirin in Nonresponders (NR) with Chronic HCV Genotype 1: Week 28 Interim Analysis - (05/07/09)
     
  6739. EASL: Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide Plus Peginterferon and Ribavirin in HCV Genotype 1 Naïve Patients: Interim Analysis Shows Increase in EVR - (05/07/09)
     
  6740. EASL: Preclinical Pharmacokinetic and ADME Characterization of VCH-222, a Novel Non-Nucleoside HCV NS5B Polymerase Inhibitor from Vertex/ViroChem - (05/07/09)
     
  6741. EASL: IDX184, A Liver-Targeted Nucleotide HCV Polymerase Inhibitor: Results of a First-in-Man Safety and Pharmacokinetic Study - (05/07/09)
     
  6742. EASL: Antiviral Activity of the Liver-Targeted Nucleotide HCV Polymerase Inhibitor IDX184 Correlates with Trough Serum Levels of the Nucleoside Metabolite in HCV-infected Chimpanzees - (05/07/09)
     
  6743. EASL: Pharmacokinetics, Safety and Tolerability of the HCV Polymerase Inhibitor ABT-333 Following Multiple Ascending Doses and Effect of Co-Administration of Ketoconazole in Healthy Subjects - (05/05/09)
     
  6744. EASL: Characterization of Resistance Mutations Selected In Vitro by Non-Nucleoside HCV Polymerase Inhibitors ABT-333 and ABT-072 - (05/05/09)
     
  6745. EASL: US Hepatitis C Burden Assessment from a Transmission Model: HCV burden reduced by new HCV drugs - (05/05/09)
     
  6746. EASL: Pharmacokinetics and Tolerability of the HCV Polymerase Inhibitor ABT-333 Following Single Ascending Doses in Healthy Adult Volunteers - (05/05/09)
     
  6747. EASL: Safety, Tolerability and Pharmacokinetics of the HCV Polymerase Inhibitor VCH-222 Following Single Dose Administration in Healthy Volunteers and Antiviral Activity in HCV-infected Individuals - (05/05/09)
     
  6748. EASL: Safety, Tolerability, and Pharmacokinetics of GS-9450 in Healthy Male and Female Volunteers - (05/05/09)
     
  6749. EASL: Abbott/Enanta - Potent HCV Protease Inhibitors with the Potential for Once-daily Dosing and Broad Genotype Coverage - (05/05/09)
     
  6750. EASL: Preclinical Characterization of ABT-072: A Novel Non-Nucleoside HCV Polymerase Inhibitor - (05/05/09)
     
  6751. EASL: Preclinical Potency, Pharmacokinetic and ADME Characterization of ABT-333, A Novel Non-Nucleoside HCV Polymerase Inhibitor - (05/05/09)
     
  6752. EASL: 2 Schering HCV Protease Inhibitors; Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients - (05/04/09)
     
  6753. Recombinant (EPO) human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials - (05/04/09)
     
  6754. EASL: EFFICACY AND SAFETY OF THE CYCLOPHILIN INHIBITOR DEBIO 025 IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN IN PREVIOUSLY NULL-RESPONDER GENOTYPE 1 HCV PATIENTS - (05/01/09)
     
  6755. EASL: SAFETY AND ANTIVIRAL ACTIVITY OF SCH 900518 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2B TO NAIVE AND TREATMENT-EXPERIENCED HCV-1 INFECTED PATIENTS - (04/30/09)
     
  6756. EASL: PegIntron Maintenance Therapy in Cirrhotic (METAVIR F4) HCV Patients Who Failed to Respond to Interferon/Ribavirin (IR) Therapy: Final Results of the EPIC3 Cirrhosis Maintenance Trial - (04/30/09)
     
  6757. EASL: HCV SPRINT-1: Final Results SVR 24 NS3 Protease Inhibitor Boceprevir plus PegIFN alpha-2b/Ribavirin HCV 1 Treatment Naïve Patients - (04/30/09)
     
  6758. EASL: Antiviral Activity and Safety of ITMN-191 (R7227) in Combination with Peginterferon alfa-2a and Ribavirin in Patients with Chronic Hepatitis C Virus - (04/29/09)
     
  6759. EASL: Antiviral activity and safety of TMC435 combined with peginterferon a-2a and ribavirin in patients with genotype-1 hepatitis C infection who failed previous IFN-based therapy - (04/29/09)
     
  6760. EASL: Antiviral Activity of Filibuvir in Combination with Pegylated Interferon Alfa-2a and Ribavirin for 28 Days in Treatment-Naive Patients Chronically Infected with HCV Genotype 1 - (04/29/09)
     
  6761. EASL: Subgroup Analysis Confirms Efficacy, Safety of Sorafenib in Patients With Late-Stage Liver Cancer: Presented at EASL - (04/29/09)
     
  6762. EASL: A FIRST CLINICAL TRIAL OF THERAPEUTIC VACCINATION USING NAKED DNA DELIVERED BY IN VIVO ELECTROPORATION SHOWS ANTIVIRAL EFFECTS IN PATIENTS WITH CHRONIC HEPATITIS C - (04/29/09)
     
  6763. EASL: Safety, Tolerability, and Pharmacokinetics after Single and Multiple Doses of MK-3281 in Healthy Subjects - (04/28/09)
     
  6764. EASL: MK-7009 Significantly Improves Rapid Viral Response (RVR) in Combination with Pegylated Interferon Alfa-2a and Ribavirinin Patients with Chronic Hepatitis C (CHC) Genotype 1 Infection - (04/28/09)
     
  6765. EASL: Metabolic Syndrome Hikes Mortality in Hepatitis C - (04/28/09)
     
  6766. EASL: Ground-Breaking Combination of 2 All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen (ITMN-191 protease + R7128 NRTI) - (04/28/09)
     
  6767. EASL: FDA Regulations for HCV Drug Development - are they too Strict? - (04/28/09)
     
  6768. EASL: Can Peginterferon and Ribavirin Be Eliminated from Therapy - (04/28/09)
     
  6769. EASL: Roche and Pharmasset start phase IIb clinical trial of R7128 nucleoside polymerase inhibitor for chronic hepatitis C - (04/28/09)
     
  6770. EASL: OPERA-1 trial (Study TMC435-C201): interim analysis of safety and antiviral activity of TMC435 in treatment-naïve genotype-1 HCV patients - (04/28/09)
     
  6771. EASL: TELAPREVIR IN HEPATITIS C GENOTYPE-1-INFECTED PATIENTS WITH PRIOR NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON-ALFA-2A/B AND RIBAVIRIN THERAPY: SVR RESULTS OF THE PROVE3 STUDY - (04/28/09)
     
  6772. EASL: Potent Antiviral Activity With A Nucleoside Polymerase (R7128) And Protease (R7227/ITMN-191) Inhibitor Combination in HCV Genotype 1: Initial Safety, Pharmacokinetics, And Virologic Results From INFORM-1 - (04/28/09)
     
  6773. EASL: EASL Day 3 Saturday - (04/28/09)
     
  6774. EASL: HCV Protease ITMN-191 + Peg/RBV for 14 Days - safety, antiviral activity - (04/28/09)
     
  6775. EASL: SCH-900518 New Schering Protease Inhibitor Monotherapy & with Peg/RBV 7-14 days - (04/28/09)
     
  6776. EASL: Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C - (04/28/09)
     
  6777. EASL: Peg-Interferon lambda + Ribavirin 4 Weeks - (04/28/09)
     
  6778. EASL: Telaprevir Effective for Genotype 2 But Not For Genotype 3 - (04/27/09)
     
  6779. EASL: Maintenance Therapy: we don't know if it provides benefit - (04/27/09)
     
  6780. EASL: HIV positive and HIV negative patients have similar survival rates following liver transplant - (04/27/09)
     
  6781. EASL: Anadys shares plunge on hepatitis C drug ANA598 safety concerns - (04/27/09)
     
  6782. EASL: Schering's protease boceprevir phase 2; Schering symposium - (04/27/09)
     
  6783. EASL: Safety, pharmacokinetics and antiviral effect of BI 207127, a novel HCV RNA polymerase inhibitor, after 5 days' oral treatment in patients with chronic hepatitis C - (04/27/09)
     
  6784. EASL: ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients - (04/24/09)
     
  6785. EASL: Tibotec HCV Protease TMC435 I Treatment-Naives Genotype 1, Monotherapy & Combination with Peg/RBV - (04/24/09)
     
  6786. EASL: New HCV Drugs II: Schering's protease boceprevir phase 2; Abbott/Enanta HCV Protease Inhibitors; Progenics PRO-206 HCV Entry Inhibitor - (04/24/09)
     
  6787. EASL: Taribavirin vs Ribavirin - (04/24/09)
     
  6788. EASL: New HCV Drugs Today at EASL 1st Day - (04/24/09)
     
  6789. EASL: EASL New HCV Drugs - (04/23/09)
     
  6790. EASL: EPIC Study Shows Maintenance Therapy Provides Benefits - (04/23/09)
     
  6791. Low-Dose Naltrexone Eases Pain and Fatigue of Fibromyalgia - (04/22/09)
     
  6792. Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-{alpha}2b - (04/22/09)
     
  6793. New Gilead HCV Drug GS-9190 - (04/22/09)
     
  6794. Celsion Receives Orphan Drug Designation for ThermoDox to Treat Primary Liver Cancer - (04/20/09)
     
  6795. IDUs Risky Behavior: < 32% share syringes/63% have unprotected vaginal sex, CDC Study - (04/10/09)
     
  6796. The cyclophilin inhibitor Debio 025 combined with PEG IFN2a significantly reduces viral load in treatment-naive hepatitis C patients: efficacy & safety - (04/09/09)
     
  6797. AASLD Practice Guidelines: Diagnosis, management, and treatment of hepatitis C: An update, pdf attached - (04/06/09)
     
  6798. HALT-C Patient Subgroups That Appear To Benefit From Maintenance Therapy - (04/06/09)
     
  6799. Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses - (04/02/09)
     
  6800. Treatment of HBV/HCV Coinfection: Releasing the Enemy Within - (04/02/09)
     
  6801. Improved Virologic Response in Chronic Hepatitis C Genotype 4 Treated With Nitazoxanide, Peginterferon, and Ribavirin - (04/02/09)
     
  6802. Nitazoxanide: Beyond Parasites Toward a Novel Agent for Hepatitis C - (04/02/09)
     
  6803. EHDRW: Virologic Outcome After geno2pheno Versus Trofile: Controversy on Using Genotype to Predict Coreceptor Use Before Maraviroc - Written by Mark Mascolini (04/01/09)
     
  6804. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV) - (04/01/09)
     
  6805. ISHLVD: Screening for Acute Hepatitis C Virus Infection (AHCV) among At-Risk Patients in an HIV Clinic - (03/30/09)
     
  6806. ISHLVD: TMC435 HCV Protease Inhibitor Safety/antiviral activity OPERA Study doses 25 & 75 mg once daily - (03/30/09)
     
  6807. Racial Differences in Response to Interferon-Based Antiviral Therapy for Hepatitis C Virus Infection: A Hardwiring Issue? EDITORIAL COMMENTARY - (03/27/09)
     
  6808. Early Changes in Hepatitis C Virus (HCV) Levels in Response to Peginterferon and Ribavirin Treatment in Patients with Chronic HCV Genotype 1 Infection - (03/27/09)
     
  6809. Hep C in HIVers may cause rapid liver disease - (03/27/09)
     
  6810. HALT-C in the final analysis: A molehill out of a mountain - does peginterferon maintenance therapy work? - (03/27/09)
     
  6811. Vertex Telaprevir & VCH-222 Preentations at EASL April 2009 - (03/20/09)
     
  6812. CROI: Effect of HIV Co-infection on the Outcome of Viral Cirrhosis Liver Transplant Candidates on the Waiting List at a Reference Center from 2001 to 2008 - (03/17/09)
     
  6813. CROI: HCV Inflames the Brain in HIV Coinfected in Acute HCV - (03/17/09)
     
  6814. CROI: 5-Year Survival of HCV/HIV-co-infected Liver Transplant Recipients in Spain: A Case/Control Study - (03/17/09)
     
  6815. CROI: Interruption of ART and Changes in Hyaluronic Acid as Marker of Liver Fibrosis Progression in Strategies for Management of ART Viral Hepatitis-co-infected Participants and Matched Controls - (03/17/09)
     
  6816. CROI: Hyaluronic Acid as a Prognostic Marker of Hepatic Coma and Liver-related Death in HIV/Viral Hepatitis Co-infected Patients - (03/17/09)
     
  6817. FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C - (03/16/09)
     
  6818. Bidding for HCV NNRTI ANA598 - (03/16/09)
     
  6819. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients - "No patient had conclusive evidence of virologic relapse" - (03/11/09)
     
  6820. In Pakistan 9 million with HCV, 5.6 million with HBV 9m suffering from hepatitis C in Pakistan, Senate told - (03/11/09)
     
  6821. Human Genome Sciences Announces Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C - (03/11/09)
     
  6822. HCV NNRTI ANA598 News Update: Anadys Keeps Surging, as Hepatitis C Drug Data Trickles In - (02/27/09)
     
  6823. Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C - (02/27/09)
     
  6824. ABBOTT AND ENANTA INITIATE PHASE 1 CLINICAL TRIAL ON ABT-450 HCV PROTEASE INHIBITOR - (02/27/09)
     
  6825. Inhibitex Completes Phase I Clinical Trials for FV-100 and Selects Lead HCV Compounds for Advanced Preclinical Studies - (02/10/09)
     
  6826. Hepatology 2009 Textbook Online by Mauss et al - (02/06/09)
     
  6827. Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients - (01/28/09)
     
  6828. Clinical Update - Debio 025 in Hepatitis C - Debiopharm starts phase IIb triple therapy study, a promising therapeutic avenue - (01/26/09)
     
  6829. Sorafenib: A glimmer of hope for unresectable hepatocellular carcinoma? - (01/23/09)
     
  6830. Complete cure of HBV-HDV co-infection after 24weeks of combination therapy with pegylated interferon and ribavirin in a patient co-infected with HBV/HCV/HDV/HIV - (01/22/09)
     
  6831. AASLD: Antiviral Efficacy of the HCV RNA Polymerase Inhibitor ANA598 in the Chimpanzee Model of HCV Infection - (01/21/09)
     
  6832. AASLD: Results of A Phase I Safety, Tolerability and Pharmacokinetic Study of ANA598, A Non-nucleoside NS5B Polymerase Inhibitor, in Healthy Volunteers - (01/21/09)
     
  6833. AASLD: In Vitro Studies Demonstrate that Combinations of Antiviral Agents that Include HCV Polymerase Inhibitor ANA598 have the Potential to Overcome Viral Resistance - (01/20/09)
     
  6834. Treatment of Fibromyalgia Syndrome With Antidepressants - (01/20/09)
     
  6835. PEGASYS Proven Effective as Hepatitis C Treatment for Latino Patients - (01/15/09)
     
  6836. Peginterferon Alfa-2a and Ribavirin in Latino and Non-Latino Whites with Hepatitis C: LATINO Study NEJM - (01/15/09)
     
  6837. LATINO Study Comments by Jules Levin - (01/15/09)
     
  6838. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans - (01/14/09)
     
  6839. The Accelerating Pace of HCV Research: A Summary of the 15th International Symposium on Hepatitis C Virus and Related Viruses - (01/13/09)
     
  6840. Bristol-Myers to Buy Rights to Hep C Drug Peg-Interferon lambda - (01/13/09)
     
  6841. Bristol-Myers to Develop Hepatitis C Drug Peg-Interferon Lambda With ZymoGenetics - (01/13/09)
     
  6842. InterMune Reports Results from Triple Combination Study of ITMN-191 - (01/13/09)
     
  6843. Peg-Interferon Lambda Phase 1b in HCV+ Patients: safety, antiviral activity - (01/13/09)
     
  6844. Telaprevir Phase 3 Studies Update - (01/12/09)
     
  6845. Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C - (01/12/09)
     
  6846. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients - (01/12/09)
     
  6847. ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection - (01/08/09)
     
  6848. Hepatitis C Drug From Anadys Shows Quick Virus-Killing Punch: potent antiviral activity displayed -2.5 log reduction in 72 hours - (01/08/09)
     
  6849. New Therapies for Hepatitis C Virus Infection: REVIEW ARTICLE - (01/08/09)
     
  6850. Influence of aminotransferase values on liver stiffness measurement: the case of HIV-infected patients with acute viral hepatitis B or C - (01/02/09)
     
  6851. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre-Clinical NS5A Program in Hepatitis C to Presidio Pharmaceuticals - (12/30/08)
     
  6852. Is there disease progression in patients who are hepatitis C virus antibody-positive and hepatitis C virus RNA-seronegative? - (12/22/08)
     
  6853. Histological changes in HCV antibody-positive, HCV RNA-negative subjects suggest persistent virus infection - (12/22/08)
     
  6854. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV - (12/19/08)
     
  6855. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial - (12/19/08)
     
  6856. Liver biopsy: The best, not the gold standard EDITORIAL vs surrogate markers - (12/19/08)
     
  6857. AASLD: REVIEW OF SELECTED LIVER CANCER ABSTRACTS FROM THE AASLD MEETING IN SF 2008 FOR NATAP - written by Robert Gish MD and Catherine Frenette MD CPMC (12/19/08)
     
  6858. Next-Generation HCV Protease Inhibitor SCH 900518 - (12/16/08)
     
  6859. Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C - (12/12/08)
     
  6860. AASLD: Evaluation of a 4 Week Lead-in Phase with Nitazoxanide (NTZ) prior to Peginterferon (PegIFN) plus NTZ for Treatment of Chronic Hepatitis C: Final Report - (12/10/08)
     
  6861. Pegasys EMEA Approval for Retreatment for 72 Weeks in Nonresponders - (12/09/08)
     
  6862. HCV Research Done Poorly and Misreported Results in NEJM on Maintenance Therapy in HALT-C Study - (12/09/08)
     
  6863. HUMAN GENOME SCIENCES ANNOUNCES ALBUFERON MEETS PRIMARY ENDPOINT IN PHASE 3 TRIAL IN CHRONIC HEPATITIS C - (12/09/08)
     
  6864. ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection - (12/03/08)
     
  6865. AASLD: Treatment-Related Anemia Is Associated With Higher SVR Rates Among Persons Treated With Peginterferon (PEG)/Ribavirin (RBV): Results From the IDEAL Study - (12/01/08)
     
  6866. AASLD: A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of the NS3/4A Protease Inhibitor ITMN-191 in Healthy Subjects - (12/01/08)
     
  6867. AASLD: Pharmacokinetic-Pharmacodynamic (PK-PD) Relationships for ITMN-191 in a Phase 1 Multiple Ascending Dose (MAD) Trial in Patients with Genotype 1 Chronic Hepatitis C Infection - (12/01/08)
     
  6868. AASLD: In Vitro activity and pharmacological properties of IDX375, a novel HCV non-nucleoside inhibitor - (12/01/08)
     
  6869. AASLD: A 72-week treatment duration with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) has a favorable risk:benefit ratio in non-responders to pegylated interferon alfa-2b (12KD) plus ribavirin: findings of the multinational REPEAT study - (11/26/08)
     
  6870. AASLD: Probability of virologic relapse during follow-up varies with the rapidity of the on-treatment virologic response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin - (11/26/08)
     
  6871. AASLD: Prediction of SVR in HCV genotype 1 patients co-infected with HIV based on virologic responses at week 4 and 12 of treatment with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS): Retrospective analysis of APRICOT - (11/26/08)
     
  6872. AASLD: Phase 2 Study of Telaprevir Administered q8h or q12h with Peginterferon Alfa-2a or Alfa-2b and Ribavirin in Treatment-naïve Patients with Genotype 1 Hepatitis C: Week 12 Interim Results - (11/26/08)
     
  6873. AASLD: Randomized study comparing Peginterferon alfa2a plus Ribavirin and Peginterferon alfa2b plus Ribavirin in naïve patients with chronic hepatitis C: Final results of the MiIan Safety and Tolerability (MIST) Study - (11/24/08)
     
  6874. AASLD: Metformin with Peginterferon Alfa-2a and Ribavirin in the Treatment of Naive Genotype 1 Chronic Hepatitis C Patients with Insulin Resistance (TRIC-1): Final Results of a Randomized and Double-Blinded Trial - (11/21/08)
     
  6875. AASLD: SVR in African American Patients: Results of the IDEAL Study (Individualized Dosing Efficacy vs Flat Dosing to Assess OptimaL Pegylated Interferon Therapy) - (11/21/08)
     
  6876. AASLD: A Study of Telaprevir Combined with Peginterferon Alfa-2a and Ribavirin in Patients with Well-documented Non-response or Relapse After Previous Peginterferon Alfa-2a and Ribavirin Treatment: Interim Analysis - (11/20/08)
     
  6877. Albuferon Pulmonary Adverse Events - (11/18/08)
     
  6878. Hepatitis C Therapeutic DNA Vaccine Delivered by Inovio Biomedical's Electroporation Technology Reduces Viral Load by Up to 99.7% Clinical Data Presented at Annual Scientific Meeting of the American Association for the Study of Liver Diseases - (11/18/08)
     
  6879. AASLD: Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in combination therapy with peginterferon alfa-2a (P) and ribavirin (R) for 28 days in P+R treatment-experienced patients with chronic hepatitis C genotype 1 infection - (11/14/08)
     
  6880. AASLD: Safety, Tolerability, and Pharmacokinetic Data Following Single- and Multiple-Dose Administration of MK-7009, a Hepatitis C Virus Non-structural 3/4a Protease Inhibitor, to Healthy Male Subjects (1910) - (11/14/08)
     
  6881. AASLD: Combination of the NS3/4A Protease Inhibitor ITMN-191 (R7227) with the Active Moiety of the NS5B Inhibitors R1626 or R7128 Enhances Replicon Clearance and Reduces the Emergence of Drug Resistant Variants - (11/12/08)
     
  6882. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C - (11/12/08)
     
  6883. AASLD: Safety, Tolerability, and Pharmacokinetic Data Following Single- and Multiple-Dose Administration of MK-7009, a Hepatitis C Virus Non-structural 3/4a Protease Inhibitor, to Healthy Male Subjects (1910) - (11/11/08)
     
  6884. AASLD: Pharmacokinetics of once-daily regimens of the novel HCV NS3/4A-protease inhibitor TMC435350, with and without peg-IFN and ribavirin, in HCV-infected individuals - (11/11/08)
     
  6885. AASLD: Inhibitory activity of TMC435350 on HCV NS3/4A proteases from genotypes 1 to 6 - (11/11/08)
     
  6886. AASLD: Potent Antiviral Response To The HCV Nucleoside Polymerase Inhibitor R7128 For 28 Days With Peg-IFN And Ribavirin: Subanalysis by Race/Ethnicity, Weight and HCV Genotype - (11/07/08)
     
  6887. AASLD: New HCV Drugs at AASLD: Vertex is Focus at Hepatitis C Meeting - (11/07/08)
     
  6888. AASLD: Antiviral Activity Of The HCV Nucleoside Polymerase Inhibitor R7128 In HCV Genotype 2 and 3 Prior Non-Responders: Results Of R7128 1500mg BID With PEG-IFN And Ribavirin For 28 Days - (11/07/08)
     
  6889. AASLD: Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers Phase I Clinical Data and Additional Preclinical Results for Non-Nucleoside HCV Polymerase Inhibitor Being Presented at AASLD - (11/07/08)
     
  6890. AASLD: Antiviral Activity of the HCV Polymerase Inhibitor PF-00868554 Administered as Monotherapy in HCV Genotype 1 Infected Subjects - (11/07/08)
     
  6891. AASLD: Telaprevir in Combination with Peginterferon-a-2a With or Without Ribavirin in the Treatment of Chronic Hepatitis C Treatment-Naive Genotype 1: Final Results of the PROVE2 Study (conducted in Europe) - (11/06/08)
     
  6892. AASLD: A Phase 2b Study of Telaprevir with Peginterferon-Alfa-2a and Ribavirin in Hepatitis C Genotype 1 Null and Partial Responders and Relapsers Following a Prior Course of Peginterferon-Alfa-2a/b and Ribavirin Therapy: PROVE3 Interim Results - (11/06/08)
     
  6893. AASLD: Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in treatment-naive patients with chronic hepatitis C genotype 1 infection given as monotherapy and in combination with peginterferon alfa-2a (P) and ribavirin (R) - (11/06/08)
     
  6894. AASLD: Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Patients with the NS3/4A Protease Inhibitor ITMN-191 Leads to Rapid Reductions in Plasma HCV RNA: Results of a Phase 1b Multiple Ascending Dose (MAD) Study - (11/05/08)
     
  6895. AASLD: Intravenous silibinin for treatment of nonresponders to peginterferon/ribavirin therapy in chronic hepatitis C - (11/05/08)
     
  6896. Bristol-Myers Squibb Foundation to Award $1.4 Million in Grants to Bridge Gaps in Hepatitis C Awareness, Prevention and Care in Asia - (11/04/08)
     
  6897. AASLD: Safety and antiviral activity of TMC435350 in treatment-naive genotype 1 HCV-infected patients - (11/04/08)
     
  6898. AASLD: Safety, Tolerability and Antiviral Activity of MK-7009, a Novel Inhibitor of the Hepatitis C Virus NS3/4A Protease, in Patients with Chronic HCV Genotype 1 Infection - (11/04/08)
     
  6899. AASLD: GlobeImmune Hepatitis C Therapeutic Vaccine, GI-5005, Doubles Viral Clearance And Increases RVR Rates In Phase 2 Clinical Trial - (11/04/08)
     
  6900. AASLD: Boceprevir Plus Peginterferon alfa-2b/Ribavirin for Treatment of Genotype 1 Chronic Hepatitis C in Previously Untreated Patients: Interim Results from the HCV SPRINT-1 Study - (11/04/08)
     
  6901. AASLD: BMS-790052 is a First-in-class Potent Hepatitis C Virus (HCV) NS5A Inhibitor for Patients with Chronic HCV Infection: Results from a Proof-of-concept Study - (11/04/08)
     
  6902. AASLD: An On-going Outbreak of Acute HCV in HIV-infected Men in New York City: Rates of Spontaneous Clearance, Treatment Responses, and Liver Fibrosis - (11/3/08)
     
  6903. AASLD: New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection - (11/3/08)
     
  6904. AASLD: Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients - (11/3/08)
     
  6905. AASLD: TIBOTEC PRESENTS INTERIM FINDINGS FOR TMC435, AN INVESTIGATIONAL GENOTYPE 1 HEPATITIS C TREATMENT, AT THE AASLD LIVER MEETING 2008 - (11/3/08)
     
  6906. AASLD: GILEAD ANNOUNCES TWO-YEAR DATA FROM PIVOTAL PHASE III STUDIES EVALUATING VIREAD FOR CHRONIC HEPATITIS B - (11/3/08)
     
  6907. GSK boosts HCV presence with Genelabs purchase - (10/31/08)
     
  6908. Roche Receives FDA Approval for Hepatitis C Viral Load Test on Its Fully Automated Real-Time PCR Platform Improved laboratory efficiencies and standardization to personalize patient care - (10/31/08)
     
  6909. Roche HCV Drug R1626 Terminated - (10/21/08)
     
  6910. Validation of a Hepatitis C Screening Tool in Primary Care - (10/20/08)
     
  6911. Tibotec Begins Enrollment for Phase III Study of Telaprevir, an Investigational Agent, in HCV Patients Who Failed Prior Treatment - (10/15/08)
     
  6912. New BMS HCV NS5A Inhibitor: From Screen Hit to Clinic - (10/14/08)
     
  6913. Hepatocellular carcinoma in long-term sustained virological responders following antiviral combination therapy for chronic hepatitis C - (10/10/08)
     
  6914. Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin - (10/10/08)
     
  6915. Treatment of the hepatitis B virus and hepatitis C virus co-infection: Still a challenge for the hepatologist - (10/10/08)
     
  6916. High relapse rate seen at week 72 for patients treated with R1626 combination therapy - (10/09/08)
     
  6917. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: Randomized study of higher doses of peginterferon a-2a and ribavirin - (10/09/08)
     
  6918. Fatigue Associated with Degree of Fibrosis: fatigue level may predict severity of fibrosis - (09/26/08)
     
  6919. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C - (09/23/08)
     
  6920. Subclinical Glucose Abnormalities & Undiagnosed Diabetes Noted in HCV+ - (09/18/08)
     
  6921. Inaugural Conference of the BHIVA Hepatitis Working Group (BHWG) - Oct 8 2008 London - (09/18/08)
     
  6922. GENOVAC starts a project to develop blocking antibodies for the therapy of hepatitis C infections (AntiHepaC) - (09/18/08)
     
  6923. R7128, a prodrug of PSI-6130 - (09/18/08)
     
  6924. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders - (09/12/08)
     
  6925. Intranasal Transmission of Hepatitis C Virus: Virological and Clinical Evidence - (09/12/08)
     
  6926. Silibinin Is a Potent Antiviral Agent in Patients With Chronic HCV not Responding to Pegylated Interferon/Ribavirin Therapy - (09/08/08)
     
  6927. Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors (Vertex's telaprevir) in Treatment-Naive Subjects - (09/04/08)
     
  6928. HCV Coinfection Increases Risk for HIV-Related Kidney Disease - (08/29/08)
     
  6929. Insulin Resistance Among Patients With Chronic Hepatitis C: Etiology and Impact on Treatment - (08/27/08)
     
  6930. Vertex Pharmaceuticals to Start Phase 3 'REALIZE' Trial with Telaprevir in Treatment-Failure HCV Patients - (08/20/08)
     
  6931. IAS: HCV Increased Risk for MI and Stroke in HIV+, Study Reported at IAC - (08/13/08) -
     
  6932. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C - (08/05/08)
     
  6933. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients - (08/05/08)
     
  6934. Erythropoiesis Stimulating Agents (ESAs) - Epoetin alfa (marketed as Procrit, Epogen), Darbepoetin alfa (marketed as Aranesp) - (08/04/08)
     
  6935. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C - (08/04/08)
     
  6936. Liver Fibrosis (accelerated) during an Outbreak of Acute Hepatitis C Virus Infection in HIV-Infected Men: A Prospective Cohort Study - (08/04/08)
     
  6937. HCV Protease Vertex/Tibotec Telaprevir Update - (08/01/08)
     
  6938. Liver Fibrosis during an Outbreak of Acute Hepatitis C Virus Infection in HIV-Infected Men: A Prospective Cohort Study - (07/30/08)
     
  6939. Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort - (07/29/08)
     
  6940. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic: several new HCV drugs in development - (07/29/08)
     
  6941. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis (increased 13% risk): A systematic review - (07/02/08)
     
  6942. Role of week 4-rapid virological response (RVR) in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals - (06/30/08)
     
  6943. Two New HCV Drugs - NS5b and NS4b NNRTI Inhibitors- in Early Research by Genelabs/Novartis - (06/26/08)
     
  6944. Vertex CEO preparing for '09 early telaprevir hepatitis C drug launch - (06/20/08)
     
  6945. Vertex Reports 52% SVR 12 Rate for a 24-week Telaprevir-based Regimen in Genotype 1 Hepatitis C Patients Who Failed Prior Treatment - (06/10/08)
     
  6946. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus - (06/02/08)
     
  6947. Market uptake of new antiviral drugs (Peginterferon + Ribavirin) for the treatment of hepatitis C - (06/02/08)
     
  6948. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3 - (06/02/08)
     
  6949. Randomized comparison of 12 or 24 weeks of peginterferon a-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection - (06/02/08)
     
  6950. Santaris Pharma Begins Human Clinical Testing of the World's First Medicine Targeted at a Human microRNA - (05/29/08)
     
  6951. DDW: Alcohol Abuse & Dependence Has Big Impact on Cirrhosis in HIV/HCV Coinfection - (05/28/08)
     
  6952. DDW: Despite Mucosal CD4+ T Cell Depletion, the Prevalence of GI Symptoms Is Low During Acute and Early HIV-1 Infection - (05/28/08)
     
  6953. Pioglitazone in chronic hepatitis C with Insulin Resistance not responding to pegylated interferon-β and ribavirin - (05/27/08)
     
  6954. Liver and heart: A new link? - ALT Predicts Heart Disease - (05/27/08)
     
  6955. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-β2b and ribavirin in patients with HBV/HCV co-infection - (05/27/08)
     
  6956. Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients EDITORIAL - (05/27/08)
     
  6957. Cerebral immune activation in chronic hepatitis C infection: A magnetic resonance spectroscopy study - (05/27/08)
     
  6958. Schering starts hepatitis C trials, Vertex falls - (05/27/08)
     
  6959. Beach Boys Guitarist Cured of HCV with Peg/RBV - (05/27/08)
     
  6960. Discovery of TMC435350, HCV Protease Inhibitor - (05/27/08)
     
  6961. DDW: Effects of Eltrombopag On Thrombopietin Levels During Antiviral Therapy in HCV Patients with Cirrhosis - (05/21/08)
     
  6962. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment - (05/21/08)
     
  6963. DDW: The Role of Cholesterol On Sustained Virological Response (SVR) in the Treatment of Genotype-1 Infected Hepatitis C (cHC) Patients with Peginterferon Alfa-2a (PEG) and Ribavirin (RBV) - (05/21/08)
     
  6964. DDW: Telaprevir, HCV Protease Inhibitor: results from PROVE1 and PROVE2 Studies at DDW - (05/20/08)
     
  6965. DDW: A Dramatic Alteration in the Cholesterol Metabolism in An HCV Infected-Liver: the Implications for HCV Infection and Treatment - (05/20/08)
     
  6966. DDW: Utility of Serum Biomarker Profiles in Predicting the Treatment Outcome in Chronic Hepatitis C Virus Patients - (05/20/08)
     
  6967. DDW: Very Early Viral Response to Treatment of Hepatitis C Virus (HCV) with Pegylated Interferon and Ribavirin: the First 24 Hours - (05/20/08)
     
  6968. DDW: A Randomized Trial of Standard vs. Dose-Escalation Dosing of Ribavirin in Combination Therapy for Chronic Hepatitis C Patients with Genotype 1 and High Viral Load - (05/20/08)
     
  6969. DDW: Metabolic Factors and Inflammatory Changes Are Responsible for Increased Gamma-Glutamyltranspeptidase Level in Chronic Hepatitis C - (05/20/08)
     
  6970. DDW: Effect of Nicotine On Innate Antiviral Pathways and HCV Replication - (05/20/08)
     
  6971. DDW: African-American Peg/RBV Response May Be Genetically Impaired: Polymorphism in the Human MHC and the Early Viral Decline During Treatment of HCV - (05/20/08)
     
  6972. DDW: Explosion Disrupts Digestive Disease Week Meeting - (05/20/08)
     
  6973. DDW: Racial/Ethnic Minorities with Chronic Hepatitis C Virus Infection Have More Severe Fatigue Than White Patients with Chronic Hepatitis C Virus Infection - (05/20/08)
     
  6974. DDW: A Dramatic Alteration in the Cholesterol Metabolism in An HCV Infected-Liver: the Implications for HCV Infection and Treatment - (05/20/08)
     
  6975. DDW: African-American Peg/RBV Response May Be Genetically Impaired: Polymorphism in the Human MHC and the Early Viral Decline During Treatment of HCV - (05/20/08)
     
  6976. DDW: Variants in Interferon-Α Pathway Genes and Response to Treatment of Chronic Hepatitis C - (05/20/08)
     
  6977. DDW: Response to Therapy with Pegylated Interferon and Ribavirin in Hispanics with Hepatitis C Compared to Non-Hispanic Whites - (05/20/08)
     
  6978. New theory suggests how hepatitis C may cause rare immune disease, mixed cryoglobulinemia - (05/19/08)
     
  6979. New York State Proposes Hepatitis-Doctor Safety-Oversight Law - (05/19/08)
     
  6980. A dozen good ideas to battle hepatitis Editorial - (05/19/08)
     
  6981. Latinos and Chronic Hepatitis C: A Singular Population - (05/19/08)
     
  6982. Correlation of FIBROSpect II With Histologic and Morphometric Evaluation of Liver Fibrosis in Chronic Hepatitis C - (05/19/08)
     
  6983. Considerations Regarding the Present and Future Roles of Colonoscopy in Colorectal Cancer Prevention - (05/19/08)
     
  6984. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C - (05/19/08)
     
  6985. World Hepatitis Alliance calls for urgent action on epidemic - (05/19/08)
     
  6986. EASL: Virologic Responses to Peginterferon Alfa-2a/Ribavirin in Treatment-Naive Latino vs Non-Latino Whites Infected With HCV Genotype 1: The LATINO Study - (05/19/08)
     
  6987. EASL: Comparing Pegasys and PegIntron at EASL 2008 Milan - (05/16/08)
     
  6988. EASL: Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication... - (05/16/08)
     
  6989. EASL: Studies of the Potential for Resistance to Nitazoxanide or Tizoxanide in HCV Replicon-Containing Cell Lines - (05/16/08)
     
  6990. EASL: RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL OF NITAZOXANIDE IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 4 - (05/16/08)
     
  6991. EASL: EVALUATION OF A 4 WEEK LEAD-IN PHASE WITH NITAZOXANIDE PRIOR TO NITAZOXANIDE+PEGINTERFERON IN TREATING CHRONIC HEPATITIS C - (05/16/08)
     
  6992. EASL: Randomized Controlled Trial of Nitazoxanide-Peginterferon-Ribavirin, Nitazoxanide-Peginterferon and Peginterferon-Ribavirin in the Treatment of Patients with Chronic Hepatitis C Genotype 4 - (05/16/08)
     
  6993. EASL: Estimating the Likelihood of Sustained Virological Response in Chronic Hepatitis C (CHC) Therapy - (05/16/08)
     
  6994. EASL: R1626* (Prodrug of R1479) Demonstrates Potent Antiviral Activity Across HCV Genotypes 1-6 In Vitro - (05/16/08)
     
  6995. EASL: Regression of Cirrhosis Occurs & Prevents Death/Events - (05/16/08)
     
  6996. EASL: SVR Eradicates HCV - (05/16/08)
     
  6997. EASL: SVR Can Prevent HCC & Other Complications - (05/16/08)
     
  6998. EASL: SVR Reversed Cirrhosis in 21% - (05/16/08)
     
  6999. EASL: Locteron Viral Kinetics and Anti-Viral Activity during Treatment with a Controlled-Release Interferon Alfa-2b in Genotype 1 Chronic Hepatitis C Patients - (05/06/08)
     
  7000. EASL: POTENT ANTIVIRAL ACTIVITY OF THE HCV NUCLEOSIDE POLYMERASE INHIBITOR, R7128, IN COMBINATION WITH PEG-IFN a-2a AND RIBAVIRIN - (05/06/08)
     
  7001. EASL: High end-of-treatment response (84%) after 4 weeks of R1626, peginterferon alfa-2a (40KD) and ribavirin followed by a further 44 weeks of peginterferon alfa-2a and ribavirin - (05/06/08)
     
  7002. EASL: RVR & Ribavirin Dose Predict SVR - (05/05/08)
     
  7003. EASL: Biolex Therapeutics Researchers Present Locteron (controlled-release interferon alpha) Phase 2a Hepatitis C Trial Results at EASL Conference - (05/05/08)
     
  7004. EASL: EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2a OR -2b PLUS RIBAVIRIN IN THE ROUTINE DAILY TREATMENT OF CHRONIC HEPATITIS C PATIENTS IN GERMANY: THE PRACTICE STUDY - (05/05/08)
     
  7005. EASL: Several Key Pegasys Studies at EASL 2008 - (05/05/08)
     
  7006. EASL: Association of Pre-Treatment and On-Treatment Factors With Null Response in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin - (05/05/08)
     
  7007. EASL: Sustained Virologic Response After Peginterferon alfa-2b and Ribavirin Treatment Predicts 99% Long-term Clearance of HCV at 5-Year Follow-up - (05/05/08)
     
  7008. EASL: Platelet Count (and fibrosis stage) Predicts Sustained Viral Response (SVR) in the Re-Treatment of Previous Interferon/Ribavirin (I/R) Non-Responders (NR): Results from the EPIC3 Program - (05/05/08)
     
  7009. EASL: Treatment of Chronic Hepatitis C with Telaprevir (TVR) in Combination with Peginterferon Alfa-2a with or without Ribavirin: Interim Results of the PROVE2 Study - (05/02/08)
     
  7010. EASL: SILIBININ IS A POTENT ANTIVIRAL AGENT IN CHRONIC HEPATITIS C NOT RESPONDING TO ANTIVIRAL COMBINATION THERAPY - (05/02/08)
     
  7011. EASL: Results of a Safety, Tolerability and Pharmacokinetic Phase I Study of VCH-916, a Novel Polymerase Inhibitor for HCV, Following Single Ascending Doses in Healthy Volunteers - (05/02/08)
     
  7012. EASL: Preclinical Pharmacokinetic and ADME Characterization of VCH-916, a Novel Non-Nuclesoside HCV NS5B Polymerase Inhibitor - (05/02/08)
     
  7013. EASL: Genotypic analysis of HCV NS5B variants selected from patients treated with VCH-759, and Viral Load Declines - (05/02/08)
     
  7014. EASL: Important Progress Toward Control of Hepatitis B and C - (05/01/08)
     
  7015. EASL: Incidence Rates and Risk Factors Associated with Hepatocellular Carcinoma (HCC) in Patients with Advanced Liver Disease Due to Hepatitis C: Results of the HALTC Trial; Is the HALT-C Study Design Flawed??? - (05/01/08)
     
  7016. EASL: Interim Results from HCV SPRINT-1: RVR/EVR from Phase 2 Study of Boceprevir Plus Peginterferon alfa-2b/Ribavirin in Treatment-Naive Subjects with Genotype-1 CHC - (04/30/08)
     
  7017. EASL: DEVELOPMENT OF NOVEL HYPERGLYGOSYLATED TYPE 1 INTERFERONS: A STRATEGY TO IMPROVE PK PERFORMANCE WITHOUT LOSS OF BIOLOGICAL POTENCY - (04/30/08)
     
  7018. EASL: New HCV Drugs Panel Discussion at EASL 2008 - (04/30/08)
     
  7019. EASL: Boceprevir (NS3 Protease Inhibitor) Combination Therapy in Non Responders: Phase II Dose Finding Study - (04/30/08)
     
  7020. EASL: Sustained Viral Response Is Dependent On Baseline Characteristics In The Re-treatment Of Previous Interferon/Ribavirin Non-responders: Final Results From The EPIC3 Program - (04/30/08)
     
  7021. EASL: Romark Announces Presentation of New Data For Nitazoxanide in Chronic Hepatitis C at EASL 2008 - (04/29/08)
     
  7022. EASL: Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C - (04/28/08)
     
  7023. EASL: Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study - (04/28/08)
     
  7024. EASL: Potent Antiviral Activity of 2nd Generation HCV Nucleotide Inhibitors, IDX102 and IDX184, in HCV-infected Chimps - (04/28/08)
     
  7025. EASL: In Vitro Activity and Pharmacologic Properties of Two Novel Series of HCV Protease Inhibitors - (04/28/08)
     
  7026. EASL: HALT-C Study Design Flawed - (04/28/08)
     
  7027. EASL: Efficacy and safety of increasing doses of the cyclophilin inhibitor Debio 025 in combination with pegylated interferon alpha-2a in treatment naive chronic HCV patients - (04/28/08)
     
  7028. EASL: Peginterferon Alfa-2a (Pegasys) plus Ribavirin versus Peginterferon alfa-2b (Pegintron) Plus Ribavirin in Naive Patients with Chronic HHCV Infection: Results of a Prospective Randomized Trial - (04/28/08)
     
  7029. EASL: Final Results of the Phase IIIb IDEAL Study (Individualized Dosing Efficacy vs. Flat Dosing to Assess OptimaL PegInterferon Therapy) - (04/28/08)
     
  7030. EASL: ONCE-DAILY REGIMENS OF THE HCV NS3/4A-PROTEASE INHIBITOR TMC435350 ARE PREDICTED TO PROVIDE THERAPEUTIC EXPOSURE IN PLASMA AND LIVER - (04/25/08)
     
  7031. EASL: Safety of the HCV Protease Inhibitor TMC435350 in Healthy Volunteers and Safety and Activity in Chronic Hepatitis C Infected Individuals: A Phase I Study - (04/25/08)
     
  7032. EASL: HCV Protease Inhibitor Telaprevir, PROVE1 Study: final results of a phase 2 study with peginterferon plus ribaviron in treatment-naive patients with hepatitis C - (04/25/08)
     
  7033. EASL: A Study of Telaprevir (TVR) with Peginterferon Alfa-2a (P) and Ribavirin (R) in Subjects with Well-Documented Prior PR Null Response, Non-Response or Relapse: Preliminary Results - (04/25/08)
     
  7034. EASL: Study shows positive findings in treating patients with advanced hepatitis C - (04/25/08)
     
  7035. EASL: COLCHICINE VERSUS PEG-INTERFERON ALFA 2B LONG TERM THERAPY: RESULTS OF THE 4 YEAR COPILOT TRIAL - (04/25/08)
     
  7036. EASL: FACTORS PREDICTIVE OF RELAPSE IN GENOTYPE 2 AND 3 PTS TREATED FOR 12 WEEKS WITH PEGIFN ALFA 2B AND WEIGHT BASED RIBAVIRIN COMBINATION - (04/25/08)
     
  7037. EASL: RIBAVIRIN CONCENTRATION AT WEEK FOUR IS AN INDEPENDEND PREDICTOR FOR SUSTAINED VIROLOGICAL RESPONSE AFTER TREATMENT OF HEPATITIS C GENOTYPE 2/3 (NORDYNAMIC TRIAL) - (04/25/08)
     
  7038. EASL: Vertex Announces Positive Interim Results with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who Failed to Achieve SVR with Previous Pegylated Interferon & Ribavirin Treatment - (04/24/08)
     
  7039. Telaprevir-Based PROVE Studies Show Significantly Higher SVR Rates in Treatment-Naive Genotype 1 Hepatitis C Patients in Half the Time of Current Treatments - (04/24/08)
     
  7040. EASL: New Oral HCV Drugs at EASL - Report 4A
     
  7041. Gilead Reports Interim Data From Phase 2 LONESTAR Study
     
  7042. EASL: New HCV Drugs - EASL & Beyond
     
  7043. HCV Update Selected Highlights: key new HCV drugs, timelines & recent news developments
     
  7044. 9 & Soon 11 New HCV Drugs in Phase 3
     
  7045. New HCV Drugs: non nucleoside polymerase inhibitors
     
  7046. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results - (04/23/08)
     
  7047. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update - (04/23/08)
     
  7048. High Prevalence of Hepatitis C Virus Infection Among Immigrants From the Former Soviet Union in the New York City Metropolitan Area: Results of a Community-Based Screening Program - (04/22/08)
     
  7049. Vertex Telaprevir HCV Protease Inhibitor Could Be A Winner; 2.5 million untreated/undiagnosed - (04/21/08)
     
  7050. Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis - (04/21/08)
     
  7051. HCV & increased risk non-Hodgkin's Lymphoma: Hepatitis C and Non-Hodgkin Lymphoma Among 4784 Cases and 6269 Controls From the International Lymphoma Epidemiology Consortium - (04/21/08)
     
  7052. Hepatic steatosis in HIV/HCV co-infected patients: Correlates, efficacy and outcomes of anti-HCV therapy: A paired liver biopsy study - (04/21/08)
     
  7053. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 - (04/18/08)
     
  7054. Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients; And New HCV Drugs in development - (04/17/08)
     
  7055. ViroPharma, Wyeth stop development of hepatitus C drug HCV-796 - (04/17/08)
     
  7056. How does interferon inhibit HCV cell entry? Commentaries - (04/16/08)
     
  7057. Targeting siRNA to arrest fibrosis - (04/16/08)
     
  7058. Fluvastatin Inhibits Hepatitis C Replication in Humans- But Not Much - (04/16/08)
     
  7059. Hepatitis C : Identification Of A Protein That Inhibits The Virus - (04/15/08)
     
  7060. Building a liver disease policy in the European Union - (04/04/08)
     
  7061. ALT Predicts Mortality & General Health - (04/04/08)
     
  7062. Positive New Info on HCV Protease Inhibitor ITMN-191 - (04/02/08)
     
  7063. New HCV Protease Inhibitor Telaprevir: 80% of Treatment-Experienced Patients Achieve Early Viral Response - (04/02/08)
     
  7064. Hepatitis C cases in New York expected to soar in a decade; 1 in 24 New Yorkers have hepatitis C: 340,000 in NYS - (03/31/08)
     
  7065. FDA Approves Label Revisions Recommending New Robetol (ribavirin) Weight-Based Dosing Regimen: PEGINTRON PLUS WEIGHT-BASED REBETOL (ribavirin) RESULTED IN HIGHER SVR THAN FLAT DOSING; LOW RELAPSE RATES IN PATIENTS WITH CHRONIC HEPATITIS C. Schering Plough press release - (03/28/08)
     
  7066. New HCV Therapy Approach - Nature Publishes Study by Santaris Pharma Scientists and Collaborators: LNA-Mediated MicroRNA Silencing in Non-Human Primates - (03/28/08)
     
  7067. U.S. hepatitis C soars in those over 45 - (03/26/08)
     
  7068. HCV Death Rates 50% Underestimated - (03/26/08)
     
  7069. UNOS Liver Transplant Waiting List: Is it a Scandal?? - (03/24/08)
     
  7070. HCV Therapy: TT-033, novel RNA interference product Oncolys and Tacere partner in hepatitis C drug development - (03/17/08)
     
  7071. HIV Proteins Accelerate Liver Disease; HIV Increases HCV Replication in a TGF-ß1-Dependent Manner - (03/14/08)
     
  7072. CROI: Hepatitis C Viremia following Sustained Virological Response to Pegylated Interferon and Ribavarin in HIV+ Men Who Have Sex with Men-Re-infection or Late Relapse? (03/13/08)
     
  7073. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus - (03/12/08)
     
  7074. Worse Survival & HCV Recurrence in Coinfected After Transplantation - (03/12/08)
     
  7075. Glucose >100 mg/dl Reduces Interferon/RBV SVR - (03/10/08)
     
  7076. PBMC Not A Reservoir for HCV for Patients Who Clear HCV RNA, Study Reports - (03/07/08)
     
  7077. CROI: Liver histology and hepatic mitochondrial function in HIV-1-infected patients on antiretroviral therapy with chronic transaminase elevation - (03/07/08)
     
  7078. Changing trends in hepatitis C-related mortality in the United States, 1995-2004 - (03/06/08)
     
  7079. FDA Grants Priority Review to GSKs ITP Drug Promacta: the drug increases platelet counts; phase III studies for use in HCV are still ongoing - (03/03/08)
     
  7080. Team Identifies Human Antibodies that Prevent Hepatitis C Virus Infection in Mouse Model - (02/28/08)
     
  7081. HCV May Directly Cause Insulin resistance - (02/28/08)
     
  7082. CROI: On-treatment responses at weeks 4 and 12 can be used to predict sustained virologic response rates in HIV HCV co-infected patients treated with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) - (02/22/08)
     
  7083. CROI: Week 4 or 12 Response to PegIFN Predicts Sustained Response With HCV/HIV - Written by Mark Mascolini (02/28/08)
     
  7084. The way forward in HCV treatment - finding the right path: New HCV Drugs, resistance - (02/27/08)
     
  7085. Nothing new in anaemia drug EPO meta-analysis, say Amgen and J&J - (02/27/08)
     
  7086. Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C - (02/22/08)
     
  7087. Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer - (02/20/08)
     
  7088. Influence of Cannabis Use on Severity of Hepatitis C Disease - (01/29/08)
     
  7089. Treatment of Hepatitis C Reduces Incidence of Non-Hodgkin's Lymphoma - (01/23/08)
     
  7090. Vertex Pharmaceuticals to Begin Phase 3 Development of Telaprevir, Investigational Hepatitis C Protease Inhibitor - (01/23/08)
     
  7091. Roche responds to announcement of 'IDEAL' hepatitis C trial results - (01/14/08)
     
  7092. SCHERING-PLOUGH REPORTS TOP-LINE RESULTS OF THE IDEAL STUDY First Large Study Comparing Leading Hepatitis C Therapies Shows Similar Sustained Response Rates; Fewer Patients Relapsed Following PEGINTRON Combination Therapy - (01/14/08)
     
  7093. IDEAL Study COMMENTARY- Doug Dieterich MD A Healthy Dose of Curiosity Clinical trial results require careful interpretation - (01/14/08)
     
  7094. Stem cell therapy for chronic liver disease-choosing the right tools for the job Commentaries - (01/14/08)
     
  7095. InterMune Announces Continuing Progress on HCV Protease Inhibitor ITMN-191 (R7227) - (01/08/08)
     
  7096. Pfizer/Benitec to develop Hepatitis C drug - (01/08/08)
     
  7097. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3 - (01/07/08)
     
  7098. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C - (01/07/08)
     
  7099. Genetic Variation May Double Risk of Liver Cancer - (01/04/08)
     
  7100. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial - (01/03/08)
     
  7101. Genetic Variation May Double Risk of Liver Cancer - (01/02/08)
     
  7102. HCV Coinfection Problem in India, Despite HAART - (12/27/07)
     
  7103. HCV Coinfection Biggest Problem in India - (12/27/07)
     
  7104. GSK files eltrombopag for chronic ITP (thrombocytopenia) with the FDA - (12/21/07)
     
  7105. Valeant Pharmaceuticals Sells Hep-C Drug Infergen to Three Rivers Pharmaceuticals, LLC for $91 Million - (12/21/07)
     
  7106. GB Virus C Reduced HCV-Liver Disease in HIV/HCV Coinfected - (12/18/07)
     
  7107. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis - (12/12/07)
     
  7108. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART - (12/12/07)
     
  7109. Liver cancer set to soar in UK - (12/04/07)
     
  7110. AASLD: Multiple dose safety and pharmacokinetic study of bavituximab in patients with chronic hepatitis C virus (HCV) infection - (11/30/07)
     
  7111. Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C - (11/29/07)
     
  7112. Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura - (11/29/07)
     
  7113. Inovio Biomedical Partner Tripep Treats First Subject in Phase I/II Study of Novel Hepatitis C DNA Vaccine - (11/28/07)
     
  7114. Medivir: Initiation of a Phase IIa Clinical Trial with Investigational Hepatitis C Protease Inhibitor TMC435350 - (11/27/07)
     
  7115. Report: about 38 million Chinese carry hepatitis C virus - (11/27/07)
     
  7116. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response - (11/27/07)
     
  7117. Inhibitex Obtains License To HCV Polymerase Inhibitors - (11/27/07)
     
  7118. Roche and Maxygen terminates hepatitis drug project - (11/27/07)
     
  7119. Pfizer snaps up Coley Pharmaceutical for $164 million - (11/19/07)
     
  7120. New HCV Gene microRNA Therapy Research - (11/19/07)
     
  7121. AASLD: Higher Caffeine Consumption is associated with Milder Fibrosis in patients with Chronic Liver Diseases - (11/16/07)
     
  7122. AASLD: Hepatitis D Virus; Triply Infected HIV/HBV/HCV Progress More Quickly - (11/16/07)
     
  7123. PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy - (11/15/07)
     
  7124. Improved cognitive function as a consequence of hepatitis C virus treatment - (11/15/07)
     
  7125. AASLD: MAINTENANCE THERAPY FOUND INEFFECTIVE HALT-C STUDY - (11/14/07)
     
  7126. AASLD: Rapid Virological Response at Week 4 Is the Best Predictor of Treatment Outcome in Patients With Chronic Hepatitis C: A Multivariate Analysis - (11/14/07)
     
  7127. AASLD: Predictability of Response: Positive and Negative Predictive Values of Rapid and Early Virologic Responses to Peginterferon alfa-2b and Ribavirin in the Treatment of Chronic Hepatitis C - (11/14/07)
     
  7128. AASLD: Final Results of the Canadian POWeR (Pegetron Prospective Optimal Weight-Based Dosing Response) Program. Sustained Virologic Response (SVR) to Weight-Based Peginterferon alfa-2b + Ribavirin in a Large, Mixed, Community and Academic Observational Study - (11/14/07)
     
  7129. AASLD: Clinical Relevance of Rapid Virological Response (RVR) in Decompensated HCV-Related Cirrhosis Treated With Peginterferon and Ribavirin - (11/14/07)
     
  7130. AASLD: Assessment of Virological Response at Week 4 and at Week 12 Optimizes Prediction of Treatment Outcome in Patients With Chronic Hepatitis C Treated With Peginterferon alfa-2b Plus Ribavirin - (11/14/07)
     
  7131. AASLD: Patients co-infected with HCV and HIV who achieve an RVR (HCV RNA <50 IU/mL at week 4) or cEVR (HCV RNA <50 IU/mL at week 12) have similar rates of SVR to mono-infected patients treated with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) - (11/13/07)
     
  7132. AASLD: Differentiation of early virologic response (EVR) into RVR, complete EVR (cEVR) and partial EVR (pEVR) allows for a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) - (11/13/07)
     
  7133. AASLD: Response-guided therapy in a prospective trial of peginterferon alfa-2a (40KD)/ribavirin treatment in patients with HCV genotype 1 or 4 - (11/13/07)
     
  7134. AASLD: What is the impact of higher sensitivity assay on response-guided therapy in hepatitis C virus (HCV)? Comparative analysis between COBAS TaqMan™ and COBAS Amplicor™ tests from two large, randomized, international trials of PEGASYS plus COPEGUS - (11/13/07)
     
  7135. AASLD: Outcomes in HIV-HCV co-infected genotype 1 patients treated with peginterferon alfa-2a (40KD) plus ribavirin 1000 or 1200 mg/day: predictions based on generalized additive models - (11/13/07)
     
  7136. AASLD: Results of a Phase I Placebo-Controlled Trial in Healthy Volunteers to Examine the Safety, Tolerability and PK of the HCV Protease Inhibitor TMC435350 after Single and Repeated Dosing in healthy volunteers - (11/13/07)
     
  7137. AASLD: In vitro activity and preclinical pharmacokinetics of the HCV protease inhibitor TMC435350 - (11/13/07)
     
  7138. AASLD: Insulin Resistance Predicts HCV Progression in Genotype 1 - (11/13/07)
     
  7139. AASLD: Pioglitazone Improved Metabolics & Liver Injury in Non-diabetics with NASH - (11/13/07)
     
  7140. AASLD: Chronic hepatitis C virus infection and risk of hepatocellular carcinoma: a community-based prospective study on 19,565 residents in Taiwan - (11/13/07)
     
  7141. AASLD: What is the best non invasive method for early prediction of cirrhosis in chronic hepatitis C? Prospective comparison between Fibroscan and serum markers (Lok index, APRI, AST/ALT ratio, platelet count and Fibrotest) - (11/13/07)
     
  7142. AASLD: HCV patients with genotype 2 or 3 who do not achieve a rapid virologic response (RVR) with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) are not easy to treat: an analysis of non-RVR patients from the ACCELERATE study - (11/13/07)
     
  7143. AASLD: High rates of sustained virologic response (SVR) in patients >50 years infected with HCV genotype 1 with positive prognostic factors treated with peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) - (11/13/07)
     
  7144. AASLD: High chance of cure in HCV genotype 1 patients with a low viral load achieving an RVR treated for 24 weeks with pegylated interferon alfa-2a (PEGASYS) plus ribavirin (COPEGUS): prospective, randomized, controlled study comparing 24 & 48 weeks of treatment - (11/13/07)
     
  7145. AASLD: The DIRECT Trial (Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy): treatment of non-responders to previous pegylated interferon plus ribavirin: sustained virologic response data - (11/9/07)
     
  7146. Positive results for GlobeImmune's hepatitis C drug in Phase I - (11/09/07)
     
  7147. AASLD: Tibotec HCV Protease Inhibitor - (11/9/07)
     
  7148. AASLD: Antiviral activity of the non-nucleoside polymerase inhibitor, VCH-759, in chronic Hepatitis C patients:Results from a randomized, double-blind, placebo -controlled, ascending multiple dose study - (11/9/07)
     
  7149. AASLD: Vital Therapies Announces Presentation of ELAD "Artificial Liver" Data at American Association for the Study of Liver Diseases 2007 Annual Meeting - (11/9/07)
     
  7150. AASLD: Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected patients - (11/9/07)
     
  7151. AASLD: Pegylated interferon alfa-2a (40KD) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2b (12KD)/RBV: final efficacy and safety outcomes of the REPEAT study - (11/8/07)
     
  7152. AASLD: Rapid and early virological response rates are increased with 12 week 360 μg/wk peginterferon alfa-2a (40KD) and standard ribavirin in HCV genotype 1 treatment naive patients: efficacy and safety analysis of the induction phase of the CHARIOT study - (11/7/07)
     
  7153. AASLD: Evaluation of Viral Variants During a Phase 2 Study (PROVE2) of Telaprevir with Peg-interferon alfa-2a and Ribavirin in Treatment-naïve HCV Genotype 1-Infected Patients - (11/7/07)
     
  7154. AASLD: Phase 2a study to evaluate the safety and tolerability and anti-viral of 4 doses of a novel, controlled-release interferon-alfa 2b (Locteron) given every 2 weeks for 12 weeks in treatment-naive patients with chronic hepatitis C (genotype 1) - (11/7/07)
     
  7155. AASLD: Antiviral Activity, Pharmacokinetics, Safety, and Tolerability of R7128, a Novel Nucleoside HCV RNA Polymerase Inhibitor, Following Multiple, Ascending, Oral Doses in Patients with HCV Genotype 1 Infection Who have Failed Prior Interferon Therapy - (11/7/07)
     
  7156. GSK launches new Phase III trials of Revolade, new drug that boosts platelet counts in patients with HCV - (11/06/07)
     
  7157. GlaxoSmithKline initiates trials of Promacta/Revolade (eltrombopag) for Increasing Plateket Count in HCV+ Individuals - (11/06/07)
     
  7158. AASLD: Interim analysis: results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C: Prove 1 - (11/7/07)
     
  7159. AASLD: A high barrier to resistance may contribute to the robust antiviral effect demonstrated by R1626 in HCV genotype 1-infected treatment-naive patients - (11/7/07)
     
  7160. AASLD: Robust Synergistic Antiviral Effect of R1626 in Combination with Peginterferon alfa-2a (40KD), with or without Ribavirin, Interim Analysis Results of Phase 2a Study - (11/7/07)
     
  7161. AASLD: Rapid and early virological response rates are increased with 12 week 360 μg/wk peginterferon alfa-2a (40KD) and standard ribavirin in HCV genotype 1 treatment naive patients: efficacy and safety analysis of the induction phase of the CHARIOT study - (11/7/07)
     
  7162. AASLD: Danazol Increases Platelet Counts in Thrombocytopenia Patients with Chronic Hepatitis C or Cirrhosis - (11/7/07)
     
  7163. AASLD: Hepatitis C Associated Systemic Cryoglobulinemia: Successful Treatment With Plasma Exchange - (11/7/07)
     
  7164. AASLD: Long-Term, Low-Dose Treatment With Pegylated Interferon alfa-2b Leads to a Significant Reduction in Fibrosis and Inflammatory Scores in Chronic Hepatitis C Nonresponder Patients With Fibrosis or Cirrhosis - (11/7/07)
     
  7165. AASLD: Gilead hepatitis C drug may have heart issue-study - (11/5/07)
     
  7166. AASLD: Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C - (11/5/07)
     
  7167. AASLD: PROVE2: phase II study of telapravir (VX-950) in combination with peginterferon alfa-2 with or without ribavirin in subjects with chronic hepatitis C, an interim analysis - (11/5/07)
     
  7168. EACS: Insulin Resistance Imperils Response to Interferon in People With HCV/HIV - (11/04/06)
     
  7169. AASLD: Roche's Oral Polymerase Inhibitor Shows Robust Antiviral Efficacy in Treatment of Chronic Hepatitis C - (11/2/07)
     
  7170. AASLD: Pegasys High Dose Induction for PegIntron Nonresponders: REPEAT Study - (11/2/07)
     
  7171. AASLD: GILEAD ANNOUNCES 48-WEEK DATA FROM TWO PIVOTAL PHASE III STUDIES EVALUATING VIREAD FOR THE TREATMENT OF CHRONIC HEPATITIS B - (11/2/07)
     
  7172. AASLD: 91% OF BARACLUDE (ENTECAVIR) TREATED PATIENTS IN A FOUR-YEAR COHORT DEMONSTRATED VIROLOGIC SUPPRESSION TO UNDETECTABLE LEVELS - (11/2/07)
     
  7173. AASLD: Roche Polymerase Inhibitor Shows Promise In Phase II - (11/2/07)
     
  7174. Potent Abbott Hepatitis C Virus Protease Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies - (11/02/07)
     
  7175. AASLD: First Studies Demonstrating Greater than 60% Sustained Viral Response Rates with Half the Standard Treatment Duration in Genotype 1 Chronic Hepatitis C Patients (Vertex press release) - (11/2/07)
     
  7176. AASLD: Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C - (11/2/07)
     
  7177. AASLD: Vertex feeling growing pains Firm scrambles for workers, space as drug shows promise - (11/2/07)
     
  7178. AASLD: Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C - (11/2/07)
     
  7179. AASLD: 2 New HCV Drugs at AASLD - (11/2/07)
     
  7180. New Hepatitis C Antiviral CB5300 Identified by Canopus BioPharma Researchers to Enter Clinical Trial Assessment - (11/01/07)
     
  7181. Human Genome Sciences Completes Enrollment Ahead of Schedule in Second Phase 3 Albuferon(R) Trial - (11/01/07)
     
  7182. New Drug CF-102 for Liver Cancer Enters Phase 1 Clinical Trials - (10/31/07)
     
  7183. Bayer and Onyx get liver cancer approval for Nexavar in EU - (10/31/07)
     
  7184. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody - (10/30/07)
     
  7185. R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection - (10/24/07)
     
  7186. INITIAL RESULTS OF PHASE II STUDY WITH HCV PROTEASE INHIBITOR BOCEPREVIR IN TREATMENT-NAIVE HEPATITIS C PATIENTS SHOW A HIGH RATE OF EARLY VIROLOGIC RESPONSE - (10/19/07)
     
  7187. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus - (10/17/07)
     
  7188. Marianne Faithfull Has Hepatitis C - (10/16/07)
     
  7189. Glucose Abnormalities Are an Independent Risk Factor for Nonresponse to Antiviral Treatment in Chronic Hepatitis C - (10/16/07)
     
  7190. Low-Dose Interferon Lozenges HCV & HIV/oral warts Study - (10/10/07)
     
  7191. Discovery of a novel class of Hepatitis C Polymerase Inhibitors - (10/10/07)
     
  7192. The Antiviral Efficacy of the Nonnucleoside HCV Polymerase Inhibitor A-848837 in the HCV Infected Chimpanzee - (10/05/07)
     
  7193. Ultrasound-Based Transient Elastography for the Detection of Hepatic Fibrosis: Systematic Review and Meta-analysis - (10/05/07)
     
  7194. Stiffness and Impedance: The New Liver Biomarkers Editorial - (10/05/07)
     
  7195. Noninvasive Diagnosis of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Splenic Doppler Impedance Index - (10/05/07)
     
  7196. Assessment of Hepatic Fibrosis With Magnetic Resonance Elastography - (10/05/07)
     
  7197. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C - (10/03/07)
     
  7198. "True" weight-based dosing versus "flat' dosing of ribavirin: Will the WIN-R please come forward? Editorial - (10/03/07)
     
  7199. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial - (10/03/07)
     
  7200. Impact of weight-based ribavirin with peginterferon alfa-2b in african americans with hepatitis C virus genotype - (10/03/07)
     
  7201. Intermune HCV Protease Trials Timeline - (10/01/07)
     
  7202. VX950+Peg Data Without RBV at AASLD Nov - (10/01/07)
     
  7203. Pharmasset HCV & HBV Drugs - (09/27/07)
     
  7204. Maxygen Announces Hold on MAXY-alpha Development Program - (09/24/07)
     
  7205. Preclinical Characterization of TMC435350, a novel macrocyclic inhibitor of the HCV NS3/4A serine protease - (09/24/07)
     
  7206. European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy - (09/24/07)
     
  7207. Helicase Target for HCV Therapy - (09/18/07)
     
  7208. Idera Pharmaceuticals Initiates Phase 1 Trial of IMO-2125 in Hepatitis C - (09/18/07)
     
  7209. XTL Biopharmaceuticals Presents a New Class of Highly Potent Small Molecule Inhibitors of Hepatitis C Affecting the NS5A Target at an International Scientific Conference - (09/18/07)
     
  7210. New Treatment for Liver Cancer 'Burns Tumors Off' N&N makes cancer breakthrough - (09/13/07)
     
  7211. The Use of Transient Elastometry for Assessing Liver Fibrosis in Patients with HIV and Hepatitis C Virus Coinfection: only detects cirrhosis - (09/13/07)
     
  7212. New therapies for hepatitis C: VX-950 (telaprevir) - (09/11/07)
     
  7213. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C - (09/11/07)
     
  7214. Possible Hepatitis C vaccine - (09/05/07)
     
  7215. Human Genome Sciences gets 40 mln usd Albuferon milestone payment from Novartis - (08/28/07)
     
  7216. HCV Care by Liver Specialists or Community-Based Practices: Pro & Con - (08/27/07)
     
  7217. Hep C vaccine shows promise - (08/21/07)
     
  7218. Intercell's therapeutic Hepatitis C vaccine meets primary endpoints in Phase II interim analysis - (08/21/07)
     
  7219. Incidence and Predictors of Hepatocellular Carcinoma in Patients With Cirrhosis - (08/20/07)
     
  7220. Risk factors (AZT) for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin - (08/17/07)
     
  7221. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients - (08/17/07)
     
  7222. Twelve-Week Treatment of Acute Hepatitis C Virus with Pegylated Interferon-a-2b in Injection Drug Users is Effective - (08/17/07)
     
  7223. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients - (08/16/07)
     
  7224. Coffee drinking and hepatocellular carcinoma risk: A meta-analysis - (08/16/07)
     
  7225. Inovio Biomedical Partner Tripep Receives Approval to Initiate Phase I/II Study of Novel Vaccine for Hepatitis C Virus - (08/16/07)
     
  7226. HCV/HIV co-infection, HCV viral load and mode of delivery: risk factors for mother-to-child transmission of hepatitis C virus? - (08/16/07)
     
  7227. Nitazoxanide+Pegasys/RBV Study for HCV - (08/15/07)
     
  7228. IAS: Hepatitis C Viral Kinetics During Treatment With Weekly Versus Twice Weekly Peg IFN-alpha-2a in HIV/HCV Co-infected Patients - (08/10/06)
     
  7229. Peregrine's Bavituximab HCV Phase Ib Study Results Selected for Oral Presentation at Upcoming AASLD Annual Meeting - (08/09/07)
     
  7230. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy: Virahep-C Study - (08/06/07)
     
  7231. Coffee Consumption and Risk of Liver Cancer: A Meta-Analysis. Coffee, 2 Cups Daily, May Reduce Risk for Liver Disease, ALT Elevations - (08/06/07)
     
  7232. Hepatitis C strongly linked to type 2 diabetes - (08/02/07)
     
  7233. InterMune Submits CTA Amendment for HCV Protease Inhibitor ITMN-191 and Provides Update on Clinical Development Program - (08/02/07)
     
  7234. VX-950 HCV Protease inhibitor at AASLD - (08/02/07)
     
  7235. Development Discontinued for ANA975, an Early Stage Compound for Treatment of Hepatitis C Virus Infection - (08/02/07)
     
  7236. Hepatitis C helicase unwinds DNA in a spring-loaded, 3-step process - (08/02/07)
     
  7237. Roche/Pharmasset HCV Polymerase Drug New Patient Study Results Expected in September - (08/02/07)
     
  7238. OraSure Technologies Announces Pre-Clinical Study Results for Prototype Rapid HCV Antibody Test at AACC Annual Meeting - (07/20/07)
     
  7239. Hepatitis C Viremia Increases the Association With Type 2 Diabetes Mellitus in a Hepatitis B and C Endemic Area: An Epidemiological Link With Virological Implication - (07/17/07)
     
  7240. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha - (07/16/07)
     
  7241. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis - (07/16/07)
     
  7242. Novartis, Idenix Suspend Tests on Hepatitis C Drug NM283 - (07/16/07)
     
  7243. Atorvastatin (Lipitor) lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase - (07/16/07)
     
  7244. Opportunities for treating chronic hepatitis B and C virus infection using RNA interference - (07/16/07)
     
  7245. Predictors of response to Pegasys/RBV of U.S. veterans to treatment for the hepatitis C virus - (07/13/07)
     
  7246. Shortened Therapy for Hepatitis C Virus Genotype 2 or 3 - Is Less More? EDITORIAL - (07/12/07)
     
  7247. Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3 (NEJM) - (07/12/07)
     
  7248. Do high lipids help clearance of hepatitis C? - (07/12/07)
     
  7249. Pharmasset and Roche Initiate Studies to Advance R7128 Polymerase Inhibitor for HCV - (07/12/07)
     
  7250. HCV/HIV Coinfection in Asia - (07/05/07)
     
  7251. HCV Replication Found in CNS in HIV+ - (07/03/07)
     
  7252. Schering Plough Ends Celgosivir Deal - (06/28/07)
     
  7253. Pakistan to launch survey on hepatitis B & C Prevalence - (06/27/07)
     
  7254. New RNAi HCV Drug - (06/22/07)
     
  7255. Inhibition of T-Cell Inflammatory Cytokines, Hepatocyte NF-κB Signaling, and HCV Infection by Standardized Silymarin (Milk thistle) - (06/20/07)
     
  7256. 67% Steatosis in HCV/HIV Coinfected: : Liver inflammation, HCV genotype 3, and BMI are associated with steatosis, a common finding in HCV-HIV-coinfected patients. - (06/20/07)
     
  7257. Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial: no ribavirin-Valopicitabine drug interaction - (06/13/07)
     
  7258. ViroPharma Announces Completion of Enrollment in 500mg BID Arms of HCV-796 Phase 2 Study - (06/13/07)
     
  7259. Roche's Hepatitis C drug Pegasys patent challenged - (06/13/07)
     
  7260. Phase III data looks promising for GSK's eltrombopag - (06/11/07)
     
  7261. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon - (06/08/07)
     
  7262. XTL-2125 Hep C Drug Fails - (06/07/07)
     
  7263. Medical Resource Utilization in Chronic Liver Disease Patients with Thrombocytopenia - (06/06/07)
     
  7264. DDW: Eltrombopag Maintains Platelet Counts During Myelosuppressive Pegylated Interferon Alpha Treatment of Chronic Hepatitis C Virus Infection - (06/05/07)
     
  7265. New HCV Therapy PYN17 - (06/04/07)
     
  7266. Cytheris to start two phase I/IIa clinical trials of CYT107, its new recombinant Interleukin-7, in Hepatitis C and oncology - (06/04/07)
     
  7267. 5% in Pakistan have HCV, 7-8 Million People - (06/04/07)
     
  7268. Free IFN/RBV in Pakistan - (06/04/07)
     
  7269. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients - (06/04/07)
     
  7270. HCV Increased NHL Risk & Appears to Drive Immunological Stimulus for Progression to Hematological Malignancy; Interferon Can Regress NHL - (06/04/07)
     
  7271. DDW: 12 weeks VX-950 Therapy - (06/04/07)
     
  7272. HCV Increased NHL Risk & Appears to Drive Immunological Stimulus for Progression to Hematological Malignancy; Interferon Can Regress NHL - (05/31/07)
     
  7273. Body composition, muscle function, and energy expenditure in patients with liver cirrhosis: a comprehensive study - (05/31/07)
     
  7274. Acute HCV in MSM in London - (05/31/07)
     
  7275. UK and Wales Fail on HCV Policy - (05/31/07)
     
  7276. Controlled Release Interferon - (05/31/07)
     
  7277. Reversibility of hepatic fibrosis and cirrhosis-is it all hype? Editorial - (05/31/07)
     
  7278. Hepatitis D virus infection - Not a vanishing disease in Europe! - (05/31/07)
     
  7279. DDW: NY Montefiore Hospital Coinfection Program Reports Success With a Multi-Disciplinary Program: Model of Care - (05/31/07)
     
  7280. CROI: HOMA-IR Is a Strong Predictor of Rapid Virologic Response in HIV/HCV-co-infected Patients Treated with Pegylated Interferon-alpha 2a and Ribavirin (05/29/07)
     
  7281. CROI: Glucose Intolerance Associated with Advancing Liver Disease (Fibrosis) (05/29/07)
     
  7282. CROI: Non-Invasive Liver Tests Studies Disappoint at CROI in Coinfection Studies (05/29/07)
     
  7283. DDW: Patterns of fat distribution and its relationship to liver histology in nonalcoholic fatty liver disease (NAFLD): does fatty liver cause lipodystrophy? - (05/25/07)
     
  7284. DDW: Diabetes Therapy Improves Peg/RBV Response - (05/25/07)
     
  7285. DDW: Early Pegasys/RBV Therapy is Cost Effective, Improves Survival & Reduces Risk for Cirrhosis - (05/25/07)
     
  7286. DDW: Efficacy and Safety of Peginterferon Alfa-2a/Ribavirin in Methadone Maintenance Patients: Randomized Comparison of Direct Observed Therapy and Self-Administration - (05/25/07)
     
  7287. DDW: Patterns of fat distribution and its relationship to liver histology in nonalcoholic fatty liver disease (NAFLD) - (05/24/07)
     
  7288. DDW: Cost-effectiveness, Survival, and Prevention of Cirrhosis with Early Treatment of Chronic Hepatitis C with Peginterferon Alfa-2a (40KD) plus Ribavirin before Progression to Advanced Liver Disease - (05/24/07)
     
  7289. DDW: HCV Can Be Cured - (05/24/07)
     
  7290. DDW: Treatment Duration and Histological Response to Peginterferon Alfa-2a/Ribavirin: 48 weeks improves liver disease in Non-SVRs better than 24 weeks - (05/24/07)
     
  7291. DDW: Safety and Tolerability of Peginterferon Alfa-2a Plus Ribavirin in HCV Patients Nontolerant or Nonresponsive to Peginterferon Alfa-2b Plus Ribavirin - (05/23/07)
     
  7292. DDW: Celgosivir with Peginterferon and Ribavirin in Chronic Hepatitis C - (05/23/07)
     
  7293. DDW: Pharmacodynamic Analysis of the Antiviral Activity of the Non-Nucleoside Polymerase Inhibitor, HCV-796, in Combination With Pegylated Interferon Alfa-2b in Treatment-Naive Patients With Chronic HCV - (05/23/07)
     
  7294. EASL: Safety, Pharmacokinetics and Antiviral effects of Boehringer Ingelheim BILB 1941, a Novel HCV RNA Polymerase, After 5 days Oral treatment in Patients with Chronic Hepatitis C - (05/21/07)
     
  7295. EASL: Phase II Proof of Concept Study of celgosivir in combination woth peginterferon alfa-2a and ribavirin in chronic hepatitis C genotype-1 non responder patients - (05/21/07)
     
  7296. DDW: HCV-Infected Liver Donors for Liver Transplantation Are Recommended Instead of Uninfected HCV-Donated Livers, from a new study presented at DDW 2007 - (05/22/07)
     
  7297. DDW: HCV-796, Polymerase Inhibitor - (05/22/07)
     
  7298. DDW: Eltrombopag Maintains Platelet Counts During Myelosuppressive Pegylated Interferon Alpha Treatment of Chronic Hepatitis C Virus Infection - (05/22/07)
     
  7299. DDW: Increased SVR rate with 48 weeks' treatment and higher RBV dose in HCV genotype 2/3 patients without a rapid virologic response (RVR) treated with peginterferon alfa-2a (40KD) (PEGASYS) plus RBV (COPEGUS) - (05/22/07)
     
  7300. DDW: Peginterferon Alfa-2a (40KD) Plus Ribavirin for 16 or 24 Wks in Pts With HCV Genotype 2/3 Infection and Advanced Fibrosis/Cirrhosis - (05/22/07)
     
  7301. DDW: Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered ''Cured''; Mitch Shiffman says 'you can cure HCV', Eugene Schiff says 'get treated'. - (05/22/07)
     
  7302. DDW: 16 vs 24 wks Pegasys/RBV in Cirrhotics & Non-Cirrhotics Genotype 2/3 from ACCELERATE Study - (05/22/07)
     
  7303. DDW: Increased SVR Rate with 48 Wks' Treatment and Higher RBV Dose in HCV Genotype 2/3 Pts Without a Rapid Virologic Response (RVR) Treated with Peginterferon Alfa-2a (40KD) (PEGASYS) Plus RBV (COPEGUS) - (05/21/07)
     
  7304. DDW: Statin Improved PegIFN/RBV SVR Rate, Improve ALTs in HCV+ - (05/21/07)
     
  7305. DDW: InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting - (05/21/07)
     
  7306. Hepatitis D virus infection - Not a vanishing disease in Europe! - (05/03/07)
     
  7307. HCV Reinfection: is there protective effect following natural HCV clearance? - (05/03/07)
     
  7308. EASL: Pegasys vs Peg/ADV for Hepatitis D Virus: Pegasys most effective - (05/03/07)
     
  7309. EASL: HCV Antiviral Activity and Resistance Analysis in Chronically Infected Chimpanzees Treated with Merck NS3/4A Protease and NS5B Polymerase Inhibitors - (05/02/07)
     
  7310. EASL: Low-Dose PegIFN Maintenance Therapy Successful - (05/02/07)
     
  7311. European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) and REBETOL(R) Combination Therapy for Hepatitis C in Patients Coinfected With HIV - (05/01/07)
     
  7312. More gay men getting hepatitis C; Increased HCV Infection Among HIV+ Gay Men - (05/01/07)
     
  7313. EASL: Albuferon Once Every 2 or 4 Weeks Interferon Looks Good in Phase 2 Study - (05/01/07)
     
  7314. EASL: Inherited Variants of Genes Involved in Insulin Signaling and Lipogenesis Influence The Risk of Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease - (05/01/07)
     
  7315. EASL: Insulin Resistance in HBV, HCV & Non-Virus Related Chronic Hepatitis (liver enzymes) - (05/01/07)
     
  7316. EASL: Insulin Resistance Inflames The Liver in HCV - (05/01/07)
     
  7317. EASL: Insulin Resistance in 424 HCV+ Patients: association with HCV replication and advanced fibrosis - (05/01/07)
     
  7318. EASL: Statins May Improve Liver Fibrosis - (05/01/07)
     
  7319. EASL: PegIntron + 2 HCV Nucleosides Show Synergy - (04/27/07)
     
  7320. New Genetic Diagnostic Tests-Financial Impact - (04/27/07)
     
  7321. EASL: R1479 (R1626), a Novel Hepatitis C Polymerase Inhibitor: Lack of Pre-Existing Resistance Mutations Supports the Observed In Vivo High Barrier to Resistance - (04/27/07)
     
  7322. EASL: ITMN-191 CONCENTRATIONS ACHIEVED IN THE LIVER OF ANIMALS PROMOTE HCV REPLICON CLEARANCE IN VITRO AND THIS EFFECT IS ENHANCED BY PEG-IFN a-2a (Pegasys) - (04/27/07)
     
  7323. EASL: HCV Protease Inhibitor ITMN-191 Resistance - (04/27/07)
     
  7324. HCV Protease Inhibitor ITMN-191 + HCV Polymerase Inhibitor R1626 Synergy - (04/27/07)
     
  7325. EASL: Lipid steatosis, metabolic variables and body composition in the setting of HIV/HCV coinfection; findings from a large randomised trial (APRICOT) - (04/26/07)
     
  7326. EASL: 400,000 IU/mL Is New Cut-Off for Low vs High Viral Load in HCV - (04/26/07)
     
  7327. EASL: Favorable Cross-Resistance Profile of Two Novel Hepatitis C Virus Inhibitors, SCH 503034 (Boceprevir) and HCV-796, and Enhanced Anti-Replicon Activity Mediated by the Combined Use of Both Compounds - (04/26/07)
     
  7328. EASL: SCH503034 & NM283 Not Cross-Resistant - (04/26/07)
     
  7329. EASL: An open label, comparative, multi-center study of peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin in the treatment of patients with chronic hepatitis C/hepatitis B dual infection versus with mono-infected chronic hepatitis C: An interim report - (04/25/07)
     
  7330. EASL: Virological response at 4 and 12 weeks predict high rates of sustained virological response in genotype 1 patients treated with peginterferon alfa-2a (40KD) plus ribavirin - (04/25/07)
     
  7331. EASL: 14 Weeks vs 24 Weeks Peg/RBV for Genotypes 2/3 - (04/20/07)
     
  7332. EASL: In vitro Resistance Selection to the HCV Nucleoside Polymerase Inhibitor R1479 (R1626) and to the Protease Inhibitor VX-950 - (04/23/07)
     
  7333. EASL: SVR Durable (99%) After 5 Years of Followup - (04/23/07)
     
  7334. EASL: 48 Weeks & High Ribavirin Dose May Improve SVR Rates for Genotype 2/3, French study by Bernard Willems - (04/23/07)
     
  7335. EASL: In Patients Who Clear HCV RNA At Week 12 (between week 8 and 12): SVR is Higher After 72 Weeks Than After 48 Weeks Treatment: Results of a Randomized Controlled Trial - (04/23/07)
     
  7336. EASL: New HCV Drug Target NS4A Antagonists - (04/23/07)
     
  7337. EASL: 3 YEARS OF ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY MINIMIZES THE RISK OF GENOTYPIC RESISTANCE TO ADV IN LAM RESISTANT PATIENTS - (04/20/07)
     
  7338. EASL: Abbott HCV Polymerase Inhibitor - (04/18/07)
     
  7339. EASL: CANNABIS USE AS AN INDEPENDENT PREDICTOR OF SEVERE STEATOSIS DURING CHRONIC HEPATITIS C - (04/19/07)
     
  7340. EASL:3-Drug HCV therapy for 12 weeks: VX950+pegIFN+RBV, interim results from phase II PROVE 1 Trial - (04/17/07)
     
  7341. EASL: HCV-796 Polymerase Inhibitor Shows 1.5 log Viral Load Reduction - (04/17/07)
     
  7342. EASL: GSK625433: A Novel and Highly potent Inhibitor of the HCV NS5B Polymerase - (04/17/07)
     
  7343. EASL: Merck HCV Protease & Polymerase Inhibitor Viral Load Reduction & Resistance in Chimps - (04/17/07)
     
  7344. EASL: GSK625433: A Novel and Highly Potent Inhibitor of the HCV NS5B Polymerase - (04/17/07)
     
  7345. EASL: Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C - (04/17/07)
     
  7346. EASL: New HCV Drug Target NS4A Antagonists - (04/17/07)
     
  7347. EASL: NM283 in Treatment-Naives Looks Better - (04/13/07)
     
  7348. EASL: NM283, HCV Polymerase Inhibitor in Non-Responders - (04/13/07)
     
  7349. Omega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines - (04/12/07)
     
  7350. EASL: Resistance to New HCV Antivirals - (04/12/07)
     
  7351. EASL: Vertex Pharmaceuticals Announces New Data for Investigational HCV Protease Inhibitor Telaprevir to be Presented at 42nd Annual Meeting of the European Association for the Study of the Liver (EASL) - (04/12/07)
     
  7352. EASL: New Clinical Study Results Indicate Higher Early Virologic Response with Celgosivir Combination Therapy in HCV Non-Responders - (04/12/07)
     
  7353. New Once Weekly Oral Interferon Belerofon in Phase 1 - (04/09/07)
     
  7354. Viral Hepatitis (HCV, HBV) in HIV Infection REVIEW by Margaret Koziel, Marion Peters - (04/09/07)
     
  7355. 33% HCV/HIV Coinfected in Milan, Italy - (04/09/07)
     
  7356. Viral Hepatitis (HCV, HBV) in HIV Infection REVIEW by Margaret Koziel, Marion Peters - (04/05/07)
     
  7357. Liver Iron Levels NOT Directly Linked to Fibrosis - (04/03/07)
     
  7358. UK Parliament adopts written declaration on Hepatitis C - (03/29/07)
     
  7359. Treatment of Chronic Hepatitis C Virus in African Americans With Genotypes 2 and 3 - (03/27/07)
     
  7360. Improved Outcomes After SVR, Interferon Therapy - (03/27/07)
     
  7361. CROI: In NYC: Liver Fibrosis During Acute HCV Infection of HIV-infected Men (03/21/07)
     
  7362. Hepatitis C virus infection is associated with insulin resistance among older adults with or at risk of HIV infection - (03/21/07)
     
  7363. U.S. sees sharp decline in hepatitis cases: CDC - (03/21/07)
     
  7364. Hepatitis C in Prison & After Release: 40% infected - (03/21/07)
     
  7365. Roche Driving PROGRESS in Treatment of Difficult-to-Cure Hepatitis C Patients With New PEGASYS (R) (peginterferon alfa-2a (40KD)) and COPEGUS(R) (ribavirin) Trial - (03/16/07)
     
  7366. Procrit/Epogen FDA Safety Warning - (03/12/07)
     
  7367. PEGASYS(R) Gets European Approval for a Shorter Treatment Duration for Some Genotype 1 and 4 Hepatitis C Patients who Show a Rapid Response to Therapy - (03/06/07)
     
  7368. Human Genome Sciences Initiates Phase 3 Clinical Trial of Albuferon(R) With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C Genotypes 2 and 3 - (02/29/07)
     
  7369. New HCV Drug R7128 Polymerase Inhibitor - (02/29/07)
     
  7370. SVR Improved Quality of Life & Sexual Function in Patients with Advanced Fibrosis in HALT-C Study - (02/20/07)
     
  7371. Hepatic Steatosis in Hepatitis C: Comparison of Diabetic and Nondiabetic Patients in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial (HALT-C Study) - (02/16/07)
     
  7372. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients - (02/15/07)
     
  7373. Non-invasive markers of liver fibrosis: How to use them in clinical practice? - (02/15/07)
     
  7374. Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C (HALT-C Study) - (02/12/07)
     
  7375. Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment - (01/26/07)
     
  7376. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients - (02/12/07)
     
  7377. Short-duration therapy for hepatitis C & RVR: suitable for all? - (02/12/07)
     
  7378. Liver Stiffness Measurement Versus Clinicians' Prediction or Both for the Assessment of Liver Fibrosis in Patients with Chronic Hepatitis C - (02/09/07)
     
  7379. Are Noninvasive Liver Fibrosis Tests Ready for Use? There are lots of questions. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C - (02/09/07)
     
  7380. Medivir: Clinical Phase I Trial with Hepatitis C Virus Protease Inhibitor Initiated - (02/09/07)
     
  7381. Gilead and Achillion Announce Positive Antiviral Activity of NS4A Antagonist in HCV, But Discontinue GS 9132 (ACH-806) Development - (02/09/07)
     
  7382. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients - (02/01/07)
     
  7383. Combination Therapy With Telaprevir and Pegylated Interferon Suppresses Both Wild-Type and Resistant Hepatitis C Virus - (02/01/07)
     
  7384. Time-Released Interferon Drug: OctoPlus initiates Locteron Phase II clinical study in chronic hepatitis C - (01/30/07)
     
  7385. Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment - (01/26/07)
     
  7386. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study - (01/26/07)
     
  7387. New Hepatitis C Culture System for Study of Virus - (01/24/07)
     
  7388. Coley Suspends Development of HCV Toll-Receptor Drug - (01/23/07)
     
  7389. Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia - (01/22/07)
     
  7390. Diabetes, HCV and Liver Transplanation - (01/22/07)
     
  7391. Arrow Therapeutics Selects a 2nd Hepatitis C Clinical Candidate - (01/22/07)
     
  7392. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis - (01/22/07)
     
  7393. Noninvasive Markers of Liver Fibrosis - (01/19/07)
     
  7394. Negative-Strand Hepatitis C Virus (HCV) RNA in Peripheral Blood Mononuclear Cells from Anti-HCV-Positive/HIV-Infected Women - (01/11/07)
     
  7395. Detection of Hepatitis C Virus (HCV) in Serum and Peripheral-Blood Mononuclear Cells from HCV-Monoinfected and HIV/HCV- Coinfected Persons - (01/11/07)
     
  7396. Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C - (01/09/07)
     
  7397. Schering and Orasure in pact to develop oral hepatitis C test - (01/09/07)
     
  7398. Successful IFN Therapy in IVDUs on Naltraxone - (01/09/07)
     
  7399. Enhancing hepatitis C treatment uptake and outcomes for injection drug users EDITORIAL - (01/09/07)
     
  7400. Diet (Food groups) and risk of hepatocellular carcinoma: A multicenter case-control study in Italy - (01/09/07)
     
  7401. Phynova Obtains FDA Approval of its IND to Enter Into a Clinical Trial of PYN17 for the Treatment of Chronic Hepatitis C - (01/09/07)
     
  7402. VX-950 Phase 2b PROVE 1 Study Interim Safety & Antiviral Activity at Week 12 - (12/20/06)
     
  7403. New HCV Drug Celgosivir/MX-3253, oral alpha-glucosidase I inhibitor - (12/20/06)
     
  7404. Vertex Pharmaceuticals Announces Results of First Interim Safety and Antiviral Analysis of the PROVE 1 Clinical Trial of Investigational HCV Protease Inhibitor Telaprevir (VX-950) - (12/20/06)
     
  7405. Human Genome Sciences Initiates Phase 3 Clinical Trial of Albuferon(R) in Combination With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C - (12/20/06)
     
  7406. Pevion Biotech Announces Its Hepatitis C Therapeutic Vaccine Enters Clinical Phase I - (12/20/06)
     
  7407. InterMune Initiates Phase 1a Clinical Trial Evaluating Hepatitis C Protease Inhibitor ITMN-191 in Collaboration with Roche - (12/20/06)
     
  7408. InterMune Initiates Phase 1a Clinical Trial Evaluating Hepatitis C Protease Inhibitor ITMN-191 in Collaboration with Roche - (12/20/06)
     
  7409. Procrit/EP- Safety Alert from FDA - (12/18/06)
     
  7410. Epoetin Alfa and Risk for Complications - (12/18/06)
     
  7411. Correction of Anemia - Payoffs and Problems EDITORIAL - (12/18/06)
     
  7412. ICAAC: The PRESCO study: role of extended therapy and/or optimal doses of ribavirin in the treatment of chronic hepatitis C in HIV-infected patients (12/12/06)
     
  7413. Fatty Liver Associated with Increased Mortality - (12/12/06)
     
  7414. Pegasys/RBV Reverses Fibrosis in HCV/HIV-Coinfected in APRICOT Study for Viral Responders, Non-responders, and Cirrhosis - (12/12/06)
     
  7415. HCV Reduces Cholesterol in Coinfected; Interferon therapy Increases Cholesterol - (12/12/06)
     
  7416. Diabetes and hepatocellular carcinoma Editorial - (12/12/06)
     
  7417. Abbott Acquires HCV Protease Inhibitors from Enanta Pharma - (12/12/06)
     
  7418. Valeant Pharmaceuticals Initiates Infergen Phase 4 Study - (12/12/06)
     
  7419. Hepatitis C Virus Replicates in the Liver of Patients Who Have a Sustained Response to Antiviral Treatment - (12/06/06)
     
  7420. Hepatitis C Virus Seropositivity in Organ Donors Reduced Survival in Heart Transplant Recipients - (12/06/06)
     
  7421. Poorer Outcomes for Recipients of Heart Allografts From HCV-Positive Donors EDITORIAL - (12/06/06)
     
  7422. HCV Infections From a Contaminated Radiopharmaceutical Used in Myocardial Perfusion Studies - (12/06/06)
     
  7423. ViroPharma and Wyeth Initiate Dosing in Phase 2 Study of HCV-796 in Treatment Naive Patients and Non-Responders - (12/06/06)
     
  7424. Christopher Kennedy Lawford Urges America to Face Its Silent Epidemic - Hepatitis C - (12/06/06)
     
  7425. Pharmasset Initiates Phase 1 Study of R7128 for HCV - (12/06/06)
     
  7426. Patients who recover from hepatitis C have lower risk of reinfection - (12/06/06)
     
  7427. Racing to The Market with New HCV Drugs Vertex May Beat Roche, Merck on Drug for Hepatitis C - (12/06/06)
     
  7428. HCV Drug R7128 Makes Progress - (12/06/06)
     
  7429. Arrow Therapeutics HCV Compound Enters Phase I - (12/04/06)
     
  7430. Saliva-based hepatitis C test developed - (12/04/06)
     
  7431. New Hepatitis C Drugs - (12/04/06)
     
  7432. Inovio Biomedical Partner Tripep Files Application for Phase I Clinical Study of Hepatitis C DNA Vaccine - (12/04/06)
     
  7433. China's Hepatitis C Prevalent Population is Ten Times that of the United States - (12/04/06)
     
  7434. AASLD: In Vitro Synergistic Antiviral Activity of ITMN-191, an Orally Active Inhibitor of the Hepatitis C Virus (HCV) NS3/4A Protease, in Combination with PEG-Interferon Alfa-2a - (11/14/06)
     
  7435. AASLD: Development of HCC in Patients who Achieve SVR to IFN-Based Therapies is Associated with Cirrhosis and Prior HBV Exposure - (11/14/06)
     
  7436. AASLD: CPG10101 HCV Toll-Receptor 9 Antagonist Phase II Study results - (11/10/06)
     
  7437. AASLD: New HBV Drug PMEO-DAPym Active In Vitro Against Drug Resistant Mutants of HBV - (11/10/06)
     
  7438. AASLD: In Vitro Resistance Studies of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-dependent RNA Polymerase - (11/08/06)
     
  7439. AASLD: Early predictors of anemia in patients with HCV genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin 1000-1200 mg/day - (11/08/06)
     
  7440. AASLD: PegIntron/RBV Effective for >65 Year Olds - (11/08/06)
     
  7441. AASLD: New Therapy Significantly Increases Platelet Count - (11/08/06)
     
  7442. AASLD: Eltrombopag, an Oral Platelet Growth Factor, Facilitates Initiation of Interferon Therapy in Subjects with HCV Associated Thrombocytopenia - (11/08/06)
     
  7443. AASLD: Merck HCV Polymerase Inhibitor - (11/08/06)
     
  7444. AASLD: In Vitro Resistance Studies of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-dependent RNA Polymerase - (11/08/06)
     
  7445. AASLD: Pegasys 270 ug/wk+RBV 1200/1600mg in Difficult To Treat Patients - (11/07/06)
     
  7446. AASLD: Pegasys Every 5 Days in PegIntron Nonresponders - (11/07/06)
     
  7447. AASLD: Hispanic Responses to PegIntron/RBV in WIN-R Study - (11/07/06)
     
  7448. AASLD: LATINO Pegasys Study: early responses - (11/07/06)
     
  7449. AASLD: Adefovir 3 & 5 Years Followup HBeAg+: safety & efficacy - (11/06/06)
     
  7450. AASLD: 16 vs 24 weeks Pegasys/RBV for Genotype 2 HCV; Taiwan Study: Week 4 Response & Ribavirin Level/Dose Predicts SVR - (11/06/06)
     
  7451. AASLD: <400,000 is New HCV RNA Cutoff In genotype 1 with Pegasys/RBV - (11/06/06)
     
  7452. AASLD: 72 Weeks Pegasys/RBV in Genotype 1 Improves SVR Rate For Patients With Early Viral Response (2 log reduction at wk 12) But HCV RNA >50 IU/mL - (11/06/06)
     
  7453. AASLD: 72 Weeks Peg/RBV for 'Slow-Responders' Improves SVR Rate - (11/06/06)
     
  7454. AASLD: 400,000 IU/ml was the best cut-off level between Low VL and High VL - (11/06/06)
     
  7455. AASLD: The cyclophilin inhibitor DEBIO-025 has a potent dual anti-HIV and anti-HCV activity in treatment-naive HIV/HCV co-infected subjects - (11/03/06)
     
  7456. AASLD: Entecavir vs Adefovir in HBeAg+ Naives 24 Weeks EARLY Study - (11/03/06)
     
  7457. AASLD: Ribavirin Dose/Levels Predicts Outcome in Pegasys/RBV ACCELERATE Study Comparing 16 vs 24 Weeks Therapy - (11/03/06)
     
  7458. AASLD: Week 4 Response Predicts SVR in Pegasys/RBV 16 Week Therapy Study in Genotypes 2/3 - (11/03/06)
     
  7459. AASLD: Win-R Study: Ribavirin Weight-Base Dosing in High Weight Patients; Treatment Responses to PegIntron/RBV for Elderly Patients and by Patient Ethnicity - (11/02/06)
     
  7460. AASLD: Weight-Based Ribavirin Improves SVR Rate for Patients >125 kg (275 lbs) - (11/02/06)
     
  7461. AASLD: Infergen (Consensus Interferon) Phase III DIRECT Study End of Treatment Results - (11/02/06)
     
  7462. AASLD: Current status of Subjects Receiving Pegays and Ribavirin Follow-On Therapy After 28 Days Treatment with the Hepatitis C Protease Inhibitor Telaprevir (VX-950), Pegasys & RBV - (11/02/06)
     
  7463. AASLD: Win-R Study: Ribavirin Weight-Base Dosing in High Weight Patients; Treatment Responses to PegIntron/RBV for Elderly Patients and by Patient Ethnicity - (11/02/06)
     
  7464. AASLD: VX-950 HCV Protease Inhibitor Resistance Profile: combination therapy suppresses drug resistance - (11/01/06)
     
  7465. AASLD: New Drug Lowers AST/ALT Levels in Chronic HCV - (11/01/06)
     
  7466. AASLD: Albuferon Phase 2 Study Results Reported in Posters at AASLD - (11/01/06)
     
  7467. AASLD: Albuferon Quality-Of-Life Reported - (11/01/06)
     
  7468. 75% of College Students Report Risk Factors for Hepatitis C - (10/31/06)
     
  7469. Colchicine May Delay Progression of Viral Cirrhosis to Liver Cancer - (10/31/06)
     
  7470. Culturing Hepatitis C for new drugs - (10/31/06)
     
  7471. HCV Alters Neurotransmission - (10/31/06)
     
  7472. HCV & Neurologic Dysfunction - (10/31/06)
     
  7473. Intermune/Roche HCV Protease Joins HCV Protease Battle - (10/31/06)
     
  7474. Intermune Inks HCV Drug Development Agreement With Roche - (10/31/06)
     
  7475. Tacere Therapeutics Secures Financing And Resumes Development Of RNAi Hepatitis C Drug - (10/31/06)
     
  7476. ROCHE PROGRESSES ITS ORAL POLYMERASE INHIBITOR INTO PHASE II DEVELOPMENT STUDY IN PATIENTS WITH HEPATITIS C - (10/31/06)
     
  7477. Novel Robust Hepatitis C Virus Mouse Efficacy Model - (10/31/06)
     
  7478. AVI BioPharma technology ineffective against hepatitis C - (10/31/06)
     
  7479. AASLD: Roche HCV Polymerase Inhibitor Shows Potency: 4 log viral load reduction - (10/31/06)
     
  7480. AASLD: Valopicitabine (NM283) plus Peg-Interferon in Treatment-Naive Hepatitis C Patients with HCV Genotype-1 Infection: HCV RNA Clearance During 24 Weeks of Treatment - (10/31/06)
     
  7481. AASLD: SELECTION AND CHARACTERIZATION OF HEPATITIS C VIRUS REPLICONS RESISTANT TO A POTENT POLYMERASE INHIBITOR A-837093 - (10/30/06)
     
  7482. AASLD: In vitro antiviral effects of combinations of Abbott HCV polymerase inhibitors with IFN or NS3/4A protease inhibitors - (10/30/06)
     
  7483. AASLD: The Antiviral Efficacy of an HCV Polymerase inhibitor in the Chimpanzee Model: Genotypic and Phenotypic Analysis - (10/30/06)
     
  7484. AASLD: Coffee Appears to Reduce Risk of Fibrosis in HCV+ - (10/30/06)
     
  7485. AASLD: Daily Cannabis Use by HCV+ Increased Odds of Moderate to Severe Fibrosis by 7- Fold - (10/30/06)
     
  7486. AASLD: Higher Fixed Dosing with PEGASYS in Difficult-to-Treat Patients - (10/30/06)
     
  7487. AASLD: Early Week 4 Response Predicts SVR in Genotype 1 - (10/30/06)
     
  7488. AASLD: Roche's Oral Polymerase Inhibitor R1626 Shows Strong Antiviral Activity in Chronic Hepatitis C Patients - (10/30/06)
     
  7489. AASLD: Update on NM283, HCV Polymerase Inhibitor, at New 200 mg Dose - (10/30/06)
     
  7490. AASLD: New Data for Investigational Hepatitis C Drug Telaprevir (VX-950) to be Presented at AASLD Meeting - (10/30/06)
     
  7491. AASLD: Valeant Pharmaceuticals Previews 24-Week Results of Direct Trial for Infergen (Consensus Interferon) - (10/30/06)
     
  7492. ICAAC: Baseline viral load (400,000 IU/mL) as a predictor of SVR rate with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in HCV/HIV Coinfected in Apricot Study - (10/16/06)
     
  7493. ICAAC: HIV Antiretroviral-Related Hyperlipidemia is Mitigated by HCV Co-Infection - (10/16/06)
     
  7494. HUMAN GENOME SCIENCES ANNOUNCES PHASE 3 CLINICAL DEVELOPMENT PROGRAM FOR ALBUFERON IN CHRONIC HEPATITIS C - (10/05/06)
     
  7495. ICAAC: Roche HCV Polymerase Inhibitor: two preclinical studies - (10/02/06)
     
  7496. ICAAC: HCV-796 Displays Potent Antiviral Activity in Replicon and in Chimeric Mice Infected with Hepatitis C Virus (HCV) - (10/02/06)
     
  7497. ICAAC: The Nucleoside Inhibitor MK-0608 Mediates Suppression of HCV Replication for >30 Days in Chronically Infected Chimpanzees - (10/02/06)
     
  7498. Insulin resistance and HCV: Will new knowledge modify clinical management? - (09/21/06)
     
  7499. GAY MEN AND HEP C - (09/21/06)
     
  7500. 28 Days of the Hepatitis C Protease Inhibitor VX-950, in Combination With PEG-Interferon-ALFA-2a and Ribavirin, Is Well-Tolerated and Demonstrates Robust Antiviral Effects - (09/18/06)
     
  7501. Viramidine Did Not Meet Efficacy Endpoint in Viser2 - (09/15/06)
     
  7502. Treatment for hepatitis C virus and cannabis use in illicit drug user patients: implications and questions - (09/15/06)
     
  7503. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C - (09/15/06)
     
  7504. Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-α2b plus ribavirin treatment in a patient with hepatitis B and C coinfection - (09/15/06)
     
  7505. New Compound Protects Against Liver Cancer - (09/11/06)
     
  7506. Hepatitis C virus therapies - (09/08/06)
     
  7507. Prevention of mortality from hepatitis B and hepatitis C - (09/08/06)
     
  7508. Treating viral hepatitis C: efficacy, side effects, and complications - (09/07/06)
     
  7509. FDA Hepatitis C Public Hearing on Study Design Issues for New Hep C Drugs - (09/07/06)
     
  7510. NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon - (08/31/06)
     
  7511. ViroPharma Announces Positive Data From Phase 1b Combination Study Of HCV-796 And Pegylated Interferon In Hepatitis C Patients - (08/31/06)
     
  7512. Hispanics Have More Aggressive Liver Disease in LA County Hepatitis Clinic - (08/31/06)
     
  7513. IAC: HCV Death Rate Doubles Among IDUs in Last 5 Years - (08/24/06)
     
  7514. Peregrine's Final HCV Phase 1a Study Results Accepted for Oral Presentation at AASLD Annual Meeting - (08/16/06)
     
  7515. Cost effectiveness of interferon or peginterferon with ribavirin for histologically mild chronic hepatitis C - (08/14/06)
     
  7516. 72 Weeks Pegasys/RBV Improves SVR for When HCV-RNA is Detectable at Week 4 - (08/09/06)
     
  7517. Pegasys/RBV in African-Americans - (08/09/06)
     
  7518. Pre-treatment LDL & T-Cholesterol Predict SVR in HCV+ - (08/08/06)
     
  7519. Acute hepatitis C: Hi Dosage and compliance Predict SVR - (08/08/06)
     
  7520. Interferon Enhancer Drug EMZ702 Study + PegIFN/RBV - (08/04/06)
     
  7521. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial - (08/01/06)
     
  7522. A low-carbohydrate diet rapidly and dramatically reduces intrahepatic triglyceride content - (08/01/06)
     
  7523. CDC Study on HCV Risk Transmission & Tattoos/Body Piercing, Snorting Drugs - (08/01/06)
     
  7524. Canada To Compensate HCV-Infected Tainted Blood Victims - (07/31/06)
     
  7525. Unique HIV Clinic in India - (07/31/06)
     
  7526. BMI, Waist Size, and Fitness & Central Adiposity Associated with NAFLD (nonalcoholic fatty liver disease) - (07/30/06)
     
  7527. GlaxoSmithKline announces FDA approval and the launch of Avandamet (rosiglitazone maleate and metformin HCl) as inital therapy in the treatment of type 2 diabetes - (07/30/06)
     
  7528. Cancer Incidence Much Higher in People with Hep B or C - (07/24/06)
     
  7529. What Is the Role of GB Virus C Infection in Hepatitis C Virus/HIV Coinfection? - (07/20/06)
     
  7530. Statin Drugs Inhibit HCV in vitro - (07/10/06)
     
  7531. Diagnostic and Prognostic Role of α-Fetoprotein in Hepatocellular Carcinoma: Both or Neither? - (07/10/06)
     
  7532. Extrahepatic replication of HCV: Insights into clinical manifestations and biological consequences - (07/06/06)
     
  7533. Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson Company, Form Collaboration to Develop and Commercialize VX-950 for Treatment of Hepatitis C - (06/30/06)
     
  7534. Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV - (06/30/06)
     
  7535. Phase 2 Study of VX-950, Pegasys, and Copegus in Hepatitis C- study sites - (06/30/06)
     
  7536. Hepatic Steatosis Is Associated with Fibrosis, Nucleoside Analogue Use, and Hepatitis C Virus Genotype 3 Infection in HIV-Seropositive Patients: Steatosis was present in 69% of patients - (06/29/06)
     
  7537. Dideoxynucleoside Analogues Should Be Used Cautiously in Patients with Hepatic Steatosis EDITORIAL - (06/29/06)
     
  7538. Anadys/Novartis HCV Toll-Receptor Drug Study Stopped for Animal Toxicity - (06/26/06)
     
  7539. A very low toxic agent induces apoptosis and reduces growth of human hepatocellular carcinoma cells - (06/23/06)
     
  7540. BREASTFEEDING & HCV TRANSMISSION - (06/23/06)
     
  7541. Drug Resistance Wksp: New HCV Polymerase Inhibitor is in Early Development; resistance at 282 is associated with polymerase drug resistance, but PSI-6130 may remain active when mutation is present - (06/20/06)
     
  7542. Drug Resistance Wksp: New achievements in hepatitis C virus research and their implications for antiviral therapy - (06/20/06)
     
  7543. Drug Resistance Wksp: Coffee, Cirrhosis, and Transaminase Enzymes - (06/14/06)
     
  7544. Drug Resistance Wksp: Selection and characterization of mutations conferring resistance to a HCV RNA dependent RNA polymerase inhibitor A-848837 in vitro - (06/14/06)
     
  7545. Drug Resistance Wksp: Merck's New HCV Polymerase Inhibitor Drug Reduces HCV Viral Load by 5.7 Log in 7 Days in Chimps - (06/14/06)
     
  7546. Coffee Consumption May Protect Liver from Alcohol - (06/13/06)
     
  7547. BMI, Insulin Resistance Contribute to Fibrosis - (06/12/06)
     
  7548. Thiazolidinediones and hepatic fibrosis: don't wait too long - (06/12/06)
     
  7549. DDW: Consensus IFN vs Pegasys for 72 Wks in Peg/RBV Relapsers - (06/12/06)
     
  7550. DDW: Consensus IFN for Peg/RBV Nonresponders in Germany - (06/12/06)
     
  7551. DDW: Hi-Dose Consensus IFN in Prior Peg/RBV Users - (06/12/06)
     
  7552. DDW: Consensus Interferon in Peg/RBV Relapsers & Nonresponders in Dallas: 48 weeks end of treatment viral response - (06/12/06)
     
  7553. HCV is Detected in Liver of HCV Antibody-Positive But HCV RNA Negative Patients, so don't assume HCV has been cleared if viral load is undetectable - (06/08/06)
     
  7554. Sexual Dysfunction is Highly Prevalent Among Men with Chronic Hepatitis C Virus Infection and Negatively Impacts Health-Related Quality of Life - (06/07/06)
     
  7555. Study Finds Diabetes is Associated with HCV & HBV, Triglycerides, Steatosis & More Severe Fibrosis - (06/07/06)
     
  7556. Novartis strengthens infectious disease portfolio by acquiring rights to Albuferon(TM), a hepatitis C interferon drug set to enter Phase III trials - (06/06/06)
     
  7557. Peginterferon alfa-2a (Pegasys) and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response - (06/06/06)
     
  7558. Study finds steatosis (fatty liver) is more common & severe in HIV coinfected compared to HCV monoinfected - (06/06/06)
     
  7559. DDW: The Impact of Growth Factors on Pegylated Interferon alfa-2b and Ribavirin Dose Reduction in Patients Treated for Genotype 1 Chronic Hepatitis C - (06/06/06)
     
  7560. DDW: Preclinical Characteristics of ITMN-191, an Orally Active Inhibitor of the HCV NS3/4A Protease Nominated for Preclinical Development - (06/06/06)
     
  7561. DDW: Pharmacokinetic Analysis and Liver Concentrations of a Series of Macrocyclic Peptidomimetic Inhibitors of HCV NS3/4A Protease: Identification of ITMN-191, a Potent NS3/4A Protease Inhibitor with High Liver Exposure Across Multiple Species - (06/06/06)
     
  7562. DDW: Growth Factors Versus Dose Reduction for Pegylated Interferon alfa-2b and Ribavirin-Associated Neutropenia and Anemia in HIV/HCV Co-Infected Patients - (06/06/06)
     
  7563. DDW: Smoking Cigarettes Reduced SVR Rates in Peg/RBV Study - (06/05/06)
     
  7564. DDW: The Effect of Liver Fibrosis and Cirrhosis on SVR in 4913 Patients With Hepatitis C: Results From The WIN-R Trial - (06/05/06)
     
  7565. DDW: Affect of Viral Load on SVR Rates to PegIntron/RBV in Genotype 1 Patients in WIN-R Study - (06/05/06)
     
  7566. DDW: Differences In Treatment Outcome To Antiviral Therapy Based On Genotype And Viral Load In Hepatitis C Genotypes 2 And 3 In The WIN-R Trial - (06/02/06)
     
  7567. Metabolics/Belly Fat Advance HCV Disease - (05/30/06)
     
  7568. EASL: A Phase 2 Dose-Escalation Study of (Albuferon) albumin interferon alfa-2b Combined with Ribavirin in Non-responders to Prior Interferon Based Therapy for Chronic Hepatitis C Infection Phase - (05/30/06)
     
  7569. EASL: Interim (Week 12) Phase 2B Virological Efficacy and Safety Results of Albuferon (albumin interferon alfa-2b) Combined with Ribavirin in Genotype 1 Treatment-naive Chronic Hepatitis C Infection - (05/30/06)
     
  7570. DDW: NM283 + Peg: differences in response between treatment naives & nonresponders; dose reductions for safety concerns - (05/26/06)
     
  7571. DDW: HCV-796, new HCV non-nucleoside- 14 day study - (05/26/06)
     
  7572. DDW: "Week 12 Antiviral Activity of Higher Doses of albumin interferon alfa-2b (Albuferon) Combined with Ribavirin in Non-responders to Prior Interferon Based Therapy for Chronic HCV-Infection" - (05/25/06)
     
  7573. DDW: Entecavir (ETV) Demonstrates Consistent Responses Throughout Baseline Disease and Demographic Subgroups for the Treatment of Lamivudine-Refractory (LVD-ref) HBeAg(+) Patients with Chronic Hepatitis B - (05/25/06)
     
  7574. DDW: Final Analysis of Virological Outcomes and Resistance During 5 Years of adefovir Dipivoxil Monotherapy in HBeAg-Negative Patients - (05/25/06)
     
  7575. DDW: 96-Week Viral Suppression Data From Two Studies Presented For BARACLUDE (entecavir) In Chronically-Infected Hepatitis B Patients - (05/24/06)
     
  7576. DDW: Results from a Cost-Effectiveness Study Demonstrate Positive Economic Impact with PEGASYS Treatment - (05/24/06)
     
  7577. DDW: G-CSF is safe and improves adherence and SVR in HCV patients with genotype 1 who develop Peg-IFNa-2b related severe neutropenia - (05/24/06)
     
  7578. DDW: African-Americans' response to Interferon: preliminary results from Virahep C Study - (05/24/06)
     
  7579. DDW: VX-950 HCV Protease Inhibitor + Pegasys/RBV: 28 days study results in treatment-naive - (05/24/06)
     
  7580. Vertex Pharmaceuticals Initiates the First of Two Major Phase II Studies of VX-950 in Treatment-Naive HCV Patients - (05/23/06)
     
  7581. DDW: ViroPharma Announces Presentation of HCV-796 Phase 1b Data at Digestive Disease Week - (05/23/06)
     
  7582. DDW: HCV Protease ITMN 191, In Vitro Resistance - - (05/23/06)
     
  7583. DDW: High Dose Albuferon -early data - (05/23/06)
     
  7584. DDW: Hepatitis Patients at Risk for Accidental Acetaminophen Toxicity - (05/23/06)
     
  7585. DDW: Reliable early prediction of viral relapse by detection of minimal residual hepatitis C viremia at treatment week 12 with Sensitive HCV Viral load Test - (05/22/06)
     
  7586. DDW: High Prevalence of Hepatitis C Virus Infection Among Russian Immigrants in the New York City Metropolitan Area: Results of A Community-Based Screening Program - (05/22/06)
     
  7587. DDW: Noninvasive Biomarker Test for Fatty Liver - (05/22/06)
     
  7588. DDW: Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients - (05/22/06)
     
  7589. DDW: The prevalence of metabolic syndrome (53%) in veterans with chronic hepatitis C virus - (05/22/06)
     
  7590. Study details hepatitis C ability to block immune system response - (05/19/06)
     
  7591. Elevated ALT Associated with Heart Disease - (05/19/06)
     
  7592. CPG 10101, new tollreceptor antagonist HCV drug, receives Fast Track Deisngation for Treatment-Refractory Patients - (05/17/06)
     
  7593. Hepatitis C: A Bitter Harvest EDITORIAL - (05/16/06)
     
  7594. The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 - (05/16/06)
     
  7595. EASL: Phase II Multi-Center, Dose-Escalating study of LB80380 (ANA380) in hepatitis B Patients with Lamivudine-Resistant YMDD Mutant HBV - (05/16/06)
     
  7596. AVI BioPharma Presents Initial Results on Hepatitis C Virus Clinical Trial at the International Conference on Antiviral Research Annual Meeting - (05/15/06)
     
  7597. EASL: NM283 HCV Polymerase Inhibitor in Previous Nonresponders to PegIFN/RBV - (05/15/06)
     
  7598. EASL: 5 Year Followup of SVRs with PegIntron/RBV-98% Continued SVR5 - (05/15/06)
     
  7599. EASL: Early Viral Response to New HCV Drug CPG 10101 Toll-Receptor Antagonist, in Combination with Pegylated Interferon and/or Ribavirin, in Chronic HCV Genotype 1 Infected Patients with Prior Relapse Response - (05/09/06)
     
  7600. EASL: Randomized, Placebo-Controlled, Dose-Escalation Trial of New HCV Drug CPG 10101 Toll-Receptor Antagonist in Patients with Chronic Hepatitis C Virus - (05/09/06)
     
  7601. EASL: Psych Disorders Caused 4 Times Higher HCV Therapy Withdrawal Rates; Quality of Life Before Therapy Lower in HCV+ with Psych Disorders - (05/08/06)
     
  7602. EASL: Viramidine Phase III Study-did not meet efficacy endpoint Valeant looking at weight-based dosing of Viramidine based on post-hoc analysis - (05/05/06)
     
  7603. EASL: Pegasys/RBV In Post Liver Transplant for Recurrent HCV - (05/05/06)
     
  7604. EASL: The HCV Protease Inhibitor SCH 503034 in Combination with PEG-IFN a-2b in the treatment of HCV-1 PEG-IFN +/- Ribavirin Non-Responders: Antiviral Activity & HCV Variant Analysis - (05/03/06)
     
  7605. EASL: PHARMACOKINETIC BOOSTING OF VX-950 AND SCH 503034, INHIBITORS OF HCV PROTEASE, BY CO-DOSING WITH RITONAVIR - (05/02/06)
     
  7606. EASL: Initial Results of a 14-Day Study of the Hepatitis C Virus Protease Inhibitor VX-950, In Combination with Peginterferon-alfa-2a - (05/02/06)
     
  7607. EASL: Interim results of a multiple ascending dose study of R1626, a novel nucleoside analogue targeting HCV polymerase, in chronic HCV patients - (05/02/06)
     
  7608. EASL: Further reduction of ribavirin dose in HCV genotype 2/3 patients receiving peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) - (05/02/06)
     
  7609. EASL: VX-950 HCV Protease Inhibitor Resistance Profile - (05/02/06)
     
  7610. EASL: Researchers Report Initial Results for 14-day Phase Ib Study of VX-950, and Pegylated Interferon, Showing Anti-HCV Activity in Combination in Hepatitis C Patients - (05/02/06)
     
  7611. EASL: New Drug for HCV Thrombocytopenia Appears Effective In Interim Study Results - (05/02/06)
     
  7612. EASL: New HCV Drugs- Protease Inhibitors & Polymerase inhibitors and Drug Resistance - (05/02/06)
     
  7613. EASL: HCV Polymerase Inhibitor Drug NM-283 Dose Reduced - (05/02/06)
     
  7614. EASL: Peginterferon alfa-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 or 3 - (05/01/06)
     
  7615. EASL: 24-week treatment regimen with peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in HCV genotype 1 or 4 'super-responders' -Week 4 Rapid Viral Response (RVR) - (05/01/06)
     
  7616. EASL: NM283, HCV Polymerase Inhibitor Study in Naives: dose change for development - (05/01/06)
     
  7617. Vertex Adds 24-Week Arm to 12-Week VX-950 study - (04/26/06)
     
  7618. EASL: Ritonavir Increases levels of Schering HCV Protease Inhibitor SCH503034 - (04/27/06)
     
  7619. Higher Dose COPEGUS(R) 400mg Tablets Approved in the Netherlands as First Step to European Availability - (04/26/06)
     
  7620. Novelos Therapeutics IND for Novel Hepatitis C Drug is Accepted by FDA; Company Is on Track to Begin Patient Enrollment by July 2006 - (04/24/06)
     
  7621. AVI-4065, an Antisense Approach to HCV Therapy - (04/24/06)
     
  7622. Phase II Study Enrolled: SCHERING-PLOUGH PROVIDES UPDATE ON ORAL HCV PROTEASE INHIBITOR SCH 503034 CLINICAL DEVELOPMENT PROGRAM FOR HEPATITIS C - (04/24/06)
     
  7623. EASL Preview of Selected Abstracts (studies reported) - (04/24/06)
     
  7624. Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Dual Infection - (04/21/06)
     
  7625. Interferon 'Enhancing' Therapy-phase I/II Study - (04/21/06)
     
  7626. 24 weeks Pegasys/RBV: Rapid Viral Response & HCV RNA Predict SVR in Genotype - (04/21/06)
     
  7627. Tailoring antiviral therapy in hepatitis C - (04/21/06)
     
  7628. Extrahepatic manifestations of hepatitis C virus infection, 2 - (04/21/06)
     
  7629. Extrahepatic Manifestations of Hepatitis C Virus - (04/19/06)
     
  7630. Hepatitis C Virus Infection in African Americans - (04/19/06)
     
  7631. HCV/HIV Coinfection Higher Death Rates Higher in VA Study - (04/19/06)
     
  7632. Genetic Host Factor May Be Associated with HCV Viral Clearance & Disease, Study Finds - (04/13/06)
     
  7633. Liver Biopsy Remains Gold Standard - (04/13/06)
     
  7634. Hepatitis C Treatment Eligibility and Outcomes Among Patients With Psychiatric Illness: successful therapy can be accomplished - (04/10/06)
     
  7635. Stanford Scientist to Discuss New Approach to Treating Hepatitis C Virus - (04/06/06)
     
  7636. HCV Therapy Successful for With Mental illness/substance abuse - (04/05/06)
     
  7637. HCV Drug Development Slowed for Two Drugs - (04/04/06)
     
  7638. SVR rates and health-related quality of life after interferon+ribavirin therapy in patients with chronic HCV and persistently normal ALT levels - (04/04/06)
     
  7639. Review article: predicting response in hepatitis C virus therapy - (04/04/06)
     
  7640. Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection - (04/04/06)
     
  7641. Researchers show laboratory hepatitis C strain is also infectious in animal models - (03/30/06)
     
  7642. Only 4% of IDUs Eligible for HCV Therapy, in this study - (03/30/06)
     
  7643. HCV Toll-Receptor Drug Actilon 12 Week Data Looks Promising - (03/23/06)
     
  7644. Depression, anemia and health-related quality of life in chronic hepatitis C: history of depression is most important predictor of quality of life & outcome for both on HCV treatment & before treatment in HCV+ individuals, study finds - (03/21/06)
     
  7645. Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin - (03/21/06)
     
  7646. SCHERING-PLOUGH AND PTC THERAPEUTICS ANNOUNCE COLLABORATION FOR DEVELOPMENT OF PTC'S PRECLINICAL HEPATITIS C COMPOUNDS - (03/21/06)
     
  7647. Valeant Releases Viramidine Data - Falls Short of Efficacy Goal - (03/21/06)
     
  7648. SCH 503034 Protease Inhibitor Monotherapy in Hepatitis C Virus Genotype-1 IFN-a Non-Responders - (03/16/06)
     
  7649. SCH 503034 HCV Protease Inhibitor Plus PEG-IFN a-2b in HCV-1 PEG-IFN a-2b Non-responders: Phase 1b Results - (03/16/06)
     
  7650. Management of Recurrent Viral Hepatitis B and C After Liver Transplantation - (03/15/06)
     
  7651. Albuferon vs Pegasys Phase 2B Study Results - (03/15/06)
     
  7652. HCV Mother-to-child transmission: HAART May Reduce HCV MTC; C-Section Did Not Reduce MTC - (03/15/06)
     
  7653. "Non-invasive evaluation of hepatic fibrosis: don't count your chickens before they're hatched" - (03/09/06)
     
  7654. HCV+ with Schizophrenia Get HCV Therapy - (03/08/06)
     
  7655. Sleep disorders and brain MRI as early indicators of subclinical hepatic encephalopathy - (03/08/06)
     
  7656. Schering-Plough Statement on Status of SCH 503034 Clinical Development Plans - (03/08/06)
     
  7657. Vertex's Hepatitis C Drug Has 'Gold Standard' Potential - (03/03/06)
     
  7658. CROI: Starting HAART Earlier Results in Highest CD4 Count (03/02/06)
     
  7659. CROI: Heart Disease in HIV: Carotid IMT, measuring plaque in arteries (03/02/06)
     
  7660. Hepatitis C Treatment for People With Severe Mental Illness & Depression - (03/01/06)
     
  7661. Coley Pharmaceutical Group Initiates Phase II Clinical Study of Actilon Toll-receptor Agonist for Hepatitis C - (02/28/06)
     
  7662. New HCV Drug Tarvacin, an 'anti-phosphotidylserine mmunotherapeutic' - (02/28/06)
     
  7663. AASLD: Safety & Efficacy of Schering HCV Protease Inhibitor + Peg-Intron for Genotype 1 Non-responders to Peginterferon/ribavirin, with & without Ribavirin Phase II Study (02/24/06)
     
  7664. Hep C Protease Inhibitor: Waging War on Hepatitis C - (02/24/06)
     
  7665. New HCV Drug Tarvacin, monoclonal antibody - (02/24/06)
     
  7666. Liver Fibrosis Found in HIV/HCV-Coinfected Patients With Normal ALT - (02/24/06)
     
  7667. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors - (02/24/06)
     
  7668. CROI: Pegasys Rapid Response at Week 4 in APRICOT Yields 75-82% SVR in Genotype 1 Patients (02/21/06)
     
  7669. Peregrine advances hepatitis C drug - (02/17/06)
     
  7670. New Compound May Protect Against Liver Cancer - (02/15/06)
     
  7671. Scientists Call For Hepatitis Treatment Of Young Injection Drug Users, Public Health Intervention - (02/08/06)
     
  7672. Vertex stock price shoots up on hepatitis C results - (02/08/06)
     
  7673. Arrow Therapeutics selects Hepatitis C clinical candidate - (02/08/06)
     
  7674. Noninvasive measures of liver fibrosis- a Review - (02/08/06)
     
  7675. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study - (02/08/06)
     
  7676. Acute hepatitis C: In search of the optimal approach to cure - (02/08/06)
     
  7677. Thalidomide in the Treatment of Chronic Hepatitis C Unresponsive to Alfa-Interferon and Ribavirin - (02/08/06)
     
  7678. 96% of IDUs Not eligible for HCV Therapy, in this study - (02/01/06)
     
  7679. Reversal of hepatic fibrosis - Fact or fantasy? - (02/01/06)
     
  7680. AASLD: Study Finds EPO Improved SVR Only in High Dose RBV Group (02/01/06)
     
  7681. HCV coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort - (02/01/06)
     
  7682. Hepatitis C's effect on HIV disease remains elusive despite three new studies; Coinfection Death Rate - (02/01/06)
     
  7683. AASLD: Study Finds EPO Improved SVR Only in High Dose RBV Group (01/31/06)
     
  7684. AASLD: WIN-R Study: final results of Weight-Based dosing study of ribavirin in treatment-naive patients (01/31/06)
     
  7685. Intl Coinfection Wrkshp: Fibrosis Progression in HIV/HCV Coinfected Patients with Paired Liver Biopsies: evaluation of risk factors (01/30/06)
     
  7686. Acute hepatitis C: In search of the optimal approach to cure Editorial - (01/30/06)
     
  7687. Schering-Plough HCV Protease Inhibitor: FDA Grants Fast Track - (01/30/06)
     
  7688. Fatty Liver (Steatosis) May Cause Fibrosis & Liver Cancer - (01/30/06)
     
  7689. Acetaminophen (Tylenol, Paracetamol) Overdose IS Easier Than Many Realize - (01/30/06)
     
  7690. HBV+HCV+HDV-dynamic diseases when in combination - (01/30/06)
     
  7691. Hope of liver cancer blood test - (01/30/06)
     
  7692. New Antisense HCV Drug AVI-4065 in Study - (01/30/06)
     
  7693. STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER? - (01/27/06)
     
  7694. HIV Sexual Transmission Risks: during acute & chronic with <400 c/ml - (01/27/06)
     
  7695. Significance of liver negative-strand HCV RNA quantitation in chronic hepatitis C - (01/25/06)
     
  7696. Intl Coinfection Wrkshp: Fatigue may be misdiagnosed as depression during anti-HCV therapy in HIV coinfected (01/25/06)
     
  7697. Intl Coinfection Wrkshp: Accelerated HCV Progression in HIV: paired liver biopsies (01/25/06)
     
  7698. Alcohol & Depression, Anemia: barriers to HCV treatment - (01/24/06)
     
  7699. Migenix to start HCV drug trial in Q2 - (01/24/06)
     
  7700. Liver Disease in HIV: predictors of severity - (01/24/06)
     
  7701. Hepatitis/HIV in Europe: 10% of HCV+ initiated therapy - (01/23/06)
     
  7702. Epidemiology of viral hepatitis and HIV co-infection - (01/23/06)
     
  7703. Management of hepatocellular carcinoma in HIV- infected patients - (01/23/06)
     
  7704. New HCV drug study: cancer drug Tarvacin - (01/23/06)
     
  7705. Consensus Interferon in IFN/RBV Non-responders - (01/23/06)
     
  7706. New HCV Drugs Discovery - (01/23/06)
     
  7707. HCV Genotype 3 Associated with ART Hepatoxicity, Perhaps Due to Fatty Liver - (01/20/06)
     
  7708. Diagnosis of Hepatic Fibrosis and Cirrhosis by FibroScan, Transient Elastography, in HIV/Hepatitis C Virus-Coinfected Patients - (01/20/06)
     
  7709. Maintenance PegIntron Study in HCV/HIV Coinfected Patients - (01/18/06)
     
  7710. HCV Impaired CD4 Response to ART, in this study - (01/18/06)
     
  7711. Intl Coinfection Wrkshp: HIV May Cause Steatosis- 50% rates of steatosis in HIV & HCV (01/18/06)
     
  7712. Intl Coinfection Wrkshp: New Drugs for HCV & HBV (01/17/06)
     
  7713. Intl Coinfection Wrkshp: Liver Transplantation in HIV Infected Patients (01/17/06)
     
  7714. Intl Coinfection Wrkshp: Optiming Response Rates to Peg/RBV in Coinfected Patients: increased Ribavirin dosing; extending therapy duration (01/13/06)
     
  7715. New Peg-Intron Maintenance Study - (01/13/06)
     
  7716. Intl Coinfection Wrkshp: TDM for ART Hepatoxicity (01/12/06)
     
  7717. Coinfection Should Be Addressed Immediately - (01/12/06)
     
  7718. Review article: drug therapy for non-alcoholic fatty liver disease - (01/12/06)
     
  7719. Viral Eradication of HCV - (01/12/06)
     
  7720. CHILDHOOD HEPATITIS C VIRUS INFECTION - (01/12/06)
     
  7721. Lipids are Lower in Chronic HCV - (01/11/06)
     
  7722. The challenge of progressive hepatitis C following liver transplantation - (01/11/06)
     
  7723. Romark to Develop Alinia(R) (nitazoxanide) as New Treatment for Chronic Hepatitis C - (01/10/06)
     
  7724. Plan to Advance Albuferon to Phase 3 in Chronic Hepatitis C - (01/10/06)
     
  7725. ICAAC: Pegasys/RBV in APRICOT Study- Adherence Improves SVR 300% in genotype 1 (01/09/06)
     
  7726. ICAAC: Coinfection Report from ICAAC 2005: 33% of coinfected with normal ALT had advanced liver disease in Spanish study (01/09/06)
     
  7727. Pioglitazone May Reduce Signs of Metabolic Syndrome & Cardiovascular Risk in Nondiabetics as well as in Diabetics - (01/09/06)
     
  7728. Bristol-Myers Squibb and Gilead Announce Data Supporting Bioequivalence for Single-Pill Fixed-Dose Regimen of Sustiva (efavirenz) and Truvada (FTC and tenofovir) - (01/09/06)
     
  7729. Gilead Announces the Advancement of HIV Integrase Inhibitor GS 9137 to a Phase II Clinical Trial - (01/09/06)
     
  7730. Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis - (01/09/06)
     
  7731. NM283+Pegasys Reduced HCV RNA by 4 log After 4 weeks - (01/09/06)
     
  7732. VX-950 + PegIFN Achieves 5.5 Log Drop in HCV RNA After 14 Days - (01/09/06)
     
  7733. Milk Thistle Interactions - (01/05/06)
     
  7734. MedMira Granted Hepatitis C Patent in Europe - (01/05/06)
     
  7735. InterMune Completes Divestiture of Infergen for up to $135.5 Million in Cash - (01/05/06)
     
  7736. Transplant/BODY PARTS SCANDAL - (01/05/06)
     
  7737. Liver Disease, Fatty Liver in HIV - (01/05/06)
     
  7738. HCC Mismanaged in Medicare Population - (01/05/06)
     
  7739. Tibotec Identifies HCV Drug Candidate - (01/05/06)
     
  7740. AASLD: Double-Dose Peginterferon Alfa-2b with weight-Based Ribavirin Improves Response for Interferon/Ribavirin Non-Responders with Hepatitis C: Final Results of RENEW Study (12/29/05)
     
  7741. EACS: HAART & SVR in APRICOT Study (12/29/05)
     
  7742. XTL-6865 To prevent Hepatitis C Reinfection Following Liver Transplant - (12/28/05)
     
  7743. Saliva-based hepatitis C test developed - (12/28/05)
     
  7744. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo - (12/28/05)
     
  7745. Editorial: 24 weeks PegIFN 2b for genotype 1/Low HCV-RNA - (12/28/05)
     
  7746. How Should TMA Be Used-- Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse - (12/28/05)
     
  7747. HCV Care & Treatment in Mass & S Dakota Prisons - (12/28/05)
     
  7748. Milk Thistle for Alcoholic and/or Hepatitis B or C Liver Diseases: study showed no benefit-A - (12/21/05)
     
  7749. Liver Fibrosis in HIV+ Patients With Hepatitis C Virus: Role of Persistently Normal Alanine Aminotransferase Levels - (12/21/05)
     
  7750. Roche New Anemia Drug Dosed 2-4 Weeks Apart - (12/21/05)
     
  7751. Antifibrotic therapy in chronic liver disease - (12/21/05)
     
  7752. ViRexx to Present Hepatitis C Vaccine Data at HepDART 2005 - (12/14/05)
     
  7753. AASLD: Double-Dose Peginterferon Alfa-2b with weight-Based Ribavirin Improves Response for Interferon/Ribavirin Non-Responders with Hepatitis C: Final Results of RENEW Study (12/14/05)
     
  7754. AASLD: Safety of Double Dose Pegasys (REPEAT Study) (12/12/05)
     
  7755. HBV, HCV, & HIV Prevalence High in Psych Hospitals - (12/12/05)
     
  7756. HCV & Coinfection-Expected Increased Hospitalizations Rates: complications expected to quadruple - (12/08/05)
     
  7757. Hospitalizations increased for liver-related complications from 8% to 13% and for chronic HCV from 1% to 5% in this period: 1996-2000; 4-fold increase - (12/08/05)
     
  7758. FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 - (12/08/05)
     
  7759. HCV RNA level is a predictor of ESLD death among persons with chronic HCV infection, study finds - (12/07/05)
     
  7760. AASLD: 24 Week Pegasys+RBV Treatment SVR in Genotype 1 Predicted by Wk 4 Response (12/07/05)
     
  7761. AASLD: 24 Week Pegasys + RBV for Genotype 1: SVR predicted by week 4 response (12/07/05)
     
  7762. HCV Protease VX950 Study Starts - (12/06/05)
     
  7763. Presco Study, Interim Results: Pegasys + Weight-Based Ribavirin Suggest Similar SVR Rates as n HCV-Monoinfected Patients - (12/06/05)
     
  7764. AASLD: Pharmacokinetics, Safety, and Tolerability of the Isatoribine Oral Prodrug ANA975 in a Phase I Heakthy Volunteer Study (12/14/05)
     
  7765. VALEANT PHARMACEUTICALS AGREES TO ACQUIRE RIGHTS TO HEP-C DRUG INFERGEN FROM INTERMUNE - (12/02/05)
     
  7766. AASLD: Five Million Americans Infected with the Hepatitis C Virus: A Corrected Estimate (12/02/05)
     
  7767. AASLD: A Phase 2 Study of Albuferon in Combination with Ribavirin in non-responders to proir interferon therapy for chronic Hepatitis C (11/28/05)
     
  7768. AASLD: NM283 +Pegasys for Nonresponders: phase II 12 weeks (11/28/05)
     
  7769. AASLD: Consensus IFN+ IFN Gamma-1b in African-American Peg Nonresponders (11/28/05)
     
  7770. AASLD: Consensus Interferon: study results at AASLD (11/17/05)
     
  7771. AASLD: Albuferon-Alpha (Albumin-Interferon Alpha) (11/17/05)
     
  7772. AASLD: REPEAT Study: Non-responders to ≥12 weeks' treatment with standard-dose pegylated interferon alfa-2b (PegIntron) plus ribavirin received standard dose of Pegasys + ribavrin or double dose Pegasys + ribavirin (11/15/05)
     
  7773. AASLD: Albuferon + Ribavirin in PegIFN Nonresponders: phase 2 study (11/15/05)
     
  7774. AASLD: SCH 503034 HCV Protease Inhibitor Monotherapy in HCV Genotype 1 IFN Nonresponders (11/15/05)
     
  7775. AASLD: VX-950 Hep C Protease Inhibitor (11/15/05)
     
  7776. AASLD: Combination therapy with SCH-503034 HCV Protease Inhibitor & PegIntron in Non-Responders: phase !b study results (11/15/05)
     
  7777. AASLD: Combination therapy with SCH-503034 HCV Protease Inhibitor & PegIntron in Non-Responders: phase !b study results (11/15/05)
     
  7778. AASLD: THE PERFORMANCE OF APRI FOR THE DIAGNOSIS OF SIGNIFICANT HEPATIC FIBROSIS IS IMPROVED BY A SIMPLE MODIFICATION (11/14/05)
     
  7779. AASLD: LONG TERM RESULTS AFTER THERAPY WITH PEGYLATED INTERFERON ALPHA 2A (PEGASYS) IN HCV POSITIVE LIVER TRANSPLANT RECIPIENTS (11/14/05)
     
  7780. AASLD: PREDICTING OUTCOME IN PATIENTS WITH HCV AFTER OLT: A 15-YEARS FOLLOW-UP (11/14/05)
     
  7781. AASLD: RECURRENT HEPATITIS C IS A RISK FACTOR FOR POOR OUTCOME AFTER LIVER RETRANSPLANTATION (11/14/05)
     
  7782. AASLD: MULTICENTER RANDOMIZED TRIAL OF HCV TREATMENT WITH PEGINTERFERON-ALFA 2A (Pegasys) AND RIBAVIRIN AFTER LIVER TRANSPLANTATION:ONE-YEAR REPORT (11/14/05)
     
  7783. AASLD: ON TREATMENT VIROLOGICAL RESPONSE OF 70% IN 100 PATIENTS TREATED WITH COMBINATION ANTIVIRAL THERAPY FOR RECURRENT HCV FOLLOWING LIVER TRANSPLANTATION (11/14/05)
     
  7784. AASLD: IS LIVER BIOPSY JUSTIFIED IN HEPATITIS C GENOTYPE 2 AND 3? (11/14/05)
     
  7785. AASLD: FIBROSCAN, MONITORING LIVER STIFFNESS: A NEW TOOL TO MEASURE LIVER FIBROSIS DURING THERAPY (11/14/05)
     
  7786. AASLD: Telbivudine (LdT) Phase 3 One Year Study Results (11/14/05)
     
  7787. AASLD: 2.2% Liver Cancer developed Among SVRs; Sexual Dysfunction among HCV+ (11/14/05)
     
  7788. AASLD: FIVE MILLION AMERICANS INFECTED WITH THE HEPATITIS C VIRUS: A CORRECTED ESTIMATE (11/14/05)
     
  7789. AASLD: VIROLOGICAL AND HISTOLOGICAL FEATURES OF HCV IN PATIENTS WITH NORMAL ALT: RESULTS OF A TEN YEAR PROPSECTIVE FOLLOW-UP STUDY (11/14/05)
     
  7790. AASLD: African-American patients had fewer office visits and were less likely to return for a second office visit (11/14/05)
     
  7791. AASLD: COFFEE DRINKING DECREASES THE RISK OF CHRONIC LIVER DISEASE IN THE UNITED STATES POPULATION (11/14/05)
     
  7792. AASLD: Troglitazone significantly reduced tumor growth in vivo, and caused tumor regression in liver cells (11/14/05)
     
  7793. AASLD: Liver Transplant Articles AASLD (11/14/05)
     
  7794. AASLD: Study Evaluations of Non-Invasive Fibrosis Tests AASLD (11/14/05)
     
  7795. AASLD: LIVER HISTOLOGY IN HEPATITIS C PATIENTS WITH NORMAL ALT LEVELS (11/14/05)
     
  7796. AASLD: Hispanics Developed Cirrhosis More Quickly Due to the presence of Fatty Liver & Diabetes (11/14/05)
     
  7797. AASLD: IMPACT OF CAFFEINE CONSUMPTION ON ALT AND HISTOLOGICAL ACTIVITY IN PATIENTS WITH CHRONIC ACTIVE HCV (11/14/05)
     
  7798. AASLD: CANNABINOIDS BLOCK INTERFERON-MEDIATED SUPPRESSION OF HEPATITIS C VIRUS (HCV) REPLICATION (11/14/05)
     
  7799. AASLD: CRYOGLOBULINEMIA IS ASSOCIATED WITH STEATOSIS AND FIBROSIS IN CHRONIC HCV (11/14/05)
     
  7800. AASLD: INDEPENDENT VALIDATION AND COMPARISON WITH FIBROSCAN, FIBROTEST AND LIVER BIOPSY OF CLINICAL GLYCOMICS FOR THE NON INVASIVE ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HCV (11/14/05)
     
  7801. New Hep C Polymerase Inhibitor HCV-796 Study in Patients - (11/11/05)
     
  7802. HCV Transmission Risks from Mother-To-Child up to 6.2% - (11/09/05)
     
  7803. Liver Steatosis Common in HIV+ - (11/09/05)
     
  7804. Hep C Hospital Charges Up 8-Fold Hepatitis C: The Uncounted Disease - (11/09/05)
     
  7805. Transplant barriers fall for HIV-positive - (11/07/05)
     
  7806. New Liver Cancer Therapy Approach Improves Survival - (11/07/05)
     
  7807. Effects of chronic liver disease on bone mineral density and bone metabolism markers in postmenopausal women - (11/07/05)
     
  7808. HCC (Liver Cancer) Deaths Doubled & Hospital Services Costs Increase Significantly - (11/05/05)
     
  7809. Roche Announces Expansion of First Major Study to Examine Efficacy of Pegasys(R) in Hepatitis C Treatment in Latinos - (11/04/05)
     
  7810. Metabolic syndrome cardiovascular disease risk and more - (11/04/05)
     
  7811. Concluding remarks: metabolic syndrome, liver and HCV - (11/04/05)
     
  7812. Interferon Controlled Release Delivery System Starts Trial - (11/03/05)
     
  7813. Interferon Decreased mtDNA Mutation Rate & Improved Liver - (11/03/05)
     
  7814. Antisense Drug ISIS 14803 Did Not Reduce HCV RNA - (11/03/05)
     
  7815. Lipids/Diabetes & HCV Liver disease - (11/03/05)
     
  7816. Hepatitis C complicated by morphine withdrawal - (11/01/05)
     
  7817. HIV/hepatitis C virus co-infection: its human face - (11/01/05)
     
  7818. Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1 - (11/01/05)
     
  7819. HCV Fatigue Reduces Quality of Life: 61% report fatigue - (11/01/05)
     
  7820. Perspectives on HIV/HCV co-infection, illicit drug use and mental illness: barriers to care - (11/01/05)
     
  7821. The neuropsychological and neurological impact of HCV infection in HIV+ - (11/01/05)
     
  7822. 17-40% of HCV-Infected Report Impaired Psych Function in HIV+ - (11/01/05)
     
  7823. New HCV Drug BLX-883, a form of alfa-interferon: Biolex Therapeutics Successfully Completes Phase 1 Study for First LEX System (TM) Produced Therapeutic Protein - (10/27/05)
     
  7824. HCV Natural History: recent study in women... - (10/25/05)
     
  7825. Merck Hep C Vaccine Research Deal - (10/25/05)
     
  7826. HCV Drug Albuferon Phase 2B Enrollment Completed - (10/25/05)
     
  7827. Recurrence of hepatitis C infection Post transplantation: Where are we now? - (10/24/05)
     
  7828. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease - (10/24/05)
     
  7829. HIV+ Liver Transplant Candidates Need Accelerated Attention, Early Referral: Require Priority - (10/24/05)
     
  7830. High HCV+ Rates in China: Past Illegal Blood Donation in China Linked to Hepatitis C Virus Infection - (10/21/05)
     
  7831. Chronic Hepatitis C in Childhood: An 18-Year Experience - (10/21/05)
     
  7832. Lack of Evidence of Sexual Transmission of Hepatitis C Virus in a Prospective Cohort Study of Men Who Have Sex With Men - (10/20/05)
     
  7833. Coffee and Tea Consumption are Associated with a Lower Incidence of Chronic Liver Disease in the United States - (10/19/05)
     
  7834. Hepatitis C virus in the semen of men coinfected with HIV- 1: prevalence and origin - (10/19/05)
     
  7835. PK of Ribavirin & NRTIs in APRICOT Study - (10/18/05)
     
  7836. New HCV Drug Candidate for Treatment - (10/18/05)
     
  7837. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source - (10/18/05)
     
  7838. PK of Ribavirin & NRTIs in APRICOT Study - (10/18/05)
     
  7839. New HCV Drug Candidate for Treatment - (10/18/05)
     
  7840. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source - (10/18/05)
     
  7841. ARTISTS/POETS with HCV - (10/14/05)
     
  7842. AASLD: FIVE MILLION AMERICANS INFECTED WITH THE HEPATITIS C VIRUS: A CORRECTED ESTIMATE - (10/13/05)
     
  7843. Herbal hepatotoxicity - (10/11/05)
     
  7844. Increased Rates of Liver Cell Death in HCV/HIV Coinfection - (10/07/05)
     
  7845. Didanosine plus ribavirin can be toxic in HIV patients treated for hepatitis C - (10/07/05)
     
  7846. Toll-Like Receptors: new therapy to stimulate immune system - (10/06/05)
     
  7847. Increased Rates of Liver Cell Death in HCV/HIV Coinfection - (10/05/05)
     
  7848. Biomarkers used to predict recurrent disease in hepatitis C transplant patients - (10/05/05)
     
  7849. 24 Week PegIntron/RBV Therapy Approved in Europe for HCV Genotype 1 & Low Viral Load - (10/05/05)
     
  7850. Presence of Hepatitis C Virus (HCV) RNA in the Genital Tracts of HCV/HIV-1-Coinfected Women - (10/05/05)
     
  7851. Undetectable HIV May Slow Fibrosis in HCV/HIV Coinfected Patients - (10/04/05)
     
  7852. New HCV Antisense Drug - (10/04/05)
     
  7853. Hepatitis C Vaccine Candidate - (10/04/05)
     
  7854. Two New HCV Polymerase Inhibitors: early study data show potency & perhaps once daily dosing - (10/04/05)
     
  7855. New HCV Drug NM283 HBV Drug LdT at AASLD - (10/03/05)
     
  7856. New HCV Protease Inhibitor VX-950 - (10/03/05)
     
  7857. Hepatitis C and liver transplantation - (10/03/05)
     
  7858. Breakthrough for HCV research: in vitro HCV replication - (10/03/05)
     
  7859. Asians 'risk fatal liver disease' - (10/03/05)
     
  7860. New HCV & HBV Drugs: XTL-6865, XTL2125 - (09/30/05)
     
  7861. Britain 'failing' on hepatitis C - (09/30/05)
     
  7862. Hepatitis C: Current approaches in pediatrics - (09/30/05)
     
  7863. Noninvasive Fibrosis Test Performs Well - (09/30/05)
     
  7864. New Toll-like Receptor Drug Actilon for HCV Therapy - (09/29/05)
     
  7865. Psych Impairment in Coinfected Women - (09/29/05)
     
  7866. Flamel Technologies Announces Positive Preliminary Results of a Phase I/II Trial of IFN-alpha-XL in Patients with Chronic Hepatitis C Virus Infection - (09/29/05)
     
  7867. Chronic Hepatitis C in Latinos: Natural History, Treatment Eligibility, Acceptance, and Outcomes - (09/29/05)
     
  7868. MIGENIX Completes First Clinical Study of Celgosivir in Chronic Hepatitis C Patients - (09/29/05)
     
  7869. Bioenvision's Phase II Trial of Virostat Very Active in Hepatitis C - (09/29/05)
     
  7870. New Hep C Protease Inhibitor - (09/21/05)
     
  7871. Liver Injury and Changes in Hepatitis C Virus (HCV) RNA Load Associated with Protease Inhibitor-Based Antiretroviral Therapy for Treatment-Naive HCV-HIV-Coinfected Patients: Lopinavir-Ritonavir versus Nelfinavir - (09/21/05)
     
  7872. PEGINTERFERON a-2b THERAPY IN ACUTE HEPATITIS C: IMPACT OF ONSET AND DURATION OF THERAPY ON SUSTAINED VIROLOGIC RESPONSE - (09/20/05)
     
  7873. Fatigue & Hypermetabolism in HCV: high HCV RNA may cause fatigue & interferon appears to reduce fatigue - (09/19/05)
     
  7874. HCV natural history in the west & developing world: The retrospective and prospective in perspective - (09/19/05)
     
  7875. (Marijuana/Hash) Endocannabinoids and liver disease - review - (09/19/05)
     
  7876. Impact of Hepatitis C Virus on Immune Restoration in HIV-Infected Patients Who Start Highly Active Antiretroviral Therapy: A Meta-analysis - (09/14/05)
     
  7877. Hepatitis C Virus Infection in HIV Type 1-Infected Individuals Does Not Accelerate a Decrease in the CD4+ Cell Count but Does Increase the Likelihood of AIDS-Defining Events - (09/14/05)
     
  7878. VA Study: HCV Increases Risk of Death Among HAART-Treated HIV+ Patients by 30-80% - (09/14/05)
     
  7879. Influence of Hepatitis C Virus Infection on HIV-1 Disease Progression and Response to Highly Active Antiretroviral Therapy - (09/14/05)
     
  7880. Hepatic steatosis with stavudine in HIV/hepatitis C virus co-infection - (09/14/05)
     
  7881. Promising Therapy for Human Hepatoma (liver cancer, HCC): Telomerase Inhibition by GRN163 - (09/13/05)
     
  7882. Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain - (09/13/05)
     
  7883. Is Cirrhosis Inevitable in HCV? - (09/13/05)
     
  7884. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C - (09/13/05)
     
  7885. Hepatocellular carcinoma in 40 HIV/HCV-coinfected versus 50 HCV-monoinfected patients. North American HCC in HIV Study Gro (09/09/05)
     
  7886. Caucasians Had Better HCV Viral Load Reductions Than African-Americans During First 3 Days & During Weeks 1-4 After Starting Peg/RBV (09/09/05)
     
  7887. Hepatitis C infection is not associated with systemic HIV-associated non-Hodgkin's lymphoma: a cohort study (09/09/05)
     
  7888. PI & NNRTI Drug Levels in Coinfected Patients (09/09/05)
     
  7889. Pegasys/RBV Improves Histology in Non-Responders & Cirrhotics (09/09/05)
     
  7890. PegIFN/RBV May Be Less Effective in Acute HCV for HIV+ (09/09/05)
     
  7891. PK of Once Daily Regimen: Fosamprenavir/r, Tenofovir and FTC in Naives (09/09/05)
     
  7892. Occult HCV- HCV RNA Found in Liver of Patients Negative for Antibody-HCV & Serum HCV RNA - (09/05/05)
     
  7893. EDITORIAL COMMENTARY Hepatitis C Virus (HCV) Occult Infection or Occult HCV RNA Detection? - (09/05/05)
     
  7894. HCV Did Not Persist in Patients with SVR - (09/05/05)
     
  7895. Divining the role of liver biopsy in hepatitis C - (09/05/05)
     
  7896. Chronic hepatitis C and 'normal' ALT levels: Treat the disease not the test - (09/05/05)
     
  7897. Gilead, Achillion initiate phase I trial evaluating GS 9132 for treatment of hep C - (09/05/05)
     
  7898. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection - (09/05/05)
     
  7899. Predicting SVR/Nonresponse at Weeks 1, 4, 12 with Pegasys/RBV - (09/05/05)
     
  7900. Reemergence of Hepatitis C Virus after 8.5 Years in a Patient with Hypogammaglobulinemia: Evidence for an Occult Viral Reservoir - (09/05/05)
     
  7901. Hepatitis A Virus Testing and Vaccination Rates are Low in HCV+ Patients - (09/05/05)
     
  7902. Noninvasive Markers of Fibrosis for Longitudinal Assessment of Fibrosis in Chronic Liver Disease: Are They Ready for Prime Time? EDITORIAL - (09/05/05)
     
  7903. Amantadine in treatment of chronic hepatitis C virus infection? - (09/05/05)
     
  7904. Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA - (09/05/05)
     
  7905. Interferon-gamma May Reverse Cirrhosis - (09/05/05)
     
  7906. CCR5-delta32 Mutation Had Higher HCV Clearance & Not Associated with Disease Outcome or Severity - (09/05/05)
     
  7907. Ondansetron Reduced IFN-Fatigue/depression - (09/05/05)
     
  7908. Genotype 4 Response to Peg/RBV; Nonresponders Improve Histologically - (09/05/05)
     
  7909. LOCTERON: New Interferon: Once Every Two weeks - (09/05/05)
     
  7910. Study finds ddI but not d4T associated with risk for symptomatic mitochondrial toxicity in RIBAVIC during IFN/RBV therapy - (09/02/05)
     
  7911. New HCV Protease Inhibitor - (08/17/05)
     
  7912. Technical considerations in liver transplantation: What a hepatologist needs to know (and every surgeon should practice) - (08/15/05)
     
  7913. Phase I Study New Hep C Drug for Peg/RBV Nonresponders - (08/11/05)
     
  7914. IAS: 24 vs 48 weeks Pegasys/RBV in HCV Genotype 2/3 Coinfection: does this study answer the question (08/01/05)
     
  7915. Liver Biopsy vs Alternative Testing in HCV/HBV - (08/09/05)
     
  7916. Peginterferon-A-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C - (08/05/05)
     
  7917. IAS: Cirrhotic Non-Responders Improve Liver Condition with Pegasys/RBV in APRICOT Study (08/05/05)
     
  7918. European Union's CHMP Adopts Positive Opinion for Shorter Course of PEGINTRON(R) and REBETOL(R) Combination Therapy for Certain Hepatitis C Patients with Genotype 1 and Low Viral Load - (08/04/05)
     
  7919. IAS: 24 vs 48 weeks Pegasys/RBV in HCV Genotype 2/3 Coinfection: does this study answer the question (08/01/05)
     
  7920. Roche Launches New Campaign to Educate Consumers About Hepatitis C - (07/29/05)
     
  7921. Epoetin Alfa Once Weekly Improves Anemia in HIV/Hepatitis C Virus-Coinfected Patients Treated With Interferon/Ribavirin: A Randomized Controlled Trial - (07/22/05)
     
  7922. Phase III Study of Consensus IFN Fully Enrolled - (07/21/05)
     
  7923. MIGENIX and Schering-Plough Sign Agreement for MX-3253 Hepatitis C Drug Development and License Option - (07/21/05)
     
  7924. Interferon Can Resolve HCV-related Arthritis: case study - (07/21/05)
     
  7925. Stealth and Cunning: Hepatitis B and Hepatitis C Viruses - (07/21/05)
     
  7926. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: Results of the HALT-C cohort - (07/21/05)
     
  7927. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy - (07/21/05)
     
  7928. New Hep C Drug for Post Transplantation: XTLbio Receives Fast Track Designation for Hepatitis C Therapy from US Food and Drug Administration - (07/21/05)
     
  7929. Complete Replication of Hepatitis C Virus in Cell Culture - (07/21/05)
     
  7930. AZT Increased Ribavirin Levels & Risk for Anemia; RBV Levels at Wks 4 & 12 Increased Viral Response - (07/21/05)
     
  7931. Unsafe Sex and Increased Incidence of Hepatitis C Virus Infection among HIV-Infected Men Who Have Sex with Men: The Swiss HIV Cohort Study - (07/21/05)
     
  7932. Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase? - (07/21/05)
     
  7933. Metabolics, Fatty Liver, Heart Disease Circulatory dysfunction in NAFLD - Which is first, which is last, and what do we do in between? EDITORIAL - (07/21/05)
     
  7934. Fatty Liver Predicted Heart Disease - (07/20/05)
     
  7935. Diagnosis of Small Hepatocellular Carcinoma - (07/11/05)
     
  7936. Neuropsychological Aspects of Coinfection with HIV and Hepatitis C Virus - (07/11/05)
     
  7937. Insulin Resistance Plays a Significant Role in Liver Fibrosis in Chronic Hepatitis C and in the Response to Antiviral Therapy - (07/07/05)
     
  7938. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study - (07/07/05)
     
  7939. Smoking and HCV infection increase the risk of non-Hodgkin lymphoma - (07/05/05)
     
  7940. Fatty Liver Accelerates Liver Disease: Steatosis, Co-factor in other liver diseases - (07/01/05)
     
  7941. Daily Cannabis Smoking as a Risk Factor for Fibrosis Progression in Chronic Hepatitis C - (06/27/05)
     
  7942. Noninvasive markers of hepatic fibrosis: Are they ready for prime time in the management of HIV/HCV co-infected patients? - (06/23/05)
     
  7943. Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3 - (06/23/05)
     
  7944. Researchers create infectious hepatitis C virus in a test tube - (06/22/05)
     
  7945. New Research Exploring How HCV Evades the Immune System: can a vaccine be found? - (06/22/05)
     
  7946. HCV Infection among Prisoners in the California State Correctional System: sexual transmission, women at risk - (06/21/05)
     
  7947. Sexual dysfunction in males with chronic hepatitis C and antiviral therapy: interferon-induced functional androgen deficiency or depression? - (06/20/05)
     
  7948. COALITION PRINCIPLES ON HIV/HCV COINFECTION POLICY - (06/20/05)
     
  7949. Progression of liver fibrosis in patients coinfected with HCV and HIV undergoing antiretroviral therapy - (06/16/05)
     
  7950. Coinfection with HIV and HCV in Injection Drug Users and Minority Populations - (06/07/05)
     
  7951. Outcomes among Patients with End-Stage Liver Disease Who Are Coinfected with HIV and HCV - (06/07/05)
     
  7952. Vertically Acquired HCV: natural history - (06/07/05)
     
  7953. New Drug Targets for HIV and Hepatitis C Virus Coinfection - (06/06/05)
     
  7954. Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial - (06/06/05)
     
  7955. Predicting SVR: 12 Better than 4 Week Early Viral Response - (06/06/05)
     
  7956. Liver Transplantation for Hepatocellular Carcinoma - (06/02/05)
     
  7957. HCV Drug NM283 Trial Fully Enrolled - (06/02/05)
     
  7958. New HCV Drug Albuferon Starts Study in Genotype 1 Naives - (06/02/05)
     
  7959. Innogenetics says hepatitis C vaccine trials 'inconclusive', extends study - (06/01/05)
     
  7960. New HCV & HBV Drugs: toll-like receptors - (06/01/05)
     
  7961. Long-Dormant Threat Surfaces: Deaths From Hepatitis C Are Expected to Triple - (05/31/05)
     
  7962. Pioglitazone: heart disease, lipids, diabetes - (05/31/05)
     
  7963. DDW: "Triple Anti-HCV Drug Therapy for Nonresponders to Peginterferon/Ribavirin: Interferon Gamma (Actimmune) + Ribavirin + Pegasys or Infergen: A Pilot Study" (05/31/05)
     
  7964. DDW: Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London: 25% of coinfected unaware they have HCV (05/31/05)
     
  7965. DDW: Psychiatric/Substance Use Barriers to HCV Treatment (05/31/05)
     
  7966. Fatty Liver Is Worse in HIV "IMPACT of HIV COINFECTION on the DEVELOPMENT of STEATOSIS (FATTY LIVER) in PATIENTS with Chronic HCV Infection" - (05/31/05)
     
  7967. Hepatitis virus-positive livers OK for transplants - (05/27/05)
     
  7968. Cognitive Impairment, HCV, HIV & Meth "Risk of Cognitive Impairment High in HCV-HIV Coinfection and Methamphetamine Addiction" - (05/26/05)
     
  7969. A cluster of acute hepatitis C virus infection among men who have sex with men - results from contact tracing and public health implications - (05/23/05)
     
  7970. DDW: Consensus Interferon + IFN Gamma in PegIFN/RBV Non-Responders (05/23/05)
     
  7971. DDW: Pegasys in IFN/RBV Relapsers & Nonresponders Canadian EAP (05/23/05)
     
  7972. DDW: SAFETY, PHARMACODYNAMIC (PD) & PHARMACOKINETIC (PK) PROFILES OF CPG 10101 (ACTILON), A NOVEL TLR9 AGONIST: comparison in normal volunteers & HCV infected individuals (05/23/05)
     
  7973. Deal to Develop Chiron's HCV Protease Inhibitors - (05/23/05)
     
  7974. DDW: VX-950: HCV PROTEASE INHIBITOR INITIAL RESULTS OF A PHASE 1b, MULTIPLE DOSE STUDY OF VX-950, A HEPATITIS C VIRUS PROTEASE INIHIBITOR (05/20/05)
     
  7975. DDW: "VALOPICITABINE (NM283) ALONE & IN COMBINATION WITH PEG-INTERFERON IN PATIENTS WITH GENOTYPE-1 CHRONIC HEPATITIS C: Preliminary results from an ongoing phase II, multicenter study" (05/20/05)
     
  7976. DDW: Double-Dose Peginteferon Alfa-2b (pegIntron) Plus Weight-Based Ribavirin for Re-Treatment of African-american Non-Responders with Hepatitis C (05/19/05)
     
  7977. DDW: InterMune presents encouraging HCV drug data on HCV protease Inhibitor (05/17/05)
     
  7978. DDW: Consensus Interferon for Peg-IFN Non Responders (05/17/05)
     
  7979. DDW: Consensus Interferon in Peg/RBV Nonresponders (05/17/05)
     
  7980. DDW: HEPATITIS B: SCIENCE & TREATMENT 2005 (05/16/05)
     
  7981. DDW: Pioglitazone Improves Fatty Liver (05/16/05)
     
  7982. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C - (05/13/05)
     
  7983. Interferon--induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression - (05/13/05)
     
  7984. Chronic hepatitis C, depression and interferon - (05/13/05)
     
  7985. VX-950-New HCV Protease Inhibitor-Shows Potency in 14-Day Study - (05/12/05)
     
  7986. NEW HEPATITIS C STUDY FOR CHILDREN (PEDS-C) - (05/09/05)
     
  7987. Fatty Diets May Lead to Cirrhosis - (05/09/05)
     
  7988. Antiviral therapy in advanced chronic liver disease due to hepatitis C virus infection: Pilot study - (05/09/05)
     
  7989. Feds Tested AIDS Drugs on Foster Kids Without Protection from Independent Advocate - (05/05/05)
     
  7990. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C in Spain - (05/05/05)
     
  7991. EASL: HIV & High HCV Viral load Increased HCV Perinatal Transmission (05/05/05)
     
  7992. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study - (05/03/05)
     
  7993. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C - (05/03/05)
     
  7994. EASL: HOMOSEXUALLY TRANSMITTED HCV-ACUTE INFECTION RELATED TO A CLUSTERED GENOTYPE 4 HCV IN HIV-1 INFECTED MEN AND INEFFICACY OF EARLY ANTIVIRAL THERAPY (05/02/05)
     
  7995. Clinical Developments in Hepatocellular Carcinoma - (05/02/05)
     
  7996. EASL: Diabetes & Lipids Associated with Liver Disease (05/27/05)
     
  7997. EASL: Ribavirin Levels & Viral Response to PegIFN/RBV HCV Therapy (05/25/05)
     
  7998. EASL: SUSTAINED RESPONSE TO PEGASYS IN HBeAg-NEGATIVE CHRONIC HEPATITIS B. (05/25/05)
     
  7999. EASL: PegIFN/Ribavirin Therapy for Cirrhotics (05/25/05)
     
  8000. EASL: PegInterferon Maintenance Therapy: EASL Report (05/25/05)
     
  8001. HCV & HBV HIV Coinfection Treatment: Consensus Statement - (05/25/05)
     
  8002. EASL: PegInterferon Maintenance Therapy: EASL Report (05/25/05)
     
  8003. EASL: PegInterferon Maintenance Therapy: EASL Report (05/22/05)
     
  8004. EASL: Viramidine- New HCV Drug: new 24/48 week Phase II study results (05/19/05)
     
  8005. EASL: NM-283 New HCV Drug, new 24 week data; New Developments in HCV at EASL (05/18/05)
     
  8006. EASL: Age & Ribavirin Dose Reductions Reduce SVR to Peginterferon+Ribavirin (05/15/05)
     
  8007. EASL: Cost Effectiveness of Peginterferon in HCV/HIV Coinfection (05/15/05)
     
  8008. EASL: Albuferon: new HCV drug (05/14/05)
     
  8009. EASL: New Hep C Drug NM283: 24 week data at EASL (05/14/05)
     
  8010. EASL: New Hepatitis C Drugs in Development: EASL Report (05/14/05)
     
  8011. Interplay between hepatitis C, liver steatosis and antiretroviral therapy in HIV-infected patients - (05/14/05)
     
  8012. Clinical Course of Chronic Hepatitis C in Patients with Very High Serum alpha-Fetoprotein Levels and Normal Hepatic Imaging - (05/14/05)
     
  8013. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus - (05/09/05)
     
  8014. What Defines Cure for HCV Infection? - (05/09/05)
     
  8015. Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy - (05/09/05)
     
  8016. HCV/HIV Coinfection: challenges & strategies for care & treatment - (05/09/05)
     
  8017. Dual hepatitis B virus and hepatitis C virus infection: To treat or not to treat, and how? EDITORIAL - (05/09/05)
     
  8018. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis - (05/09/05)
     
  8019. Interplay between hepatitis C, liver steatosis and antiretroviral therapy in HIV-infected patients - (05/09/05)
     
  8020. Nonresponders to Previous Chronic Hepatitis C Treatment - (05/09/05)
     
  8021. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy - (05/09/05)
     
  8022. Management of cirrhosis due to chronic hepatitis C - (05/06/05)
     
  8023. Clinical Course of Chronic Hepatitis C in Patients with Very High Serum alpha-Fetoprotein Levels and Normal Hepatic Imaging - (05/06/05)
     
  8024. Hepatitis B or hepatitis C and HIV (05/05/05)
     
  8025. Sensitive HCV RNA Test: use at week 24 - (03/31/05)
     
  8026. Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment - (03/31/05)
     
  8027. Statins and hepatotoxicity: Focus on patients with fatty liver - (03/31/05)
     
  8028. Mitochondrial DNA depletion in liver tissue of patients infected with hepatitis C virus: contributing effect of HIV infection? - (03/31/05)
     
  8029. Sex and Hepatitis C Transmission - (03/31/05)
     
  8030. Insulin Resistance Impairs Response to IFN/RBV - (03/31/05)
     
  8031. Roche Announces New Study to Evaluate Pegasys and Copegus to Treat Hepatitis C in Liver Transplant Patients - (03/22/05)
     
  8032. Pegasys + Methadone PK - (03/21/05)
     
  8033. Second Forum on Liver Transplantation: Liver transplantation for hepatitis C: how to control the virus? - (03/18/05)
     
  8034. Should we treat patients with chronic hepatitis C on the waiting list? - (03/18/05)
     
  8035. Diabetes Increases Risk of Liver Cancer - (03/15/05)
     
  8036. CROI: 12th CROI HCV Report - (03/08/05)
     
  8037. First European recommendations for the treatment of patients co-infected with HIV and Hepatitis B and C viruses - (03/07/05)
     
  8038. CROI: Accelerated Liver Disease Progression in HCV/HIV Coinfection - (03/07/05)
     
  8039. FDA Approves Pegasys and Copegus as Only Hepatitis C Treatment for HIV Patients - (03/02/05)
     
  8040. HCV, HIV & Non-Hodgins Lymphoma - (03/02/05)
     
  8041. CROI: Sexual HCV Transmission Reported Among MSM - (03/02/05)
     
  8042. CROI: AZT Causes Anemia During Ribavirin/Interferon Therapy; EPO Improves Anemia - (03/01/05)
     
  8043. How Hepatitis C Short-Circuits the Immune System - (02/22/05)
     
  8044. Coinfected Patients Can Respond Better Than previously Observed - (02/22/05)
     
  8045. Medicaid Utilization of IFN/RBV for HCV Therapy - (02/22/05)
     
  8046. CD8/CTLs Predict Response to IFN/RBV Therapy - (02/22/05)
     
  8047. Infection with concurrent multiple hepatitis C virus genotypes is associated with faster HIV disease progression - (02/18/05)
     
  8048. The Spectrum of Chronic Hepatitis C Virus Infection in the Virginia Correctional System: Development of a Strategy for the Evaluation and Treatment of Inmates with HCV - (02/18/05)
     
  8049. ViroPharma Announces Start of HCV-796 Phase 1 Program - (02/15/05)
     
  8050. Hepatitis B or Hepatitis C and HIV-infection Diagnosis/Care/Treatent - (02/11/05)
     
  8051. Study Finds Interferon Reduces Cancer Risk in HCV+ Cirrhotics - (02/10/05)
     
  8052. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma (liver cancer) - (02/09/05)
     
  8053. Early discontinuation of 'ineffective' anti-viral therapy may prove less popular with patients than with health care providers - (02/08/05)
     
  8054. Inapprorpriate Rejection for HCV Therapy for Psychiatric Disorder - (02/08/05)
     
  8055. Vitamin E Did Not Reduce Risk for Ribavirin-associated Anemia - (02/07/05)
     
  8056. Why HCV Therapy Is Not Utilized in Coinfection - (02/07/05)
     
  8057. Iron and Hepatitis C - (02/07/05)
     
  8058. Pegasys Approved for Coinfection in Europe - (02/03/05)
     
  8059. Small Molecule, Toll-Like Receptor 7 Agonist, a Potential Frontline Oral Treatment for HCV - (02/02/05)
     
  8060. Study Finds that Severity of Liver Damage May Predict Risk for Hepatotoxicity on HAART - (02/02/05)
     
  8061. HIV and Hepatitis C Virus Coinfection Update - (02/01/05)
     
  8062. Hepatitis C Treatment - (02/01/05)
     
  8063. Antiviral Therapy for Hepatitis C - (02/01/05)
     
  8064. HCV/HIV COINFECTION TREATMENT & COGNITIVE IMPAIRMENT - (02/01/05)
     
  8065. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression - (02/01/05)
     
  8066. Hepatitis New Drug Research - (01/26/05)
     
  8067. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C - (01/25/05)
     
  8068. CD4 Deficiency May Explain HIV Affect on HCV - (01/20/05)
     
  8069. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels - (01/19/05)
     
  8070. Assessing fibrosis without a liver biopsy: Are we there yet? - (01/19/05)
     
  8071. The potential of RNA interference as a tool in the management of viral hepatitis - (01/13/05)
     
  8072. Liver transplantation in HIV-infected recipients - (01/13/05)
     
  8073. Liver Disease in Pregnancy- (01/12/05)
     
  8074. Hepatitis C Virus Among African-American Persons - (01/12/05)
     
  8075. New HCV Drug NM283 + PegIFN- 12 weeks data - (01/10/05)
     
  8076. New HCV Drug Reduces HCV RNA - (01/10/05)
     
  8077. Researcher cites "bias" toward Peg-Intron in trial - (01/10/05)
     
  8078. New HCV Drug- Polymerase Inhibitor - (01/06/05)
     
  8079. Studies Showing that HCV is Not Persistent & SVR is Durable - (01/05/05)
     
  8080. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection - (01/03/05)
     
  8081. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C- 2 Editorials - (01/03/05)
     
  8082. Toxicities Associated with Oxymatrine - (01/03/05)
     
  8083. Oxymatrine: medicinal herb for treating hepatitis C & B - (01/03/05)
     
  8084. Medicinal Herbs for HCV (oxymatrin) - (12/30/04)
     
  8085. Complementary and alternative therapies in the treatment of chronic hepatitis C: a systematic review - (12/30/04)
     
  8086. Hep C Maintenance Therapy Study in Coinfection: ACTG Study - (12/23/04)
     
  8087. PegIntron + Ribavirin in Coinfected Patiernts, RIBAVIC Study Results - (12/16/04)
     
  8088. Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected Patients - (12/16/04)
     
  8089. Hepatocellular Carcinoma - (12/15/04)
     
  8090. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination - (12/13/04)
     
  8091. Prevalence of hepatic steatosis (fatty liver) in an urban population in the United States: Impact of ethnicity - (12/13/04)
     
  8092. NIH Action plan for liver disease research - (12/13/04)
     
  8093. The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy - (12/08/04)
     
  8094. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome - (12/08/04)
     
  8095. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir - (12/08/04)
     
  8096. AASLD: Pegasys/RBV Improves Fibrosis in Responders, relapsers & Nonresponders with Advanced Fibrosis - (12/06/04)
     
  8097. ICAAC: Predictability of SVR at Week 4 in Coinfection in APRICOT Study - (12/06/04)
     
  8098. Controlling pain in liver biopsy, or "we will probably need to repeat the biopsy in a year or two to assess the response" - (12/03/04)
     
  8099. Early Prediction of Hepatitis C Virus (HCV) Infection Relapse in Nonresponders to Primary Interferon Therapy by means of HCV RNA Whole-Blood Analysis - (12/03/04)
     
  8100. The management of side-effects during therapy for hepatitis C - (12/03/04)
     
  8101. Hepatitis C: It's a long way to new therapy, it's a long way to go... - (12/01/04)
     
  8102. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: A population-based study - (12/01/04)
     
  8103. BILN 2061 HCV Protease Inhibitor Development Held Due to Toxicity - (11/30/04)
     
  8104. Roche Announces First Major Study to Examine Efficacy of Hepatitis C Treatment in Latinos - (11/29/04)
     
  8105. Infrequent Reinfection after Successful Treatment for Hepatitis C Virus Infection in Injection Drug Users - (11/29/04)
     
  8106. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients - (11/29/04)
     
  8107. HCV coinfection increases mortality in HIV patients - (11/22/04)
     
  8108. Response to Hepatitis C Therapy Can Last for Years - (11/22/04)
     
  8109. Celebrities with hepatitis C - (11/18/04)
     
  8110. ICAAC: Predicting outcomes in people with HIV and HCV by Mark Mascolini - (11/16/04)
     
  8111. HIV and HCV infection rates higher than expected in London drug users - (11/15/04)
     
  8112. AASLD: Pegasys/RBV 16 vs 24 Weeks for Genotype 2 & 3 - (11/15/04)
     
  8113. AASLD: Peg-IFN Maintenance Therapy Study: interim analysis at 2 yrs shows positive results - (11/15/04)
     
  8114. Vitamin E warning sounded - (11/12/04)
     
  8115. AASLD: Prolonged Pegasys+RBV Therapy to 72 Weeks May Improve SVR in Patients Who were HCV RNA+ after 4 weeks & slow responders - (11/10/04)
     
  8116. AASLD: HCV & HIV Prevalence in NYC Drug Rehab Facility - (11/09/04)
     
  8117. AASLD: Pilot Study, Hi-Dose Pegasys Induction- 37% SVR for IFN/RBV Nonresponders - (11/09/04)
     
  8118. AASLD: Durability of SVR, 5 Year follow-up Pegasys plus Copegus - (11/09/04)
     
  8119. AASLD: Nonresponders in Apricot Achieve Histologic Response, Improve Liver - (11/05/04)
     
  8120. ICAAC: Failure of PegIFN/RBV in People With HCV/HIV Predicted at 12 Weeks by Mark Mascolini - (11/02/04)
     
  8121. AASLD: NEW HCV PROTEASE INHIBITOR STARTS FIRST 14-DAY HUMAN STUDY IN NOVEMBER - (11/04/04)
     
  8122. AASLD: Consensus Interferon for Peg/RBV Nonresponders - (11/02/04)
     
  8123. AASLD: New HCV Drug NM283 + Peginterferon Study - (11/02/04)
     
  8124. AASLD: Viramidine, substitute for ribavirin: end-of-treatment response in therapy-naïve patients - (11/01/04)
     
  8125. Co-occurring Hepatitis C, Substance Use, and Psychiatric Illness: Treatment Issues and Developing Integrated Models of Care - (10/29/04)
     
  8126. New HCV Polymerase Drug: Roche partners with Pharmasset - (10/28/04)
     
  8127. Prevalence of HCV/HIV Coinfection in Children with Perinatal HIV - (10/27/04)
     
  8128. Occult hepatitis B in HCV+ - (10/25/04)
     
  8129. Twice Weekly PegIntron Controversy - (10/14/04)
     
  8130. Occult HBV Seen in 26% of HCV+ - (10/14/04)
     
  8131. Potential future therapeutic options for Hepatitis C - (10/14/04)
     
  8132. Thymosin-a + Interferon for HCV Not effective in Study - (10/14/04)
     
  8133. New HCV Drug Starts 12-week Study in Patients - (10/14/04)
     
  8134. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death - (10/12/04)
     
  8135. FDA Grants Priority Review to Pegasys with Copegus for HCV in HIV Patients - (10/07/04)
     
  8136. How effective is HAART in HCV and HIV coinfection? - (10/07/04)
     
  8137. Valeant Pharmaceuticals to Present Viramidine End-of-Treatment Data From Phase 2 Clinical Trial - (10/07/04)
     
  8138. Liver Biopsy: how it is performed - (10/07/04)
     
  8139. Interferon Alpha-2b and Ribavirin for Patients with Chronic Hepatitis C and Normal ALT - (10/07/04)
     
  8140. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study - (10/07/04)
     
  8141. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study - (10/05/04)
     
  8142. Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C Genotype 4 - (10/05/04)
     
  8143. Clearance of Hepatitis C Virus after Newly Acquired Infection in IDUs - (10/04/04)
     
  8144. Genelabs, Gilead Team Up In Potential $46M HCV Bid - (10/04/04)
     
  8145. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study; 33% showed progression of at least 1 fibrosis point - (10/04/04)
     
  8146. Michigan prisons get $1.2M to test for hepatitis C - (10/01/04)
     
  8147. Fatty Liver Accelerates Fibrosis: diabetes, mitochondrial dyfunction, obesity associated - (09/30/04)
     
  8148. Long-Term Outcomes in HCV with SVR: cure, regression of fibrosis - (09/29/04)
     
  8149. Acute hepatitis C in HIV-infected men who have sex with men - (09/28/04)
     
  8150. NIH Action plan for Liver Disease Research: Call for public comment - (09/28/04)
     
  8151. EPO for Anemia During IFN/RBV Therapy for HCV - (09/28/04)
     
  8152. Frequent Hepatitis C Virus Superinfection in Injection Drug Users - (09/22/04)
     
  8153. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections - (09/22/04)
     
  8154. RBV Kinetics--Improves Early Response - (09/22/04)
     
  8155. Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients - (09/22/04)
     
  8156. Hepatitis C Virus Infection in United States Correctional Institutions - (09/20/04)
     
  8157. Alcohol and Hepatitis C: Implications for Disease Progression and Treatment - (09/20/04)
     
  8158. Cost-effectiveness of Combination Peginterferon Alfa-2a (Pegasys) and Ribavirin Compared with Interferon Alfa-2b (Intron A) and Ribavirin in HCV Patients - (09/20/04)
     
  8159. HIV/HCV Coinfection Update: special issues, natural history/medical management - (09/20/04)
     
  8160. Medical Clinic Notifies Patients of Possible Hepatitis Exposure During Exams - (09/14/04)
     
  8161. Consensus Interferon Study for Peginterferon Nonresponders: 41 study sites - (09/13/04)
     
  8162. Chiron Grants Nonexclusive HCV License to InterMune & Limits HCV Research - (09/13/04)
     
  8163. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation - (09/13/04)
     
  8164. Long-Term Outcomes for Liver Transplantation Due to HCV: NIDDK study - (09/08/04)
     
  8165. Vertex Pharma Reports Completion of Dosing in the Phase Ia Clinical Study of VX-950, an Oral HCV Protease Inhibitor for the Treatment of Hepatitis C - (09/08/04)
     
  8166. Strong Association of Hepatitis C Virus (HCV) Infection and Thrombocytopenia: - (09/07/04)
     
  8167. Hepatitis C infection and injection drug use: The role of hepatologists in evolving treatment efforts - (09/07/04)
     
  8168. The Risk For Sexual Transmission of the Hepatitis C Virus: MSM; Heterosexual - (09/07/04)
     
  8169. Reported Hepatitis C Cases Up in Wisconsin - (09/03/04)
     
  8170. Hepatitis C infection and injection drug use: The role of hepatologists in evolving treatment efforts - (09/03/04)
     
  8171. Pegasys + Copegus Coinfection Request for FDA Approval Filed by Roche - (09/02/04)
     
  8172. Can You Have Multiple Genotypes? - (09/02/04)
     
  8173. Intrahepatic CD4+ Cell Depletion in Hepatitis C Virus/HIV-Coinfected Patients - (09/01/04)
     
  8174. How Durable is the HCV Sustained Viral Response? - (08/30/04)
     
  8175. Solid-Organ Transplantation in HIV-Infected Patients in the Potent Antiretroviral Therapy Era - (08/30/04)
     
  8176. Simvastatin has long-term survival benefit: heart disease & cancer examined - (08/30/04)
     
  8177. Treatment of Chronic Hepatitis C in Blacks and Non-Hispanic Whites - (08/25/04)
     
  8178. Risk of HIV & Hepatitis Infections From Blood & Tissue Donors - (08/25/04)
     
  8179. Neuropsychiatric impact of hepatitis C on advanced HIV - (08/20/04)
     
  8180. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients - (08/19/04)
     
  8181. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy - (08/19/04)
     
  8182. HCV Worsens HIV's Neuropsychiatric Impact - (08/19/04)
     
  8183. Treatment of HCV infection in patients with advanced cirrhosis - (08/17/04)
     
  8184. Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase? - (08/09/04)
     
  8185. Hepatitis C testing in HIV infected patients - (08/09/04)
     
  8186. Sexual Transmission of HCV - (08/09/04)
     
  8187. HCV Prevents Hypertriglyceridemia - (08/09/04)
     
  8188. HCV Protease Inhibitors-BILN 2061: a major step toward new therapeutic strategies in hepatitis C - (08/09/04)
     
  8189. HAART and the HCV-infected liver: friend or foe? - (08/09/04)
     
  8190. Hepatitis Viruses & HIV Co-infection: pathogenesis & treatment - (08/06/04)
     
  8191. Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection - (08/05/04)
     
  8192. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance - (08/04/04)
     
  8193. Long-term follow-up after successful interferon therapy of acute hepatitis C - (08/04/04)
     
  8194. Mt Sinai School of Medicine Press Release on APRICOT COINFECTION STUDY RESULTS - (08/04/04)
     
  8195. Hepatitis C Virus Infection in Cocaine Users: A Silent Epidemic; study suggests snorting cocaine is transmission risk - (08/03/04)
     
  8196. ACTG 5071-Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons - (07/29/04)
     
  8197. APRICOT- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients - (07/29/04)
     
  8198. Treating Hepatitis C in "Difficult-to-Treat" Patients - (07/29/04)
     
  8199. Role of Vitamin K2 in the Development of Hepatocellular Carcinoma in Women With Viral Cirrhosis of the Liver - (07/26/04)
     
  8200. XV International AIDS Conference in Bangkok: Early 12-Week Viral Response in HCV/HIV Coinfection Predicts Sustained Viral Response (SVR) in APRICOT Study - (07/26/04)
     
  8201. XV International AIDS Conference in Bangkok: Factors That Predict Response to Pegasys + Ribavirin (Copegus) in HCV/HIV Co-infection in the APRICOT Study - (07/26/04)
     
  8202. XV International AIDS Conference in Bangkok: IMPACT OF HCV VIREMIA ON HIV DISEASE PROGRESSION IN WOMEN: HCV INCREASES RISK FOR AIDS (WIHS) - (07/22/04)
     
  8203. XV International AIDS Conference in Bangkok: Mitochondrial DNA depletion in HIV-infected patients is enhanced with chronic hepatitis C and treatment with pegylated interferon plus ribavirin - (07/22/04)
     
  8204. XV International AIDS Conference in Bangkok: Safety of Pegasys Plus Ribavirin in HIV/HCV Co-infection (APRICOT STUDY) - (07/20/04)
     
  8205. Hepatitis C Outbreak Adds a New Woe to Drug Rehab Centers - (07/20/04)
     
  8206. New Illinois Law Permits Organ Donors With H.I.V. - (07/19/04)
     
  8207. XV International AIDS Conference in Bangkok: New Pegasys Study data: 43% of non-responders have histological improvement - (07/12/04)
     
  8208. Thyroid disorders common in patients with chronic hepatitis C - (07/09/04)
     
  8209. HCV Acute Infection: immune and clinical responses - (07/06/04)
     
  8210. Perinatal Transmission and Viral Evolution of Hepatitis C Virus Quasispecies in Infants Coinfected With HIV - (06/30/04)
     
  8211. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients - (06/30/04)
     
  8212. Hepatitis C, interferon, and risk of rejection after liver transplantation - (06/30/04)
     
  8213. Feds review complaints that Chiron hinders HCV research - (06/28/04)
     
  8214. Weight Loss Improves Fatty Liver - (06/23/04)
     
  8215. Harm Reduction for Substance Abuse in the Psychiatric Setting - (06/23/04)
     
  8216. Treating Co-Occurring Substance Use Disorders and Hepatitis C: role of alcohol, IVDU & psychiatry in HCV - (06/23/04)
     
  8217. The effect of a herbal medicine (Mao-to) for the prevention of interferon-induced psychiatric complications in chronic hepatitis C: a pilot study - (06/23/04)
     
  8218. VA Hepatitis C Prevalence Study Results Summary and VA Hepatitis C Program Actions - (06/11/04)
     
  8219. New HCV Protease Inhibitor Study Planned for 2004 4th Quarter - (06/08/04)
     
  8220. New Pegasys Study for HCV+ Untreated Patients with Genotype 1, High Weight & High Viral Load - (06/07/04)
     
  8221. The Future Face of Coinfection: Prevalence and Incidence of HIV and Hepatitis C Virus Coinfection Among Young Injection Drug Users (30% coinfection rate) in Vancouver - (06/07/04)
     
  8222. DDW: Doctors Conclude Majority of Both HCV & Coinfected Not Elgible for IFN/RBV - (06/07/04)
     
  8223. PegIntron (Peginterferon Alfa-2b) and Ribavirin for the Treatment of Chronic Hepatitis C in Blacks and Non-Hispanic Whites - (06/01/04)
     
  8224. PegIntron plus Ribavirin study in African-Americans - (06/01/04)
     
  8225. Pegasys plus Ribavirin for African-Americans with Genotype 1 - (06/01/04)
     
  8226. DDW: MMPD (new HCV Drug), Pegasys, & Ribavirin Study - (05/28/04)
     
  8227. DDW: NM283: new oral HCV drug, polymerase inhibitor - (05/26/04)
     
  8228. Newly Published Study Investigates Pegasys and Copegus (ribavirin) for the Treatment of Chronic Hepatitis C In Black Americans - (05/26/04)
     
  8229. Decline in lung function, impaired response to salbutamol in HCV+ asthmatics - (05/25/04)
     
  8230. DDW: Study Examines HCV & Mistletoe & Herbal Concoction, When Interferon Fails - (05/20/04)
     
  8231. DDW: Consensus Interferon for Nonresponders- revisited - (05/19/04)
     
  8232. DDW: Consensus Interferon in Peg/RBV Nonresponders - (05/18/04)
     
  8233. DDW: Twice Weekly Higher Dosing of PegIntron Had Better Viral Response Rates in Genotype 1 Patients - (05/17/04)
     
  8234. DDW: Viramidine May Not Lead to Ribavirin Associated Anemia: "Clinical Study of Viramidine in Treatment of Hepatitis C Supports RBC-Sparing Mechanisms of Action" - (05/17/04)
     
  8235. Long-term outcome of hepatitis C in children - (05/13/04)
     
  8236. Hepatitis C Virus (HCV) Diversity in HIV-HCV Coinfected Subjects Initiating Highly Active Antiretroviral Therapy - (05/10/04)
     
  8237. HCV/HIV Coinfection & Lipid Abnormalities - (05/04/04)
     
  8238. Veteran Denied Liver Transplant: files law suit - (05/03/04)
     
  8239. EASL: ALBUFERON: New HCV Drug Dosed Every Every 2-4 Weeks by subcutaneous injection - (04/28/04)
     
  8240. EASL: Model to Predict Outcome of Pegasys plus Ribavirin Therapy - (04/27/04)
     
  8241. EASL: Small, Unrandomized Study Compares Pegasys to PegIntron - (04/26/04)
     
  8242. EASL: Daily Cannabis Smoking as a Risk Factor for Fibrosis Progression in Chronic Hepatitis C - (04/23/04)
     
  8243. Hepatitis C Virus (HCV) Diversity in HIV-HCV Coinfected Subjects Initiating Highly Active Antiretroviral Therapy - (04/22/04)
     
  8244. EASL: First Major Study Showing 12 Week Viral Response to Pegasys/ribavirin in Coinfected Patients Predicts Outcome - (04/22/04)
     
  8245. EASL: 18 Months Therapy (Pegasys+Ribavirin): study found relapse rate reduced by 70%; viral response rate in genotype 1 increased by 50% - (04/21/04)
     
  8246. EASL: Study Finds Undetectable HIV Viral Load Slows Liver Disease Progression in HCV/HIV Coinfection - (04/19/04)
     
  8247. EASL: New Drugs for HCV; Viramidine: 24 week study results - (04/19/04)
     
  8248. EASL: New HCV Drug, NM283, polymerase inhibitor: first data in patient: 1 log viral load decline in highest dose - (04/19/04)
     
  8249. Drinking Alcohol and Risk for Progression of Liver Disease - (04/13/04)
     
  8250. Treating Non-Responders with Pegasys plusRibavirin: HALT-C Study - (04/13/04)
     
  8251. Superinfection with HCV in HBV+ Patients Worsens Hepatitis - (04/13/04)
     
  8252. Schering-Plough launches generic hepatitis C drug By Bill Berkrot and Ransdell Pierson - (04/12/04)
     
  8253. Prices Much Higher Than Expected for New Generic Ribavirin from Three Rivers - (04/12/04)
     
  8254. Study Finds Quality of Life for Pegasys-Ribavirin Better Than for Interferon-Ribavirin and It Improves For Sustained Viral Responders - (04/12/04)
     
  8255. Psychological Stress May Accelerate HCV Progression - (04/12/04)
     
  8256. Three Rivers Pharmaceuticals announces FDA Approval of Ribasphere™ (Ribavirin capsules) 200mg for the Treatment of Chronic Hepatitis C - (04/08/04)
     
  8257. 75% HCV/HIV Coinfection Rates in SF Homeless- few treated - (04/07/04)
     
  8258. AASLD response to recommendations on screening HCV by US Preventive Services Task force - (04/05/04)
     
  8259. Hepatitis A - (04/05/04)
     
  8260. Prevention and treatment of hepatocellular carcinoma - (04/02/04)
     
  8261. Obesity and diabetes as a risk factor for hepatocellular carcinoma - (04/02/04)
     
  8262. Drinking Alcohol and Risk for Progression of Liver Disease - (04/01/04)
     
  8263. Intra-hepatic messenger RNA levels for interferons and related genes in hepatitis C virus/HIV co-infected patients - (03/30/04)
     
  8264. The patient's perspective in hepatitis C: coping with HCV, doctors, adherence, depression - (03/30/04)
     
  8265. Hepatitis C virus-infected patients (41%) report communication problems with physicians - (03/29/04)
     
  8266. CROI: EPO Once Weekly Improves Anemia & Quality of Life in Coinfected Patients Treated with Interferon/Ribavirin - (03/29/04)
     
  8267. Innogenetics reports significantly improved liver fibrosis in hepatitis C patients after 3 years of therapeutic vaccination - (03/26/04)
     
  8268. Ribavirin's antiviral effect aids interferon in hepatitis C therapy - (03/24/04)
     
  8269. Diagnosis, Management and Treatment of Hepatitis C: AASLD PRACTICE GUIDELINES - (03/22/04)
     
  8270. Stigma of Hepatitis C and Lack of Awareness Stops Americans From Getting Tested and Treated - (03/18/04)
     
  8271. Hepatitis C Leads to Insulin Resistance in Mice & Perhaps Diabetes in HCV+ - (03/12/04)
     
  8272. NIH budget approved at $28 billion: Concerns over FY 2005 funding - (03/12/04)
     
  8273. Drug-Induced Liver Injury Associated with Antiretroviral Therapy that Includes HIV-1 Protease Inhibitors - (03/08/04)
     
  8274. CROI: Evaluation of HCV RNA and Liver Injury in HCV/HIV Coinfected Patients Initiating Lopinavir/r or Nelfinavir-based Therapy - (03/08/04)
     
  8275. CROI: CROI Report- HIV/HCV Co-Infection: Organ Transplantation and Liver Cancer - (03/08/04)
     
  8276. Peginterferon-alpha2a (Pegasys) and Ribavirin Combination Therapy in Chronic Hepatitis C A Randomized Study of Treatment Duration and Ribavirin Dose - (03/04/04)
     
  8277. PDF FORMAT - National HIV/Hepatitis C Co-Infection Coalition letter to Congress and to the Administration - (03/04/04)
     
  8278. Hepatitis C. Development of new drugs and clinical trials: Promises and pitfalls - (03/04/04)
     
  8279. SCHERING-PLOUGH ANNOUNCES AVAILABILITY OF PEG-INTRON REDIPEN - (03/01/04)
     
  8280. CROI: Hepatitis C and HIV: incremental advances; plenary talk on HCV protease, new drug research & basic science; final results of 3 important co-infection studies - Reported for NATAP by David Margolis, MD, University of Texas, Southwestern Medical Center (02/26/04)
     
  8281. CROI: Peg/RBV treatment, liver transplants, RBV/nuke interaction study, HCV & HAART response - Reported by Nancy Shulman, MD, Stanford University (02/26/04)
     
  8282. CROI: HCV/HIV Coinfection May Cause Depression & Cognitive Dysfunction Compared to HIV Monoinfection - (02/26/04)
     
  8283. CROI: PegIntron Plus Ribaivin in HCV/HIV Coinfection: French RIBAVIC Study - (02/19/04)
     
  8284. CROI: ACTG 5071: Pegasys plus Ribavirin vs IFN/RBV in HCV/HIV Coinfection - (02/19/04)
     
  8285. CROI: HIV Vaccine $$, ADAP & Hepatitis - (02/13/04)
     
  8286. CROI: Ribavirin-NRTIs Interaction Study - (02/12/04)
     
  8287. CROI: Pegylated Interferon plus Ribavirin: Pegasys/RBV in Co-infection (APRICOT Study, 72-week results) - (02/11/04)
     
  8288. CROI: Hepatitis C and Neuropsychological Function In Treatment Naive HIV-1-infected Subjects - A5097s Baseline Analysis - (02/09/04)
     
  8289. Health-Related Quality of Life of Patients with HIV Disease: Impact of Hepatitis C Coinfection - (02/09/04)
     
  8290. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient data - (02/03/04)
     
  8291. Liver disease research funding - (02/03/04)
     
  8292. Hepatitis Vaccination Promoted for Gay Men - (02/02/04)
     
  8293. Methamphetamine: medical implications, HIV & Hepatitis - (02/02/04)
     
  8294. Scope of Worldwide Hepatitis C Problem - (01/30/04)
     
  8295. Pilot Study of the Relationship Between Histologic Progression and Hepatic Iron Concentration in Chronic Hepatitis C - (01/30/04)
     
  8296. Infection with Hepatitis C Virus Genotype 4 in the United States - (01/30/04)
     
  8297. Outcome of Liver Transplantation for Patients Infected by Hepatitis C, Including Those Infected by Genotype 4 - (01/28/04)
     
  8298. Hepatitis C Lawsuit for Exposure to Reused Syringes in Clinic - (01/28/04)
     
  8299. Low Dose PegIntron and Ribavirin in Small Study: efficacy and safety - (01/28/04)
     
  8300. Schering-Plough Announces Availability of REBETOL(R) Oral Solution For Use in Treating Pediatric Hepatitis C - (01/27/04)
     
  8301. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy - (01/27/04)
     
  8302. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches - (01/27/04)
     
  8303. HEP DART: NM 283 new HCV Inhibitor - (01/26/04)
     
  8304. HEP DART: Combination Interferon Therapy: Infergen plus Actimmune - (01/26/04)
     
  8305. HEP DART: Merimepodib (VX-497), New HCV Drug - (01/27/04)
     
  8306. Care of patients with hepatitis C and HIV co-infection: Consensus Panel Recommendations - (01/26/04)
     
  8307. Steatosis in Hepatitis C: What Does It Mean? - (01/22/04)
     
  8308. Hepatotoxicity Safety Change to Label of Viramune (nevirapine) - (01/20/04)
     
  8309. GB Virus Type C Coinfection in HIV-Infected African Mothers and Their Infants, KwaZulu Natal, South Africa - (01/20/04)
     
  8310. GB Virus Type C: A Virus in Search of a Disease or a Role in HIV Therapy? - (01/20/04)
     
  8311. Coley Pharmaceutical Group Initiates Phase I Clinical Trials of Actilon(TM) for Chronic Hepatitis C Infection - (01/16/04)
     
  8312. Global Burden of Disease (GBD) for Hepatitis C - (01/15/04)
     
  8313. Treatment considerations in patients with hepatitis C and cirrhosis - (01/15/04)
     
  8314. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection - (01/14/04)
     
  8315. PDF FORMAT - Structural Biology of Hepatitis C Virus - (01/14/04)
     
  8316. Pioglitazone Improves Liver, Body Fat, Glucose - (01/08/04)
     
  8317. Study highlights possible root of HCV persistence - (01/07/04)
     
  8318. Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression - (01/06/04)